Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/089835
Kind Code:
A1
Abstract:
Diazanaphthalene compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a diazanaphthalene compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Inventors:
KC SUNIL KUMAR (US)
MAK CHI CHING (US)
CAO JIANGUO (US)
BOLLU VENKATAIAH (US)
CHIRUTA CHANDRAMOULI (US)
MITTAPALLI GOPI KUMAR (US)
EASTMAN BRIAN WALTER (US)
Application Number:
PCT/US2018/058564
Publication Date:
May 09, 2019
Filing Date:
October 31, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SAMUMED LLC (US)
KC SUNIL KUMAR (US)
MAK CHI CHING (US)
CAO JIANGUO (US)
BOLLU VENKATAIAH (US)
CHIRUTA CHANDRAMOULI (US)
MITTAPALLI GOPI KUMAR (US)
EASTMAN BRIAN WALTER (US)
International Classes:
C07D487/04; A61K31/4375; A61K31/498; A61P25/00; A61P35/00; C07D471/04
Domestic Patent References:
WO2017005137A12017-01-12
WO2007125405A22007-11-08
WO2013169793A22013-11-14
WO2012080284A22012-06-21
WO2017189829A12017-11-02
WO2017189823A22017-11-02
WO2018183964A12018-10-04
WO1987005297A11987-09-11
WO2001053268A22001-07-26
WO2005009997A12005-02-03
Foreign References:
US201213614296A2012-09-13
US201314019229A2013-09-05
US201514664517A2015-03-20
US6440102B12002-08-27
US6648873B22003-11-18
US6120484A2000-09-19
US4164559A1979-08-14
US4474752A1984-10-02
US6911211B22005-06-28
US6377849B12002-04-23
US33781506A2006-01-24
Other References:
LIANG JUN ET AL: "Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 27, no. 18, 12 August 2017 (2017-08-12), pages 4370 - 4376, XP085186059, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2017.08.022
BRUNTON ET AL.: "Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 13th ed.", 2017, THE MCGRAW-HILL COMPANIES
CHOU; TALALAY, ADVANCES IN ENZYME REGULATION, vol. 22, 1984, pages 27 - 55
THE AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 184, no. 1, 2011, pages 92 - 9
BRITISH JOURNAL OF PHARMACOLOGY, vol. 163, no. 1, 2011, pages 141 - 172
"Remington: The Science and Practice of Pharmacy, 22nd ed", 2012, PHARMACEUTICAL PRESS
LEYNS, L. ET AL., CELL, vol. 88, no. 6, 1997, pages 747 - 756
"March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th ed", 2013, JOHN WILEY & SONS
CAREY; SUNDBERG: "Advanced Organic Chemistry, 5th ed", 2007, SPRINGER
"Comprehensive Organic Transformations: A Guide to Functional Group Transformations, 2nd ed.", 1999, JOHN WILEY & SONS
P. WUTS: "Greene's Protective Groups in Organic Synthesis, 5th ed.", 2014, JOHN WILEY & SONS
Attorney, Agent or Firm:
FOLLETT, Angela D. et al. (US)
Download PDF:
Claims:
WHAT IS CLAIMED IS:

1. A compound, or a pharmaceuticall acceptable salt thereof, of Formula I:

wherein:

R1, R2, R4, and R5 are independently absent or selected from the group consisting of H, halide, unsubstituted -(C1-3 haloalkyl), and unsubstituted -(C1-3 alkyl);

R3 is selected from the group consisting of -aryl optionally substituted with 1-5 R7 and - heteroaryl optionally substituted with 1-4 R8;

R6 is selected from the group consisting of -(C1-4 alkylene)paryl substituted with 1-5 R9, - (C2-4 alkenylene)paryl substituted with 1-5 R9, -(C1-4 alkylene)pheteroaryl optionally substituted with 1-6 R10; -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R11, -(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R12, -(C1-4 alkylene)N(R1 )(R14), - N(R15)(R16), -CF(Ci-9 alkyl)2, -(C1-4 alkylene)pO(C3-9 alkyl), and -(C2-9 alkynyl) optionally substituted with one or more halides; wherein each alkyl of -CF(Ci-9 alkyl)2 is, independently, optionally substituted with one or more halides; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents; wherein -(C1-4 alkenylene) is, optionally substituted with one or more substituents;

R7 is selected from the group consisting of halide and -N(R17)2;

each R8 is independently selected from the group consisting of H, halide, unsubstituted - (Ci-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -N(R15)(R18), -(C1-4 alkylene)pXR19, -C(=0)N(R15)2, -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R20, and -carbocyclyl optionally substituted with 1-12 R21; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents;

alternatively, two adjacent R8 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 R22 and -carbocyclyl optionally substituted with 1-12 R21;

each R9 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C 1-9 haloalkyl), -XR2 ,-C(=0)N(R15)2, -(Ci-4 alkylene)pN(R24)2, -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R22, and -(C1-4 alkylene )pcarbocyclyl optionally substituted with 1-12 R21; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents; with the proviso that when Y2 is N then R9 is not -OMe or ^— / ;

each R10 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(Ci-9 haloalkyl), -CN, -XR23, -C(=0)N(R15)2, -(Ci-4 alkylene)pN(R24)2, -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R22, and -(C1-4 alkylene )pcarbocyclyl optionally substituted with 1-12 R21; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R11 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(Ci-9 haloalkyl), -(Ci-4 alkylene)pOR19, -(C1-4 alkylene )pheterocyclyl optionally substituted with 1-10 R22, -(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R21, -N(R15)(R25), -C(=0)(R26), -(Ci-4 alkylene)C(=0)OR27, -(C1-4 alkylene)aryl optionally substituted with one or more halides, -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides, and -S02(R28); wherein each -(Ci-4 alkylene) is, independently, optionally substituted with one or more substituents;

alternatively, two R11 attached to the same carbon atom can together represent =0 to form a carbonyl group;

each R12 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(Ci-9 haloalkyl), -(Ci-4 alkylene)pOR19, -N(R15)(R29), -C(=0)(R26), -C(=0)OR27, -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R22, and -(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R21; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R13 is selected from the group consisting of H, unsubstituted -(C1-9 alkyl), unsubstituted - (C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R20, and -carbocyclyl optionally substituted with 1-12 R21; wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents;

R14 is selected from the group consisting of unsubstituted -(C1-9 alkyl), unsubstituted -(C2- 9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1 -10 R20, and -carbocyclyl optionally substituted with 1-12 R21; wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents; each R15 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl);

R16 is selected from the group consisting of -(C1-4 alkylene )pheterocyclyl optionally substituted with 1-10 R20, and— (C1-4 alkylene )pcarbocyclyl optionally substituted with 1-12 R21; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R17 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl); alternatively, two adjacent R17 are taken together to form a -heterocyclyl ring optionally substituted with 1-10 R22;

R18 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), - (C=0)R15, and -(C1-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R19 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene )pcarbocyclyl optionally substituted with 1 -12 R21; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R20 independently is selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -N(R15)2, and -(C1-4 alkylene)pcarbocyclyl optionally substituted with 1 -12 R21; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R21 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN;

each R22 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -N(R15)2, -C(=0)R34, and -(C1-4 alkylene)pcarbocyclyl optionally substituted with 1 - 12 R21; wherein each -(Ci-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R23 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)N(R15)2, -(C1-4 alkylene )paryl optionally substituted with 1 -10 R30, -(C1-4 alkylene)pheterocyclyl optionally substituted with 1 -12 R31, and -(C1-4 alkylene )pcarbocyclyl optionally substituted with 1-12 R21; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R24 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene )N(R15)2; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R25 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R32, -(Ci-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R21, -(C1-4 alkylene)OR33; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R26 is selected from the group consisting of H, unsubstituted -(C3-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)paryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene )pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R27 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)paryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), and -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R28 is selected from the group consisting of unsubstituted -(C1-5 alkyl), unsubstituted -(C2- 5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)paryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents;

each R29 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R32, -(Ci-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R21, -(C1-4 alkylene)OR33, and -C(=0)0(Ci-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R30 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN;

each R31 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -C(=0)R34, -N(R24)2, and -(C1-4 alkylene)pcarbocyclyl optionally substituted with 1- 12 R21; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R32 is independently selected from the group consisting of halide and unsubstituted - (Ci-5 alkyl);

each R33 is independently selected from the group consisting of H and unsubstituted -(Ci-

5 alkyl);

each R34 is independently selected from the group consisting of -0(Ci-5 alkyl) and a heteroaryl optionally substituted with 1-6 R35;

each R35 is a -heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl);

each X is selected from the group consisting of O and S;

Y3 is CH or nitrogen;

Y1, Y2, Y4, and Y5 are independently selected from the group consisting of carbon and nitrogen; wherein

if Y1 is nitrogen then Y2, Y4, and Y5 are carbon, Y3 is CH, and R4 is absent;

if Y2 is nitrogen then Y1, Y4, and Y5 are carbon, Y3 is CH, and R5 is absent;

if Y3 is nitrogen then Y1, Y2, Y4, and Y5 are carbon;

if Y4 is nitrogen then Y1, Y2, and Y5 are carbon, Y3 is CH, and R1 is absent; if Y5 is nitrogen then Y1, Y2, and Y4 are carbon, Y3 is CH, and R2 is absent; and each p is independently 0 or 1.

2. The compound of claim 1, wherein R1, R2, R4, and R5 are H.

3. The compound according to any one of claims 1 -2, wherein R3 is selected from the group consisting of pyrazolyl, imidazolyl, triazolyl, thiadiazolyl, and oxazolyl, each optionally substituted with 1-4 R8.

4. The compound according to any one of claims 1-3, wherein R3 is selected from the group consisting of pyrazol-4-yl, imidazol-5-yl, l,2,3-triazol-4-yl, thiadiazol-2-yl, and oxazol-5- yl, each optionally substituted with 1-4 R8.

5. The compound according to any one of claims 1-4, wherein R3 is an unsubstituted pyrazol-4-yl,.

6. The compound according to any one of claims 1-5, wherein R3 is a pyrazol-4-yl, substituted with one -(C1-3 alkyl).

7. The compound according to any one of claims 1-6, wherein R3 is a imidazol-5-yl, substituted with one -(C1-3 alkyl).

8. The compound according to any one of claims 1-7, wherein R3 is a imidazol-5-yl, substituted with two -(C1-3 alkyl).

9. The compound according to any one of claims 1-8, wherein R3 is an unsubstituted l,2,3-triazol-4-yl.

10. The compound according to any one of claims 1-9, wherein R3 is a l,2,3-triazol-4- yl, substituted with one -(C1-3 alkyl).

11. The compound according to any one of claims 1-10, wherein R3 is an unsubstituted thiadiazol-2-yl.

12. The compound according to any one of claims 1-11, wherein R3 is a thiadiazol-2-yl, substituted with one -(C1-3 alkyl).

13. The compound according to any one of claims 1-12, wherein R3 is an unsubstituted oxazol-5 -yl.

14. The compound according to any one of claims 1-13, wherein R3 is a oxazol-5-yl, substituted with one -(C1-3 alkyl).

15. The compound according to any one of claims 1-14, wherein R6 is -heterocyclyl, optionally substituted with 1-2 R11.

16. The compound according to any one of claims 1-15, wherein R6 is a - Grbheterocyclyl optionally substituted with 1-2 R11.

17. The compound according to any one of claims 1-16, wherein R6 is either a piperidinyl or a pyrrolidinyl both optionally substituted with 1-2 R11.

18. The compound according to any one of claims 1-17, wherein R6 is a piperidinyl substituted with one -N(R15)(R25).

19. The compound according to any one of claims 1-18, wherein R15 and R25 are independently selected from the group consisting of H, Me, and -Ci-t haloalkyl.

20. The compound according to any one of claims 1-19, wherein the compound of Formula I is selected from the group consisting of:

N-(2-( lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)- 1 -isobutylpiperidine-4-carboxamide [1] ;

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)cyclopropanecarboxamide [2];

4,4-difluoro-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)cyclohexane-l-carboxamide

[3];

fr «5-4-methoxy-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)cyclohexane-l- carboxamide [4];

trans-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-4-morpholinocyclohexane- 1 - carboxamide [5];

trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N-(2-( 1 -methyl- 1 H-pyrazol -4 -yl)-l ,6-naphthyridin-7-yl) cyclohexane-1 -carboxamide [6];

trans-N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)-l ,6-naphthyridin-7-yl)-4-((4-methylpiperazin- 1 -yl)

methyl)cyclohexane - 1 -carboxamide [7] ;

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(pyrrolidin-l-yl)acetamide [8];

(S)-2-(3 -fluoropyrrolidin- 1 -yl)-N-(2-( 1 -methyl- 1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)

acetamide [9];

(S)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)tetrahydrofuran-2 -carboxamide [10] ; N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)piperidine-4-carboxamide [11];

1 -methyl -N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7-yl)piperidine -4 -carboxamide [12]; 1 -isopropyl-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4-carboxamide

[13];

1 -(fert-butyl)-N-(2-( 1 -methyl- 1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)piperidine-4-carboxamide

[14];

l-cyclopropyl-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide

[15];

1 -isobutyl-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)piperidine-4-carboxamide

[16]; N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l-neopentylpiperidine-4-carboxamide

[17];

1 -(2-fluoroethyl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)piperidine-4- carboxamide [18];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [19];

1 -butyl -N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)piperidine-4-carboxamide [20] ; 1 -benzoyl -N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4-carboxamide

[21];

l-(2,2-difluoropropyl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)piperidine-4- carboxamide [22];

N-(2-( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)azetidine-3 -carboxamide [23] ;

1 -(2,2-difluoroethyl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4- carboxamide [24];

1 -(2-fluoro-2-methylpropyl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperidine- 4-carboxamide [25];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l-(oxetan-3-yl)piperidine-4- carboxamide [26];

N-(2-( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)- 1 -((3-methyloxetan-3 -yl)methyl)

piperidine-4-carboxamide [27];

1 -(2-methoxyethyl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4- carboxamide [28];

l-(2-isopropoxyethyl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)piperidine-4- carboxamide [29];

1 , 1 -diisobutyl-4-((2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)carbamoyl)piperidin- 1 - ium [30];

4-fluoro-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4-carboxamide [31] ; 4-fluoro- 1 -methyl -N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4- carboxamide [32];

4-fluoro- 1 -isobutyl-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4- carboxamide [33];

(S)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)piperidine-3-carboxamide [34]; (R)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)piperidine-3-carboxamide [35]; (S)- 1 -isobutyl-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperidine-3 -carboxamide

[36];

(R)-l -isobutyl-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperidine-3 -carboxamide

[37];

N-(2-( l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)tetrahydro-2H-pyran-4-carboxamide

[38];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7-y 1) -2-(piperidin- 1 -yl)acetamide [39] ; 2-(4-fluoropiperidin-l -yl)-N-(2-( 1 -methyl- 1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)acetamide

[40];

fr «5-4-amino-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)cyclohexane- 1 - carboxamide [41];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-2-(4 -methylpiperazin- 1 -yl)acetamide

[42];

(S)-N-(2-( l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)piperidine-2 -carboxamide [43]; 2-(4-isobutylpiperazin-l -yl)-N-(2-(l -methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)acetamide

[44];

2-(3,3-dimethylazetidin-l-yl)-N-(2-( l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)acetamide

[45];

(R)-2-(3-fluoropyrrolidin- 1 -yl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)

acetamide [46];

(S)-N-(2-( l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(2-methylpyrrolidin-l -yl)

acetamide [47];

2-(3-azabicyclo[3.1.0]hexan-3 -yl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl) acetamide [48];

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(2-(l -methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl) acetamide [49];

N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperidin- 1 -yl)acetamide

[50];

N-(2-( l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-(trifluoromethyl)piperidin-l -yl) acetamide [51];

2-(4-(difluoromethyl)piperidin-l-yl)-N-(2-( l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl) acetamide [52];

N-(2-( l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(6-azaspiro[2.5]octan-6-yl)acetamide

[53]; N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-2-(pyrrolidin- 1 -yl)propanamide [54] ; (R)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(2-methylpyrrolidin-l-yl)

acetamide [55];

2-(cyclobutyl(methyl)amino)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)acetamide

[56];

2-(diethylamino)-N-(2-( 1 -methyl- 1 H-pyrazol -4 -yl)-l ,6-naphthyridin-7-yl)acetamide [57] ;

7-(2-fluoroethyl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-7-azaspiro[3.5]

nonane-2 -carboxamide [58];

4-methyl-N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7-yl)piperazine - 1 -carboxamide [59] ; (S)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(pyrrolidin-l-yl)propanamide

[60];

(R)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(pyrrolidin-l-yl)propanamide

[61];

(R)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)pyrrolidine-2 -carboxamide [62] ; 2-methyl-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-azaspiro[3.3]heptane-6- carboxamide [63];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(2,2,2-trifluoroacetyl)-2-azaspiro[3.3] heptane-6-carboxamide [64] ;

2-(2-fluoroethyl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-azaspiro[3.3]

heptane-6-carboxamide [65] ;

fr «5-4-(dimethylamino)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)cyclohexane-l- carboxamide [66];

l-acetyl-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide [67]; N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)- 1 -(( 1 -(trifluoromethyl)cyclopropyl) methyl)piperidine -4 -carboxamide [68] ;

(S)-l-(2-fluoropropyl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)piperidine-4- carboxamide [69];

(R)-l-(2-fluoropropyl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)piperidine-4- carboxamide [70];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l-(methylsulfonyl)piperidine-4- carboxamide [71];

l'-methyl-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)-[ 1 ,4'-bipiperidine] -4- carboxamide [72]; fra«s-4-(hydroxymethyl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)cyclohexane- 1 - carboxamide [73];

methyl 2 -(4 -((2-( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 , 6-naphthyridin-7 -yl)carbamoyl)piperidin- 1 -yl) acetate [74];

1- benzyl-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide [75]; N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)- 1 -(2-(pyrrolidin-l -yl)acetyl)piperidine-

4-carboxamide [76];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-moφholinoacetamide [77];

(S)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-2-(3 -methylmo holino)acetamide

[78];

(R)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)-2-(3 -methylmo holino)acetamide

[79];

(S)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(2-methylmo holino)acetamide

[80];

2- ((2R,6S)-2,6-dimethylmoφholino)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl) acetamide [81];

2-((lS,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6- naphthyridin-7-yl)acetamide [82];

2-((lR,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6- naphthyridin-7-yl)acetamide [83];

2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl) acetamide [84];

(S)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-moφholinopropanamide [85]; N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(moφholin-2-yl)acetamide [86]; N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-methylmoφholin-2-yl)acetamide

[87];

2-(4-ethylpiperazin-l-yl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)acetamide [88]; 2-(4-isopropylpiperazin- 1 -yl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)acetamide

[89];

2-(4-cyclopropylpiperazin- 1 -yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)

acetamide [90];

2-(4-(2-fluoroethyl)piperazin- 1 -yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl) acetamide [91]; (S)-2-(2,4-dimethylpiperazin-l-yl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl) acetamide [92];

1 -(2-hydroxyethyl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4- carboxamide [93];

N-(2-( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)- 1 -(pyridin-2-ylmethyl)piperidine-4- carboxamide [94];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l-(oxazol-2-ylmethyl)piperidine-4- carboxamide [95];

(R)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)- 1 -oxotetrahydro- lH-pyrrolo[ 1 ,2-c] imidazole-2(3H)-carboxamide [96];

(R)-l -methyl -N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)pyrrolidine-2-carboxamide

[97];

N-(2-( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)- 1 -(tetrahydro-2H-pyran-4-yl)piperidine- 4-carboxamide [98];

N-(2-( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)- 1 -(pyrimidin-2-ylmethyl)piperidine-4- carboxamide [99];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l-(pyrazin-2-ylmethyl)piperidine-4- carboxamide [100];

1 -((5 -methyl- 1 ,2,4-oxadiazol-3-yl)methyl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7- yl)piperidine-4-carboxamide [101];

1 -(2-hydroxy-2-methylpropyl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)

piperidine-4-carboxamide [102];

fert-butyl 2-(4-((2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)carbamoyl)piperidin-l- yl)acetate [103];

2-(4-((2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)carbamoyl)piperidin-l -yl)acetic acid

[104];

2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)

acetamide [105];

fert-butyl (2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)carbamate [106];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)but-2-ynamide [107];

trans-4-((2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)carbamoyl)cyclohexane- 1 - carboxylic acid [108];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-3-moφholinopropanamide [109]; trans-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-3-moφholinocyclobutane- 1 - carboxamide [110];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)quinuclidine-4-carboxamide [111]; N-(2-( 1 -methyl-lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)-2-(piperidin- 1 -yl)propanamide [112]; 1 -isobutyl-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)azepane-4-carboxamide [113]; 2-(4-methoxypiperidin- 1 -yl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)acetamide

[114];

2- (4-hydroxypiperidin-l -yl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)acetamide

[115];

3- (hydroxymethyl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)bicyclo[ 1.1.1]

pentane-1 -carboxamide [116];

1 -methyl -N-(2-( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)azepane-4-carboxamide [117]; fr «5-4-(dimethylamino)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)cyclohexane-l- carboxamide [118];

fr «5-4-(bis(methyl-£/3)amino)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)

cyclohexane-1 -carboxamide [119];

N-(2-( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-3-((4-methylpiperazin- 1 -yl)methyl) bicyclo[l .1. l]pentane-l -carboxamide [120];

methyl trans-4-((2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)carbamoyl)cyclohexane- 1 - carboxylate [121];

2-( 1 -isobutylpyrrolidin-3 -yl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)acetamide

[122];

trans -N-(2-( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 , 6-naphthyridin-7-yl) -4 -(4 -methylpiperazine - 1 - carbonyl)cyclohexane- 1 -carboxamide [123] ;

1 -isobutyl-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)piperidine-4-carboxamide

[124];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l-(phenylsulfonyl)piperidine-4- carboxamide [125];

8 -methyl -N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7-yl) -3 , 8 -diazabicyclo [3.2.1] octane - 3-carboxamide [126];

3 -methyl -N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7-yl) -3 , 8 -diazabicyclo [3.2.1] octane - 8-carboxamide [127];

(lR,3s,5S)-3-amino-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-8-azabicyclo[3.2.1] octane-8-carboxamide [128]; (lR,3s,5S)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-3-((3,3,3-trifluoropropyl) amino)-8 -azabicyclo [3.2.1] octane -8 -carboxamide [ 129] ;

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6- naphthyridin-7-yl)-8-azabicyclo[3.2. l]octane-8-carboxamide [130];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)morpholine -4 -carboxamide [131];

4-(dimethylamino)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperidine- 1 - carboxamide [132];

(S)-2,4-dimethyl-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)piperazine- 1 - carboxamide [133];

1 -methyl-3 -(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7-yl) - 1 -( 1 -methylpiperidin-4 -yl)urea

[134];

1 -(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-3 -( 1 -methylpiperidin-4-yl)urea [135] ; 4-isopropyl-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperazine-l -carboxamide

[136];

(R)-3,4-dimethyl-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)piperazine- 1 - carboxamide [137];

N-(2-( lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l -yl)isonicotinamide [138] ; N-(2-( 1 -methyl-lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)-3 -(piperazin- 1 -yl)benzamide [139] ; N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-3 -(4 -methylpiperazin- 1 -yl)benzamide

[140];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-3 -(pyrrolidin- 1 -ylmethyl)benzamide

[141];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-3-(piperidin-4-yloxy)benzamide [142]; N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-3 -(( 1 -methylpiperidin-4-yl)oxy)

benzamide [143];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7-y 1) -4 -(piperidin-4-yloxy)benzamide [144]; N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-4-(( 1 -methylpiperidin-4-yl)oxy)

benzamide [145];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(piperazin-l-yl)isonicotinamide [146]; N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-2-(4 -methylpiperazin- 1 -yl)

isonicotinamide [147];

2-(4-isopropylpiperazin- 1 -yl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)

isonicotinamide [148]; 2-(4-cyclopropylpiperazin- 1 -yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl) isonicotinamide [149];

2-(4-(2-fluoroethyl)piperazin- 1 -yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl) isonicotinamide [150];

N-(2-( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-6-(4-methylpiperazin- 1 -yl)nicotinamide

[151];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-5-(piperidin-4-yloxy)nicotinamide

[152];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(piperidin-4-yloxy)isonicotinamide

[153];

N-(2-( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-2-(( 1 -methylpiperidin-4-yl)oxy)

isonicotinamide [154];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7-y 1) -5 -(piperidin-4-ylamino)nicotinamide

[155];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-5 -(( 1 -methylpiperidin-4-yl)amino) nicotinamide [156];

2-(4-aminopiperidin-l-yl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)

isonicotinamide [157];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-(methylamino)piperidin-l-yl) isonicotinamide [158];

2-(4-(dimethylamino)piperidin-l -yl)-N-(2-( 1 -methyl- 1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl) isonicotinamide [159];

2-(( 1 -isopropylpiperidin-4-yl)oxy)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl) isonicotinamide [160];

2-(3 -aminoazetidin- 1 -yl)-N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)

isonicotinamide [161];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl) isonicotinamide [162];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-mo holinoisonicotinamide [163]; 2-((2-(dimethylamino)ethyl)amino)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl) isonicotinamide [164];

2-(2-(dimethylamino)ethoxy)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)

isonicotinamide [165]; 2-(4-isobutylpiperazin-l-yl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl) isonicotinamide [166];

2-(azetidin-3 -yloxy)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide

[167];

N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-2-(( 1 -methylazetidin-3 -yl)oxy)

isonicotinamide [168];

2-(4-ethylpiperazin-l-yl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)

isonicotinamide [169];

4-((dimethylamino)methyl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)benzamide

[170];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-3 -( 1 -methylpiperidin-4 -yl)benzamide

[171];

N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-3-((4-methylpiperazin- 1 -yl)methyl) benzamide [172];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)isonicotinamide [173];

2-hydroxy-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)isonicotinamide [174];

2-isopropoxy-N-(2-( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 , 6 -naphthyridin-7 -yl)isonicotinamide [ 175] ; N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-2-( 1 -methylpiperidin-4 -yl)

isonicotinamide [176];

r-methyl-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-r,2',3',6'-tetrahydro-[2,4'- bipyridine]-4-carboxamide [177];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-(6-(4-methylpiperazin-l-yl)

nicotinoyl)piperazin- 1 -yl)isonicotinamide [178] ;

2-(4-hydroxy-4-methyl-4 4-piperazin-l-yl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7- yl)isonicotinamide [179];

2- methyl-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-6-(4-methylpiperazin-l-yl) isonicotinamide [180];

3- methyl-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [181];

2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)

isonicotinamide [182];

2-((2S,6R)-2,6-dimethylmo holino)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl) isonicotinamide [183]; N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(2J-diazaspiro[3.5]nonan-2-yl) isonicotinamide [184];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(7-methyl-2 -diazaspiro[3.5]nonan-

2-yl)isonicotinamide [185];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(2,7-diazaspiro[3.5]nonan-7-yl)

isonicotinamide [186];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(2-methyl-2,7-diazaspiro[3.5]nonan-

7-yl)isonicotinamide [187];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7- yl)isonicotinamide [188];

N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-2-(( 1 -methylpiperidin-4-yl)thio)

isonicotinamide [189];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-2-(4 -methylpiperazin- 1 -yl)pyrimidine - 4-carboxamide [190];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-6-(4 -methylpiperazin- 1 -yl)pyridazine -4 - carboxamide [191];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-6-(4 -methylpiperazin- 1 -yl)pyrimidine -

4-carboxamide [192];

N-(2 -( 1 -methyl - 1 H-pyrazol -4-yl) - 1 ,6 -naphthyridin-7-yl) -2 -phenylacetamide [193];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-3-phenylpropanamide [194];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(pyridin-3-yl)acetamide [195];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-3 -(pyridin-3 -yl)propanamide [196]; N-(2-( 1 -methyl -1 H-pyrazol -4-yl)- 1 ,6-naphthyridin-7-yl)-2-(pyridin-4-yl)acetamide [197] ;

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-3-(pyridin-4-yl)propanamide [198]; N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)isoindoline-5-carboxamide [199];

2-methyl-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)isoindoline-5-carboxamide

[200];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l,2,3,4-tetrahydroisoquinoline-7- carboxamide [201];

2-methyl-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l,2,3,4- tetrahydroisoquinoline-7 -carboxamide [202] ;

2-methyl-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l,2,3,4- tetrahydroisoquinoline-6-carboxamide [203] ; N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l,2,3,4 etrahydroisoquinoline-6- carboxamide [204];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7-yl) - 1 H-indole-5 -carboxamide [205] ;

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)benzofuran-5-carboxamide [206];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)furo[2,3-c]pyridine-5-carboxamide

[207];

N-(2 -( 1 -methyl - 1 H-pyrazol-4-yl) -1,6 -naphthyridin-7 -yl)benzo [b]thiophene -5 -carboxamide [208] ; N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)benzofuran-6-carboxamide [209];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)benzo [d] oxazole -6 -carboxamide [210]; N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)benzo[d]thiazole-6-carboxamide [211]; N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)benzo [d] oxazole -5 -carboxamide [212]; N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)benzo[d]thiazole-5-carboxamide [213]; N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)quinoline -3 -carboxamide [214];

N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)quinoline-6-carboxamide [215] ;

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)quinoxaline-6-carboxamide [216];

5-chloro-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [217];

3-chloro-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [218];

2- (2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7- yl)isonicotinamide [219];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(5-methyl-2,5-diazabicyclo[2.2.1] heptan-2-yl)isonicotinamide [220] ;

3- fluoro-N-(2-( 1 -methyl- 1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl) isonicotinamide [221];

N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-2-((4-methylpiperazin- 1 -yl)methyl) isonicotinamide [222];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(mo holinomethyl)isonicotinamide

[223];

N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-2-(pyrrolidin- 1 -ylmethyl)

isonicotinamide [224];

N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-2-(2-(4-methylpiperazin- 1 -yl)pyridin-4- yl)acetamide [225]; 1 -methyl -N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7-yl) - 1 H-indazole -5 -carboxamide

[226];

1 -methyl -N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7-yl) - 1 H-benzo [d] imidazole-5 - carboxamide [227];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l-(piperidin-4-yl)-lH-pyrazole-4- carboxamide [228];

N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- pyrazole -4 -carboxamide [229];

1 -( 1 -ethylpiperidin-4-yl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)- lH-pyrazole-

4-carboxamide [230];

1 -( 1 -(2-fluoroethyl)piperidin-4-yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-lH- pyrazole -4 -carboxamide [231];

1- (l-isopropylpiperidin-4-yl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-lH- pyrazole -4 -carboxamide [232];

1 -( 1 -cyclopropylpiperidin-4-yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)- 1H- pyrazole -4 -carboxamide [233];

isopropyl 4-(4-((2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)carbamoyl)-lH-pyrazol-l- yl)piperidine-l-carboxylate [234];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l-(piperidin-4-yl)-lH-l,2,3-triazole-4- carboxamide [235];

N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- 1,2,3- triazole -4 -carboxamide [236];

1 -( 1 -(2-fluoroethyl)piperidin-4-yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-lH- l,2,3-triazole-4-carboxamide [237];

1 -( 1 -isopropylpiperidin-4-yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-lH-l ,2,3 - triazole -4 -carboxamide [238];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-2-(4 -methylpiperazin- 1 -yl)oxazole -5 - carboxamide [239];

2- (3 -(dimethylamino)azetidin- 1 -yl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl) oxazole -4 -carboxamide [240];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(piperidin-4-yl)oxazole-4- carboxamide [241];

N-(2-( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-2-( 1 -methylpiperidin-4-yl)oxazole-4- carboxamide [242]; 2-( 1 -(2-fluoroethyl)piperidin-4-yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl) oxazole-4-carboxamide [243];

2-( 1 -isopropylpiperidin-4-yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)oxazole-4- carboxamide [244];

N-(2 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl)-2-(4 -methylpiperazin- 1 -yl)oxazole -4 - carboxamide [245];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl) thiazole-5 -carboxamide [246];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(piperidin-4-yl)thiazole-4- carboxamide [247];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)thiazole-4- carboxamide [248];

2-( 1 -(2-fluoroethyl)piperidin-4-yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl) thiazole-4-carboxamide [249] ;

2-( 1 -isopropylpiperidin-4-yl)-N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)thiazole-4- carboxamide [250];

l-methyl-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl-8-£/)piperidine-4-carboxamide

[251];

N-(2-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)- 1 -(2-(methyl-£¾)propyl- 1 , 1 ,2,3,3,3- 6) piperidine-4-carboxamide [252];

N^-il-methyl-lH-pyrazol^-y^-l^-naphthyridin^-y^^-ipyrrolidin-l-yl^^^^-i ^acetamide

[253];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-(methyl-£/3)piperazin-l-yl)

acetamide [254];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(moφholino-ί s)acetamide [255]; ( S) -N-(2 -( 1 -(methyl -ds) - 1 H-pyrazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl) -2 -(pyrrolidin- 1 -yl)propanamide

[256];

1 -isobutyl-N-(2-( 1 -(methyl -<¾)-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4-carboxamide

[257];

N-(2-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl)

acetamide [258];

N-(2-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-2-(pyrrolidin-l -yl)acetamide [259] ; N-(2-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-2-(piperidin-l -yl)acetamide [260] ; N-(2-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)- 1 -(3,3,3 -trifluoropropyl)piperidine- 4-carboxamide [261];

N-(2-(lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-(methyl- 3)piperazin-l-yl)isonicotinamide

[262];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-(methyl-£/3)piperazin-l-yl)

isonicotinamide [263];

N-(2-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [264];

N-(2-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-2-(4-(methyl-<i3)piperazin- 1 -yl) isonicotinamide [265];

N-(2-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)- 1 -(piperidin-4-yl)-lH-pyrazole-4- carboxamide [266];

N-(2-( 1 -(methyl-^)- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-l -( 1 -methylpiperidin-4-yl)-lH- pyrazole-4-carboxamide [267];

N-(2-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,6-naphthyridin -7 -yl)-2-(piperidin-4-yl)oxazole-4- carboxamide [268];

N-(2-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-2-( 1 -methylpiperidin-4-yl)oxazole- 4-carboxamide [269];

N-(2-( 1 -ethyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)-2-(pyrrolidin-l -yl)acetamide [270] ;

N-(2-( l-cyclopropyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2 -(pyrrolidin-1 -yl)acetamide [271]; N-(2-(l-cyclopropyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l-(3,3,3-trifluoropropyl)piperidine-

4-carboxamide [272];

N-(2-( 1 -( 1 -methylpiperidin-4-yl)-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)

cyclohexanecarboxamide [273];

2-(pyrrolidin- 1 -yl)-N-(2-(5-(trifluoromethyl)- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)acetamide

[274];

N-(2-(5-(hydroxymethyl)-l -methyl-lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)-l -methylpiperidine- 4-carboxamide [275];

N-(2-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)tetrahydro-2H-pyran-

4-carboxamide [276];

N-(2-(5-(azetidin-l-ylmethyl)-l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-4,4- difluorocyclohexane- 1 -carboxamide [277] ;

4,4-difluoro-N-(2-( 1 -methyl -5 -(pyrrolidin-1 -ylmethyl)- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl) cyclohexane-1 -carboxamide [278]; 4,4-difluoro-N-(2-( 1 -methyl -5 -(piperidin-1 -ylmethyl)- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl) cyclohexane-l-carboxamide [279];

2-(2 -fluoroethyl) -N-(2 -( 1 -methyl -5 -(piperidin- 1 -ylmethyl) - 1 H-pyrazol -4 -yl) - 1 , 6-naphthyridin-7- yl)-2-azaspiro[3.3]heptane-6-carboxamide [280] ;

fert-butyl 6-((2-( 1 -methyl -5 -(piperidin- 1 -ylmethyl) -1 H-pyrazol -4 -yl)-l ,6-naphthyridin-7- yl)carbamoyl)-2-azaspiro[3.3]heptane-2-carboxylate [281] ;

2-fluoro-2 -methyl -N-(2-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7- yl)propanamide [282];

2-(diethylamino)-N-(2-( 1 -methyl-5 -(piperidin- 1 -ylmethyl) -1 H-pyrazol -4 -yl)-l ,6-naphthyridin-7- yl)acetamide [283];

fr «5-4-methoxy-N-(2-(l -methyl -5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-l,6-naphthyridin-7- yl)cyclohexane - 1 -carboxamide [284] ;

fr «5-4-(hydroxymethyl)-N-(2-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,6- naphthyridin-7 -yl)cyclohexane - 1 -carboxamide [285] ;

(R)-N-(2-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)pyrrolidine-

2-carboxamide [286];

l-isobutyl-N-(2-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl) piperidine-4-carboxamide [287];

N-(2-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)- 1 -(oxetan-3- yl)piperidine -4 -carboxamide [288] ;

1 -benzoyl -N-(2-( 1 -methyl -5 -(piperidin-1 -ylmethyl)- 1 H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl) piperidine-4-carboxamide [289];

N-(2-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)tetrahydro-2H- pyran-4-carboxamide [290];

N-(2-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)-2-(4- methylpiperidin- 1 -yl)acetamide [291] ;

N-(2-( 1 -(difluoromethyl)-l H-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl) isonicotinamide [292];

N-(2-( 1 -ethyl- 1 H-pyrazol-4-yl) - 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [293];

N-(2-(l-isopropyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-3-(piperidin-4-yloxy)benzamide

[294];

N-(2-(l-isopropyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-3-((l-methylpiperidin-4-yl)oxy) benzamide [295]; N-(2-(l-isopropyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-4-(piperidin-4-yloxy)benzamide [296];

N-(2-( 1 -cyclopropyl-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [297];

4-fluoro-N-(2-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)benzamide

[298];

4- (difluoromethoxy)-N-(2-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl) benzamide [299];

5- fluoro-N-(2-(l-(l-methylpiperidin-4-yl)-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)nicotinam

[300];

N2 -methyl -N5-(2-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)pyridine-

2,5-dicarboxamide [301];

1 -isopropyl-N-(2-( 1 -( 1 -methylpiperidin-4-yl)-lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-lH- pyrazole-4-carboxamide [302];

2-methyl-N-(2-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)thiazole-5- carboxamide [303];

N-(2-(5-amino-l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [304];

4-(difluoromethoxy)-N-(2-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl) benzamide [305];

N-(2-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4- methylpiperazin-l-yl)isonicotinamide [306];

N-(2-(5-(hydroxymethyl)- 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl)-2-(7-methyl-2,7- diazaspiro[3.5]nonan-2-yl)isonicotinamide [307];

4-fluoro-N-(2-(l-methyl-5-(pyrrolidin-l-ylmethyl)-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl) benzamide [308];

4-fluoro-N-(2-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)

benzamide [309];

4-(difluoromethoxy)-N-(2-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-l,6- naphthyridin-7-yl)benzamide [310];

N-(2-( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)-3-(pyrrolidin-

1 -ylmethyl)benzamide [311];

N-(2-( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l , 6-naphthyridin-7 -yl)-2-(7-methyl-

2,7-diazaspiro[3.5]nonan-2-yl)isonicotinamide [312]; N-(2-( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)-2- moφholinoisonicotinamide [313];

N-(2-( 1 -methyl -5 -^ο ^1ίηοΓηεΐ1τγ1)-1Η^^ο1-4^1)- 1 ,6-naphthyridin-7-yl)-2- moφholinoisonicotinamide [314];

N-(2-(4,5 ,6,7-tetrahydropyrazolo[ 1 ,5-a]pyrazin-3 -yl)-l ,6-naphthyridin-7-yl)- 1 -(( 1 -

(trifluoromethyl)cyclopropyl)methyl)piperidine -4 -carboxamide [315];

3,3-difluoro-N-(2-(5-methyl-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,6-naphthyridin-7- yl)cyclobutane - 1 -carboxamide [316];

N-((4,4-difluorocyclohexyl)methyl)-2-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a] pyrazin-3-yl)-l,6-naphthyridin-7 -amine [317];

N-(2-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)-l-

(( 1 -(trifluoromethyl)cyclopropyl)methyl)piperidine-4-carboxamide [318] ;

N-(2-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)-2-

(pyrrolidin- 1 -yl)acetamide [319] ;

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(2-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5- a]pyrazin-3-yl)- 1 ,6-naphthyridin-7-yl)acetamide [320] ;

(R)-N-(2-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[ 1 ,5 -a]pyrazin-3 -yl)-l ,6-naphthyridin-7- yl)-l-isobutylpiperidine-3-carboxamide [321];

N-(2-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl) piperidine-4-carboxamide [322];

4-fluoro-N-(2-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,6- naphthyridin-7-yl)- 1 -isobutylpiperidine-4-carboxamide [323] ;

N-(2-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)-2-

(4-methylpiperazin- 1 -yl)acetamide [324] ;

4-fluoro-N-(2-(4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)benzamide

[325];

N-(2-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)-3-

(4-methylpiperazin- 1 -yl)benzamide [326] ;

N5-(2-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)-

N2-methylpyridine-2,5 -dicarboxamide [327] ;

N-(2-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)-6-

(4-methylpiperazin- 1 -yl)nicotinamide [328] ;

2-(azetidin-3-yloxy)-N-(2-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,6- naphthyridin-7-yl)isonicotinamide [329] ; N-(2-(l-methyl-lH-pyrazol-5-yl)-l,6-naphthyridin-7-yl)-l-(3,3,3 rifluoropropyl)piperidine-4- carboxamide [330];

1 -methyl -N-(2 -( 1 -methyl - 1 H-pyrazol -3 -yl) - 1 ,6 -naphthyridin-7-yl)piperidine -4 -carboxamide

[331];

N-(2 -( 1 -methyl - 1 H-pyrazol -3 -yl) - 1 ,6 -naphthyridin-7 -yl)-2-(4 -methylpiperazin- 1 -yl)

isonicotinamide [332];

2-fluoro-2 -methyl -N-(2-( 1 -methyl-lH- 1 ,2,3 -triazol-4-yl)-l ,6-naphthyridin-7-yl)propanamide

[333];

2,2,3, 3-tetramethyl-N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)cyclopropane-l- carboxamide [334];

fr «5-N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-4-(pyrrolidin-l-yl)

cyclohexane - 1 -carboxamide [335] ;

fr rø-N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-4-mo holinocyclohexane-l- carboxamide [336];

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-2-(piperidin-l-yl)acetamide [337]; 1 -ethyl -4-fluoro-N-(2-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)-l ,6-naphthyridin-7-yl)piperidine-4- carboxamide [338];

4-fluoro- 1 -isobutyl-N-(2-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)-l ,6-naphthyridin-7-yl)piperidine-4- carboxamide [339];

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-l-(3,3,3-trifluoropropyl)piperidine- 4-carboxamide [340];

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)cyclopropanecarboxamide [341]; 4,4-difluoro-N-(2-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)- 1 ,6-naphthyridin-7-yl)cyclohexane- 1 - carboxamide [342];

fr «5-4-(dimethylamino)-N-(2-( 1 -methyl-lH- 1 ,2,3-triazol-4-yl)- 1 ,6-naphthyridin-7-yl)

cyclohexane - 1 -carboxamide [343] ;

fr «5-N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-4-((4-methylpiperazin-l-yl) methyl)cyclohexane - 1 -carboxamide [344] ;

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide [345]; 1 -isobutyl-N-(2-( 1 -methyl- lH-1 ,2,3-triazol-4-yl)-l ,6-naphthyridin -7 -yl)piperidine-4- carboxamide [346];

N-(2-( 1 -methyl- lH-1 ,2,3-triazol-4-yl)- 1 ,6-naphthyridin -7 -yl)- 1 -(( 1 -(trifluoromethyl)cyclopropyl) methyl)piperidine -4 -carboxamide [347] ; N-(2-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,6-naphthyridin-7-yl)- 1 -((3-methyloxetan-3 -yl)methyl) piperidine-4-carboxamide [348];

N-(2-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,6-naphthyridin-7-yl)- 1 -(2-(pyrrolidin- 1 -yl)acetyl)

piperidine-4-carboxamide [349];

1 '-methyl-N-(2-( 1 -methyl- lH-1 ,2,3 -triazol-4-yl)-l ,6-naphthyridin-7-yl)-[ 1 ,4'-bipiperidine] -4- carboxamide [350];

(R)-N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)piperidine-3-carboxamide [351]; (R)-l-isobutyl-N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)piperidine-3- carboxamide [352];

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-2-(pyrrolidin-l-yl)acetamide [353]; N-(2-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl)

acetamide [354];

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl) acetamide [355];

1 -(2-hydroxy-2-methylpropyl)-N-(2-( 1 -methyl- IH- 1 ,2,3-triazol-4-yl)- 1 ,6-naphthyridin-7-yl) piperidine-4-carboxamide [356];

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-2-moφholinoacetamide [357]; 2-(4-methoxypiperidin-l-yl)-N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)

acetamide [358];

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)mo holine-4-carboxamide [359]; N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-l-(piperidin-4-yl)-lH-pyrazole-4- carboxamide [360];

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-l-(l-methylpiperidin-4-yl)-lH- pyrazole-4-carboxamide [361];

1 -( 1 -ethylpiperidin-4-yl)-N-(2-( 1 -methyl- IH- 1 ,2,3 -triazol-4-yl)- 1 ,6-naphthyridin-7-yl)-lH- pyrazole-4-carboxamide [362];

l-(l-isopropylpiperidin-4-yl)-N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-lH- pyrazole-4-carboxamide [363];

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-l-(piperidin-4-yl)-lH-l,2,3- triazole-4-carboxamide [364];

1 -( 1 -(2-fluoroethyl)piperidin-4-yl)-N-(2-( 1 -methyl-lH- 1 ,2,3-triazol-4-yl)-l ,6-naphthyridin-7-yl)- lH-l,2,3-triazole-4-carboxamide [365];

l-(l-isopropylpiperidin-4-yl)-N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-lH- l,2,3-triazole-4-carboxamide [366]; N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-2-(piperidin-4-yl)oxazole-4- carboxamide [367];

N-(2-(l-methyl-lH-l,2,3 riazol-4-yl)-l,6-naphthyridin-7-yl)-2-(l-methylpiperidin-4-yl)oxazole- 4-carboxamide [368];

2-( 1 -isopropylpiperidin-4-yl)-N-(2-( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)-l ,6-naphthyridin-7-yl) oxazole-4-carboxamide [369];

2-fluoro-N-(2-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)-l ,6-naphthyridin-7-yl)benzamide [370] ;

N-(2-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,6-naphthyridin-7-yl)-3 -(( 1 -methylpiperidin-4-yl)oxy) benzamide [371];

N2-methyl-N5-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)pyridine-2,5- dicarboxamide [372];

N-(2-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,6-naphthyridin-7-yl)-6-(4-methylpiperazin- 1 -yl)

nicotinamide [373];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(2-( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)- 1 ,6-naphthyridin-7-yl) isonicotinamide [374];

N-(2-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,6-naphthyridin-7-yl)-2-( 1 -methylpiperidin-4-yl)

isonicotinamide [375];

2-(4-(dimethylamino)piperidin-l-yl)-N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7- yl)isonicotinamide [376];

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-2-moφholinoisonicotinamide

[377];

N-(2-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [378];

2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(2-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)-l ,6-naphthyridin-7-yl) isonicotinamide [379];

2-(4-isopropylpiperazin-l -yl)-N-(2-( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)-l ,6-naphthyridin-7-yl) isonicotinamide [380];

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-2-(piperidin-4-ylamino)

isonicotinamide [381];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(2-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)-l ,6- naphthyridin-7-yl)isonicotinamide [382] ;

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-2-((l-methylpiperidin-4-yl)thio) isonicotinamide [383]; 2-methyl-N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-l,2,3,4- tetrahydroisoquinoline-6-carboxamide [384] ;

N-(2-(l-methyl-lH-l,2,3 riazol-4-yl)-l,6-naphthyridin-7-yl)-2-(piperazin-l-yl)isonicotinami

[385];

N-(2-(l-methyl-lH-l,2,3 riazol-4-yl)-l,6-naphthyridin-7-yl)-2-(2-(4-methylpiperazin-l-yl) pyridin-4-yl)acetamide [386];

1 , 1 -bis(methyl-£¾)-4-(4-((2-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)- 1 ,6-naphthyridin-7-yl)carbamoyl) pyridin-2-yl)piperazin- 1 -ium [387] ;

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-(methyl-d3)piperazin-l-yl) isonicotinamide [388];

N-(2-(l-methyl-lH-l,2,3-triazol-5-yl)-l,6-naphthyridin-7-yl)-l-(3,3,3-trifluoropropyl)piperidine- 4-carboxamide [389];

N-(2-(4-methyl-4H-l ,2,4-triazol-3 -yl)- 1 ,6-naphthyridin-7-yl)-2-moφholinoacetamide [390] ; N-(2-(4-methyl-4H-l ,2,4-triazol-3 -yl)- 1 ,6-naphthyridin-7-yl)- 1 -(3,3,3 -trifluoropropyl)piperidine- 4-carboxamide [391];

4-fluoro- 1 -isobutyl-N-(2-(4-methyl-4H- 1 ,2,4-triazol-3 -yl)-l ,6-naphthyridin-7-yl)piperidine-4- carboxamide [392];

N-(2-(4,5-dimethyl-4H-l,2,4-triazol-3-yl)-l,6-naphthyridin-7-yl)-2-moφholinoacetamide [393]; N-(2-(4,5-dimethyl-4H-l,2,4-triazol-3-yl)-l,6-naphthyridin-7-yl)-l-(3,3,3-trifluoropropyl)

piperidine-4-carboxamide [394];

N-(2-( 1H- 1 ,2,3 -triazol-1 -yl)- 1 ,6-naphthyridin-7-yl)-4-fluoro- 1 -isobutylpiperidine-4-carboxamide

[395];

N-(2-(2H- 1 ,2,3 -triazol-2-yl)- 1 ,6-naphthyridin-7-yl)-4-fluoro- 1 -isobutylpiperidine-4-carboxamide

[396];

N-(2-( 1H- 1 ,2,4-triazol-l -yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l -yl)isonicotinamide

[397];

1 -isobutyl-N-(2-( 1 -methyl- lH-tetrazol-5-yl)-l ,6-naphthyridin-7-yl)piperidine-4-carboxamide

[398];

2,2,3, 3-tetramethyl-N-(2-( 1 -methyl -IH-imidazol -5 -yl)- 1 ,6-naphthyridin-7-yl)cyclopropane- 1 - carboxamide [399];

4,4-difluoro-N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)cyclohexane-l- carboxamide [400];

N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(piperidin-l-yl)acetamide [401]; 2 -fluoro-2 -methyl -N-(2-( 1 -methyl -IH-imidazol -5 -yl)- 1 ,6-naphthyridin-7-yl)propanamide [402] ; 1 -fluoro-N-(2-( 1 -methyl- lH-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)cyclopropane- 1 -carboxamide

[403];

2-methyl-N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-azaspiro[3.3]heptane-6- carboxamide [404];

1 -fluoro -N-(2 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 , 6-naphthyridin-7-yl)cyclohexane - 1 -carboxamide

[405];

fr «5-4-methoxy-N-(2-( 1 -methyl- lH-imidazol-5-yl)- 1 ,6-naphthyridin-7-yl)cyclohexane-l - carboxamide [406];

fr «5-4-(hydroxymethyl)-N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)cyclohexane- 1 -carboxamide [407];

N-(2 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 , 6-naphthyridin-7 -yl)azetidine -3 -carboxamide [408] ;

(R) -N-(2 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 , 6-naphthyridin-7 -yl)tetrahydrofuran-2 -carboxamide

[409];

1- (2-methoxyethyl)-N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)piperidine-4- carboxamide [410];

N-(2 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 , 6-naphthyridin-7 -yl) - 1 -(3 , 3 ,3 -trifluoropropyl)piperidine -4 - carboxamide [411];

1 -isobutyl-N-(2-( 1 -methyl- lH-imidazol-5-yl)-l ,6-naphthyridin -7 -yl)piperidine-4-carboxamide

[412];

N-(2-( 1 -methyl-lH-imidazol-5-yl)- 1 ,6-naphthyridin-7-yl)- 1 -(methylsulfonyl)piperidine-4- carboxamide [413];

N-(2-( 1 -methyl-lH-imidazol-5-yl)- 1 ,6-naphthyridin -7 -yl)-2-(pyrrolidin- 1 -yl)propanamide [414] ;

2- isopropoxy-N-(2-( 1 -methyl- lH-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)acetamide [415] ;

3- isopropoxy-N-(2-( 1 -methyl -1 H-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)propanamide [416] ; N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)cyclopropanecarboxamide [417]; N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)cyclohexanecarboxamide [418]; N-(2-( 1 ,2-dimethyl- lH-imidazol-5-yl)-l ,6-naphthyridin-7-yl)-4,4-difluorocyclohexane- 1 - carboxamide [419];

(S)-N-(2-( 1 ,2-dimethyl- lH-imidazol-5 -yl)- 1 ,6-naphthyridin -7 -yl)tetrahydrofuran-2 -carboxamide

[420];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-3,3-difluorocyclobutane-l- carboxamide [421];

N-(2-( 1 ,2-dimethyl- lH-imidazol-5-yl)-l ,6-naphthyridin-7-yl)- 1 -fluorocyclopropane-1 - carboxamide [422]; N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridm^ [423]; N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridm^

[424];

1 -methyl -N-(2-( 1 -methyl- 1 H-imidazol-5 ^

[425];

l-ethyl-N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-lH-pyrazole-4-carboxamide

[426];

1 -isopropyl-N-(2-( 1 -methyl- lH-imidazol-5-yl)- 1 ,6-naphthyridin-7-yl)- lH-pyrazole-4- carboxamide [427];

1 -cyclopropyl-N-(2-( 1 -methyl -lH-imidazol -5 -yl)- 1 ,6-naphthyridin-7-yl)- lH-pyrazole-4- carboxamide [428];

1- isobutyl-N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-lH-pyrazole-4-carboxamide

[429];

1 -methyl -N-(2 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 ,6 -naphthyridin-7 -yl) - 1 H-pyrazole -3 -carboxamide

[430];

N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(l-methyl-lH-pyrazol-4-yl)

acetamide [431];

1 -methyl -N-(2 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 ,6 -naphthyridin-7 -yl) - 1 H-imidazole -4 -carboxamide

[432];

1 -isopropyl-N-(2-( 1 -methyl- lH-imidazol-5-yl)- 1 ,6-naphthyridin-7-yl)- lH-imidazole-4- carboxamide [433];

N-(2-( 1 -methyl-lH-imidazol-5-yl)-l ,6-naphthyridin-7-yl)- 1 -(tetrahydro-2H-pyran-4-yl)- 1H- imidazole -4 -carboxamide [434] ;

1 ,2-dimethyl-N-(2-( 1 -methyl -1 H-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)- lH-imidazole-5- carboxamide [435];

1 -methyl-N-(2-( 1 -methyl-lH-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)-lH-l ,2,4-triazole-3 - carboxamide [436];

2- methyl-N-(2-( 1 -methyl-lH-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)oxazole-4-carboxamide [437] ; 2-isopropyl-N-(2-( 1 -methyl- lH-imidazol-5-yl)- 1 ,6-naphthyridin-7-yl)oxazole-4-carboxamide

[438];

4-methyl-N-(2-( 1 -methyl-lH-imidazol-5 -yl)- 1 ,6-naphthyridin -7 -yl)oxazole-2 -carboxamide [439] ; 4-methyl-N-(2-( 1 -methyl-lH-imidazol-5 -yl)- 1 ,6-naphthyridin -7 -yl)thiazole-2 -carboxamide [440] ; 2-methyl-N-(2-( 1 -methyl-lH-imidazol-5 -yl)- 1 ,6-naphthyridin -7 -yl)thiazole -4 -carboxamide [441] ; 5 -methyl -N-(2 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 ,6 -naphthyridin-7 -yl) - 1 , 3 ,4 -oxadiazole -2 - carboxamide [442];

5 -methyl -N-(2 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 ,6 -naphthyridin-7 -yl) - 1 , 3 ,4 -thiadiazole -2 - carboxamide [443];

1 -isopropyl -N-(2-( 1 -isopropyl- lH-imidazol-5-yl)- 1 ,6-naphthyridin-7-yl)- lH-pyrazole-4- carboxamide [444];

N-(2-( 1 ,2-dimethyl- lH-imidazol-5-yl)-l ,6-naphthyridin-7-yl)- 1 -methyl- lH-pyrazole-4- carboxamide [445];

N-(2-( l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-l-isopropyl-lH-pyrazole-4- carboxamide [446];

N-(2-( l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-methylthiazole-5-carboxamide

[447];

4-fluoro-N-(2-( 1 -methyl- lH-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)benzamide [448] ;

4-(difluoromethoxy)-N-(2-( l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)benzamide [449]; N-(2 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 , 6-naphthyridin-7 -yl) -3 -(pyrrolidin- 1 -ylmethyl)benzamide

[450];

2-fluoro-N-(2-( l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)benzamide-3,4,5,6-£/4 [451] ; 4-fluoro-N-(2-( l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)benzamide-2,3,5,6-£/4 [452] ; 2-chloro-N-(2-( l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)benzamide-3,4,5,6-£/4 [453]; 4-chloro-N-(2-( 1 -methyl- 1 H-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)benzamide-2,3 ,5,6-d4 [454] ; 4-(methyl-£/3)-N-(2-(l -methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)benzamide [455];

4-methyl-N-(2-( 1 -methyl-lH-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)benzamide-2,3 ,5,6-d4 [456] ; 4-(methyl-£/3)-N-(2-(l -methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)benzamide-2,3,5,6-ii4

[257];

4-(methoxy-£/3)-N-(2-( l -methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)benzamide [458]; 4-(methoxy- 3)-N-(2-( l -methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)benzamide-2,3,5,6-£/4

[459];

4-methoxy-N-(2-( 1 -methyl- 1 H-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)benzamide-2,3,5,6-<¾ [460] ; (E)-N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-3-(phenyl-2,3,4,5,6- j)

acrylamide [461];

(E)-N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-3-(phenyl-2,3,4,5,6- j)

acrylamide-2,3-£/2 [462];

N-(2-( l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(4-fluorophenyl)acetamide-2,2- d2 [463] ; (E)-N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-^

[464];

(E)-N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-3-(phenyl-2,3,4,5,6- j)acrylam 2,2-d2 [465];

2-(4-fluorophenyl)-N-(2-(l-methyl-lH-imidazol-5-yl^^

[466];

N-(2 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 , 6-naphthyridin-7 -yl) -2-(4 -methylpiperazin- 1 -yl)

isonicotinamide [467];

2-(dimethylamino)-N-(2-( 1 -methyl- lH-imidazol-5-yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide

[468];

2-(3 -aminoazetidin- 1 -yl)-N-(2-( 1 -methyl -lH-imidazol -5 -yl)- 1 ,6-naphthyridin-7-yl)

isonicotinamide [469];

N-(2-( 1 -methyl-lH-imidazol-5-yl)- 1 ,6-naphthyridin-7-yl)-2-(pyrrolidin- 1 -yl)isonicotinamide

[470];

N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(piperidin-l-yl)isonicotinamide

[471];

N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-moφholinoisonicotinamide [472]; 2-(4-isopropylpiperazin- 1 -yl)-N-(2-( 1 -methyl- lH-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)

isonicotinamide [473];

2-(4-cyclopropylpiperazin- 1 -yl)-N-(2-( 1 -methyl- lH-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)

isonicotinamide [474];

N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(2,7-diazaspiro[3.5]nonan-2-yl) isonicotinamide [475];

N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(7-methyl-2,7-diazaspiro[3.5]nonan-

2-yl)isonicotinamide [476];

N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)isoindoline-5-carboxamide [477]; 2-methyl-N-(2-( 1 -methyl-lH-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)isoindoline-5 -carboxamide

[478];

2-(azetidin-l-yl)-N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)isonicotinamide [479]; 2-methoxy-N-(2-( 1 -methyl- 1 H-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide [480] ; 2-methyl-N-(2-( 1 -methyl-lH-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide [481] ;

2-cyano-N-(2-( 1 -methyl-lH-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide [482] ;

2-(3,3-difluoroazetidin-l-yl)-N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)

isonicotinamide [483]; 2-(4,4-difluoropiperidin-l -yl)-N-(2-( 1 -methyl- lH-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl) isonicotinamide [484];

2-isopropoxy-N-(2-( 1 -methyl -IH-imidazol -5 -yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide [485] ; N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(pyrrolidin-l-yl-2,2,5,5-£/4)

isonicotinamide [486];

N-(2-( 1 -methyl-lH-imidazol-5-yl)- 1 ,6-naphthyridin-7-yl)-2-(pyrrolidin- 1 -yl-<¾)isonicotinamide

[487];

N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(piperidin-l-yl- ;o)isonicotinamide

[488];

N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(moφholino-ί s)isonicotinamide

[489];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-4-isopropoxybenzamide [490]; N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-4-(piperidin-4-yloxy)benzamide

[491];

4-(benzyloxy)-N-(2-( 1 ,2-dimethyl- lH-imidazol-5-yl)- 1 ,6-naphthyridin-7-yl)benzamide [492] ; N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-fluorobenzamide-3,4,5,6-£/4

[493];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-4-fluorobenzamide-2,3,5,6-£/4

[494];

2-chloro-N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)benzamide-3,4,5,6-£/4

[495];

4-chloro-N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)benzamide-2,3,5,6-£/4

[496];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-4-(methyl- 3)benzamide [497]; N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-4-methylbenzamide-2,3,5,6-£/4

[498];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-4-(methyl-£/3)benzamide-2,3,5,6-£/4

[499];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-4-(methoxy-£/3)benzamide [500]; N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-4-(methoxy-£/3)benzamide-2,3,5,6- d4 [501];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-4-methoxybenzamide-2,3,5,6-£/4

[502]; N-(2-( 1 ,2-dimethyl- lH-imidazol-5-yl)-l ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl) isonicotinamide [503];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-nap

[504];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(pyrrolidin-l-yl)isonicotm^

[505];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphth^^

[506];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(pyrrolidin-l-yl-2,2,5,5- 4) isonicotinamide [507];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(pyrrolidin-l-yl-£/s)

isonicotinamide [508];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(piperidin-l-yl-£/;o)

isonicotinamide [509];

[510];

N-(2-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)

cyclopropanecarboxamide [511];

N-(2-(7-methyl-5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)

cyclopropanecarboxamide [512];

3,3-difluoro-N-(2-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)

cyclobutane-l-carboxamide [513];

(R)-N-(2-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)pyrrolidine-2- carboxamide [514];

(R)-N-(2-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)piperidine-3- carboxamide [515];

l-methyl-N-(2-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)piperidine-

4-carboxamide [516];

N-(2-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)-l-((l-

(trifluoromethyl)cyclopropyl)methyl)piperidine -4 -carboxamide [517];

l-benzoyl-N-(2-(5,6J,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)piperidine-

4-carboxamide [518];

4-fluoro-l-isobutyl-N-(2-(5,6J,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl) piperidine-4-carboxamide [519]; (R)-2-(2-methylpyrrolidin-l-yl)-N-(2-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6- naphthyridin-7-yl)acetamide [520];

2-(cyclobutyl(methyl)amino)-N-(2-(5,6J,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6- naphthyridin-7-yl)acetamide [521];

4-fluoro-N-(2-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)benzamide

[522];

4-isopropoxy-N-(2-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6-naphthyridin-7-yl)

benzamide [523];

4-(difluoromethoxy)-N-(2-(5,6,7,8-tetrahydroim

benzamide [524];

2-((2-(dimethylamino)ethyl)amino)-N-(2-(5,6J,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-l,6- naphthyridin-7-yl)isonicotinamide [525] ;

2-(( 1 -isopropylpiperidin-4-yl)oxy)-N-(2-(5,6,7,8-tetrahydroimidazo[ 1 ,2-a]pyrazin-3 -yl)- 1 ,6- naphthyridin-7-yl)isonicotinamide [526] ;

N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)- 1 -(3,3,3 -trifluoropropyl)piperidine-4-carboxamide

[527];

N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)cyclopropanecarboxamide [528];

(R) -N-(2 -(oxazol -5 -yl) - 1 , 6-naphthyridin-7 -yl)tetrahydrofuran-2-carboxamide [529] ;

(R)-N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)piperidine-3-carboxamide [530];

N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)tetrahydro-2H-pyran-4-carboxamide [531] ;

N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)- 1 -(2-(pyrrolidin- 1 -yl)acetyl)piperidine-4-carboxamide

[532];

1 '-methyl -N-(2 -(oxazol -5 -yl)- 1 ,6-naphthyridin-7-yl)-[ 1 ,4'-bipiperidine] -4-carboxamide [533] ; c/. ·-4-moφholino-N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)cyclohexane-l-carboxamide [534]; 2-(cyclobutyl(methyl)amino)-N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)acetamide [535];

N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)-2-(pyrrolidin- 1 -yl)acetamide [536] ;

(R) -2 -(2-methylpyrrolidin- 1 -yl) -N-(2 -(oxazol -5 -yl) -1,6 -naphthyridin-7 -yl)acetamide [537] ; 2-(4-methylpiperazin- 1 -yl)-N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)acetamide [538] ;

fr «5-4-((4-methylpiperazin-l-yl)methyl)-N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)cyclohexane- 1-carboxamide [539];

l-(2,2-difluoropropyl)-N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide [540]; fr «5-4-(hydroxymethyl)-N-(2-(2-methyloxazol-5-yl)- 1 ,6-naphthyridin-7-yl)cyclohexane- 1 - carboxamide [541]; trans -4 -(methylamino) -N-(2-(2 -methyloxazol -5 -yl) - 1 , 6-naphthyridin-7-yl)cyclohexane - 1 - carboxamide [542];

trans-4-(( 1 ,3 -difluoropropan-2-yl)amino)-N-(2-(2-methyloxazol-5 -yl)- 1 ,6-naphthyridin-7-yl) cyclohexane - 1 -carboxamide [543] ;

fr «5-N-(2-(2-methyloxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)-4-((propan-2-yl-l , 1 , 1 ,3,3,3-d6)amino) cyclohexane - 1 -carboxamide [544] ;

fr «5-4-((2,2-difluoroethyl)amino)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)

cyclohexane - 1 -carboxamide [545] ;

fr «5-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)-4-((3,3,3-trifluoropropyl)amino)

cyclohexane - 1 -carboxamide [546] ;

fr «5-4-((2-methoxyethyl)amino)-N-(2-(2-methyloxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)

cyclohexane -1 -carboxamide [547];

fr «5-4-(dimethylamino)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)cyclohexane-l- carboxamide [548];

fr «5-4-(bis(methyl-£/3)amino)-N-(2-(2-methyloxazol-5-yl)- 1 ,6-naphthyridin-7-yl)cyclohexane- 1 - carboxamide [549];

c/5-4-(dimethylamino)-N-(2-(2-methyloxazol-5-yl)- 1 ,6-naphthyridin-7-yl)cyclohexane- 1 - carboxamide [550];

fr «5-4-((2,2-difluoroethyl)(methyl)amino)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl) cyclohexane -1 -carboxamide [551];

fr «5-4-(methyl(oxetan-3-yl)amino)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)

cyclohexane - 1 -carboxamide [552] ;

fr «5-4-((2-fluoroethyl)amino)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)cyclohexane-l- carboxamide [553];

fr «5-4-(2-(fluoromethyl)aziridin-l-yl)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)

cyclohexane - 1 -carboxamide [554] ;

trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N-(2-(2-methyloxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)

cyclohexane - 1 -carboxamide [555] ;

fr «5-N-(2-(2-methyloxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)-3-morpholinocyclobutane- 1 - carboxamide [556];

fr rø-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)-4-moφholinocyclohexane-l- carboxamide [557];

N-(2-(2-methyloxazol-5-yl)- 1 ,6-naphthyridin-7-yl)-2-(piperidin- 1 -yl)acetamide [558] ;

2-(4-methoxypiperidin-l-yl)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)acetamide [559]; N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)acetamide [560]; N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)mo holine-4-carboxamide [561];

N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)-2-mo holinoacetamide [562];

N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)-3-mo holinopropanamide [563];

1 -methyl -N-(2 -(2 -methyloxazol -5 -yl)- 1 ,6-naphthyridin-7-yl)piperidine-4 -carboxamide [564] ; 1 -(2,2-difluoropropyl)-N-(2-(2-methyloxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)piperidine-4- carboxamide [565];

N-(2-(2-methyloxazol-5-yl)- 1 ,6-naphthyridin-7-yl)-4-mo holinopiperidine- 1 -carboxamide [566] ; 4-((l,3-difluoropropan-2-yl)amino)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)

piperidine-1 -carboxamide [567];

( 1 R,3s,5 S)-3 -(( 1 ,3-difluoropropan-2-yl)amino)-N-(2-(2-methyloxazol-5 -yl)- 1 ,6-naphthyridin-7- yl)-8-azabicyclo[3.2.1] octane -8 -carboxamide [568];

( 1 R,3s,5 S)-3 -(( 1 ,3-difluoropropan-2-yl)amino)-N-(2-(2-methyloxazol-5 -yl)- 1 ,6-naphthyridin-7- yl)-8-azabicyclo[3.2.1] octane -8 -carboxamide [569];

4-(dimethylamino) -N-(2-(2 -methyloxazol -5 -yl) - 1 ,6 -naphthyridin-7 -yl)piperidine - 1 -carboxamide

[570];

4-((2,2-difluoroethyl)(methyl)amino)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)

piperidine-1 -carboxamide [571];

(3S,4S)-4-amino-3-fluoro-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)piperidine-l- carboxamide [572];

(3S,4S)-3-fluoro-4-(methylamino)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)piperidine- 1 -carboxamide [573];

(3R,4R)-4-amino-3-fluoro-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)piperidine-l- carboxamide [574];

(3R,4R)-3 -fluoro-4-(methylamino)-N-(2-(2-methyloxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)piperidine- 1 -carboxamide [575];

4-((2-fluoroethyl)amino)-N-(2-(2-methyloxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)piperidine- 1 - carboxamide [576];

4-((2,2-difluoroethyl)amino)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)piperidine-l- carboxamide [577];

(lR,3s,5S)-3-amino-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)-8-azabicyclo[3.2.1] octane-8-carboxamide [578];

(lR,3r,5S)-3-amino-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)-8-azabicyclo[3.2.1]

octane-8-carboxamide [579]; (lR,3r,5S)-3-((2-fluoroethyl)amino)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [580];

( 1 R,3r,5 S)-3-((2,2-difluoroethyl)amino)-N-(2-(2-methyloxazol-5-yl)- 1 ,6-naphthyridin-7-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [581];

(lR,3s,5S)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)-3-((3,3,3-trifluoropropyl)amino)-

8 -azabicyclo [3.2.1] octane -8 -carboxamide [582] ;

(3S,4S)-3-fluoro-4-(isopropylamino)-N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)

piperidine-1 -carboxamide [583];

N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H)- carboxamide [584];

2-methyl-N-(2 -(2 -methyloxazol -5 -yl) - 1 ,6 -naphthyridin-7 -yl) -5 , 6-dihydroimidazo [ 1 ,2 -a] pyrazine -

7(8H)-carboxamide [585];

N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)-2-(mo holino-ί s)acetamide [586];

fr «5-N-(2-(2-methyloxazol-4-yl)- 1 ,6-naphthyridin-7-yl)-4-(4-methylpiperazin- 1 -yl)cyclohexane-

1 -carboxamide [587];

N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [588];

2- ( lH-imidazol- 1 -yl)-N-(2-(2-methyloxazol-5-yl)-l ,6-naphthyridin-7-yl)acetamide [589] ;

4-(difluoromethoxy)-N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)benzamide [590] ;

3- ((l-methylpiperidin-4-yl)oxy)-N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)benzamide [591]; N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide [592] ;

2-(3 -aminoazetidin-1 -yl)-N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide [593] ;

2-(l-methylpiperidin-4-yl)-N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)isonicotinamide [594]; r-methyl-N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)-l',2',3',6'-tetrahydro-[2,4'-bipyridine]-4- carboxamide [595];

2-(4-methylpiperazin- 1 -yl)-N-(2-(oxazol-5-yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide [596] ; 2-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)

isonicotinamide [597];

N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)-2-(2,7-diazaspiro[3.5]nonan-7-yl)isonicotinamide

[598];

N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)-2-(piperidin-4-ylamino)isonicotinamide [599] ;

2-methyl-N-(2 -(oxazol -5 -yl) - 1 , 6-naphthyridin-7 -yl)isoindoline -5 -carboxamide [600] ;

N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)-l,2,3,4-tetrahydroisoquinoline-7-carboxamide [601]; N-(2-(2-methyloxazol-5-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[602];

N-(2-(3-methylisoxazol-5-yl)-l,6-naphthyridin-7-yl)-l-(3,3,3 rifluoropropyl)piperidine-4- carboxamide [603];

4-fluoro-l-isobutyl-N-(2-(5-methyl-l,3,4-oxadiazol-2-yl)-l,6-naphthyridin-7-yl)piperidine-4- carboxamide [604];

1 -isobutyl-N-(2-(5-methyl- 1 ,3,4-oxadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4-carboxamide

[605];

N-(2-(5-(dimethylamino)-l,3,4-oxadiazol-2-yl)-l,6-napfa

[606];

N-(2-(5-(dimethylamino)-l,3,4-oxadiazol-2-yl)-l,6-napfa

carboxamide [607];

N-(2-(5-methyl-l,3,4-oxadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [608];

3 , 3 -difluoro -N-(2 -(thiazol-5 -yl) - 1 , 6 -naphthyridin-7 -yl)cyclobutane- 1 -carboxamide [609] ;

2-methyl-N-(2-(thiazol-5-yl)-l,6-naphthyridin-7-yl)-2-azaspiro[3 ]heptane-6-carboxam

[610];

1 -fluoro-N-(2-(thiazol-5-yl)- 1 ,6-naphthyridin-7-yl)cyclohexane-l -carboxamide [611];

fra«s-4-(dimethylamino)-N-(2-(thiazol-5-yl)- 1 ,6-naphthyridin-7-yl)cyclohexane- 1 -carboxamide

[612];

trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N -(2 -(thiazol-5 -yl)- 1 ,6-naphthyridin-7-yl)cyclohexane-l - carboxamide [613];

N-(2-(thiazol-5-yl)-l,6-naphthyridin-7-yl)azetidine-3-carboxamide [614];

1- methyl-N-(2-(miazol-5-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide [615];

1 -(2,2-difluoropropyl)-N-(2-(thiazol-5 -yl)- 1 ,6-naphthyridin-7-yl)piperidine-4-carboxamide [616] ; 1 -(oxetan-3 -yl) -N-(2-(thiazol -5 -yl) - 1 ,6 -naphthyridin-7-yl)piperidine -4 -carboxamide [617];

1 -(2 -(pyrrolidin- 1 -yl)acetyl) -N-(2 -(thiazol-5 -yl) - 1 , 6-naphthyridin-7 -yl)piperidine -4-carboxamide

[618];

r-methyl-N-(2-(thiazol-5-yl)-l,6-naphthyridin-7-yl)-[l,4'-bipiperidine]-4-carboxamide [619];

2- (pyrrolidin- 1 -yl)-N-(2-(thiazol-5-yl)- 1 ,6-naphthyridin-7-yl)propanamide [620] ;

2-(piperidin-l-yl)-N-(2-(thiazol-5-yl)-l,6-naphthyridin-7-yl)acetamide [621];

2-(4-methylpiperazin-l -yl)-N-(2-(thiazol-5-yl)-l ,6-naphthyridin-7-yl)acetamide [622] ;

2-moφholino-N-(2-(thiazol-5-yl)-l,6-naphthyridin-7-yl)acetamide [623];

4-(piperidin-4-yloxy)-N-(2-(thiazol-5-yl)-l,6-naphthyridin-7-yl)benzamide [624]; N-(2-(thiazol-5-yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide [625] ;

6-(4-methylpiperazin-l -yl)-N-(2-(thiazol-5-yl)-l ,6-naphthyridin-7-yl)nicotinamide [626] ;

l'-me l-N-(2-(thiazol-5-yl)-l,6-naph ^

carboxamide [627];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(2-(thiazol-5 -yl)-l ,6-naphthyridin-7-yl)isonicotinamide

[628];

2-(4-(dimethylamino)piperidin-l-yl)-N-(2-(thiazol-5-yl)-l,6-naphthyridin-7-yl)isonicotinan^

[629];

2-(4-methylpiperazin-l-yl)-N-(2-(1hiazol-5-yl)-l,6-naphthyridin-7-yl)isonicotinamid [630]; 2-(( 1 -methylpiperidin-4-yl)thio)-N-(2-(thiazol-5 -yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide [631] ; N-(2-(thiazol-5-yl)- 1 ,6-naphthyridin-7-yl)- 1 ,2,3,4-tetrahydroisoquinoline-7 -carboxamide [632] ; fr «5-4-((l,3-difluoropropan-2-yl)amino)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6- naphthyridin-7 -yl)cyclohexane - 1 -carboxamide [633] ;

N-(2-(2-methylthiazol-5-yl)-l,6-naphthyridin-7-yl)mo holine-4-carboxamide [634];

N-(2-(2-methylthiazol-5-yl)-l,6-naphthyridin-7-yl)-2-(pyrrolidin-l-yl)acetamide [635];

2-((lR,4R)-2-oxa-5-azabicyclo[2.2. l]heptan-5-yl)-N-(2-(2-methylthiazol-5-yl)-l,6-naphthyridin-

7-yl)acetamide [636];

N-(2-(2-methylthiazol-5-yl)-l,6-naphthyridin-7-yl)-2-moφholinoacetamide [637];

N-(2-(2-methylthiazol-5-yl)-l,6-naphthyridin-7-yl)-2-(moφholino-ί s)acetamide [638];

2-(4-methylpiperazin- 1 -yl)-N-(2-(2-methylthiazol-5-yl)- 1 ,6-naphthyridin-7-yl)acetamide [639] ;

1- methyl-N-(2-(2-methylthiazol-5-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide [640]; N-(2-(2-methylthiazol-5-yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide [641] ;

N-(2-(2-methylthiazol-5-yl)-l,6-naphthyridin-7-yl)nicotinamide [642];

2- (4-methylpiperazin- 1 -yl)-N-(2-(2-methylthiazol-5-yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide

[643];

fr rø-N-(2-(5-methyl-l,3,4 hiadiazol-2-yl)-l,6-naphthyridin-7-yl)-4-moφholinocyclohexane-l- carboxamide [644];

fr «5-N-(2-(5-methyl-l,3,4 hiadiazol-2-yl)-l,6-naphthyridin-7-yl)-4-(4-methylpiperazin-l-yl) cyclohexane - 1 -carboxamide [645] ;

4-isopropyl-N-(2-(5-methyl-l,3,4 hiadiazol-2-yl)-l,6-naphthyridin-7-yl)piperazine-l- carboxamide [646];

4-((2-methoxyethyl)(methyl)amino)-N-(2-(5-^

piperidine-1 -carboxamide [647]; 4-(( 1 ,3 -difluoropropan-2-yl)amino)-N-(2-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl) piperidine-1 -carboxamide [648];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-4-((3,3,3-trifluoropropyl)amino) piperidine-1 -carboxamide [649];

4-((2-fluoroethyl)amino)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)piperidine-

1 -carboxamide [650];

(3R,4S)-4-amino-3-fluoro-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)

piperidine-1 -carboxamide [651];

(3R,4R)-4-amino-3-fluoro-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)

piperidine-1 -carboxamide [652];

(3 S,4S)-3 -fluoro-N-(2-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)-l ,6-naphthyridin-7-yl)-4-(methylamino) piperidine-1 -carboxamide [653];

(3R,4R)-3 -fluoro-N-(2-(5 -methyl- 1 ,3 ,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)-4-(methylamino) piperidine-1 -carboxamide [654];

4-amino-3,3-difluoro-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)piperidine-l- carboxamide [655];

(3R,4R)-3 -fluoro-4-(isopropylamino)-N-(2-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)-l ,6-naphthyridin-7- yl)piperidine-l -carboxamide [656];

(3R,4S)-3-fluoro-4-(isopropylamino)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7- yl)piperidine-l -carboxamide [657];

3,3-difluoro-4-(isopropylamino)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl) piperidine-1 -carboxamide [658];

(3 S,4S)-3 -fluoro-N-(2-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)-l , 6-naphthyridin-7-yl)-4-((propan-2-yl-

1, 1,1,3,3,3 -d<;)amino)piperidine - 1 -carboxamide [659] ;

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6- naphthyridin-7-yl)-8-azabicyclo[3.2. l]octane-8-carboxamide [660];

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6- naphthyridin-7-yl)-8-azabicyclo[3.2. l]octane-8-carboxamide [661];

4-(dimethylamino)-N-(2-(2-methylthiazol-5-yl)- 1 ,6-naphthyridin-7-yl)piperidine- 1 -carboxamide

[662];

4-((2,2-difluoroethyl)amino)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)

piperidine-1 -carboxamide [663];

4-((2,2-difluoroethyl)(methyl-£/3)amino)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-

7-yl)piperidine-l -carboxamide [664]; N-(2-(5-methyl-l ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)-4-mo holinopiperidine- 1 - carboxamide [665];

N-(2-(5-methyl-l,3,4 hiadiazol-2-yl)-l,6-naphthyridin-7-yl)-4-(4-methylpiperazin-l-yl)

piperidine-1 -carboxamide [666];

(R)-3,4-dimethyl-N-(2-(5-methyl-l,3,4 hiadiazol-2-yl)-l,6-naphthyridin-7-yl)piperazine-l^ carboxamide [667];

(S)-3,4-dimethyl-N-(2-(5-methyl-l,3,4 hiadiazol-2-yl)-l,6-naphthyridin-7-yl)piperazine-l- carboxamide [668];

(lR,3r,5S)-3-((2-fluoroethyl)amino)-N-(2-(5-methy

yl)-8-azabicyclo[3.2.1] octane -8 -carboxamide [669];

(lR,3r,5S)-3-((2,2-difluoroethyl)amino)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridm

7-yl)-8-azabicyclo[3.2. l]octane-8-carboxamide [670];

( lR,3r,5 S)-3-amino-N-(2-(5-methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)-8-azabicyclo

[3.2.1] octane -8 -carboxamide [671];

( 1 S,4S)-5 -methyl -N-(2 -(5 -methyl-1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)-2,5-diazabicyclo

[2.2. l]heptane-2 -carboxamide [672];

(lR,4R)-5-methyl-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2,5-diazabicyclo

[2.2. l]heptane-2 -carboxamide [673];

8-methyl-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-3,8-diazabicyclo[3.2.1] octane-3 -carboxamide [674];

3-methyl-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-3,8-diazabicyclo[3.2.1] octane-8-carboxamide [675];

N-(2-(5-methyl-l,3,4-miadiazol-2-yl)-l,6-naphthyridin-7-yl)-5,6-dihydroimidazo[l,2-a]pyrazin^

7(8H)-carboxamide [676];

2-(4-methylpiperazin- 1 -yl)-N-(2-(5-methylthiazol-2-yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide

[677];

2-(4-methylpiperazin-l-yl)-N-(2-(4-methylthiazol-2-yl)-l,6-naphthyridin-7-yl)isonicotinamide

[678];

N-(2-(2-(methylamino)thiazol-5-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide [679]; l-methyl-N-(2-(2-(methylamino)thiazol-5-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide

[680];

N-(2-(2-(diethylamino)thiazol-5-yl)- 1 ,6-naphthyridin-7-yl)-2-(4-fluoropiperidin- 1 -yl)acetamide

[681]; N-(2-(2-(diethylamino)thiazol-5-yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl)acetamide

[682];

N-(2-(2-aminothiazol-5-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[683];

N-(2-(2-(methylamino)thiazol-5-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [684];

N-(2-(2-(dimethylamino)thiazol-5-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [685];

2-(4 sopropylpiperazin-l-yl)-N-(2-(2-(methylamino)thiazol-5-yl)-l,6-naphthyridin-7-yl)

isonicotinamide [686];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(2-(2-(methylamino)thiazol-5-yl)- 1 ,6-naphthyridin-7-yl) isonicotinamide [687];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(2-(2-(dimethylamino)thiazol-5 -yl)- 1 ,6-naphthyridin-7-yl) isonicotinamide [688];

2-(3 -aminoazetidin- 1 -yl) -N-(2-(2-(dimethylamino)thiazol-5 -yl)- 1 ,6-naphthyridin-7-yl)

isonicotinamide [689];

N-(2-(5-chlorothiazol-2-yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide

[690];

2-(7-(2-(4-methylpiperazin-l-yl)isonicotinamido)-l,6-naphthyridin-2-yl)thiazole-5-carboxamide

[691];

N-(2-(isothiazol-4-yl)-l,6-naphthyridin-7-yl)-l-methylpiperidine-4-carboxamide [692];

N-(2-(l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-4-(difluoromethoxy)benzamide [693];

N-(2-(l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-4-(piperidin-4-yloxy)benzamide [694];

N-(2-(l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-4-((l-methylpiperidin-4-yl)oxy)benzamide

[695];

N-(2-(l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-3-((l-methylpiperidin-4-yl)oxy)benzamide

[696];

N5-(2-(l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-N2-methylpyridine-2,5-dicarboxamide [697]; N-(2-(l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-6-(4-methylpiperazin-l-yl)nicotinamide

[698];

N-(2-(l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-l'-methyl-1^2',3',6'-tetrahydro-[2,4'- bipyridine] -4 -carboxamide [699] ;

N-(2-( 1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)-2-(3-(dimethylamino)azetidin- 1 -yl)

isonicotinamide [700]; N-(2-(l,3,4 hiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)isonicotinam

[701];

N-(2-(l,3,4 hiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-(4-isopropylpiperazin-l-yl)isonicotinam

[702];

N-(2-(l,3,4 hiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-mo holinoisonicotinamide [703];

1 -fluoro-N-(2-(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)cyclohexane-l - carboxamide [704];

fr «5-4-methoxy-N-(2-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)-l ,6-naphthyridin-7-yl)cyclohexane- 1 - carboxamide [705];

c/5-4-methoxy-N-(2-(5-methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)cyclohexane- 1 - carboxamide [706];

fr «5-4-amino-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)cyclohexane-l- carboxamide [707];

fr «5-4-(dimethylamino)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)

cyclohexane-1 -carboxamide [708];

fr rø-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-4-moφholinocyclohexane-l- carboxamide [709];

fr «5-4-(hydroxymethyl)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7- yl)cyclohexane - 1 -carboxamide [710];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide [711]; 4-fluoro-N-(2-(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4-carboxamide

[712];

l-methyl-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide

[713];

4-fluoro-l-methyl-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)piperidine-4- carboxamide [714];

1 -(2-fluoroethyl)-N-(2-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4- carboxamide [715];

1 -(2,2-difluoroethyl)-N-(2-(5-methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4- carboxamide [716];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-l-(3,3,3-trifluoropropyl)piperidine- 4-carboxamide [717];

1 -(2,2-difluoropropyl)-N-(2-(5 -methyl-1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4- carboxamide [718]; 1 -benzoyl -N-(2-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4-carboxamide [719];

N-(2-(5-methyl-l ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)-2-(pyrrolidin- 1 -yl)acetamide [720] ; N-(2-(5-methyl-l ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)-2-(piperidin- 1 -yl)acetamide [721] ; 2-(4-methoxypiperidin- 1 -yl)-N-(2-(5-methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)

acetamide [722];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

acetamide [723];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-mo holinoacetamide [724]; (R)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-(3- methylmorpholino)acetamide [725];

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl) acetamide [726];

2-((lR,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6- naphthyridin-7-yl)acetamide [727];

2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-

7-yl)acetamide [728];

2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin- 7-yl)acetamide [729];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-(l,4-oxazepan-4-yl)acetamide

[730];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-mo holinoacetamide-2,2-ί 2

[731];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-(mo holino-ί s)acetamide [732]; 1 -methyl-3-(2-(5 -methyl-1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)- 1 -( 1 -methylpiperidin-4- yl)urea [733];

(3S,4S)-4-amino-3-fluoro-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)

piperidine-l-carboxamide [734];

(3 S,4S)-4-(dimethylamino)-3 -fluoro-N-(2-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)-l ,6-naphthyridin-7- yl)piperidine-l-carboxamide [735];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)mo holine-4-carboxamide [736]; N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-4-(methylamino)piperidine-l- carboxamide [737]; 4-(dimethylamino)-N-(2-(5 -methyl-1

carboxamide [738];

4-((2,2-difluoroethyl)(methyl)amino)-N-(2-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7- yl)piperidine-l -carboxamide [739];

(3S,4S)-3-fluoro-4-(isopropylamino)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7- yl)piperidine-l -carboxamide [740];

2-methyl-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-5,6-dihydroimidazo[l,2-a] pyrazine-7(8H)-carboxamide [741];

4-methyl-N-(2-(5 -methyl-1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)piperazine- 1 -carboxamide

[742];

N-(2-(5-methyl-l ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- pyrazole -4 -carboxamide [743];

1 -( 1 -isopropylpiperidin-4-yl)-N-(2-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)- 1H- pyrazole -4 -carboxamide [744];

N-(2-(5-methyl-l ,3,4-thiadiazol-2-yl)- 1 ,6-naphthyridin-7-yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- l,2,3-triazole-4-carboxamide [745];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-(piperidin-4-yl)oxazole-4- carboxamide [746];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-(l-methylpiperidin-4-yl)oxazole- 4-carboxamide [747];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(2-(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)-l ,6-naphthyridin-7-yl) isonicotinamide [748];

r-methyl-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-l',2',3',6'-tetrahydro-[2,4'- bipyridine] -4 -carboxamide [749];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [750];

2-(methyl(l-methylpiperidin-4-yl)amino)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6- naphthyridin-7-yl)isonicotinamide [751] ;

2-(azetidin-3-yloxy)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)isonicotinamide

[752];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-3-((l-methylpiperidin-4-yl)oxy) benzamide [753];

N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-((l-methylpiperidin-4-yl)thio) isonicotinamide [754]; 6-(4-methylpiperazin-l-yl)-N-(2-(5-(trifluoromethyl)-l,3,4 hiadiazol-2-yl)-l,6-naphthyridin-7- yl)nicotinamide [755];

2-(4-methylpiperazin-l-yl)-N-(2-(5-(trifluoromethyl)-l,3,4-thiadiazol-2-yl)-l,6-naphthyridin-7- yl)isonicotinamide [756];

N-(2-(5-amino-l,3,4 hiadiazol-2-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [757];

N-(2-(5-(dimethylamino)-l,3,4-thiadiazol-2-yl)-l,6-napfa

yl)isonicotinamide [758];

N-(2-(3-amino-5 -fluorophenyl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [759];

N-(2-(3-fluoro-5-(isopropylamino)phenyl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [760];

1 -methyl -N-(2 -(pyridin-2 -yl) - 1 , 6-naphthyridin-7-yl)piperidine -4-carboxamide [761 ] ;

2-(4-methylpiperazin-l-yl)-N-(2-(pyridin-2-yl)-l,6-naphthyridin-7-yl)isonicotinamide [762]; 2-(4-methylpiperazin-l-yl)-N-(2-(pyridin-4-yl)-l,6-naphthyridin-7-yl)isonicotinamide [763]; N-(2-(pyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)cyclopropanecarboxamide [764] ;

N-(2 -(pyridin-3 -yl) - 1 , 6 -naphthyridin-7 -yl) -2 -(pyrrolidin- 1 -yl)acetamide [765] ;

1 -methyl -N-(2 -(pyridin-3 -yl)-l ,6-naphthyridin-7-yl)piperidine-4-carboxamide [766] ;

N-(2-(pyridin-3-yl)-l,6-naphthyridin-7-yl)quinuclidine-4-carboxamide [767];

2-morpholino-N-(2-(pyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)acetamide [768] ;

2-(moφholino-ί s)- -(2-(pyridin-3-yl)-l,6-naphthyridin-7-yl)acetamide [769];

2-(4-methylpiperazin-l -yl)-N-(2 -(pyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)acetamide [770] ;

2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(2-(pyridin-3-yl)- 1 ,6-naphthyridin-7-yl)acetamide [771] ; 2-(4-methylpiperazin-l -yl)-N-(2 -(pyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)isonicotinamide [772] ; 2-(2 -methyl- IH-imidazol- 1 -yl)-N-(2-(pyridin-3-yl)- 1 ,6-naphthyridin-7-yl)acetamide [773] ; 2-(lH-imidazol-l-yl)-N-(2-(pyridin-3-yl)-l,6-naphthyridin-7-yl)acetamide [774];

2-(piperidin-4-yl)-N-(2-(pyridin-3-yl)-l,6-naphthyridin-7-yl)oxazole-4-carboxamide [775]; 2-(l-methylpiperidin-4-yl)-N-(2-(pyridin-3-yl)-l,6-naphthyridin-7-yl)oxazole-4-carboxamide

[776];

2-(l-isopropylpiperidin-4-yl)-N-(2-(pyridin-3-yl)-l,6-naphthyridin-7-yl)oxazole-4-carboxamide

[777];

fr rø-N-(2-(5-fluoropyridin-3-yl)-l,6-naphthyridin-7-yl)-3-moφholinocyclobutane-l- carboxamide [778]; fr «5-N-(2-(5-fluoropyridin-3-yl)-l,6-naphthyridin-7-yl)-4-((4-methylpiperazin-l-yl)methyl) cyclohexane-l-carboxamide [779];

N-(2-(5-fluoropyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(pyrrolidin-l-yl)acetamide [780];

N-(2-(5-fluoropyridin-3 -yl)-l ,6-naphthyridin-7-yl)- 1 -methylpiperidine-4-carboxamide [781] ; N-(2-(5-fluoropyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)acetamide [782]; N-(2-(6-fluoropyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)acetamide [783]; N-(2-(5-fluoropyridin-3-yl)-l,6-naphthyridin-7-yl)-2-moφholinoacetamide [784];

N-(2-(5-fluoropyridin-3-yl)-l,6-naphthyridin-7-yl)-3-moφholinopropanamide [785];

N-(2-(5-fluoropyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)isonicotinam

[786];

N-(2-(5-fluoropyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide

[787];

N-(2-(5-fluoropyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(l-methylpiperidin-4-yl)oxazole-4- carboxamide [788];

N-(2-(5-fluoropyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(l-isopropylpiperidin-4-yl)oxazole-4- carboxamide [789];

N-(2-(5-chloropyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)isonicotinami

[790];

N-(2-(5-methylpyridin-3-yl)-l,6-naphthyridin-7-yl)-2-moφholinoacetamide [791];

N-(2-(5-(difluoromethyl)pyridin-3-yl)-l,6-naphthyridin-7-yl)-3-(piperidin-4-yl)benzamide [792]; N-(2-(5-(difluoromethyl)pyridin-3-yl)-l,6-naphthyridin-7-yl)-3-(l-methylpiperidin-4-yl)

benzamide [793];

N-(2-(5-(difluoromethyl)pyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [794];

2-(4-methylpiperazin-l-yl)-N-(2-(5-(trifluoromethyl)pyridin-3-yl)-l,6-naphthyridin-7-yl)

acetamide [795];

2-(4-methylpiperazin-l-yl)-N-(2-(6-(trifluoromethyl)pyridin-3-yl)-l,6-naphthyridin-7-yl)

acetamide [796];

N-(2-(5-(hydroxymethyl)pyridin-3-yl)-l,6-naphthyridin-7-yl)-l-methylpiperidine-4-carboxamide

[797];

N-(2-(5-cyanopyridin-3 -yl)-l ,6-naphthyridin-7-yl)- 1 -methylpiperidine-4-carboxamide [798] ; N-(2-(5-methoxypyridin-3-yl)-l,6-naphthyridin-7-yl)-l-methylpiperidine-4-carboxamide [799]; N-(2-(5-methoxypyridin-3-yl)-l,6-naphthyridin-7-yl)-2-moφholinoacetamide [800]; N-(2-(5-methoxypyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [801];

4-fluoro-N-(2-(5-(piperidin-4-yloxy)pyridin-3-yl)-l,6-naphthyridin-7-yl)benzamide [802];

N-(2-(5-aminopyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)-4-fluorobenzamide [803] ;

N-(2-(5-aminopyridin-3-yl)-l,6-naphthyridin-7-yl)-4-(piperidin-4-yloxy)benzamide [804];

N-(2-(5-aminopyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide

[805];

N-(2-(5-aminopyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide

[806];

N-(2-(6-aminopyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide

[807];

N-(2-(6-(methylamino)pyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [808];

N-(2-(5-(isopropylamino)pyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)-3 -(piperidin-4-yl)benzamide [809] ; N-(2-(5-(isopropylamino)pyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)-3 -( 1 -methylpiperidin-4-yl)

benzamide [810];

N-(2-(5-(isopropylamino)pyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [811];

N-(2-(5-(piperidin-4-ylamino)pyridin-3-yl)-l,6-naphthyridin-7-yl)cyclohexanecarboxamide

[812];

4-fluoro-N-(2-(5-(piperidin-4-ylamino)pyridin-3-yl)-l,6-naphthyridin-7-yl)benzamide [813]; 4-fluoro-N-(2-(5-(( 1 -methylpiperidin-4-yl)amino)pyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)benzamide

[814];

N-(2-(5-acetamidopyridin-3-yl)-l,6-naphthyridin-7-yl)-l-methylpiperidine-4-carboxamide [815]; N-(2-(5-(dimethylamino)pyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [816];

N-(2-(6-(dimethylamino)pyridin-3-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [817];

l-methyl-N-(2-(5-(pyrrolidin-l-yl)pyridin-3-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide

[818];

N-(2-(5-(pyrrolidin- 1 -ylmethyl)pyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)cyclopropanecarboxamide

[819];

4-fluoro-N-(2-(5-(pyrrolidin- 1 -ylmethyl)pyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)benzamide [820] ; N-(2-(5-((4-hydroxypiperidin-l-yl)methyl)pyridin-3-yl)-l,6-naphthyridin-7-yl) cyclopropanecarboxamide [821];

4-fluoro-N-(2-(5-((4-hydroxypiperidin-l-yl)methyl)pyridin-3-yl)-l,6-naphthyridin-7-yl)

benzamide [822];

N-(2-(5-(piperazin-l-ylmethyl)pyridin-3-yl)-l,6-naphthyridin-7-yl)cyclopropanecarboxamide

[823];

N-(2-(5 -((4-methylpiperazin- 1 -yl)methyl)pyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)

cyclopropanecarboxamide [824];

N-(2-(5-(mo holinomethyl)pyridin-3-yl)-l,6-naphthyridin-7-yl)cyclopropanecarboxamide [825]; N-methyl-5-(7-(l-methylpiperidine-4-carbo [826]; N-methyl-5-(7-(2-(4-methylpiperazin-l-yl)isonicotinamido)-l,6-naphthyridin-2-yl)nicotinam

[827];

N-(2 -(pyridin-3 -yl -di) - 1 ,6 -naphthyridin-7 -yl) -2-(pyrrolidin- 1 -yl)acetamide [828] ;

2-(4-methylpiperazin- 1 -yl)-N-(2-(pyridin-3 -yl-<¾)- 1 ,6-naphthyridin-7-yl)acetamide [829] ;

2-moφholino-N-(2-(pyridin-3-yl-ί 4()-l,6-naphthyridin-7-yl)acetamide [830];

1 -methyl -N-(2-(2-methylpyrimidin -5 -yl)- 1 ,6-naphthyridin-7-yl)piperidine-4-carboxamide [831] ; 2-(4-methylpiperazin-l-yl)-N-(2-(2-methylpyrimidin-5-yl)-l,6-naphthyridin-7-yl)isonicotinamide

[832];

N-(2 -(2-aminopyrimidin-5 -yl)- 1 , 6 -naphthyridin-7 -yl)- 1 -methylpiperidine -4 -carboxamide [833] ; 2-morpholino-N-(2-(pyridazin-3 -yl)-l ,6-naphthyridin-7-yl)acetamide [834] ;

2-moφholino-N-(2-(pyridazin-4-yl)-l,6-naphthyridin-7-yl)acetamide [835];

N-(2 -(pyridazin-4-yl) -1,6 -naphthyridin-7 -yl) -2 -(pyrrolidin- 1 -yl)acetamide [836] ;

trans -3 -ιηοφ1ιο1ίηο-Ν-(2 -(pyrazin-2-yl) - 1 ,6 -naphthyridin-7 -yl)cyclobutane - 1 -carboxamide [837] ; trans -4 -(dimethylamino) -N-(2 -(pyrazin-2-yl) - 1 , 6-naphthyridin-7-yl)cyclohexane - 1 -carboxamide

[838];

fr rø-4-moφholino-N-(2-(pyrazin-2-yl)-l,6-naphthyridin-7-yl)cyclohexane-l-carboxamide

[839];

trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N-(2-(pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl)cyclohexane- 1 -carboxamide [840];

fr «5-4-((4-methylpiperazin-l-yl)methyl)-N-(2-(pyrazin-2-yl)-l,6-naphthyridin-7-yl)c

yclohexane - 1 -carboxamide [841];

N-(2-(pyrazin-2-yl)-l,6-naphthyridin-7-yl)-2-(pyrrolidin-l-yl)acetamide [842];

l-methyl-N-(2-(pyrazin-2-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide [843];

4-fluoro-l -methyl -N-(2-(pyrazin-2-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide [844]; l-(2-fluoroethyl)-N-(2-(pyrazin-2-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide [845];

1- (oxetan-3-yl)-N-(2-(pyrazin-2-yl)-l,6-naphthyridin-7-yl)piperidine-4-carboxamide [846];

2- moφholino-N-(2-(pyrazin-2-yl)-l,6-naphthyridin-7-yl)acetamide [847];

l-methyl-N-(2-(pyrazin-2-yl)-l,6-naphthyridin-7-yl)azepane-4-carboxamide [848];

1- isobutyl-N-(2-(pyrazin-2-yl)-l,6-naphthyridin-7-yl)azepane-4-carboxamide [849];

1 -(2-hydroxy-2-methylpropyl)-N-(2-(pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl)azepane-4-carboxamide

[850];

4-(moφholinomethyl)-N-(2-(pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl)benzamide [851] ;

2- (4-methylpiperazin-l-yl)-N-(2-(pyrazin-2-yl)-l,6-naphthyridin-7-yl)isonicotinamide [852]; N-(2-(6-(methylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [853];

N-(2-(6-(isopropylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)azetidine-3-carboxamide [854]; N-(2-(6-(isopropylamino)pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl)- 1 -methylpiperidine-4-carboxamide

[855];

N-(2-(6-(isopropylamino)pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl)- 1 -methylpiperidine-4-carboxamide

[856];

1 -(2-fluoroethyl)-N-(2-(6-(isopropylamino)pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl)piperidine-4- carboxamide [857];

l-isopropyl-N-(2-(6-(isopropylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)piperidine-4- carboxamide [858];

l-isopentyl-N-(2-(6-(isopropylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)piperidine-4- carboxamide [859];

N-(2-(6-(isopropylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-3-(piperidin-4-yl)benzamide [860]; N-(2-(6-(isopropylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-3-(l-methylpiperidin-4-yl)

benzamide [861];

N-(2-(6-(isopropylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-l-(piperidin-4-yl)-lH-l,2,3- triazole-4-carboxamide [862];

l-(l-(2-fluoroethyl)piperidin-4-yl)-N-(2-(6-(isopropylamino)pyrazin-2-yl)-l,6-naphthyridin-7- yl)- 1H- 1 ,2,3 -triazole-4-carboxamide [863] ;

N-(2-(6-(isopropylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-l-(l-isopropylpiperidin-4-yl)-lH- l,2,3-triazole-4-carboxamide [864];

N-(2-(6-(isopropylamino)pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [865]; N-(2-(6-(fer^butylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-2-(3-(dimethylamino)azetidin-l- yl)isonicotinamide [866];

N-(2-(6-(fert-butylamino)pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl)- 1 '-methyl- 1 ',2',3 ',6'-tetrahydro-

[2,4'-bipyridine]-4-carboxamide [867];

N-(2-(6-(fer^butylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [868];

N-(2-(6-(fer^butylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-2-(4-isopropylpiperazin-l-yl) isonicotinamide [869];

N-(2-(6-(ferί-butylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-2-moφholinoisonicotinamide

[870];

N-(2-(6-(((3-fluoroazetidin-3-yl)methyl)amino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)

cyclopropanecarboxamide [871];

4-fluoro-N-(2-(6-(((3-fluoroazetidin-3-yl)methyl)amino)pyrazin-2-yl)-l,6-naphthyridin-7-yl) benzamide [872];

N-(2-(6-(piperidin-4-ylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)cyclobutanecarboxamide

[873];

3.3- difluoro-N-(2-(6-(piperidin-4-ylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)cyclobutane-l- carboxamide [874];

N-(2-(6-(piperidin-4-ylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)cyclopentanecarboxamide

[875];

4.4- difluoro-N-(2-(6-(piperidin-4-ylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)cyclohexane-l- carboxamide [876];

N-(2-(6-(piperidin-4-ylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)tetrahydro-2H-pyran-4- carboxamide [877];

4-fluoro-N-(2-(6-(piperidin-4-ylamino)pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl)benzamide [878] ; N-(2-(6-(((3S,4S)-3-fluoropiperidin-4-yl)amino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)

cyclopropanecarboxamide [879];

4-fluoro-N-(2-(6-(((3S,4S)-3-fluoropiperidin-4-yl)amino)pyrazin-2-yl)-l,6-naphthyridin-7-yl) benzamide [880];

N-(2-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)

cyclobutanecarboxamide [881];

N-(2-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)

cyclopentanecarboxamide [882] ; 4-fluoro-N-(2-(6-((l-methylpiperidin-4-yl)amm^

[883];

N-(2-(6-((1 sopropylpiperidin-4-yl)amino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)

cyclopropanecarboxamide [884];

3,3-difluoro-N-(2-(6-((l-isopropylpiperidin-4-yl)amino)pyrazin-2-yl)-l,6-naphthyridin-7-yl) cyclobutane-l-carboxamide [885];

N-(2-(6-((1 sopropylpiperidin-4-yl)amino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)

cyclopentanecarboxamide [886] ;

4-fluoro-N-(2-(6-(( 1 -isopropylpiperidin-4-yl)amino)pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl) benzamide [887];

N-(2-(6-(dimethylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [888];

N-(2-(6-(diethylamino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [889];

N-(2-(6-(3-aminoazetidin-l-yl)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-4-fluorobenzamide [890]; 2-(4-methylpiperazin- 1 -yl)-N-(2-(6-(pyrrolidin- 1 -yl)pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl) isonicotinamide [891];

N-(2-(6-(azetidin-3-ylmethoxy)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-4-fluorobenzamide [892]; N-(2-(6-(azetidin-3 -yloxy)pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl)-4-fluorobenzamide [893] ; N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yl)-l,6-naphthyridin-7-yl)-l-(l-methylpiperidin-4-yl)-lH- pyrazole-4-carboxamide [894];

N-(2-(lH-pyrrolo[3,2-b]pyridin-6-yl)-l,6-naphthyridin-7-yl)-l-(l-methylpiperidin-4-yl)-lH- pyrazole-4-carboxamide [895];

N-(2-( lH-pyrrolo[2,3 -c]pyridin-4-yl)- 1 ,6-naphthyridin-7-yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- pyrazole-4-carboxamide [896];

N-(2-(lH-pyrrolo[2,3-b]pyridin-5-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [897];

N-(2-(lH-pyrrolo[3,2-b]pyridin-6-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [898];

N-(2-(lH-pyrrolo[2,3-c]pyridin-4-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [899];

2-(4-methylpiperazin-l-yl)-N-(2-(oxazolo[5,4-b]pyridin-6-yl)-l,6-naphthyridin-7-yl)

isonicotinamide [900]; N-(2-(2-methyl-lH-pyrrolo[2,3-b]pyridin-5-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l- yl)isonicotinamide [901];

N-(2-(3-methyl-lH-pyrrolo[2,3-b]pyridin-5-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l- yl)isonicotinamide [902];

N-(2-(2-methyl-lH-pyrrolo[3,2-b]pyridin-6-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l- yl)isonicotinamide [903];

N-(2-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [904];

N-(2-(5H-pyrrolo[2,3-b]pyrazin-3-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l- yl)isonicotinamide [905];

1 -isopropyl-N-(2-(6-(piperidin-4-ylamino)pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl)- lH-pyrazole-4- carboxamide [906];

l-isopropyl-N-(2-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-lH- pyrazole-4-carboxamide [907];

fr «5-4-((2-fluoroethyl)amino)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)

cyclohexane-l-carboxamide [4535];

fr «5-4-((2-methoxyethyl)amino)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)

cyclohexane-l-carboxamide [4536];

fert-butyl (fr «5-4-((2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)carbamoyl)cyclohexyl) carbamate [4537];

N-(2-( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,6-naphthyridin-7-yl)-2-(( 1 -methylpiperidin-4-yl)amino) isonicotinamide [4538];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)thiazole-5- carboxamide [4539];

N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4-methylpiperazin-l-yl)thiazole-5- carboxamide [4540];

N-(2-( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)-2-(2,7- diazaspiro[3.5]nonan-2-yl)isonicotinamide [4541] ;

N-(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin-7-yl)-4-(piperidin-4-yloxy)benzamide

[4542];

N-(2-( 1 -methyl-lH-tetrazol-5 -yl)- 1 ,6-naphthyridin-7-yl)- 1 -(3,3,3-trifluoropropyl)piperidine-4- carboxamide [4543];

N-(2-(l,2-dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)-2-(pyrrolidin-l-yl)propanamide

[4544]; N-(2-( 1 ,2-dimethyl- lH-imidazol-5-yl)-l ,6-naphthyridin-7-yl)-2-(piperidin- 1 -yl)propanamide

[4545];

4-isopropoxy-N-(2-(7-methyl-5,6J,8-tetrahydroim ^

yl)benzamide [4546];

trans-3 -mo holino-N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)cyclobutane- 1 -carboxamide

[4547];

fr «5-4-(hydroxymethyl)-N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)cyclohexane-l-carboxamide

[4548];

N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)piperidine-4-carboxamide [4549] ;

4-morpholino-N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)piperidine- 1 -carboxamide [4550] ; N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)-4-(piperidin-4-yloxy)benzamide [4551];

N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)-3-(piperidin-4-yloxy)benzamide [4552] ;

2-methyl-N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl)-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H)- carboxamide [4553];

2-( lH-imidazol-1 -yl)-N-(2-(oxazol-5 -yl)- 1 ,6-naphthyridin-7-yl)acetamide [4554] ;

trans -4 -(hydroxymethyl) -N-(2-(thiazol -5 -yl) - 1 ,6 -naphthyridin-7-yl)cyclohexane - 1 -carboxamide

[4555];

fr «5-4-(dimethylamino)-N-(2-(thiazol-5 -yl)- 1 ,6-naphthyridin-7-yl)cyclohexane- 1 -carboxamide

[4556];

N-(2 -(thiazol-5 -yl) - 1 , 6-naphthyridin-7 -yl) - 1 -(( 1 -(trifluoromethyl)cyclopropyl)methyl)piperidine - 4-carboxamide [4557];

fr «5-4-(hydroxymethyl)-N-(2-(2-methylthiazol-5-yl)-l,6-naphthyridin-7-yl)cyclohexane-l- carboxamide [4558];

fr «5-4-(dimethylamino)-N-(2-(2-methylthiazol-5-yl)- 1 ,6-naphthyridin-7-yl)cyclohexane- 1 - carboxamide [4559];

N-(2-(2-methylthiazol-5-yl)-l,6-naphthyridin-7-yl)-l-(oxetan-3-yl)piperidine-4 -carboxamide

[4560];

N-(2-(2-methylthiazol-5-yl)-l,6-naphthyridin-7-yl)-l-(2-(pyrrolidin-l-yl)acetyl)piperidine-4- carboxamide [4561];

2-((lS,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(2-(5-methyl-l,3,4-thiadiazol-2-yl)-l,6- naphthyridin-7-yl)acetamide [4562] ;

N-(2-(5-(cyano(4-hydroxypiperidin- 1 -yl)methyl)pyridin-3 -yl)- 1 ,6-naphthyridin-7-yl)

cyclopropanecarboxamide [4563]; 4-fluoro-N-(2-(6-(( 1 -methylazetidin-3 -yl)methoxy)pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl) benzamide [4564] ;

l-isopropyl-N-(2-(6-(( l-methylpiperidin-4-yl)amino)pyrazin-2-yl)-l,6-naphthyridin-7-yl)-lH- pyrazole -4 -carboxamide [4565]; or a pharmaceutically acceptable salt thereof.

21. The compound according to any one of claims 1-19, wherein the compound of Formula I is selected from the group consisting of:

N-(7-( lH-pyrazol-4-yl)quinazolin-2-yl)-l -isobutylpiperidine-4-carboxamide [908];

N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2 -yl)cyclopropanecarboxamide [909] ;

4,4-difluoro-N-(7-( 1 -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)cyclohexane- 1 -carboxamide [910] ; fr «5-4-methoxy-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)cyclohexane- 1 -carboxamide

[911];

fr rø-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-4-moφholinocyclohexane-l - carboxamide [912];

trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)

cyclohexane - 1 -carboxamide [913] ;

fr «5-N-(7-(l -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-4-((4-methylpiperazin-l -yl)methyl) cyclohexane - 1 -carboxamide [914] ;

N-(7-(l -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(pyrrolidin-l -yl)acetamide [915];

(S)-2-(3 -fluoropyrrolidin- 1 -yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)acetamide [916] ; ( S) -N-(7 -( 1 -methyl - 1 H-pyrazol-4-yl)quinazolin-2-yl)tetrahydrofuran-2 -carboxamide [917]; N-(7 -( 1 -methyl - 1 H-pyrazol-4-yl)quinazolin-2 -yl)piperidine -4 -carboxamide [918];

l-methyl-N-(7-(l -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide [919] ; 1 -isopropyl-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide [920] ; 1 -(fert-butyl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide [921] ; l-cyclopropyl-N-(7-(l -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide [922] ; 1 -isobutyl-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide [923] ; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -neopentylpiperidine-4-carboxamide [924] ; 1 -(2 -fluoroethyl) -N-(7-( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2 -yl)piperidine -4 -carboxamide

[925];

N-(7-(l -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [926];

1 -butyl -N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2 -yl)piperidine -4 -carboxamide [927] ;

1 -benzoyl -N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide [928] ; l-(2,2-difluoropropyl)-N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4- carboxamide [929];

N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2-yl)azetidine -3 -carboxamide [930] ;

l-(2,2-difluoroethyl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide

[931];

1 -(2-fluoro-2-methylpropyl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4- carboxamide [932];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(oxetan-3-yl)piperidine-4-carboxamide

[933];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -((3-methyloxetan-3 -yl)methyl)piperidine-4- carboxamide [934];

1- (2-methoxyethyl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide

[935];

1 -(2-isopropoxyethyl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4- carboxamide [936];

1 , 1 -diisobutyl-4-((7-( 1 -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)carbamoyl)piperidin- 1 -ium

[937];

4-fluoro-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide [938] ; 4-fluoro- 1 -methyl -N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide

[939];

4-fluoro- 1 -isobutyl-N-(7-( 1 -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide

[940];

(S)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-3-carboxamide [941];

(R)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-3-carboxamide [942];

(S)-l-isobutyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-3-carboxamide [943]; (R)-l-isobutyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-3-carboxamide [944]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)tetrahydro-2H-pyran-4-carboxamide [945] ; N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(piperidin-l-yl)acetamide [946];

2- (4-fluoropiperidin-l -yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)acetamide [947] ; trans -4 -amino -N-(7-( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2 -yl)cyclohexane - 1 -carboxamide

[948];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl)acetamide [949] ; (S)-N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-2 -carboxamide [950];

2-(4-isobutylpiperazin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)acetamide [951]; 2-(3,3-dimethylazetidin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)acetamide [952]; (R)-2-(3-fluoropyrrolidin- 1 -yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)acetamide [953] ; (S)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(2-methylpyrrolidin-l-yl)acetamide

[954];

2-(3-azabicyclo[3.1.0]hexan-3-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)acetamide

[955];

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)acetamide

[956];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperidin- 1 -yl)acetamide [957] ; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-(trifluoromethyl)piperidin- 1 -yl)acetamide

[958];

2-(4-(difluoromethyl)piperidin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)acetamide

[959];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(6-azaspiro[2.5]octan-6-yl)acetamide [960]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(pyrrolidin-l -yl)propanamide [961] ;

(R)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(2-methylpyrrolidin-l-yl)acetamide

[962];

2-(cyclobutyl(methyl)amino)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)acetamide [963] ; 2-(diethylamino) -N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2 -yl)acetamide [964] ;

7-(2-fluoroethyl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-7-azaspiro[3.5]nonane-2- carboxamide [965];

4-methyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperazine-l-carboxamide [966]; (S)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl)propanamide [967]; (R)-N-(7-( 1 -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(pyrrolidin- 1 -yl)propanamide [968] ; (R) -N-(7 -( 1 -methyl - 1 H-pyrazol-4 -yl)quinazolin-2-yl)pyrrolidine -2-carboxamide [969] ;

2-methyl-N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2-yl) -2 -azaspiro [3.3 ]heptane -6 - carboxamide [970];

N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(2,2,2-trifluoroacetyl)-2-azaspiro[3.3]

heptane-6-carboxamide [971];

2-(2-fluoroethyl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-azaspiro[3.3]heptane-6- carboxamide [972];

fr «5-4-(dimethylamino)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)cyclohexane- 1 - carboxamide [973];

l-acetyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide [974]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(( 1 -(trifluoromethyl)cyclopropyl)methyl) piperidine-4-carboxamide [975];

(S)-l-(2-fluoropropyl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4- carboxamide [976];

(R)-l-(2-fluoropropyl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4- carboxamide [977];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(piperidin-l-yl)propanamide [978];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(methylsulfonyl)piperidine-4-carboxamide

[979];

1 '-methyl -N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-[ 1 ,4'-bipiperidine] -4-carboxamide

[980];

fr «5-4-(hydroxymethyl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)cyclohexane-l- carboxamide [981];

methyl 2 -(4-((7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2 -yl)carbamoyl)piperidin- 1 -yl)acetate

[982];

1- benzyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide [983]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(2-(pyrrolidin-l -yl)acetyl)piperidine-4- carboxamide [984];

N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2-yl) -2 -morpholinoacetamide [985] ;

(S)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(3-methylmoφholino)acetamide [986]; (R)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(3-methylmoφholino)acetamide [987]; (S)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(2-methylmoφholino)acetamide [988];

2- ((2R,6S)-2,6-dimethylmoφholino)-N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)acetamide

[989];

2-((lS,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2- yl)acetamide [990];

2-((lR,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2- yl)acetamide [991];

2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)

acetamide [992];

(S)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-mo holinopropanamide [993];

N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(mo holin-2-yl)acetamide [994];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylmo holin-2-yl)acetamide [995] ; 2-(4-ethylpiperazin-l -yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)acetamide [996] ; 2-(4-isopropylpiperazin-l -yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)acetamide [997] ; 2-(4-cyclopropylpiperazin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)acetamide

[998];

2-(4-(2-fluoroethyl)piperazin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)acetamide

[999];

(S)-2-(2,4-dimethylpiperazin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)acetamide

[1000];

1 -(2 -hydroxy ethyl) -N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2 -yl)piperidine -4-carboxamide

[1001];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(pyridin-2-ylmethyl)piperidine-4- carboxamide [1002];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(oxazol-2-ylmethyl)piperidine-4- carboxamide [1003];

(R)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -oxotetrahydro-lH-pyrrolo[ 1 ,2-c]

imidazole-2(3H)-carboxamide [1004] ;

(R)-l-methyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)pyrrolidine-2-carboxamide

[1005];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(tetrahydro-2H-pyran-4-yl)piperidine-4- carboxamide [1006];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(pyrimidin-2-ylmethyl)piperidine-4- carboxamide [1007];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(pyrazin-2-ylmethyl)piperidine-4- carboxamide [1008];

1 -((5 -methyl- 1 ,2,4-oxadiazol-3-yl)methyl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2- yl)piperidine -4 -carboxamide [1009] ;

1- (2-hydroxy-2-methylpropyl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4- carboxamide [1010];

fert-butyl 2 -(4-((7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2 -yl)carbamoyl)piperidin- 1 -yl)acetate

[1011];

2- (4-((7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)carbamoyl)piperidin-l-yl)acetic acid [1012]; 2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(7-( 1 -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)acetamide

[1013];

tert-butyl (7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)carbamate [1014] ;

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)but-2-ynamide [1015]; trans -4 -((7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2 -yl)carbamoyl)cyclohexane - 1 -carboxylic acid [1016];

N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2-yl) -3 -morpholinopropanamide [1017];

fr rø-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-3-moφholinocyclobutane-l-carboxamide

[1018];

N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2 -yl)quinuclidine -4-carboxamide [1019];

1 -isobutyl-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)azepane-4-carboxamide [1020] ;

2-(4-methoxypiperidin- 1 -yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)acetamide [1021] ;

2- (4-hydroxypiperidin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)acetamide [1022];

3- (hydroxymethyl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)bicyclo[ 1.1. l]pentane- 1 - carboxamide [1023];

1 -methyl -N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2-yl)azepane -4 -carboxamide [ 1024] ;

fr «5-4-(dimethylamino)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)cyclohexane- 1 - carboxamide [1025];

fr «5-4-(bis(methyl-£/3)amino)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)cyclohexane-l- carboxamide [1026];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-3-((4-methylpiperazin- 1 -yl)methyl)bicyclo

[1.1. l]pentane-l -carboxamide [1027];

methyl trans-4-((7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)carbamoyl)cyclohexane- 1 - carboxylate [1028];

2-( 1 -isobutylpyrrolidin-3-yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)acetamide [1029] ; fr «5-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-4-(4-methylpiperazine-l-carbonyl)

cyclohexane-1 -carboxamide [1030];

1 -isobutyl-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide [1031] ; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(phenylsulfonyl)piperidine-4-carboxamide

[1032];

8 -methyl -N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2-yl) -3 , 8 -diazabicyclo [3.2.1] octane -3 - carboxamide [1033];

3 -methyl -N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2-yl) -3 , 8 -diazabicyclo [3.2.1] octane -8 - carboxamide [1034];

(lR,3s,5S)-3-amino-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-8-azabicyclo[3.2.1]octane- 8-carboxamide [1035];

(lR,3s,5S)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-3-((3,3,3-trifluoropropyl)amino)-8- azabicyclo[3.2.1] octane -8 -carboxamide [1036]; ( 1 R,3s,5 S)-3 -(( 1 ,3-difluoropropan-2-yl)amino)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2- yl)-8-azabicyclo[3.2.1] octane -8 -carboxamide [1037];

N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2-yl)morpholine -4 -carboxamide [ 1038] ;

4-(dimethylamino)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-l-carboxamide

[1039];

(S)-2,4-dimethyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperazine-l -carboxamide

[1040];

1 -methyl-3-(7-( 1 -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -( 1 -methylpiperidin-4-yl)urea

[1041];

1 -(7-( 1 -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-3 -( 1 -methylpiperidin-4-yl)urea [1042] ;

4-isopropyl-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperazine-l -carboxamide [1043] ; (R)-3,4-dimethyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)piperazine-l -carboxamide

[1044];

N-(7-(lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [1045]; N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-3-(piperazin-l-yl)benzamide [1046];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-3-(4-methylpiperazin- 1 -yl)benzamide [1047] ; N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-3-(pyrrolidin-l-ylmethyl)benzamide [1048]; N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-3-(piperidin-4-yloxy)benzamide [1049]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-3-(( 1 -methylpiperidin-4-yl)oxy)benzamide

[1050];

N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-4-(piperidin-4-yloxy)benzamide [1051]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-4-(( 1 -methylpiperidin-4-yl)oxy)benzamide

[1052];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(piperazin-l-yl)isonicotinamide [1053];

[1054];

2-(4-isopropylpiperazin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)isonicotinamide

[1055];

2-(4-cyclopropylpiperazin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)

isonicotinamide [1056];

2-(4-(2-fluoroethyl)piperazin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)

isonicotinamide [1057];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-6-(4-methylpiperazin- 1 -yl)nicotinamide

[1058];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-5-(piperidin-4-yloxy)nicotinamide [1059]; N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(piperidin-4-yloxy)isonicotinamide [1060]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(( 1 -methylpiperidin-4-yl)oxy)

isonicotinamide [1061];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-5-(piperidin-4-ylamino)nicotinamide [1062]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-5-(( 1 -methylpiperidin-4-yl)amino)nicotinamide

[1063];

2-(4-aminopiperidin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)isonicotinamide

[1064];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-(methylamino)piperidin- 1 -yl)

isonicotinamide [1065];

2-(4-(dimethylamino)piperidin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)

isonicotinamide [1066];

2-(( 1 -isopropylpiperidin-4-yl)oxy)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)

isonicotinamide [1067];

2-(3 -aminoazetidin- 1 -yl)-N-(7-( 1 -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)isonicotinamide

[1068];

2-(3-(dimethylamino)azetidin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)

isonicotinamide [1069];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-mo holinoisonicotinamide [1070];

2-((2-(dimethylamino)ethyl)amino)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)

isonicotinamide [1071];

2-(2-(dimethylamino)ethoxy)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)isonicotinamide

[1072];

2-(4-isobutylpiperazin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)isonicotinamide

[1073];

2-(azetidin-3-yloxy)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)isonicotinamide [1074]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(( 1 -methylazetidin-3 -yl)oxy)isonicotinamide

[1075];

2-(4-ethylpiperazin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)isonicotinamide

[1076];

4-((dimethylamino)methyl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)benzamide [1077]; N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-3-(l-methylpiperidin-4-yl)benzamide [1078]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-3-((4-methylpiperazin- 1 -yl)methyl)benzamide

[1079]; N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)isonicotinamide [1080];

2-hydroxy-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)isonicotinamide [1081] ;

2-isopropoxy-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)isonicotinamide [1082];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-( 1 -methylpiperidin-4-yl)isonicotinamide

[1083];

r-methyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-l',2',3',6'-tetrahydro-[2,4'- bipyridine]-4-carboxamide [1084];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-(6-(4-methylpiperazin- 1 -yl)

nicotinoyl)piperazin- 1 -yl)isonicotinamide [1085] ;

2-(4-hydroxy-4-methyl-4 4-piperazin-l-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl) isonicotinamide [1086];

2-methyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-6-(4-methylpiperazin-l-yl)

isonicotinamide [1087];

3 -methyl -N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2-yl) -2-(4 -methylpiperazin- 1 -yl)

isonicotinamide [1088];

2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(7-( 1 -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)isonicotinamide

[1089];

2-((2S,6R)-2,6-dimethylmo holino)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)

isonicotinamide [1090];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(2,7-diazaspiro[3.5]nonan-2-yl)

isonicotinamide [1091];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl) isonicotinamide [1092];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(2,7-diazaspiro[3.5]nonan-7-yl)

isonicotinamide [1093];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(2-methyl-2,7-diazaspiro[3.5]nonan-7-yl) isonicotinamide [1094];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl) isonicotinamide [1095];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(( 1 -methylpiperidin-4-yl)thio)

isonicotinamide [1096];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl)pyrimidine-4- carboxamide [1097]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-6-(4-methylpiperazin- 1 -yl)pyridazine-4- carboxamide [1098];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-6-(4-methylpiperazin- 1 -yl)pyrimidine-4- carboxamide [1099];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-phenylacetamide [1100] ;

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-3-phenylpropanamide [1101];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(pyridin-3 -yl)acetamide [1102] ;

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-3-(pyridin-3 -yl)propanamide [1103] ;

N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(pyridin-4-yl)acetamide [1104];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-3-(pyridin-4-yl)propanamide [1105];

N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2 -yl)isoindoline -5 -carboxamide [1106] ;

2-methyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)isoindoline-5-carboxamide [1107]; N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-l,2,3,4-tetrahydroisoquinoline-7 -carboxamide

[1108];

2-methyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-l,2,3,4-tetrahydroisoquinoline-7- carboxamide [1109];

2-methyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-l,2,3,4-tetrahydroisoquinoline-6- carboxamide [1110];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-l,2,3,4-tetrahydroisoquinoline-6-carboxamide

[1111];

N-(7-(l-methyl-lH-pyrazol-4-yl quinazolin-2-yl) - 1 H-indole -5 -carboxamide [1112];

N-(7-(l-methyl-lH-pyrazol-4-yl quinazolin-2 -yl)benzofuran-5 -carboxamide [1113];

N-(7-( 1 -methyl- 1 H-pyrazol -4 -yl quinazolin-2 -yl)furo [2,3 -c]pyridine-5 -carboxamide [1114]; N-(7-(l-methyl-lH-pyrazol-4-yl quinazolin-2-yl)benzo[b]thiophene-5 -carboxamide [1115]; N-(7-(l-methyl-lH-pyrazol-4-yl quinazolin-2 -yl)benzofuran-6-carboxamide [1116];

N-(7-(l-methyl-lH-pyrazol-4-yl quinazolin-2 -yl)benzo [d] oxazole -6 -carboxamide [111 ]; N-(7-(l-methyl-lH-pyrazol-4-yl quinazolin-2 -yl)benzo [d]thiazole -6-carboxamide [1118]; N-(7-(l-methyl-lH-pyrazol-4-yl quinazolin-2 -yl)benzo [d] oxazole -5 -carboxamide [1119]; N-(7-(l-methyl-lH-pyrazol-4-yl quinazolin-2 -yl)benzo [d]thiazole -5 -carboxamide [1120]; N-(7-(l-methyl-lH-pyrazol-4-yl quinazolin-2 -yl)quinoline -3 -carboxamide [1121];

N-(7-(l-methyl-lH-pyrazol-4-yl quinazolin-2 -yl)quinoline-6-carboxamide [1122] ;

N-(7-(l-methyl-lH-pyrazol-4-yl quinazolin-2 -yl )quinoxaline -6 -carboxamide [1123];

5-chloro-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [1124]; 3-chloro-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [1125];

2- (2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)

isonicotinamide [1126];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2- yl)isonicotinamide [1127];

3- fluoro-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [1128];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-((4-methylpiperazin- 1 -yl)methyl)

isonicotinamide [1129];

N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(mo holinomethyl)isonicotinamide [1130]; N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(pyrrolidin-l-ylmethyl)isonicotinamide

[1131];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(2-(4-methylpiperazin-l-yl)pyridin-4-yl) acetamide [1132];

1 -methyl -N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2-yl) - 1 H-indazole -5 -carboxamide [1133]; 1 -methyl -N-(7 -( 1 -methyl - 1 H-pyrazol -4 -yl)quinazolin-2-yl) - 1 H-benzo [d] imidazole-5 - carboxamide [1134];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(piperidin-4-yl)-lH-pyrazole-4-carboxamide

[1135];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazole-4- carboxamide [1136];

1 -( 1 -ethylpiperidin-4-yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-lH-pyrazole-4- carboxamide [1137];

l-(l-(2-fluoroethyl)piperidin-4-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-lH- pyrazole -4 -carboxamide [1138];

1 -( 1 -isopropylpiperidin-4-yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- lH-pyrazole-4- carboxamide [1139];

1 -( 1 -cyclopropylpiperidin-4-yl)-N-(7-( 1 -methyl-lH-pyrazol-4-yl)quinazolin-2-yl)- lH-pyrazole- 4-carboxamide [1140];

isopropyl 4-(4-((7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)carbamoyl)-lH-pyrazol-l- yl)piperidine-l -carboxylate [1141];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-l-(piperidin-4-yl)-lH-l,2,3-triazole-4- carboxamide [1142]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- 1 ,2,3-triazole-4- carboxamide [1143];

l-(l-(2-fluoroethyl)piperidin-4-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-lH-l,2,3- triazole-4-carboxamide [1144];

1- (l-isopropylpiperidin-4-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-lH-l,2,3- triazole-4-carboxamide [1145];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl)oxazole-5 - carboxamide [1146];

2- (3 -(dimethylamino)azetidin- 1 -yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)oxazole-4- carboxamide [1147];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide

[1148];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-( 1 -methylpiperidin-4-yl)oxazole-4- carboxamide [1149];

2-(l-(2-fluoroethyl)piperidin-4-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)oxazole-4- carboxamide [1150];

2-(l-isopropylpiperidin-4-yl)-N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)oxazole-4- carboxamide [1151];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl)oxazole-4- carboxamide [1152];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)thiazole-5 - carboxamide [1153];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(piperidin-4-yl)thiazole-4-carboxamide

[1154];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl)thiazole-4- carboxamide [1155];

2-(l-(2-fluoroethyl)piperidin-4-yl)-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)thiazole-4- carboxamide [1156];

2-( 1 -isopropylpiperidin-4-yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)thiazole-4- carboxamide [1157];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(2-(methyl- 3)propyl- 1 , 1 ,2,3, 3,3-£/e)

piperidine-4-carboxamide [1158];

N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl -2,2,5, 5-<¾)acetamide [1159]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-(methyl-£/3)piperazin-l-yl)acetamide [1160];

N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(mo holino-ί s)acetamide [1161];

( S) -N-(7 -( 1 -(methyl -ds) - 1 H-pyrazol -4 -yl)quinazolin-2 -yl)-2 -(pyrrolidin- 1 -yl)propanamide

[1162];

l-isobutyl-N-(7-(l-(methyl- 3)-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide

[1163];

N-(7-(l-(methyl-£/3)-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)acetamide

[1164];

N-(7-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(pyrrolidin- 1 -yl)acetamide [1165] ; N-(7-(l-(methyl-£/3)-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(piperidin-l-yl)acetamide [1166];

N-(7-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(3,3,3 -trifluoropropyl)piperidine-4- carboxamide [1167];

N-(7-(lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-(methyl-£/3)piperazin-l-yl)isonicotinamide [1168]; N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-(methyl- 3)piperazin- 1 -yl)isonicotinamide

[1169];

N-(7-(l-(methyl- 3)-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[1170];

N-(7-( 1 -(methyl-^)- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-(methyl-£/3)piperazin-l -yl)

isonicotinamide [1171];

N-(7-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(piperidin-4-yl)- lH-pyrazole-4- carboxamide [1172];

N-(7-( 1 -(methyl -<¾)- 1 H-pyrazol -4 -yl)quinazolin -2 -yl)- 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazole-4- carboxamide [1173];

N-(7-(l -(methyl-^)- 1 H-pyrazol -4 -yl)quinazolin -2 -yl)-2-(piperidin-4-yl)oxazole-4-carboxamide

[1174];

N-(7-( 1 -(methyl -<¾)- 1 H-pyrazol -4 -yl)quinazolin -2 -yl)-2-( 1 -methylpiperidin-4-yl)oxazole-4- carboxamide [1175];

N-(7-( 1 -ethyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(pyrrolidin-l -yl)acetamide [1176] ;

N-(7-(l-cyclopropyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl)acetamide [1177]; N-(7-(l-cyclopropyl-lH-pyrazol-4-yl)quinazolin-2-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [1178];

N-(7-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)quinazolin-2-yl)cyclohexanecarboxamide

[1179]; 2-(pyrrolidin- 1 -yl)-N-(7-(5-(trifluoromethyl)- lH-pyrazol-4-yl)quinazolin-2-yl)acetamide [1180] ; N-(7-(5-(hydroxymethyl)- 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -methylpiperidine-4- carboxamide [1181];

N-(7-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)tetrahydro-2H-pyran-4- carboxamide [1182];

N-(7-(5-(azetidin-l-ylmethyl)-l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-4,4- difluorocyclohexane- 1 -carboxamide [1183] ;

4,4-difluoro-N-(7-( 1 -methyl -5 -(pyrrolidin-1 -ylmethyl)- lH-pyrazol-4-yl)quinazolin-2-yl)

cyclohexane-1 -carboxamide [1184];

4,4-difluoro-N-(7-( 1 -methyl -5 -(piperidin-1 -ylmethyl)- lH-pyrazol-4-yl)quinazolin-2-yl)

cyclohexane-1 -carboxamide [1185];

2-(2 -fluoroethyl) -N-(7 -( 1 -methyl -5 -(piperidin- 1 -ylmethyl) - 1 H-pyrazol -4 -yl)quinazolin-2 -yl) -2 - azaspiro [3.3] heptane -6 -carboxamide [1186];

fert-butyl 6-((7-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)quinazolin-2-yl)carbamoyl)-

2-azaspiro [3.3] heptane -2 -carboxylate [1187];

2-fluoro-2 -methyl -N-(7-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)quinazolin-2-yl) propanamide [1188];

2-(diethylamino)-N-(7-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)-lH-pyrazol-4-yl)quinazolin-2-yl) acetamide [1189];

fr «5-4-methoxy-N-(7-( 1 -methyl-5 -(piperidin-1 -ylmethyl)- lH-pyrazol-4-yl)quinazolin-2-yl) cyclohexane-1 -carboxamide [1190];

fr «5-4-(hydroxymethyl)-N-(7-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)quinazolin-2- yl)cyclohexane - 1 -carboxamide [1191];

(R)-N-(7-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)quinazolin-2-yl)pyrrolidine-2- carboxamide [1192];

l-isobutyl-N-(7-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-

4-carboxamide [1193];

N-(7-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -(oxetan-3 -yl)

piperidine-4-carboxamide [1194];

l-benzoyl-N-(7-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-

4-carboxamide [1195];

N-(7-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)quinazolin-2-yl)tetrahydro-2H-pyran- 4-carboxamide [1196]; N-(7-( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperidin- l-yl)acetamide [1197];

N-(7-(l-(difluoromethyl)-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [1198];

N-(7-( 1 -ethyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide

[1199];

N-(7-(l-isopropyl-lH-pyrazol-4-yl)quinazolin-2-yl)-3 -(piperidin -4-yloxy)benzamide [1200]; N-(7-( 1 -isopropyl- lH-pyrazol-4-yl)quinazolin-2-yl)-3 -(( 1 -methylpiperidin-4-yl)oxy)benzamide

[1201];

N-(7-(l -isopropyl- lH-pyrazol-4-yl)quinazolin-2-yl)-4-(piperidin-4-yloxy)benzamide [1202]; N-(7-(l-cyclopropyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [1203];

4-fluoro-N-(7-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)quinazolin-2-yl)benzamide [1204] ;

4- (difluoromethoxy)-N-(7-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)quinazolin-2-yl)

benzamide [1205];

5- fluoro-N-(7-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)quinazolin-2-yl)nicotinamide [1206] ; N2 -methyl -N5-(7-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)quinazolin-2-yl)pyridine-2,5- dicarboxamide [1207];

1 -isopropyl -N-(7-( 1 -( 1 -methylpiperidin-4-yl)-lH-pyrazol-4-yl)quinazolin-2-yl)- lH-pyrazole-4- carboxamide [1208];

2-methyl-N-(7-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)quinazolin-2-yl)thiazole-5 - carboxamide [1209];

N-(7-(5 -amino- 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l -yl)

isonicotinamide [1210];

4-(difluoromethoxy)-N-(7-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)

benzamide [1211];

N-(7-(5-(hydroxymethyl)- 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl) isonicotinamide [1212];

N-(7-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(7-methyl-2,7-diazaspiro

[3.5]nonan-2-yl)isonicotinamide [1213];

4-fluoro-N-(7-(l-methyl-5-(pyrrolidin-l-ylmethyl)-lH-pyrazol-4-yl)quinazolin-2-yl)benzamide

[1214];

4-fluoro-N-(7-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)quinazolin-2-yl)benzamide

[1215]; 4-(difluoromethoxy)-N-(7-( 1 -methyl-5 -(pi

benzamide [1216];

N-(7-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)quinazolin-2-yl)-3-(pyrrolidin-l - ylmethyl)benzamide [1217];

N-(7-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(7-methyl -2,7- diazaspiro[3.5]nonan-2-yl)isonicotinamide [1218] ;

N-(7-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)quinazolin-2-yl)-2- moφholinoisonicotinamide [1219];

N-(7-( 1 -methyl-5 -(morpholinomethyl)- lH-pyrazol-4-yl)quinazolin-2-yl)-2- moφholinoisonicotinamide [1220];

N-(7-(4,5,6,7-tetrahydropyrazolo[ 1 ,5-a]pyrazin-3 -yl)quinazolin-2-yl)- 1 -(( 1 -(trifluoromethyl) cyclopropyl)methyl)piperidine-4-carboxamide [1221] ;

3,3-difluoro-N-(7-(5-methyl-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)quinazolin-2-yl) cyclobutane-l-carboxamide [1222];

N-((4,4-difluorocyclohexyl)methyl)-7-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]

pyrazin-3 -yl)quinazolin-2 -amine [1223] ;

N-(7-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)quinazolin-2-yl)-l-((l-

(trifluoromethyl)cyclopropyl)methyl)piperidine -4 -carboxamide [ 1224] ;

N-(7-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)quinazolin-2-yl)-2-

(pyrrolidin- 1 -yl)acetamide [1225];

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(7-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a] pyrazin-3 -yl)quinazolin-2-yl)acetamide [1226] ;

(R)-N-(7-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[ 1 ,5 -a]pyrazin-3 -yl)quinazolin-2-yl)- 1 - isobutylpiperidine-3 -carboxamide [1227] ;

N-(7-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)quinazolin-2-yl)piperidine-

4-carboxamide [1228];

4-fluoro-N-(7-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)quinazolin-2-yl)-

1 -isobutylpiperidine -4-carboxamide [1229];

N-(7-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)quinazolin-2-yl)-2-(4- methylpiperazin- 1 -yl)acetamide [1230] ;

4-fluoro-N-(7-(4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)quinazolin-2-yl)benzamide [1231]; N-(7-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)quinazolin-2-yl)-3-(4- methylpiperazin- 1 -yl)benzamide [1232]; N5-(7-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)quinazolin-2-yl)-N2- methylpyridine-2,5 -dicarboxamide [1233] ;

N-(7-(5-(2-fluoroethyl)-4,5,6J-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)quinazolin-2-yl)-6-(4- methylpiperazin- 1 -yl)nicotinamide [1234];

2-(azetidin-3-yloxy)-N-(7-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl) quinazolin-2-yl)isonicotinamide [1235];

N-(7-( 1 -methyl- lH-pyrazol-5 -yl)quinazolin-2-yl)- 1 -(3,3,3-trifluoropropyl)piperidine-4- carboxamide [1236];

1- methyl-N-(7-(l-methyl-lH-pyrazol-3-yl)quinazolin-2-yl)piperidine-4-carboxamide [1237]; N-(7-( 1 -methyl- lH-pyrazol -3 -yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide

[1238];

2- fluoro-2 -methyl -N-(7-( 1 -methyl-lH- 1 ,2,3 -triazol-4-yl)quinazolin-2-yl)propanamide [1239] ; 2,2,3, 3-tetramethyl-N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)cyclopropane-l- carboxamide [1240];

fr «5-N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-4-(pyrrolidin-l-yl)cyclohexane-l- carboxamide [1241];

trans-N-(7-( 1 -methyl- lH-1 ,2,3-triazol-4-yl)quinazolin-2-yl)-4-mo holinocyclohexane- 1 - carboxamide [1242];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-2-(piperidin-l-yl)acetamide [1243]; 1 -ethyl -4-fluoro-N-(7-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide

[1244];

4-fluoro- 1 -isobutyl-N-(7-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)quinazolin-2-yl)piperidine-4- carboxamide [1245];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [1246];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)cyclopropanecarboxamide [1247];

4,4-difluoro-N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)cyclohexane-l -carboxamide

[1248];

trans -4 -(dimethylamino) -N-(7-( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)quinazolin-2-yl)cyclohexane- 1 - carboxamide [1249];

fr «5-N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-4-((4-methylpiperazin-l-yl)methyl) cyclohexane-1 -carboxamide [1250];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide [1251]; 1- isobutyl-N-(7-(l-methyl-lH-l,2,3 riazol-4-yl)quinazolin-2-yl)piperidine-4-carboxamide

[1252];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-l-((l-(trifluoromethyl)cyclopropyl)

methyl)piperidine -4 -carboxamide [1253];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-l-((3-methyloxetan-3-yl)methyl)

piperidine-4-carboxamide [1254];

N-(7-(l-methyl-lH-l,2,3 riazol-4-yl)quinazolin-2-yl)-l-(2-(pyrrolidin-l-yl)acetyl)piperidine-4- carboxamide [1255];

1 '-methyl-N-(7-( 1 -methyl- 1H- 1,2,3 -triazol-4-yl)quinazolin-2-yl)-[ 1 ,4'-bipiperidine] -4- carboxamide [1256];

(R)-N-(7-( 1 -methyl-lH- 1 ,2,3-triazol-4-yl)quinazolin-2-yl)piperidine-3 -carboxamide [1257] ; (R)-l-isobutyl-N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)piperidine-3-carboxamide

[1258];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl)acetamide [1259]; N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)acetamide

[1260];

2- (7-azabicyclo[2.2.1]heptan-7-yl)-N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)

acetamide [1261];

1 -(2-hydroxy-2-methylpropyl)-N-(7-( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)quinazolin-2-yl)piperidine-

4-carboxamide [1262];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-2-moφholinoacetamide [1263];

2-(4-methoxypiperidin-l-yl)-N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)acetamide

[1264];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)mo holine-4-carboxamide [1265];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-l-(piperidin-4-yl)-lH-pyrazole-4- carboxamide [1266];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [1267];

1 -( 1 -ethylpiperidin-4-yl)-N-(7-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)quinazolin-2-yl)- lH-pyrazole-4- carboxamide [1268];

l-(l-isopropylpiperidin-4-yl)-N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-lH- pyrazole-4-carboxamide [1269];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-l-(piperidin-4-yl)-lH-l,2,3-triazole-4- carboxamide [1270]; l-(l-(2-fluoroethyl)piperidin-4-yl)-N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-lH- l,2,3-triazole-4-carboxamide [1271];

1- (l-isopropylpiperidin-4-yl)-N-(7-(l-methyl-lH-l,2,3 riazol-4-yl)quinazolin-2-yl)-lH-l,2,3- triazole-4-carboxamide [1272];

N-(7-(l-methyl-lH-l,2,3 riazol-4-yl)quinazolin-2-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide

[1273];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-2-(l-methylpiperidin-4-yl)oxazole-4- carboxamide [1274];

2- (1 sopropylpiperidin-4-yl)-N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)oxazole-4- carboxamide [1275];

2-fluoro-N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)benzamide [1276];

N-(7-(l-methyl-lH-l,2,3 riazol-4-yl)quinazolin-2-yl)-3-((l-methylpiperidin-4-yl)oxy)benzamide

[1277];

N2 -methyl -N5-(7-(l-methyl-lH-l,2,3 riazol-4-yl)quinazolin-2-yl)pyridine-2,5-dicarboxamide

[1278];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-6-(4-methylpiperazin-l-yl)nicotinamide

[1279];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(7-( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)quinazolin-2-yl)

isonicotinamide [1280];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-2-(l-methylpiperidin-4-yl)isonicotinamide

[1281];

2-(4-(dimethylamino)piperidin-l-yl)-N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl) isonicotinamide [1282];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-2-moφholinoisonicotinamide [1283]; N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[1284];

2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(7-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)quinazolin-2-yl)

isonicotinamide [1285];

2-(4-isopropylpiperazin-l -yl)-N-(7-( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)quinazolin-2-yl)

isonicotinamide [1286];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-2-(piperidin-4-ylamino)isonicotinamide

[1287];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(7-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)quinazolin-2-yl) isonicotinamide [1288]; N-(7-(l-methyl-lH-l,2,3 riazol-4-yl)quinazolin-2-yl)-2-((l-methylpiperidin-4-yl)thio) isonicotinamide [1289];

2-methyl-N-(7-(l-methyl-lH-l,2,3 riazol-4-yl)quinazolin-2-yl)-l,2,3,4 etrahydroisoquinoline- 6-carboxamide [1290];

N-(7-(l-methyl-lH-l,2,3 riazol-4-yl)quinazolin-2-yl)-2-(piperazin-l-yl)isonicotinamide [1291]; N-(7-(l-methyl-lH-l,2,3 riazol-4-yl)quinazolin-2-yl)-2-(2-(4-methylpiperazin-l-yl)pyridin-4-yl) acetamide [1292];

1 , 1 -bis(methyl-£¾)-4-(4-((7-( 1 -methyl- 1H- 1,2,3 -triazol-4-yl)quinazolin-2-yl)carbamoyl)pyridin-

2-yl)piperazin-l-ium [1293];

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-2-(4-(methyl-£/3)piperazin-l-yl)

isonicotinamide [1294];

N-(7-(l-methyl-lH-l,2,3-triazol-5-yl)quinazolin-2-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [1295];

N-(7-(4-methyl-4H-l,2,4-triazol-3-yl)quinazolin-2-yl)-2-moφholinoacetamide [1296];

N-(7-(4-methyl-4H-l,2,4-triazol-3-yl)quinazolin-2-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [1297];

4-fluoro- 1 -isobutyl-N-(7-(4-methyl-4H- 1 ,2,4-triazol-3 -yl)quinazolin-2-yl)piperidine-4- carboxamide [1298];

N-(7-(4,5-dimethyl-4H-l,2,4-triazol-3-yl)quinazolin-2-yl)-2-mo holinoacetamide [1299];

N-(7-(4,5-dimethyl-4H-l,2,4-triazol-3-yl)quinazolin-2-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [1300];

N-(7-( 1H- 1 ,2,3 -triazol- 1 -yl)quinazolin-2-yl)-4-fluoro- 1 -isobutylpiperidine-4 -carboxamide

[1301];

N-(7-(2H- 1 ,2,3 -triazol-2-yl)quinazolin-2-yl)-4-fluoro- 1 -isobutylpiperidine-4 -carboxamide

[1302];

N-(7-(lH-l,2,4-triazol-l-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [1303]; 1 -isobutyl-N-(7-( 1 -methyl- lH-tetrazol-5-yl)quinazolin-2-yl)piperidine-4-carboxamide [1304] ; 2,2,3, 3-tetramethyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)cyclopropane-l- carboxamide [1305];

4,4-difluoro-N-(7-( 1 -methyl-lH-imidazol-5 -yl)quinazolin-2-yl)cyclohexane- 1 -carboxamide

[1306];

N-(7 -( 1 -methyl - 1 H-imidazol-5 -yl)quinazolin-2 -yl) -2 -(piperidin- 1 -yl)acetamide [ 1307] ;

2-fluoro-2 -methyl -N-(7-( 1 -methyl- lH-imidazol-5-yl)quinazolin-2-yl)propanamide [1308] ;

1 -fluoro-N-(7-( 1 -methyl- lH-imidazol-5-yl)quinazolin-2-yl)cyclopropane-l -carboxamide [1309] ; 2-methyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-azaspiro[3.3]heptane-6- carboxamide [1310];

1 -fluoro-N-(7-( 1 -methyl- lH-imidazol-5-yl)quinazolin-2-yl)cyclohexane-l -carboxamide [1311]; fr «5-4-methoxy-N-(7-( 1 -methyl- lH-imidazol-5 -yl)quinazolin-2-yl)cyclohexane-l -carboxamide

[1312];

trans -4 -(hydroxymethyl) -N-(7-( 1 -methyl - 1 H-imidazol -5 -yl)quinazolin-2 -yl)cyclohexane - 1 - carboxamide [1313];

N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)azetidine-3-carboxamide [1314];

(R)-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)tetrahydrofuran-2 -carboxamide [1315]; l-(2-methoxyethyl)-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)piperidine-4-carboxamide

[1316];

N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [1317];

1- isobutyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)piperidine-4-carboxamide [1318]; N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-l-(methylsulfonyl)piperidine-4-carboxamide

[1319];

N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl)propanamide [1320];

2- isopropoxy-N-(7 -( 1 -methyl - 1 H-imidazol -5 -yl)quinazolin-2 -yl)acetamide [1321];

3 -isopropoxy-N-(7 -( 1 -methyl - 1 H-imidazol -5 -yl)quinazolin-2 -yl)propanamide [ 1322] ;

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)cyclopropanecarboxamide [1323];

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)cyclohexanecarboxamide [1324];

N-(7-( 1 ,2-dimethyl- lH-imidazol-5-yl)quinazolin-2-yl)-4,4-difluorocyclohexane- 1 -carboxamide

[1325];

(S)-N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)tetrahydrofuran-2 -carboxamide [1326]; N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-3,3-difluorocyclobutane-l -carboxamide

[1327];

N-(7-( 1 ,2-dimethyl- lH-imidazol-5-yl)quinazolin-2-yl)- 1 -fluorocyclopropane- 1 -carboxamide

[1328];

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)mo holine-4-carboxamide [1329];

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)mo holine-ί s-4-carboxamide [1330]; l-methyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-lH-pyrazole-4-carboxamide [1331]; 1 -ethyl -N-(7-( 1 -methyl- lH-imidazol-5-yl)quinazolin-2-yl)- lH-pyrazole -4 -carboxamide [1332] ; l-isopropyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-lH-pyrazole-4 -carboxamide

[1333]; l-cyclopropyl-N-(7-(l-methyl-lH midazol-5-yl)quinazolin-2-yl)-lH-pyrazole-4-carboxamide

[1334];

1 -isobutyl-N-(7-( 1 -methyl- lH-imidazol-5-yl)quinazolin-2-yl)- lH-pyrazole-4 -carboxamide

[1335];

1 -methyl -N-(7 -( 1 -methyl - 1 H-imidazol-5 -yl)quinazolin-2-yl) - 1 H-pyrazole -3 -carboxamide [1336]; N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(l-methyl-lH-pyrazol-4-yl)acetamide

[1337];

l-methyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-lH-imidazole-4-carboxamide

[1338];

l-isopropyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-lH-imidazole-4 -carboxamide

[1339];

N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-l-(tetrahydro-2H-pyran-4-yl)-lH-imidazole- 4-carboxamide [1340];

1 ,2-dimethyl -N-(7 -( 1 -methyl - 1 H-imidazol -5 -yl)quinazolin-2 -yl) - 1 H-imidazole -5 -carboxamide

[1341];

1- methyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-lH-l,2,4-triazole-3-carboxamide

[1342];

2- methyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)oxazole-4-carboxamide [1343]; 2-isopropyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)oxazole-4-carboxamide [1344]; 4-methyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)oxazole-2 -carboxamide [1345];

4- methyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)thiazole-2 -carboxamide [1346]; 2-methyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)thiazole-4-carboxamide [1347];

5 -methyl -N-(7 -( 1 -methyl - 1 H-imidazol-5 -yl)quinazolin-2-yl) -1,3,4 -oxadiazole -2 -carboxamide

[1348];

5- methyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-l,3,4-thiadiazole-2 -carboxamide

[1349];

l-isopropyl-N-(7-(l-isopropyl-lH-imidazol-5-yl)quinazolin-2-yl)-lH-pyrazole-4-carboxamide

[1350];

N-(7-( 1 ,2-dimethyl- lH-imidazol-5-yl)quinazolin-2-yl)- 1 -methyl- lH-pyrazole-4 -carboxamide

[1351];

N-(7-( 1 ,2-dimethyl- lH-imidazol-5-yl)quinazolin-2-yl)- 1 -isopropyl- lH-pyrazole-4-carboxamide

[1352];

N-(7-( 1 ,2-dimethyl- lH-imidazol-5-yl)quinazolin-2-yl)-2-methylthiazole-5 -carboxamide [1353] ; 4-fluoro-N-(7-(l -methyl- lH-imidazol-5-yl)quinazolin-2-yl)benzamide [1354]; 4-(difluoromethoxy)-N-(7-( 1 -methyl- lH-imidazol-5 -yl)quinazolin-2-yl)benzamide [1355] ;

N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-3-(pyrrolidin-l-ylmethyl)benzamide [1356]; 2-fluoro-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)benzamide-3,4,5,6-£/4 [1357];

4-fluoro-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)benzamide-2,3,5,6-£/4 [1358];

2-chloro-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)benzamide-3,4,5,6-£/4 [1359];

4-chloro-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)benzamide-2,3,5,6-£/4 [1360];

4-(methyl-£/3)-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)benzamide [1361];

4-methyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)benzamide-2,3,5,6-£/4 [1362];

4-(methyl-£/3)-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)benzamide-2,3,5,6-£/4 [1363]; 4-(methoxy-< 3) -N-(7 -( 1 -methyl- 1 H-imidazol -5 -yl)quinazolin-2 -yl)benzamide [ 1364] ;

4-(methoxy-£/3)-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)benzamide-2,3, 5,6-<¾ [1365]; 4-methoxy-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)benzamide-2,3, [1366]; (E)-N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-3-(phenyl-2,3,4,5,6-£/j)acrylamide

[1367];

(E)-N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-3-(phenyl-2,3,4,5,6-£/j)acrylamide- 2,2-d2 [1368];

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(4-fluorophenyl)acetamide-2,2-£/2

[1369];

(E)-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-3-(phenyl-2,3,4,5,6-£/j acrylamide [1370]; (E)-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-3-(phenyl-2,3,4,5,6-£/j)acrylamide-2,3-£/2

[1371];

2-(4-fluorophenyl)-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)acetamide-2,2-d2 [1372]; N-(7 -( 1 -methyl - 1 H-imidazol-5 -yl)quinazolin-2 -yl) -2 -(4-methylpiperazin- 1 -yl)isonicotinamide

[1373];

2-(dimethylamino)-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)isonicotinamide [1374]; 2-(3 -aminoazetidin- 1 -yl) -N-(7 -( 1 -methyl - 1 H-imidazol -5 -yl)quinazolin-2 -yl)isonicotinamide

[1375];

N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl)isonicotinamide [1376]; N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(piperidin-l-yl)isonicotinamide [1377]; N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-moφholinoisonicotinamide [1378];

2-(4-isopropylpiperazin- 1 -yl)-N-(7-( 1 -methyl- lH-imidazol-5 -yl)quinazolin-2-yl)isonicotinamide

[1379];

2-(4-cyclopropylpiperazin- 1 -yl)-N-(7-( 1 -methyl- lH-imidazol-5 -yl)quinazolin-2-yl)

isonicotinamide [1380]; N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(2,7-diazaspiro[3.5]nonan-2-yl) isonicotinamide [1381];

N-(7-(l-methyl-lH midazol-5-yl)quinazolin-2-yl)-2-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl) isonicotinamide [1382];

N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)isoindoline-5-carboxamide [1383] ;

2-methyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)isoindoline-5-carboxamide [1384]; 2-(azetidin-l-yl)-N-(7-(l-methyl-lH midazol-5-yl)quinazolin-2-yl)isonicotinamide [1385]; 2-methoxy-N-(7-( 1 -methyl- lH-imidazol -5 -yl)quinazolin-2-yl)isonicotinamide [1386] ;

2-methyl-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)isonicotinamide [1387];

2-cyano-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)isonicotinamide [1388];

2-(3,3-difluoroazetidin-l-yl)-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)isonicotinamide

[1389] ;

2-(4,4-difluoropiperidin-l-yl)-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)isonicotinam

[1390] ;

2-isopropoxy-N-(7 -( 1 -methyl - 1 H-imidazol -5 -yl)quinazolin-2 -yl)isonicotinamide [1391];

N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl^

[1392] ;

N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl-iis)isonicotinamide [1393]; N-(7 -( 1 -methyl - 1 H-imidazol-5 -yl)quinazolin-2 -yl) -2 -(piperidin- 1 -yl -di o)isonicotinamide [1394] ; N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(moφholino-ί s)isonicotinamide [1395]; N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-4-isopropoxybenzamide [1396] ;

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-4-(piperidin-4-yloxy)benzamide [1397]; 4-(benzyloxy) -N-(7 -( 1 ,2 -dimethyl - 1 H-imidazol -5 -yl)quinazolin-2 -yl)benzamide [1398];

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-fluorobenzamide-3,4,5,6-£/4 [1399]; N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-4-fluorobenzamide-2,3,5,6-£/4 [1400]; 2-chloro-N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)benzamide-3,4,5,6-£/4 [1401]; 4-chloro-N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)benzamide-2,3,5,6-£/4 [1402]; N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-4-(methyl-£/3)benzamide [1403];

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-4-methylbenzamide-2,3,5,6-£/4 [1404]; N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-4-(methyl-£/3)benzamide-2,3,5,6-£/4

[1405] ;

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-4-(methoxy-£/3)benzamide [1406] ;

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-4-(methoxy-£/3)benzamide-2,3,5,6-£/4

[1407] ; N-iT-il^-dimethyl-lH-imidazol-S-y^quinazolin^-y^^-methoxybenzamide^^^^-^ [1408]; N-(7-( 1 ,2-dimethyl- lH-imidazol-5-yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [1409];

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-moφholinoisonicotinamide [1410]; N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl)isonicotinam [1411]; N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(dimethylamino)isonicotm^ [1412]; N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl -2,2,5, 5-aV)

isonicotinamide [1413];

N-(7-( 1 ,2-dimethyl- lH-imidazol-5 -yl)quinazolin -2 -yl)-2 -(pyrrolidin-1 -yl-a's)isonicotinamide

[1414];

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolm^

[1415];

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(moφholino-α's)isonicotinamide [1416]; N-(7-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)quinazolin-2-yl)cyclopropanecarboxamide

[1417];

N-(7-(7-methyl-5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)quinazolin-2-yl)

cyclopropanecarboxamide [1418];

3,3-difluoro-N-(7-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)quinazolin-2-yl)cyclobutane-l- carboxamide [1419];

(R)-N-(7-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)quinazolin-2-yl)pyrrolidine-2- carboxamide [1420];

(R)-N-(7-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)quinazolin-2-yl)piperidine-3- carboxamide [1421];

l-methyl-N-(7-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)quinazolin-2-yl)piperidine-4- carboxamide [1422];

N-(7-(5 ,6,7, 8-tetrahydroimidazo [ 1 ,2-a]pyrazin-3 -yl)quinazolin-2-yl)- 1 -(( 1 -(trifluoromethyl) cyclopropyl)methyl)piperidine-4-carboxamide [1423] ;

l-benzoyl-N-(7-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)quinazolin-2-yl)piperidine-4- carboxamide [1424];

4-fluoro-l-isobutyl-N-(7-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)quinazolin-2-yl)

piperidine-4-carboxamide [1425];

(R)-2-(2-methylpyrrolidin-l-yl)-N-(7-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)quinazolin-

2-yl)acetamide [1426]; 2-(cyclobutyl(methyl)amino)-N-(7- yl)acetamide [1427];

4-fluoro-N-(7-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)quinazolin-2-yl)benzamide [1428]; 4-isopropoxy-N-(7-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)quinazolin-2-yl)benzamide

[1429];

4-(difluoromethoxy)-N-(7-(5,6J,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)quinazolin-2-yl)

benzamide [1430];

2-((2-(dimethylamino)ethyl)amino)-N-(7-(^^

quinazolin-2-yl)isonicotinamide [1431];

2-((1 sopropylpiperidin-4-yl)oxy)-N-(7-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)

quinazolin-2-yl)isonicotinamide [1432];

N-(7-(oxazol-5-yl)quinazolin-2-yl)-l-(3,3,3-trifluoropropyl)piperidine-4-carboxamide [1433]; N-(7-(oxazol-5-yl)quinazolin-2-yl)cyclopropanecarboxamide [1434];

(R)-N-(7-(oxazol-5-yl)quinazolin-2-yl)tetrahydrofuran-2 -carboxamide [1435];

(R)-N-(7-(oxazol-5-yl)quinazolin-2-yl)piperidine-3-carboxamide [1436];

N-(7-(oxazol-5 -yl)quinazolin-2-yl)tetrahydro-2H-pyran-4-carboxamide [1437] ;

N-(7 -(oxazol-5 -yl)quinazolin-2-yl) - 1 -(2 -(pyrrolidin- 1 -yl)acetyl)piperidine -4 -carboxamide [ 1438] ; r-methyl-N-(7-(oxazol-5-yl)quinazolin-2-yl)-[l,4'-bipiperidine]-4-carboxamide [1439];

c/. ·-4-moφholino-N-(7-(oxazol-5-yl)quinazolin-2-yl)cyclohexane-l -carboxamide [1440] ;

2-(cyclobutyl(methyl)amino)-N-(7-(oxazol-5-yl)quinazolin-2-yl)acetamide [1441];

N-(7-(oxazol-5-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl)acetamide [1442];

(R)-2-(2-methylpyrrolidin- 1 -yl)-N-(7 -(oxazol-5 -yl)quinazolin-2-yl)acetamide [1443] ;

2-(4 -methylpiperazin- 1 -yl) -N-(7 -(oxazol -5 -yl)quinazolin-2 -yl)acetamide [ 1444] ;

fr «5-4-((4-methylpiperazin-l-yl)methyl)-N-(7-(oxazol-5-yl)quinazolin-2-yl)cyclohexane-l- carboxamide [1445];

l-(2,2-difluoropropyl)-N-(7-(oxazol-5-yl)quinazolin-2-yl)piperidine-4-carboxamide [1446]; fra«s-4-(hydroxymethyl)-N-(7-(2-methyloxazol-5 -yl)quinazolin-2-yl)cyclohexane- 1 -carboxamide

[1447];

fra«s-4-(methylamino)-N-(7-(2-methyloxazol-5 -yl)quinazolin-2-yl)cyclohexane- 1 -carboxamide

[1448];

trans-4-(( 1 ,3 -difluoropropan-2-yl)amino)-N-(7-(2-methyloxazol-5 -yl)quinazolin-2-yl)

cyclohexane-1 -carboxamide [1449];

fr «5-N-(7-(2-methyloxazol-5 -yl)quinazolin-2-yl)-4-((propan-2-yl- 1,1, 1 ,3,3,3-£¾;)amino)

cyclohexane-1 -carboxamide [1450]; trans -4 -((2,2 -difluoroethyl)amino)-N-(7 -(2-methyloxazol -5 -yl)quinazolin-2 -yl)cyclohexane - 1 - carboxamide [1451];

fr «5-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-4-((3,3,3-trifluoropropyl)amino)cyclohexane- 1 -carboxamide [1452];

fr «5-4-((2-methoxyethyl)amino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)cyclohexane-l- carboxamide [1453];

trans -4 -(dimethylamino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)cyclohexane-l -carboxamide

[1454];

fr «5-4-(bis(methyl- 3)amino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)cyclohexane-l- carboxamide [1455];

c/5-4-(dimethylamino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)cyclohexane-l-carboxamide

[1456];

fr «5-4-((2,2-difluoroethyl)(methyl)amino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)

cyclohexane-1 -carboxamide [1457];

fr «5-4-(methyl(oxetan-3-yl)amino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)cyclohexane-l- carboxamide [1458];

fr «5-4-((2-fluoroethyl)amino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)cyclohexane-l- carboxamide [1459];

fr «5-4-(2-(fluoromethyl)aziridin-l-yl)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)cyclohexane- 1 -carboxamide [1460];

trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N-(7-(2-methyloxazol-5 -yl)quinazolin-2-yl)cyclohexane- 1 -carboxamide [1461];

fr rø-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-3-mo holinocyclobutane-l -carboxamide

[1462];

fr rø-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-4-mo holinocyclohexane-l-carboxamide

[1463];

N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-2-(piperidin-l-yl)acetamide [1464];

2-(4-methoxypiperidin-l-yl)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)acetamide [1465]; N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)acetamide [1466];

N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)moφholine-4-carboxamide [1467];

N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-2-mo holinoacetamide [1468];

N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-3-moφholinopropanamide [1469];

1 -methyl -N-(7-(2-methyloxazol-5 -yl)quinazolin-2-yl)piperidine-4-carboxamide [1470] ; l-(2,2-difluoropropyl)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)piperidine-4 -carboxamide

[1471];

N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-4-moφholinopiperidine-l -carboxamide [1472]; 4-(( 1 ,3 -difluoropropan-2-yl)amino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)piperidine- 1 - carboxamide [1473];

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [1474];

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [1475];

4-(dimethylamino)-N-(7-(2-methyloxazol-5 -yl)quinazolin-2-yl)piperidine- 1 -carboxamide [1476] ; 4-((2,2-difluoroethyl)(methyl)amino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)piperidine-l- carboxamide [1477];

(3S,4S)-4-amino-3-fluoro-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)piperidine-l-carboxamide

[1478];

(3 S,4S)-3 -fluoro-4-(methylamino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)piperidine- 1 - carboxamide [1479];

(3R,4R)-4-amino-3-fluoro-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)piperidine-l-carboxamide

[1480];

(3R,4R)-3-fluoro-4-(methylamino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)piperidine-l- carboxamide [1481];

4-((2-fluoroethyl)amino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)piperidine-l-carboxamide

[1482];

4-((2,2-difluoroethyl)amino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)piperidine-l- carboxamide [1483];

(lR,3s,5S)-3-amino-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-8-azabicyclo[3.2.1]octane-8- carboxamide [1484];

(lR,3r,5S)-3-amino-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-8-azabicyclo[3.2.1]octane-8- carboxamide [1485];

(lR,3r,5S)-3-((2-fluoroethyl)amino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-8-azabicyclo

[3.2.1] octane -8 -carboxamide [I486];

(lR,3r,5S)-3-((2,2-difluoroethyl)amino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [1487];

(lR,3s,5S)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-3-((3,3,3-trifluoropropyl)amino)-8- azabicyclo[3.2.1] octane -8 -carboxamide [1488]; (3S,4S)-3-fluoro-4-(isopropylamino)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)piperidine-l- carboxamide [1489];

N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H)- carboxamide [1490];

2-methyl-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H)- carboxamide [1491];

N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-2-(moφholino-ί s)acetamide [1492];

fr «5-N-(7-(2-methyloxazol-4-yl)quinazolin-2-yl)-4-(4-methylpiperazin-l-yl)cyclohexane-l- carboxamide [1493];

N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [1494];

2- (lH-imidazol-l-yl)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)acetamide [1495];

4-(difluoromethoxy)-N-(7-(oxazol-5-yl)quinazolin-2-yl)benzamide [1496];

3- ((l-methylpiperidin-4-yl)oxy)-N-(7-(oxazol-5-yl)quinazolin-2-yl)benzamide [1497];

N-(7-(oxazol-5-yl)quinazolin-2-yl)isonicotinamide [1498];

2-(3 -aminoazetidin- 1 -yl)-N-(7-(oxazol-5 -yl)quinazolin-2-yl)isonicotinamide [1499] ;

2-( 1 -methylpiperidin-4-yl)-N-(7-(oxazol-5 -yl)quinazolin-2-yl)isonicotinamide [1500] ;

r-methyl-N-(7-(oxazol-5-yl)quinazolin-2-yl)-r,2',3',6'-tetrahydro-[2,4'-bipyridine]-4- carboxamide [1501];

2-(4-methylpiperazin-l -yl)-N-(7-(oxazol-5-yl)quinazolin-2-yl)isonicotinamide [1502] ;

2-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-N-(7-(oxazol-5-yl)quinazolin-2-yl)isonicotinamide

[1503];

N-(7-(oxazol-5-yl)quinazolin-2-yl)-2-(2,7-diazaspiro[3.5]nonan-7-yl)isonicotinamide [1504]; N-(7-(oxazol-5-yl)quinazolin-2-yl)-2-(piperidin-4-ylamino)isonicotinamide [1505];

2-methyl-N-(7-(oxazol-5 -yl)quinazolin-2-yl)isoindoline-5 -carboxamide [1506] ;

N-(7-(oxazol-5-yl)quinazolin-2-yl)-l,2,3,4-tetrahydroisoquinoline-7-carboxamide [1507];

N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [1508]; N-(7-(3-methylisoxazol-5-yl)quinazolin-2-yl)-l-(3,3,3 rifluoropropyl)piperidine-4-carboxamide

[1509];

4- fluoro-l-isobutyl-N-(7-(5 -methyl- 1,3, 4-oxadiazol-2-yl)quinazolin-2-yl)piperidine-4- carboxamide [1510];

l-isobutyl-N-(7-(5-methyl-l,3,4-oxadiazol-2-yl)quinazolin-2-yl)piperidine-4 -carboxamide

[1511];

N-(7-(5-(dimethylamino)-l,3,4-oxadiazol-2-yl)quinazolin-2-yl)piperidine-4-carboxamide [1512]; N-(7-(5-(dimethylamino)-l,3,4-oxadiazol-2-yl)quinazolin-2-yl)-l-methylpiperidine-4^ carboxamide [1513];

N-(7-(5-methyl-l,3,4-oxadiazol-2-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinami

[1514];

3,3-difluoro-N-(7-(thiazol-5-yl)quinazolin-2-yl)cyclobutane-l-carboxamide [1515];

2-methyl-N-(7-(thiazol-5-yl)quinazolin-2-yl)-2-azaspiro[3.3]heptane-6-carboxamide [1516]; 1 -fluoro -N-(7 -(thiazol-5 -yl)quinazolin-2 -yl)cyclohexane - 1 -carboxamide [1517];

trans -4 -(dimethylamino) -N-(7 -(thiazol-5 -yl)quinazolin-2-yl)cyclohexane - 1 -carboxamide [1518]; trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N-(7-(thiazol-5 -yl)quinazolin-2-yl)cyclohexane- 1 - carboxamide [1519];

N-(7-(thiazol-5-yl)quinazolin-2-yl)azetidine-3-carboxamide [1520];

l-methyl-N-(7-(thiazol-5-yl)quinazolin-2-yl)piperidine-4-carboxamide [1521];

l-(2,2-difluoropropyl)-N-(7-(thiazol-5-yl)quinazolin-2-yl)piperidine-4-carboxamide [1522]; l-(oxetan-3-yl)-N-(7-(thiazol-5-yl)quinazolin-2-yl)piperidine-4-carboxamide [1523];

1- (2-(pyrrolidin-l-yl)acetyl)-N-(7-(thiazol-5-yl)quinazolin-2-yl)piperidine-4-carboxamide [1524]; r-methyl-N-(7-(thiazol-5-yl)quinazolin-2-yl)-[l,4'-bipiperidine]-4-carboxamide [1525];

2- (pyrrolidin-l-yl)-N-(7-(thiazol-5-yl)quinazolin-2-yl)propanamide [1526];

2-(piperidin-l-yl)-N-(7-(thiazol-5-yl)quinazolin-2-yl)acetamide [1527];

2-(4-methylpiperazin-l-yl)-N-(7-(thiazol-5-yl)quinazolin-2-yl)acetamide [1528];

2-moφholino-N-(7-(thiazol-5-yl)quinazolin-2-yl)acetamide [1529];

4-(piperidin-4-yloxy)-N-(7-(thiazol-5-yl)quinazolin-2-yl)benzamide [1530];

N-(7-(thiazol-5-yl)quinazolin-2-yl)isonicotinamide [1531];

6-(4-methylpiperazin-l-yl)-N-(7-(thiazol-5-yl)quinazolin-2-yl)nicotinamide [1532];

r-methyl-N-(7-(miazol-5-yl)quinazolin-2-yl)-l',2',3',6'-tetrahydro-[2,4'-bipyridine]-4- carboxamide [1533];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(7-(thiazol-5 -yl)quinazolin-2-yl)isonicotinamide [1534] ; 2-(4-(dimethylamino)piperidin-l -yl)-N-(7-(thiazol-5-yl)quinazolin-2-yl)isonicotinamide [1535] ; 2-(4-methylpiperazin-l-yl)-N-(7-(thiazol-5-yl)quinazolin-2-yl)isonicotinamide [1536];

2-((l-memylpiperidin-4-yl)thio)-N-(7-(thiazol-5-yl)quinazolin-2-yl)isonicotinamide [1537]; N-(7-(thiazol-5-yl)quinazolin-2-yl)-l,2,3,4-tetrahydroisoquinoline-7-carboxamide [1538];

trans-4-(( 1 ,3 -difluoropropan-2-yl)amino)-N-(7-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)quinazolin-2-yl) cyclohexane-1 -carboxamide [1539];

N-(7-(2-methylthiazol-5-yl)quinazolin-2-yl)mo holine-4-carboxamide [1540];

N-(7-(2-methylthiazol-5-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl)acetamide [1541]; 2-((lR,4R)-2-oxa-5-azabicyclo[2.2 ]heptan-5-yl)-N-(7-(2-methylthiazol-5-yl)quinazolin-2-yl) acetamide [1542];

N-(7-(2-methylthiazol-5-yl)quinazolin-2-yl)-2-moφholinoacetamide [1543];

N-(7-(2-methylthiazol-5 -yl)quinazolin-2-yl)-2-(mo holino-ί s)acetamide [1544] ;

2-(4-methylpiperazin-l-yl)-N-(7-(2-methylthiazol-5-yl)quinazolin-2-yl)acetamide [1545];

1 -methyl -N-(7 -(2 -methylthiazol-5 -yl)quinazolin-2-yl)piperidine -4 -carboxamide [1546];

N-(7-(2-methylthiazol-5-yl)quinazolin-2-yl)isonicotinamide [1547];

N-(7-(2-methylthiazol-5 -yl)quinazolin-2-yl)nicotinamide [1548] ;

2-(4-methylpiperazin-l-yl)-N-(7-(2-methylthiazol-5-yl)quinazolin-2-yl)isonicotinamide [1549]; fr rø-N-(7-(5-methyl-l,3,4 hiadiazol-2-yl)quinazolin-2-yl)-4-moφholinocyclohexane-l- carboxamide [1550];

fr «5-N-(7-(5-methyl-l,3,4 hiadiazol-2-yl)quinazolin-2-yl)-4-(4-methylpiperazin-l-yl)

cyclohexane-1 -carboxamide [1551];

4-isopropyl-N-(7-(5-methyl-l,3,4 hiadiazol-2-yl)quinazolin-2-yl)piperazine-l-carboxamide

[1552];

4-((2-methoxyethyl)(methyl)amino)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)

piperidine-1 -carboxamide [1553];

4-(( 1 ,3 -difluoropropan-2-yl)amino)-N-(7-(5 -methyl- 1 ,3 ,4-thiadiazol-2-yl)quinazolin-2-yl)

piperidine-1 -carboxamide [1554];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-4-((3,3,3-trifluoropropyl)amino)piperidine-

1 -carboxamide [1555];

4-((2-fluoroethyl)amino)-N-(7-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperidine- 1 - carboxamide [1556];

(3R,4S)-4-amino-3-fluoro-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperidine-l- carboxamide [1557];

(3R,4R)-4-amino-3-fluoro-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperidine-l- carboxamide [1558];

(3S,4S)-3-fluoro-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-4-(methylamino)

piperidine-1 -carboxamide [1559];

(3R,4R)-3 -fluoro-N-(7-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)quinazolin-2-yl)-4-(methylamino)

piperidine-1 -carboxamide [1560];

4-amino-3,3 -difluoro-N-(7-(5-methyl- 1 ,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperidine- 1 - carboxamide [1561]; (3R,4R)-3-fluoro-4-(isopropylamino)-N-(7-(5-methyl-l,3,4 hiadiazol-2-yl)quinazolin-2-yl) piperidine-l-carboxamide [1562];

(3R,4S)-3-fluoro-4-(isopropylamino)-N-(7-(5-methyl-l,3,4-1hiadiazol-2-yl)quinazolin-2-yl) piperidine-l-carboxamide [1563];

3,3-difluoro-4-(isopropylamino)-N-(7-(5-methyl-l,3,4-miadiazol-2-yl)quinazolin-2-yl)pi^

1- carboxamide [1564];

(3S,4S)-3-fluoro-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-4-((propan-2-yl-

1, 1,1,3,3,3 -d<;)amino)piperidine - 1 -carboxamide [1565];

( 1 R,3s,5 S)-3 -(( 1 ,3-difluoropropan-2-yl)amino)-N-(7-(5-methyl- 1 ,3,4-thiadiazol-2-yl)quinazolin-

2- yl) -8 -azabicyclo [3.2.1] octane -8 -carboxamide [1566];

( 1 R,3s,5 S)-3 -(( 1 ,3-difluoropropan-2-yl)amino)-N-(7-(5 -methyl-1 ,3,4-thiadiazol-2-yl)quinazolin-

2-yl) -8 -azabicyclo [3.2.1] octane -8 -carboxamide [1567];

4-(dimethylamino)-N-(7-(2-methylthiazol-5-yl)quinazolin-2-yl)piperidine-l -carboxamide [1568]; 4-((2,2-difluoroethyl)amino)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperidine carboxamide [1569];

4-((2,2-difluoroethyl)(methyl-£/3)amino)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl) piperidine-l-carboxamide [1570];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-4-moφholinopiperidine-l -carboxamide

[1571];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-4-(4-methylpiperazin-l-yl)piperidine-l- carboxamide [1572];

(R)-3,4-dimethyl-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperazine-l-carboxamide

[1573];

(S)-3,4-dimethyl-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperazine-l-carboxamide

[1574];

(lR,3r,5S)-3-((2-fluoroethyl)amino)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [1575];

(lR,3r,5S)-3-((2,2-difluoroethyl)amino)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [1576];

(lR,3r,5S)-3-amino-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-8-azabicyclo[3.2.1] octane-8-carboxamide [1577];

(lS,4S)-5-methyl-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2,5-diazabicyclo[2.2.1

]heptane-2 -carboxamide [1578]; (lR,4R)-5-methyl-N-(7-(5-methyl-l,3,4 hiadiazol-2-yl)quinazolin-2-yl)-2,5-diazabicycloP heptane-2-carboxamide [1579];

8-methyl-N-(7-(5-methyl-l,3,4 hiadiazol-2-yl)quinazolin-2-yl)-3,8-diazabicyclo[3.2.1]octane-3- carboxamide [1580];

3-methyl-N-(7-(5-methyl-l,3,4 hiadiazol-2-yl)quinazolin-2-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxamide [1581];

N-(7-(5-methyl-l,3,4 hiadiazol-2-yl)quinazolin-2-yl)-5,6-dihydroimidazo[l,2-a]pyrazine^

carboxamide [1582];

2-(4-methylpiperazin-l-yl)-N-(7-(5-methylthiazol-2-yl)quinazolin-2-yl)isonicotinamide [1583]; 2-(4-methylpiperazin- 1 -yl)-N-(7-(4-methylthiazol-2-yl)quinazolin-2-yl)isonicotinamide [1584] ; N-(7-(2-(methylamino)thiazol-5-yl)quinazolin-2-yl)piperidine-4-carboxamide [1585];

1 -methyl -N-(7-(2-(methylamino)thiazol-5 -yl)quinazolin-2-yl)piperidine-4-carboxamide [1586] ; N-(7-(2-(diethylamino)thiazol-5-yl)quinazolin-2-yl)-2-(4-fluoropiperidin-l-yl)acetamide [1587]; N-(7-(2-(diemylamino)thiazol-5-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)acetam [1588]; N-(7-(2-aminothiazol-5 -yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide [1589] ; N-(7-(2-(methylamino)thiazol-5-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinam

[1590];

N-(7-(2-(dimethylamino)thiazol-5-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinami

[1591];

2-(4-isopropylpiperazin-l-yl)-N-(7-(2-(methylamino)thiazol-5-yl)quinazolin-2-yl)

isonicotinamide [1592];

2-(3-(dimethylamino)azetidin-l-yl)-N-(7-(2-(methylamino)thiazol-5-yl)quinazolin-2-yl)

isonicotinamide [1593];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(7-(2-(dimethylamino)thiazol-5 -yl)quinazolin-2-yl)

isonicotinamide [1594];

2-(3 -aminoazetidin- 1 -yl)-N-(7-(2-(dimethylamino)thiazol-5 -yl)quinazolin-2-yl)isonicotinamide

[1595];

N-(7-(5-chloromiazol-2-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [1596]; 2-(2-(2-(4-methylpiperazin-l-yl)isonicotinamido)quinazolin-7-yl)thiazole-5-carboxamide [1597]; N-(7-(isothiazol-4-yl)quinazolin-2-yl)-l-methylpiperidine-4-carboxamide [1598];

N-(7-( 1 ,3 ,4-thiadiazol-2-yl)quinazolin-2-yl)-4-(difluoromethoxy)benzamide [1599] ;

N-(7-(l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-4-(piperidin-4-yloxy)benzamide [1600];

N-(7-(l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-4-((l-methylpiperidin-4-yl)oxy)benzamide [1601]; N-(7-(l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-3-((l-methylpiperidin-4-yl)oxy)benzamide [1602]; N5-(7-(l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-N2-^ [1603]; N-(7-(l,3,4 hiadiazol-2-yl)quinazolin-2-yl)-6-(4-methylpiperazin-l-yl)nicotinamide [1604]; N-(7-(l,3,4-thiadiazol-2-yl)quin^

carboxamide [1605];

N-(7-(l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-(3-(dm

[1606];

N-(7-(l,3,4 hiadiazol-2-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinami [1607]; N-(7-(l,3,4 hiadiazol-2-yl)quinazolin-2-yl)-2-(4 sopropylpiperazin-l-yl)isonicotinamide [1608]; N-(7-(l,3,4 hiadiazol-2-yl)quinazolin-2-yl)-2-moφholinoisonicotinamide [1609];

1 -fluoro-N-(7-(5-methyl- 1 ,3,4-thiadiazol-2-yl)quinazolin-2-yl)cyclohexane- 1 -carboxamide

[1610];

fr «5-4-methoxy-N-(7-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)quinazolin-2-yl)cyclohexane- 1 - carboxamide [1611];

c/5-4-methoxy-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)cyclohexane-l-carboxamide

[1612];

fr «5-4-amino-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)cyclohexane-l-carboxamide

[1613];

trans -4 -(dimethylamino) -N-(7 -(5 -methyl -1,3,4 -thiadiazol-2-yl)quinazolin-2 -yl)cyclohexane - 1 - carboxamide [1614];

fr rø-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-4-moφholinocyclohexane-l- carboxamide [1615];

fr «5-4-(hydroxymethyl)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)cyclohexane-l- carboxamide [1616];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperidine-4-carboxamide [1617];

4-fluoro-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperidine-4-carboxamide [1618]; l-methyl-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperidine-4-carboxamide [1619]; 4-fluoro-l-methyl-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperidine-4- carboxamide [1620];

1 -(2-fluoroethyl)-N-(7-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperidine-4-carboxamide

[1621];

l-(2,2-difluoroethyl)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperidine-4- carboxamide [1622];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [1623]; 1- (2,2-difluoropropyl)-N-(7-(5-methyl-l,3,4 hiadiazol-2-yl)quinazolin-2-yl)piperidine-4- carboxamide [1624];

1 -benzoyl -N-(7-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperidine-4-carboxamide

[1625];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl)acetamide [1626]; N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-(piperidin-l-yl)acetamide [1627];

2- (4-methoxypiperidin-l-yl)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)acetamid^

[1628];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)acetamide

[1629];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-moφholinoacetamide [1630];

(R)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-(3-methylmoφholino)acetamide

[1631];

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)

acetamide [1632];

2-((lR,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)

quinazolin-2-yl)acetamide [1633];

2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl) acetamide [1634];

2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl) acetamide [1635];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-(l,4-oxazepan-4-yl)acetamide [1636]; N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-moφholinoacetamide-2,2-ί 2 [1637]; N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-(moφholino-ί s)acetamide [1638]; 1 -methyl-3 -(7-(5 -methyl- 1 ,3 ,4-thiadiazol-2-yl)quinazolin-2-yl)- 1 -( 1 -methylpiperidin-4-yl)urea

[1639];

(3S,4S)-4-amino-3-fluoro-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)piperidine-l- carboxamide [1640];

(3 S,4S)-4-(dimethylamino)-3 -fluoro-N-(7-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)quinazolin-2-yl) piperidine-l-carboxamide [1641];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)moφholine-4-carboxamide [1642];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-4-(methylamino)piperidine-l-carboxamide

[1643]; 4-(dimethylamino) -N-(7-(5 -methyl -1,3,4 -thiadiazol -2 -yl)quinazolin-2 -yl)piperidine - 1 - carboxamide [1644];

4-((2,2-difluoroethyl)(methyl)amino)-N-(7-(5-m

piperidine-1 -carboxamide [1645];

(3S,4S)-3-fluoro-4-(isopropylamino)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)

piperidine-1 -carboxamide [1646];

2-methyl-N-(7-(5-methyl-l,3,4 hiadiazol-2-yl)quinazolin-2-yl)-5,6-dihydroimidazo[l,2-a]

pyrazine-7(8H)-carboxamide [1647];

4-methyl-N-(7-(5-methyl-l,3,4 hiadiazol-2-yl)quinazolin-2-yl)piperazine-l-carboxamide [1648]; N-(7-(5-methyl-l,3,4 hiadiazol-2-yl)quinazolin-2-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-^ carboxamide [1649];

1 -( 1 -isopropylpiperidin-4-yl)-N-(7-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)quinazolin-2-yl)- lH-pyrazole- 4-carboxamide [1650];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-l-(l-methylpiperidin-4-yl)-lH-l,2,3- triazole -4 -carboxamide [1651];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide

[1652];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-(l-methylpiperidin-4-yl)oxazole-4- carboxamide [1653];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(7-(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)quinazolin-2-yl)

isonicotinamide [1654];

r-methyl-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-l',2',3',6'-tetrahydro-[2,4'- bipyridine] -4 -carboxamide [1655];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[1656];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(7-(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)quinazolin-2-yl) isonicotinamide [1657];

2-(azetidin-3-yloxy)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)isonicotinamide

[1658];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-3-((l-methylpiperidin-4-yl)oxy)benzamide

[1659];

N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-((l-methylpiperidin-4-yl)thio)

isonicotinamide [1660]; 6-(4-methylpiperazin-l-yl)-N-(7-(5-(trifluoromethyl)-l,3,4 hiadiazol-2-yl)quinazolin-2-yl) nicotinamide [1661];

2-(4-methylpiperazin-l-yl)-N-(7-(5-(trifluoromethyl)-l,3,4 hiadiazol-2-yl)quinazolin-2-yl) isonicotinamide [1662];

N-(7-(5-amino-l,3,4 hiadiazol-2-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotina^

[1663];

N-(7-(5-(dimethylamino)-l,3,4-miadiazol-2-yl)qum^

isonicotinamide [1664];

N-(7-(3-amino-5-fluorophenyl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[1665];

N-(7-(3-fluoro-5-(isopropylamino)phenyl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [1666];

1 -methyl -N-(7-(pyridin-2-yl)quinazolin-2-yl)piperidine-4-carboxamide [1667] ;

2-(4-methylpiperazin-l-yl)-N-(7-(pyridin-2-yl)quinazolin-2-yl)isonicotinamide [1668];

2-(4-methylpiperazin-l-yl)-N-(7-(pyridin-4-yl)quinazolin-2-yl)isonicotinamide [1669];

N-(7-(pyridin-3 -yl)quinazolin-2-yl)cyclopropanecarboxamide [1670] ;

N-(7-(pyridin-3-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl)acetamide [1671];

1 -methyl -N-(7-(pyridin-3 -yl)quinazolin-2-yl)piperidine-4-carboxamide [1672] ;

N-(7 -(pyridin-3 -yl)quinazolin-2-yl)quinuclidine -4 -carboxamide [ 1673] ;

2-moφholino-N-(7-(pyridin-3-yl)quinazolin-2-yl)acetamide [1674];

2-(moφholino-ί s)- -(7-(pyridin-3-yl)quinazolin-2-yl)acetamide [1675];

2-(4-methylpiperazin-l-yl)-N-(7-(pyridin-3-yl)quinazolin-2-yl)acetamide [1676];

2-(4-methyl- 1 ,4-diazepan-l -yl)-N-(7-(pyridin-3 -yl)quinazolin-2-yl)acetamide [1677] ;

2-(4-methylpiperazin-l-yl)-N-(7-(pyridin-3-yl)quinazolin-2-yl)isonicotinamide [1678];

2-(2-methyl-lH-imidazol-l-yl)-N-(7-(pyridin-3-yl)quinazolin-2-yl)acetamide [1679];

2-(lH-imidazol-l-yl)-N-(7-(pyridin-3-yl)quinazolin-2-yl)acetamide [1680];

2-(piperidin-4-yl)-N-(7-(pyridin-3-yl)quinazolin-2-yl)oxazole-4-carboxamide [1681];

2-(l-methylpiperidin-4-yl)-N-(7-(pyridin-3-yl)quinazolin-2-yl)oxazole-4-carboxamide [1682]; 2-(l-isopropylpiperidin-4-yl)-N-(7-(pyridin-3-yl)quinazolin-2-yl)oxazole-4-carboxamide [1683]; fr rø-N-(7-(5-fluoropyridin-3-yl)quinazolin-2-yl)-3-mo holinocyclobutane-l -carboxamide

[1684];

fr «5-N-(7-(5-fluoropyridin-3-yl)quinazolin-2-yl)-4-((4-methylpiperazin-l-yl)methyl)

cyclohexane-1 -carboxamide [1685];

N-(7-(5-fluoropyridin-3-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl)acetamide [1686]; N-(7-(5-fluoropyridin-3-yl)quinazolin-2-yl)-l-methylpiperidine-4-carboxamide [1687];

N-(7-(5-fluoropyridin-3 -yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl)acetamide [1688] ;

N-(7-(6-fluoropyridin-3-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)acetamide [1689];

N-(7-(5-fluoropyridin-3-yl)quinazolin-2-yl)-2-mo holinoacetamide [1690];

N-(7 -(5 -fluoropyridin-3 -yl)quinazolin-2 -yl) -3 -mo holinopropanamide [1691];

N-(7-(5-fluoropyridin-3-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [1692]; N-(7-(5-fluoropyridin-3-yl)quinazolin-2-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide [1693]; N-(7-(5-fluoropyridin-3-yl)quinazolin-2-yl)-2-(l-methylpiperidin-4-yl)oxazole-4-carboxamide

[1694];

N-(7-(5-fluoropyridin-3-yl)quinazolin-2-yl)-2-(l-isopropylpiperidin-4-yl)oxazole-4-carboxamide

[1695];

N-(7-(5-chloropyridin-3-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [1696]; N-(7-(5-methylpyridin-3-yl)quinazolin-2-yl)-2-mo holinoacetamide [1697];

N-(7-(5-(difluoromethyl)pyridin-3-yl)quinazolin-2-yl)-3-(piperidin-4-yl)benzamide [1698]; N-(7-(5-(difluoromethyl)pyridin-3-yl)quinazolin-2-yl)-3-(l-methylpiperidin-4-yl)benzamide

[1699];

N-(7-(5-(difluoromethyl)pyridin-3-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamid

[1700];

2-(4-methylpiperazin- 1 -yl)-N-(7-(5 -(trifluoromethyl)pyridin-3 -yl)quinazolin-2-yl)acetamide

[1701];

2-(4-methylpiperazin-l-yl)-N-(7-(6-(trifluoromethyl)pyridin-3-yl)quinazolin-2-yl)acetamide

[1702];

N-(7-(5-(hydroxymethyl)pyridin-3-yl)quinazolin-2-yl)-l-methylpiperidine-4-carboxamide

[1703];

N-(7-(5-cyanopyridin-3-yl)quinazolin-2-yl)-l-methylpiperidine-4-carboxamide [1704];

N-(7-(5-methoxypyridin-3-yl)quinazolin-2-yl)-l-methylpiperidine-4-carboxamide [1705];

N-(7-(5-methoxypyridin-3-yl)quinazolin-2-yl)-2-moφholinoacetamide [1706];

N-(7-(5-methoxypyridin-3-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinam [1707]; 4-fluoro-N-(7-(5-(piperidin-4-yloxy)pyridin-3-yl)quinazolin-2-yl)benzamide [1708];

N-(7 -(5 -aminopyridin-3 -yl)quinazolin-2 -yl) -4 -fluorobenzamide [ 1709] ;

N-(7-(5-aminopyridin-3-yl)quinazolin-2-yl)-4-(piperidin-4-yloxy)benzamide [1710];

N-(7-(5-aminopyridin-3-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [1711]; N-(7-(5-aminopyridin-3-yl)quinazolin-2-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide [1712]; N-(7-(6-aminopyridin-3-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [1713]; N-(7-(6-(methylamino)pyridin-3-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [1714];

N-(7-(5-(isopropylamino)pyridin-3-yl)quinazolin-2-yl)-3-(piperidin-4-yl)benzamide [1715]; N-(7-(5-(isopropylamino)pyridin-3-yl)quinazolin-2-yl)-3-(l-methylpiperidin-4-yl)benzamide

[1716];

N-(7-(5-(isopropylamino)pyridin-3-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [1717];

N-(7-(5-(piperidin-4-ylamino)pyridin-3-yl)quinazolin-2-yl)cyclohexanecarboxamide [1718]; 4-fluoro-N-(7-(5-(piperidin-4-ylamino)pyridin-3-yl)quinazolin-2-yl)benzamide [1719];

4-fluoro-N-(7-(5-((l-methylpiperidin-4-yl)amino)pyridin-3-yl)quinazolin-2-yl)benzamide [1720]; N-(7 -(5 -acetamidopyridin-3 -yl)quinazolin-2 -yl)- 1 -methylpiperidine -4 -carboxamide [ 1721 ] ; N-(7-(5-(dimethylamino)pyridin-3-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinami

[1722];

N-(7-(6-(dimethylamino)pyridin-3 -yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide

[1723];

1- methyl-N-(7-(5-(pyrrolidin-l-yl)pyridin-3-yl)quinazolin-2-yl)piperidine-4-carboxamide [1724]; N-(7-(5-(pyrrolidin-l-ylmethyl)pyridin-3-yl)quinazolin-2-yl)cyclopropanecarboxamide [1725]; 4-fluoro-N-(7-(5-(pyrrolidin-l -ylmethyl)pyridin-3-yl)quinazolin-2-yl)benzamide [1726] ;

N-(7-(5 -((4-hydroxypiperidin- 1 -yl)methyl)pyridin-3 -yl)quinazolin-2-yl)

cyclopropanecarboxamide [1727];

4-fluoro-N-(7-(5-((4-hydroxypiperidin-l-yl)methyl)pyridin-3-yl)quinazolin-2-yl)benzamide

[1728];

N-(7-(5-(piperazin-l-ylmethyl)pyridin-3-yl)quinazolin-2-yl)cyclopropanecarboxamide [1729]; N-(7-(5-((4-methylpiperazin-l-yl)methyl)pyridin-3-yl)quinazolin-2-yl)cyclopropanecarboxamide

[1730];

N-(7-(5-(mo holinomethyl)pyridin-3-yl)quinazolin-2-yl)cyclopropanecarboxamide [1731]; N-methyl-5-(2-(l-methylpiperidine-4-carboxamido)quinazolin-7-yl)nicotinamide [1732];

N-methyl-5-(2-(2-(4-methylpiperazin-l-yl)isonicotinamido)quinazolin-7-yl)nicotinamide [1733]; N-(7-(pyridin-3-yl-£/4)quinazolin-2-yl)-2-(pyrrolidin-l-yl)acetamide [1734];

2- (4-methylpiperazin- 1 -yl)-N-(7-(pyridin-3 -yl-d4)quinazolin-2-yl)acetamide [1735] ;

2-moφholino-N-(7-(pyridin-3-yl-ί 4()quinazolin-2-yl)acetamide [1736];

1 -methyl -N-(7 -(2 -methylpyrimidin-5 -yl)quinazolin-2 -yl)piperidine -4 -carboxamide [1737] ;

2-(4-methylpiperazin-l-yl)-N-(7-(2-methylpyrimidin-5-yl)quinazolin-2-yl)isonicotinamide

[1738]; N-(7-(2-aminopyrimidin-5-yl)quinazolin-2-yl)-l -methylpiperidine-4-carboxamide [1739] ;

2-moφholino-N-(7-(pyridazin-3-yl)quinazolin-2-yl)acetamide [1740];

2-moφholino-N-(7-(pyridazin-4-yl)quinazolin-2-yl)acetamide [1741];

N-(7-(pyridazin-4-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl)acetamide [1742];

trans-3 -mo holino-N-(7-(pyrazin-2-yl)quinazolin-2-yl)cyclobutane- 1 -carboxamide [1743] ; fr «5-4-(dimethylamino)-N-(7-(pyrazin-2-yl)quinazolin-2-yl)cyclohexane-l -carboxamide [1744]; fr rø-4-mo holino-N-(7-(pyrazin-2-yl)quinazolin-2-yl)cyclohexane-l -carboxamide [1745]; fr «5-4-((3-fluoroazetidin- 1 -yl)methyl)-N-(7-(pyrazin-2-yl)quinazolin-2-yl)cyclohexane- 1 - carboxamide [1746];

fr «5-4-((4-methylpiperazin- 1 -yl)methyl)-N-(7-(pyrazin-2-yl)quinazolin-2-yl)cyclohexane- 1 - carboxamide [1747];

N-(7-(pyrazin-2-yl)quinazolin-2-yl)-2-(pyrrolidin- 1 -yl)acetamide [1748] ;

1 -methyl -N-(7-(pyrazin -2 -yl)quinazolin-2-yl)piperidine-4-carboxamide [1749] ;

4-fluoro-l-methyl-N-(7-(pyrazin-2-yl)quinazolin-2-yl)piperidine-4-carboxamide [1750];

l-(2-fluoroethyl)-N-(7-(pyrazin-2-yl)quinazolin-2-yl)piperidine-4-carboxamide [1751];

1- (oxetan-3-yl)-N-(7-(pyrazin-2-yl)quinazolin-2-yl)piperidine-4-carboxamide [1752];

2- moφholino-N-(7-(pyrazin-2-yl)quinazolin-2-yl)acetamide [1753];

l-methyl-N-(7-(pyrazin-2-yl)quinazolin-2-yl)azepane-4-carboxamide [1754];

l-isobutyl-N-(7-(pyrazin-2-yl)quinazolin-2-yl)azepane-4-carboxamide [1755];

1- (2-hydroxy-2-methylpropyl)-N-(7-(pyrazin-2-yl)quinazolin-2-yl)azepane-4-carboxamide

[1756];

4-(moφholinomethyl)-N-(7-(pyrazin-2-yl)quinazolin-2-yl)benzamide [1757];

2- (4-methylpiperazin- 1 -yl)-N-(7-(pyrazin-2-yl)quinazolin-2-yl)isonicotinamide [1758] ;

N-(7-(6-(methylamino)pyrazin-2-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[1759];

N-(7-(6-(isopropylamino)pyrazin-2-yl)quinazolin-2-yl)azetidine-3-carboxamide [1760];

N-(7-(6-(isopropylamino)pyrazin-2-yl)quinazolin-2-yl)piperidine-4-carboxamide [1761];

N-(7-(6-(isopropylamino)pyrazin-2-yl)quinazolin-2-yl)-l-methylpiperidine-4 -carboxamide

[1762];

l-(2-fluoroethyl)-N-(7-(6-(isopropylamino)pyrazin-2-yl)quinazolin-2-yl)piperidine-4- carboxamide [1763];

l-isopropyl-N-(7-(6-(isopropylamino)pyrazin-2-yl)quinazolin-2-yl)piperidine-4-carboxamide

[1764]; l-isopentyl-N-(7-(6-(isopropylamino)pyrazin-2-yl)quinazolin-2-yl)piperidine-4-carboxamide

[1765];

N-(7-(6-(isopropylamino)pyrazin-2-yl)quinazolin-2-yl)-3-(piperidin-4-yl)benzamide [1766]; N-(7-(6-(isopropylamino)pyrazin-2-yl)quinazolin-2-yl)-3 -( 1 -methylpiperidin-4-yl)benzamide

[1767];

N-(7-(6-(isopropylamino)pyrazin-2-yl)quinazolin-2^

carboxamide [1768];

l-(l-(2-fluoroethyl)piperidin-4-yl)-N-(7-(6-(isopropylamino)pyrazin-2-yl)quinazolin-2-yl)-lH- l,2,3-triazole-4-carboxamide [1769];

N-(7-(6-(isopropylamino)pyrazin-2-yl)quinazolin-2-yl)-l-(l-isopropylpiperidin-4-yl)-lH-l,2,3- triazole -4 -carboxamide [1770];

N-(7-(6-(isopropylamino)pyrazin-2-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [1771];

N-(7-(6-(fer^butylamino)pyrazin-2-yl)quinazolin-2-yl)-2-(3-(dimethylamino)azetidin-l-yl) isonicotinamide [1772];

N-(7-(6-(fer^butylamino)pyrazin-2-yl)quinazolin-2-yl)-r-methyl-r,2',3',6'-tetrahydro-[2,4'- bipyridine] -4 -carboxamide [1773];

N-(7-(6-(feri-butylamino)pyrazin-2-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [1774];

N-(7-(6-(feri-butylamino)pyrazin-2-yl)quinazolin-2-yl)-2-(4-isopropylpiperazin-l-yl)

isonicotinamide [1775];

N-(7-(6-(ferί-butylamino)pyrazin-2-yl)quinazolin-2-yl)-2-moφholinoisonicotinamide [1776]; N-(7-(6-(((3-fluoroazetidin-3-yl)methyl)amino)pyrazin-2-yl)quinazolin-2-yl)

cyclopropanecarboxamide [1777];

4-fluoro-N-(7-(6-(((3-fluoroazetidin-3-yl)methyl)amino)pyrazin-2-yl)quinazolin-2-yl)benzamide

[1778];

N-(7-(6-(piperidin-4-ylamino)pyrazin-2-yl)quinazolin-2-yl)cyclobutanecarboxamide [1779];

3.3- difluoro-N-(7-(6-(piperidin-4-ylamino)pyrazin-2-yl)quinazolin-2-yl)cyclobutane-l- carboxamide [1780];

N-(7-(6-(piperidin-4-ylamino)pyrazin-2-yl)quinazolin-2-yl)cyclopentanecarboxamide [1781];

4.4- difluoro-N-(7-(6-(piperidin-4-ylamino)pyrazin-2-yl)quinazolin-2-yl)cyclohexane-l- carboxamide [1782];

N-(7-(6-(piperidin-4-ylamino)pyrazin-2-yl)quinazolin-2-yl)tetrahydro-2H-pyran-4-carboxamide

[1783]; 4-fluoro-N-(7-(6-(piperidin-4-ylamino)pyrazin-2-yl)quinazolin-2-yl)benzamide [1784];

N-(7-(6-(((3S,4S)-3-fluoropiperidin-4-yl)amino)pyrazin-2-yl)quinazolin-2-yl)

cyclopropanecarboxamide [1785];

4-fluoro-N-(7-(6-(((3S,4S)-3-fluoropiperidin-4-yl)amino)pyrazin-2-yl)quinazolin-2-yl)benzamide

[1786];

N-(7-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2-yl)quinazolin-2-yl)cyclobutanecarboxamide

[1787];

N-(7-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2-yl)quinazolin-2-yl)cyclopentanecarboxamide

[1788];

4-fluoro-N-(7-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2-yl)quinazolin-2-yl)benzamide [1789]; N-(7-(6-((l-isopropylpiperidin-4-yl)amino)pyrazin-2-yl)quinazolin-2-yl)

cyclopropanecarboxamide [1790];

3,3-difluoro-N-(7-(6-((l-isopropylpiperidin-4-yl)amino)pyrazin-2-yl)quinazolin-2-yl)

cyclobutane-l-carboxamide [1791];

N-(7-(6-((l-isopropylpiperidin-4-yl)amino)pyrazin-2-yl)quinazolin-2-yl)

cyclopentanecarboxamide [1792];

4-fluoro-N-(7-(6-((l-isopropylpiperidin-4-yl)amino)pyrazin-2-yl)quinazolin-2-yl)benzamide

[1793];

N-(7-(6-(dimethylamino)pyrazin-2-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l- yl)isonicotinamide [1794];

N-(7-(6-(diethylamino)pyrazin-2-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l-yl)isonicotinami

[1795];

N-(7-(6-(3-aminoazetidin-l-yl)pyrazin-2-yl)quinazolin-2-yl)-4-fluorobenzamide [1796];

2-(4-methylpiperazin- 1 -yl)-N-(7-(6-(pyrrolidin- 1 -yl)pyrazin-2-yl)quinazolin-2-yl)isonicotinamide

[1797];

N-(7-(6-(azetidin-3-ylmethoxy)pyrazin-2-yl)quinazolin-2-yl)-4-fluorobenzamide [1798];

N-(7-(6-(azetidin-3-yloxy)pyrazin-2-yl)quinazolin-2-yl)-4-fluorobenzamide [1799];

N-(7-(lH-pyrrolo[2,3-b]pyridin-5-yl)quinazolin-2-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [1800];

N-(7-(lH-pyrrolo[3,2-b]pyridin-6-yl)quinazolin-2-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [1801];

N-(7-(lH-pyrrolo[2,3-c]pyridin-4-yl)quinazolin-2-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [1802]; N-(7-( lH-pyrrolo[2,3-b]pyridin-5-yl)quinazo^

[1803] ;

N-(7-( lH-pyrrolo[3,2-b]pyridin-6-yl)quinazolm^

[1804] ;

N-(7 -( 1 H-pyrrolo [2,3 -c] pyridin-4 -yl)quinazolin-2-yl)-2-(4-methylpiperazin-l -yl)isonicotinamide

[1805] ;

2-(4-methylpiperazin-l -yl)-N-(7-(oxazolo[5,4-b]pyridin-6-yl)quinazolin-2-yl)isonicotinamide

[1806] ;

N-(7-(2-methyl-lH-pyrrolo[2,3-b]pyridin-5-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l -yl)

isonicotinamide [1807];

N-(7-(3-methyl-lH-pyrrolo[2,3-b]pyridin-5-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l -yl)

isonicotinamide [1808];

N-(7-(2-methyl-lH-pyrrolo[3,2-b]pyridin-6-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l -yl)

isonicotinamide [1809];

N-(7-(5H-pyrrolo[2,3-b]pyrazin-2-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l -yl)isonicotinamide

[1810] ;

N-(7-(5H-pyrrolo[2,3-b]pyrazin-3-yl)quinazolin-2-yl)-2-(4-methylpiperazin-l -yl)isonicotinamide

[1811] ;

l-isopropyl-N-(7-(6-(piperidin-4-ylamino)pyrazin-2-yl)quinazolin-2-yl)-lH-pyrazole-4- carboxamide [1812];

l-isopropyl-N-(7-(6-(( l-methylpiperidin-4-yl)amino)pyrazin-2-yl)quinazolin-2-yl)-lH-pyrazole- 4-carboxamide [1813];

fr «5-4-((2-fluoroethyl)amino)-N-(7-( l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)cyclohexane-l - carboxamide [4566];

fra«s-4-((2-methoxyethyl)amino)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)cyclohexane- 1 -carboxamide [4567];

fert-butyl (trans-4-((7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)carbamoyl)cyclohexyl) carbamate [4568];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(( 1 -methylpiperidin-4-yl)amino)

isonicotinamide [4569];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl)thiazole-5 - carboxamide [4570];

N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylpiperazin- 1 -yl)thiazole-5 - carboxamide [4571]; N-(7-( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(2,7-diazaspiro[3.5] nonan-2-yl)isonicotinamide [4572] ;

N-(7-(l-methyl-lH-l,2,3-triazol-4-yl)quinazolin-2-yl)-4-(piperidin-4-yloxy)benzamide [4573]; N-(7-( 1 -methyl- lH-tetrazol-5 -yl)quinazolin-2-yl)- 1 -(3,3,3-trifluoropropyl)piperidine-4- carboxamide [4574];

N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(pyrrolidin-l-yl)propanamide [4575]; N-(7-(l,2-dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(piperidin-l-yl)propanamide [4576]; 4-isopropoxy-N-(7-(7-methyl-5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)quinazolin-2-yl) benzamide [4577];

trans-3 -morpholino-N-(7-(oxazol-5 -yl)quinazolin-2-yl)cyclobutane- 1 -carboxamide [4578] ; fr «5-4-(hydroxymethyl)-N-(7-(oxazol-5-yl)quinazolin-2-yl)cyclohexane-l -carboxamide [4579]; N-(7-(oxazol-5-yl)quinazolin-2-yl)piperidine-4-carboxamide [4580];

4-moφholino-N-(7-(oxazol-5-yl)quinazolin-2-yl)piperidine-l -carboxamide [4581];

N-(7-(oxazol-5-yl)quinazolin-2-yl)-4-(piperidin-4-yloxy)benzamide [4582];

N-(7-(oxazol-5-yl)quinazolin-2-yl)-3-(piperidin-4-yloxy)benzamide [4583];

2-methyl-N-(7-(oxazol-5-yl)quinazolin-2-yl)-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H)- carboxamide [4584];

2-(lH-imidazol-l-yl)-N-(7-(oxazol-5-yl)quinazolin-2-yl)acetamide [4585];

fr «5-4-(hydroxymethyl)-N-(7-(thiazol-5-yl)quinazolin-2-yl)cyclohexane-l-carboxamide [4586]; fr «5-4-(dimethylamino)-N-(7-(thiazol-5-yl)quinazolin-2-yl)cyclohexane-l -carboxamide [4587]; N-(7-(thiazol-5-yl)quinazolin-2-yl)-l-((l-(trifluoromethyl)cyclopropyl)methyl)piperidine-4- carboxamide [4588];

fr «5-4-(hydroxymethyl)-N-(7-(2-methylthiazol-5-yl)quinazolin-2-yl)cyclohexane-l- carboxamide [4589];

fr «5-4-(dimethylamino)-N-(7-(2-methylthiazol-5 -yl)quinazolin-2-yl)cyclohexane- 1 -carboxamide

[4590];

N-(7-(2-methylthiazol-5-yl)quinazolin-2-yl)-l-(oxetan-3-yl)piperidine-4-carboxamide [4591]; N-(7-(2-methylthiazol-5 -yl)quinazolin-2-yl)- 1 -(2-(pyrrolidin- 1 -yl)acetyl)piperidine-4- carboxamide [4592];

2-((lS,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)

quinazolin-2-yl)acetamide [4593];

N-(7-(5-(cyano(4-hydroxypiperidin-l-yl)methyl)pyridin-3-yl)quinazolin-2-yl)

cyclopropanecarboxamide [4594]; 4-fluoro-N-(7-(6-(( 1 -methylazetidin-3 -yl)methoxy)pyrazin-2-yl)quinazolin-2-yl)benzamide

[4595] ;

l-isopropyl-N-(7-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2-yl)quinazolin-2-yl)-lH-pyrazole- 4-carboxamide [4596]; or a pharmaceutically acceptable salt thereof.

22. The compound according to any one of claims 1-19, wherein the compound of Formula I is selected from the group consisting of:

N-(6-( lH-pyrazol-4-yl)cinnolin-3-yl)-l -isobutylpiperidine-4-carboxamide [1814];

N-(6-( l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)cyclopropanecarboxamide [1815];

4,4-difluoro-N-(6-( l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)cyclohexane-l -carboxamide [1816] ; fr «5-4-methoxy-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin -3 -yl)cyclohexane- 1 -carboxamide

[1817] ;

trans -N-(6-( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -4 -morpholinocyclohexane - 1 -carboxamide

[1818] ;

trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3-yl)

cyclohexane-1 -carboxamide [1819];

fr «5-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-4-((4-methylpiperazin-l-yl)methyl)

cyclohexane-1 -carboxamide [1820];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -2 -(pyrrolidin- 1 -yl)acetamide [1821] ;

(S)-2-(3 -fluoropyrrolidin- 1 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)acetamide [1822] ; (S)-N-(6-( l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)tetrahydrofuran-2 -carboxamide [1823];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)piperidine -4 -carboxamide [1824] ;

1 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)piperidine -4 -carboxamide [ 1825] ;

1 -isopropyl-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-4-carboxamide [1826] ; 1 -(fert-butyl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)piperidine-4-carboxamide [1827] ; l-cyclopropyl-N-(6-(l -methyl-lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-4-carboxamide [1828]; 1 -isobutyl-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)piperidine-4-carboxamide [1829] ; N-(6-( l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l -neopentylpiperidine-4-carboxamide [1830] ; 1 -(2 -fluoroethyl) -N-(6-( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)piperidine -4 -carboxamide

[1831] ;

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) - 1 -(3 ,3 , 3 -trifluoropropyl)piperidine -4 - carboxamide [1832];

1 -butyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)piperidine -4 -carboxamide [1833];

1 -benzoyl -N-(6-( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)piperidine -4 -carboxamide [ 1834] ; l-(2,2-difluoropropyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-4-carboxam

[1835];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)azetidine -3 -carboxamide [1836];

1 -(2,2-difluoroethyl)-N-(6 -(1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)piperidine -4 -carboxamide

[1837];

1 -(2 -fluoro-2 -methylpropyl)-N-(6 -( 1 -methyl- 1 H-pyrazol -4 -yl)cinnolin-3 -yl)piperidine -4 - carboxamide [1838];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l-(oxetan-3-yl)piperidine-4-carboxamide [1839]; N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)- 1 -((3-methyloxetan-3 -yl)methyl)piperidine-4- carboxamide [1840];

1- (2-methoxyethyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-4 -carboxamide

[1841];

1 -(2-isopropoxyethyl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin -3 -yl)piperidine-4-carboxamide

[1842];

1 , 1 -diisobutyl-4-((6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)carbamoyl)piperidin-l -ium [1843] ; 4-fluoro-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-4-carboxamide [1844];

4-fluoro- 1 -methyl -N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)piperidine-4-carboxamide

[1845];

4-fluoro- 1 -isobutyl-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)piperidine-4-carboxamide

[1846];

(S)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-3-carboxamide [1847];

(R)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-3-carboxamide [1848];

(S)- 1 -isobutyl-N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3-yl)piperidine -3 -carboxamide [1849] ; (R)-l-isobutyl-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-3-carboxamide [1850]; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)tetrahydro-2H-pyran-4-carboxamide [1851]; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(piperidin-l-yl)acetamide [1852];

2- (4-fluoropiperidin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide [1853]; trans -4 -amino -N-(6-( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)cyclohexane - 1 -carboxamide

[1854];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)acetamide [1855]; (S)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-2 -carboxamide [1856];

2-(4-isobutylpiperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide [1857]; 2-(3,3-dimethylazetidin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide [1858]; (R)-2-(3-fluoropyrrolidin- 1 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)acetamide [1859] ; (S)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)-2-(2-methylpyrrolidin- 1 -yl)acetamide [1860] ; 2-(3-azabicyclo[3.1.0]hexan-3-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide

[1861];

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide

[1862];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperidin-l-yl)acetamide [1863]; N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)-2-(4-(trifluoromethyl)piperidin- 1 -yl)acetamide

[1864];

2-(4-(difluoromethyl)piperidin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide

[1865];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(6-azaspiro[2.5]octan-6-yl)acetamide [1866]; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(pyrrolidin-l-yl)propanamide [1867];

(R)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3-yl)-2-(2-methylpyrrolidin- 1 -yl)acetamide [1868] ; 2-(cyclobutyl(methyl)amino)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide [1869]; 2-(diethylamino)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide [1870];

7-(2-fluoroethyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-7-azaspiro[3.5]nonane-2- carboxamide [1871];

4-methyl-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)piperazine-l-carboxamide [1872];

(S)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(pyrrolidin-l-yl)propanamide [1873]; (R)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(pyrrolidin-l-yl)propanamide [1874]; (R)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)pyrrolidine-2-carboxamide [1875];

2-methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -2 -azaspiro [3.3] heptane -6-carboxamide

[1876];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(2,2,2-trifluoroacetyl)-2-azaspiro[3.3]heptane- 6-carboxamide [1877];

2-(2-fluoroethyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-azaspiro[3.3]heptane-6- carboxamide [1878];

trans -4 -(dimethylamino) -N-(6 -( 1 -methyl - 1 H-pyrazol-4 -yl)cinnolin-3 -yl)cyclohexane - 1 - carboxamide [1879];

1 -acetyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)piperidine -4 -carboxamide [ 1880] ;

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) - 1 -(( 1 -(trifluoromethyl)cyclopropyl)methyl)

piperidine-4-carboxamide [1881];

(S)- 1 -(2-fluoropropyl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)piperidine -4 -carboxamide

[1882]; (R)-l-(2-fluoropropyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-4-carboxamide

[1883];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(piperidin-l-yl)propanamide [1884];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l-(methylsulfonyl)piperidine-4 -carboxamide

[1885];

1 '-methyl -N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)-[ 1 ,4'-bipiperidine] -4-carboxamide

[1886];

fr «5-4-(hydroxymethyl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)cyclohexane- 1 - carboxamide [1887];

methyl 2-(4-((6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)carbamoyl)piperidin-l-yl)acetate

[1888];

1 -benzyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)piperidine -4 -carboxamide [ 1889] ;

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l-(2-(pyrrolidin-l-yl)acetyl)piperidine-4- carboxamide [1890];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)-2-morpholinoacetamide [1891];

(S)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(3-methylmo holino)acetamide [1892]; (R)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(3-methylmo holino)acetamide [1893]; (S)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(2-methylmo holino)acetamide [1894]; 2-((2R,6S)-2,6-dimethylmoφholino)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide

[1895];

2-((lS,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3- yl)acetamide [1896];

2-((lR,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3- yl)acetamide [1897];

2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide

[1898];

(S)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-moφholinopropanamide [1899];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(moφholin-2-yl)acetamide [1900];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylmoφholin-2-yl)acetamide [1901]; 2-(4-ethylpiperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide [1902];

2-(4-isopropylpiperazin-l -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)acetamide [1903] ; 2-(4-cyclopropylpiperazin- 1 -yl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)acetamide [1904] ; 2-(4-(2-fluoroethyl)piperazin- 1 -yl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)acetamide

[1905]; (S)-2-(2,4-dimethylpiperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide

[1906];

1 -(2-hydroxyethyl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)piperidine-4-carboxamide

[1907];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l-(pyridin-2-ylmethyl)piperidine-4-carboxamide

[1908];

N-(6-( 1 -methyl -IH-pyrazol -4 -yl)cinnolin-3 -yl)- 1 -(oxazol-2-ylmethyl)piperidine-4-carboxamide

[1909];

(R)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l-oxotetrahydro-lH-pyrrolo[l,2-c]imidazole-

2(3H)-carboxamide [1910];

(R)-l -methyl -N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)pyrrolidine-2-carboxamide [1911]; N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) - 1 -(tetrahydro -2H-pyran-4 -yl)piperidine -4 - carboxamide [1912];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) - 1 -(pyrimidin-2-ylmethyl)piperidine -4- carboxamide [1913];

N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)- 1 -(pyrazin-2-ylmethyl)piperidine-4-carboxamide

[1914];

1 -((5 -methyl- 1 ,2,4-oxadiazol-3-yl)methyl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)

piperidine-4-carboxamide [1915];

1- (2-hydroxy-2-methylpropyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-4- carboxamide [1916];

tert-butyl 2-(4-((6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)carbamoyl)piperidin-l-yl)acetate

[1917];

2- (4-((6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)carbamoyl)piperidin-l-yl)acetic acid [1918]; 2-(4-methyl-l,4-diazepan-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide [1919]; tert-butyl (6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)carbamate [1920];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)but-2-ynamide [1921];

fr «5-4-((6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)carbamoyl)cyclohexane-l-carboxylic acid

[1922];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-3-moφholinopropanamide [1923];

trans-N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)-3 -mo holinocyclobutane- 1 -carboxamide

[1924];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)quinuclidine-4-carboxamide [1925];

l-isobutyl-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)azepane-4-carboxamide [1926]; 2-(4-methoxypiperidin- 1 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)acetamide [1927] ;

2- (4-hydroxypiperidin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide [1928];

3- (hydroxymethyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)bicyclo[l . l . l]pentane-l- carboxamide [1929];

1 -methyl -N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)azepane-4-carboxamide [1930] ;

trans -4 -(dimethylamino) -N-(6 -( 1 -methyl - 1 H-pyrazol-4 -yl)cinnolin-3 -yl)cyclohexane - 1 - carboxamide [1931];

fr «5-4-(bis(methyl-d3)amino)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)cyclohexane-l- carboxamide [1932];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-3-((4-methylpiperazin-l-yl)methyl)bicyclo[ 1.1.1] pentane-1 -carboxamide [1933];

methyl fr «5-4-((6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)carbamoyl)cyclohexane-l- carboxylate [1934];

2-(l-isobutylpyrrolidin-3-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide [1935]; fr «5-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-4-(4-methylpiperazine-l-carbonyl)

cyclohexane-1 -carboxamide [1936];

1 -isobutyl-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)piperidine-4-carboxamide [1937] ; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l-(phenylsulfonyl)piperidine-4-carboxamide

[1938];

8 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -3 , 8 -diazabicyclo [3.2.1] octane -3 - carboxamide [1939];

3 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -3 , 8 -diazabicyclo [3.2.1] octane -8 - carboxamide [1940];

(lR,3s,5S)-3-amino-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-8-azabicyclo[3.2.1]octane-8- carboxamide [1941];

(lR,3s,5S)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-3-((3,3,3-trifluoropropyl)amino)-8- azabicyclo[3.2.1] octane -8 -carboxamide [1942];

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [1943];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)mo holine -4-carboxamide [1944];

4- (dimethylamino) -N-(6-( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)piperidine - 1 -carboxamide

[1945];

(S)-2,4-dimethyl-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)piperazine- 1 -carboxamide

[1946]; 1 -methyl -3 -(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) - 1 -( 1 -methylpiperidin-4 -yl)urea [1947]; 1 -(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)-3 -( 1 -methylpiperidin-4-yl)urea [1948] ;

4-isopropyl-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)piperazine-l -carboxamide [1949]; (R)-3 ,4-dimethyl-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)piperazine- 1 -carboxamide

[1950];

N-(6-(lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [1951];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -3 -(piperazin- 1 -yl)benzamide [ 1952] ;

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-3-(4-methylpiperazin-l-yl)benzamide [1953]; N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)-3 -(pyrrolidin- 1 -ylmethyl)benzamide [1954] ; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-3-(piperidin-4-yloxy)benzamide [1955];

N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)-3 -(( 1 -methylpiperidin-4-yl)oxy)benzamide

[1956];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-4-(piperidin-4-yloxy)benzamide [1957];

N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)-4-(( 1 -methylpiperidin-4-yl)oxy)benzamide

[1958];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -2 -(piperazin- 1 -yl)isonicotinamide [1959];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[I960];

2-(4-isopropylpiperazin-l -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)isonicotinamide

[1961];

2-(4-cyclopropylpiperazin- 1 -yl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)isonicotinamide

[1962];

2-(4-(2-fluoroethyl)piperazin- 1 -yl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)

isonicotinamide [1963];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-6-(4-methylpiperazin-l-yl)nicotinamide [1964]; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-5-(piperidin-4-yloxy)nicotinamide [1965];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(piperidin-4-yloxy)isonicotinamide [1966]; N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)-2-(( 1 -methylpiperidin-4-yl)oxy)isonicotinamide

[1967];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-5-(piperidin-4-ylamino)nicotinamide [1968]; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-5-((l-methylpiperidin-4-yl)amino)nicotinamide

[1969];

2-(4-aminopiperidin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)isonicotinamide [1970]; N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)-2-(4 -(methylamino)piperidin- 1 -yl)

isonicotinamide [1971];

2-(4-(dimethylamino)piperidin-l -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)

isonicotinamide [1972];

2-(( 1 -isopropylpiperidin-4-yl)oxy)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3-yl)

isonicotinamide [1973];

2-(3 -aminoazetidin- 1 -yl)-N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)isonicotinamide [1974] ; 2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3-yl)

isonicotinamide [1975];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-moφholinoisonicotinamide [1976];

2-((2-(dimethylamino)ethyl)amino)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)

isonicotinamide [1977];

2-(2-(dimethylamino)ethoxy)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)isonicotinamide

[1978];

2-(4-isobutylpiperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)isonicotinamide

[1979];

2-(azetidin-3 -yloxy)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin -3 -yl)isonicotinamide [1980] ; N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)-2-(( 1 -methylazetidin-3 -yl)oxy)isonicotinamide

[1981];

2-(4-ethylpiperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)isonicotinamide [1982]; 4-((dimethylamino)methyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)benzamide [1983]; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-3-(l-methylpiperidin-4-yl)benzamide [1984]; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-3-((4-methylpiperazin-l-yl)methyl)benzamide

[1985];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)isonicotinamide [ 1986] ;

2-hydroxy-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)isonicotinamide [1987];

2-isopropoxy-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)isonicotinamide [1988];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(l-methylpiperidin-4-yl)isonicotinamide

[1989];

r-methyl-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l',2',3',6'-tetrahydro-[2,4'-bipyridine]-

4-carboxamide [1990];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -2 -(4-(6 -(4-methylpiperazin- 1 -yl)

nicotinoyl)piperazin- 1 -yl)isonicotinamide [1991] ; 2-(4-hydroxy-4-methyl-4 4-piperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl) isonicotinamide [1992];

2-methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -6 -(4-methylpiperazin- 1 -yl)

isonicotinamide [1993];

3 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -2 -(4-methylpiperazin- 1 -yl)

isonicotinamide [1994];

2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3-yl)isonicotinamide

[1995];

2-((2S,6R)-2,6-dimethylmo holino)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)

isonicotinamide [1996];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(2,7-diazaspiro[3.5]nonan-2-yl)isonicotinamide

[1997];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl) isonicotinamide [1998];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(2,7-diazaspiro[3.5]nonan-7-yl)isonicotinamide

[1999];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(2-methyl-2,7-diazaspiro[3.5]nonan-7-yl) isonicotinamide [2000];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3-yl)

isonicotinamide [2001];

N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)-2-(( 1 -methylpiperidin-4-yl)thio)isonicotinamide

[2002];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)pyrimidine-4- carboxamide [2003];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-6-(4-methylpiperazin-l-yl)pyridazine-4- carboxamide [2004];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-6-(4-methylpiperazin-l-yl)pyrimidine-4- carboxamide [2005];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-phenylacetamide [2006];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-3-phenylpropanamide [2007];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -2 -(pyridin-3 -yl)acetamide [2008] ;

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -3 -(pyridin-3 -yl)propanamide [2009] ;

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -2 -(pyridin-4-yl)acetamide [2010];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -3 -(pyridin-4-yl)propanamide [2011]; N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)isoindoline -5 -carboxamide [2012] ;

2-methyl-N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)isoindoline -5 -carboxamide [2013]; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l,2,3,4-tetrahydroisoquinoline-7-carboxamide

[2014];

2-methyl-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l,2,3,4-tetrahydroisoquinoline-7- carboxamide [2015];

2-methyl-N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) - 1 ,2, 3 ,4 -tetrahydroisoquinoline -6 - carboxamide [2016];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l,2,3,4-tetrahydroisoquinoline-6-carboxamide

[2017];

N-(6 ■( 1 -methyl - 1 H-pyrazol -4 -y ll))cinnolin-3 -yl) - 1 H-indole -5 -carboxamide [2018];

N-(6■(l-methyl-lH-pyrazol-4-yll))cinnolin-3-yl)benzofuran-5 -carboxamide [2019];

N-(6■( 1 -methyl - 1 H-pyrazol -4 -y ll))cinnolin-3-yl)furo[2,3-c]pyridine-5-carboxamide [2020]; N-(6■(l-methyl-lH-pyrazol-4-yll))cinnolin-3 -yl)benzo [b]thiophene-5 -carboxamide [2021 ] ; N-(6■(l-methyl-lH-pyrazol-4-yll))cinnolin-3-yl)benzofuran-6-carboxamide [2022];

N-(6■(l-methyl-lH-pyrazol-4-yll))cinnolin-3 -yl)benzo [d] oxazole -6-carboxamide [2023] ; N-(6■( 1 -methyl - 1 H-pyrazol -4 -y ll))cinnolin-3-yl)benzo[d]thiazole-6-carboxamide [2024]; N-(6■(l-methyl-lH-pyrazol-4-yll))cinnolin-3 -yl)benzo [d] oxazole -5 -carboxamide [2025] ; N-(6■( 1 -methyl - 1 H-pyrazol -4 -y ll))cinnolin-3-yl)benzo[d]thiazole-5-carboxamide [2026]; N-(6■( 1 -methyl - 1 H-pyrazol -4 -y ll))cinnolin-3 -yl)quinoline-3 -carboxamide [2027] ;

N-(6■( 1 -methyl - 1 H-pyrazol -4 -y ll))cinnolin-3 -yl)quinoline -6 -carboxamide [2028] ;

N-(6■( 1 -methyl - 1 H-pyrazol -4 -y ll))cinnolin-3 -yl)quinoxaline-6-carboxamide [2029] ;

5-chloro-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [2030];

3-chloro-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [2031];

2- (2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)

isonicotinamide [2032];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2- yl)isonicotinamide [2033];

3- fluoro-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [2034];

N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)-2-((4-methylpiperazin- 1 -yl)methyl)

isonicotinamide [2035]; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(mo holinomethyl)isonicotinamide [2036]; N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)-2-(pyrrolidin- 1 -ylmethyl)isonicotinamide [2037] ; N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)-2-(2-(4-methylpiperazin- 1 -yl)pyridin-4-yl)

acetamide [2038];

1 -methyl -N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)- lH-indazole -5 -carboxamide [2039] ; 1 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)- 1 H-benzo [d] imidazole -5 -carboxamide

[2040];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l-(piperidin-4-yl)-lH-pyrazole-4 -carboxamide

[2041];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [2042];

1 -( 1 -ethylpiperidin-4-yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3-yl)- lH-pyrazole-4- carboxamide [2043];

1 -( 1 -(2-fluoroethyl)piperidin-4-yl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)- lH-pyrazole- 4-carboxamide [2044];

1 -( 1 -isopropylpiperidin-4-yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)- lH-pyrazole-4- carboxamide [2045];

l-(l-cyclopropylpiperidin-4-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-lH-pyrazole-4- carboxamide [2046];

isopropyl 4-(4-((6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)carbamoyl)-lH-pyrazol-l-yl) piperidine-l-carboxylate [2047];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l-(piperidin-4-yl)-lH-l,2,3-triazole-4- carboxamide [2048];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l-(l-methylpiperidin-4-yl)-lH-l,2,3-triazole-4- carboxamide [2049];

1- (l-(2-fluoroethyl)piperidin-4-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-lH-l,2,3- triazole -4 -carboxamide [2050];

1 -( 1 -isopropylpiperidin-4-yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)- 1H- 1 ,2,3 -triazole-4- carboxamide [2051];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)oxazole-5- carboxamide [2052];

2- (3 -(dimethylamino)azetidin- 1 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3-yl)oxazole-4- carboxamide [2053];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide [2054]; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(l-methylpiperidin-4-yl)oxazole-4- carboxamide [2055];

2-( 1 -(2-fluoroethyl)piperidin-4-yl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)oxazole-4- carboxamide [2056];

2-( 1 -isopropylpiperidin-4-yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)oxazole-4- carboxamide [2057];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)oxazole-4- carboxamide [2058];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3-yl)thiazole-5- carboxamide [2059];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -2 -(piperidin-4-yl)thiazole -4 -carboxamide [2060] ; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)thiazole-4- carboxamide [2061];

2-( 1 -(2-fluoroethyl)piperidin-4-yl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)cinnolin-3 -yl)thiazole-4- carboxamide [2062];

2-( 1 -isopropylpiperidin-4-yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)cinnolin-3 -yl)thiazole-4- carboxamide [2063];

1 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl)cinnolin-3 -yl -4 - )piperidine-4-carboxamide [2064] ; N-(6-( l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l-(2 -(methyl -d3)propyl-l, 1,2,3, 3,3-£¾;)piperidine- 4-carboxamide [2065];

N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(pyrrolidin-l-yl-2,2,5,5-£/4)acetamide [2066]; N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)-2-(4-(methyl-<i3)piperazin- 1 -yl)acetamide [2067] ; N-(6-(l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(mo holino-ί s)acetamide [2068];

( S) -N-(6 -( 1 -(methyl -ds)-\ H-pyrazol -4 -yl)cinnolin-3 -yl)-2-(pyrrolidin- 1 -yl)propanamide [2069] ; l-isobutyl-N-(6-(l-(methyl-£/3)-lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-4-carboxamide [2070]; N-(6-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)cinnolin-3 -yl)-2-(4-methylpiperazin-l -yl)acetamide [2071] ; N-(6-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)cinnolin-3 -yl)-2-(pyrrolidin- 1 -yl)acetamide [2072] ;

N-(6-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)cinnolin-3-yl)-2-(piperidin- 1 -yl)acetamide [2073] ;

N-(6-( 1 -(methyl -ds)- lH-pyrazol-4-yl)cinnolin-3 -yl)- 1 -(3,3, 3-trifluoropropyl)piperidine-4- carboxamide [2074];

N-(6-(lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-(methyl-£/3)piperazin-l-yl)isonicotinamide [2075]; N-(6-( 1 -methyl -1 H-pyrazol -4 -yl)cinnolin-3 -yl)-2-(4-(methyl-<i3)piperazin- 1 -yl)isonicotinamide

[2076]; N-(6-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)cinnolin-3 -yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide

[2077];

N-(6-( 1 -(methyl - 3)- lH-pyrazol-4-yl)cinnolin-3 -yl)-2-(4-(methyl-£/3)piperazin- 1 -yl)

isonicotinamide [2078];

N-(6-(l-(methyl-£/3)-lH-pyrazol-4-yl)cinnolin-3-yl)-l-(piperidin-4-yl)-lH-pyrazole-4- carboxamide [2079];

N-(6-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)cinnolin-3 -yl)- 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazole-4- carboxamide [2080];

N-(6-( 1 -(methyl - 3)- lH-pyrazol-4-yl)cinnolin-3 -yl)-2-(piperidin-4-yl)oxazole-4-carboxamide

[2081];

N-(6-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)cinnolin-3 -yl)-2-( 1 -methylpiperidin-4-yl)oxazole-4- carboxamide [2082];

N-(6-( 1 -ethyl- lH-pyrazol-4-yl)cinnolin-3-yl)-2-(pyrrolidin- 1 -yl)acetamide [2083] ;

N-(6-(l-cyclopropyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(pyrrolidin-l-yl)acetamide [2084];

N-(6-(l-cyclopropyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [2085];

N-(6-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)cinnolin-3-yl)cyclohexanecarboxamide [2086] ; 2-(pyrrolidin-l-yl)-N-(6-(5-(trifluoromethyl)-lH-pyrazol-4-yl)cinnolin-3-yl)acetamide [2087]; N-(6-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-l-methylpiperidine-4- carboxamide [2088];

N-(6-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)tetrahydro-2H-pyran-4- carboxamide [2089];

N-(6-(5-(azetidin-l-ylmethyl)-l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-4,4-difluorocyclohexane-

1-carboxamide [2090];

4,4-difluoro-N-(6-(l-methyl-5-(pyrrolidin-l-ylmethyl)-lH-pyrazol-4-yl)cinnolin-3-yl)

cyclohexane-l-carboxamide [2091];

4,4-difluoro-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)cinnolin-3-yl)

cyclohexane-l-carboxamide [2092];

2-(2 -fluoroethyl) -N-(6 -( 1 -methyl -5 -(piperidin- 1 -ylmethyl) - 1 H-pyrazol -4 -yl)cinnolin-3 -yl) -2 - azaspiro [3.3] heptane -6 -carboxamide [2093] ;

fert-butyl 6-((6 -( 1 -methyl -5 -(piperidin- 1 -ylmethyl) - 1 H-pyrazol -4 -yl)cinnolin-3 -yl)carbamoyl) -2 - azaspiro [3.3] heptane -2 -carboxylate [2094] ;

2-fluoro-2-methyl-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)cinnolin-3-yl)

propanamide [2095]; 2-(diethylamino)-N-(6-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)-lH-pyrazol-4-yl)cinnolin-3 -yl) acetamide [2096];

fr «5-4-methoxy-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)cinnolin-3-yl)

cyclohexane-l-carboxamide [2097];

fra«s-4-(hydroxymethyl)-N-(6-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)cinnolin-3- yl)cyclohexane - 1 -carboxamide [2098] ;

(R)-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)cinnolin-3-yl)pyrrolidine-2- carboxamide [2099];

l-isobutyl-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-4- carboxamide [2100];

N-(6-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)cinnolin-3-yl)- 1 -(oxetan-3 -yl)

piperidine-4-carboxamide [2101];

l-benzoyl-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)cinnolin-3-yl)piperidine-4- carboxamide [2102];

N-(6-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)cinnolin-3-yl)tetrahydro-2H-pyran-4- carboxamide [2103];

N-(6-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperidin- 1 - yl)acetamide [2104];

N-(6-( 1 -(difluoromethyl)- lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [2105];

N-(6-( 1 -ethyl- lH-pyrazol-4-yl)cinnolin-3 -yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide [2106] ; N-(6-(l-isopropyl-lH-pyrazol-4-yl)cinnolin-3-yl)-3-(piperidin-4-yloxy)benzamide [2107]; N-(6-(l-isopropyl-lH-pyrazol-4-yl)cinnolin-3-yl)-3-((l-methylpiperidin-4-yl)oxy)benzamide

[2108];

N-(6-(l-isopropyl-lH-pyrazol-4-yl)cinnolin-3-yl)-4-(piperidin-4-yloxy)benzamide [2109]; N-(6-(l-cyclopropyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2110];

4-fluoro-N-(6-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)cinnolin-3-yl)benzamide [2111];

4- (difluoromethoxy)-N-(6-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)cinnolin-3-yl)benzamide

[2112];

5- fluoro-N-(6-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)cinnolin-3-yl)nicotinamide [2113]; N2 -methyl -N5-(6-(l-(l-methylpiperidin-4-yl)-lH-pyrazol-4-yl)cinnolin-3-yl)pyridine-2,5- dicarboxamide [2114]; 1- isopropyl-N-(6-(l-(l-methylpiperidin-4-yl)-lH-pyrazol-4-yl)cinnolin-3-yl)-lH-pyrazole-4- carboxamide [2115];

2- methyl-N-(6-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)cinnolin-3 -yl)thiazole-5 - carboxamide [2116];

N-(6-(5 -amino- 1 -methyl- lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [2117];

4-(difluoromethoxy)-N-(6-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl) benzamide [2118];

N-(6-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [2119];

N-(6-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-2-(7-methyl-2,7-diazaspiro

[3.5]nonan-2-yl)isonicotinamide [2120];

4-fluoro-N-(6-(l -methyl -5-(pyrrolidin-l-ylmethyl)-lH-pyrazol-4-yl)cinnolin-3-yl)benzamide

[2121];

4-fluoro-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)cinnolin-3-yl)benzamide

[2122];

4-(difluoromethoxy)-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)cinnolin-3- yl)benzamide [2123];

N-(6-( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)cinnolin-3-yl)-3-(pyrrolidin- 1 - ylmethyl)benzamide [2124];

N-(6-( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)cinnolin-3-yl)-2-(7-methyl -2,7- diazaspiro[3.5]nonan-2-yl)isonicotinamide [2125] ;

N-(6-( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)cinnolin-3-yl)-2- moφholinoisonicotinamide [2126];

N-(6-( 1 -methyl -5 -(morpholinomethyl)- lH-pyrazol-4-yl)cinnolin-3 -yl)-2- moφholinoisonicotinamide [2127];

N-(6-(4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)cinnolin-3-yl)-l-((l-(trifluoromethyl) cyclopropyl)methyl)piperidine-4-carboxamide [2128] ;

3 ,3 -difluoro-N-(6-(5 -methyl-4,5 ,6,7-tetrahydropyrazolo [ 1 ,5 -a]pyrazin-3 -yl)cinnolin-3 - yl)cyclobutane - 1 -carboxamide [2129];

N-((4,4-difluorocyclohexyl)methyl)-6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5- a]pyrazin-3 -yl)cinnolin-3 -amine [2130];

N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)cinnolin-3-yl)-l-((l-

(trifluoromethyl)cyclopropyl)methyl)piperidine -4 -carboxamide [2131]; N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)cinnolin-3-yl)-2-

(pyrrolidin- 1 -yl)acetamide [2132] ;

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[ l,5- a]pyrazin-3 -yl)cinnolin-3 -yl)acetamide [2133];

(R)-N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[ l,5-a]pyrazin-3-yl)cinnolin-3-yl)-l - isobutylpiperidine-3 -carboxamide [2134] ;

N-(6-(5-(2-fluoroethyl)-4,5,6j etrahydropyrazolo[l,5-a]pyrazin-3-yl)cinnolin-3-yl)piperidine-4- carboxamide [2135];

4-fluoro-N-(6-(5-(2-fluoroethyl)-4,5,6j etrahydropyrazolo[ l,5-a]pyrazin-3-yl)cinnolin-3-yl)-l - isobutylpiperidine-4-carboxamide [2136] ;

N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)cinnolin-3-yl)-2-(4- methylpiperazin- 1 -yl)acetamide [2137] ;

4-fluoro-N-(6-(4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)cinnolin-3-yl)benzamide [2138]; N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)cinnolin-3-yl)-3-(4- methylpiperazin- 1 -yl)benzamide [2139];

N5-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)cinnolin-3-yl)-N2- methylpyridine-2,5 -dicarboxamide [2140] ;

N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)cinnolin-3-yl)-6-(4- methylpiperazin- 1 -yl)nicotinamide [2141] ;

2-(azetidin-3-yloxy)-N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3- yl)cinnolin-3 -yl)isonicotinamide [2142] ;

N-(6 -( 1 -methyl - 1 H-pyrazol -5 -yl)cinnolin-3 -yl) - 1 -(3 ,3 , 3 -trifluoropropyl)piperidine -4 - carboxamide [2143];

1 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -3 -yl)cinnolin-3 -yl)piperidine -4 -carboxamide [2144] ;

N-(6-( l-methyl-lH-pyrazol-3-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l -yl)isonicotinamide

[2145] ;

2-fluoro-2 -methyl -N-(6-( l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)propanamide [2146]; 2,2,3, 3-tetramethyl-N-(6-(l -methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)cyclopropane-l - carboxamide [2147];

trans-N-(6-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)cinnolin-3 -yl)-4-(pyrrolidin- 1 -yl)cyclohexane-l - carboxamide [2148];

trans-N-(6-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)cinnolin-3 -yl)-4-moφholinocyclohexane- 1 - carboxamide [2149];

N-(6-( l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-2-(piperidin-l-yl)acetamide [2150]; 1 -ethyl -4-fluoro-N-(6-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)cinnolin-3 -yl)piperidine-4-carboxamide [2151];

4-fluoro- 1 -isobutyl-N-(6-( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)cinnolin-3 -yl)piperidine-4-carboxamide

[2152];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [2153];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)cyclopropanecarboxamide [2154];

4,4-difluoro-N-(6-( 1 -methyl-lH-1 ,2,3 -triazol-4-yl)cinnolin-3-yl)cyclohexane- 1 -carboxamide

[2155];

trans -4 -(dimethylamino) -N-(6 -( 1 -methyl - 1 H- 1 ,2, 3 -triazol -4 -yl)cinnolin-3 -yl)cyclohexane - 1 - carboxamide [2156];

fr «5-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-4-((4-methylpiperazin-l-yl)methyl) cyclohexane-1 -carboxamide [2157];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)piperidine-4-carboxamide [2158];

1- isobutyl-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)piperidine-4-carboxamide [2159]; N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-l-((l-(trifluoromethyl)cyclopropyl)methyl) piperidine-4-carboxamide [2160];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-l-((3-methyloxetan-3-yl)methyl)piperidine- 4-carboxamide [2161];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-l-(2-(pyrrolidin-l-yl)acetyl)piperidine-4- carboxamide [2162];

1 '-methyl -N-(6-( 1 -methyl- lH-1 ,2,3 -triazol-4-yl)cinnolin-3-yl)-[ 1 ,4'-bipiperidine]-4-carboxamide

[2163];

(R)-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)piperidine-3-carboxamide [2164];

(R)-l-isobutyl-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)piperidine-3-carboxamide

[2165];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-2-(pyrrolidin-l-yl)acetamide [2166];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)acetamide [2167];

2- (7-azabicyclo[2.2.1]heptan-7-yl)-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)acetamide

[2168];

1 -(2-hydroxy-2-methylpropyl)-N-(6-( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)cinnolin-3 -yl)piperidine-4- carboxamide [2169];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-2-moφholinoacetamide [2170]; 2-(4-methoxypiperidin-l-yl)-N-(6-(l-methyl-lH-l,2,3 riazol-4-yl)cinnolin-3-yl)acetamide

[2171];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)mo holine-4-carboxamide [2172];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-l-(piperidin-4-yl)-lH-pyrazole-4- carboxamide [2173];

N-(6-(l-methyl-lH-l,2,3 riazol-4-yl)cinnolin-3-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [2174];

1 -( 1 -ethylpiperidin-4-yl)-N-(6-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)cinnolin-3 -yl)-lH-pyrazole-4- carboxamide [2175];

l-(l-isopropylpiperidin-4-yl)-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-lH-pyrazole-4- carboxamide [2176];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-l-(piperidin-4-yl)-lH-l,2,3-triazole-4- carboxamide [2177];

l-(l-(2-fluoroethyl)piperidin-4-yl)-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-lH-l,2,3- triazole -4 -carboxamide [2178] ;

1- (l-isopropylpiperidin-4-yl)-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-lH-l,2,3- triazole -4 -carboxamide [2179] ;

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-2-(piperidin-4-yl)oxazole-4 -carboxamide

[2180];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-2-(l-methylpiperidin-4-yl)oxazole-4- carboxamide [2181];

2- (l-isopropylpiperidin-4-yl)-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)oxazole-4- carboxamide [2182];

2-fluoro-N-(6-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)cinnolin-3-yl)benzamide [2183] ;

N-(6-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)cinnolin-3 -yl)-3 -(( 1 -methylpiperidin-4-yl)oxy)benzamide

[2184];

N2 -methyl -N5-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)pyridine-2,5-dicarboxamide

[2185];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-6-(4-methylpiperazin-l-yl)nicotinamide

[2186];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)cinnolin-3 -yl)

isonicotinamide [2187];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-2-(l-methylpiperidin-4-yl)isonicotinamide

[2188]; 2-(4-(dimethylamino)piperidin-l-yl)-N-(6-(l-methyl-lH-l,2,3 riazol-4-yl)cinnolin-3-yl) isonicotinamide [2189];

N-(6-(l-methyl-lH-l,2,3 riazol-4-yl)cinnolin-3-yl)-2-moφholinoisonicotinamide [2190];

N-(6-(l-methyl-lH-l,2,3 riazol-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinam

[2191];

2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(6-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)cinnolin-3-yl)

isonicotinamide [2192];

2-(4-isopropylpiperazin-l-yl)-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)isonicotinamide

[2193];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-2-(piperidin-4-ylamino)isonicotinamide

[2194];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(6-( 1 -methyl- IH- 1 ,2,3 -triazol-4-yl)cinnolin-3 - yl)isonicotinamide [2195];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-2-((l-methylpiperidin-4-yl)thio)

isonicotinamide [2196];

2-methyl-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-l,2,3,4-tetrahydroisoquinoline-6- carboxamide [2197];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-2-(piperazin-l-yl)isonicotinamide [2198]; N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-2-(2-(4-methylpiperazin-l-yl)pyridin-4- yl)acetamide [2199];

1 , 1 -bis(methyl-£/3)-4-(4-((6-( 1 -methyl- IH- 1 ,2,3 -triazol-4-yl)cinnolin-3 -yl)carbamoyl)pyridin-2- yl)piperazin-l-ium [2200];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)cinnolin-3-yl)-2-(4-(methyl-£/3)piperazin-l-yl)

isonicotinamide [2201];

N-(6-(l-methyl-lH-l,2,3-triazol-5-yl)cinnolin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [2202];

N-(6-(4-methyl-4H-l,2,4-triazol-3-yl)cinnolin-3-yl)-2-moφholinoacetamide [2203];

N-(6-(4-methyl-4H-l,2,4-triazol-3-yl)cinnolin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [2204];

4-fluoro- 1 -isobutyl-N-(6-(4-methyl-4H- 1 ,2,4-triazol-3 -yl)cinnolin-3 -yl)piperidine-4-carboxamide

[2205];

N-(6-(4,5 -dimethyl -4H- 1 ,2,4-triazol-3 -yl)cinnolin-3 -yl)-2-moφholinoacetamide [2206] ;

N-(6-(4,5 -dimethyl -4H- 1 ,2,4-triazol-3 -yl)cinnolin-3 -yl)- 1 -(3 ,3 ,3 -trifluoropropyl)piperidine-4- carboxamide [2207]; N-(6-( 1H- 1 ,2,3 -triazol- 1 -yl)cinnolin-3 -yl)-4-fluoro-l -isobutylpiperidine-4 -carboxamide [2208] ; N-(6-(2H- 1 ,2,3 -triazol-2-yl)cinnolin-3 -yl)-4-fluoro-l -isobutylpiperidine-4 -carboxamide [2209] ; N-(6-(lH-l,2,4-triazol-l-yl)cirmolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [2210]; 1 -isobutyl-N-(6-( 1 -methyl- lH-tetrazol-5-yl)cinnolin-3-yl)piperidine-4-carboxamide [2211] ; 2,2,3, 3-tetramethyl-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)cyclopropane-l-carboxamide

[2212];

4,4-difluoro-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)cyclohexane-l-carboxamide [2213]; N-(6 -( 1 -methyl - 1 H-imidazol-5 -yl)cinnolin-3 -yl) -2-(piperidin- 1 -yl)acetamide [2214];

2-fluoro-2 -methyl -N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)propanamide [2215];

1 -fluoro-N-(6-( 1 -methyl- lH-imidazol-5-yl)cinnolin-3-yl)cyclopropane- 1 -carboxamide [2216] ; 2-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-azaspiro[3.3]heptane-6 -carboxamide

[2217];

1 -fluoro-N-(6-( 1 -methyl- lH-imidazol-5 -yl)cinnolin-3-yl)cyclohexane- 1 -carboxamide [2218] ; fr «5-4-methoxy-N-(6-( 1 -methyl- lH-imidazol-5-yl)cinnolin-3 -yl)cyclohexane- 1 -carboxamide

[2219];

fr «5-4-(hydroxymethyl)-N-(6-( 1 -methyl -lH-imidazol -5 -yl)cinnolin-3 -yl)cyclohexane- 1 - carboxamide [2220];

N-(6-( 1 -methyl- lH-imidazol-5-yl)cinnolin-3 -yl)azetidine-3 -carboxamide [2221] ;

(R)-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)tetrahydrofuran-2 -carboxamide [2222]; l-(2-methoxyethyl)-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)piperidine-4 -carboxamide

[2223];

N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [2224];

1- isobutyl-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)piperidine-4-carboxamide [2225]; N-(6 -( 1 -methyl - 1 H-imidazol-5 -yl)cinnolin-3 -yl) - 1 -(methylsulfonyl)piperidine -4 -carboxamide

[2226];

N-(6-( 1 -methyl-lH-imidazol-5-yl)cinnolin-3 -yl)-2-(pyrrolidin- 1 -yl)propanamide [2227] ;

2- isopropoxy-N-(6-( 1 -methyl- lH-imidazol-5 -yl)cinnolin-3-yl)acetamide [2228] ;

3- isopropoxy-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)propanamide [2229];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)cyclopropanecarboxamide [2230];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)cyclohexanecarboxamide [2231];

N-(6-( 1 ,2-dimethyl- lH-imidazol-5 -yl)cinnolin-3-yl)-4,4-difluorocyclohexane- 1 -carboxamide

[2232];

(S)-N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)tetrahydrofuran-2 -carboxamide [2233]; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-3,3-difluorocyclobutane-l-carboxami

[2234] ;

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-l-fluorocyclopropane-l -carboxamide

[2235] ;

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)moφholine-4-carboxamide [2236];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)moφholine-ί s-4-carboxamide [2237];

1 -methyl -N-(6 -( 1 -methyl - 1 H-imidazol-5 -yl)cinnolin-3 -yl) - 1 H-pyrazole -4-carboxamide [2238] ; 1 -ethyl -N-(6-( 1 -methyl- lH-imidazol-5 -yl)cinnolin-3 -yl)- 1 H-pyrazole-4-carboxamide [2239] ; 1 -isopropyl-N-(6-( 1 -methyl- lH-imidazol-5-yl)cinnolin-3 -yl)- 1 H-pyrazole -4 -carboxamide [2240] ;

1- cyclopropyl-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-lH-pyrazole-4 -carboxamide

[2241] ;

1 -isobutyl-N-(6-( 1 -methyl- lH-imidazol-5-yl)cinnolin-3-yl)- lH-pyrazole-4-carboxamide [2242] ; 1 -methyl -N-(6 -( 1 -methyl - 1 H-imidazol-5 -yl)cinnolin-3 -yl) - 1 H-pyrazole -3 -carboxamide [2243] ; N-(6-( 1 -methyl-lH-imidazol-5-yl)cinnolin-3 -yl)-2-( 1 -methyl- lH-pyrazol-4-yl)acetamide [2244] ; 1 -methyl -N-(6 -( 1 -methyl - 1 H-imidazol-5 -yl)cinnolin-3 -yl) - 1 H-imidazole -4 -carboxamide [2245] ; 1 -isopropyl-N-(6-( 1 -methyl- lH-imidazol-5-yl)cinnolin-3 -yl)- 1 H-imidazole -4 -carboxamide

[2246] ;

N-(6-( 1 -methyl-lH-imidazol-5-yl)cinnolin-3 -yl)- 1 -(tetrahydro-2H-pyran-4-yl)- 1 H-imidazole -4- carboxamide [2247];

1 ,2-dimethyl-N-(6 -( 1 -methyl - 1 H-imidazol -5 -yl)cinnolin-3 -yl) - 1 H-imidazole -5 -carboxamide

[2248] ;

1 -methyl -N-(6-( 1 -methyl-lH-imidazol-5 -yl)cinnolin-3-yl)- 1H- 1 ,2,4-triazole-3-carboxamide

[2249] ;

2- methyl-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)oxazole-4-carboxamide [2250];

2-isopropyl-N-(6-( 1 -methyl- lH-imidazol-5-yl)cinnolin-3 -yl)oxazole -4 -carboxamide [2251] ; 4-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)oxazole-2 -carboxamide [2252];

4- methyl-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)thiazole-2 -carboxamide [2253] ;

2-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)thiazole-4-carboxamide [2254] ;

5- methyl-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-l,3,4-oxadiazole-2 -carboxamide

[2255] ;

5-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-l,3,4-thiadiazole-2 -carboxamide

[2256] ;

l-isopropyl-N-(6-(l-isopropyl-lH-imidazol-5-yl)cinnolin-3-yl)-lH-pyrazole-4 -carboxamide

[2257] ; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-l-methyl-lH-pyrazole-4-carboxamid^

[2258];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-l-isopropyl-lH-pyrazole-4-carboxamide

[2259];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-methylthiazole-5-carboxamide [2260]; 4-fluoro-N-(6-( 1 -methyl-lH-imidazol-5 -yl)cinnolin-3-yl)benzamide [2261] ;

4-(difluoromethoxy)-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)benzamide [2262];

N-(6 -( 1 -methyl - 1 H-imidazol-5 -yl)cinnolin-3 -yl) -3 -(py rrolidin- 1 -ylmethyl)benzamide [2263] ; 2-fluoro-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)benzamide-3,4,5,6-£/4 [2264];

4-fluoro-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)benzamide-2,3,5,6-£/4 [2265];

2-chloro-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)benzamide-3,4,5,6-£/4 [2266];

4-chloro-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)benzamide-2,3,5,6-£/4 [2267];

4-(methyl-<i3)-N-(6-( 1 -methyl- lH-imidazol-5-yl)cinnolin -3 -yl)benzamide [2268] ;

4-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)benzamide-2,3,5,6-£/4 [2269];

4-(methyl-£/3)-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)benzamide-2,3,5,6-£/4 [2270]; 4-(methoxy-£/3)-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)benzamide [2271];

4-(methoxy- 3)-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)benzamide-2,3,5,6-ii4 [2272]; 4-methoxy-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)benzamide-2,3,5,6-£/4 [2273];

(E)-N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-3-(phenyl-2,3,4,5,6-£/j)acrylamide

[2274];

(E)-N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-3-(phenyl-2,3,4,5,6- j)acrylamide-2,3-£/2

[2275];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-(4-fluorophenyl)acetamide-2,2-£/2 [2276]; (E)-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-3-(phenyl-2,3,4,5,6-£/j)acrylamide [2277]; (E)-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-3-(phenyl-2,3,4,5,6-£/j)acrylamide-2,3-£/2

[2278];

2-(4-fluorophenyl)-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)acetamide-2,2-£/2 [2279]; N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2280];

2-(dimethylamino)-N-(6 -(1 -methyl - 1 H-imidazol -5 -yl)cinnolin-3 -yl)isonicotinamide [2281]; 2-(3 -aminoazetidin- 1 -yl) -N-(6 -( 1 -methyl - 1 H-imidazol -5 -yl)cinnolin-3 -yl)isonicotinamide [2282] ; N-(6-( 1 -methyl-lH-imidazol-5-yl)cinnolin-3 -yl)-2-(pyrrolidin- 1 -yl)isonicotinamide [2283] ; N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-(piperidin-l-yl)isonicotinamide [2284];

N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-mo holinoisonicotinamide [2285]; 2-(4-isopropylpiperazin- 1 -yl)-N-(6-( 1 -methyl- lH-imidazol-5 -yl)cinnolin-3 -yl)isonicotinamide [2286];

2-(4-cyclopropylpiperazin- 1 -yl)-N-(6-( 1 -methyl- lH-imidazol-5 -yl)cinnolin-3-yl)isonicotinamide

[2287];

N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-(2,7-diazaspiro[3.5]nonan-2-yl)

isonicotinamide [2288];

N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl) isonicotinamide [2289];

N-(6-( 1 -methyl-lH-imidazol-5-yl)cinnolin-3 -yl)isoindoline-5 -carboxamide [2290] ;

2-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)isoindoline-5-carboxamide [2291]; 2-(azetidin-l-yl)-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)isonicotinamide [2292];

2-methoxy-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)isonicotinamide [2293];

2-methyl-N-(6-( 1 -methyl- 1 H-imidazol-5 -yl)cinnolin-3 -yl)isonicotinamide [2294] ;

2-cyano-N-(6-( 1 -methyl- 1 H-imidazol-5 -yl)cinnolin-3 -yl)isonicotinamide [2295] ;

2-(3,3-difluoroazetidin-l-yl)-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)isonicotinamide

[2296];

2-(4,4-difluoropiperidin-l -yl)-N-(6-( 1 -methyl- lH-imidazol-5 -yl)cinnolin-3 -yl)isonicotinamide

[2297];

2-isopropoxy-N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)isonicotinamide [2298];

N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-(pyrrolidin-l-yl-2,2,5,5-^)isonicotinamide

[2299];

N-(6-( 1 -methyl-lH-imidazol-5-yl)cinnolin-3 -yl)-2-(pyrrolidin- 1 -yl-<¾)isonicotinamide [2300] ; N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-(piperidin-l-yl-£/;o)isonicotinamide [2301]; N-(6-(l-methyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-(mo holino-ί s)isonicotinamide [2302]; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-4-isopropoxybenzamide [2303];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-4-(piperidin-4-yloxy)benzamide [2304]; 4-(benzyloxy)-N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)benzamide [2305];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-fluorobenzamide-3,4,5,6-£/4 [2206]; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-4-fluorobenzamide-2,3,5,6-£/4 [2307]; 2-chloro-N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)benzamide-3,4,5,6-£/4 [2308]; 4-chloro-N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)benzamide-2,3,5,6-£/4 [2309]; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-4-(methyl-£/3)benzamide [2310];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-4-methylbenzamide-2,3,5,6-£/4 [2311]; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-4-(methyl-£/3)benzamide-2,3,5,6-£/4 [2312]; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-4-(methoxy-£/3)benzamide [2313];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-4-(methoxy-£/3)benzamide-2,3, 5,6-<¾ [2314]; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-4-methoxybenzamide-2,3,5,6-£/4 [2315]; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotm

[2316];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-mo holinoisonicotinamide [2317];

N-(6-( 1 ,2-dimethyl- lH-imidazol-5-yl)cinnolin-3-yl)-2-(pyrrolidin- 1 -yl)isonicotinamide [2318] ; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinno [2319]; N-(6-( 1 ,2-dimethyl- lH-imidazol-5-yl)cinnolin-3-yl)-2-(pyrrolidin- 1 -yl -2,2,5,5 -dj)

isonicotinamide [2320];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-(pyrrolidin-l-yl- s)isonicotinamide

[2321];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-(piperidin-l-yl- ;o)isonicotinamide

[2322];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)cinnolin-3-yl)-2-(moφholino-ί s)isonicotinamide [2323]; N-(6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)cinnolin-3-yl)cyclopropanecarboxamide

[2324];

N-(6-(7-methyl-5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)cinnolin-3-yl)

cyclopropanecarboxamide [2325];

3,3-difluoro-N-(6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)cinnolin-3-yl)cyclobutane-l- carboxamide [2326];

(R)-N-(6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)cinnolin-3-yl)pyrrolidine-2-carboxamide

[2327];

(R)-N-(6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)cinnolin-3-yl)piperidine-3-carboxamide

[2328];

l-methyl-N-(6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)cinnolin-3-yl)piperidine-4- carboxamide [2329];

N-(6-(5,6,7,8-tetrahydroimidazo[ 1 ,2-a]pyrazin-3 -yl)cinnolin-3 -yl)- 1 -(( 1 -(trifluoromethyl)

cyclopropyl)methyl)piperidine-4-carboxamide [2330] ;

l-benzoyl-N-(6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)cinnolin-3-yl)piperidine-4- carboxamide [2331];

4-fluoro-l-isobutyl-N-(6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)cinnolin-3-yl)piperidine- 4-carboxamide [2332]; (R)-2-(2-methylpyrrolidin-l-yl)-N-(6-(5,6,7,8 etra

yl)acetamide [2333];

2-(cyclobutyl(methyl)amino)-N-(6-(5,6J,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)cinnolin-3 yl)acetamide [2334];

4-fluoro-N-(6-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)cinnolin-3-yl)benzamide [2335]; 4-isopropoxy-N-(6-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)cinnolin-3-yl)benzamide

[2336];

4-(difluoromethoxy)-N-(6-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)cinnolin-3-yl)

benzamide [2337];

2-((2-(dimethylamino)ethyl)amino)-N^

3-yl)isonicotinamide [2338];

2-((1 sopropylpiperidin-4-yl)oxy)-N-(6-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)cinnolin-

3-yl)isonicotinamide [2339];

N-(6-(oxazol-5-yl)cinnolin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine-4-carboxamide [2340]; N-(6-(oxazol-5-yl)cinnolin-3-yl)cyclopropanecarboxamide [2341];

(R)-N-(6-(oxazol-5-yl)cinnolin-3-yl)tetrahydrofuran-2-carboxamide [2342];

(R)-N-(6-(oxazol-5-yl)cinnolin-3-yl)piperidine-3-carboxamide [2343];

N-(6-(oxazol-5-yl)cinnolin-3-yl)tetrahydro-2H-pyran-4-carboxamide [2344];

N-(6-(oxazol-5-yl)cinnolin-3-yl)-l-(2-(pyrrolidin-l-yl)acetyl)piperidine-4-carboxamide [2345]; r-methyl-N-(6-(oxazol-5-yl)cinnolin-3-yl)-[l,4'-bipiperidine]-4-carboxamide [2346];

cz's -4-morpholino-N-(6-(oxazol-5 -yl)cinnolin-3 -yl)cyclohexane- 1 -carboxamide [2347] ;

2-(cyclobutyl(methyl)amino)-N-(6-(oxazol-5-yl)cinnolin-3-yl)acetamide [2348];

N-(6-(oxazol-5 -yl)cinnolin-3-yl)-2-(pyrrolidin- 1 -yl)acetamide [2349] ;

(R)-2-(2-methylpyrrolidin-l-yl)-N-(6-(oxazol-5-yl)cinnolin-3-yl)acetamide [2350];

2-(4-methylpiperazin- 1 -yl)-N-(6-(oxazol-5 -yl)cinnolin-3-yl)acetamide [2351] ;

fr «5-4-((4-methylpiperazin-l-yl)methyl)-N-(6-(oxazol-5-yl)cinnolin-3-yl)cyclohexane-l- carboxamide [2352];

l-(2,2-difluoropropyl)-N-(6-(oxazol-5-yl)cinnolin-3-yl)piperidine-4-carboxamide [2353];

trans -4 -(hydroxymethyl)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)cyclohexane-l -carboxamide

[2354];

trans -4 -(methylamino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)cyclohexane-l -carboxamide

[2355];

trans-4-(( 1 ,3 -difluoropropan-2-yl)amino)-N-(6-(2-methyloxazol-5 -yl)cinnolin-3 -yl)cyclohexane- 1 -carboxamide [2356]; fr «5-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-4-((propan-2-yl-l, l, l,3,3,3-£/6)amino) cyclohexane-1 -carboxamide [2357];

fra«s-4-((2,2-difluoroemyl)amino)-N-(6-(2^

carboxamide [2358];

fr «5-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-4-((3,3,3-trifluoropropyl)amino)cyclohexane-l- carboxamide [2359];

trans -4 -((2-methoxyethyl)amino) -N-(6 -(2 -methyloxazol-5 -yl)cinnolin-3 -yl)cyclohexane - 1 - carboxamide [2360];

trans -4 -(dimethylamino) -N-(6 -(2-methyloxazol -5 -yl)cinnolin-3 -yl)cyclohexane- 1 -carboxamide

[2361];

fr «5-4-(bis(methyl-£/3)amino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)cyclohexane-l- carboxamide [2362];

c/5-4-(dimethylamino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)cyclohexane-l-carboxamide

[2363];

fr «5-4-((2,2-difluoroethyl)(methyl)amino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)

cyclohexane-1 -carboxamide [2364];

fr «5-4-(methyl(oxetan-3-yl)amino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)cyclohexane-l- carboxamide [2365];

trans -4 -((2-fluoroethyl)amino) -N-(6 -(2-methyloxazol -5 -yl)cinnolin-3 -yl)cyclohexane - 1 - carboxamide [2366];

fr «5-4-(2-(fluoromethyl)aziridin-l-yl)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)cyclohexane-l- carboxamide [2367];

fr «5-4-((3-fluoroazetidin-l-yl)methyl)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)cyclohexane-l- carboxamide [2368];

fr rø-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-3-mo holinocyclobutane-l -carboxamide [2369]; fr rø-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-4-mo holinocyclohexane-l-carboxamide

[2370];

N-(6-(2-methyloxazol-5 -yl)cinnolin-3 -yl)-2-(piperidin-l -yl)acetamide [2371] ;

2-(4-methoxypiperidin- 1 -yl)-N-(6-(2-methyloxazol-5-yl)cinnolin-3 -yl)acetamide [2372] ;

N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)acetamide [2373];

N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)moφholine-4-carboxamide [2374];

N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-2-mo holinoacetamide [2375];

N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-3-moφholinopropanamide [2376];

1 -methyl -N-(6-(2 -methyloxazol-5 -yl)cinnolin-3 -yl)piperidine-4-carboxamide [2377] ; l-(2,2-difluoropropyl)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)piperidine-4-carboxamide

[2378];

N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-4-mo holinopiperidine-l-carboxamide [2379]; 4-((l,3-difluoropropan-2-yl)amino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)piperidine-l- carboxamide [2380];

( lR,3s,5 S)-3 -(( 1 ,3-difluoropropan-2-yl)amino)-N-(6-(2-methyloxazol-5 -yl)cinnolin-3 -yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [2381];

( lR,3s,5 S)-3 -(( 1 ,3-difluoropropan-2-yl)amino)-N-(6-(2-methyloxazol-5 -yl)cinnolin-3 -yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [2382];

4-(dimethylamino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)piperidine-l -carboxamide [2383]; 4-((2,2-difluoroethyl)(methyl)amino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)piperidine-l- carboxamide [2384];

(3 S,4S)-4-amino-3-fluoro-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)piperidine-l -carboxamide

[2385];

(3S,4S)-3-fluoro-4-(methylamino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)piperidine-l- carboxamide [2386];

(3 R,4R)-4-amino-3-fluoro-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)piperidine-l -carboxamide

[2387];

(3R,4R)-3-fluoro-4-(methylamino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)piperidine-l- carboxamide [2388];

4-((2-fluoroethyl)amino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)piperidine-l -carboxamide

[2389];

4-((2,2-difluoroethyl)amino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)piperidine-l-carboxamide

[2390];

(lR,3s,5S)-3-amino-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-8-azabicyclo[3.2.1]octane-8- carboxamide [2391];

(lR,3r,5S)-3-amino-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-8-azabicyclo[3.2.1]octane-8- carboxamide [2392];

(lR,3r,5S)-3-((2-fluoroethyl)amino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [2393];

(lR,3r,5S)-3-((2,2-difluoroethyl)amino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [2394];

(lR,3s,5S)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-3-((3,3,3-trifluoropropyl)amino)-8- azabicyclo [3.2.1] octane -8 -carboxamide [2395]; (3S,4S)-3-fluoro-4-(isopropylamino)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)piperidine-l- carboxamide [2396];

N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H)-carboxamide

[2397];

2-methyl-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H)- carboxamide [2398];

N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-2-(moφholino-ί s)acetamide [2399];

fr «5-N-(6-(2-methyloxazol-4-yl)cinnolin-3-yl)-4-(4-methylpiperazin-l-yl)cyclohexane-l- carboxamide [2400];

N-(6-(2-methyloxazol-5 -yl)cinnolin-3 -yl)-l -( 1 -methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [2401];

2- (lH-imidazol-l-yl)-N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)acetamide [2402];

4-(difluoromethoxy)-N-(6-(oxazol-5-yl)cinnolin-3-yl)benzamide [2403];

3- ((l-methylpiperidin-4-yl)oxy)-N-(6-(oxazol-5-yl)cinnolin-3-yl)benzamide [2404];

N-(6-(oxazol-5-yl)cinnolin-3-yl)isonicotinamide [2405];

2-(3 -aminoazetidin- 1 -yl)-N-(6-(oxazol-5 -yl)cinnolin-3-yl)isonicotinamide [2406] ;

2-(l-methylpiperidin-4-yl)-N-(6-(oxazol-5-yl)cinnolin-3-yl)isonicotinamide [2407];

r-methyl-N-(6-(oxazol-5-yl)cinnolin-3-yl)-r,2',3',6' etrahydro-[2,4'-bipyridine]-4-carboxamide

[2408];

2-(4-methylpiperazin- 1 -yl)-N-(6-(oxazol-5 -yl)cinnolin-3 -yl)isonicotinamide [2409] ;

2-(7-methyl-2 -diazaspiro[3.5]nonan-2-yl)-N-(6-(oxazol-5-yl)cinnolin-3-yl)isonicotinamide

[2410];

N-(6-(oxazol-5-yl)cinnolin-3-yl)-2-(2,7-diazaspiro[3.5]nonan-7-yl)isonicotinamide [2411]; N-(6-(oxazol-5-yl)cinnolin-3-yl)-2-(piperidin-4-ylamino)isonicotinamide [2412];

2-methyl-N-(6-(oxazol-5-yl)cinnolin-3-yl)isoindoline-5-carboxamide [2413];

N-(6-(oxazol-5-yl)cinnolin-3-yl)-l,2,3,4-tetrahydroisoquinoline-7-carboxamide [2414];

N-(6-(2-methyloxazol-5-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [2415]; N-(6-(3-methylisoxazol-5-yl)cinnolin-3-yl)-l-(3,3,3 rifluoropropyl)piperidine-4-carboxamide

[2416];

4- fluoro- 1 -isobutyl-N-(6-(5 -methyl- 1 ,3 ,4-oxadiazol-2-yl)cinnolin-3 -yl)piperidine-4-carboxamide

[2417];

l-isobutyl-N-(6-(5-methyl-l,3,4-oxadiazol-2-yl)cinnolin-3-yl)piperidine-4-carboxamide [2418]; N-(6-(5-(dimethylamino)-l,3,4-oxadiazol-2-yl)cinnolin-3-yl)piperidine-4-carboxamide [2419]; N-(6-(5-(dimethylamino)- 1 ,3,4-oxadiazol-2-yl)cinnolin-3 -yl)- 1 -methylpiperidine-4-carboxamide

[2420];

N-(6-(5-methyl-l,3,4-oxadiazol-2-yl)cinnolin-3-yl)-2-(4-m

[2421];

3 , 3 -difluoro -N-(6 -(thiazol-5 -yl)cinnolin-3 -yl)cyclobutane - 1 -carboxamide [2422] ;

2-methyl-N-(6-(thiazol-5-yl)cinnolin-3-yl)-2-azaspiro[3.3]heptane-6-carboxamide [2423]; 1 -fluoro-N-(6-(thiazol-5-yl)cinnolin-3 -yl)cyclohexane- 1 -carboxamide [2424] ;

trans -4 -(dimethylamino) -N-(6 -(thiazol-5 -yl)cinnolin-3 -yl)cyclohexane - 1 -carboxamide [2425] ; trans -4 -((3 -fluoroazetidin- 1 -yl)methyl) -N-(6 -(thiazol -5 -yl)cinnolin-3 -yl)cyclohexane - 1 - carboxamide [2426];

N-(6-(thiazol-5-yl)cinnolin-3-yl)azetidine-3-carboxamide [2427];

l-methyl-N-(6-(thiazol-5-yl)cinnolin-3-yl)piperidine-4-carboxamide [2428];

1 -(2,2-difluoropropyl)-N-(6-(thiazol-5 -yl)cinnolin-3 -yl)piperidine-4-carboxamide [2429] ;

l-(oxetan-3-yl)-N-(6-(thiazol-5-yl)cinnolin-3-yl)piperidine-4-carboxamide [2430];

1- (2-(pyrrolidin-l-yl)acetyl)-N-(6-(thiazol-5-yl)cinnolin-3-yl)piperidine-4-carboxamide [2431]; 1 '-methyl -N-(6-(thiazol-5-yl)cinnolin-3 -yl)-[ 1 ,4'-bipiperidine] -4-carboxamide [2432] ;

2- (pyrrolidin- 1 -yl) -N-(6-(thiazol-5 -yl)cinnolin-3 -yl)propanamide [2433] ;

2-(piperidin- 1 -yl)-N-(6-(thiazol-5 -yl)cinnolin-3 -yl)acetamide [2434] ;

2-(4-methylpiperazin-l-yl)-N-(6-(thiazol-5-yl)cinnolin-3-yl)acetamide [2435];

2-moφholino-N-(6-(thiazol-5-yl)cinnolin-3-yl)acetamide [2436];

4-(piperidin-4-yloxy)-N-(6-(thiazol-5-yl)cinnolin-3-yl)benzamide [2437];

N-(6-(thiazol-5-yl)cinnolin-3-yl)isonicotinamide [2438] ;

6-(4-methylpiperazin-l-yl)-N-(6-(thiazol-5-yl)cinnolin-3-yl)nicotinamide [2439];

r-methyl-N-(6-(miazol-5-yl)cinnolin-3-yl)-r,2',3',6'-tetrahydro-[2,4'-bipyridine]-4-carboxamide

[2440];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-(thiazol-5 -yl)cinnolin-3-yl)isonicotinamide [2441] ; 2-(4-(dimethylamino)piperidin-l-yl)-N-(6-(miazol-5-yl)cinnolin-3-yl)isonicotinamide [2442]; 2-(4-methylpiperazin-l-yl)-N-(6-(thiazol-5-yl)cinnolin-3-yl)isonicotinamide [2443];

2-((l-methylpiperidin-4-yl)thio)-N-(6-(miazol-5-yl)cinnolin-3-yl)isonicotinamide [2444];

N-(6-(thiazol-5-yl)cinnolin-3-yl)-l,2,3,4-tetrahydroisoquinoline-7 -carboxamide [2445];

fr «5-4-((l,3-difluoropropan-2-yl)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl) cyclohexane-1 -carboxamide [2446];

N-(6-(2-methylthiazol-5-yl)cinnolin-3-yl)moφholine-4-carboxamide [2447];

N-(6 -(2-methylthiazol-5 -yl)cinnolin-3 -yl) -2 -(pyrrolidin- 1 -yl)acetamide [2448] ; 2-(( 1 R,4R)-2-oxa-5 -azabicyclo [2.2.1 ]heptan-5 -yl) -N-(6-(2-methylthiazol-5 -yl)cinnolin-3 - yl)acetamide [2449];

N-(6-(2-methylthiazol-5-yl)cinnolin-3-yl)-2-mo holinoacetamide [2450];

N-(6-(2-methylthiazol-5-yl)cinnolin-3-yl)-2-(mo holino-ί s)acetamide [2451];

2-(4-methylpiperazin- 1 -yl)-N-(6-(2-methylthiazol-5 -yl)cinnolin-3-yl)acetamide [2452] ;

1- methyl-N-(6-(2-methylthiazol-5-yl)cinnolin-3-yl)piperidine-4-carboxamide [2453];

N-(6-(2-methylthiazol-5-yl)cinnolin-3-yl)isonicotinamide [2454];

N-(6-(2-methylthiazol-5-yl)cinnolin-3-yl)nicotinamide [2455] ;

2- (4-methylpiperazin- 1 -yl)-N-(6-(2-methylthiazol-5 -yl)cinnolin-3-yl)isonicotinamide [2456] ; fr rø-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-4-moφholinocyclohexane-l- carboxamide [2457];

fr «5-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-4-(4-methylpiperazin-l-yl)

cyclohexane-1 -carboxamide [2458];

4-isopropyl-N-(6-(5 -methyl- 1 ,3 ,4-thiadiazol-2-yl)cinnolin-3 -yl)piperazine- 1 -carboxamide [2459] ; 4-((2-methoxyethyl)(methyl)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)

piperidine-1 -carboxamide [2460];

4-(( 1 ,3 -difluoropropan-2-yl)amino)-N-(6-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)cinnolin-3 -yl)

piperidine-1 -carboxamide [2461];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-4-((3,3,3-trifluoropropyl)amino)piperidine-l- carboxamide [2462];

4-((2-fluoroethyl)amino)-N-(6-(5 -methyl- 1 ,3 ,4-thiadiazol-2-yl)cinnolin-3 -yl)piperidine- 1 - carboxamide [2463];

(3R,4S)-4-amino-3-fluoro-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)piperidine-l- carboxamide [2464];

(3R,4R)-4-amino-3-fluoro-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)piperidine-l- carboxamide [2465];

(3S,4S)-3-fluoro-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-4-(methylamino)piperidine-

1 -carboxamide [2466];

(3R,4R)-3-fluoro-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-4-(methylamino)

piperidine-1 -carboxamide [2467];

4-amino-3,3-difluoro-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)piperidine-l- carboxamide [2468];

(3R,4R)-3 -fluoro-4-(isopropylamino)-N-(6-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)cinnolin-3 -yl)

piperidine-1 -carboxamide [2469]; (3R,4S)-3-fluoro-4-(isopropylamino)-N-(6-(5-methyl-l,3,4-1hiadiazol-2-yl)cinnolin-3-yl) piperidine-l-carboxamide [2470];

3,3-difluoro-4-(isopropylamino)-N-(6-(5-methy^

carboxamide [2471];

(3S,4S)-3-fluoro-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-4-((propan-2-yl-l, 1,1,3,3,3-

£/e)amino)piperidine- 1 -carboxamide [2472] ;

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(6-(5-m

yl)-8-azabicyclo[3.2.1] octane -8 -carboxamide [2473];

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3- yl)-8-azabicyclo[3.2. l]octane-8-carboxamide [2474];

4-(dimethylamino)-N-(6-(2-methylthiazol-5-yl)cinnolin-3 -yl)piperidine- 1 -carboxamide [2475] ; 4-((2,2-difluoroethyl)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)piperidine-l- carboxamide [2476];

4-((2,2-difluoroethyl)(methyl- 3)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cirmolin-3- yl)piperidine-l -carboxamide [2477];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-4-moφholinopiperidine-l -carboxamide

[2478];

N-(6-(5-methyl-l ,3,4-thiadiazol-2-yl)cinnolin-3 -yl)-4-(4-methylpiperazin- 1 -yl)piperidine- 1 - carboxamide [2479];

(R)-3,4-dimethyl-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)piperazine-l -carboxamide

[2480];

(S)-3 ,4-dimethyl-N-(6-(5 -methyl- 1 ,3 ,4-thiadiazol-2-yl)cinnolin-3 -yl)piperazine- 1 -carboxamide

[2481];

(lR,3r,5S)-3-((2-fluoroethyl)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [2482];

(lR,3r,5S)-3-((2,2-difluoroethyl)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [2483];

(lR,3r,5S)-3-amino-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-8-azabicyclo[3.2.1] octane-8-carboxamide [2484];

(l S,4S)-5-methyl-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-2,5-diazabicyclo[2.2.1] heptane-2 -carboxamide [2485] ;

(lR,4R)-5-methyl-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-2,5-diazabicyclo[2.2.1] heptane-2 -carboxamide [2486] ; 8-methyl-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-3,8-diazabicyclo[3.2.1]octane-3- carboxamide [2487];

3-methyl-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-3,8-diazabicyclo[3.2.1]octane-8- carboxamide [2488];

N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H^ carboxamide [2489];

2-(4-methylpiperazin- 1 -yl)-N-(6-(5 -methylthiazol-2-yl)cinnolin-3 -yl)isonicotinamide [2490] ; 2-(4-methylpiperazin-l-yl)-N-(6-(4-methylmiazol-2-yl)cinnolin-3-yl)isonicotinam [2491]; N-(6-(2-(methylamino)thiazol-5-yl)cinnolin-3-yl)piperidine-4-carboxamide [2492];

1- methyl-N-(6-(2-(methylamino)thiazol-5-yl)cinnolin-3-yl)piperidine-4-carboxamide [2493]; N-(6-(2-(diethylamino)thiazol-5-yl)cinnolin-3-yl)-2-(4-fluoropiperidin-l-yl)acetam [2494]; N-(6-(2-(diethylamino)thiazol-5-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)acetami [2495]; N-(6-(2-aminothiazol-5-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamid [2496]; N-(6-(2-(methylamino)thiazol-5-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinam

[2497];

N-(6-(2-(dimethylamino)thiazol-5-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinam

[2498];

2- (4 sopropylpiperazin-l-yl)-N-(6-(2-(methylamino)thiazol-5-yl)cinnolin-3-yl)isonicotinamide

[2499];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-(2-(methylamino)thiazol-5 -yl)cinnolin-3 -yl)

isonicotinamide [2500];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-(2-(dimethylamino)thiazol-5 -yl)cinnolin-3-yl)

isonicotinamide [2501];

2-(3 -aminoazetidin- 1 -yl)-N-(6-(2-(dimethylamino)thiazol-5 -yl)cinnolin-3-yl)isonicotinamide

[2502];

N-(6-(5-chlorothiazol-2-yl)cinnolin-3 -yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide [2503] ; 2-(3 -(2-(4-methylpiperazin- 1 -yl)isonicotinamido)cinnolin-6-yl)thiazole-5 -carboxamide [2504] ; N-(6-(isothiazol-4-yl)cinnolin-3-yl)-l-methylpiperidine-4-carboxamide [2505];

N-(6-(l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-4-(difluoromethoxy)benzamide [2506];

N-(6-(l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-4-(piperidin-4-yloxy)benzamide [2507];

N-(6-(l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-4-((l-methylpiperidin-4-yl)oxy)benzamide [2508]; N-(6-( 1 ,3,4-thiadiazol-2-yl)cinnolin-3-yl)-3 -(( 1 -methylpiperidin-4-yl)oxy)benzamide [2509] ; N5-(6-(l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-N2-methylpyridine-2,5-dicarboxamide [2510]; N-(6-(l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-6-(4-methylpiperazin-l-yl)nicotinamide [2511]; N-(6-(l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-l'^

carboxamide [2512];

N-(6 -( 1 , 3 ,4-thiadiazol -2 -yl)cinnolin-3 -yl) -2 -(3 -(dimethylamino)azetidin- 1 -yl)isonicotinamide

[2513];

N-(6-(l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [2514]; N-(6-(l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-2-(4 sopropylpiperazin-l-yl)isonicotinamide [2515]; N-(6-(l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-2-moφholinoisonicotinamide [2516];

1 -fluoro-N-(6-(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)cinnolin-3 -yl)cyclohexane-l -carboxamide [2517] ; fr «5-4-methoxy-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)cyclohexane-l -carboxamide

[2518];

cz's -4-methoxy-N-(6-(5 -methyl- 1 ,3 ,4-thiadiazol-2-yl)cinnolin-3 -yl)cyclohexane- 1 -carboxamide

[2519];

trans -4 -amino -N-(6-(5 -methyl -1,3,4 -thiadiazol -2 -yl)cinnolin-3 -yl)cyclohexane - 1 -carboxamide

[2520];

fr «5-4-(dimethylamino)-N-(6-(5 -methyl-1 ,3,4-thiadiazol-2-yl)cinnolin-3 -yl)cyclohexane- 1 - carboxamide [2521];

fr rø-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-4-moφholinocyclohexane-l- carboxamide [2522];

fr «5-4-(hydroxymethyl)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)cyclohexane-l- carboxamide [2523];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)piperidine-4-carboxamide [2524];

4-fluoro-N-(6-(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)cinnolin-3 -yl)piperidine-4-carboxamide [2525] ; l-methyl-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)piperidine-4-carboxamide [2526]; 4-fluoro-l-methyl-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)piperidine-4-carboxamide

[2527];

1 -(2-fluoroethyl)-N-(6-(5 -methyl- 1 ,3 ,4-thiadiazol-2-yl)cinnolin-3-yl)piperidine-4-carboxamide

[2528];

l-(2,2-difluoroethyl)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)piperidine-4- carboxamide [2529];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [2530];

l-(2,2-difluoropropyl)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)piperidine-4- carboxamide [2531];

l-benzoyl-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)piperidine-4-carboxamide [2532]; N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-2-(pyrrolidin-l-yl)acetamide [2533];

N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-2-(piperidin-l-yl)acetamide [2534];

2-(4-methoxypiperidin- 1 -yl)-N-(6-(5-methyl- 1 ,3,4-thiadiazol-2-yl)cinnolin-3 -yl)acetamide

[2535];

N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)acetamide [2536]; N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-2-moφholinoacetamide [2537];

(R)-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-2-(3-methylmoφholino)acetamide

[2538];

2-(7-azabicyclo[2.2 ]heptan-7-yl)-N-(6-(5-methyl-l,3,4-th^

[2539];

2-((lR,4R)-2-oxa-5-azabicyclo[2.2. l]heptan-5-yl)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-

3-yl)acetamide [2540];

2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3- yl)acetamide [2541];

2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3- yl)acetamide [2542];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-2-(l,4-oxazepan-4-yl)acetamide [2543]; N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-2-moφholinoacetamide-2,2-ί 2 [2544]; N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-2-(moφholino-ί s)acetamide [2545];

l-methyl-3-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnoh^

[2546];

(3S,4S)-4-amino-3-fluoro-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)piperidine-l- carboxamide [2547];

(3 S,4S)-4-(dimethylamino)-3 -fluoro-N-(6-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)cinnolin-3 -yl)

piperidine-l-carboxamide [2548];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)mo holine-4-carboxamide [2549];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-4-(methylamino)piperidine-l-carboxam

[2550];

4-(dimethylamino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)piperidine-l-carbox

[2551];

4-((2,2-difluoroethyl)(methyl)amino)-N-(6-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)cinnolin-3 -yl)

piperidine-l-carboxamide [2552];

(3S,4S)-3-fluoro-4-(isopropylamino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)

piperidine-l-carboxamide [2553]; 2-methyl-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-5,6-dihydroimidazo[l,2-a]

7(8H)-carboxamide [2554];

4-methyl-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)piperazine-l-carboxamide [2555]; N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)cinnolin-3-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [2556];

1 -( 1 -isopropylpiperidin-4-yl)-N-(6-(5 -methyl- 1 ,3 ,4-thiadiazol-2-yl)cinnolin-3 -yl)- lH-pyrazole-4- carboxamide [2557];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-l-(l-methylpiperidin-4-yl)-lH-l,2,3-triazo 4-carboxamide [2558];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide

[2559];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-2-(l-methylpiperidin-4-yl)oxazole-4- carboxamide [2560];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-(5 -methyl- 1 ,3 ,4-thiadiazol-2-yl)cinnolin-3 - yl)isonicotinamide [2561];

r-methyl-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-r,2',3',6'-tetrahydro-[2,4'- bipyridine] -4 -carboxamide [2562] ;

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2563];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(6-(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)cinnolin-3 -yl) isonicotinamide [2564];

2-(azetidin-3-yloxy)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)isonicotinamide [2565]; N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-3-((l-methylpiperidin-4-yl)oxy)benzamide

[2566];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-2-((l-methylpiperidin-4-yl)thio)

isonicotinamide [2567];

6-(4-methylpiperazin-l-yl)-N-(6-(5-(trifluoromethyl)-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)

nicotinamide [2568];

2-(4-methylpiperazin-l-yl)-N-(6-(5-(trifluoromethyl)-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)

isonicotinamide [2569];

N-(6-(5-amino-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2570];

N-(6-(5-(dimethylamino)-l,3,4-thiadiazol-2-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [2571]; N-(6-(3-amino-5 -fluorophenyl)cinnolin-3 -yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide [2572] ; N-(6-(3-fluoro-5-(isopropylamino)phenyl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [2573];

1 -methyl -N-(6-(pyridin-2-yl)cinnolin-3 -yl)piperidine-4-carboxamide [2574] ;

2-(4-methylpiperazin-l-yl)-N-(6-(pyridin-2-yl)cinnolin-3-yl)isonicotinamide [2575];

2-(4-methylpiperazin-l-yl)-N-(6-(pyridin-4-yl)cinnolin-3-yl)isonicotinamide [2576];

N-(6-(pyridin-3-yl)cinnolin-3-yl)cyclopropanecarboxamide [2577];

N-(6-(pyridin-3 -yl)cinnolin-3-yl)-2-(pyrrolidin- 1 -yl)acetamide [2578] ;

1 -methyl -N-(6-(pyridin-3 -yl)cinnolin-3 -yl)piperidine-4-carboxamide [2579] ;

N-(6-(pyridin-3-yl)cinnolin-3-yl)quinuclidine-4-carboxamide [2580];

2-moφholino-N-(6-(pyridin-3-yl)cinnolin-3-yl)acetamide [2581] ;

2-(moφholino-ί s)- -(6-(pyridin-3-yl)cinnolin-3-yl)acetamide [2582];

2-(4-methylpiperazin- 1 -yl)-N-(6-(pyridin-3 -yl)cinnolin-3 -yl)acetamide [2583] ;

2-(4-methyl- 1 ,4-diazepan-l -yl)-N-(6-(pyridin-3 -yl)cinnolin-3-yl)acetamide [2584] ;

2-(4-methylpiperazin- 1 -yl)-N-(6-(pyridin-3 -yl)cinnolin-3 -yl)isonicotinamide [2585] ;

2-(2-methyl-lH-imidazol-l-yl)-N-(6-(pyridin-3-yl)cinnolin-3-yl)acetamide [2586];

2-(lH-imidazol-l-yl)-N-(6-(pyridin-3-yl)cinnolin-3-yl)acetamide [2587];

2-(piperidin-4-yl)-N-(6-(pyridin-3-yl)cinnolin-3-yl)oxazole-4-carboxamide [2588];

2-( 1 -methylpiperidin-4-yl)-N-(6-(pyridin-3 -yl)cinnolin-3 -yl)oxazole-4-carboxamide [2589] ; 2-(l-isopropylpiperidin-4-yl)-N-(6-(pyridin-3-yl)cinnolin-3-yl)oxazole-4-carboxamide [2590]; fr rø-N-(6-(5-fluoropyridin-3-yl)cinnolin-3-yl)-3-mo holinocyclobutane-l-carboxamide [2591]; fr «5-N-(6-(5-fluoropyridin-3-yl)cinnolin-3-yl)-4-((4-methylpiperazin-l-yl)methyl)cyclohexane-

1-carboxamide [2592];

N-(6-(5-fluoropyridin-3-yl)cinnolin-3-yl)-2-(pyrrolidin-l-yl)acetamide [2593];

N-(6-(5-fluoropyridin-3-yl)cinnolin-3-yl)-l-methylpiperidine-4-carboxamide [2594];

N-(6-(5-fluoropyridin-3-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)acetamide [2595];

N-(6-(6-fluoropyridin-3-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)acetamide [2596];

N-(6-(5-fluoropyridin-3-yl)cinnolin-3-yl)-2-moφholinoacetamide [2597];

N-(6-(5-fluoropyridin-3-yl)cinnolin-3-yl)-3-moφholinopropanamide [2598];

N-(6-(5-fluoropyridin-3-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [2599]; N-(6-(5-fluoropyridin-3-yl)cinnolin-3-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide [2600]; N-(6-(5-fluoropyridin-3-yl)cinnolin-3-yl)-2-(l-methylpiperidin-4-yl)oxazole-4-carboxamide

[2601]; N-(6-(5-fluoropyridin-3-yl)cinnolin-3-yl)-2-(l-isopropylpiperidin-4-yl)oxazole-4-carboxamide

[2602];

N-(6-(5-chloropyridin-3-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [2603]; N-(6-(5-methylpyridin-3-yl)cinnolin-3-yl)-2-mo holinoacetamide [2604];

N-(6-(5-(difluoromethyl)pyridin-3-yl)cinnolin-3-yl)-3-(piperidin-4-yl)benzamide [2605];

N-(6-(5-(difluoromethyl)pyridin-3-yl)cinnolin-3-yl)-3-(l-methylpiperidin-4-yl)benzamide [2606]; N-(6-(5-(difluoromethyl)pyridin-3-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2607];

2-(4-methylpiperazin-l-yl)-N-(6-(5-(trifluoromethyl)pyridin-3-yl)cinnolin-3-yl)acetamide [2608]; 2-(4-methylpiperazin-l-yl)-N-(6-(6-(trifluoromethyl)pyridin-3-yl)cinnolin-3-yl)acetamide [2609]; N-(6-(5-(hydroxymethyl)pyridin-3-yl)cinnolin-3-yl)-l-methylpiperidine-4-carboxamide [2610]; N-(6-(5-cyanopyridin-3-yl)cinnolin-3-yl)-l-methylpiperidine-4-carboxamide [2611];

N-(6-(5-methoxypyridin-3-yl)cinnolin-3-yl)-l-methylpiperidine-4-carboxamide [2612];

N-(6 -(5 -methoxypyridin-3 -yl)cinnolin-3 -yl) -2 -morpholinoacetamide [2613];

N-(6-(5-methoxypyridin-3-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide [2614]; 4-fluoro-N-(6-(5-(piperidin-4-yloxy)pyridin-3-yl)cinnolin-3-yl)benzamide [2615];

N-(6-(5-aminopyridin-3-yl)cinnolin-3-yl)-4-fluorobenzamide [2616];

N-(6-(5-aminopyridin-3-yl)cinnolin-3-yl)-4-(piperidin-4-yloxy)benzamide [2617];

N-(6 -(5 -aminopyridin-3 -yl)cinnolin-3 -yl) -2 -(4 -methylpiperazin- 1 -yl)isonicotinamide [2618]; N-(6-(5-aminopyridin-3-yl)cinnolin-3-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide [2619];

N-(6-(6-aminopyridin-3 -yl)cinnolin-3-yl) -2 -(4 -methylpiperazin- 1 -yl)isonicotinamide [2620] ; N-(6-(6-(methylamino)pyridin-3-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2621];

N-(6-(5-(isopropylamino)pyridin-3-yl)cinnolin-3-yl)-3-(piperidin-4-yl)benzamide [2622];

N-(6-(5 -(isopropylamino)pyridin-3 -yl)cinnolin-3 -yl)-3 -( 1 -methylpiperidin-4-yl)benzamide

[2623];

N-(6-(5-(isopropylamino)pyridin-3-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2624];

N-(6-(5-(piperidin-4-ylamino)pyridin-3-yl)cinnolin-3-yl)cyclohexanecarboxamide [2625];

4-fluoro-N-(6-(5-(piperidin-4-ylamino)pyridin-3-yl)cinnolin-3-yl)benzamide [2626];

4-fluoro-N-(6-(5 -(( 1 -methylpiperidin-4-yl)amino)pyridin-3 -yl)cinnolin-3 -yl)benzamide [2627] ; N-(6-(5-acetamidopyridin-3-yl)cinnolin-3-yl)-l-methylpiperidine-4-carboxamide [2628];

N-(6-(5-(dimethylamino)pyridin-3-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2629]; N-(6-(6-(dimethylamino)pyridin-3-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2630];

1- methyl-N-(6-(5-(pyrrolidin-l-yl)pyridin-3-yl)cinnolin-3-yl)piperidine-4-carboxamide [2631]; N-(6 -(5 -(pyrrolidin- 1 -ylmethyl)pyridin-3 -yl)cinnolin-3 -yl)cyclopropanecarboxamide [2632] ; 4-fluoro-N-(6-(5-(pyrrolidin-l-ylmethyl)pyridin-3-yl)cinnolin-3-yl)benzamide [2633];

N-(6-(5-((4-hydroxypiperidin-l-yl)methyl)pyridin-3-yl)cinnolin-3-yl)cyclopropanecarboxamide

[2634];

4-fluoro-N-(6-(5-((4-hydroxypiperidin-l-yl)methyl)pyridin-3-yl)cinnolin-3-yl)benzamide [2635]; N-(6-(5 -(piperazin- 1 -ylmethyl)pyridin-3 -yl)cinnolin-3 -yl)cyclopropanecarboxamide [2636] ; N-(6-(5 -((4-methylpiperazin- 1 -yl)methyl)pyridin-3 -yl)cinnolin-3 -yl)cyclopropanecarboxamide

[2637];

N-(6-(5-(mo holinomethyl)pyridin-3-yl)cinnolin-3-yl)cyclopropanecarboxamide [2638];

N-methyl-5-(3-(l-methylpiperidine-4-carboxamido)cinnolin-6-yl)nicotinamide [2639];

N-methyl-5 -(3 -(2 -(4-methylpiperazin- 1 -yl)isonicotinamido)cinnolin-6-yl)nicotinamide [2640] ; N-(6-(pyridin-3-yl-£/4()cinnolin-3-yl)-2-(pyrrolidin-l-yl)acetamide [2641];

2- (4-methylpiperazin- 1 -yl)-N-(6-(pyridin-3 -yl-d.i)cinnolin-3-yl)acetamide [2642] ;

2-morpholino-N-(6-(pyridin-3 -yl-<¾)cinnolin-3 -yl)acetamide [2643] ;

1- methyl-N-(6-(2-methylpyrimidin-5-yl)cinnolin-3-yl)piperidine-4-carboxamide [2644];

2- (4-methylpiperazin-l-yl)-N-(6-(2-methylpyrimidin-5-yl)cinnolin-3-yl)isonicotinamide [2645]; N-(6-(2-aminopyrimidin-5-yl)cinnolin-3-yl)-l-methylpiperidine-4-carboxamide [2646];

2-moφholino-N-(6-(pyridazin-3 -yl)cinnolin-3 -yl)acetamide [2647] ;

2-moφholino-N-(6-(pyridazin-4-yl)cinnolin-3 -yl)acetamide [2648] ;

N-(6-(pyridazin -4 -yl)cinnolin-3-yl) -2 -(pyrrolidin- 1 -yl)acetamide [2649] ;

fr rø-3-mo holino-N-(6-(pyrazin-2-yl)cinnolin-3-yl)cyclobutane-l -carboxamide [2650];

trans -4 -(dimethylamino) -N-(6 -(pyrazin-2-yl)cinnolin-3 -yl)cyclohexane - 1 -carboxamide [2651]; trans -4 -Γηοφηο1ίηο-Ν-(6 -(pyrazin-2-yl)cinnolin-3 -yl)cyclohexane - 1 -carboxamide [2652] ;

fr «5-4-((3-fluoroazetidin-l-yl)methyl)-N-(6-(pyrazin-2-yl)cinnolin-3-yl)cyclohexane-l- carboxamide [2653];

trans-4-( (4-methylpiperazin- 1 -yl)methyl)-N-(6-(pyrazin-2-yl)cinnolin-3-yl)cyclohexane- 1 - carboxamide [2654];

N-(6-(pyrazin-2-yl)cinnolin-3-yl)-2-(pyrrolidin-l-yl)acetamide [2655];

1 -methyl -N-(6-(pyrazin -2 -yl)cinnolin-3 -yl)piperidine-4-carboxamide [2656] ;

4-fluoro-l -methyl-N-(6-(pyrazin-2-yl)cinnolin-3-yl)piperidine-4-carboxamide [2657] ;

1 -(2-fluoroethyl)-N-(6-(pyrazin-2-yl)cinnolin-3 -yl)piperidine-4-carboxamide [2658] ; 1- (oxetan-3-yl)-N-(6-(pyrazin-2-yl)cinnolin-3-yl)piperidine-4-carboxamide [2659];

2- moφholino-N-(6-(pyrazin-2-yl)cinnolin-3-yl)acetamide [2660] ;

1 -methyl -N-(6-(pyrazin -2 -yl)cinnolin-3 -yl)azepane-4-carboxamide [2661] ;

1 -isobutyl-N-(6-(pyrazin-2-yl)cinnolin-3 -yl)azepane-4-carboxamide [2662] ;

1- (2 -hydroxy -2 -methylpropyl)-N-(6-(pyrazin-2-yl)cinnolin-3-yl)azepane-4-carboxamide [2663]; 4-(moφholinomethyl)-N-(6-(pyrazin-2-yl)cinnolin-3-yl)benzamide [2664];

2- (4-methylpiperazin-l-yl)-N-(6-(pyrazin-2-yl)cinnolin-3-yl)isonicotinamide [2665];

N-(6-(6-(methylamino)pyrazin-2-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2666];

N-(6-(6-(isopropylamino)pyrazin-2-yl)cinnolin-3-yl)azetidine-3-carboxamide [2667];

N-(6-(6-(isopropylamino)pyrazin-2-yl)cinnolin-3-yl)piperidine-4-carboxamide [2668];

N-(6-(6-(isopropylamino)pyrazin-2-yl)cinnolin-3-yl)-l-methylpiperidine-4-carboxamide [2669]; l-(2-fluoroethyl)-N-(6-(6-(isopropylamino)pyrazin-2-yl)cinnolin-3-yl)piperidine-4-carboxamide

[2670];

l-isopropyl-N-(6-(6-(isopropylamino)pyrazin-2-yl)cinnolin-3-yl)piperidine-4-carboxamide

[2671];

l-isopentyl-N-(6-(6-(isopropylamino)pyrazin-2-yl)cinnolin-3-yl)piperidine-4-carboxamide

[2672];

N-(6-(6-(isopropylamino)pyrazin-2-yl)cinnolin-3-yl)-3-(piperidin-4-yl)benzamide [2673]; N-(6-(6-(isopropylamino)pyrazin-2-yl)cinnolin-3-yl)-3-(l-methylpiperidin-4-yl)benzamide

[2674];

N-(6-(6-(isopropylamino)pyrazin-2-yl)cinnolin-3-yl)-l-(piperidin-4-yl)-lH-l,2,3-triazole-4- carboxamide [2675];

l-(l-(2-fluoroethyl)piperidin-4-yl)-N-(6-(6-(isopropylamino)pyrazin-2-yl)cinnolin-3-yl)-lH- l,2,3-triazole-4-carboxamide [2676];

N-(6-(6-(isopropylamino)pyrazin-2-yl)cinnolin-3-yl)-l-(l-isopropylpiperidin-4-yl)-lH-l,2,3- triazole-4-carboxamide [2677];

N-(6-(6-(isopropylamino)pyrazin-2-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2678];

N-(6-(6-(feri-butylamino)pyrazin-2-yl)cinnolin-3-yl)-2-(3-(dimethylamino)azetidin-l-yl)

isonicotinamide [2679];

N-(6-(6-(fer^butylamino)pyrazin-2-yl)cinnolin-3-yl)-r-methyl-r,2',3',6'-tetrahydro-[2,4'- bipyridine] -4 -carboxamide [2680] ; N-(6-(6-(fer^butylamino)pyrazin-2-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2681];

N-(6-(6-(fer^butylamino)pyrazin-2-yl)cinnolin-3-yl)-2-(4-isopropylpiperazin-l-yl)

isonicotinamide [2682];

N-(6-(6-(feri-butylamino)pyrazin-2-yl)cinnolin-3 -yl)-2-mo holinoisonicotinamide [2683] ; N-(6-(6-(((3-fluoroazetidin-3-yl)methyl)amino)pyrazin-2-yl)cinnolin-3-yl)

cyclopropanecarboxamide [2684];

4-fluoro-N-(6-(6-(((3-fluoroazetidin-3-yl)methyl)amino)pyrazin-2-yl)cinnolin-3-yl)benzami

[2685];

N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)cinnolin-3 -yl)cyclobutanecarboxamide [2686] ;

3.3- difluoro-N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)cinnolin-3-yl)cyclobutane-l-carboxami

[2687];

N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)cinnolin-3 -yl)cyclopentanecarboxamide [2688] ;

4.4- difluoro-N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)cinnolin-3-yl)cyclohexane-l- carboxamide [2689];

N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)cinnolin-3-yl)tetrahydro-2H-pyran-4-carboxamide

[2690];

4-fluoro-N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)cinnolin-3-yl)benzamide [2691];

N-(6-(6-(((3S,4S)-3-fluoropiperidin-4-yl)amino)pyrazin-2-yl)cinnolin-3-yl)

cyclopropanecarboxamide [2692];

4-fluoro-N-(6-(6-(((3S,4S)-3-fluoropiperidin-4-yl)amino)pyrazin-2-yl)cinnolin-3-yl)benzamide

[2693];

N-(6-(6-(( 1 -methylpiperidin-4-yl)amino)pyrazin-2-yl)cinnolin-3 -yl)cyclobutanecarboxamide

[2694];

N-(6-(6-(( 1 -methylpiperidin-4-yl)amino)pyrazin-2-yl)cinnolin-3 -yl)cyclopentanecarboxamide

[2695];

4-fluoro-N-(6-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2-yl)cinnolin-3-yl)benzamide [2696]; N-(6-(6-((l-isopropylpiperidin-4-yl)amino)pyrazin-2-yl)cinnolin-3-yl)cyclopropanecarboxamide

[2697];

3,3-difluoro-N-(6-(6-((l-isopropylpiperidin-4-yl)amino)pyrazin-2-yl)cinnolin-3-yl)cyclobutane- 1-carboxamide [2698];

N-(6-(6-((l-isopropylpiperidin-4-yl)amino)pyrazin-2-yl)cinnolin-3-yl)cyclopentanecarboxamide

[2699]; 4-fluoro-N-(6-(6-(( 1 -isopropylpiperidin-4-yl)amino)pyrazin-2-yl)cinnolin-3 -yl)benzamide

[2700];

N-(6-(6-(dimethylamino)pyrazin-2-yl)cinnolin-3 -yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide

[2701];

N-(6-(6-(diethylamino)pyrazin-2-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2702];

N-(6-(6-(3-aminoazetidin-l-yl)pyrazin-2-yl)cinnolin-3-yl)-4-fluorobenzamide [2703];

2-(4-methylpiperazin- 1 -yl)-N-(6-(6-(pyrrolidin- 1 -yl)pyrazin-2-yl)cinnolin-3 -yl)isonicotinamide

[2704];

N-(6-(6-(azetidin-3-ylmethoxy)pyrazin-2-yl)cinnolin-3-yl)-4-fluorobenzamide [2705];

N-(6-(6-(azetidin-3-yloxy)pyrazin-2-yl)cinnolin-3-yl)-4-fluorobenzamide [2706];

N-(6-( lH-pyrrolo[2,3 -b]pyridin-5 -yl)cinnolin-3-yl)- 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazole-4- carboxamide [2707];

N-(6-(lH-pyrrolo[3,2-b]pyridin-6-yl)cinnolin-3-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [2708];

N-(6-(lH-pyrrolo[2,3-c]pyridin-4-yl)cinnolin-3-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [2709];

N-(6-( IH-pyrrolo [2,3 -b]pyridin-5 -yl)cinnolin-3 -yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide

[2710];

N-(6-(lH-pyrrolo[3,2-b]pyridin-6-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinami

[2711];

N-(6-(lH-pyrrolo[2,3-c]pyridin-4-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinami

[2712];

2-(4-methylpiperazin-l-yl)-N-(6-(oxazolo[5,4-b]pyridin-6-yl)cinnolin-3-yl)isonicotinamide

[2713];

N-(6-(2-methyl-lH-pyrrolo[2,3-b]pyridin-5-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [2714];

N-(6-(3-methyl-lH-pyrrolo[2,3-b]pyridin-5-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [2715];

N-(6-(2-methyl-lH-pyrrolo[3,2-b]pyridin-6-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [2716];

N-(6-(5H-pyrrolo[2,3-b]pyrazin-2-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[2717]; N-(6-(5H-pyrrolo[2,3-b]pyrazin-3-yl)cinnolin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamid^

[2718] ;

l-isopropyl-N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)cinnolin-3-yl)-lH-pyrazole-4- carboxamide [2719];

l-isopropyl-N-(6-(6-(( l-methylpiperidin-4-yl)amino)pyrazin-2-yl)cinnolin-3-yl)-lH-pyrazole-4- carboxamide [2720]; or a pharmaceutically acceptable salt thereof.

23. The compound according to any one of claims 1-19, wherein the compound of Formula I is selected from the group consisting of:

N-(3 -( lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)- 1 -isobutylpiperidine-4-carboxamide [2721] ; N-(3-( l-methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)cyclopropanecarboxamide [2722];

4,4-difluoro-N-(3-( l-methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)cyclohexane-l-carboxamide

[2723] ;

fr «5-4-methoxy-N-(3-(l -methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)cyclohexane-l - carboxamide [2724];

trans-N-(3-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-4-morpholinocyclohexane- 1 - carboxamide [2725];

trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N-(3-( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl) cyclohexane-1 -carboxamide [2726];

trans-N-(3-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-4-((4-methylpiperazin- 1 -yl)

methyl)cyclohexane- 1 -carboxamide [2727] ;

N-(3 -( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-(pyrrolidin- 1 -yl)acetamide [2728] ; (S)-2-(3 -fluoropyrrolidin- 1 -yl)-N-(3-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)

acetamide [2729];

(S)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)tetrahydrofuran -2 -carboxamide

[2730] ;

N-(3 -( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)piperidine-4-carboxamide [2731] ;

1 -methyl -N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6-yl)piperidine -4 -carboxamide

[2732] ;

1 -isopropyl-N-(3-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4-carboxamide

[2733] ;

1 -(fert-butyl)-N-(3-( 1 -methyl- 1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)piperidine-4-carboxamide

[2734] ;

l-cyclopropyl-N-(3-(l -methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide

[2735] ; 1 -isobutyl-N-(3-( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)piperidine-4-carboxamide

[2736];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-l-neopentylpiperidine-4-carboxamide

[2737];

l-(2-fluoroethyl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)piperidine-4- carboxamide [2738];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [2739];

1 -butyl -N-(3 -( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)piperidine-4-carboxamide

[2740];

1 -benzoyl -N-(3-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4-carboxamide

[2741];

l-(2,2-difluoropropyl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)piperidine-4- carboxamide [2742];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)azetidine-3-carboxamide [2743];

1 -(2,2-difluoroethyl)-N-(3-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4- carboxamide [2744];

1 -(2-fluoro-2-methylpropyl)-N-(3 -( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)piperidine-

4-carboxamide [2745];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-l-(oxetan-3-yl)piperidine-4- carboxamide [2746];

N-(3 -( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)- 1 -((3-methyloxetan-3 -yl)methyl) piperidine-4-carboxamide [2747];

1 -(2-methoxyethyl)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4- carboxamide [2748];

l-(2-isopropoxyethyl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)piperidine-4- carboxamide [2749];

1 , 1 -diisobutyl-4-((3-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)carbamoyl)piperidin- 1 - ium [2750];

4-fluoro-N-(3 -( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4-carboxamide

[2751];

4-fluoro- 1 -methyl -N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4- carboxamide [2752]; 4-fluoro- 1 -isobutyl-N-(3-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4- carboxamide [2753];

(S)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-3-carboxamide [2754] ; (R)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)piperidine-3-carboxamide [2755]; (S)- 1 -isobutyl-N-(3 -( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-3 -carboxamide

[2756];

(R)-l-isobutyl-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)piperidine-3-carboxamide

[2757];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)tetrahydro-2H-pyran-4-carboxamide

[2758];

N-(3 -( 1 -methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2-(piperidin- 1 -yl)acetamide [2759] ; 2-(4-fluoropiperidin-l-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)acetamide

[2760];

fr «5-4-amino-N-(3-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)cyclohexane- 1 - carboxamide [2761];

N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)-2-(4 -methylpiperazin- 1 -yl)acetamide

[2762];

(S)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-2 -carboxamide [2763] ; 2-(4-isobutylpiperazin-l-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)acetamide

[2764];

2-(3,3-dimethylazetidin- 1 -yl)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)acetamide

[2765];

(R)-2-(3-fluoropyrrolidin- 1 -yl)-N-(3 -( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)

acetamide [2766];

(S)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(2-methylpyrrolidin-l-yl)

acetamide [2767];

2-(3-azabicyclo[3.1.0]hexan-3 -yl)-N-(3 -( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl) acetamide [2768];

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) acetamide [2769];

N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)-2-(4 -methylpiperidin- 1 -yl)acetamide

[2770];

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-(4-(trifluoromethyl)piperidin- 1 -yl) acetamide [2771]; 2-(4-(difluoromethyl)piperidin-l-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) acetamide [2772];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2-(6-azaspiro[2.5]octan-6-yl)acetamide

[2773];

N-(3 -( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-(pyrrolidin-l -yl)propanamide [2774] ; (R)-N-(3-( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2-(2-methylpyrrolidin- 1 -yl)

acetamide [2775];

2-(cyclobutyl(methyl)amino)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)acetamide

[2776];

2-(diethylamino)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)acetamide [2777]; 7-(2-fluoroethyl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-7-azaspiro[3.5]

nonane-2-carboxamide [2778] ;

4-methyl-N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6-yl)piperazine - 1 -carboxamide

[2779];

(S)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(pyrrolidin- 1 -yl)propanamide

[2780];

(R)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(pyrrolidin-l-yl)propanamide

[2781];

(R)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)pyrrolidine-2 -carboxamide [2782] ; 2-methyl-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-azaspiro[3.3]heptane-6- carboxamide [2783];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(2,2,2-trifluoroacetyl)-2-azaspiro[3.3] heptane-6-carboxamide [2784] ;

2-(2-fluoroethyl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-azaspiro[3.3]

heptane-6-carboxamide [2785] ;

trans -4 -(dimethylamino) -N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6-yl)cyclohexane - 1 - carboxamide [2786];

1 -acetyl -N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)piperidine-4 -carboxamide

[2787];

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)- 1 -(( 1 -(trifluoromethyl)cyclopropyl) methyl)piperidine -4 -carboxamide [2788] ;

(S)-l-(2-fluoropropyl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)piperidine-4- carboxamide [2789]; (R)-l-(2-fluoropropyl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)piperidine-4- carboxamide [2790];

N-(3 -( 1 -methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2-(piperidin- 1 -yl)propanamide [2791] ; N-(3 -( 1 -methyl - 1 H-pyrazol -4-yl) - 1 ,7 -naphthyridin-6-yl) - 1 -(methylsulfonyl)piperidine -4 - carboxamide [2792];

1 '-methyl -N-(3 -( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-[ 1 ,4'-bipiperidine] -4- carboxamide [2793];

fr «5-4-(hydroxymethyl)-N-(3-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)cyclohexane- 1 - carboxamide [2794];

methyl 2 -(4 -((3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 , 7-naphthyridin-6 -yl)carbamoyl)piperidin- 1 -yl) acetate [2795];

1 -benzyl -N-(3 -( 1 -methyl -1 H-pyrazol -4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4 -carboxamide

[2796];

N-(3 -( 1 -methyl -1 H-pyrazol -4-yl)- 1 ,7-naphthyridin-6-yl)- 1 -(2-(pyrrolidin-l -yl)acetyl)piperidine-

4-carboxamide [2797];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-moφholinoacetamide [2798];

(S)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(3 -methylmorpholino)acetamide

[2799];

(R)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(3-methylmo holino)acetamide

[2800];

(S)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(2-methylmo holino)acetamide

[2801];

2-((2R,6S)-2,6-dimethylmoφholino)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) acetamide [2802];

2-((lS,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7- naphthyridin-6-yl)acetamide [2803] ;

2-((lR,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7- naphthyridin-6-yl)acetamide [2804] ;

2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) acetamide [2805];

(S)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-moφholinopropanamide [2806] ; N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(moφholin-2-yl)acetamide [2807]; N-(3 -( 1 -methyl -1 H-pyrazol -4-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylmoφholin-2-yl)acetamide

[2808]; 2-(4-ethylpiperazin-l-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)acetamide

[2809];

2-(4-isopropylpiperazin-l-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)acetamide

[2810];

2-(4-cyclopropylpiperazin- 1 -yl)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)

acetamide [2911];

2-(4-(2-fluoroethyl)piperazin- 1 -yl)-N-(3-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl) acetamide [2812];

(S)-2-(2,4-dimethylpiperazin-l-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) acetamide [2813];

1 -(2-hydroxyethyl)-N-(3 -( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4- carboxamide [2814];

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)- 1 -(pyridin-2-ylmethyl)piperidine-4- carboxamide [2815];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-l-(oxazol-2-ylmethyl)piperidine-4- carboxamide [2816];

(R)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)- 1 -oxotetrahydro- lH-pyrrolo[ 1 ,2-c] imidazole-2(3H)-carboxamide [2817] ;

(R) - 1 -methyl -N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)pyrrolidine-2 -carboxamide

[2818];

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)- 1 -(tetrahydro-2H-pyran-4-yl)piperidine- 4-carboxamide [2819];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-l-(pyrimidin-2-ylmethyl)piperidine-4- carboxamide [2820];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-l-(pyrazin-2-ylmethyl)piperidine-4- carboxamide [2821];

1 -((5 -methyl- 1 ,2,4-oxadiazol-3-yl)methyl)-N-(3-( 1 -methyl- 1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6- yl)piperidine -4 -carboxamide [2822] ;

1- (2-hydroxy-2-methylpropyl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)

piperidine-4-carboxamide [2823];

fert-butyl 2-(4-((3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)carbamoyl)piperidin-l-yl) acetate [2824];

2- (4-((3-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)carbamoyl)piperidin-l -yl)acetic acid

[2825]; 2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(3-( 1 -methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl) acetamide [2826];

fert-butyl (3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)carbamate [2827];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)but-2-ynamide [2828];

trans-4-((3 -( 1 -methyl -lH-pyrazol -4 -yl)-l ,7-naphthyridin-6-yl)carbamoyl)cyclohexane- 1 - carboxylic acid [2829];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-3-moφholinopropanamide [2830]; trans-N-(3-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-3-moφholinocyclobutane- 1 - carboxamide [2831];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)quinuclidine-4-carboxamide [2832]; 1 -isobutyl-N-(3-( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)azepane-4-carboxamide

[2833];

2-(4-methoxypiperidin- 1 -yl)-N-(3 -( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)acetamide

[2834];

2- (4-hydroxypiperidin-l -yl)-N-(3 -( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)acetamide

[2835];

3- (hydroxymethyl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)bicyclo[l . l . l]

pentane-1 -carboxamide [2836];

1- methyl-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)azepane-4-carboxamide [2837]; fr «5-4-(dimethylamino)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)cyclohexane-l- carboxamide [2838];

fr «5-4-(bis(methyl-£/3)amino)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)

cyclohexane-1 -carboxamide [2839];

N-(3 -( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-3-((4-methylpiperazin- 1 -yl)methyl) bicyclo[l .1. l]pentane-l -carboxamide [2840];

methyl trans A-((3-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)carbamoyl)cyclohexane- 1 - carboxylate [2841];

2- ( 1 -isobutylpyrrolidin-3 -yl)-N-(3-( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)acetamide

[2842];

trans -N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 , 7-naphthyridin-6-yl) -4 -(4 -methylpiperazine - 1 - carbonyl)cyclohexane- 1 -carboxamide [2843] ;

1 -isobutyl-N-(3-( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)piperidine-4-carboxamide

[2844]; N-(3-(l-methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-l-(phenylsulfonyl)piperidine-4- carboxamide [2845];

8 -methyl -N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6-yl) -3 , 8 -diazabicyclo [3.2.1] octane - 3-carboxamide [2846];

3 -methyl -N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6-yl) -3 , 8 -diazabicyclo [3.2.1] octane - 8-carboxamide [2847];

(lR,3s,5S)-3-amino-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-8-azabicyclo[3.2.1] octane-8-carboxamide [2848];

(lR,3s,5S)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-3-((3,3,3-trifluoropropyl) amino)-8 -azabicyclo [3.2.1 ]octane-8 -carboxamide [2849] ;

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7- naphthyridin-6 -yl) -8 -azabicyclo [3.2.1] octane-8 -carboxamide [2850] ;

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)mo holine-4-carboxamide [2851] ; 4-(dimethylamino)-N-(3-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine- 1 - carboxamide [2852];

(S)-2,4-dimethyl-N-(3-( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)piperazine- 1 - carboxamide [2853];

1 -methyl-3 -(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6-yl) - 1 -( 1 -methylpiperidin-4 -yl)urea

[2854];

1 -(3 -( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-3 -( 1 -methylpiperidin-4-yl)urea [2855] ; 4-isopropyl-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)piperazine-l -carboxamide

[2856];

(R)-3,4-dimethyl-N-(3-( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)piperazine- 1 - carboxamide [2857];

N-(3 -( lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l -yl)isonicotinamide

[2858];

N-(3 -( 1 -methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-3 -(piperazin- 1 -yl)benzamide [2859] ; N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)-3 -(4 -methylpiperazin- 1 -yl)benzamide

[2860];

N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)-3 -(pyrrolidin- 1 -ylmethyl)benzamide

[2861];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-3-(piperidin-4-yloxy)benzamide [2862]; N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-3-(( 1 -methylpiperidin-4-yl)oxy)

benzamide [2863]; N-(3-(l-methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-4-(piperidin-4-yloxy)benzamide [2864]; N-(3 -( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-4-(( 1 -methylpiperidin-4-yl)oxy)

benzamide [2865];

N-(3 -( 1 -methyl - 1 H-pyrazol -4-yl) - 1 ,7 -naphthyridin-6-y 1) -2 -(piperazin- 1 -yl)isonicotinamide

[2866];

N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)-2-(4 -methylpiperazin- 1 -yl)

isonicotinamide [2867];

2-(4-isopropylpiperazin-l-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)

isonicotinamide [2868];

2-(4-cyclopropylpiperazin- 1 -yl)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)

isonicotinamide [2869];

2-(4-(2-fluoroethyl)piperazin- 1 -yl)-N-(3-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl) isonicotinamide [2870];

N-(3 -( 1 -methyl -1 H-pyrazol -4-yl)- 1 ,7-naphthyridin-6-yl)-6-(4-methylpiperazin- 1 -yl)nicotinamide

[2871];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-5-(piperidin-4-yloxy)nicotinamide

[2872];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(piperidin-4-yloxy)isonicotinamide

[2873];

N-(3 -( 1 -methyl -1 H-pyrazol -4-yl)- 1 ,7-naphthyridin-6-yl)-2-(( 1 -methylpiperidin-4-yl)oxy)

isonicotinamide [2874];

N-(3 -( 1 -methyl - 1 H-pyrazol -4-yl) - 1 ,7 -naphthyridin-6-yl) -5 -(piperidin-4-ylamino)nicotinamide

[2875];

N-(3 -( 1 -methyl -1 H-pyrazol -4-yl)- 1 ,7-naphthyridin-6-yl)-5-(( 1 -methylpiperidin-4-yl)amino) nicotinamide [2876];

2-(4-aminopiperidin- 1 -yl)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)

isonicotinamide [2877];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4-(methylamino)piperidin-l-yl) isonicotinamide [2878];

2-(4-(dimethylamino)piperidin-l-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) isonicotinamide [2879];

2-((l-isopropylpiperidin-4-yl)oxy)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) isonicotinamide [2880]; 2-(3 -aminoazetidin- 1 -yl)-N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)

isonicotinamide [2881];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(3-( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl) isonicotinamide [2882];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-moφholinoisonicotinamide [2883]; 2-((2-(dimethylamino)ethyl)amino)-N-(3-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl) isonicotinamide [2884];

2-(2-(dimethylamino)ethoxy)-N-(3 -( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)

isonicotinamide [2885];

2-(4-isobutylpiperazin-l-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)

isonicotinamide [2886];

2-(azetidin-3-yloxy)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)isonicotinamide

[2887];

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-(( 1 -methylazetidin-3 -yl)oxy)

isonicotinamide [2888];

2-(4-ethylpiperazin-l-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)

isonicotinamide [2889];

4-((dimethylamino)methyl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)benzamide

[2890];

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-3-( 1 -methylpiperidin-4-yl)benzamide

[2891];

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-3-((4-methylpiperazin- 1 -yl)methyl) benzamide [2892];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)isonicotinamide [2893];

2-hydroxy-N-(3-( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)isonicotinamide [2894] ; 2-isopropoxy-N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 , 7-naphthyridin-6 -yl)isonicotinamide [2895] ; N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-( 1 -methylpiperidin-4-yl)

isonicotinamide [2896];

r-methyl-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-r,2',3',6'-tetrahydro-[2,4'- bipyridine]-4-carboxamide [2897];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4-(6-(4-methylpiperazin-l-yl) nicotinoyl)piperazin- 1 -yl)isonicotinamide [2898] ;

2-(4-hydroxy-4-methyl-4 4-piperazin-l-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-

6-yl)isonicotinamide [2899]; 2-methyl-N-(3-(l-methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-6-(4-methylpiperazin-l-yl) isonicotinamide [2900];

3 -methyl -N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6-yl) -2 -(4-methylpiperazin- 1 -yl) isonicotinamide [2901];

2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(3-( 1 -methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)

isonicotinamide [2902];

2-((2S,6R)-2,6-dimethylmo holino)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6- yl)isonicotinamide [2903];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(2,7-diazaspiro[3.5]nonan-2-yl)

isonicotinamide [2904];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(7-methyl-2,7-diazaspiro[3.5]nonan-

2-yl)isonicotinamide [2905];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(2,7-diazaspiro[3.5]nonan-7-yl)

isonicotinamide [2906];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(2-methyl-2,7-diazaspiro[3.5]nonan-

7-yl)isonicotinamide [2907];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(3 -( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6- yl)isonicotinamide [2908];

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-(( 1 -methylpiperidin-4-yl)thio)

isonicotinamide [2909];

N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)-2-(4 -methylpiperazin- 1 -yl)pyrimidine - 4-carboxamide [2910];

N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)-6-(4 -methylpiperazin- 1 -yl)pyridazine -4 - carboxamide [2911];

N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)-6-(4 -methylpiperazin- 1 -yl)pyrimidine -

4-carboxamide [2912];

N-(3 -( 1 -methyl - 1 H-pyrazol -4-yl) - 1 ,7 -naphthyridin-6-yl) -2 -phenylacetamide [2913];

N-(3 -( 1 -methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-3 -phenylpropanamide [2914] ;

N-(3 -( 1 -methyl -1 H-pyrazol -4-yl)- 1 ,7-naphthyridin-6-yl)-2-(pyridin-3-yl)acetamide [2915] ; N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)-3 -(pyridin-3 -yl)propanamide [2916]; N-(3 -( 1 -methyl -1 H-pyrazol -4-yl)- 1 ,7-naphthyridin-6-yl)-2-(pyridin-4-yl)acetamide [2917] ; N-(3 -( 1 -methyl -1 H-pyrazol -4-yl)- 1 ,7-naphthyridin-6-yl)-3-(pyridin-4-yl)propanamide [2918] ; N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)isoindoline-5-carboxamide [2919]; 2-methyl-N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)isoindoline-5 -carboxamide

[2920];

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-l ,2,3,4-tetrahydroisoquinoline-7- carboxamide [2921];

2-methyl-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-l,2,3,4- tetrahydroisoquinoline-7 -carboxamide [2922] ;

2- methyl-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-l,2,3,4- tetrahydroisoquinoline-6-carboxamide [2923] ;

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-l ,2,3,4-tetrahydroisoquinoline-6- carboxamide [2924];

N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6-yl) - 1 H-indole-5 -carboxamide [2925] ; N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)benzofuran-5-carboxamide [2926]; N-(3-(l-methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)furo[2,3-c]pyridine-5-carboxamide

[2927];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)benzo[b]thiophene-5-carboxamide

[2928];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)benzofuran-6-carboxamide [2929]; N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)benzo [d] oxazole -6 -carboxamide [2930] ; N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)benzo[d]thiazole-6-carboxamide [2931]; N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)benzo[d] oxazole -5 -carboxamide [2932] ; N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)benzo[d]thiazole-5-carboxamide [2933]; N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)quinoline -3 -carboxamide [2934] ;

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)quinoline-6-carboxamide [2935] ;

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)quinoxaline-6-carboxamide [2936]; 5-chloro-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [2937];

3- chloro-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [2938];

2- (2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) isonicotinamide [2939];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(5-methyl-2,5-diazabicyclo[2.2.1] heptan-2-yl)isonicotinamide [2940] ;

3- fluoro-N-(3 -( 1 -methyl- 1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl) isonicotinamide [2941]; N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-((4-methylpiperazin- 1 -yl)methyl) isonicotinamide [2942];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(moφholinomethyl)isonicotinamide

[2943];

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-(pyrrolidin- 1 -ylmethyl)

isonicotinamide [2944];

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-(2-(4-methylpiperazin- 1 -yl)pyridin-4- yl)acetamide [2945];

1 -methyl -N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6-yl) - 1 H-indazole -5 -carboxamide

[2946];

1 -methyl -N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6-yl) - 1 H-benzo [d] imidazole-5 - carboxamide [2947];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-l-(piperidin-4-yl)-lH-pyrazole-4- carboxamide [2948];

N-(3 -( 1 -methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- pyrazole -4 -carboxamide [2949];

1 -( 1 -ethylpiperidin-4-yl)-N-(3-( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)- lH-pyrazole-

4-carboxamide [2950];

l-(l-(2-fluoroethyl)piperidin-4-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-lH- pyrazole -4 -carboxamide [2951];

1 -( 1 -isopropylpiperidin-4-yl)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-lH- pyrazole -4 -carboxamide [2952];

1 -( 1 -cyclopropylpiperidin-4-yl)-N-(3-( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)- 1H- pyrazole -4 -carboxamide [2953];

isopropyl 4-(4-((3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)carbamoyl)-lH-pyrazol-l- yl)piperidine-l-carboxylate [2954];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-l-(piperidin-4-yl)-lH-l,2,3-triazole-4- carboxamide [2955];

N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- 1,2,3- triazole -4 -carboxamide [2956];

l-(l-(2-fluoroethyl)piperidin-4-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-lH- l,2,3-triazole-4-carboxamide [2957];

1 -( 1 -isopropylpiperidin-4-yl)-N-(3 -( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl) - 1H- 1 ,2,3 - triazole -4 -carboxamide [2958]; N-(3 -( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l -yl)oxazole-5 - carboxamide [2959];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(3-( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl) oxazole -4 -carboxamide [2960] ;

N-(3 -( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-(piperidin-4-yl)oxazole-4- carboxamide [2961];

N-(3 -( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-( 1 -methylpiperidin-4-yl)oxazole-4- carboxamide [2962];

2-(l-(2-fluoroethyl)piperidin-4-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) oxazole -4 -carboxamide [2963] ;

2-( 1 -isopropylpiperidin-4-yl)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)oxazole-4- carboxamide [2964];

N-(3 -( 1 -methyl - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl)-2-(4 -methylpiperazin- 1 -yl)oxazole -4 - carboxamide [2965];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(3-( 1 -methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl) thiazole-5 -carboxamide [2966] ;

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(piperidin-4-yl)thiazole-4- carboxamide [2967];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)thiazole-4- carboxamide [2968];

2-(l-(2-fluoroethyl)piperidin-4-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) thiazole-4-carboxamide [2969] ;

2-(l-isopropylpiperidin-4-yl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)thiazole-4- carboxamide [2970];

1 -methyl -N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl-5 - )piperidine-4-carboxamide

[2971] ;

N-(3 -( 1 -methyl -1 H-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)- 1 -(2 -(methyl -<¾)propyl- 1 , 1 ,2,3,3, 3-de) piperidine-4-carboxamide [2972];

N-iS-il-methyl-lH-pyrazol^-y^-l -naphthyridin-e-y^^-ipyrrolidin-l-yl^^^^-i ^acetamide

[2973] ;

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4-(methyl-£/3)piperazin-l-yl)

acetamide [2974];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(moφholino-ί s)acetamide [2975]; ( S) -N-(3 -( 1 -(methyl -ds) - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl) -2 -(pyrrolidin- 1 -yl)propanamide

[2976];

l-isobutyl-N-(3-(l-(methyl-£/3)-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide

[2977];

N-(3-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

acetamide [2978];

N-(3-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(pyrrolidin-l -yl)acetamide

[2979];

N-(3-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(piperidin-l -yl)acetamide [2980] ; N-(3-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)-l ,7 -naphthyridin-6 -yl)- 1 -(3,3,3 -trifluoropropyl)piperidine- 4-carboxamide [2981];

N-(3 -( lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2-(4-(methyl-£/3)piperazin- 1 -yl)isonicotinamide

[2982];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4-(methyl-£/3)piperazin-l-yl)

isonicotinamide [2983];

N-(3-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [2984];

N-(3-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-(methyl-<i3)piperazin-l -yl) isonicotinamide [2985];

N-(3-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)- 1 -(piperidin-4-yl)-lH-pyrazole-4- carboxamide [2986];

N-(3-( 1 -(methyl -d3)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-l -( 1 -methylpiperidin-4-yl)-lH- pyrazole-4-carboxamide [2987];

N-(3-( 1 -(methyl-^)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(piperidin-4-yl)oxazole-4- carboxamide [2988];

N-(3-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-( 1 -methylpiperidin-4-yl)oxazole- 4-carboxamide [2989];

N-(3 -( 1 -ethyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2-(pyrrolidin-l -yl)acetamide [2990] ; N-(3-(l-cyclopropyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(pyrrolidin-l-yl)acetamide

[2991];

N-(3-(l-cyclopropyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-l-(3,3,3-trifluoropropyl)piperidine-

4-carboxamide [2992];

N-(3 -( 1 -( 1 -methylpiperidin-4-yl)-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)

cyclohexanecarboxamide [2993]; 2-(pyrrolidin- 1 -yl)-N-(3 -(5 -(trifluoromethyl)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)acetamide

[2994];

N-(3-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-l-methylpiperidine- 4-carboxamide [2995];

N-(3-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)tetrahydro-2H-pyran-

4-carboxamide [2996];

N-(3-(5-(azetidin-l-ylmethyl)-l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-4,4- difluorocyclohexane- 1 -carboxamide [2997] ;

4,4-difluoro-N-(3 -( 1 -methyl -5 -(pyrrolidin-1 -ylmethyl)- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl) cyclohexane-1 -carboxamide [2998];

4,4-difluoro-N-(3 -( 1 -methyl -5 -(piperidin-1 -ylmethyl)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl) cyclohexane-1 -carboxamide [2999];

2-(2 -fluoroethyl) -N-(3 -( 1 -methyl -5 -(piperidin- 1 -ylmethyl) - 1 H-pyrazol -4 -yl) - 1 , 7-naphthyridin-6- yl)-2-azaspiro[3.3]heptane-6-carboxamide [3000] ;

fert-butyl 6 -((3 -( 1 -methyl -5 -(piperidin- 1 -ylmethyl) - 1 H-pyrazol -4 -yl) - 1 , 7-naphthyridin-6-yl) carbamoyl)-2-azaspiro[3.3]heptane-2-carboxylate [3001];

2-fluoro-2 -methyl -N-(3-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6- yl)propanamide [3002];

2-(diethylamino)-N-(3-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-l,7-naphthyridin-6- yl)acetamide [3003];

fr «5-4-methoxy-N-(3-(l -methyl -5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-l,7-naphthyridin-6- yl)cyclohexane - 1 -carboxamide [3004] ;

fr «5-4-(hydroxymethyl)-N-(3-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,7- naphthyridin-6 -yl)cyclohexane - 1 -carboxamide [3005] ;

(R)-N-(3-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)pyrrolidine-

2-carboxamide [3006];

l-isobutyl-N-(3-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) piperidine-4-carboxamide [3007];

N-(3 -( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)- 1 -(oxetan-3 -yl) piperidine-4-carboxamide [3008];

1 -benzoyl -N-(3 -( 1 -methyl -5 -(piperidin- 1 -ylmethyl) - 1 H-pyrazol -4 -yl) - 1 ,7 -naphthyridin-6 -yl) piperidine-4-carboxamide [3009];

N-(3 -( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)tetrahydro-2H- pyran-4-carboxamide [3010] ; N-(3 -( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2-(4- methylpiperidin- 1 -yl)acetamide [3011] ;

N-(3 -( 1 -(difluoromethyl)-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl) isonicotinamide [3012];

N-(3-(l-ethyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3013];

N-(3-(l-isopropyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-3-(piperidin-4-yloxy)benzamide

[3014];

N-(3-(l-isopropyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-3-((l-methylpiperidin-4-yl)oxy) benzamide [3015];

N-(3-(l-isopropyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-4-(piperidin-4-yloxy)benzamide

[3016];

N-(3 -( 1 -cyclopropyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [3017];

4-fluoro-N-(3 -( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)benzamide

[3018];

4- (difluoromethoxy)-N-(3 -( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl) benzamide [3019];

5- fluoro-N-(3 -( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)nicotinamide

[3020];

N2 -methyl -N5-(3 -( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)pyridine- 2,5-dicarboxamide [3021];

1- isopropyl-N-(3-(l-(l-methylpiperidin-4-yl)-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-lH- pyrazole-4-carboxamide [3022];

2- methyl-N-(3 -( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)thiazole-5- carboxamide [3023];

N-(3-(5-amino-l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [3024];

4-(difluoromethoxy)-N-(3-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) benzamide [3025];

N-(3-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4- methylpiperazin-l-yl)isonicotinamide [3026];

N-(3-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(7-methyl-2,7- diazaspiro[3.5]nonan-2-yl)isonicotinamide [3027] ; 4-fluoro-N-(3 -( 1 -methyl-5-(pyrrolidin- 1 -ylmethyl)-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl) benzamide [3028];

4-fluoro-N-(3-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) benzamide [3029];

4-(difluoromethoxy)-N-(3-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-l,7- naphthyridin-6-yl)benzamide [3030] ;

N-(3 -( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-3-(pyrrolidin-

1 -ylmethyl)benzamide [3031 ] ;

N-(3 -( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l , 7-naphthyridin-6-yl)-2-(7-methyl-

2,7-diazaspiro[3.5]nonan-2-yl)isonicotinamide [3032];

N-(3 -( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2- moφholinoisonicotinamide [3033] ;

N-(3 -( 1 -methyl -5 -^ο ηο1ίηοΓηεΐ1τγ1)-1Η^^ο1-4^1)- 1 ,7-naphthyridin-6-yl)-2- moφholinoisonicotinamide [3034] ;

N-(3 -(4,5 ,6,7-tetrahydropyrazolo[ 1 ,5 -a]pyrazin-3 -yl)-l ,7-naphthyridin-6-yl)- 1 -(( 1 -

(trifluoromethyl)cyclopropyl)methyl)piperidine-4-carboxamide [3035];

3,3-difluoro-N-(3-(5-methyl-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,7-naphthyridin-6- yl)cyclobutane - 1 -carboxamide [3036] ;

N-((4,4-difluorocyclohexyl)methyl)-3-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a] pyrazin-3-yl)-l ,7-naphthyridin-6-amine [3037] ;

N-(3-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl)-l-

(( 1 -(trifluoromethyl)cyclopropyl)methyl)piperidine-4-carboxamide [3038] ;

N-(3-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl)-2-

(pyrrolidin- 1 -yl)acetamide [3039] ;

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(3-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a] pyrazin-3-yl)-l,7-naphthyridin-6-yl)acetamide [3040];

(R)-N-(3 -(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[ 1 ,5 -a]pyrazin-3 -yl)-l ,7-naphthyridin-6- yl)-l -isobutylpiperidine -3 -carboxamide [3041 ] ;

N-(3 -(5 -(2-fluoroethyl)-4,5 ,6,7-tetrahydropyrazolo [ 1 ,5 -a]pyrazin-3 -yl)- 1 ,7-naphthyridin-6-yl) piperidine-4-carboxamide [3042];

4-fluoro-N-(3-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,7- naphthyridin-6-yl)- 1 -isobutylpiperidine-4-carboxamide [3043] ;

N-(3-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl)-2-

(4-methylpiperazin- 1 -yl)acetamide [3044] ; 4-fluoro-N-(3-(4,5,6,7 etrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl)benzamide

[3045];

N-(3-(5-(2-fluoroethyl)-4,5,6j etrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl)-3-

(4-methylpiperazin- 1 -yl)benzamide [3046] ;

N5-(3 -(5 -(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[ 1 ,5 -a]pyrazin-3-yl)-l ,7-naphthyridin-6-yl)-

N2-methylpyridine-2,5 -dicarboxamide [3047] ;

N-(3-(5-(2-fluoroethyl)-4,5,6j etrahydropyrazolo[l,5-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl)-6-

(4-methylpiperazin- 1 -yl)nicotinamide [3048] ;

2-(azetidin-3 -yloxy)-N-(3 -(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[ 1 ,5 -a]pyrazin-3 -yl)-l ,7- naphthyridin-6-yl)isonicotinamide [3049] ;

N-(3-(l-methyl-lH-pyrazol-5-yl)-l ,7-naphthyridin-6-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [3050];

1 -methyl -N-(3 -( 1 -methyl - 1 H-pyrazol -3 -yl) - 1 ,7 -naphthyridin-6-yl)piperidine -4 -carboxamide

[3051];

N-(3 -( 1 -methyl - 1 H-pyrazol -3 -yl) - 1 ,7 -naphthyridin-6 -yl)-2-(4 -methylpiperazin- 1 -yl)

isonicotinamide [3052];

2-fluoro-2 -methyl -N-(3 -( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)-l ,7-naphthyridin-6-yl)propanamide

[3053];

2,2,3, 3-tetramethyl-N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)cyclopropane-l- carboxamide [3054];

fr «5-N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-4-(pyrrolidin-l-yl)

cyclohexane-1 -carboxamide [3055];

fr rø-N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-4-mo holinocyclohexane-l- carboxamide [3056];

N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-2-(piperidin-l-yl)acetamide [3057]; 1 -ethyl -4-fluoro-N-(3 -( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)-l ,7-naphthyridin-6-yl)piperidine-4- carboxamide [3058];

4-fluoro- 1 -isobutyl-N-(3-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)-l ,7-naphthyridin-6-yl)piperidine-4- carboxamide [3059];

N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-l-(3,3,3-trifluoropropyl)piperidine- 4-carboxamide [3060];

N-(3 -( 1 -methyl- lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)cyclopropanecarboxamide [3061] ; 4,4-difluoro-N-(3 -( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)- 1 ,7-naphthyridin-6-yl)cyclohexane- 1 - carboxamide [3062]; fra«s-4-(dimethylamino)-N-(3 -( 1 -methyl-lH- 1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl) cyclohexane-1 -carboxamide [3063];

fra«s-N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l ,7-naphthyridin-6-yl)-4-((4-methylpiperazin-l-yl) methyl)cyclohexane - 1 -carboxamide [3064] ;

N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide [3065]; 1 -isobutyl-N-(3-( 1 -methyl- lH-1 ,2,3-triazol-4-yl)-l ,7-naphthyridin-6-yl)piperidine-4- carboxamide [3066];

N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)-l -(( 1 -(trifluoromethyl)cyclopropyl) methyl)piperidine -4 -carboxamide [3067] ;

N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-l-((3-methyloxetan-3-yl)

methyl)piperidine -4 -carboxamide [3068] ;

N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)-l -(2-(pyrrolidin- 1 -yl)

acetyl)piperidine-4-carboxamide [3069] ;

r-methyl-N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-[l,4'-bipiperidine]-4- carboxamide [3070];

(R)-N-(3 -( 1 -methyl-lH- 1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-3 -carboxamide

[3071];

(R)-l -isobutyl-N-(3 -( 1 -methyl-lH-1 ,2,3 -triazol-4-yl)- 1 ,7-naphthyridin-6-yl)piperidine-3- carboxamide [3072];

N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-2-(pyrrolidin-l-yl)acetamide

[3073];

N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

acetamide [3074];

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl) acetamide [3075];

1 -(2-hydroxy-2-methylpropyl)-N-(3-( 1 -methyl- lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl) piperidine-4-carboxamide [3076];

N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-moφholinoacetamide [3077] ; 2-(4-methoxypiperidin-l-yl)-N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)

acetamide [3078];

N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)morpholine-4 -carboxamide [3079] ; N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-l-(piperidin-4-yl)-lH-pyrazole-4- carboxamide [3080]; N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)- 1 -( 1 -methylpiperidin-4-yl)-lH- pyrazole-4-carboxamide [3081];

1 -( 1 -ethylpiperidin-4-yl)-N-(3-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)- 1 ,7-naphthyridin-6-yl)-lH- pyrazole-4-carboxamide [3082];

l-(l-isopropylpiperidin-4-yl)-N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-lH- pyrazole-4-carboxamide [3083];

N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-l-(piperidin-4-yl)-lH-l,2,3- triazole-4-carboxamide [3084];

1 -( 1 -(2-fluoroethyl)piperidin-4-yl)-N-(3-( 1 -methyl-lH- 1 ,2,3-triazol-4-yl)-l ,7-naphthyridin-6-yl)- lH-l,2,3-triazole-4-carboxamide [3085];

1- (l-isopropylpiperidin-4-yl)-N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-lH- l,2,3-triazole-4-carboxamide [3086];

N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-2-(piperidin-4-yl)oxazole-4- carboxamide [3087];

N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-( 1 -methylpiperidin-4-yl)oxazole- 4-carboxamide [3088];

2- (l-isopropylpiperidin-4-yl)-N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl) oxazole-4-carboxamide [3089];

2-fluoro-N-(3 -( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)-l ,7-naphthyridin-6-yl)benzamide [3090] ;

N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)-3-(( 1 -methylpiperidin-4-yl)oxy) benzamide [3091];

N2-methyl-N5-(3 -( 1 -methyl-lH- 1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)pyridine-2,5- dicarboxamide [3092];

N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)-6-(4-methylpiperazin- 1 -yl)

nicotinamide [3093];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(3-( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl) isonicotinamide [3094];

N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-( 1 -methylpiperidin-4-yl)

isonicotinamide [3095];

2-(4-(dimethylamino)piperidin-l-yl)-N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6- yl)isonicotinamide [3096];

N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-moφholinoisonicotinamide

[3097]; N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl) isonicotinamide [3098];

2-(4-methyl-l,4-diazepan-l-yl)-N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl) isonicotinamide [3099];

2-(4-isopropylpiperazin-l -yl)-N-(3-( 1 -methyl- IH- 1 ,2,3-triazol-4-yl)-l ,7-naphthyridin-6-yl) isonicotinamide [3100];

N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(piperidin-4-ylamino)

isonicotinamide [3101];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(3 -( 1 -methyl- IH- 1 ,2,3 -triazol-4-yl)-l ,7- naphthyridin-6-yl)isonicotinamide [3102] ;

N-(3 -( 1 -methyl-lH-1 ,2,3-triazol-4-yl)- 1 ,7-naphthyridin-6-yl)-2-(( 1 -methylpiperidin-4-yl)thio) isonicotinamide [3103];

2-methyl-N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-l,2,3,4- tetrahydroisoquinoline-6-carboxamide [3104] ;

N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-2-(piperazin-l-yl)isonicotinamide

[3105];

N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-2-(2-(4-methylpiperazin-l-yl) pyridin-4-yl)acetamide [3106];

1 , 1 -bis(methyl-£/3)-4-(4-((3-( 1 -methyl- IH- 1 ,2,3 -triazol-4-yl)- 1 ,7-naphthyridin-6-yl)carbamoyl) pyridin-2-yl)piperazin-l-ium iodide [3107];

N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4-(methyl-£/3)piperazin-l-yl) isonicotinamide [3108];

N-(3-(l-methyl-lH-l,2,3-triazol-5-yl)-l,7-naphthyridin-6-yl)-l-(3,3,3-trifluoropropyl)piperidine- 4-carboxamide [3109];

N-(3 -(4-methyl-4H-l ,2,4-triazol-3 -yl)- 1 ,7-naphthyridin-6-yl)-2-moφholinoacetamide [3110]; N-(3 -(4-methyl-4H-l ,2,4-triazol-3 -yl)- 1 ,7-naphthyridin-6-yl)- 1 -(3,3,3 -trifluoropropyl)piperidine- 4-carboxamide [3111];

4-fluoro- 1 -isobutyl-N-(3-(4-methyl-4H- 1 ,2,4-triazol-3 -yl)-l ,7-naphthyridin-6-yl)piperidine-4- carboxamide [3112];

N-(3-(4,5-dimethyl-4H-l,2,4-triazol-3-yl)-l,7-naphthyridin-6-yl)-2-moφholinoacetamide [3113]; N-(3-(4,5-dimethyl-4H-l,2,4-triazol-3-yl)-l,7-naphthyridin-6-yl)-l-(3,3,3- trifluoropropyl)piperidine-4-carboxamide [3114];

N-(3 -( IH- 1 ,2,3 -triazol-1 -yl)- 1 ,7-naphthyridin-6-yl)-4-fluoro- 1 -isobutylpiperidine-4-carboxamide

[3115]; N-(3 -(2H- 1 ,2,3 -triazol-2-yl)- 1 ,7-naphthyridin-6-yl)-4-fluoro- 1 -isobutylpiperidine-4-carboxamide

[3116];

N-(3 -( 1H- 1 ,2,4-triazol-l -yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l -yl)isonicotinamide

[3117];

1- isobutyl-N-(3-(l-methyl-lH etrazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide

[3118];

2,2,3, 3-tetramethyl-N-(3-( 1 -methyl -IH-imidazol -5 -yl)- 1 ,7-naphthyridin-6-yl)cyclopropane- 1 - carboxamide [3119];

4,4-difluoro-N-(3 -( 1 -methyl -IH-imidazol -5 -yl)-l ,7-naphthyridin-6-yl)cyclohexane- 1 - carboxamide [3120];

N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-(piperidin-l-yl)acetamide [3121];

2 - fluoro-2 -methyl -N-(3 -( 1 -methyl -IH-imidazol -5 -yl)- 1 ,7-naphthyridin-6-yl)propanamide [3122] ; 1 -fluoro-N-(3 -( 1 -methyl- lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)cyclopropane- 1 -carboxamide

[3123];

2-methyl-N-(3 -( 1 -methyl-lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)-2-azaspiro[3.3]heptane-6- carboxamide [3124];

1 -fluoro-N-(3 -( 1 -methyl- lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)cyclohexane-l -carboxamide

[3125];

fr «5-4-methoxy-N-(3-( 1 -methyl- lH-imidazol-5-yl)- 1 ,7-naphthyridin-6-yl)cyclohexane-l - carboxamide [3126];

fr «5-4-(hydroxymethyl)-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)cyclohexane- 1 -carboxamide [3127];

N-(3 -( 1 -methyl-lH-imidazol-5-yl)-l ,7-naphthyridin-6-yl)azetidine-3 -carboxamide [3128] ;

(R) -N-(3 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 , 7-naphthyridin-6 -yl)tetrahydrofuran-2 -carboxamide

[3129];

1 -(2-methoxyethyl) -N-(3 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 , 7-naphthyridin-6-yl)piperidine -4 - carboxamide [3130];

N-(3 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 , 7-naphthyridin-6 -yl) - 1 -(3 , 3 ,3 -trifluoropropyl)piperidine -4 - carboxamide [3131];

l-isobutyl-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide

[3132];

N-(3 -( 1 -methyl-lH-imidazol-5-yl)- 1 ,7-naphthyridin-6-yl)- 1 -(methylsulfonyl)piperidine-4- carboxamide [3133];

N-(3 -( 1 -methyl-lH-imidazol-5-yl)- 1 ,7-naphthyridin-6-yl)-2-(pyrrolidin- 1 -yl)propanamide [3134] ; 2- isopropoxy-N-(3 -( 1 -methyl -lH-imidazol -5 -yl)- 1,7-naphthyridin-6-yl)acetamide [3135];

3- isopropoxy-N-(3 -( 1 -methyl -lH-imidazol -5 -yl)- 1,7-naphthyridin-6-yl)propanamide [3136]; N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)cyclopropanecarboxamide [3137]; N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)cyclohexanecarboxamide [3138]; N-(3 -( 1 ,2-dimethyl- lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-4,4-difluorocyclohexane- 1 - carboxamide [3139];

(S)-N-(3 -( 1 ,2-dimethyl- lH-imidazol-5 -yl)- 1,7-naphthyridin-6-yl)tetrahydrofuran-2 -carboxamide

[3140];

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-3,3-difluorocyclobutane-l- carboxamide [3141];

N-(3 -( 1 ,2-dimethyl- lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)- 1 -fluorocyclopropane-1 - carboxamide [3142];

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)moφholine-4-carboxamide [3143]; N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)moφholine-ίs-4-carboxamide

[3144];

1 -methyl -N-(3 -( 1 -methyl-lH-imidazol-5 -yl)- 1,7-naphthyridin-6-yl)-lH-pyrazole-4-carboxamide

[3145];

l-ethyl-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-lH-pyrazole-4-carboxamide

[3146];

1 -isopropyl-N-(3 -( 1 -methyl- lH-imidazol-5-yl)- 1,7-naphthyridin-6-yl)- lH-pyrazole-4- carboxamide [3147];

1 -cyclopropyl-N-(3 -( 1 -methyl -lH-imidazol -5 -yl)- 1,7-naphthyridin-6-yl)- lH-pyrazole-4- carboxamide [3148];

l-isobutyl-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-lH-pyrazole-4-carboxamide

[3149];

1 -methyl -N-(3 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1,7 -naphthyridin-6 -yl) - 1 H-pyrazole -3 -carboxamide

[3150];

N-(3 -( 1 -methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-( 1 -methyl- lH-pyrazol-4-yl)

acetamide [3151];

1 -methyl -N-(3 -( 1 -methyl-lH-imidazol-5 -yl)- 1,7-naphthyridin-6-yl)-lH-imidazole-4 -carboxamide

[3152];

1 -isopropyl-N -(3 -( 1 -methyl- lH-imidazol-5-yl)- 1,7-naphthyridin-6-yl)- lH-imidazole-4- carboxamide [3153]; N-(3 -( 1 -methyl-lH-imidazol-5-yl)-l ,7-naphthyridin-6-yl)- 1 -(tetrahydro-2H-pyran-4-yl)- 1H- imidazole-4-carboxamide [3154];

1 ,2-dimethyl-N-(3 -( 1 -methyl -lH-imidazol -5 -yl)- 1 ,7-naphthyridin-6-yl)- lH-imidazole-5- carboxamide [3155];

1 -methyl -N-(3 -( 1 -methyl-lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)-lH-l ,2,4-triazole-3 - carboxamide [3156];

2-methyl-N-(3 -( 1 -methyl-lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)oxazole-4-carboxamide

[3157] ;

2-isopropyl-N-(3 -( 1 -methyl- lH-imidazol-5-yl)- 1 ,7-naphthyridin-6-yl)oxazole-4 -carboxamide

[3158] ;

4-methyl-N-(3 -( 1 -methyl-lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)oxazole-2 -carboxamide

[3159] ;

4-methyl-N-(3 -( 1 -methyl-lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)thiazole-2 -carboxamide

[3160] ;

2-methyl-N-(3 -( 1 -methyl-lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)thiazole-4 -carboxamide

[3161] ;

5 -methyl -N-(3 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 ,7 -naphthyridin-6 -yl) - 1 , 3 ,4 -oxadiazole -2 - carboxamide [3162];

5 -methyl -N-(3 -( 1 -methyl - 1 H-imidazol-5 -yl) - 1 ,7 -naphthyridin-6 -yl) - 1 , 3 ,4 -thiadiazole -2 - carboxamide [3163];

1 -isopropyl-N-(3 -( 1 -isopropyl- lH-imidazol-5-yl)- 1 ,7-naphthyridin-6-yl)- lH-pyrazole-4- carboxamide [3164];

N-(3 -( 1 ,2-dimethyl- lH-imidazol-5-yl)-l ,7-naphthyridin-6-yl)- 1 -methyl- lH-pyrazole-4- carboxamide [3165];

N-(3-( l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-l-isopropyl-lH-pyrazole-4- carboxamide [3166];

N-(3-( l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-methylthiazole-5-carboxamide

[3167] ;

4-fluoro-N-(3 -( 1 -methyl- lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)benzamide [3168] ;

4-fluoro-N-(3-( l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)benzamide-2,3,5,6-£/4 [3169] ; 2-chloro-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)benzamide-3,4,5,6-£/4 [3170]; 4-chloro-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)benzamide-2,3,5,6-£/4 [3171]; 4-(methyl-c? 3) -N-(3 -( 1 -methyl - 1 H-imidazol -5 -yl) - 1 , 7-naphthyridin-6 -yl)benzamide [3172] ; 4-methyl-N-(3 -( 1 -methyl-lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)benzamide-2,3 ,5,6-d4 [3173] ; 4-(methyl-d3)-N-(3-( 1 -methyl- lH-imi

[3174];

4-(methoxy-£/3)-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)benzamide [3175]; 4-(methoxy- 3)-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)benzamide-2,3,5,6-ii4

[3176];

4-methoxy-N-(3 -( 1 -methyl- lH-imidazol -5 -yl)- 1 ,7-naphthyridin-6-yl)benzamide-2,3,5,6-<¾

[3177];

(E)-N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-3-(phenyl-2,3,4,5,6- j)

acrylamide [3178];

(E)-N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-3-(phenyl-2,3,4,5,6- j)

acrylamide-2,3-£/2 [3179];

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-(4-fluorophenyl)acetamide-2,2- d2 [3180];

(E)-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-3-(phenyl-2,3,4,5,6-£/j)acrylamide

[3181];

(E)-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-3-(phenyl-2,3,4,5,6-£/j)acrylamide- 2,2-d2 [3182];

2-(4-fluorophenyl)-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)acetamide-2,2-£/2

[3183];

N-(3 -( 1 -methyl-lH-imidazol-5-yl)-l ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [3184];

2-(dimethylamino)-N-(3 -( 1 -methyl- lH-imidazol-5-yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide

[3185];

2-(3 -aminoazetidin- 1 -yl)-N-(3 -( 1 -methyl -lH-imidazol -5 -yl)- 1 ,7-naphthyridin-6-yl)

isonicotinamide [3186];

N-(3 -( 1 -methyl-lH-imidazol-5-yl)- 1 ,7-naphthyridin-6-yl)-2-(pyrrolidin- 1 -yl)isonicotinamide

[3187];

N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-(piperidin-l-yl)isonicotinamide

[3188];

N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-moφholinoisonicotinamide [3189]; 2-(4-isopropylpiperazin- 1 -yl)-N-(3-( 1 -methyl- lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)

isonicotinamide [3190];

2-(4-cyclopropylpiperazin- 1 -yl)-N-(3-( 1 -methyl- lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)

isonicotinamide [3191]; N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-(2,7-diazaspiro[3.5]nonan-2-yl) isonicotinamide [3192];

N-(3-(l-methyl-lH midazol-5-yl)-l,7-naphthyridin-6-yl)-2-(7-methyl-2,7-diazaspiro[3.5]nonan-

2-yl)isonicotinamide [3193];

N-(3-(l-methyl-lH midazol-5-yl)-l,7-naphthyridin-6-yl)isoindoline-5-carboxamide [3194] ; 2-methyl-N-(3 -( 1 -methyl-lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)isoindoline-5 -carboxamide

[3195] ;

2-(azetidin- 1 -yl)-N-(3 -( 1 -methyl-lH-imidazol-5-yl)-l ,7-naphthyridin-6-yl)isonicotinamide

[3196] ;

2-methoxy-N-(3 -( 1 -methyl- IH-imidazol -5 -yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide [3197] ; 2-methyl-N-(3 -( 1 -methyl-lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide [3198] ; 2-cyano-N-(3 -( 1 -methyl-lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide [3199] ; 2-(3,3-difluoroazetidin-l-yl)-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)

isonicotinamide [3200];

2-(4,4-difluoropiperidin-l -yl)-N-(3 -( 1 -methyl- lH-imidazol-5 -yl)- 1 ,7-naphthyridin-6-yl)

isonicotinamide [3201];

2-isopropoxy-N-(3 -( 1 -methyl -IH-imidazol -5 -yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide [3202] ; N-(3 -( 1 -methyl-lH-imidazol-5-yl)- 1 ,7-naphthyridin-6-yl)-2-(pyrrolidin- 1 -yl -2,2,5, 5-<¾)

isonicotinamide [3203];

N-(3 -( 1 -methyl-lH-imidazol-5-yl)- 1 ,7-naphthyridin-6-yl)-2-(pyrrolidin- 1 -yl-<¾)isonicotinamide

[3204] ;

N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-(piperidin-l-yl-£/;o)isonicotinamide

[3205] ;

N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-(moφholino-ί s)isonicotinamide

[3206] ;

N-(3 -( 1 ,2-dimethyl- lH-imidazol-5-yl)-l ,7-naphthyridin-6-yl)-4-isopropoxybenzamide [3207] ; N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-4-(piperidin-4-yloxy)benzamide

[3208] ;

4-(benzyloxy)-N-(3-( 1 ,2-dimethyl- lH-imidazol-5-yl)- 1 ,7-naphthyridin-6-yl)benzamide [3209] ; N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-fluorobenzamide-3,4,5,6-£/4

[3210] ;

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-4-fluorobenzamide-2,3,5,6-£/4

[3211] ; 2-chloro-N-(3-(l,2-dimethyl-lH midazol-5-yl)-l -naphthyridin-6-yl)benzamide-3 ,4,5,6-<¾

[3212] ;

4-chloro-N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l -naphthyridin-6-yl)benzamide-2,3,5,6-<¾

[3213] ;

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-4-(methyl-ii3)benzamide [3214]; N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthy^

[3215] ;

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthy^

[3216] ;

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-4-(methoxy-d3)benzamide [3217] ; N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthy^

d4 [3218] ;

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthy^

[3219] ;

N-(3 -( 1 ,2-dimethyl- lH-imidazol-5-yl)-l ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [3220];

[3221] ;

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthy^

[3222] ;

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-(dimethylamino)isoni

[3223] ;

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-(pyrrolidin-l-yl-2,2,5,5-ii4) isonicotinamide [3324];

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-(pyrrolidin-l-yl-£/s)

isonicotinamide [3225];

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-(piperidin-l-yl-£/;o)

isonicotinamide [3226];

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-(moφholino- s)isonicotinamide

[3227] ;

N-(3-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl)

cyclopropanecarboxamide [3228];

N-(3-(7-methyl-5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl)

cyclopropanecarboxamide [3229]; 3,3-difluoro-N-(3-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl) cyclobutane-l-carboxamide [3230];

(R)-N-(3-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l ,7-naphthyridin-6-yl)pyrrolidine-2- carboxamide [3231];

(R)-N-(3 -(5,6,7,8-tetrahydroimidazo[ 1 ,2-a]pyrazin-3-yl)- 1 ,7-naphthyridin-6-yl)piperidine-3 - carboxamide [3232];

l-methyl-N-(3-(5,6,7,8-tetrahydroimidazo[l,2-a]py

4-carboxamide [3233];

N-(3-(5,6J,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl)-l-((l-

(trifluoromethyl)cyclopropyl)methyl)piperidine-4-carboxamide [3234];

1- benzoyl-N-(3-(5,6J,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl)piperidine-

4-carboxamide [3235];

4-fluoro-l-isobutyl-N-(3-(5,6J,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl) piperidine-4-carboxamide [3236];

(R)-2-(2-methylpyrrolidin-l-yl)-N-(3-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-l,7- naphthyridin-6-yl)acetamide [3237] ;

2- (cyclobutyl(methyl)amino)-N-(3-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,7- naphthyridin-6-yl)acetamide [3238] ;

4-fluoro-N-(3-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl)benzamide

[3239];

4-isopropoxy-N-(3-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-l,7-naphthyridin-6-yl)

benzamide [3240];

4-(difluoromethoxy)-N-(3-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-l,7-naphthyridin-6- yl)benzamide [3241];

2-((2-(dimethylamino)ethyl)amino)-N-(3-(5,6J,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-l,7- naphthyridin-6-yl)isonicotinamide [3242] ;

2-(( 1 -isopropylpiperidin-4-yl)oxy)-N-(3 -(5,6,7,8-tetrahydroimidazo[ 1 ,2-a]pyrazin-3 -yl)- 1 ,7- naphthyridin-6-yl)isonicotinamide [3243] ;

N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)- 1 -(3,3,3 -trifluoropropyl)piperidine -4 -carboxamide

[3244];

N-(3-(oxazol-5-yl)-l,7-naphthyridin-6-yl)cyclopropanecarboxamide [3245];

(R)-N-(3 -(oxazol-5 -yl)-l ,7-naphthyridin-6-yl)tetrahydrofuran-2 -carboxamide [3246] ;

(R)-N-(3-(oxazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-3-carboxamide [3247];

N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)tetrahydro-2H-pyran -4 -carboxamide [3248] ; N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)- 1 -(2-(pyrrolidin- 1 -yl)acetyl)piperidine-4-carboxamide

[3249];

1 '-methyl -N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)-[ 1 ,4'-bipiperidine] -4-carboxamide [3250] ; c/. ·-4-moφholino-N-(3-(oxazol-5-yl)-l,7-naphthyridin-6-yl)cyclohexane-l-carboxamide [3251]; 2-(cyclobutyl(methyl)amino)-N-(3-(oxazol-5-yl)-l,7-naphthyridin-6-yl)acetamide [3252];

N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)-2-(pyrrolidin- 1 -yl)acetamide [3253] ;

(R)-2-(2-methylpyrrolidin- 1 -yl)-N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)acetamide [3254] ; 2-(4-methylpiperazin- 1 -yl)-N-(3-(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)acetamide [3255] ;

fr «5-4-((4-methylpiperazin-l-yl)methyl)-N-(3-(oxazol-5-yl)-l,7-naphthyridin-6-yl)cyclohexane- 1-carboxamide [3256];

1- (2,2-difluoropropyl)-N-(3-(oxazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide

[3257];

4-(difluoromethoxy)-N-(3 -( 1 -methyl- lH-imidazol-5-yl)-l ,7-naphthyridin-6-yl)benzamide [3258] ; N-(3 -( 1 -methyl-lH-imidazol-5-yl)- 1 ,7-naphthyridin-6-yl)-3-(pyrrolidin- 1 -ylmethyl)benzamide

[3259];

2- fluoro-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)benzamide-3,4,5,6-£/4 [3260]; fr «5-4-(hydroxymethyl)-N-(3-(2-methyloxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)cyclohexane- 1 - carboxamide [3261];

trans -4 -(methylamino) -N-(3 -(2 -methyloxazol -5 -yl) - 1 , 7-naphthyridin-6-yl)cyclohexane - 1 - carboxamide [3262];

fr «5-4-((l,3-difluoropropan-2-yl)amino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl) cyclohexane-1 -carboxamide [3263];

fr «5-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)-4-((propan-2-yl-l, l,l,3,3,3-£/6)

amino)cyclohexane-l -carboxamide [3264];

fr «5-4-((2,2-difluoroethyl)amino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)

cyclohexane-1 -carboxamide [3265];

fr «5-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)-4-((3,3,3- trifluoropropyl)amino)cyclohexane - 1 -carboxamide [3266] ;

fr «5-4-((2-methoxyethyl)amino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)

cyclohexane-1 -carboxamide [3267];

fr «5-4-(dimethylamino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)cyclohexane-l- carboxamide [3268];

fr «5-4-(bis(methyl-£/3)amino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)cyclohexane-l- carboxamide [3269]; c/5-4-(dimethylamino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)cyclohexane-l- carboxamide [3270];

fr «5-4-((2,2-difluoroe1hyl)(methyl)amino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl) cyclohexane-1 -carboxamide [3271];

fr «5-4-(methyl(oxetan-3-yl)amino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)

cyclohexane-1 -carboxamide [3272];

trans -4 -((2-fluoroethyl)amino) -N-(3 -(2 -methyloxazol -5 -yl) - 1 , 7-naphthyridin-6 -yl)cyclohexane-l- carboxamide [3273];

fr «5-4-(2-(fluoromethyl)aziridin-l-yl)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)

cyclohexane-1 -carboxamide [3274];

trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N-(3-(2-methyloxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)

cyclohexane-1 -carboxamide [3275];

fr «5-N-(3-(2-methyloxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)-3-morpholinocyclobutane- 1 - carboxamide [3276];

fr rø-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)-4-moφholinocyclohexane-l- carboxamide [3277];

N-(3 -(2-methyloxazol-5-yl)- 1 ,7-naphthyridin-6-yl)-2-(piperidin- 1 -yl)acetamide [3278] ;

2-(4-methoxypiperidin-l-yl)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)acetamide

[3279];

N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)acetamide [3280]; N-(3 -(2-methyloxazol-5-yl)- 1 ,7-naphthyridin-6-yl)mo holine-4-carboxamide [3281] ;

N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)-2-mo holinoacetamide [3282];

N-(3 -(2-methyloxazol-5-yl)- 1 ,7-naphthyridin-6-yl)-3 -mo holinopropanamide [3283] ;

1 -methyl -N-(3 -(2 -methyloxazol -5 -yl)- 1 ,7-naphthyridin-6-yl)piperidine-4 -carboxamide [3284] ; 1 -(2,2-difluoropropyl)-N-(3-(2-methyloxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)piperidine-4- carboxamide [3285];

N-(3 -(2-methyloxazol-5-yl)- 1 ,7-naphthyridin-6-yl)-4-moφholinopiperidine- 1 -carboxamide

[3286];

4-((l,3-difluoropropan-2-yl)amino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)

piperidine-1 -carboxamide [3287];

( lR,3s,5 S)-3 -(( 1 ,3-difluoropropan-2-yl)amino)-N-(3 -(2-methyloxazol-5 -yl)- 1 ,7-naphthyridin-6- yl)-8-azabicyclo[3.2.1] octane -8 -carboxamide [3288];

( lR,3s,5 S)-3 -(( 1 ,3-difluoropropan-2-yl)amino)-N-(3 -(2-methyloxazol-5 -yl)- 1 ,7-naphthyridin-6- yl)-8-azabicyclo[3.2.1] octane -8 -carboxamide [3289]; 4-(dimethylamino) -N-(3 -(2 -methyloxazol -5 -yl) - 1 ,7 -naphthyridin-6 -yl)piperidine - 1 -carboxamide

[3290] ;

4-((2,2-difluoroethyl)(methyl)amino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)

piperidine-1 -carboxamide [3291];

(3S,4S)-4-amino-3-fluoro-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-l- carboxamide [3292];

(3S,4S)-3-fluoro-4-(methylamino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)piperidine- 1 -carboxamide [3293];

(3R,4R)-4-amino-3-fluoro-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-l- carboxamide [3294];

(3R,4R)-3-fluoro-4-(methylamino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-

1 -carboxamide [3295];

4-((2-fluoroethyl)amino)-N-(3-(2-methyloxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)piperidine- 1 - carboxamide [3296];

4-((2,2-difluoroethyl)amino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-l- carboxamide [3297];

(lR,3s,5S)-3-amino-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)-8-azabicyclo[3.2.1] octane-8-carboxamide [3298] ;

(lR,3r,5S)-3-amino-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)-8-azabicyclo[3.2.1] octane-8-carboxamide [3299] ;

( lR,3r,5 S)-3-((2-fluoroethyl)amino)-N-(3 -(2-methyloxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [3300];

(lR,3r,5S)-3-((2,2-difluoroethyl)amino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [3301];

(lR,3s,5S)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)-3-((3,3,3-trifluoropropyl)amino)-

8 -azabicyclo [3.2.1] octane -8 -carboxamide [3302] ;

(3S,4S)-3-fluoro-4-(isopropylamino)-N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6- yl)piperidine - 1 -carboxamide [3303] ;

N-(3-(2-methyloxazol-5-yl)-l,7-naphthyridin-6-yl)-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H)- carboxamide [3304];

2-methyl-N-(3 -(2 -methyloxazol -5 -yl)- 1 ,7-naphthyridin-6-yl)-5,6-dihydroimidazo[ 1 ,2-a]pyrazine-

7(8H)-carboxamide [3305] ;

N-(3 -(2-methyloxazol-5-yl)- 1 ,7-naphthyridin-6-yl)-2-(mo holino-ί s)acetamide [3306] ; fra«s-N-(3-(2-methyloxazol-4-yl)- 1 ,7-naphthyridin-6-yl)-4-(4-methylpiperazin- 1 -yl)cyclohexane- 1-carboxamide [3307];

N-(3-(2-methyloxazol-5-yl)-l ,7-naphthyridin-6-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [3308];

2- ( lH-imidazol- 1 -yl)-N-(3 -(2-methyloxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)acetamide [3309] ;

4-(difluoromethoxy)-N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)benzamide [3310] ;

3- ((l-methylpiperidin-4-yl)oxy)-N-(3-(oxazol-5-yl)-l ,7-naphthyridin-6-yl)benzamide [3311]; N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide [3312] ;

2-(3-aminoazetidin-l -yl)-N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide [3313] ; 2-(l-methylpiperidin-4-yl)-N-(3-(oxazol-5-yl)-l,7-naphthyridin-6-yl)isonicotinamide [3314]; l'-methyl-N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)-l ',2',3',6'-tetrahydro-[2,4'-bipyridine] -4- carboxamide [3315];

2-(4-methylpiperazin-l-yl)-N-(3-(oxazol-5-yl)-l,7-naphthyridin-6-yl)isonicotinamide [3316]; 2-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-N-(3-(oxazol-5-yl)-l,7-naphthyridin-6-yl)

isonicotinamide [3317];

N-(3 -(oxazol-5 -yl)-l ,7-naphthyridin-6-yl)-2-(2,7-diazaspiro[3.5]nonan-7-yl)isonicotinamide

[3318];

N-(3 -(oxazol-5 -yl)-l J-naphthyridin-6-yl)-2-(piperidin-4-ylamino)isonicotinamide [3319];

2-methyl-N-(3 -(oxazol-5 -yl)-l ,7-naphthyridin-6-yl)isoindoline-5 -carboxamide [3320] ;

N-(3-(oxazol-5-yl)-l ,7-naphthyridin-6-yl)-l,2,3,4-tetrahydroisoquinoline-7-carboxamide [3321]; N-(3-(2-methyloxazol-5-yl)-l ,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[3322];

N-(3-(3-methylisoxazol-5-yl)-l,7-naphthyridin-6-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [3323];

4- fluoro-l-isobutyl-N-(3-(5-methyl-l,3,4-oxadiazol-2-yl)-l,7-naphthyridin-6-yl)piperidine-4- carboxamide [3324];

l-isobutyl-N-(3-(5-methyl-l,3,4-oxadiazol-2-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide

[3325];

N-(3-(5-(dimethylamino)-l,3,4-oxadiazol-2-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxami

[3326];

N-(3-(5-(dimethylamino)-l,3,4-oxadiazol-2-yl)-l,7-nap

carboxamide [3327];

N-(3-(5-methyl-l,3,4-oxadiazol-2-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3328]; 3 , 3 -difluoro -N-(3 -(thiazol-5 -yl) - 1 , 7 -naphthyridin-6 -yl)cyclobutane- 1 -carboxamide [3329] ;

2-methyl-N-(3-(thiazol-5-yl)-l,7-naphthyridin-6-yl)-2-azaspiro[3 ]heptane-6-carboxamide

[3330];

1 -fluoro-N-(3 -(thiazol-5 -yl)- 1 ,7-naphthyridin-6-yl)cyclohexane-l -carboxamide [3331] ;

fr «5-4-(dimethylamino)-N-(3 -(thiazol-5-yl)- 1 ,7-naphthyridin-6-yl)cyclohexane- 1 -carboxamide

[3332];

fr «5-4-((3-fluoroazetidin- 1 -yl)methyl)-N-(3 -(thiazol-5 -yl)- 1 ,7-naphthyridin-6-yl)cyclohexane-l - carboxamide [3333];

N-(3 -(thiazol-5-yl)- 1 ,7-naphthyridin-6-yl)azetidine-3-carboxamide [3334] ;

l-methyl-N-(3-(thiazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide [3335];

1 -(2,2-difluoropropyl)-N-(3-(thiazol-5 -yl)- 1 ,7-naphthyridin-6-yl)piperidine-4-carboxamide

[3336];

1- (oxetan-3-yl)-N-(3-(thiazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide [3337];

1 -(2-(pyrrolidin- 1 -yl)acetyl)-N-(3 -(thiazol-5-yl)-l ,7-naphthyridin-6-yl)piperidine-4-carboxamide

[3338];

1 '-methyl -N-(3 -(thiazol-5 -yl)- 1 ,7-naphthyridin-6-yl)-[ 1 ,4'-bipiperidine] -4-carboxamide [3339] ;

2- (pyrrolidin- 1 -yl)-N-(3 -(thiazol-5 -yl)- 1 ,7-naphthyridin-6-yl)propanamide [3340] ;

2-(piperidin-l-yl)-N-(3-(thiazol-5-yl)-l,7-naphthyridin-6-yl)acetamide [3341];

2-(4-methylpiperazin-l-yl)-N-(3-(thiazol-5-yl)-l,7-naphthyridin-6-yl)acetamide [3342];

2-moφholino-N-(3-(thiazol-5-yl)-l,7-naphthyridin-6-yl)acetamide [3343];

4-(piperidin-4-yloxy)-N-(3-(thiazol-5-yl)-l,7-naphthyridin-6-yl)benzamide [3344];

N-(3 -(thiazol-5-yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide [3345] ;

6-(4-methylpiperazin-l-yl)-N-(3-(thiazol-5-yl)-l,7-naphthyridin-6-yl)nicotinamide [3346]; r-methyl-N-(3 -(thiazol-5 -yl)- 1 ,7-naphthyridin-6-yl)- 1 ',2',3 ',6'-tetrahydro-[2,4'-bipyridine] -4- carboxamide [3347];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(3-(thiazol-5 -yl)-l ,7-naphthyridin-6-yl)isonicotinamide

[3348];

2-(4-(dimethylamino)piperidin-l-yl)-N-(3-(thiazol-5-yl)-l,7-naphthyridin-6-yl)isonicotinamide

[3349];

2-(4-methylpiperazin-l-yl)-N-(3-(thiazol-5-yl)-l,7-naphthyridin-6-yl)isonicotinamide [3350]; 2-(( 1 -methylpiperidin-4-yl)thio)-N-(3-(thiazol-5 -yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide

[3351];

N-(3 -(thiazol-5-yl)- 1 ,7-naphthyridin-6-yl)- 1 ,2,3,4-tetrahydroisoquinoline-7 -carboxamide [3352] ; trans-4-(( 1 ,3 -difluoropropan-2-yl)amino)-N-(3 -(5 -methyl- 1 ,3,4-thiadiazol-2-yl)-l ,7- naphthyridin-6-yl)cyclohexane- 1 -carboxamide [3353] ;

N-(3-(2-methylthiazol-5-yl)-l,7-naphthyridin-6-yl)mo holine-4-carboxamide [3354];

N-(3-(2-methylthiazol-5-yl)-l,7-naphthyridin-6-yl)-2-(pyrrolidin-l-yl)acetamide [3355];

2-((lR,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(3-(2-methylthiazol-5-yl)-l,7-naphthyridin-

6-yl)acetamide [3356];

N-(3 -(2-methylthiazol-5-yl)- 1 ,7-naphthyridin-6-yl)-2-moφholinoacetamide [3357] ;

N-(3 -(2-methylthiazol-5 -yl)- 1 ,7-naphthyridin-6-yl)-2-(moφholino-ί s)acetamide [3358] ;

2-(4-methylpiperazin-l-yl)-N-(3-(2-methylthiazol-5-yl)-l,7-naphthyridin-6-yl)acetamide [3359];

1- methyl-N-(3-(2-methylthiazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide [3360]; N-(3 -(2-methylthiazol-5-yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide [3361] ;

N-(3 -(2-methylthiazol-5 -yl)- 1 ,7-naphthyridin-6-yl)nicotinamide [3362] ;

2- (4-methylpiperazin-l-yl)-N-(3-(2-methylthiazol-5-yl)-l,7-naphthyridin-6-yl)isonicotinamide

[3363];

fr rø-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-4-moφholinocyclohexane-l- carboxamide [3364];

fr «5-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-4-(4-methylpiperazin-l-yl) cyclohexane-1 -carboxamide [3365];

4-isopropyl-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)piperazine-l- carboxamide [3366];

4-((2-methoxyethyl)(methyl)amino)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl) piperidine-1 -carboxamide [3367];

4-(( 1 ,3 -difluoropropan-2-yl)amino)-N-(3-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl) piperidine-1 -carboxamide [3368];

N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl)-4-((3,3,3-trifluoropropyl)amino) piperidine-1 -carboxamide [3369];

4-((2-fluoroethyl)amino)-N-(3-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)piperidine-

1 -carboxamide [3370];

(3R,4S)-4-amino-3-fluoro-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)

piperidine-1 -carboxamide [3371];

(3R,4R)-4-amino-3-fluoro-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)

piperidine-1 -carboxamide [3372];

(3S,4S)-3-fluoro-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-4-(methylamino) piperidine-1 -carboxamide [3373]; (3R,4R)-3 -fluoro-N-(3-(5 -methyl- 1 ,3 ,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)-4-(methylamino) piperidine-l-carboxamide [3374];

4-amino-3,3-difluoro-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)piperidine-l- carboxamide [3375];

(3R,4R)-3-fluoro-4-(isopropylamino)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6- yl)piperidine-l-carboxamide [3376];

(3R,4S)-3 -fluoro-4-(isopropylamino)-N-(3 -(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)-l ,7-naphthyridin-6- yl)piperidine-l-carboxamide [3377];

3,3-difluoro-4-(isopropylamino)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl) piperidine-l-carboxamide [3378];

(3S,4S)-3-fluoro-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-4-((propan-2-yl-

1, 1, 1 ,3 ,3 ,3 -d6)amino)piperidine- 1 -carboxamide [3379] ;

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7- naphthyridin-6-yl)-8-azabicyclo[3.2. l]octane-8-carboxamide [3380];

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7- naphthyridin-6-yl)-8-azabicyclo[3.2.1]octane-8-carboxamide [3381];

4-(dimethylamino)-N-(3-(2-methylthiazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-l-carboxamide

[3382];

4-((2,2-difluoroethyl)amino)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)

piperidine-l-carboxamide [3383];

4-((2,2-difluoroethyl)(methyl-d3)amino)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-

6-yl)piperidine-l -carboxamide [3384];

N-(3 -(5-methyl-l ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)-4-mo holinopiperidine- 1 - carboxamide [3385];

N-(3 -(5-methyl-l ,3,4-thiadiazol -2 -yl)- 1 ,7-naphthyridin-6-yl)-4-(4-methylpiperazin- 1 -yl)

piperidine-l-carboxamide [3386];

(R)-3,4-dimethyl-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)piperazine-l- carboxamide [3387];

(S)-3,4-dimethyl-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)piperazine-l- carboxamide [3388];

(lR,3r,5S)-3-((2-fluoroethyl)amino)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6- yl)-8-azabicyclo[3.2. l]octane-8-carboxamide [3389];

(lR,3r,5S)-3-((2,2-difluoroethyl)amino)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-

6-yl)-8-azabicyclo[3.2. l]octane-8-carboxamide [3390]; ( lR,3r,5 S)-3-amino-N-(3 -(5-methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)-8-azabicyclo

[3.2.1] octane -8 -carboxamide [3391];

( 1 S,4S)-5 -methyl -N-(3 -(5 -methyl-1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)-2,5-diazabicyclo

[2.2. l]heptane-2 -carboxamide [3392];

(lR,4R)-5-methyl-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-2,5-diazabicyclo

[2.2. l]heptane-2 -carboxamide [3393];

8-methyl-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-3,8-diazabicyclo[3.2.1] octane-3 -carboxamide [3394];

3-methyl-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-3,8-diazabicyclo[3.2.1] octane-8-carboxamide [3395];

N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl)-5,6-dihydroimidazo[l,2-a]pyrazine-

7(8H)-carboxamide [3396];

2-(4-methylpiperazin-l-yl)-N-(3-(5-methylthiazol-2-yl)-l,7-naphthyridin-6-yl)isonicotinamide

[3397];

2-(4-methylpiperazin- 1 -yl)-N-(3-(4-methylthiazol-2-yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide

[3398];

N-(3 -(2-(methylamino)thiazol-5 -yl)-l ,7-naphthyridin-6-yl)piperidine-4 -carboxamide [3399] ;

1- methyl-N-(3-(2-(methylamino)thiazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide

[3400];

N-(3 -(2-(diethylamino)thiazol-5-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-fluoropiperidin- 1 -yl)acetamide

[3401];

N-(3 -(2-(diethylamino)thiazol-5-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)acetamide

[3402];

N-(3-(2-aminothiazol-5-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[3403];

N-(3-(2-(methylamino)thiazol-5-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3404];

N-(3 -(2-(dimethylamino)thiazol-5 -yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l -yl)

isonicotinamide [3405];

2- (4-isopropylpiperazin-l-yl)-N-(3-(2-(methylamino)thiazol-5-yl)-l,7-naphthyridin-6-yl)

isonicotinamide [3406];

2-(3-(dimethylamino)azetidin-l-yl)-N-(3-(2-(methylamino)thiazol-5-yl)-l,7-naphthyridin-6-yl) isonicotinamide [3407]; 2-(3 -(dimethylamino)azetidin-l -yl)-N-(3-(2-(dimethylamino)thiazol-5 -yl)- 1 ,7-naphthyridin-6-yl) isonicotinamide [3408];

2-(3 -aminoazetidin- 1 -yl) -N-(3 -(2-(dimethylamino)thiazol-5 -yl)- 1 ,7-naphthyridin-6-yl)

isonicotinamide [3409];

N-(3 -(5 -chlorothiazol-2-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide

[3410];

2-(6-(2-(4-methylpiperazin-l-yl)isonicotinamido)-l,7-naphthyridin-3-yl)thiazole-5-carboxamide

[3411];

N-(3 -(isothiazol-4-yl)- 1 ,7-naphthyridin-6-yl)-l -methylpiperidine-4-carboxamide [3412] ;

N-(3-(l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-4-(difluoromethoxy)benzamide [3413]; N-(3-(l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-4-(piperidin-4-yloxy)benzamide [3414]; N-(3-(l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-4-((l-methylpiperidin-4-yl)oxy)benzamide

[3415];

N-(3-(l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-3-((l-methylpiperidin-4-yl)oxy)benzamide

[3416];

N5-(3 -( 1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)-N2-methylpyridine-2,5-dicarboxamide

[3417];

N-(3 -( 1 , 3 ,4-thiadiazol -2 -yl) - 1 , 7-naphthyridin-6 -yl) -6 -(4-methylpiperazin- 1 -yl)nicotinamide

[3418];

N-(3-(l,3,4-thiadiazol-2-yl)-l -naphthyridin-6-yl)-l'-methyl-l',2',3',6'-tetrahydro-[2,4'- bipyridine] -4 -carboxamide [3419];

N-(3 -( 1 ,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl)-2-(3-(dimethylamino)azetidin- 1 -yl)

isonicotinamide [3420];

N-(3-(l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[3421];

N-(3-(l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-2-(4-isopropylpiperazin-l-yl)isonicotinamide

[3422];

N-(3-(l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-2-mo holinoisonicotinamide [3423];

1 -fluoro-N-(3 -(5-methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)cyclohexane-l - carboxamide [3424];

fr «5-4-methoxy-N-(3-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl)cyclohexane- 1 - carboxamide [3425];

c/5-4-methoxy-N-(3 -(5-methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)cyclohexane- 1 - carboxamide [3426]; fr «5-4-amino-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl)cyclohexane-l- carboxamide [3427];

fr «5-4-(dimethylamino)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl)

cyclohexane-l-carboxamide [3428];

fr rø-N-(3-(5-methyl-l,3,4 hiadiazol-2-yl)-l,7-naphthyridin-6-yl)-4-moφholinocyclohexane-l- carboxamide [3429];

fr «5-4-(hydroxymethyl)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)

cyclohexane-l-carboxamide [3430];

N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide [3431]; 4-fluoro-N-(3 -(5-methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4-carboxamide

[3432];

1 -methyl -N-(3 -(5 -methyl-1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4-carboxamide

[3433];

4-fluoro-l-methyl-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)piperidine-4- carboxamide [3434];

1 -(2-fluoroethyl)-N-(3-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4- carboxamide [3435];

l-(2,2-difluoroethyl)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)piperidine-4- carboxamide [3436];

N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl)-l-(3,3,3-trifluoropropyl)piperidine- 4-carboxamide [3437];

l-(2,2-difluoropropyl)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)piperidine-4- carboxamide [3438];

1- benzoyl-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide

[3439];

N-(3 -(5-methyl-l ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)-2-(pyrrolidin- 1 -yl)acetamide

[3440];

N-(3 -(5-methyl-l ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)-2-(piperidin- 1 -yl)acetamide [3441] ;

2- (4-methoxypiperidin-l-yl)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)

acetamide [3442];

N-(3 -(5-methyl-l ,3,4-thiadiazol -2 -yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

acetamide [3443];

N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-2-mo holinoacetamide [3444]; (R)-N-(3-(5-methyl-l,3,4 hiadiazol-2-yl)-l,7-naphthyridin-6-yl)-2-(3-methylmoφholino) acetamide [3445];

2-(7-azabicyclo[2.2 ]heptan-7-yl)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl) acetamide [3446];

2-((lR,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7- naphthyridin-6-yl)acetamide [3447] ;

2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-

6-yl)acetamide [3448];

2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l ,7-naphthyridin- 6-yl)acetamide [3449];

N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl)-2-(l,4-oxazepan-4-yl)acetamide

[3450];

N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl)-2-mo holinoacetamide-2,2-ί 2

[3451];

N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl)-2-(mo holino-ί s)acetamide [3452]; 1 -methyl-3-(3 -(5 -methyl-1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)- 1 -( 1 -methylpiperidin-4-yl) urea [3453];

(3S,4S)-4-amino-3-fluoro-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)

piperidine-1 -carboxamide [3454];

(3S,4S)-4-(dimethylamino)-3-fluoro-N-(3-(5^

piperidine-1 -carboxamide [3455];

N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl)mo holine-4-carboxamide [3456]; N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl)-4-(methylamino)piperidine-l- carboxamide [3457];

4-(dimethylamino)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl)piperidine-l- carboxamide [3458];

4-((2,2-difluoroethyl)(methyl)amino)-N-(3-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6- yl)piperidine - 1 -carboxamide [3459] ;

(3S,4S)-3-fluoro-4-(isopropylamino)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6- yl)piperidine - 1 -carboxamide [3460] ;

2-methyl-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-5,6-dihydroimidazo[l,2-a] pyrazine-7(8H)-carboxamide [3461];

4-methyl-N-(3 -(5 -methyl-1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)piperazine- 1 -carboxamide

[3462]; N-(3 -(5-methyl-l ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- pyrazole-4-carboxamide [3463];

1 -( 1 -isopropylpiperidin-4-yl)-N-(3-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)- 1H- pyrazole-4-carboxamide [3464];

N-(3 -(5-methyl-l ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- l,2,3-triazole-4-carboxamide [3465];

N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-2-(piperidin-4-yl)oxazole-4- carboxamide [3466];

N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-2-(l-methylpiperidin-4-yl)oxazole- 4-carboxamide [3467];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(3-(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)-l ,7-naphthyridin-6-yl) isonicotinamide [3468];

r-methyl-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-l',2',3',6'-tetrahydro-[2,4'- bipyridine] -4 -carboxamide [3469] ;

N-(3 -(5-methyl-l ,3,4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [3470];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(3 -(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)-l ,7- naphthyridin-6-yl)isonicotinamide [3471] ;

2-(azetidin-3-yloxy)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)isonicotinamide

[3472];

N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-3-((l-methylpiperidin-4-yl)oxy) benzamide [3473];

N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-2-((l-methylpiperidin-4-yl)thio) isonicotinamide [3474];

6-(4-methylpiperazin-l-yl)-N-(3-(5-(trifluoromethyl)-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6- yl)nicotinamide [3475];

2-(4-methylpiperazin-l-yl)-N-(3-(5-(trifluoromethyl)-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6- yl)isonicotinamide [3476];

N-(3-(5-amino-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3477];

N-(3-(5-(dimethylamino)-l,3,4-thiadiazol-2-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l- yl)isonicotinamide [3478];

N-(3 -(3-amino-5 -fluorophenyl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [3479]; N-(3-(3-fluoro-5-(isopropylamino)phenyl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [3480];

1 -methyl -N-(3 -(pyridin-2-yl)-l ,7-naphthyridin-6-yl)piperidine-4-carboxamide [3481] ;

2-(4-methylpiperazin-l -yl)-N-(3 -(pyridin-2-yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide [3482] ; 2-(4-methylpiperazin-l -yl)-N-(3 -(pyridin-4-yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide [3483] ; N-(3 -(pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)cyclopropanecarboxamide [3484] ;

N-(3 -(pyridin-3 -yl) - 1 , 7 -naphthyridin-6 -yl) -2 -(pyrrolidin- 1 -yl)acetamide [3485] ;

1 -methyl -N-(3 -(pyridin-3 -yl)-l ,7-naphthyridin-6-yl)piperidine-4-carboxamide [3486] ;

N-(3 -(pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)quinuclidine-4-carboxamide [3487] ;

2-morpholino-N -(3 -(pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)acetamide [3488] ;

2-(moφholino-ί s)- -(3-(pyridin-3-yl)-l,7-naphthyridin-6-yl)acetamide [3489];

2-(4-methylpiperazin-l -yl)-N-(3 -(pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)acetamide [3490] ;

2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(3-(pyridin-3-yl)- 1 ,7-naphthyridin-6-yl)acetamide [3491] ; 2-(4-methylpiperazin-l -yl)-N-(3 -(pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)isonicotinamide [3492] ; 2-(2 -methyl- IH-imidazol- 1 -yl)-N-(3-(pyridin-3-yl)- 1 ,7-naphthyridin-6-yl)acetamide [3493] ; 2-(lH-imidazol-l-yl)-N-(3-(pyridin-3-yl)-l,7-naphthyridin-6-yl)acetamide [3494];

2-(piperidin-4-yl)-N-(3-(pyridin-3-yl)-l,7-naphthyridin-6-yl)oxazole-4-carboxamide [3495]; 2-( 1 -methylpiperidin-4-yl)-N-(3 -(pyridin-3 -yl)-l ,7-naphthyridin-6-yl)oxazole-4-carboxamide

[3496];

2-(l-isopropylpiperidin-4-yl)-N-(3-(pyridin-3-yl)-l,7-naphthyridin-6-yl)oxazole-4-carboxamide

[3497];

fr rø-N-(3-(5-fluoropyridin-3-yl)-l,7-naphthyridin-6-yl)-3-moφholinocyclobutane-l- carboxamide [3498];

fr «5-N-(3-(5-fluoropyridin-3-yl)-l,7-naphthyridin-6-yl)-4-((4-methylpiperazin-l-yl)methyl) cyclohexane-l-carboxamide [3499];

N-(3 -(5-fluoropyridin-3 -yl)-l ,7-naphthyridin-6-yl)-2-(pyrrolidin- 1 -yl)acetamide [3500] ;

N-(3 -(5-fluoropyridin-3 -yl)-l ,7-naphthyridin-6-yl)- 1 -methylpiperidine-4-carboxamide [3501] ; N-(3-(5-fluoropyridin-3-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)acetamide [3502]; N-(3-(6-fluoropyridin-3-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)acetamide [3503]; N-(3-(5-fluoropyridin-3-yl)-l,7-naphthyridin-6-yl)-2-moφholinoacetamide [3504];

N-(3-(5-fluoropyridin-3-yl)-l,7-naphthyridin-6-yl)-3-moφholinopropanamide [3505];

N-(3-(5-fluoropyridin-3-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[3506]; N-(3-(5-fluoropyridin-3-yl)-l ,7-naphthyridin-6-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide [3507];

N-(3-(5-fluoropyridin-3-yl)-l,7-naphthyridin-6-yl)-2-(l-methylpiperidin-4-yl)oxazole-4- carboxamide [3508];

N-(3-(5-fluoropyridin-3-yl)-l,7-naphthyridin-6-yl)-2-(l-isopropylpiperidin-4-yl)oxazole-4- carboxamide [3509];

N-(3-(5-chloropyridin-3-yl)-l ,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[3510];

N-(3-(5-methylpyridin-3-yl)-l,7-naphthyridin-6-yl)-2-moφholinoacetamide [3511];

N-(3-(5-(difluoromethyl)pyridin-3-yl)-l ,7-naphthyridin-6-yl)-3-(piperidin-4-yl)benzamide

[3512];

N-(3 -(5-(difluoromethyl)pyridin-3-yl)- 1 ,7-naphthyridin-6-yl)-3 -( 1 -methylpiperidin-4-yl)

benzamide [3513];

N-(3 -(5-(difluoromethyl)pyridin-3-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [3514];

2-(4-methylpiperazin-l-yl)-N-(3-(5-(trifluoromethyl)pyridin-3-yl)-l,7-naphthyridin-6-yl)

acetamide [3515];

2-(4-methylpiperazin-l-yl)-N-(3-(6-(trifluoromethyl)pyridin-3-yl)-l,7-naphthyridin-6-yl)

acetamide [3516];

N-(3-(5-(hydroxymethyl)pyridin-3-yl)-l ,7-naphthyridin-6-yl)-l-methylpiperidine-4-carboxamide

[3517];

N-(3 -(5-cyanopyridin-3 -yl)-l ,7-naphthyridin-6-yl)- 1 -methylpiperidine-4-carboxamide [3518] ; N-(3 -(5-methoxypyridin-3 -yl)-l ,7-naphthyridin-6-yl)- 1 -methylpiperidine-4-carboxamide [3519] ; N-(3 -(5 -methoxypyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)-2-moφholinoacetamide [3520] ;

N-(3 -(5 -methoxypyridin-3 -yl)-l ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide

[3521];

4-fluoro-N-(3-(5-(piperidin-4-yloxy)pyridin-3-yl)-l,7-naphthyridin-6-yl)benzamide [3522]; N-(3 -(5-aminopyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)-4-fluorobenzamide [3523] ;

N-(3-(5-aminopyridin-3-yl)-l,7-naphthyridin-6-yl)-4-(piperidin-4-yloxy)benzamide [3524]; N-(3 -(5-aminopyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide

[3525];

N-(3-(5-aminopyridin-3-yl)-l,7-naphthyridin-6-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide

[3526]; N-(3 -(6-aminopyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)isonicotinamide [3527];

N-(3-(6-(methylamino)pyridin-3-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3528];

N-(3 -(5-(isopropylamino)pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)-3 -(piperidin-4-yl)benzamide

[3529];

N-(3 -(5-(isopropylamino)pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)-3 -( 1 -methylpiperidin-4-yl)

benzamide [3530];

N-(3 -(5-(isopropylamino)pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [3531];

N-(3-(5-(piperidin-4-ylamino)pyridin-3-yl)-l,7-naphthyridin-6-yl)cyclohexanecarboxamide

[3532];

4-fluoro-N-(3-(5-(piperidin-4-ylamino)pyridin-3-yl)-l,7-naphthyridin-6-yl)benzamide [3533]; 4-fluoro-N-(3 -(5-(( 1 -methylpiperidin-4-yl)amino)pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)benzamide

[3534];

N-(3 -(5 -acetamidopyridin-3 -yl) - 1 ,7 -naphthyridin-6 -yl) - 1 -methylpiperidine -4 -carboxamide

[3535];

N-(3-(5-(dimethylamino)pyridin-3-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3536];

N-(3-(6-(dimethylamino)pyridin-3-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3537];

l-methyl-N-(3-(5-(pyrrolidin-l-yl)pyridin-3-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide

[3538];

N-(3 -(5 -(pyrrolidin- 1 -ylmethyl)pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)cyclopropanecarboxamide

[3539];

4-fluoro-N-(3 -(5 -(pyrrolidin- 1 -ylmethyl)pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)benzamide [3540] ; N-(3-(5-((4-hydroxypiperidin-l-yl)methyl)pyridin-3-yl)-l,7-naphthyridin-6-yl)

cyclopropanecarboxamide [3541];

4-fluoro-N-(3-(5-((4-hydroxypiperidin-l-yl)methyl)pyridin-3-yl)-l,7-naphthyridin-6-yl)

benzamide [3542];

N-(3 -(5 -(piperazin- 1 -ylmethyl)pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)cyclopropanecarboxamide

[3543];

N-(3 -(5 -((4-methylpiperazin- 1 -yl)methyl)pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)

cyclopropanecarboxamide [3544]; N-(3-(5-(mo holinomethyl)pyridin-3-yl)-l,7-naphthyridin-6-yl)cyclopropanecarboxamide

[3545];

N-methyl-5-(6-(l-methylpiperidine-4-carboxamido)-l,7-naphthyridin-3-yl)nicotinamide [3546]; N-methyl-5-(6-(2-(4-methylpiperazin-l-yl)isonicotinamido)-l ,7-naphthyridin-3-yl)nicotinamide

[3547];

N-(3 -(pyridin-3 -yl-<¾)- 1 ,7-naphthyridin-6-yl)-2-(pyrrolidin-l -yl)acetamide [3548] ;

2-(4-methylpiperazin- 1 -yl)-N -(3 -(pyridin-3 -yl-<¾)- 1 ,7-naphthyridin-6-yl)acetamide [3549] ;

2-moφholino-N-(3-(pyridin-3-yl-ί 4)-l,7-naphthyridin-6-yl)acetamide [3550];

1 -methyl -N-(3 -(2-methylpyrimidin-5 -yl)- 1 ,7-naphthyridin-6-yl)piperidine-4-carboxamide [3551] ; 2-(4-methylpiperazin-l-yl)-N-(3-(2-methylpyrimidin-5-yl)-l,7-naphthyridin-6-yl)isonicotinamide

[3552];

N-(3-(2-aminopyrimidin-5-yl)-l,7-naphthyridin-6-yl)-l-methylpiperidine-4-carboxamide [3553]; 2-moφholino-N-(3-(pyridazin-3-yl)-l,7-naphthyridin-6-yl)acetamide [3554];

2-moφholino-N-(3-(pyridazin-4-yl)-l,7-naphthyridin-6-yl)acetamide [3555];

N-(3 -(pyridazin-4-yl) -1,7 -naphthyridin-6 -yl) -2 -(pyrrolidin- 1 -yl)acetamide [3556] ;

fr rø-3-moφholino-N-(3-(pyrazin-2-yl)-l,7-naphthyridin-6-yl)cyclobutane-l-carboxamide

[3557];

fr «5-4-(dimethylamino)-N-(3 -(pyrazin-2-yl)-l ,7-naphthyridin-6-yl)cyclohexane- 1 -carboxamide

[3558];

fr rø-4-moφholino-N-(3-(pyrazin-2-yl)-l,7-naphthyridin-6-yl)cyclohexane-l-carboxamide

[3559];

trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N-(3-(pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)cyclohexane-

1 -carboxamide [3560];

fr «5-4-((4-methylpiperazin-l-yl)methyl)-N-(3-(pyrazin-2-yl)-l,7-naphthyridin-6-yl)

cyclohexane-1 -carboxamide [3561];

N-(3-(pyrazin-2-yl)-l,7-naphthyridin-6-yl)-2-(pyrrolidin-l-yl)acetamide [3562];

l-methyl-N-(3-(pyrazin-2-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide [3563];

4-fluoro-l -methyl -N-(3-(pyrazin-2-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide [3564];

1- (2-fluoroethyl)-N-(3-(pyrazin-2-yl)-l,7-naphthyridin-6-yl)piperidine-4-carboxamide [3565]; 1 -(oxetan-3-yl)-N-(3 -(pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4-carboxamide [3566] ;

2- moφholino-N-(3-(pyrazin-2-yl)-l,7-naphthyridin-6-yl)acetamide [3567];

1 -methyl -N-(3 -(pyrazin-2 -yl) - 1 , 7-naphthyridin-6 -yl)azepane -4 -carboxamide [3568] ;

l-isobutyl-N-(3-(pyrazin-2-yl)-l,7-naphthyridin-6-yl)azepane-4-carboxamide [3569]; 1 -(2-hydroxy-2-methylpropyl)-N-(3 -(pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)azepane-4-carboxamide

[3570];

4-(moφholinomethyl)-N-(3-(pyrazin-2-yl)-l,7-naphthyridin-6-yl)benzamide [3571];

2-(4-methylpiperazin-l-yl)-N-(3-(pyrazin-2-yl)-l,7-naphthyridin-6-yl)isonicotinami

N-(3 -(6-(methylamino)pyrazin-2-yl)-l ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [3573];

N-(3 -(6-(isopropylamino)pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)azetidine-3-carboxamide [3574] ; N-(3 -(6-(isopropylamino)pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)piperidine-4-carboxamide [3575] ; N-(3 -(6-(isopropylamino)pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)- 1 -methylpiperidine-4-carboxamide

[3576];

l-(2-fluoroethyl)-N-(3-(6-(isopropylamino)pyrazin-2-yl)-l ,7-naphthyridin-6-yl)piperidine-4- carboxamide [3577];

l-isopropyl-N-(3-(6-(isopropylamino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)piperidine-4- carboxamide [3578];

l-isopentyl-N-(3-(6-(isopropylamino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)piperidine-4- carboxamide [3579];

N-(3-(6-(isopropylamino)pyrazin-2-yl)-l ,7-naphthyridin-6-yl)-3-(piperidin-4-yl)benzamide

[3580];

N-(3 -(6-(isopropylamino)pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)-3-( 1 -methylpiperidin-4-yl)

benzamide [3581];

N-(3-(6-(isopropylamino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)-l-(piperidin-4-yl)-lH-l,2,3- triazole-4-carboxamide [3582];

l-(l-(2-fluoroethyl)piperidin-4-yl)-N-(3-(6-(isopropylamino)pyrazin-2-yl)-l,7-naphthyridin-6- yl)- 1H- 1 ,2,3 -triazole-4-carboxamide [3583] ;

N-(3 -(6-(isopropylamino)pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)- 1 -( 1 -isopropylpiperidin-4-yl)-lH- l,2,3-triazole-4-carboxamide [3584];

N-(3 -(6-(isopropylamino)pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [3585];

N-(3-(6-(feri-butylamino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)-2-(3-(dimethylamino)azetidin-l- yl)isonicotinamide [3586];

N-(3-(6-(fert-butylamino)pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)- 1 '-methyl- 1 ',2',3 ',6'-tetrahydro-

[2,4'-bipyridine]-4-carboxamide [3587];

N-(3-(6-(feri-butylamino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3588]; N-(3-(6-(fer^butylamino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)-2-(4-isopropylpiperazin-l-yl) isonicotinamide [3589];

N-(3-(6-(fer^butylamino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)-2-moφholinoisonicotinamide

[3590];

N-(3-(6-(((3-fluoroazetidin-3-yl)methyl)amino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)

cyclopropanecarboxamide [3591];

4-fluoro-N-(3-(6-(((3-fluoroazetidin-3-yl)methyl)amino)pyrazin-2-yl)-l ,7-naphthyridin-6-yl) benzamide [3592];

N-(3-(6-(piperidin-4-ylamino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)cyclobutanecarboxamide

[3593];

3.3- difluoro-N-(3-(6-(piperidin-4-ylamino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)cyclobutane-l- carboxamide [3594];

N-(3-(6-(piperidin-4-ylamino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)cyclopentanecarboxamide

[3595];

4.4- difluoro-N-(3 -(6-(piperidin-4-ylamino)pyrazin-2-yl)-l ,7-naphthyridin-6-yl)cyclohexane- 1 - carboxamide [3596];

N-(3-(6-(piperidin-4-ylamino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)tetrahydro-2H-pyran-4- carboxamide [3597];

4-fluoro-N-(3 -(6-(piperidin-4-ylamino)pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)benzamide [3598] ; N-(3-(6-(((3S,4S)-3-fluoropiperidin-4-yl)amino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)

cyclopropanecarboxamide [3599];

4-fluoro-N-(3-(6-(((3S,4S)-3-fluoropiperidin-4-yl)amino)pyrazin-2-yl)-l,7-naphthyridin-6-yl) benzamide [3600];

N-(3-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)

cyclobutanecarboxamide [3601];

N-(3-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)

cyclopentanecarboxamide [3602];

4-fluoro-N-(3-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)benzamide

[3603];

N-(3-(6-((l-isopropylpiperidin-4-yl)amino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)

cyclopropanecarboxamide [3604];

3,3-difluoro-N-(3-(6-((l-isopropylpiperidin-4-yl)amino)pyrazin-2-yl)-l,7-naphthyridin-6-yl) cyclobutane- 1 -carboxamide [3605] ; N-(3-(6-((1 sopropylpiperidin-4-yl)amino)pyrazin-2-yl)-l,7-naphthyridin-6-yl) cyclopentanecarboxamide [3606];

4-fluoro-N-(3 -(6-(( 1 -isopropylpiperidin-4-yl)amino)pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)

benzamide [3607];

N-(3-(6-(dimethylamino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3608];

N-(3 -(6-(diethylamino)pyrazin-2-yl)-l ,7-naphthyridin-6-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [3609];

N-(3-(6-(3-aminoazetidin-l-yl)pyrazin-2-yl)-l,7-naphthyridin-6-yl)-4-fluorobenzamide [3610]; 2-(4-methylpiperazin- 1 -yl)-N-(3-(6-(pyrrolidin- 1 -yl)pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)

isonicotinamide [3611];

N-(3 -(6-(azetidin-3 -ylmethoxy)pyrazin-2-yl)-l ,7-naphthyridin-6-yl)-4-fluorobenzamide [3612] ; N-(3 -(6-(azetidin-3 -yloxy)pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)-4-fluorobenzamide [3613] ; N-(3 -( lH-pyrrolo[2,3-b]pyridin-5-yl)- 1 ,7-naphthyridin-6-yl)- 1 -( 1 -methylpiperidin-4-yl)-lH- pyrazole-4-carboxamide [3614];

N-(3 -( lH-pyrrolo[3,2-b]pyridin-6-yl)- 1 ,7-naphthyridin-6-yl)- 1 -( 1 -methylpiperidin-4-yl)-lH- pyrazole-4-carboxamide [3615];

N-(3 -( lH-pyrrolo[2,3-c]pyridin-4-yl)-l ,7-naphthyridin-6-yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- pyrazole-4-carboxamide [3616];

N-(3-(lH-pyrrolo[2,3-b]pyridin-5-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3617];

N-(3-(lH-pyrrolo[3,2-b]pyridin-6-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3618];

N-(3-(lH-pyrrolo[2,3-c]pyridin-4-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3619];

2-(4-methylpiperazin-l-yl)-N-(3-(oxazolo[5,4-b]pyridin-6-yl)-l,7-naphthyridin-6-yl)

isonicotinamide [3620];

N-(3-(2-methyl-lH-pyrrolo[2,3-b]pyridin-5-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l- yl)isonicotinamide [3621];

N-(3-(3-methyl-lH-pyrrolo[2,3-b]pyridin-5-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l- yl)isonicotinamide [3622];

N-(3-(2-methyl-lH-pyrrolo[3,2-b]pyridin-6-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l- yl)isonicotinamide [3623]; N-(3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [3624];

N-(3-(5H-pyrrolo[2,3-b]pyrazin-3-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3625];

l-isopropyl-N-(3-(6-(piperidin-4-ylamino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)-lH-pyrazole-4- carboxamide [3626];

l-isopropyl-N-(3-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)-lH- pyrazole-4-carboxamide [3627];

fr «5-4-((2-fluoroethyl)amino)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

cyclohexane-l-carboxamide [4597];

fr «5-4-((2-methoxyethyl)amino)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

cyclohexane-l-carboxamide [4598];

fert-butyl (fr «5-4-((6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)carbamoyl)cyclohexyl) carbamate [4599];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(( 1 -methylpiperidin-4-yl)amino) isonicotinamide [4600];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2 -naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)thiazole-5- carboxamide [4601];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2 -naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)thiazole-5- carboxamide [4602];

N-(6-( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(2,7- diazaspiro[3.5]nonan-2-yl)isonicotinamide [4603] ;

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-4-(piperidin-4-yloxy)benzamide

[4604];

N-(6-(l-methyl-lH etrazol-5-yl)-2J-naphthyridin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [4605];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl)propanamide

[4606];

N-(6-( 1 ,2-dimethyl- lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)-2-(piperidin- 1 -yl)propanamide

[4607];

4-isopropoxy-N-(6-(7-methyl-5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7-naphthyridin-3- yl)benzamide [4608];

trans-3 -mo holino-N-(6-(oxazol-5 -yl)-2,7-naphthyridin-3-yl)cyclobutane- 1 -carboxamide

[4609]; fr «5-4-(hydroxymethyl)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane-l-carboxamide

[4610] ;

N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide [4611];

4-moφholino-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)piperidine-l -carboxamide [4612] ;

N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)-4-(piperidin-4-yloxy)benzamide [4613];

N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)-3-(piperidin-4-yloxy)benzamide [4614];

2-methyl-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)-5,6-dm^

carboxamide [4615];

2-(lH-imidazol-l -yl)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)acetamide [4616];

trans -4 -(hydroxymethyl) -N-(6-(thiazol -5 -yl) -2 ,7 -naphthyridin-3 -yl)cyclohexane - 1 -carboxamide

[4617] ;

fr «5-4-(dimethylamino)-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane-l-carboxamide

[4618] ;

N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)-l -((l -(trifluoromethyl)cyclopropyl)methyl)piperidine- 4-carboxamide [4619];

fr «5-4-(hydroxymethyl)-N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane-l- carboxamide [4620];

fr «5-4-(dimethylamino)-N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane-l- carboxamide [4621];

N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)-l -(oxetan-3-yl)piperidine-4 -carboxamide

[4622] ;

N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)-l -(2-(pyrrolidin-l-yl)acetyl)piperidine-4- carboxamide [4623];

2-((l S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7- naphthyridin-3 -yl)acetamide [4624] ;

N-(6-(5-(cyano(4-hydroxypiperidin-l-yl)methyl)pyridin-3-yl)-2,7-naphthyridin-3-yl)

cyclopropanecarboxamide [4625];

4-fluoro-N-(6-(6-(( l-methylazetidin-3-yl)methoxy)pyrazin-2-yl)-2,7-naphthyridin-3-yl)

benzamide [4626] ;

l-isopropyl-N-(6-(6-(( l-methylpiperidin-4-yl)amino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-lH- pyrazole-4-carboxamide [4627]; or a pharmaceutically acceptable salt thereof.

24. The compound according to any one of claims 1-19, wherein the compound of Formula I is selected from the group consisting of:

N-(6-( lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1 -isobutylpiperidine-4-carboxamide [3628] ; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)cyclopropanecarboxamide [3629]; 4,4-difluoro-N-(6-(l-methyl-lH-pyrazol-4-yl)-2 ,7-naphthyridin-3-yl)cyclohexane-l-carboxamide

[3630];

fr «5-4-methoxy-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)cyclohexane-l- carboxamide [3631];

trans-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin -3 -yl)-4-morpholinocyclohexane- 1 - carboxamide [3632];

trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) cyclohexane-1 -carboxamide [3633];

fr «5-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-4-((4-methylpiperazin-l-yl) methyl)cyclohexane - 1 -carboxamide [3634] ;

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(pyrrolidin- 1 -yl)acetamide [3635] ; (S)-2-(3 -fluoropyrrolidin- 1 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

acetamide [3636];

(S)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)tetrahydrofuran-2 -carboxamide

[3637];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide [3638];

1 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl)piperidine -4 -carboxamide

[3639];

l-isopropyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-4 -carboxamide

[3640];

1 -(fert-butyl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin -3 -yl)piperidine-4-carboxamide

[3641];

l-cyclopropyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide

[3642];

1 -isobutyl-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)piperidine-4-carboxamide

[3643];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l-neopentylpiperidine-4-carboxamide

[3644];

1 -(2-fluoroethyl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)piperidine-4- carboxamide [3645];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [3646]; 1 -butyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl)piperidine -4 -carboxamide

[3647];

l-benzoyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-4 -carboxamide

[3648];

l-(2,2-difluoropropyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-4- carboxamide [3649];

N-(6 -( 1 -methyl - 1 H-pyrazol -4-yl) -2 ,7 -naphthyridin-3 -yl)azetidine -3 -carboxamide [3650] ;

l-(2,2-difluoroethyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-4- carboxamide [3651];

l-(2-fluoro-2-methylpropyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-

4-carboxamide [3652];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l-(oxetan-3-yl)piperidine-4- carboxamide [3653];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1 -((3-methyloxetan-3 -yl)methyl)

piperidine-4-carboxamide [3654];

l-(2-methoxyethyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-4- carboxamide [3655];

l-(2-isopropoxyethyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-4- carboxamide [3656];

1 , 1 -diisobutyl-4-((6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)carbamoyl)piperidin- 1 - ium [3657];

4-fluoro-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)piperidine-4-carboxamide

[3658];

4-fluoro-l-methyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-4- carboxamide [3659];

4-fluoro- 1 -isobutyl-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-4- carboxamide [3660];

(S)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-3-carboxamide [3661]; (R)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-3-carboxamide [3662]; (S)- 1 -isobutyl-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-3 -carboxamide

[3663];

(R)-l-isobutyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-3-carboxamide

[3664]; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)tetrahydro-2H-pyran-4-carboxamide

[3665];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(piperidin- 1 -yl)acetamide [3666] ; 2-(4-fluoropiperidin-l -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)acetamide

[3667];

fr «5-4-amino-N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)cyclohexane- 1 - carboxamide [3668];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)acetamide

[3669];

(S)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-2 -carboxamide [3670]; 2-(4-isobutylpiperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)acetamide

[3671];

2-(3,3-dimethylazetidin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2J-naphthyridin-3-yl)acetamide

[3672];

(R)-2-(3-fluoropyrrolidin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

acetamide [3673];

(S)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(2-methylpyrrolidin-l-yl)

acetamide [3674];

2-(3-azabicyclo[3.1.0]hexan-3-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) acetamide [3675];

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) acetamide [3676];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2 ,7 -naphthyridin-3 -yl)-2-(4 -methylpiperidin- 1 -yl)acetamide

[3677];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(4-(trifluoromethyl)piperidin- 1 -yl) acetamide [3678];

2-(4-(difluoromethyl)piperidin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) acetamide [3679];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(6-azaspiro[2.5]octan-6-yl)acetamide

[3680];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl)propanamide [3681]; (R)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(2-methylpyrrolidin- 1 -yl)

acetamide [3682]; 2-(cyclobutyl(methyl)amino)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)acetamide [3683];

2-(diethylamino)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)acetamide [3684] ; 7-(2-fluoroethyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-7-azaspiro[3.5]

nonane-2-carboxamide [3685] ;

4-methyl-N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2 ,7 -naphthyridin-3 -yl)piperazine - 1 -carboxamide

[3686];

(S)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl)propanamide

[3687];

(R)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl)propanamide

[3688];

(R)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)pyrrolidine-2 -carboxamide [3689]; 2-methyl-N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2 ,7 -naphthyridin-3 -yl) -2 -azaspiro [3.3 ]heptane -6 - carboxamide [3690];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(2,2,2-trifluoroacetyl)-2-azaspiro[3.3] heptane-6-carboxamide [3691];

2-(2-fluoroethyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-azaspiro[3.3]

heptane-6-carboxamide [3692] ;

trans -4 -(dimethylamino) -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl)cyclohexane - 1 - carboxamide [3693];

1 -acetyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl)piperidine -4 -carboxamide

[3694];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1 -(( 1 -(trifluoromethyl)cyclopropyl) methyl)piperidine -4 -carboxamide [3695] ;

(S)- 1 -(2-fluoropropyl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)piperidine-4- carboxamide [3696];

(R)-l-(2-fluoropropyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-4- carboxamide [3697];

N-(6 -( 1 -methyl - 1 H-pyrazol-4-yl) -2 ,7 -naphthyridin-3 -y 1) -2 -(piperidin- 1 -yl)propanamide [3698] ; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l-(methylsulfonyl)piperidine-4- carboxamide [3699];

1 '-methyl -N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-[ 1 ,4'-bipiperidine] -4- carboxamide [3700]; fra«s-4-(hydroxymethyl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)cyclohexane- 1 - carboxamide [3701];

methyl 2-(4-((6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)carbamoyl)piperidin- 1 -yl) acetate [3702];

1 -benzyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl)piperidine -4 -carboxamide

[3703];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2 ,7 -naphthyridin-3 -yl)- 1 -(2 -(pyrrolidin- 1 -yl)acetyl)piperidine -

4-carboxamide [3704];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-moφholinoacetamide [3705];

(S)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(3-methylmo holino)acetamide

[3706];

(R)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(3 -methylmorpholino)acetamide

[3707];

(S)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(2-methylmo holino)acetamide

[3708];

2-((2R,6S)-2,6-dimethylmoφholino)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) acetamide [3709];

2-((lS,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7- naphthyridin-3 -yl)acetamide [3710] ;

2-((lR,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7- naphthyridin-3 -yl)acetamide [3711];

2-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) acetamide [3712];

(S)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-moφholinopropanamide [3713]; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(moφholin-2-yl)acetamide [3714]; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylmoφholin-2-yl)acetamide

[3715];

2-(4-ethylpiperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)acetamide

[3716];

2-(4-isopropylpiperazin- 1 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)acetamide

[3717];

2-(4-cyclopropylpiperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

acetamide [3718]; 2-(4-(2-fluoroethyl)piperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) acetamide [3719];

(S)-2-(2,4-dimethylpiperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) acetamide [3720];

1 -(2-hydroxyethyl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)piperidine-4- carboxamide [3721];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1 -(pyridin-2-ylmethyl)piperidine-4- carboxamide [3722];

N-(6 -( 1 -methyl - 1 H-pyrazol -4-yl) -2 ,7 -naphthyridin-3 -y 1) - 1 -(oxazol-2 -ylmethyl)piperidine -4 - carboxamide [3723];

(R)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1 -oxotetrahydro- lH-pyrrolo[ 1 ,2-c] imidazole-2(3H)-carboxamide [3724] ;

(R)-l -methyl -N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin -3 -yl)pyrrolidine-2 -carboxamide

[3725];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1 -(tetrahydro-2H-pyran-4-yl)piperidine- 4-carboxamide [3726];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1 -(pyrimidin-2-ylmethyl)piperidine-4- carboxamide [3727];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l-(pyrazin-2-ylmethyl)piperidine-4- carboxamide [3728];

1 -((5 -methyl- 1 ,2,4-oxadiazol-3-yl)methyl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 - yl)piperidine -4 -carboxamide [3729] ;

1 -(2-hydroxy-2-methylpropyl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)

piperidine-4-carboxamide [3730];

fert-butyl 2-(4-((6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)carbamoyl)piperidin- 1 -yl) acetate [3731];

2-(4-((6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)carbamoyl)piperidin-l-yl)acetic acid

[3732];

2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)

acetamide [3733];

fert-butyl (6-( 1 -methyl- 1 H-pyrazol-4-yl) -2,7-naphthyridin-3 -yl)carbamate [3734] ;

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)but-2-ynamide [3735];

trans-4-((6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)carbamoyl)cyclohexane- 1 - carboxylic acid [3736]; N-(6-( l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3-moφholinopropanamide [3737]; trans-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3 -moφholinocyclobutane- 1 - carboxamide [3738];

N-(6-( l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)quinuclidine-4-carboxamide [3739]; 1 -isobutyl-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)azepane-4-carboxamide

[3740] ;

2-(4-methoxypiperidin- 1 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)acetamide

[3741] ;

2- (4-hydroxypiperidin-l -yl)-N-(6-( l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)acetamide

[3742] ;

3- (hydroxymethyl)-N-(6-(l -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)bicyclo[l . l . l]

pentane-1 -carboxamide [3743] ;

1- methyl-N-(6-(l -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)azepane-4-carboxamide [3744]; fr «5-4-(dimethylamino)-N-(6-(l -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)cyclohexane-l - carboxamide [3745];

fra«s-4-(bis(methyl-d3)amino)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)

cyclohexane-1 -carboxamide [3746];

N-(6-( l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3-((4-methylpiperazin-l-yl)methyl) bicyclo[l .1. l]pentane-l -carboxamide [3747];

methyl trans-4-((6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)carbamoyl)cyclohexane- 1 - carboxylate [3748];

2- ( 1 -isobutylpyrrolidin-3 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)acetamide

[3749] ;

fr «5-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-4-(4-methylpiperazine-l - carbonyl)cyclohexane- 1 -carboxamide [3750] ;

1 -isobutyl-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)piperidine-4-carboxamide

[3751] ;

N-(6-( l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l -(phenylsulfonyl)piperidine-4- carboxamide [3752];

8 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl) -3 , 8 -diazabicyclo [3.2.1] octane - 3 -carboxamide [3753];

3 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl) -3 , 8 -diazabicyclo [3.2.1] octane - 8-carboxamide [3754]; (lR,3s,5S)-3-amino-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-8-azabicyclo[3.2.1] octane-8-carboxamide [3755];

(lR,3s,5S)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2 -naphthyridin-3-yl)-3-((3,3,3-trifluoropropyl) amino)-8 -azabicyclo [3.2.1 ]octane-8 -carboxamide [3756] ;

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7- naphthyridin-3-yl)-8-azabicyclo[3.2.1]octane-8-carboxamide [3757];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl)morpholine -4 -carboxamide [3758] ; 4-(dimethylamino)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-l- carboxamide [3759];

(S)-2,4-dimethyl-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperazine- 1 - carboxamide [3760];

1 -methyl-3 -(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl) - 1 -( 1 -methylpiperidin-4 -yl)urea

[3761];

1 -(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3 -( 1 -methylpiperidin-4-yl)urea [3762] ; 4-isopropyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperazine-l -carboxamide

[3763];

(R)-3,4-dimethyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperazine-l- carboxamide [3764];

N-(6-(lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[3765];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3 -(piperazin- 1 -yl)benzamide [3766] ; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3-(4-methylpiperazin-l-yl)benzamide

[3767];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl)-3 -(pyrrolidin- 1 -ylmethyl)benzamide

[3768];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3-(piperidin-4-yloxy)benzamide [3769]; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3-((l-methylpiperidin-4-yl)oxy)

benzamide [3770];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-4-(piperidin-4-yloxy)benzamide [3771]; N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-4-(( 1 -methylpiperidin-4-yl)oxy)

benzamide [3772];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(piperazin-l-yl)isonicotinamide

[3773]; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [3774];

2-(4-isopropylpiperazin- 1 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [3775];

2-(4-cyclopropylpiperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [3776];

2-(4-(2-fluoroethyl)piperazin- 1 -yl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl) isonicotinamide [3777];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-6-(4-methylpiperazin- 1 -yl)nicotinamide

[3778];

N-(6 -( 1 -methyl - 1 H-pyrazol -4-yl) -2 ,7 -naphthyridin-3 -y 1) -5 -(piperidin-4-yloxy)nicotinamide

[3779];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-4-yloxy)isonicotinamide

[3780];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(( 1 -methylpiperidin-4-yl)oxy)

isonicotinamide [3781];

N-(6 -( 1 -methyl - 1 H-pyrazol -4-yl) -2 ,7 -naphthyridin-3 -y 1) -5 -(piperidin-4-ylamino)nicotinamide

[3782];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-5-((l-methylpiperidin-4-yl)amino) nicotinamide [3783];

2-(4-aminopiperidin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [3784];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-(methylamino)piperidin-l-yl) isonicotinamide [3785];

2-(4-(dimethylamino)piperidin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) isonicotinamide [3786];

2-(( 1 -isopropylpiperidin-4-yl)oxy)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) isonicotinamide [3787];

2-(3 -aminoazetidin- 1 -yl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [3788];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) isonicotinamide [3789];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-moφholinoisonicotinamide [3790]; 2-((2-(dimethylamino)ethyl)amino)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) isonicotinamide [3791];

2-(2-(dimethylamino)ethoxy)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [3792];

2-(4-isobutylpiperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [3793];

2-(azetidin-3-yloxy)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2 -naphthyridin-3-yl)isonicotinamide

[3794];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(( 1 -methylazetidin-3 -yl)oxy)

isonicotinamide [3795];

2-(4-ethylpiperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [3796];

4-((dimethylamino)methyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)benzamide

[3797];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl)-3 -( 1 -methylpiperidin-4 -yl)benzamide

[3798];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3-((4-methylpiperazin-l-yl)methyl) benzamide [3799];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)isonicotinamide [3800];

2-hydroxy-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)isonicotinamide [3801] ; 2-isopropoxy-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)isonicotinamide [3802]; N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-( 1 -methylpiperidin-4 -yl)

isonicotinamide [3803];

r-methyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-r,2',3',6'-tetrahydro-[2,4'- bipyridine] -4 -carboxamide [3804] ;

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-(6-(4-methylpiperazin-l-yl) nicotinoyl)piperazin- 1 -yl)isonicotinamide [3805] ;

2-(4-hydroxy-4-methyl-4 4-piperazin-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-

3-yl)isonicotinamide [3806];

2-methyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-6-(4-methylpiperazin-l-yl) isonicotinamide [3807];

3 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2 ,7 -naphthyridin-3 -yl) -2 -(4-methylpiperazin- 1 -yl) isonicotinamide [3808]; 2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl) isonicotinamide [3809];

2-((2S,6R)-2,6-dimethylmoφholino)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) isonicotinamide [3810];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(2,7-diazaspiro[3.5]nonan-2-yl)

isonicotinamide [3811];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(7-methyl-2,7-diazaspiro[3.5]nonan-

2-yl)isonicotinamide [3812];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(2,7-diazaspiro[3.5]nonan-7-yl)

isonicotinamide [3813];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(2-methyl-2,7-diazaspiro[3.5]nonan-

7-yl)isonicotinamide [3814];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3- yl)isonicotinamide [3815];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(( 1 -methylpiperidin-4-yl)thio)

isonicotinamide [3816];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)pyrimidine- 4-carboxamide [3817];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-6-(4-methylpiperazin-l-yl)pyridazine-4- carboxamide [3818];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-6-(4-methylpiperazin-l-yl)pyrimidine-

4-carboxamide [3819];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-phenylacetamide [3820];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3-phenylpropanamide [3821];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(pyridin-3-yl)acetamide [3822]; N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl)-3 -(pyridin-3 -yl)propanamide [3823] ; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(pyridin-4-yl)acetamide [3824]; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3-(pyridin-4-yl)propanamide [3825]; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)isoindoline-5-carboxamide [3826]; 2-methyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)isoindoline-5-carboxamide

[3827];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l,2,3,4-tetrahydroisoquinoline-7- carboxamide [3828]; 2-methyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l,2,3,4- tetrahydroisoquinoline-7 -carboxamide [3829] ;

2- methyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l,2,3,4- tetrahydroisoquinoline-6-carboxamide [3830] ;

N-(6-(l-methyl-lH-pyrazol-4-yl)-2J-naphthyridin-3-yl)-l,2,3,4-tetrahydroisoquinoline-6- carboxamide [3831];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2 ,7 -naphthyridin-3 -yl) - 1 H-indole-5 -carboxamide [3832] ; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)benzofuran-5-carboxamide [3833]; N-(6-(l-methyl-lH-pyrazol-4-yl)-2J-naphthyridin-3-yl)furo[2,3-c]pyridine-5-carboxamide

[3834];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)benzo[b]thiophene-5-carboxamide

[3835];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)benzofuran-6-carboxamide [3836]; N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl)benzo [d] oxazole -6 -carboxamide [3837] ; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)benzo[d]thiazole-6-carboxamide [3838]; N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl)benzo [d] oxazole -5 -carboxamide [3839] ; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)benzo[d]thiazole-5-carboxamide [3840]; N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl)quinoline -3 -carboxamide [3841];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl)quinoline -6-carboxamide [3842] ;

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)quinoxaline-6-carboxamide [3843]; 5-chloro-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [3844];

3- chloro-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [3845];

2- (2,5-diazabicyclo[2.2.1]heptan-2-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) isonicotinamide [3846];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(5-methyl-2,5-diazabicyclo[2.2.1] heptan-2-yl)isonicotinamide [3847] ;

3- fluoro-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(4-methylpiperazin- 1 -yl) isonicotinamide [3848];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-((4-methylpiperazin- 1 -yl)methyl) isonicotinamide [3849];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(mo holinomethyl)isonicotinamide

[3850]; N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(pyrrolidin- 1 -ylmethyl)

isonicotinamide [3851];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(2-(4-methylpiperazin- 1 -yl)pyridin-4- yl)acetamide [3852];

1 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2 ,7 -naphthyridin-3 -yl) - 1 H-indazole -5 -carboxamide

[3853];

1 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2 ,7 -naphthyridin-3 -yl) - 1 H-benzo [d] imidazole-5 - carboxamide [3854];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l-(piperidin-4-yl)-lH-pyrazole-4- carboxamide [3855];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- pyrazole -4 -carboxamide [3856];

1 -( 1 -ethylpiperidin-4-yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)- lH-pyrazole- 4-carboxamide [3857];

l-(l-(2-fluoroethyl)piperidin-4-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-lH- pyrazole -4 -carboxamide [3858];

l-(l-isopropylpiperidin-4-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-lH- pyrazole -4 -carboxamide [3859];

1 -( 1 -cyclopropylpiperidin-4-yl)-N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1H- pyrazole -4 -carboxamide [3860];

isopropyl 4-(4-((6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)carbamoyl)-lH-pyrazol-l- yl)piperidine-l-carboxylate [3861];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l-(piperidin-4-yl)-lH-l,2,3-triazole-4- carboxamide [3862];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- 1,2,3- triazole -4 -carboxamide [3863];

l-(l-(2-fluoroethyl)piperidin-4-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-lH- l,2,3-triazole-4-carboxamide [3864];

1- (l-isopropylpiperidin-4-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-lH-l,2,3- triazole -4 -carboxamide [3865];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)oxazole-5- carboxamide [3866];

2- (3 -(dimethylamino)azetidin- 1 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) oxazole -4 -carboxamide [3867]; N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-4-yl)oxazole-4- carboxamide [3868];

N-(6-( 1 -methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-( 1 -methylpiperidin-4-yl)oxazole-4- carboxamide [3869];

2-(l-(2-fluoroethyl)piperidin-4-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) oxazole-4-carboxamide [3870];

2-(1 sopropylpiperidin-4-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)oxazole-4- carboxamide [3871];

N-(6 -( 1 -methyl - 1 H-pyrazol -4 -yl) -2 ,7 -naphthyridin-3 -yl)-2-(4 -methylpiperazin- 1 -yl)oxazole -4 - carboxamide [3872];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) thiazole-5 -carboxamide [3873];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-4-yl)thiazole-4- carboxamide [3874];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)thiazole-4- carboxamide [3875];

2-(l-(2-fluoroethyl)piperidin-4-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) thiazole-4-carboxamide [3876] ;

2-(l-isopropylpiperidin-4-yl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)thiazole-4- carboxamide [3877];

l-methyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl-4-£/)piperidine-4-carboxamide

[3878];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l-(2-(methyl-d3)propyl-l, l,2,3,3,3- 6) piperidine-4-carboxamide [3879];

N-ie-il-methyl-lH-pyrazol^-y^^J-naphthyridin-S-y^^-ipyrrolidin-l-yl^^^^-i ^acetamide

[3880];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-(methyl-£/3)piperazin-l-yl)

acetamide [3881];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(moφholino-d8)acetamide [3882]; ( S) -N-(6 -( 1 -(methyl -ds) - 1 H-pyrazol -4 -yl) -2,7 -naphthyridin-3 -yl) -2 -(pyrrolidin- 1 -yl)propanamide

[3883];

l-isobutyl-N-(6-(l-(methyl-£/3)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide

[3884]; N-(6-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin- 1 -yl) acetamide [3885];

N-(6-(l-(methyl-£/3)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl)acetamide

[3886];

N-(6-(l-(methyl-£/3)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-l-yl)acetamide [3887]; N-(6-( 1 -(methyl -<¾)- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1 -(3,3,3 -trifluoropropyl)piperidine- 4-carboxamide [3888];

N-(6-( lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(4-(methyl- 3)piperazin- 1 -yl)isonicotinamide

[3889];

N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-(methyl-£/3)piperazin-l-yl)

isonicotinamide [3890];

N-(6-( 1 -(methyl-^)- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [3891];

N-(6-(l-(methyl-£/3)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-(methyl-£/3)piperazin-l-yl) isonicotinamide [3892];

N-(6-( 1 -(methyl-^)- lH-pyrazol-4-yl)-2,7-naphthyridin -3 -yl)- 1 -(piperidin-4-yl)-lH-pyrazole-4- carboxamide [3893];

N-(6-(l-(methyl- 3)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l-(l-methylpiperidin-4-yl)-lH- pyrazole-4-carboxamide [3894];

N-(6-(l-(methyl-£/3)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-4-yl)oxazole-4- carboxamide [3895];

N-(6-( 1 -(methyl-^)- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-( 1 -methylpiperidin-4-yl)oxazole- 4-carboxamide [3896];

N-(6-( 1 -ethyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(pyrrolidin-l -yl)acetamide [3897] ; N-(6-(l-cyclopropyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl)acetamide

[3898];

N-(6-(l-cyclopropyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine-

4-carboxamide [3899];

N-(6-(l-(l -methylpiperidin-4-yl) - 1 H-pyrazol -4 -yl) -2, 7-naphthyridin-3 -yl)

cyclohexanecarboxamide [3900];

2-(pyrrolidin-l-yl)-N-(6-(5-(trifluoromethyl)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)acetamide

[3901];

N-(6-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l-methylpiperidine- 4-carboxamide [3902]; N-(6-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)tetrahydro-2H-pyran-

4-carboxamide [3903];

N-(6-(5-(azetidin-l-ylmethyl)-l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-4,4- difluorocyclohexane - 1 -carboxamide [3904] ;

4,4-difluoro-N-(6-(l-methyl-5-(pyrrolidin-l-ylmethyl)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl^ cyclohexane-1 -carboxamide [3905];

4,4-difluoro-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-2 -naphthyridin-3-yl) cyclohexane-1 -carboxamide [3906];

2-(2 -fluoroethyl) -N-(6 -( 1 -methyl -5 -(piperidin- 1 -ylmethyl) - 1 H-pyrazol -4 -yl) -2, 7-naphthyridin-3 - yl)-2-azaspiro[3.3]heptane-6-carboxamide [3907] ;

fert-butyl 6-((6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) carbamoyl)-2-azaspiro[3.3]heptane-2-carboxylate [3908];

2-fluoro-2 -methyl -N-(6-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3 - yl)propanamide [3909];

2-(diethylamino)-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-2,7-naphthyridin-3- yl)acetamide [3910];

fr «5-4-methoxy-N-(6-( 1 -methyl-5 -(piperidin-1 -ylmethyl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3 - yl)cyclohexane - 1 -carboxamide [3911];

fr «5-4-(hydroxymethyl)-N-(6-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-2,7- naphthyridin-3 -yl)cyclohexane - 1 -carboxamide [3912];

(R)-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)pyrrolidine-

2-carboxamide [3913];

l-isobutyl-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) piperidine-4-carboxamide [3914];

N-(6-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1 -(oxetan-3 -yl) piperidine-4-carboxamide [3915];

l-benzoyl-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) piperidine-4-carboxamide [3916];

N-(6-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)tetrahydro-2H- pyran-4-carboxamide [3917];

N-(6-( 1 -methyl-5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(4- methylpiperidin- 1 -yl)acetamide [3918] ;

N-(6-(l-(difluoromethyl)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [3919]; N-(6-(l-ethyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3920];

N-(6-(l-isopropyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3-(piperidin-4-yloxy)benzamide

[3921];

N-(6-(l-isopropyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3-((l-methylpiperidin-4-yl)oxy) benzamide [3922];

N-(6-(l-isopropyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-4-(piperidin-4-yloxy)benzamide

[3923];

N-(6-(l-cyclopropyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [3924];

4-fluoro-N-(6-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)benzamide

[3925];

4- (difluoromethoxy)-N-(6-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl) benzamide [3926];

5- fluoro-N-(6-(l-(l-methylpiperidin-4-yl)-lH-pyrazol-4-yl)-2 ,7-naphthyridin-3-yl)nicotinamide

[3927];

N2 -methyl -N5-(6-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)pyridine- 2,5-dicarboxamide [3928];

1- isopropyl-N-(6-(l-(l-methylpiperidin-4-yl)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-lH- pyrazole-4-carboxamide [3929];

2- methyl-N-(6-( 1 -( 1 -methylpiperidin-4-yl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)thiazole-5- carboxamide [3930];

N-(6-(5-amino-l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [3931];

4-(difluoromethoxy)-N-(6-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) benzamide [3932];

N-(6-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4- methylpiperazin-l-yl)isonicotinamide [3933];

N-(6-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(7-methyl-2,7- diazaspiro[3.5]nonan-2-yl)isonicotinamide [3934] ;

4-fluoro-N-(6-(l-methyl-5-(pyrrolidin-l-ylmethyl)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) benzamide [3935];

4-fluoro-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

benzamide [3936]; 4-(difluoromethoxy)-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH-pyrazol-4-yl)-2,7- naphthyridin-3 -yl)benzamide [3937] ;

N-(6-( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-3-(pyrrolidin- l-ylmethyl)benzamide [3938];

N-(6-( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(7-methyl-

2,7-diazaspiro[3.5]nonan-2-yl)isonicotinamide [3939];

N-(6-( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)-2- moφholinoisonicotinamide [3940] ;

N-(6 -( 1 -methyl -5 -(mo holinomethyl) - 1 H-pyrazol -4 -yl)-2,7 -naphthyridin-3 -yl) -2 - moφholinoisonicotinamide [3941];

N-(6-(4,5 ,6,7-tetrahydropyrazolo[ 1 ,5 -a]pyrazin-3 -yl)-2,7-naphthyridin-3-yl)- 1 -(( 1 -

(trifluoromethyl)cyclopropyl)methyl)piperidine-4-carboxamide [3942];

3.3- difluoro-N-(6-(5-methyl-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-2,7-naphthyridin-3- yl)cyclobutane- 1 -carboxamide [3943] ;

4.4- difluoro-N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-2,7- naphthyridin-3 -yl)cyclohexane - 1 -carboxamide [3944] ;

N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)-l-

(( 1 -(trifluoromethyl)cyclopropyl)methyl)piperidine-4-carboxamide [3945] ;

N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)-2-

(pyrrolidin- 1 -yl)acetamide [3946] ;

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a] pyrazin-3-yl)-2,7-naphthyridin-3-yl)acetamide [3947];

(R)-N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-2,7-naphthyridin-3- yl)-l-isobutylpiperidine-3-carboxamide [3948];

N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl) piperidine-4-carboxamide [3949];

4-fluoro-N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-2,7- naphthyridin-3 -yl)- 1 -isobutylpiperidine-4-carboxamide [3950] ;

N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)-2-

(4-methylpiperazin- 1 -yl)acetamide [3951] ;

4-fluoro-N-(6-(4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)benzamide

[3952];

N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)-3- (4-methylpiperazin- 1 -yl)benzamide [3953] ; N5-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)-

N2-methylpyridine-2,5 -dicarboxamide [3954] ;

N-(6-(5-(2-fluoroethyl)-4,5,6j etrahydropyrazolo[l,5-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)-6-

(4-methylpiperazin- 1 -yl)nicotinamide [3955] ;

2-(azetidin-3-yloxy)-N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-3-yl)-2,7- naphthyridin-3 -yl)isonicotinamide [3956] ;

N-(6 -( 1 -methyl - 1 H-pyrazol-5 -yl) -2 ,7 -naphthyridin-3 -yl) - 1 -(3 ,3 , 3 -trifluoropropyl)piperidine -4 - carboxamide [3957];

1 -methyl -N-(6 -( 1 -methyl - 1 H-pyrazol -3 -yl) -2 ,7 -naphthyridin-3 -yl)piperidine -4 -carboxamide

[3958] ;

N-(6-( l-methyl-lH-pyrazol-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l -yl)

isonicotinamide [3959];

2-fluoro-2 -methyl -N-(6-( l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)propanamide

[3960] ;

2,2,3,3-tetramethyl-N-(6-(l -methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)cyclopropane-l - carboxamide [3961];

trans-N-(6-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)-2,7-naphthyridin-3 -yl)-4-(pyrrolidin- 1 -yl)

cyclohexane-1 -carboxamide [3962];

fr rø-N-(6-(l-methyl-lH-l ,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-4-mo holinocyclohexane-l- carboxamide [3963];

N-(6-( l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-l -yl)acetamide [3964]; 1 -ethyl -4-fluoro-N-(6-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)-2,7-naphthyridin-3 -yl)piperidine-4- carboxamide [3965];

4-fluoro- 1 -isobutyl-N-(6-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)-2,7-naphthyridin-3 -yl)piperidine-4- carboxamide [3966];

N-(6-( l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-l -(3,3,3-trifluoropropyl)piperidine- 4-carboxamide [3967];

N-(6-( l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)cyclopropanecarboxamide [3968] ; 4,4-difluoro-N-(6-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)-2,7-naphthyridin-3-yl)cyclohexane- 1 - carboxamide [3969];

fr «5-4-(dimethylamino)-N-(6-( l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)

cyclohexane-1 -carboxamide [3970];

fr «5-N-(6-(l-methyl-lH-l ,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-4-((4-methylpiperazin-l -yl) methyl)cyclohexane- 1 -carboxamide [3971] ; N-(6-(l-methyl-lH-l,2,3 riazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide [3972]; 1 -isobutyl-N-(6-( 1 -methyl- lH-1 ,2,3-triazol-4-yl)-2,7-naphthyridin -3 -yl)piperidine-4- carboxamide [3973];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-l-((l-(trifluoromethyl)cyclopropyl) methyl)piperidine -4 -carboxamide [3974] ;

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-l-((3-methyloxetan-3-yl)methyl) piperidine-4-carboxamide [3975];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-l-(2-(pyrrolidin-l-yl)acetyl)

piperidine-4-carboxamide [3976];

1 '-methyl-N-(6-( 1 -methyl- lH-1 ,2,3 -triazol-4-yl)-2,7-naphthyridin-3 -yl)-[ 1 ,4'-bipiperidine] -4- carboxamide [3977];

(R)-N-(6-( 1 -methyl-lH- 1 ,2,3-triazol-4-yl)-2,7-naphthyridin-3 -yl)piperidine-3 -carboxamide

[3978];

(R)-l-isobutyl-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)piperidine-3- carboxamide [3979];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl)acetamide

[3980];

N-(6-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(4-methylpiperazin- 1 -yl)

acetamide [3981];

2-(7-azabicyclo[2.2.1]heptan-7-yl)-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl) acetamide [3982];

1 -(2-hydroxy-2-methylpropyl)-N-(6-( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)-2,7-naphthyridin-3 -yl) piperidine-4-carboxamide [3983];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-2-moφholinoacetamide [3984]; 2-(4-methoxypiperidin-l-yl)-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)

acetamide [3985];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)mo holine-4-carboxamide [3986]; N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-l-(piperidin-4-yl)-lH-pyrazole-4- carboxamide [3987];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-l-(l-methylpiperidin-4-yl)-lH- pyrazole -4 -carboxamide [3988];

1 -( 1 -ethylpiperidin-4-yl)-N-(6-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)-2,7-naphthyridin-3-yl)-lH- pyrazole -4 -carboxamide [3989]; l-(l-isopropylpiperidin-4-yl)-N-(6-(l-methyl-lH-l,2,3 riazol-4-yl)-2,7-naphthyridin-3-yl)-lH- pyrazole-4-carboxamide [3990];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-l-(piperidin-4-yl)-lH-l,2,3- triazole -4 -carboxamide [3991 ] ;

1 -( 1 -(2-fluoroethyl)piperidin-4-yl)-N-(6-( 1 -methyl-lH- 1 ,2,3-triazol-4-yl)-2 ,7-naphthyridin-3-yl)- lH-l,2,3-triazole-4-carboxamide [3992];

1- (l-isopropylpiperidin-4-yl)-N-(6-(l-methyl-lH-l,2,3 riazol-4-yl)-2,7-naphthyridin-3-yl)-lH- l,2,3-triazole-4-carboxamide [3993];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-4-yl)oxazole-4- carboxamide [3994];

N-(6-(l-methyl-lH-l,2,3 riazol-4-yl)-2,7-naphthyridin-3-yl)-2-(l-methylpiperidin-4-yl)oxazole- 4-carboxamide [3995];

2- ( 1 -isopropylpiperidin-4-yl)-N-(6-( 1 -methyl- 1H- 1 ,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl) oxazole -4 -carboxamide [3996];

2-fluoro-N-(6-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)-2,7-naphthyridin-3 -yl)benzamide [3997] ;

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-3-((l-methylpiperidin-4-yl)oxy) benzamide [3998];

N2-methyl-N5-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)pyridine-2,5- dicarboxamide [3999];

N-(6-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)-2,7-naphthyridin-3 -yl)-6-(4-methylpiperazin- 1 -yl)

nicotinamide [4000];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-( 1 -methyl- 1H- 1 ,2,3 -triazol-4-yl)-2,7-naphthyridin-3 -yl) isonicotinamide [4001];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-2-(l-methylpiperidin-4-yl)

isonicotinamide [4002];

2-(4-(dimethylamino)piperidin-l-yl)-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3- yl)isonicotinamide [4003];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-2-moφholinoisonicotinamide

[4004];

N-(6-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)-2,7-naphthyridin-3 -yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [4005];

2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(6-( 1 -methyl-lH-1 ,2,3-triazol-4-yl)-2,7-naphthyridin-3 -yl) isonicotinamide [4006]; 2-(4 sopropylpiperazin-l-yl)-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl) isonicotinamide [4007];

N-(6-(l-methyl-lH-l,2,3 riazol-4-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-4-ylamino)

isonicotinamide [4008];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(6-( 1 -methyl- IH- 1 ,2,3 -triazol-4-yl)-2,7- naphthyridin-3 -yl)isonicotinamide [4009] ;

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-2-((l-methylpiperidin-4-yl)thio) isonicotinamide [4010];

2-methyl-N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-l,2,3,4- tetrahydroisoquinoline-6-carboxamide [4011] ;

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-2-(piperazin-l-yl)isonicotinamide

[4012];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-2-(2-(4-methylpiperazin-l-yl) pyridin-4-yl)acetamide [4013];

1 , 1 -bis(methyl-£/3)-4-(4-((6-( 1 -methyl- IH- 1 ,2,3 -triazol-4-yl)-2,7-naphthyridin-3 -yl)carbamoyl) pyridin-2-yl)piperazin-l-ium iodide [4014];

N-(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4-(methyl-£/3)piperazin-l-yl) isonicotinamide [4015];

N-(6-(l-methyl-lH-l,2,3-triazol-5-yl)-2,7-naphthyridin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine- 4-carboxamide [4016];

N-(6-(4-methyl-4H-l,2,4-triazol-3-yl)-2,7-naphthyridin-3-yl)-2-moφholinoacetamide [4017]; N-(6-(4-methyl-4H-l,2,4-triazol-3-yl)-2,7-naphthyridin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine- 4-carboxamide [4018];

4-fluoro- 1 -isobutyl-N-(6-(4-methyl-4H- 1 ,2,4-triazol-3 -yl)-2,7-naphthyridin-3 -yl)piperidine-4- carboxamide [4019];

N-(6-(4,5-dimethyl-4H-l,2,4-triazol-3-yl)-2,7-naphthyridin-3-yl)-2-moφholinoacetamide [4020]; N-(6-(4,5-dimethyl-4H-l,2,4-triazol-3-yl)-2,7-naphthyridin-3-yl)-l-(3,3,3-trifluoropropyl)

piperidine-4-carboxamide [4021];

N-(6-( IH- 1 ,2,3 -triazol-1 -yl)-2,7-naphthyridin-3-yl)-4-fluoro- 1 -isobutylpiperidine-4-carboxamide

[4022];

N-(6-(2H- 1 ,2,3 -triazol-2-yl)-2,7-naphthyridin-3-yl)-4-fluoro- 1 -isobutylpiperidine-4-carboxamide

[4023];

N-(6-(lH-l,2,4-triazol-l-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[4024]; 1- isobutyl-N-(6-(l-methyl-lH etrazol-5-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide

[4025];

2,2,3, 3 etramethyl-N-(6-(l-methyl-lH midazol-5-yl)-2,7-naphthyridin-3-yl)cyclopropane-l- carboxamide [4026];

4,4-difluoro-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane-l- carboxamide [4027];

N-(6-(l-methyl-lH midazol-5-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-l-yl)acetamide [4028];

2 - fluoro-2 -methyl -N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)propanamide [4029]; 1 -fluoro-N-(6-( 1 -methyl- lH-imidazol-5 -yl)-2,7-naphthyridin-3-yl)cyclopropane- 1 -carboxamide

[4030];

2-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-azaspiro[3.3]heptane-6- carboxamide [4031];

1 -fluoro-N-(6-( 1 -methyl- lH-imidazol-5 -yl)-2,7-naphthyridin-3-yl)cyclohexane-l -carboxamide

[4032];

fr «5-4-methoxy-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane-l- carboxamide [4033];

fr «5-4-(hydroxymethyl)-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane- 1 -carboxamide [4034];

N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)azetidine-3-carboxamide [4035];

(R)-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)tetrahydrofuran-2 -carboxamide

[4036];

1 -(2-methoxyethyl) -N-(6 -( 1 -methyl - 1 H-imidazol-5 -yl) -2, 7-naphthyridin-3 -yl)piperidine -4 - carboxamide [4037];

N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [4038];

1 -isobutyl-N-(6-( 1 -methyl- lH-imidazol-5-yl)-2,7-naphthyridin -3 -yl)piperidine-4-carboxamide

[4039];

N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-l-(methylsulfonyl)piperidine-4- carboxamide [4040];

N-(6-( 1 -methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)-2-(pyrrolidin- 1 -yl)propanamide [4041] ;

2- isopropoxy-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)acetamide [4042];

3- isopropoxy-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)propanamide [4043]; N-(6-( 1 ,2-dimethyl- lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)cyclopropanecarboxamide [4044] ; N-(6-( 1 ,2-dimethyl- lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)cyclohexanecarboxamide [4045] ; N-(6-( 1 ,2-dimethyl- lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)-4,4-difluorocyclohexane- 1 - carboxamide [4046];

(S)-N-(6-( 1 ,2-dimethyl- lH-imidazol-5 -yl)-2,7-naphthyridin-3 -yl)tetrahydrofuran-2 -carboxamide

[4047] ;

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-3,3-difluorocyclobutane-l- carboxamide [4048];

N-(6-( 1 ,2-dimethyl- lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)-l -fluorocyclopropane-1 - carboxamide [4049];

N-(6-( 1 ,2-dimethyl- lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)moφholine -4 -carboxamide [4050] ; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)moφholine-ί s-4-carboxamide

[4051] ;

l-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-lH-pyrazole-4-carboxamide

[4052] ;

l-ethyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-lH-pyrazole-4-carboxamide

[4053] ;

1 -isopropyl-N-(6-( 1 -methyl- lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)- lH-pyrazole-4- carboxamide [4054];

1 -cyclopropyl-N-(6-( 1 -methyl -lH-imidazol -5 -yl)-2,7-naphthyridin-3 -yl)- lH-pyrazole-4- carboxamide [4055];

l-isobutyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-lH-pyrazole-4-carboxamide

[4056] ;

l-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-lH-pyrazole-3-carboxamide

[4057] ;

N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(l-methyl-lH-pyrazol-4-yl)

acetamide [4058];

l-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-lH-imidazole-4 -carboxamide

[4059] ;

1 -isopropyl-N-(6-( 1 -methyl- lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)- lH-imidazole-4- carboxamide [4060];

N-(6-( 1 -methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)- 1 -(tetrahydro-2H-pyran-4-yl)- 1H- imidazole -4 -carboxamide [4061];

l,2-dimethyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-lH-imidazole-5- carboxamide [4062]; 1 -methyl -N-(6-( 1 -methyl-lH-imidazol-5 -yl)-2,7-naphthyridin-3 -yl)-lH-l ,2,4-triazole-3 - carboxamide [4063];

2-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2 -naphthyridin-3-yl)oxazole-4-carboxamide

[4064];

2-isopropyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)oxazole-4 -carboxamide

[4065];

4-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)oxazole-2 -carboxamide

[4066];

4- methyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2 -naphthyridin-3-yl)thiazole-2 -carboxamide

[4067];

2-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2 -naphthyridin-3-yl)thiazole-4 -carboxamide

[4068];

5- methyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-l,3,4-oxadiazole-2- carboxamide [4069];

5 -methyl-N-(6 -( 1 -methyl - 1 H-imidazol-5 -yl) -2 ,7 -naphthyridin-3 -yl) - 1 , 3 ,4 -thiadiazole -2 - carboxamide [4070];

1 -isopropyl-N-(6-( 1 -isopropyl- lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)- lH-pyrazole-4- carboxamide [4071];

N-(6-( 1 ,2-dimethyl- lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)- 1 -methyl- lH-pyrazole-4- carboxamide [4072];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-l-isopropyl-lH-pyrazole-4- carboxamide [4073];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-methylthiazole-5-carboxamide

[4074];

4-fluoro-N-(6-( 1 -methyl- lH-imidazol-5 -yl)-2,7-naphthyridin-3-yl)benzamide [4075] ;

4-(difluoromethoxy)-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)benzamide [4076]; N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-3-(pyrrolidin-l-ylmethyl)benzamide

[4077];

2-fluoro-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)benzamide-3,4,5,6-£/4 [4078]; 4-fluoro-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)benzamide-2,3,5,6-£/4 [4079]; 2-chloro-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)benzamide-3,4,5,6-£/4 [4080]; 4-chloro-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)benzamide-2,3,5,6-£/4 [4081]; 4-(methyl-£¾)-N-(6-( 1 -methyl- lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)benzamide [4082] ;

4-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)benzamide-2,3,5,6-£/4 [4083]; 4-(methyl-d3)-N-(6-( 1 -methyl- lH-imida^^

[4084];

4-(methoxy- 3)-N-(6-(l-memyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)benzamide [4085]; 4-(methoxy-d3)-N-(6-( 1 -memyl-lH-imidazol^^

[4086];

4-methoxy-N-(6-(l -methyl- lH-imidazol-5-yl)-2 -napht^^

[4087];

(E)-N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-3-(phenyl-2,3,4,5,6-£/j)

acrylamide [4088];

(E)-N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-3-(phenyl-2,3,4,5,6-£/j)

acrylamide-2,3-£/2 [4089];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphth^

d2 [4090];

(E)-N-(6-(l -methyl- lH-imidazol-5-yl)-2 ,7-naphthyridin-3-yl)-3-(phenyl-2,3,4,5,6-£/j)acrylamide

[4091];

(E)-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-3-(phenyl-2,3,4,5,6-£/j)acrylamide- 2,2-d2 [4092];

2-(4-fluorophenyl)-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)acetamide-2,2-£/2

[4093];

N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4094];

2-(dimethylamino)-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)isonicotinamide

[4095];

2-(3 -aminoazetidin- 1 -yl) -N-(6 -( 1 -methyl - 1 H-imidazol -5 -yl) -2,7 -naphthyridin-3 -yl)

isonicotinamide [4096];

N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl)isonicotinamide

[4097];

N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-l-yl)isonicotinamide

[4098];

N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-moφholinoisonicotinamide [4099]; 2-(4-isopropylpiperazin-l-yl)-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [4100];

2-(4-cyclopropylpiperazin- 1 -yl)-N-(6-( 1 -methyl- lH-imidazol-5 -yl)-2,7-naphthyridin-3 -yl)

isonicotinamide [4101]; N-(6-(l-methyl-lH midazol-5-yl)-2,7-naphthyridin-3-yl)-2-(2,7-diazaspiro[3.5]nonan-2-yl) isonicotinamide [4102];

N-(6-(l-methyl-lH midazol-5-yl)-2,7-naphthyridin-3-yl)-2-(7-methyl-2,7-diazaspiro[3.5]nonan-

2-yl)isonicotinamide [4103];

N-(6-(l-methyl-lH midazol-5-yl)-2,7-naphthyridin-3-yl)isoindoline-5-carboxamide [4104] ; 2-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2 -naphthyridin-3-yl)isoindoline-5-carboxamide

[4105] ;

2-(azetidin-l-yl)-N-(6-(l-methyl-lH midazol-5-yl)-2,7-naphthyridin-3-yl)isonicotinam

[4106] ;

2-methoxy-N-(6-( 1 -methyl- lH-imidazol -5 -yl)-2,7-naphthyridin-3-yl)isonicotinamide [4107] ; 2-methyl-N-(6-(l-methyl-lH-imidazol-5-yl)-2 -naphthyridin-3-yl)isonicotinamide [4108]; 2-cyano-N-(6-(l-methyl-lH-imidazol-5-yl)-2 -naphthyridin-3-yl)isonicotinamide [4109]; 2-(3,3-difluoroazetidin-l-yl)-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [4110];

2-(4,4-difluoropiperidin-l-yl)-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [4111];

2-isopropoxy-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)isonicotinamide [4112] ; N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl-2,2,5,5-£/4)

isonicotinamide [4113];

N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl- s)isonicotinamide

[4114] ;

N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-l-yl- ;o)isonicotinamide

[4115] ;

N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(moφholino-ί s)isonicotinamide

[4116] ;

N-(6-( 1 ,2-dimethyl- lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)-4-isopropoxybenzamide [4117]; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-4-(piperidin-4-yloxy)benzamide

[4118] ;

4-(benzyloxy)-N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)benzamide [4119] ; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-fluorobenzamide-3,4,5,6-£/4

[4120] ;

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-4-fluorobenzamide-2,3,5,6-£/4

[4121] ; 2-chloro-N-(6-(l,2-dimethyl-lH midazol-5-yl)-2 -naphthyridin-3-yl)benzamide-3 ,4,5,6-<¾

[4122] ;

4-chloro-N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2 -naphthyridin-3-yl)benzamide-2,3,5,6-<¾

[4123] ;

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-4-(methyl-ii3)benzamide [4124]; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthy^

[4125] ;

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthy^

[4126] ;

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-4-(methoxy- 3)benzamide [4127] ; N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthy^

d4 [4128] ;

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthy^

[4129] ;

N-(6-( 1 ,2-dimethyl- lH-imidazol-5-yl)-2,7-naphthyridin-3 -yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [4130];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-na

[4131] ;

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthy^

[4132] ;

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-na

[4133] ;

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl-2,2,5,5-ii4) isonicotinamide [4134];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl-£/s)

isonicotinamide [4135];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-l-yl-£/;o)

isonicotinamide [4136];

N-(6-(l,2-dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(moφholino- s)isonicotinamide

[4137] ;

N-(6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)

cyclopropanecarboxamide [4138];

N-(6-(7-methyl-5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)

cyclopropanecarboxamide [4139]; 3,3-difluoro-N-(6-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl) cyclobutane-l-carboxamide [4140];

(R)-N-(6-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-2J-naphthyridin-3-yl)pyrrolidine-2- carboxamide [4141];

(R)-N-(6-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-2J-naphthyridin-3-yl)piperidine-3- carboxamide [4142];

l-methyl-N-(6-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)piperidm^

4-carboxamide [4143];

N-(6-(5,6J,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)-l-((l-

(trifluoromethyl)cyclopropyl)methyl)piperidine -4 -carboxamide [4144] ;

1- benzoyl-N-(6-(5,6J,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)piperidine-

4-carboxamide [4145];

4-fluoro-l-isobutyl-N-(6-(5,6J,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl) piperidine-4-carboxamide [4146];

(R)-2-(2-methylpyrrolidin-l-yl)-N-(6-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7- naphthyridin-3 -yl)acetamide [4147] ;

2- (cyclobutyl(methyl)amino)-N-(6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7- naphthyridin-3 -yl)acetamide [4148] ;

4-fluoro-N-(6-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)benzamide

[4149];

4-isopropoxy-N-(6-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7-naphthyridin-3-yl)

benzamide [4150];

4-(difluoromethoxy)-N-(6-(5,6,7,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7-naphthyridin-3-y^ benzamide [4151];

2-((2-(dimethylamino)ethyl)amino)-N-(6-(5,6J,8 etrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7- naphthyridin-3 -yl)isonicotinamide [4152] ;

2-((l-isopropylpiperidin-4-yl)oxy)-N-(6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-2,7- naphthyridin-3 -yl)isonicotinamide [4153] ;

N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine-4 -carboxamide

[4154];

N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)cyclopropanecarboxamide [4155];

(R)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)tetrahydrofuran-2 -carboxamide [4156];

(R)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)piperidine-3-carboxamide [4157];

N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)tetrahydro-2H-pyran-4-carboxamide [4158]; N-(6-(oxazol-5 -yl)-2,7-naphthyridin-3 -yl)- 1 -(2-(pyrrolidin- 1 -yl)acetyl)piperidine-4-carboxamide [4159] ;

r-methyl-N-(6-(oxazol-5-yl)-2J-naphthyridin-3-yl)-[l,4'-bipiperidine]-4-carboxamide [4160]; c/. ·-4-moφholino-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane-l -carboxamide [4161]; 2-(cyclobutyl(methyl)amino)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)acetamide [4162];

N-(6-(oxazol-5 -yl)-2,7-naphthyridin-3 -yl)-2-(pyrrolidin- 1 -yl)acetamide [4163] ;

(R)-2-(2-methylpyrrolidin- 1 -yl)-N-(6-(oxazol-5 -yl)-2,7-naphthyridin-3 -yl)acetamide [4164] ; 2-(4-methylpiperazin- 1 -yl)-N-(6-(oxazol-5 -yl)-2,7-naphthyridin-3-yl)acetamide [4165] ;

fr «5-4-((4-methylpiperazin-l -yl)methyl)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane- 1-carboxamide [4166];

l-(2,2-difluoropropyl)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide

[4167] ;

fr «5-4-(hydroxymethyl)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane-l- carboxamide [4168];

fr «5-4-(methylamino)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane-l - carboxamide [4169];

trans-4-(( 1 ,3 -difluoropropan-2-yl)amino)-N-(6-(2-methyloxazol-5 -yl)-2,7-naphthyridin-3 -yl) cyclohexane- 1 -carboxamide [4170];

fr «5-N-(6-(2-methyloxazol-5-yl)-2 -naphthyridin-3-yl)-4-((propan-2-yl-l, l, l,3,3,3-£/6)amino) cyclohexane -1 -carboxamide [4171];

fr «5-4-((2,2-difluoroethyl)amino)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)

cyclohexane -1 -carboxamide [4172];

fr «5-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-4-((3,3,3-trifluoropropyl)amino)

cyclohexane -1 -carboxamide [4173];

fr «5-4-((2-methoxyethyl)amino)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)

cyclohexane -1 -carboxamide [4174];

trans -4 -(dimethylamino) -N-(6 -(2 -methyloxazol -5 -yl) -2 ,7-naphthyridin-3 -yl)cyclohexane - 1 - carboxamide [4175];

fr «5-4-(bis(methyl-£/3)amino)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane-l- carboxamide [4176];

c/5-4-(dimethylamino)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane-l- carboxamide [4177];

fr «5-4-((2,2-difluoroethyl)(methyl)amino)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl) cyclohexane -1 -carboxamide [4178]; fr «5-4-(methyl(oxetan-3-yl)amino)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl) cyclohexane-1 -carboxamide [4179];

frara -4 -((2-fluoroemyl)amino) -N-(6 -(2 -meft

carboxamide [4180];

fr «5-4-(2-(fluoromethyl)aziridin-l-yl)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl) cyclohexane-1 -carboxamide [4181];

trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N-(6-(2-methyloxazol-5 -yl)-2,7-naphthyridin-3 -yl) cyclohexane-1 -carboxamide [4182];

fr rø-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-3-moφholinocyclobutane-l- carboxamide [4183];

fr rø-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-4-moφholinocyclohexane-l- carboxamide [4184];

N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-l-yl)acetamide [4185];

2-(4-methoxypiperidin-l-yl)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)acetamide

[4186];

N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)acetamide [4187]; N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)mo holine-4-carboxamide [4188];

N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-2-mo holinoacetamide [4189];

N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-3-moφholinopropanamide [4190];

1 -methyl -N-(6 -(2 -methyloxazol -5 -yl) -2,7 -naphthyridin-3 -yl)piperidine -4 -carboxamide [4191]; 1 -(2,2-difluoropropyl)-N-(6-(2-methyloxazol-5 -yl)-2,7-naphthyridin-3 -yl)piperidine-4- carboxamide [4192];

N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-4-moφholinopiperidine-l-carboxamide

[4193];

4-((l,3-difluoropropan-2-yl)amino)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)

piperidine-1 -carboxamide [4194];

( 1 R,3s,5 S)-3 -(( 1 ,3-difluoropropan-2-yl)amino)-N-(6-(2-methyloxazol-5 -yl)-2,7-naphthyridin-3 - yl)-8-azabicyclo[3.2.1] octane -8 -carboxamide [4195];

( 1 R,3s,5 S)-3 -(( 1 ,3-difluoropropan-2-yl)amino)-N-(6-(2-methyloxazol-5 -yl)-2,7-naphthyridin-3 - yl)-8-azabicyclo[3.2.1] octane -8 -carboxamide [4196];

4-(dimethylamino)-N-(6-(2-methyloxazol-5 -yl)-2,7-naphthyridin-3 -yl)piperidine- 1 -carboxamide

[4197];

4-((2,2-difluoroethyl)(methyl)amino)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)

piperidine-1 -carboxamide [4198]; (3S,4S)-4-amino-3-fluoro-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)piperidine-l- carboxamide [4199];

(3S,4S)-3-fluoro-4-(methylamino)-N-(6-(2-^

1-carboxamide [4200];

(3R,4R)-4-amino-3-fluoro-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)piperidine-l- carboxamide [4201];

(3R,4R)-3-fluoro-4-(methylamino)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)piperidine-

1-carboxamide [4202];

4-((2-fluoroethyl)amino)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)piperidine-l- carboxamide [4203];

4-((2,2-difluoroethyl)amino)-N-(6-(2-methyloxazol-5-yl)-2J-naphthyridin-3-yl)piperidm^

carboxamide [4204];

(lR,3s,5S)-3-amino-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-8-azabicyclo[3.2.1] octane-8-carboxamide [4205];

(lR,3r,5S)-3-amino-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-8-azabicyclo[3.2.1] octane-8-carboxamide [4206];

(lR,3r,5S)-3-((2-fluoroethyl)amino)-N-(6-(2-methyloxazol-5-yl)-2 -naphthyridin-3-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [4207];

(lR,3r,5S)-3-((2,2-difluoroethyl)amino)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-8- azabicyclo[3.2.1] octane -8 -carboxamide [4208];

(lR,3s,5S)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-3-((3,3,3-trifluoropropyl)amino)-

8 -azabicyclo [3.2.1] octane -8 -carboxamide [4209] ;

(3S,4S)-3-fluoro-4-(isopropylamino)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)

piperidine- 1-carboxamide [4210];

N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H)- carboxamide [4211];

2-methyl-N-(6 -(2 -methyloxazol -5 -yl) -2 ,7 -naphthyridin-3 -yl) -5 , 6-dihydroimidazo [ 1 ,2 -a] pyrazine -

7(8H)-carboxamide [4212];

N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-2-(mo holino-ί s)acetamide [4213];

fr «5-N-(6-(2-methyloxazol-4-yl)-2,7-naphthyridin-3-yl)-4-(4-methylpiperazin-l-yl)cyclohexane-

1-carboxamide [4214];

N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)-l-(l-methylpiperidin-4-yl)-lH-pyrazole-4- carboxamide [4215];

2-(lH-imidazol-l-yl)-N-(6-(2-methyloxazol-5-yl)-2,7-naphthyridin-3-yl)acetamide [4216]; 4-(difluoromethoxy)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)benzamide [4217];

3- ((l-methylpiperidin-4-yl)oxy)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)benzamide [4218]; N-(6 -(oxazol -5 -yl) -2,7 -naphthyridin-3 -yl)isonicotinamide [4219];

2-(3-aminoazetidin-l-yl)-N-(6-(oxazol-5-yl)-2 -naphthyridin-3-yl)isonicotinamide [4220]; 2-(l-methylpiperidin-4-yl)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)isonicotinamide [4221]; r-methyl-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)-l',2',3',6'-tetrahydro-[2,4'-bipyridine]-4- carboxamide [4222];

2-(4-methylpiperazin-l-yl)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)isonicotinamide [4223]; 2-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [4224];

N-(6-(oxazol-5-yl)-2J-naphthyridin-3-yl)-2-(2,7-diazaspiro[3.5]nonan-7-yl)isonicotinamide

[4225];

N-(6-(oxazol-5 -yl)-2,7-naphthyridin-3 -yl)-2-(piperidin-4-ylamino)isonicotinamide [4226] ; 2-methyl-N-(6-(oxazol-5 -yl)-2,7-naphthyridin-3 -yl)isoindoline-5 -carboxamide [4227] ;

N-(6-(oxazol-5-yl)-2J-naphthyridin-3-yl)-l,2,3,4-tetrahydroisoquinoline-7-carboxamide [4228]; N-(6-(2-methyloxazol-5-yl)-2 -naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[4229];

N-(6-(3-methylisoxazol-5-yl)-2,7-naphthyridin-3-yl)-l-(3,3,3-trifluoropropyl)piperidine-4- carboxamide [4230];

4- fluoro- 1 -isobutyl-N-(6-(5 -methyl- 1 ,3 ,4-oxadiazol-2-yl)-2,7-naphthyridin-3 -yl)piperidine-4- carboxamide [4231];

1- isobutyl-N-(6-(5-methyl-l,3,4-oxadiazol-2-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide

[4232];

N-(6-(5-(dimethylamino)-l,3,4-oxadiazol-2-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide

[4233];

N-(6-(5-(dimethylamino)-l,3,4-oxadiazol-2-yl)-2,7-naphthyridin-3-yl)-l-methylpiperidine-4- carboxamide [4234];

N-(6-(5-methyl-l,3,4-oxadiazol-2-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4235];

3,3-difluoro-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)cyclobutane-l-carboxamide [4236];

2- methyl-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)-2-azaspiro[3.3]heptane-6-carboxamide

[4237];

l-fluoro-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane-l -carboxamide [4238]; fr «5-4-(dimethylamino)-N-(6-(1hiazol-5-yl)-2,7-naphthyridin-3-yl)cyclohexane-l-carboxamide [4239];

frara -4 -((3 -fluoroazetidin- 1 -yl)methyl) -N-(6 ^

carboxamide [4240];

N-(6 -(thiazol-5 -yl) -2,7 -naphthyridin-3 -yl)azetidine -3 -carboxamide [4241];

1- methyl-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide [4242];

1 -(2,2-difluoropropyl)-N-(6-(thiazol-5 -yl)-2,7-naphthyridin-3 -yl)piperidine-4-carboxamide

[4243];

1 -(oxetan-3 -yl) -N-(6 -(thiazol-5 -yl) -2 ,7 -naphthyridin-3 -yl)piperidine -4 -carboxamide [4244] ; 1 -(2-(pyrrolidin- 1 -yl)acetyl)-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3 -yl)piperidine-4-carboxamide

[4245];

r-methyl-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)-[l,4'-bipiperidine]-4-carboxamide [4246];

2- (pyrrolidin- 1 -yl)-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3 -yl)propanamide [4247] ;

2-(piperidin- 1 -yl)-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3 -yl)acetamide [4248] ;

2-(4-methylpiperazin-l-yl)-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)acetamide [4249];

2-moφholino-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)acetamide [4250];

4-(piperidin-4-yloxy)-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)benzamide [4251];

N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)isonicotinamide [4252];

6-(4-methylpiperazin-l-yl)-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)nicotinamide [5253]; r-methyl-N-(6-(miazol-5-yl)-2,7-naphthyridin-3-yl)-l 2^3^6'-tetrahydro-[2,4'-bipyridine]-4- carboxamide [4254];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-(thiazol-5 -yl)-2,7-naphthyridin-3-yl)isonicotinamide

[4255];

2-(4-(dimethylamino)piperidin-l-yl)-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)isonicotinamide

[4256];

2-(4-methylpiperazin-l-yl)-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)isonicotinamide [4257]; 2-(( 1 -methylpiperidin-4-yl)thio)-N-(6-(thiazol-5 -yl)-2,7-naphthyridin-3 -yl)isonicotinamide

[4258];

N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)-l,2,3,4-tetrahydroisoquinoline-7 -carboxamide [4259]; fr «5-4-((l,3-difluoropropan-2-yl)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7- naphthyridin-3 -yl)cyclohexane - 1 -carboxamide [4260] ;

N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)mo holine-4-carboxamide [4261];

N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl)acetamide [4262]; 2-((lR,4R)-2-oxa-5-azabicyclo[2.2. l]heptan-5-yl)-N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-

3-yl)acetamide [4263];

N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)-2-moφholinoacetamide [4264];

N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)-2-(moφholino-ί s)acetamide [4265];

2-(4-methylpiperazin-l-yl)-N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)acetamide [4266];

1- methyl-N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide [4267]; N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)isonicotinamide [4268];

N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)nicotinamide [4269];

2- (4-methylpiperazin-l-yl)-N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)isonicotinamide

[4270];

fr rø-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl)-4-moφholinocyclohexane-l- carboxamide [4271];

fra«s-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-napfa

cyclohexane-l-carboxamide [4272];

4-isopropyl-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl)piperazine-l- carboxamide [4273];

4-((2-methoxyethyl)(methyl)amino)-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl) piperidine-l-carboxamide [4274];

4-(( 1 ,3 -difluoropropan-2-yl)amino)-N-(6-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl) piperidine-l-carboxamide [4275];

N-(6-(5-methyl-l,3,4-miadiazol-2-yl)-2J-naphthyridin-3-yl)-4-((3,3,3-trifluoropropyl)amino) piperidine-l-carboxamide [4276];

4-((2-fluoroethyl)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2J-naphthyridin-3-yl)piperidine-

1-carboxamide [4277];

(3R,4S)-4-amino-3-fluoro-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)

piperidine-l-carboxamide [4278];

(3R,4R)-4-amino-3-fluoro-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)

piperidine-l-carboxamide [4279];

(3S,4S)-3-fluoro-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)-4-(methylamino) piperidine-l-carboxamide [4280];

(3R,4R)-3-fluoro-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2J-naphthyridin-3-yl)-4-(methylamino) piperidine-l-carboxamide [4281];

4-amino-3,3-difluoro-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)piperidine-l- carboxamide [4282]; (3R,4R)-3-fluoro-4-(isopropylamino)-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3- yl)piperidine - 1 -carboxamide [4283] ;

(3 R,4 S) -3 -fluoro-4 -(isopropylamino) -N-(6 -(5 -mrt^

yl)piperidine - 1 -carboxamide [4284] ;

3,3-difluoro-4-(isopropylamino)-N-(6-(5-methyl-l,3,4-miadiazol-2-yl)-2,7-naphthyridm

piperidine-1 -carboxamide [4285];

(3S,4S)-3-fluoro-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl)-4-((propan-2-yl-

1, 1,1,3,3,3 -d<;)amino)piperidine - 1 -carboxamide [4286] ;

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7- naphthyridin-3 -yl) -8 -azabicyclo [3.2.1] octane -8 -carboxamide [4287] ;

(lR,3s,5S)-3-((l,3-difluoropropan-2-yl)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7- naphthyridin-3-yl)-8-azabicyclo[3.2.1]octane-8-carboxamide [4288];

4-(dimethylamino)-N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)piperidine-l-carboxamide

[4289];

4-((2,2-difluoroethyl)amino)-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl)

piperidine-1 -carboxamide [4290];

4-((2,2-difluoroethyl)(methyl-d3)amino)-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2,7-naphthyridm

3 -yl)piperidine - 1 -carboxamide [4291];

N-(6-(5-methyl-l,3,4-miadiazol-2-yl)-2,7-naphthyridin-3-yl)-4-mo holinopiperidine-l- carboxamide [4292];

N-(6-(5-methyl-l,3,4-1hiadiazol-2-yl)-2,7-naphthyridin-3-yl)-4-(4-methylpiperazin-l-yl)

piperidine-1 -carboxamide [4293];

(R)-3,4-dimethyl-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl)piperazine-l- carboxamide [4294];

(S)-3,4-dimethyl-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl)piperazine-l- carboxamide [4295];

(lR,3r,5S)-3-((2-fluoroethyl)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3- yl)-8 -azabicyclo [3.2. l]octane-8-carboxamide [4296];

(lR,3r,5S)-3-((2,2-difluoroethyl)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-

3-yl)-8-azabicyclo[3.2. l]octane-8-carboxamide [4297];

(lR,3r,5S)-3-amino-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)-8-azabicyclo

[3.2.1] octane -8 -carboxamide [4298];

(lS,4S)-5-methyl-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)-2,5-diazabicyclo

[2.2. l]heptane-2 -carboxamide [4299]; (lR,4R)-5-methyl-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2 -naphthyridin-3-yl)-2,5-diazabicyclo

[2.2. l]heptane-2-carboxamide [4300];

8-methyl-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2 -naphthyridin-3-yl)-3,8-diazabicyclo[3.2.1^ octane-3-carboxamide [4301];

3-methyl-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2 -naphthyridin-3-yl)-3,8-diazabicyclo[3.2.1^ octane-8-carboxamide [4302];

N-(6-(5-methyl-l,3,4-miadiazol-2-yl)-2J-naphthyri^^

7(8H)-carboxamide [4303];

2-(4-methylpiperazin-l-yl)-N-(6-(5-methylthiazol-2-yl)-2 -naphthyridin-3-yl)isonicotinamide

[4304];

2-(4-methylpiperazin-l-yl)-N-(6-(4-methylthiazol-2-yl)-2 -naphthyridin-3-yl)isonicotinamide

[4305];

N-(6 -(2-(methylamino)thiazol -5 -yl) -2, 7-naphthyridin-3 -yl)piperidine -4 -carboxamide [4306] ;

1- methyl-N-(6-(2-(methylamino)thiazol-5-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide

[4307];

N-(6-(2-(diethylamino)thiazol-5-yl)-2J-naphthyridin-3-yl)-2-(4-fluoropiperidin-l-yl)acetamide

[4308];

N-(6-(2-(diethylamino)thiazol-5-yl)-2J-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)acetamid^

[4309];

N-(6-(2-aminothiazol-5-yl)-2 ,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[4310];

N-(6-(2-(methylamino)thiazol-5-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4311];

N-(6-(2-(dimethylamino)thiazol-5-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4312];

2- (4 sopropylpiperazin-l-yl)-N-(6-(2-(methylamino)thiazol-5-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [4313];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-(2-(methylamino)thiazol-5-yl)-2,7-naphthyridin-3 -yl) isonicotinamide [4314];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-(2-(dimethylamino)thiazol-5 -yl)-2,7-naphthyridin-3-yl) isonicotinamide [4315];

2-(3-aminoazetidin-l-yl)-N-(6-(2-(dimethylamino)thiazol-5-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [4316]; N-(6-(5-chlorothiazol-2-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[4317];

2-(6-(2-(4-methylpiperazin-l-yl)isonicotinamido)-2J-naphthyridin-3-yl)thiazole-5-carboxamid

[4318];

N-(6-(isothiazol-4-yl)-2J-naphthyridin-3-yl)-l-methylpiperidine-4-carboxamide [4319];

N-(6-(l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl)-4-(difluoromethoxy)benzamide [4320]; N-(6-(l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)-4-(piperidin-4-yloxy)benzamide [4321]; N-(6-(l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl)-4-((l-methylpiperidin-4-yl)oxy)benzam

[4322];

N-(6-(l,3,4 madiazol-2-yl)-2,7-naphthyridin- [4323];

N5-(6-(l,3,4 hiadiazol-2-yl)-2J-naphthyridin-3-yl)-N2-methylpyridine-2,5-dicarboxamide

[4324];

N-(6-(l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)-6-(4-^

[4325];

N-(6-(l,3,4 hiadiazol-2-yl)-2 -naphthyridin-3-yl)-l'-methyl-1^2^3^6' etrahydro-[2,4'- bipyridine] -4 -carboxamide [4326] ;

N-(6-(l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl)-2-(3-(dimethylamino)azetidin-l-yl^

isonicotinamide [4327];

N-(6-( 1 ,3 ,4-thiadiazol-2-yl)-2,7-naphthyridin-3 -yl)-2-(4-methylpiperazin-l -yl)isonicotinamide

[4328];

N-(6-( 1 ,3 ,4-thiadiazol-2-yl)-2,7-naphthyridin-3 -yl)-2-(4-isopropylpiperazin-l -yl)isonicotinamide

[4329];

N-(6-(l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl)-2-mo holinoisonicotinamide [4330];

l-fluoro-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)cyclohexane-l- carboxamide [4331];

fr «5-4-methoxy-N-(6-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3 -yl)cyclohexane- 1 - carboxamide [4332];

c/5-4-methoxy-N-(6-(5-methyl- 1 ,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3 -yl)cyclohexane- 1 - carboxamide [4333];

fr «5-4-amino-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)cyclohexane-l- carboxamide [4334];

fr «5-4-(dimethylamino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)

cyclohexane-1 -carboxamide [4335]; fr rø-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl)-4-moφholinocyclohexane-l- carboxamide [4336];

fr «5-4-(hydroxymethyl)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)

cyclohexane-l-carboxamide [4337];

N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2J-naphthyridin-3-yl)piperidine-4-carboxamide [4338]; 4-fluoro-N-(6-(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)-2,7-naphthyridin-3 -yl)piperidine-4-carboxamide

[4339];

l-methyl-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2J-naphthyridin-3-yl)piperidine-4-carbo

[4340];

4-fluoro-l-methyl-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl)piperidine-4- carboxamide [4341];

l-(2-fluoroethyl)-N-(6-(5-methyl-l,3,4-tma^

carboxamide [4342];

1 -(2,2-difluoroethyl)-N-(6-(5 -methyl- 1 ,3 ^

carboxamide [4343];

N-(6-(5-methyl-l,3,4-miadiazol-2-yl)-2J-naphthyridin-3-yl)-l-(3,3,3-trifluoropropyl)piperi 4-carboxamide [4344];

l-(2,2-difluoropropyl)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2J-naphthyridin-3-yl)piperidm carboxamide [4345];

1- benzoyl-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2J-naphthyridin-3-yl)piperidine-4-carboxamide

[4346];

N-(6-(5-methyl-l,3,4-miadiazol-2-yl)-2J-naphthyridin-3-yl)-2-(pyrrolidin-l-yl)acetami

[4347];

N-(6-(5-methyl-l,3,4-miadiazol-2-yl)-2J-naphthyridin-3-yl)-2-(piperidin-l-yl)acetamide [4348];

2- (4-methoxypiperidin-l-yl)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2 -naphthyridin-3-yl)

acetamide [4349];

N-(6-(5-methyl-l,3,4-miadiazol-2-yl)-2 -naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

acetamide [4350];

N-(6-(5-methyl-l,3,4-miadiazol-2-yl)-2 -naphthyridin-3-yl)-2-mo holinoacetamide [4351]; (R)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)-2-(3-methylmoφholino)

acetamide [4352];

2-(7-azabicyclo[2.2 ]heptan-7-yl)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl) acetamide [4353]; 2-((lR,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7- naphthyridin-3 -yl)acetamide [4354] ;

2-(3-oxa-8-azabicyclo[3.2 ]octan-8-yl)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-

3-yl)acetamide [4355];

2-(8-oxa-3-azabicyclo[3.2 ]octan-3-yl)-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2J-naphthyridin- 3-yl)acetamide [4356];

N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2J-naphthyridin-3-yl)-2-(l,4-oxazepan-4-yl)acetamide

[4357];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2 -naphthyridm^

[4358];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2J-naphthyr ^^ [4359]; 1 -methyl-3-(6-(5 -methyl-1 ,3,4-thiadiazol-2-yl)-2 ,7-naphthyridin-3-yl)- 1 -( 1 -methylpiperidin-4-yl) urea [4360];

(3S,4S)-4-amino-3-fluoro-N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2,7-naphthyridin-3-yl)

piperidine-l-carboxamide [4361];

(3 S,4S)-4-(dimethylamino)-3 -fluoro-N-(6-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl) piperidine-l-carboxamide [4362];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2 -naphthyridin-3-yl)mo holine-4-carboxamide [4363]; N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2 -naphthyridm^

carboxamide [4364];

4-(dimethylamino)-N-(6-(5-methyl-l,3,4-thiadiaz

carboxamide [4365];

4-((2,2-difluoroethyl)(methyl)amino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2 -naphthyr

yl)piperidine - 1 -carboxamide [4366] ;

(3S,4S)-3-fluoro-4-(isopropylamino)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3- yl)piperidine-l -carboxamide [4367];

2-methyl-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2 -naphthyridin-3-yl)-5,6-dihydroimida

pyrazine-7(8H)-carboxamide [4368];

4-methyl-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2 -naphthyridin-3-yl)piperazine-l-carboxami

[4369];

N-(6-(5-methyl-l,3,4-miadiazol-2-yl)-2J-naphthyridin-3-yl)-l-(l-methylpiperidin-4

pyrazole -4 -carboxamide [4370];

1 -( 1 -isopropylpiperidin-4-yl)-N-(6-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)- 1H- pyrazole -4 -carboxamide [4371]; N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)-l-(l-methylpi^

l,2,3-triazole-4-carboxamide [4372];

N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2J-naphthyridin-3-yl)-2-(piperidin-4-yl)oxazole-4- carboxamide [4373];

N-(6-(5-methyl-l,3,4 hiadiazol-2-yl)-2 -naphthyridin-3-yl)-2-(l-methylpiperidin-4-yl)oxa 4-carboxamide [4374];

2-(3 -(dimethylamino)azetidin- 1 -yl)-N-(6-(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl) isonicotinamide [4375];

r-methyl-N-(6-(5 -methyl- 1 ,3,4-thiadiazol-2-yl)-2 ,7-naphthyridin-3 -yl)-l ',2',3 ',6'-tetrahydro-[2,4'- bipyridine] -4-carboxamide [4376];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2 -naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4377];

2-(methyl( 1 -methylpiperidin-4-yl)amino)-N-(6-(5-methyl- 1 ,3 ,4-thiadiazol-2-yl)-2,7- naphthyridin-3 -yl)isonicotinamide [4378] ;

2-(azetidin-3-yloxy)-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)isonicotinamide

[4379];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2J-naphthyridin-3-yl)-3-((l-methylpiperidin-4-yl)oxy) benzamide [4380];

N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2 -naphthyridin-3-yl)-2-((l-methylpiperidin-4-yl)thio) isonicotinamide [4381];

6-(4-methylpiperazin-l-yl)-N-(6-(5-(trifluoromethyl)-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3- yl)nicotinamide [4382];

2-(4-methylpiperazin-l-yl)-N-(6-(5-(trifluoromethyl)-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3- yl)isonicotinamide [4383];

N-(6-(5-amino-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4384];

N-(6-(5-(dimethylamino)-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l- yl)isonicotinamide [4385];

N-(6-(3-amino-5 -fluorophenyl)-2,7-naphthyridin-3 -yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [4386];

N-(6-(3-fluoro-5-(isopropylamino)phenyl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [4387];

1 -methyl -N-(6 -(pyridin-2 -yl) -2, 7-naphthyridin-3 -yl)piperidine -4 -carboxamide [4388] ;

2-(4-methylpiperazin-l-yl)-N-(6-(pyridin-2-yl)-2,7-naphthyridin-3-yl)isonicotinamide [4389]; 2-(4-methylpiperazin-l-yl)-N-(6-(pyridin-4-yl)-2,7-naphthyridin-3-yl)isonicotinamide [4390]; N-(6-(pyridin-3 -yl)-2,7-naphthyridin-3 -yl)cyclopropanecarboxamide [4391] ;

N-(6 -(pyridin-3 -yl) -2,7 -naphthyridin-3 -yl) -2 -(pyrrolidin- 1 -yl)acetamide [4392] ;

1 -methyl -N-(6 -(pyridin-3 -yl) -2,7 -naphthyridin-3 -yl)piperidine -4-carboxamide [4393] ;

N-(6-(pyridin-3 -yl)-2,7-naphthyridin-3 -yl)quinuclidine-4-carboxamide [4394] ;

2-moφholino-N-(6-(pyridin-3-yl)-2,7-naphthyridin-3-yl)acetamide [4395];

2-(moφholino-ί s)- -(6-(pyridin-3-yl)-2,7-naphthyridin-3-yl)acetamide [4396];

2-(4-methylpiperazin-l-yl)-N-(6-(pyridin-3-yl)-2,7-naphthyridin-3-yl)acetamide [4397];

2-(4-methyl- 1 ,4-diazepan- 1 -yl)-N-(6-(pyridin-3-yl)-2,7-naphthyridin-3-yl)acetamide [4398] ; 2-(4-methylpiperazin-l-yl)-N-(6-(pyridin-3-yl)-2,7-naphthyridin-3-yl)isonicotinamide [4399]; 2-(2-methyl-lH-imidazol-l-yl)-N-(6-(pyridin-3-yl)-2,7-naphthyridin-3-yl)acetamide [4400]; 2-(lH-imidazol-l-yl)-N-(6-(pyridin-3-yl)-2,7-naphthyridin-3-yl)acetamide [4401];

2-(piperidin-4-yl)-N-(6-(pyridin-3-yl)-2,7-naphthyridin-3-yl)oxazole-4-carboxamide [4402]; 2-( 1 -methylpiperidin-4-yl)-N-(6-(pyridin-3 -yl)-2,7-naphthyridin-3 -yl)oxazole-4-carboxamide

[4403];

2-(l-isopropylpiperidin-4-yl)-N-(6-(pyridin-3-yl)-2,7-naphthyridin-3-yl)oxazole-4-carboxamide

[4404];

fr rø-N-(6-(5-fluoropyridin-3-yl)-2,7-naphthyridin-3-yl)-3-moφholinocyclobutane-l- carboxamide [4405];

fr «5-N-(6-(5-fluoropyridin-3-yl)-2,7-naphthyridin-3-yl)-4-((4-methylpiperazin-l-yl)methyl) cyclohexane-l-carboxamide [4406];

N-(6-(5-fluoropyridin-3 -yl)-2,7-naphthyridin-3 -yl)-2-(pyrrolidin- 1 -yl)acetamide [4407] ;

N-(6-(5-fluoropyridin-3-yl)-2,7-naphthyridin-3-yl)-l-methylpiperidine-4-carboxamide [4408]; N-(6-(5-fluoropyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)acetamide [4409]; N-(6-(6-fluoropyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)acetamide [4410]; N-(6-(5-fluoropyridin-3-yl)-2,7-naphthyridin-3-yl)-2-moφholinoacetamide [4411];

N-(6-(5-fluoropyridin-3-yl)-2,7-naphthyridin-3-yl)-3-moφholinopropanamide [4412];

N-(6-(5-fluoropyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[4413];

N-(6-(5-fluoropyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide

[4414];

N-(6-(5-fluoropyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(l-methylpiperidin-4-yl)oxazole-4- carboxamide [4415]; N-(6-(5-fluoropyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(l-isopropylpiperidin-4-yl)oxazole-4- carboxamide [4416];

N-(6-(5-chloropyridin-3-yl)-2 -naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[4417];

N-(6-(5-methylpyridin-3-yl)-2,7-naphthyridin-3-yl)-2-moφholinoacetamide [4418];

N-(6-(5-(difluoromethyl)pyridin-3-yl)-2,7-naphthyridin-3-yl)-3-(piperidin-4-yl)benzamide

[4419];

N-(6-(5-(difluoromethyl)pyridin-3-yl)-2,7-naphthyridin-3-yl)-3-(l-methylpiperidin-4-yl)

benzamide [4420];

N-(6-(5-(difluoromethyl)pyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4421];

2-(4-methylpiperazin-l-yl)-N-(6-(5-(trifluoromethyl)pyridin-3-yl)-2,7-naphthyridin-3-yl)

acetamide [4422];

2-(4-methylpiperazin-l-yl)-N-(6-(6-(trifluoromethyl)pyridin-3-yl)-2,7-naphthyridin-3-yl)

acetamide [4423];

N-(6-(5-(hydroxymethyl)pyridin-3-yl)-2 -naphthyridin-3-yl)-l-methylpiperidine-4-carboxamide

[4424];

N-(6-(5-cyanopyridin-3-yl)-2,7-naphthyridin-3-yl)-l-methylpiperidine-4-carboxamide [4425]; N-(6-(5-methoxypyridin-3-yl)-2,7-naphthyridin-3-yl)-l-methylpiperidine-4-carboxamide [4426]; N-(6-(5-methoxypyridin-3-yl)-2,7-naphthyridin-3-yl)-2-moφholinoacetamide [4427];

N-(6-(5-methoxypyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[4428];

4-fluoro-N-(6-(5-(piperidin-4-yloxy)pyridin-3-yl)-2,7-naphthyridin-3-yl)benzamide [4429]; N-(6-(5-aminopyridin-3-yl)-2,7-naphthyridin-3-yl)-4-fluorobenzamide [4430];

N-(6-(5-aminopyridin-3-yl)-2,7-naphthyridin-3-yl)-4-(piperidin-4-yloxy)benzamide [4431]; N-(6-(5-aminopyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinam

[4432];

N-(6-(5-aminopyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide

[4433];

N-(6-(6-aminopyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)isonicotinamide

[4434];

N-(6-(6-(methylamino)pyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4435]; N-(6-(5-(isopropylamino)pyridin-3-yl)-2J-naphthyridin-3-yl)-3-(piperidin-4-yl)benzamide [4436];

N-(6-(5-(isopropylamino)pyridin-3-yl)-2,7-naphthyridin-3-yl)-3-(l-methylpiperidin-4-yl)

benzamide [4437];

N-(6-(5-(isopropylamino)pyridin-3-yl)-2J-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4438];

N-(6-(5-(piperidin-4-ylamino)pyridin-3-yl)-2,7-naphthyridin-3-yl)cyclohexanecarboxamide

[4439];

4-fluoro-N-(6-(5-(piperidin-4-ylamino)pyridin-3-yl)-2,7-naphthyridin-3-yl)benzamide [4440]; 4-fluoro-N-(6-(5-((l-methylpiperidin-4-yl)amino)pyridin-3-yl)-2,7-naphthyridin-3-yl)benzami

[4441];

N-(6-(5-acetamidopyridin-3-yl)-2,7-naphthyridin-3-yl)-l-methylpiperidine-4-carboxamide

[4442];

N-(6-(5-(dimethylamino)pyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4443];

N-(6-(6-(dimethylamino)pyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4444];

l-methyl-N-(6-(5-(pyrrolidin-l-yl)pyridin-3-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide

[4445];

N-(6-(5-(pyrrolidin-l-ylmethyl)pyridin-3-yl)-2,7-naphthyridin-3-yl)cyclopropanecarboxamide

[4446];

4-fluoro-N-(6-(5-(pyrrolidin-l-ylmethyl)pyridin-3-yl)-2,7-naphthyridin-3-yl)benzamide [4447]; N-(6-(5-((4-hydroxypiperidin-l-yl)methyl)pyridin-3-yl)-2,7-naphthyridin-3-yl)

cyclopropanecarboxamide [4448];

4-fluoro-N-(6-(5-((4-hydroxypiperidin- 1 -yl)methyl)pyridin-3 -yl)-2,7-naphthyridin-3 -yl)

benzamide [4449];

N-(6-(5-(piperazin-l-ylmethyl)pyridin-3-yl)-2,7-naphthyridin-3-yl)cyclopropanecarboxamide

[4450];

N-(6-(5-((4-methylpiperazin-l-yl)methyl)pyridin-3-yl)-2,7-naphthyridin-3-yl)

cyclopropanecarboxamide [4451];

N-(6-(5-(mo holinomethyl)pyridin-3-yl)-2,7-naphthyridin-3-yl)cyclopropanecarboxamide

[4452];

N-methyl-5-(6-(l-methylpiperidine-4-carboxamido)-2,7-naphthyridin-3-yl)nicotinamide [4453]; N-methyl-5-(6-(2-(4-methylpiperazin-l-yl)isonicoti

[4454];

N-(6-(pyridin-3-yl^)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl)acetamide [4455];

2-(4-methylpiperazin- 1 -yl)-N-(6-(pyridin-3 -yl-^)-2,7-naphthyridin-3-yl)acetamide [4456] ;

2-moφholino-N-(6-(pyridin-3-yl-ί 4()-2,7-naphthyridin-3-yl)acetamide [4457];

1- methyl-N-(6-(2-methylpyrimidin-5-yl)-2 -naphthyridin-3-yl)piperidine-4-carboxamide [4458];

2- (4-methylpiperazin-l-yl)-N-(6-(2-methylpyrimidin-5-yl)-2,7-naphthyridin-3-yl)isonicotinami

[4459];

N-(6-(2-aminopyrimidin-5-yl)-2,7-naphthyridin-3 -yl)- 1 -methylpiperidine-4-carboxamide [4460] ; 2-moφholino-N-(6-(pyridazin-3-yl)-2,7-naphthyridin-3-yl)acetamide [4461];

2-moφholino-N-(6-(pyridazin-4-yl)-2,7-naphthyridin-3-yl)acetamide [4462];

N-(6-(pyridazin-4-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl)acetamide [4463];

trans -3 -ηιοφ1ιο1ίηο-Ν-(6 -(pyrazin-2-yl) -2 ,7 -naphthyridin-3 -yl)cyclobutane - 1 -carboxamide

[4464];

trans -4 -(dimethylamino) -N-(6 -(pyrazin-2-yl) -2, 7-naphthyridin-3 -yl)cyclohexane - 1 -carboxamide

[4465];

fr rø-4-moφholino-N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3 -yl)cyclohexane- 1 -carboxamide

[4466];

trans-4-((3 -fluoroazetidin- 1 -yl)methyl)-N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3 -yl)cyclohexane-

1 -carboxamide [4467];

fr «5-4-((4-methylpiperazin-l-yl)methyl)-N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3-yl)

cyclohexane-1 -carboxamide [4468];

N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl)acetamide [4469];

l-methyl-N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide [4470];

4-fluoro-l -methyl -N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide [4471]; l-(2-fluoroethyl)-N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide [4472];

1- (oxetan-3-yl)-N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide [4473];

2- moφholino-N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3-yl)acetamide [4474];

1 -methyl -N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3 -yl)azepane-4-carboxamide [4475] ;

l-isobutyl-N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3-yl)azepane-4-carboxamide [4476];

1- (2-hydroxy-2-methylpropyl)-N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3-yl)azepane-4-carboxamide

[4477];

4-(moφholinomethyl)-N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3 -yl)benzamide [4478] ;

2- (4-methylpiperazin-l-yl)-N-(6-(pyrazin-2-yl)-2,7-naphthyridin-3-yl)isonicotinamide [4479]; N-(6-(6-(methylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [4480];

N-(6-(6-(isopropylamino)pyrazin-2-yl)-2J-naphthyridin-3-yl)azetidine-3-carboxamide [4481]; N-(6-(6-(isopropylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)piperidine-4-carboxamide [4482]; N-(6-(6-(isopropylamino)pyrazin-2-yl)-2,7-naphthyridin-3 -yl)- 1 -methylpiperidine-4-carboxamide

[4483];

l-(2-fluoroethyl)-N-(6-(6-(isopropylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)piperidine-4- carboxamide [4484];

l-isopropyl-N-(6-(6-(isopropylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)piperidine-4- carboxamide [4485];

l-isopentyl-N-(6-(6-(isopropylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)piperidine-4- carboxamide [4486];

N-(6-(6-(isopropylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-3-(piperidin-4-yl)benzamide

[4487];

N-(6-(6-(isopropylamino)pyrazin-2-yl)-2J-naphthyridin-3-yl)-3-(l-methylpiperidin-4-yl)

benzamide [4488];

N-(6-(6-(isopropylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-l-(piperidin-4-yl)-lH-l,2,3- triazole -4 -carboxamide [4489];

1 -( 1 -(2-fluoroethyl)piperidin-4-yl)-N-(6-(6-(isopropylamino)pyrazin-2-yl)-2,7-naphthyridin yl)- 1H- 1 ,2,3 -triazole-4-carboxamide [4490] ;

N-(6-(6-(isopropylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-l-(l-isopropylpiperidin-4-yl)-lH- l,2,3-triazole-4-carboxamide [4491];

N-(6-(6-(isopropylamino)pyrazin-2-yl)-2,7-naphthyridin-3 -yl)-2-(4-methylpiperazin- 1 -yl)

isonicotinamide [4492];

N-(6-(6-(feri-butylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-2-(3-(dimethylamino)azetidin-l- yl)isonicotinamide [4493];

N-(6-(6-(feri-butylamino)pyrazin-2-yl)-2,7-naphthyridin-3 -yl)- 1 '-methyl- 1 ',2',3 ',6'-tetrahydro-

[2,4'-bipyridine]-4-carboxamide [4494];

N-(6-(6-(feri-butylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4495];

N-(6-(6-(feri-butylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-2-(4-isopropylpiperazin-l-yl) isonicotinamide [4496];

N-(6-(6-(ferί-butylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-2-moφholinoisonicotinamide

[4497]; N-(6-(6-(((3-fluoroazetidin-3-yl)methyl)amino)pyrazin-2-yl)-2,7-naphthyridin-3-yl) cyclopropanecarboxamide [4498];

4-fluoro-N-(6-(6-(((3-fluoroazetidin-3-yl)methyl)amino)pyrazin-2-yl)-2,7-naphthyridin-3-yl) benzamide [4499];

N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)cyclobutanecarboxamide

[4500];

3.3- difluoro-N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)cyclobutane-l- carboxamide [4501];

N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)cyclopentanecarboxamide

[4502];

4.4- difluoro-N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)cyclohexane-l- carboxamide [4503];

N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)tetrahydro-2H-pyran-4- carboxamide [4504];

4-fluoro-N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)-2,7-naphthyridin-3 -yl)benzamide [4505] ; N-(6-(6-(((3S,4S)-3-fluoropiperidin-4-yl)amino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)

cyclopropanecarboxamide [4506];

4-fluoro-N-(6-(6-(((3S,4S)-3-fluoropiperidin-4-yl)amino)pyrazin-2-yl)-2,7-naphthyridin-3-yl) benzamide [4507];

N-(6-(6-(( 1 -methylpiperidin-4-yl)amino)pyrazin-2-yl)-2,7-naphthyridin-3 -yl)

cyclobutanecarboxamide [4508] ;

N-(6-(6-(( 1 -methylpiperidin-4-yl)amino)pyrazin-2-yl)-2,7-naphthyridin-3 -yl)

cyclopentanecarboxamide [4509];

4-fluoro-N-(6-(6-(( 1 -methylpiperidin-4-yl)amino)pyrazin-2-yl)-2,7-naphthyridin-3 -yl)benzamide

[4510];

N-(6-(6-((l-isopropylpiperidin-4-yl)amino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)

cyclopropanecarboxamide [4511];

3,3-difluoro-N-(6-(6-((l-isopropylpiperidin-4-yl)amino)pyrazin-2-yl)-2,7-naphthyridin-3-yl) cyclobutane-1 -carboxamide [4512];

N-(6-(6-((l-isopropylpiperidin-4-yl)amino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)

cyclopentanecarboxamide [4513];

4-fluoro-N-(6-(6-(( 1 -isopropylpiperidin-4-yl)amino)pyrazin-2-yl)-2,7-naphthyridin-3 -yl)

benzamide [4514]; N-(6-(6-(dimethylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl) isonicotinamide [4515];

N-(6-(6-(diethylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4516];

N-(6-(6-(3-aminoazetidin-l-yl)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-4-fluorobenzamide [4517]; 2-(4-methylpiperazin- 1 -yl)-N-(6-(6-(pyrrolidin- 1 -yl)pyrazin-2-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [4518];

N-(6-(6-(azetidin-3-ylmethoxy)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-4-fluorobenzamide [4519]; N-(6-(6-(azetidin-3-yloxy)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-4-fluorobenzamide [4520]; N-(6-(lH-pyrrolo[2,3-b]pyridin-5-yl)-2,7-naphthyridin-3-yl)-l-(l-methylpiperidin-4-yl)-lH- pyrazole-4-carboxamide [4521];

N-(6-(lH-pyrrolo[3,2-b]pyridin-6-yl)-2,7-naphthyridin-3-yl)-l-(l-methylpiperidin-4-yl)-lH- pyrazole-4-carboxamide [4522];

N-(6-( lH-pyrrolo[2,3-c]pyridin-4-yl)-2,7-naphthyridin-3 -yl)- 1 -( 1 -methylpiperidin-4-yl)- 1H- pyrazole-4-carboxamide [4523];

N-(6-(lH-pyrrolo[2,3-b]pyridin-5-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4524];

N-(6-(lH-pyrrolo[3,2-b]pyridin-6-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4525];

N-(6-(lH-pyrrolo[2,3-c]pyridin-4-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4526];

2-(4-methylpiperazin-l-yl)-N-(6-(oxazolo[5,4-b]pyridin-6-yl)-2,7-naphthyridin-3-yl)

isonicotinamide [4527];

N-(6-(2-methyl-lH-pyrrolo[2,3-b]pyridin-5-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l- yl)isonicotinamide [4528];

N-(6-(3-methyl-lH-pyrrolo[2,3-b]pyridin-5-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l- yl)isonicotinamide [4529];

N-(6-(2-methyl-lH-pyrrolo[3,2-b]pyridin-6-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l- yl)isonicotinamide [4530];

N-(6-(5H-pyrrolo[2,3-b]pyrazin-2-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4531];

N-(6-(5H-pyrrolo[2,3-b]pyrazin-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methylpiperazin-l-yl)

isonicotinamide [4532]; l-isopropyl-N-(6-(6-(piperidin-4-ylamino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-lH-pyrazole-4- carboxamide [4533];

l-isopropyl-N-(6-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2-yl)-2,7-naphthyridin-3-yl)-lH- pyrazole-4-carboxamide [4534];

fra«s-4-((2-fluoroethyl)amino)-N-(3 -( 1 -methyl-lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6-yl)

cyclohexane-l-carboxamide [4628];

fr «5-4-((2-methoxyethyl)amino)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)

cyclohexane-l-carboxamide [4629];

fert-butyl (fr «5-4-((3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)carbamoyl)cyclohexyl) carbamate [4630];

N-(3 -( 1 -methyl -lH-pyrazol -4 -yl)- 1 ,7-naphthyridin-6-yl)-2-(( 1 -methylpiperidin-4-yl)amino) isonicotinamide [4631];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)thiazole-5- carboxamide [4632];

N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin-l-yl)thiazole-5- carboxamide [4633];

N-(3 -( 1 -methyl -5 -(piperidin- 1 -ylmethyl)- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2-(2,7- diazaspiro[3.5]nonan-2-yl)isonicotinamide [4634] ;

N-(3-(l-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl)-4-(piperidin-4-yloxy)benzamide

[4635];

N-(3 -( 1 -methyl-lH-tetrazol-5 -yl)- 1 ,7-naphthyridin-6-yl)- 1 -(3,3,3-trifluoropropyl)piperidine-4- carboxamide [4636];

N-(3-(l,2-dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-(pyrrolidin-l-yl)propanamide

[4637];

N-(3 -( 1 ,2-dimethyl- lH-imidazol-5-yl)-l ,7-naphthyridin-6-yl)-2-(piperidin- 1 -yl)propanamide

[4638];

4-isopropoxy-N-(3-(7-methyl-5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3-yl)-l,7-naphthyridin-6- yl)benzamide [4639];

trans-3 -mo holino-N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)cyclobutane- 1 -carboxamide

[4640];

fr «5-4-(hydroxymethyl)-N-(3-(oxazol-5-yl)-l,7-naphthyridin-6-yl)cyclohexane-l-carboxamide

[4641];

N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)piperidine-4-carboxamide [4642] ;

4-πιοφ1ιο1ίηο-Ν -(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)piperidine- 1 -carboxamide [4643] ; N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)-4-(piperidin-4-yloxy)benzamide [4644] ;

N-(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)-3-(piperidin-4-yloxy)benzamide [4645] ;

2-methyl-N-(3-(oxazol-5-yl)-l,7-naphthyridin-6-yl)-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H)- carboxamide [4646];

2-( lH-imidazol-1 -yl)-N -(3 -(oxazol-5 -yl)- 1 ,7-naphthyridin-6-yl)acetamide [4647] ;

trans -4 -(hydroxymethyl) -N -(3 -(thiazol -5 -yl) - 1 ,7 -naphthyridin-6-yl)cyclohexane - 1 -carboxamide

[4648] ;

fr «5-4-(dimethylamino)-N-(3 -(thiazol-5-yl)- 1 ,7-naphthyridin-6-yl)cyclohexane- 1 -carboxamide

[4649] ;

N-(3-(thiazol-5-yl)-l,7-naphthyridin-6-yl)-l -((l -(trifluoromethyl)cyclopropyl)methyl)piperidine- 4-carboxamide [4650];

fr «5-4-(hydroxymethyl)-N-(3-(2-methylthiazol-5-yl)- l,7-naphthyridin-6-yl)cyclohexane-l- carboxamide [4651];

fr «5-4-(dimethylamino)-N-(3 -(2-methylthiazol-5-yl)- 1 ,7-naphthyridin-6-yl)cyclohexane- 1 - carboxamide [4652];

N-(3-(2-methylthiazol-5-yl)-l,7-naphthyridin-6-yl)-l -(oxetan-3-yl)piperidine-4 -carboxamide

[4653] ;

N-(3 -(2-methylthiazol-5-yl)- 1 ,7-naphthyridin-6-yl)- 1 -(2-(pyrrolidin- 1 -yl)acetyl)piperidine-4- carboxamide [4654];

2-((l S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7- naphthyridin-6-yl)acetamide [4655] ;

N-(3 -(5-(cyano(4-hydroxypiperidin- 1 -yl)methyl)pyridin-3 -yl)- 1 ,7-naphthyridin-6-yl)

cyclopropanecarboxamide [4656];

4-fluoro-N-(3 -(6-(( 1 -methylazetidin-3 -yl)methoxy)pyrazin-2-yl)- 1 ,7-naphthyridin-6-yl)

benzamide [4657] ;

l-isopropyl-N-(3-(6-(( l-methylpiperidin-4-yl)amino)pyrazin-2-yl)-l,7-naphthyridin-6-yl)-lH- pyrazole -4 -carboxamide [4658]; or a pharmaceutically acceptable salt thereof.

25. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1-24, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

26. A method of treating a disorder or disease in a patient, wherein the disorder or disease is selected from the group consisting of: chronic inflammation, systemic inflammation, diabetes, cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, a bone or cartilage disease, a neurological condition/disorder/disease, osteoarthritis, lung disease, a fibrotic disorder, the method comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1-24, or a pharmaceutically acceptable salt, or a pharmaceutical composition.

27. A method of claim 26, wherein the disorder or disease is cancer.

28. A method of claim 26, wherein the disorder or disease is pulmonary fibrosis.

29. A method of claim 26, wherein the disorder or disease is idiopathic pulmonary fibrosis (IPF).

30. The method of claim 26, wherein the disorder or disease is lung disease.

31. A method of claim 26, wherein the disorder or disease is degenerative disc disease.

32. A method of claim 26, wherein the disorder or disease is a bone/osteoporotic fracture.

33. A method of claim 26, wherein the disorder or disease is a bone or cartilage disease.

34. A method of claim 26, wherein the disorder or disease is osteoarthritis.

35. A method of claim 26, wherein the disorder or disease is a neurological condition/disorder/disease .

36. The method of claim 27, wherein the cancer is selected from the group consisting of: osteoma, hemangioma, granuloma, xanthoma, osteitis deformans, meningioma, meningiosarcoma, and gliomatosis, astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, oligodendrocytoma, schwannoma, retinoblastoma, and congenital tumors, neurofibroma, meningioma, glioma, and sarcoma.

37. The method of claim 35, wherein the disorder or disease is a neurological condition/disorder/disease, wherein the neurological condition/disorder/disease is selected from the group consisting of: frontotemporal dementias, dementia with lewy bodies, prion diseases, multiple system atrophy, inclusion body myositis, degenerative myopathies, diabetic neuropathy, other metabolic neuropathies, endocrine neuropathies, orthostatic hypotension, and Charcot-Marie- Tooth disease.

38. The method of claim 35, wherein the disorder or disease is a neurological condition/disorder/disease, wherein the neurological condition/disorder/disease is selected from the group consisting of: Alzheimer's disease, amyotrophic lateral sclerosis (ALS), down syndrome, frontotemporal dementia (FTD) including FTD with Parkinsonism- 17 (FTDP-17), behavioural variant frontotemporal dementia (bvFTD), FTD in patients with motor neuron disease (MND) (typically amyotrophic lateral sclerosis, also called FTD -ALS), corticobasal degeneration (CBD) (also called corticobasal ganglionic degeneration), progressive supranuclear palsy, primary progressive aphasia (PPA), Prion Diseases, globular glial tauopathy (GGT), myotonic dystrophy type 1 (DM1) (also called Steinert disease), myotonic dystrophy type 2 (DM2) (also called proximal myotonic myopathy), Guam complex, argyrophilic grain disease, dementia pugilistica, postencephalitic parkinsonism, lewy body dementia, Parkinson's disease, Pick's disease, and additional diseases with pronounced neurodegeneration such as autism, dementia, epilepsy, Huntington's disease, multiple sclerosis; diseases and disorders associated with acquired brain injury such as chronic traumatic encephalopathy, traumatic brain injury, tumor, and stroke.

39. A method of claim 38, wherein the disorder or disease is Alzheimer's disease.

40. The method of claim 35, wherein the disorder or disease is a neurological condition/disorder/disease associated with tau protein, amyloid, alpha-synuclein, Tar DNA-binding Protein of 43KDa (TDP-43), Prion protein PrP or fused in sarcoma (FUS) pathology.

41. The method of claim 26, wherein the disorder or disease is a fibrotic disorder, wherein the fibrotic disorder is selected from the group consisting of: skin fibrosis; scleroderma; progressive systemic fibrosis; lung fibrosis; muscle fibrosis; kidney fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic scar formation; uterine fibrosis; renal fibrosis; cirrhosis of the liver, liver fibrosis; adhesions; chronic obstructive pulmonary disease; fibrosis following myocardial infarction; pulmonary fibrosis; fibrosis and scarring associated with diffuse/interstitial lung disease; central nervous system fibrosis; fibrosis associated with proliferative vitreoretinopathy (PVR); restenosis; endometriosis; ischemic disease, and radiation fibrosis.

42. The method of claim 26, wherein the disorder or disease is systemic inflammation.

43. The method of claim 26, wherein the disorder or disease is chronic inflammation associated eye disorders, joint pain, arthritis (rheumatoid, osteo, psoriatic gout), cancers (colon, breast, lung, pancreas, and others), gastrointestinal disorders (ulcerative colitis and inflammatory bowel diseases), pulmonary disorders (chronic obstructive pulmonary disorder and asthma), allergies, skin disorders (atopic dermatitis and psoriasis), diabetes, pancreatitis, tendonitis, hepatitis, heart disease, myocarditis, stroke, lupus, and neurological disorders such as multiple sclerosis, Parkinson's and dementia including Alzheimer's disease.

44. The method of claim 26, wherein the patient is a human.

45. The method of claim 26, wherein the compound inhibits one or more proteins in the Wnt pathway.

46. The method of claim 26, wherein the compound inhibits signaling induced by one or more Wnt proteins.

47. The method of claim 26, wherein the compound inhibits DYRK1A.

48. The method of claim 26, wherein the compound inhibits GSK3 .

49. The method of claim 26, wherein the compound inhibits DYRK1A and GSK3 .

50. The method of claim 26, wherein the compound inhibits a kinase activity.

51. A method of preventing or reducing angiogenesis in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound according to any one of claims 1-24, or a pharmaceutically acceptable salt, or a pharmaceutical composition.

Description:
DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND

USE THEREOF

RELATED APPLICATIONS

[001] This application claims the benefit of U.S. Provisional Application No. 62/579,883, filed October 31, 2017, which is incorporated herein by reference in its entirety.

BACKGROUND

Technical Field

[002] This disclosure relates to inhibitors of one or more proteins in the Wnt pathway, including inhibitors of one or more Wnt proteins, and compositions comprising the same. More particularly, it concerns the use of a diazanaphthalene compound or salts or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt- related disease states, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Background

[003] The Wnt growth factor family includes more than 10 genes identified in the mouse and at least 19 genes identified in the human. Members of the Wnt family of signaling molecules mediate many short-and long-range patterning processes during invertebrate and vertebrate development. The Wnt signaling pathway is known for its role in the inductive interactions that regulate growth and differentiation, and it also plays roles in the homeostatic maintenance of post-embryonic tissue integrity. Wnt stabilizes cytoplasmic β-catenin, which stimulates the expression of genes including c-myc, c jun, fra-1, and cyclin Dl. In addition, misregulation of Wnt signaling can cause developmental defects and is implicated in the genesis of several human cancers. The Wnt pathway has also been implicated in the maintenance of stem or progenitor cells in a growing list of adult tissues including skin, blood, gut, prostate, muscle, and the nervous system. [004] Dual specificity tyrosine-phosphorylation-regulated kinase 1A is an enzyme that in humans is encoded by the DYRKIA gene. DYRKIA is a member of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family. DYRKIA contains a nuclear targeting signal sequence, a protein kinase domain, a leucine zipper motif, and a highly conservative 13 - consecutive-histidine repeat. It catalyzes its autophosphorylation on serine/threonine and tyrosine residues. It may play a significant role in a signaling pathway regulating cell proliferation and may be involved in brain development. DYRKIA is localized in the Down syndrome critical region of chromosome 21, and is considered to be a candidate gene for learning defects associated with Down syndrome. DYRKIA is also expressed in adult brain neurons, indicating that DYRKIA may play a role in the mature central nervous system. Thus, several lines of evidence point to some synaptic functions of DYRKIA. For instance, it has been found that DYRKIA phosphorylates and modulates the interaction of several components of the endocytic protein complex machinery (Dynamin 1, Amphiphysin, and Synaptojanin). suggesting a role in synaptic vesicle recycling. In addition, a polymorphism (SNP) in DYRKIA was found to be associated with HIV-1 replication in monocyte-derived macrophages, as well as with progression to AIDS in two independent cohorts of HIV-1 -infected individuals.

SUMMARY

[005] The present disclosure provides methods and reagents, involving contacting a cell with an agent, such as a diazanaphthalene compound, in a sufficient amount to antagonize a Wnt activity, e.g., to reverse or control an aberrant growth state or correct a genetic disorder due to mutations in Wnt signaling components.

[006] The present disclosure also provides methods and reagents, involving contacting a cell with an agent, such as a diazanaphthalene compound, in a sufficient amount to antagonize DYRKIA activity, e.g., i) to normalize prenatal and early postnatal brain development; ii) to improve cognitive function in youth and adulthood; and/or iii) to attenuate Alzheimer' s-type neurodegeneration.

[007] Some embodiments disclosed herein include Wnt and/or DYRKIA inhibitors containing a diazanaphthalene core. Other embodiments disclosed herein include pharmaceutical compositions and methods of treatment using these compounds.

[008] One embodiment disclosed herein includes a compound having the structure of Formula I:

as well as prodrugs and pharmaceutically acceptable salts thereof.

[009] In some embodiments of Formula (I):

R 1 , R 2 , R 4 , and R 5 arc independently absent or selected from the group consisting of H, halide, unsubstituted -(C1-3 haloalkyl), and unsubstituted -(C1-3 alkyl);

R 3 is selected from the group consisting of -aryl optionally substituted with 1-5 R 7 and - heteroaryl optionally substituted with 1-4 R 8 ;

R 6 is selected from the group consisting of -(C1-4 alkylene) p aryl substituted with 1-5 R 9 , - (C2-4 alkenylene)paryl substituted with 1-5 R 9 , -(C1-4 alkylene)pheteroaryl optionally substituted with 1-6 R 10 ; -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 11 , -(C1-4 alkylene)pCarbocyclyl optionally substituted with 1-12 R 12 , -(C1-4 alkylene)N(R 13 )(R 14 ), - N(R 15 )(R 16 ), -CF(Ci-9 alkyl) 2 , -(C1-4 alkylene) P 0(C 3 -9 alkyl), and -(C2-9 alkynyl) optionally substituted with one or more halides; wherein each alkyl of -CF(Ci-9 alkyl) 2 is, independently, optionally substituted with one or more halides; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein; wherein -(C1-4 alkenylene) is, optionally substituted with one or more substituents as defined anywhere herein;

R 7 is selected from the group consisting of halide and -N(R 17 )2;

each R 8 is independently selected from the group consisting of H, halide, unsubstituted - (Ci-9 alkyl). unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(C1-4 alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(CM alky lene ) p heterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyi optionally substituted with 1-12 R 21 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

alternatively, two adjacent R 8 are taken together to form a ring which is selected from the group consisting of-heterocyclyl optionally substituted with 1-10 R 22 and -carbocyclyi optionally substituted with 1-12 R 21 ;

each R 9 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstiuited -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -XR 23 ,-C(=0)N(R 15 ) 2 , -(Ci-4 alkylene) p N(R 24 ) 2 , -(C1- alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein; with the proviso that when Y 2 is N then R 9 is not -OMe or ^— / ;

each R 10 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -XR 23 , -C(=0)N(R 15 ) 2 , -(Ci-4 alkylcnc)pN(R 24 ) 2 , -(C1-4 alkylcnc)phctcrocyclyl optionally substituted with 1-10 R 22 , and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 11 is independently selected from the group consisting of halide, unsubstituted -(O- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(Ci-4 alkylene)pOR 19 , -(C1-4 alkylene ) p heterocyclyl optionally substituted with 1-10 R 22 , -(C1-4 alkylene)pCarbocyclyl optionally substituted with 1-12 R 21 , -N(R 15 )(R 25 ), -C(=0)(R 26 ), -(Ci -4 alkylene)C(=0)OR 27 , -(Ci- 4 alkylene)aryl optionally substituted with one or more halides, -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides, and -SC>2(R 28 ); wherein each -(Ci-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

alternatively, two R 11 attached to the same carbon atom can together represent =0 to form a carbonyl group;

each R 12 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(Ci-4 alkylene)pOR 19 , -N(R 15 )(R 29 ), -C(=0)(R 26 ), -C(=0)OR 27 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently , optionally substituted with one or more substituents as defined anywhere herein;

R 13 is selected from the group consisting of H, unsubstituted -(C1-9 alkyl), unsubstituted - (C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents as defined anywhere herein;

R 14 is selected from the group consisting of unsubstituted -(C1-9 alkyl), unsubstituted -(C2- 9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein -(Ci-4 alkylene) is, optionally substituted with one or more substituents as defined anywhere herein;

each R 15 is selected from the group consisting of H, unsubstituted -(G-s alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl);

R 16 is selected from the group consisting of -(G-4 alkylene)pheterocj'clyl optionally substituted with 1-10 R 20 , and— (C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

R 17 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl); alternatively, two adjacent R 17 are taken togetl er to form a -heterocyclyl ring optionally substituted with 1-10 R 22 ;

R 18 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), - (C=0)R 15 , and -(C1-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 19 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(G-5 alkyl), and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 20 independently is selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(G-5 alkenyl), unsubstituted -(G-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH. -N(R 15 )2, and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 21 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(G-5 alkenyl), unsubstituted -(G-5 alkynyl), unsubstituted -(G-s haloalkyl), and -CN;

each R 22 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(G-5 alkynyl), unsubstituted -(G-5 haloalkyl). -CN, -OH, -N(R 15 ) 2 , -C(=0)R 34 , and -(Ci- 4 alkylene) p carbocyclyl optionally substituted with 1- 12 R 21 ; wherein each -(Ci-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 23 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)N(R 15 ) 2 , -(C1-4 alkylene ) p aryl optionally substituted with 1-10 R 30 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-12 R 31 . and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 24 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)pl eterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene)N(R 15 )2; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein; each R 25 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 32 , -(Ci- 4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(C1-4 alkylene)OR 33 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

R 26 is selected from the group consisting of H, unsubstituted -(C3 5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene ) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

R 27 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), and -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(G- 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein; R 28 is selected from the group consisting of unsubstituted -(C1-5 alkyl), unsubstituted -(G- 5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents as defined anywhere herein;

each R 29 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C 1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 32 , -(G-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(C1-4 alkylene)OR 33 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 30 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(G-5 haloalkyl), and -CN;

each R 31 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(G-5 alkenyl), unsubstituted -(G-5 alkynyl), unsubstituted -(G-5 haloalkyl), -CN, -OH, -C(=0)R 34 , -N(R 24 ) 2 , and -(G- 4 alkylene) p carbocyclyl optionally substituted with 1- 12 R 21 ; wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;

each R 32 is independently selected from the group consisting of halide and unsubstituted - (G-5 alkyl);

each R 33 is independently selected from the group consisting of H and unsubstituted -(G-

5 alkyl);

each R 34 is a heteroaryl optionally substituted with 1-6 R 35 ;

each R 35 is a -heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(G-5 alkyl);

each X is selected from the group consisting of 0 and S;

Y 3 is CH or nitrogen;

Y 1 , Y 2 , Y 4 , and Y 5 are independently selected from the group consisting of carbon and nitrogen; wherein

if Y 1 is nitrogen then Y 2 , Y 4 , and Y 5 are carbon, Y 3 is CH, and R 4 is absent;

if Y 2 is nitrogen then Y 1 , Y 4 , and Y 5 are carbon, Y 3 is CH, and R 5 is absent;

if Y 3 is nitrogen then Y 1 , Y 2 , Y 4 , and Y 5 are carbon; if Y 4 is nitrogen then Y 1 , Y 2 , and Y 5 are carbon, Y 3 is CH, and R 1 is absent;

if Y 5 is nitrogen then Y 1 , Y 2 , and Y 4 are carbon, Y 3 is CH, and R 2 is absent; and each p is independently 0 or 1.

[010] One embodiment disclosed herein includes a compound having the structure of Formula I:

as well as prodrugs and pharmaceutically acceptable salts thereof.

[Oil] In another embodiment of Formula (I) :

R 1 , R 2 , R 4 , and R 5 are independently absent or selected from the group consisting of H, halide, unsubstituted haloalkyl), and unsubstituted alkyl);

R 3 is selected from the group consisting of -aryl optionally substituted with 1-5 R 7 and - heteroaryl optionally substituted with 1-4 R 8 ;

R 6 is selected from the group consisting of -(Ci-4 alkylene) p aryl substituted with 1-5 R 9 , - (C2-4 alkenylene)paryl substituted with 1-5 R 9 , -(C1-4 alkylene)pheteroaryl optionally substituted with 1-6 R 10 ; -(C1-4 alkylene)pheterocyclyl optionally substituted with 1 -10 R 11 , -(C1-4 alkylene)pCarbocyclyl optionally substituted with 1 -12 R 12 , -(C1- 4 alkylene)N(R 13 )(R 14 ), - N(R 15 )(R 16 ), -CF(Ci-9 alkyl) 2 , -(C1- alkylene)pO(C 3 -9 alkyl), and -(C2-9 alkynyl) optionally substituted with one or more halides; wherein each alkyl of -CF(Ci-9 alkyl)2 is, independently, optionally substituted with one or more halides; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents; wherein -(C1-4 alkenylene) is, optionally substituted with one or more substituents;

R 7 is selected from the group consisting of halide and -N(R 17 ) 2 ;

each R 8 is independently selected from the group consisting of H, halide, unsubstituted - (Ci-9 alkyl). unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(C1-4 alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C 1 - 4 alkylene) is, independently, optionally substituted with one or more substituents; alternatively, two adjacent R 8 are taken together to form a ring which is selected from the group consisting of-heterocyclyl optionally substituted with 1-10 R 22 and -carbocyclyl optionally substituted with 1-12 R 21 ;

each R 9 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), XR 23 , G=0)N(R 15 ) 2 , -(Ci-4 alkylene)pN(R 24 ) 2 , -(C1- alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents; with the proviso that when Y 2 is N then R 9 is not -OMe or ;

each R 10 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -XR 23 , -C(=0)N(R 15 ) 2 , -(CM alkylene) p N(R 24 ) 2 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(C1-4 alkylene )pCarbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 11 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(G-9 alkynyl), unsubstituted -(G-9 haloalkyl), -(G-4 alkylene)pOR 19 , -(G-4 alkylene) p heterocyclyl optionally substituted with 1 -10 R 22 , -(G-4 alkylene)pCarbocyclyl optionally substituted with 1-12 R 21 , -N(R 15 )(R 25 ), -C(=0)(R 26 ), -(G -4 alkylene)C(=0)OR 27 , -(G- 4 alkylene)aryl optionally substituted with one or more halides, -(G-4 alkylene)pheteroaryl optionally substituted with one or more halides, and -S0 2 (R 28 ); wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents;

alternatively, two R 11 attached to the same carbon atom can together represent =0 to form a carbonyl group;

each R 12 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(G-9 alkenyl), unsubstituted -(G-9 alkynyl), unsubstituted -(G-9 haloalkyl), -(G-4 alkylene)pOR 19 , -N(R 15 )(R 29 ), -C(=0)(R 2e ), -C(=0)OR 27 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(G-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(G-4 alkylene) is, independently , optionally substituted with one or more substituents;

R 13 is selected from the group consisting of H, unsubstituted -(G-9 alkyl), unsubstituted - (G-9 alkenyl), unsubstituted -(G-9 alkynyl), unsubstituted -(G-9 haloalkyl), -(G-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 , wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents;

R 14 is selected from the group consisting of unsubstituted -(Ci-9 alkyl), unsubstituted -(G- 9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents; each R 15 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl);

R 16 is selected from the group consisting of -(C1- alkylene) p heterocj'clyl optionally substituted with 1-10 R 20 , and— (C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 17 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl); alternatively, two adjacent R 17 are taken together to form a -heterocyclyl ring optionally substituted with 1-10 R 22 ;

R 18 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), - (C=0)R 15 , and -(C1-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(G-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 19 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(G-s alkyl), and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 20 independently is selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(G-5 haloalkyl), -CN, -OR -N(R 15 ) 2 , and -(G- 4 alkylene) p carbocyclyl optionally substituted with 1 -12 R 21 ; wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents; each R 21 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN;

each R 22 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -N(R 15 ) 2 , C(=0)R 34 , and -(C1- alkylene) p carbocyclyl optionally substituted with 1- 12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 23 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)N(R 15 ) 2 , -(C1-4 alkylene ) p aryl optionally substituted with 1-10 R 30 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-12 R 31 . and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 24 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)pl eterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene)N(R 15 )2; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 25 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 32 , -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(C1-4 alkylene)OR 33 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 26 is selected from the group consisting of H, unsubstituted -(C3-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), -(C1-4 alkylene) p heteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene ) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 27 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), and -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

2 8 is selected from the group consisting of unsubstituted -(C1-5 alkyl), unsubstituted -(C2- 5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene ) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents;

each R 29 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 32 , -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(Ci_ 4 alkylene)OR 33 , and -C(=0)0(Ci 5 alkyl); wherein each -(Ci- 4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 3n is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN;

each R 31 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -C(=0)R 34 , -N(R 24 ) 2 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1- 12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 32 is independently selected from the group consisting of halide and unsubstituted - (Ci-5 alkyl);

each R 33 is independently selected from the group consisting of H and unsubstituted -(Ci-

5 alkyl);

each R 34 is independently selected from the group consisting of -0(Ci-5 alkyl) and a heteroaryl optionally substituted with 1 -6 R 35 ;

each R 35 is a -heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl);

each X is selected from the group consisting of 0 and S;

Y 3 is CH or nitrogen; Y 1 , Y 2 , Υ 4 , and Υ 5 are independently selected from the group consisting of carbon and nitrogen; wherein

if Y 1 is nitrogen then Y 2 , Y 4 , and Y 5 are carbon, Y 3 is CH, and R 4 is absent;

if Y 2 is nitrogen then Y 1 , Y 4 , and Y 5 are carbon, Y 3 is CH, and R 5 is absent;

if Y 3 is nitrogen then Y 1 , Y 2 , Y 4 , and Y 5 are carbon;

if Y 4 is nitrogen then Y 1 , Y 2 , and Y 5 are carbon, Y 3 is CH, and R 1 is absent;

if Y 5 is nitrogen then Y 1 , Y 2 , and Y 4 are carbon, Y 3 is CH, and R 2 is absent; and each p is independently 0 or 1.

[012] Another embodiment disclosed herein includes a compound having the structure of Formula la:

as well as prodrugs and pharmaceutically acceptable salts thereof.

[013] In another embodiment of Formula (la):

R 1 , R 2 , and R 5 are independently absent or selected from the group consisting of H, halide, unsubstituted -(Ci-3 haloalkyl), and unsubstituted -(C1-3 alkyl);

R 3 is selected from the group consisting of -aryl optionally substituted with 1-5 R 7 and - heteroaryl optionally substituted with 1-4 R 8 ;

R fi is selected from the group consisting of -(C1-4 alkylene) p aryl substituted with 1-5 R 9 , - (C2-4 alkenylene)paryl substituted with 1-5 R 9 , -(C1-4 alkylene)pheteroaryl optionally substituted with 1-6 R 10 ; -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 11 , -(C1-4 alkylene)pCarbocyclyl optionally substituted with 1-12 R 12 , -(C1-4 alkylene)N(R lj )(R 14 ), - N(R 15 )(R 16 ), -CF(Ci-9 alkyl) 2 , -(C1- alkylene)pO(C 3 -9 alkyl), and -(C2-9 alkynyl) optionally substituted with one or more halides; wherein each alkyl of -CF(Ci-9 alkyl)2 is, independently, optionally substituted with one or more halides; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents; wherein -(C1-4 alkenylene) is, optionally substituted with one or more substituents;

R 7 is selected from the group consisting of halide and -N(R 17 ) 2 ;

each R 8 is independently selected from the group consisting of H, halide, unsubstituted - (Ci-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(C1- alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(C1- alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyi optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

alternatively, two adjacent R 8 are taken together to form a ring which is selected from the group consisting of-heterocyclyl optionally substituted with 1-10 R 22 and -carbocyclyi optionally substituted with 1-12 R 21 ;

each R 9 is independently selected from the group consisting of halide, unsubstituted -(G- alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(G-9 alkynyl), unsubstituted -(G-9 haloalkyl), -XR 23 ,-C(=0)N(R 15 ) 2 , -(Ci-4 alkylene) p N(R 24 ) 2 , -(G-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(G-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 10 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstrtuted -(G-9 alkynyl), unsubstituted -(G-9 haloalkyl), -CN, -XR 23 , -G=0)N(R 15 ) 2 , -(G-4 alkylene) p N(R 24 ) 2 , -(G- 4 alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(G-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 11 is independently selected from the group consisting of halide, unsubstituted -(G 9 alkyl), unsubstituted -(G-9 alkenyl), unsubstituted -(G-9 alkynyl), unsubstituted -(G-9 haloalkyl), -(G-4 alkylene)pOR 19 , -(G-4 alkylene ) p heterocyclyl optionally substituted with 1 -10 R 22 , -(G-4 alkylene)pCarbocyclyl optionally substituted with 1-12 R 21 , -N(R 15 )(R 25 ), -C(=0)(R 26 ), -(G-4 alkylene)C(=0)OR 27 , -(G-4 alkylene)aryl optionally substituted with one or more halides, -(G-4 alkylene )pheteroaryl optionally substituted with one or more halides, and -SC>2(R 28 ); wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents;

alternatively, two R 11 attached to the same carbon atom can together represent =0 to form a carbonyl group;

each R 12 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(G-9 alkenyl), unsubstituted -(G-9 alkynyl), unsubstituted -(G-9 haloalkyl), -(G-4 alkylene)pOR 19 , -N(R 15 )(R 29 ), -C(=0)(R 26 ), -C(=0)OR 27 , -(G- 4 alkylene)pheterocyclyl optionally substituted with 1 -10 R 22 , and -(G-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(G-4 alkylene) is, independently , optionally substituted with one or more substituents; R 13 is selected from the group consisting of H, unsubstituted -(C1-9 alkyl), unsubstituted - (C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents;

R 14 is selected from the group consisting of unsubstituted -(C1-9 alkyl), unsubstituted -(C2- 9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents; each R 15 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl);

R 16 is selected from the group consisting of -(C1-4 alkylene) p heteroc}'clyl optionally substituted witli 1-10 R 20 , and— (C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 17 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl); alternatively, two adjacent R 17 are taken together to form a -heterocyclyl ring optionally substituted with 1-10 R 22 ;

R 18 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), - (C=0)R 15 , and -(C1-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 19 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1 -12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 20 independently is selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH. -N(R 15 )?, and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1 -12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents; each R 21 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN;

each R 22 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -N(R 15 ) 2 , C(=0)R 34 , and -(C1- alkylene) p carbocyclyl optionally substituted with 1- 12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 23 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)N(R 15 ) 2 , -(C1-4 alkylene ) p aryl optionally substituted with 1-10 R 30 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-12 R 31 . and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 24 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)pl eterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene)N(R 15 )2; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 25 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 32 , -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(C1-4 alkylene)OR 33 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 26 is selected from the group consisting of H, unsubstituted -(C3-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), -(C1-4 alkylene) p heteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene ) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 27 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), and -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

2 8 is selected from the group consisting of unsubstituted -(C1-5 alkyl), unsubstituted -(C2- 5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene ) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents;

each R 29 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 32 , -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(Ci_ 4 alkylene)OR 33 , and -C(=0)0(Ci 5 alkyl); wherein each -(Ci- 4 alky lene) is, independently, optionally substituted with one or more substituents;

each R 3n is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN;

each R 31 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -C(=0)R 34 , -N(R 24 ) 2 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1- 12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 32 is independently selected from the group consisting of halide and unsubstituted - (Ci-5 alkyl);

each R 33 is independently selected from the group consisting of H and unsubstituted -(Ci-

5 alkyl);

each R 34 is independently selected from the group consisting of -0(Ci-5 alkyl) and a heteroaryl optionally substituted with 1 -6 R 35 ;

each R 35 is a -heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl);

each X is selected from the group consisting of 0 and S;

each p is independently 0 or 1. [014] Another embodiment disclosed herein includes a compound having the structure of Formula lb:

lb

as well as prodrugs and pharmaceutically acceptable salts thereof.

[015] In another embodiment of Formula (lb):

R 1 , R 2 , and R 4 are independently absent or selected from the group consisting of H, halide, unsubstituted -(Ci-3 haloalkyl), and unsubstituted -(Ci-3 alkyl);

R 3 is selected from the group consisting of -aryl optionally substituted with 1-5 R 7 and - heteroaryl optionally substituted with 1-4 R 8 ;

R s is selected from the group consisting of -(Ci-4 alkylene) p aryl substituted with 1-5 R 9 , - (C2 4 alkenylene)paryl substituted with 1-5 R 9 , -(C1-4 alkylene)pheteroaryl optionally substituted with 1-6 R 10 ; -(C1-4 alkylene)pheterocyclyl optionally substituted with 1 -10 R 11 , -(Ci-4 alkylene)pCarbocyclyl optionally substituted with 1 -12 R 12 , -(C1-4 alkylene)N(R 13 )(R 14 ), - N(R 15 )(R 16 ), -CF(Ci-9 alkyl) 2 , -(C1-4 alkylene) p O(C 3 - 9 alkyl), and -(C2-9 alkynyl) optionally substituted with one or more halides; wherein each alkyl of -CF(Ci-9 alkyl)2 is, independently, optionally substituted with one or more halides; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents; wherein -(C1-4 alkenylene) is, optionally substituted with one or more substituents;

R 7 is selected from the group consisting of halide and -N(R 17 )2;

each R 8 is independently selected from the group consisting of H, halide, unsubstituted - (Ci-9 alkyl). unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(C1- alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(C1- alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyi optionally substituted with 1-12 R 21 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents;

alternatively, two adjacent R 8 are taken together to form a ring which is selected from the group consisting of-heterocyclyl optionally substituted with 1-10 R 22 and -carbocyclyi optionally substituted with 1-12 R 21 ; each R 9 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -XR 23 ,-C(=0)N(R 15 ) 2 , -(Ci-4 alkylene)pN(R 24 ) 2 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents; with the proviso that R 9 is not -OMe or \— / ;

each R 10 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -XR 23 , -C(=0)N(R 15 ) 2 , -(Ci-4 alkylene) p N(R 24 ) 2 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 11 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(Ci-4 alkylene)pOR 19 , -(C1-4 alkylene ) p heterocyclyl optionally substituted with 1 -10 R 22 , -(C1-4 alkylene)pCarbocyclyl optionally substituted with 1-12 R 21 , -N(R 15 )(R 25 ), -C(=0)(R 26 ), -(Ci -4 alkylene)C(=0)OR 27 , -(C1-4 alkylene)aryl optionally substituted with one or more halides, -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides, and -SC>2(R 28 ); wherein each -(Ci-4 alkylene) is, independently, optionally substituted with one or more substituents;

alternatively, two R 11 attached to the same carbon atom can together represent =0 to form a carbonyl group;

each R 12 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(Ci-4 alkylene)pOR 19 , -N(R 15 )(R 29 ), -C(=0)(R 26 ), -C(=0)OR 27 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1 -10 R 22 , and -(C1-4 alkylcnc) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently , optionally substituted with one or more substituents;

R 13 is selected from the group consisting of H, unsubstituted -(C1-9 alkyl), unsubstituted - (C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylcnc)phctcrocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents; R 14 is selected from the group consisting of unsubstituted -(C1-9 alkyl), unsubstituted -(C2- 9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents; each R 15 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl);

R 16 is selected from the group consisting of -(C1- alkylene) p heterocj r clyl optionally substituted with 1-10 R 20 , and— (C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 17 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl); alternatively, two adjacent R 17 are taken together to form a -heterocyclyl ring optionally substituted with 1-10 R 22 ;

R 18 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), - (C=0)R 15 , and -(C1-4 alkylene)plieterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 19 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)plieterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 20 independently is selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH. -N(R 15 )2, and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 21 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN; each 22 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -N(R 15 ) 2 , -C(=0)R 34 , and -(G- 4 alkylene) p carbocyclyl optionally substituted with 1- 12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 23 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)N(R 15 )2, -(C1-4 alkylene ) p aryl optionally substituted with 1-10 R 30 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-12 R 31 , and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(Ci- 4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 24 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene)N(R 15 ) 2 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 25 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 32 , -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(C1-4 alkylene)OR 33 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 26 is selected from the group consisting of H, unsubstituted -(C3-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene ) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 27 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl). -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), and -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(G-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 28 is selected from the group consisting of unsubstituted -(C1-5 alkyl), unsubstituted -(G- 5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(G-s haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene ) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents;

each R 29 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(G-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 32 , -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(C1-4 alkylene)OR 33 , and -C(=0)0(Ci-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 30 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(G-5 alkenyl), unsubstituted -(G-5 alkynyl), unsubstituted -(G-s haloalkyl), and -CN;

each R 31 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(G-5 alkynyl), unsubstituted -(G-5 haloalkyl), -CN, -OH, -C(=0)R 34 , -N(R 24 ) 2 , and -(G-4 alkylene) p carbocyclyl optionally substituted with 1- 12 R 21 ; wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 32 is independently selected from the group consisting of halide and unsubstituted - (G-5 alkyl);

each R 33 is independently selected from the group consisting of H and unsubstituted -(G-

5 alkyl);

each R 34 is independently selected from the group consisting of -0(G-5 alkyl) and a heteroaryl optionally substituted with 1-6 R 35 ;

each R 35 is a -heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(G-5 alkyl);

each X is selected from the group consisting of 0 and S;

each p is independently 0 or 1.

[016] Another embodiment disclosed herein includes a compound having the structure of Formula Ic:

Ic

as well as prodrugs and pharmaceutically acceptable salts thereof.

[017] In another embodiment of Formula (Ic):

R 1 , R 2 , R 4 , and R 5 are independently absent or selected from the group consisting of H, halide, unsubstituted -(Ci-3 haloalkyl), and unsubstituted -(Ci-3 alkyl);

R 3 is selected from the group consisting of -aryl optionally substituted with 1-5 R 7 and - heteroaryl optionally substituted with 1-4 R 8 ;

R 6 is selected from the group consisting of -(Ci-4 alkylene) p aryl substituted with 1-5 R 9 , - (C2-4 alkenylene)paryl substituted with 1-5 R 9 , -(C1-4 alkylene)pheteroaryl optionally substituted with 1-6 R 10 ; -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 11 , -(C1-4 alkylene)pCarbocyclyl optionally substituted with 1-12 R 12 , -(C1-4 alkylene)N(R 13 )(R 14 ), - N(R 15 )(R 16 ), -CF(Ci-9 alkyl) 2 , -(C1- alkylene)pO(C 3 -9 alkyl), and -(C2-9 alkynyl) optionally substituted with one or more halides; wherein each alkyl of -CF(Ci-9 alkyl)2 is, independently, optionally substituted with one or more halides; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents; wherein -(C1-4 alkenylene) is, optionally substituted with one or more substituents;

R 7 is selected from the group consisting of halide and -N(R 17 ) 2 ;

each R 8 is independently selected from the group consisting of H, halide, unsubstituted - (Ci-9 alkyl). unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(C1-4 alkylene) P XR 19 , -C(=0)N(R 15 ) 2 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyi optionally substituted with 1-12 R 21 ; wherein each -(C 1 - 4 alkylene) is, independently, optionally substituted with one or more substituents;

alternatively, two adjacent R 8 are taken together to form a ring which is selected from the group consisting of-heterocyclyl optionally substituted with 1-10 R 22 and -carbocyclyi optionally substituted with 1-12 R 21 ;

each R 9 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -XR 23 ,-C(=0)N(R 15 ) 2 , -(Ci-4 alkylene)pN(R 24 ) 2 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 10 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -XR 23 , C(=0)N(R 15 ) 2 , -(Ci-4 alkylene) p N(R 24 ) 2 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 11 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(Ci-4 alkylene)pOR 19 , -(C1-4 alkylene ) p heterocyclyl optionally substituted witli 1-10 R 22 , -(C1-4 alkylene)pCarbocyclyl optionally substituted with 1-12 R 21 , -N(R 15 )(R 25 ), -C(=0)(R 26 ), -(Ci -4 alkylene)C(=0)OR 27 , -(C1-4 alkylene)aryl optionally substituted with one or more halides, -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides, and -S02(R 28 ); wherein each -(Ci-4 alkylene) is, independently, optionally substituted with one or more substituents;

alternatively, two R 1 1 attached to the same carbon atom can together represent =0 to form a carbonyl group;

each R 12 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(Ci-4 alkylene)pOR 19 , -N(R 15 )(R 29 ), -C(=0)(R 26 ), -C(=0)OR 27 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(C1-4 alkylene) p carbocyclyl optionally substituted witli 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 13 is selected from the group consisting of H, unsubstituted -(C1-9 alkyl), unsubstituted - (C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents;

R 14 is selected from the group consisting of unsubstituted -(C1-9 alkyl), unsubstituted -(C 2 - 9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents; each R 15 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl); R 16 is selected from the group consisting of -(C1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 20 , and— (C 1-4 alky lene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 17 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl); alternatively, two adjacent R 17 are taken together to form a -heterocyclyl ring optionally substituted with 1-10 R 22 ;

R 18 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), - (C=0)R 15 , and -(C1-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 19 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 20 independently is selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(G-5 alkynyl), unsubstituted -(G-5 haloalkyl), -CN, -OH. -N(R 15 )2, and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 21 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(G-5 alkenyl), unsubstituted -(G-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN;

each R 22 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(G-5 alkynyl), unsubstituted -(G-5 haloalkyl), -CN, -OH, -N(R 15 ) 2 , -C(=0)R 34 , and -(G- 4 alkylene) p carbocyclyl optionally substituted with 1 - 12 R 21 ; wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 23 is independently selected from the group consisting of H, unsubstituted -(G-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(G-5 haloalkyl). -(Ci-4 alkylene)N(R 15 ) 2 , -(C1-4 alkylene) p aryl optionally substituted with 1 -10 R 30 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1 -12 R 31 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 24 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene)N(R 15 )2; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 25 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 32 , -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(C1-4 alkylene)OR 33 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 26 is selected from the group consisting of H, unsubstituted -(C3 5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene ) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 27 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), and -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 28 is selected from the group consisting of unsubstituted -(C1-5 alkyl), unsubstituted -(C2- 5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene) p heteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene ) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents;

each R 29 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(G-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(G-s haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 32 , -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(C1-4 alkylene)OR 33 , and -C(=0)0(G-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 30 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(G-5 alkenyl), unsubstituted -(G-5 alkynyl), unsubstituted -(G-5 haloalkyl), and -CN;

each R 31 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(G-5 alkenyl), unsubstituted -(G-5 alkynyl), unsubstituted -(G-5 haloalkyl), -CN, -OH, -C(=0)R 34 , -N(R 24 ) 2 , and -(G- 4 alkylene) p carbocyclyl optionally substituted with 1- 12 R 21 ; wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 32 is independently selected from the group consisting of halide and unsubstituted - (G-5 alkyl);

each R 33 is independently selected from the group consisting of H and unsubstituted -(G-

5 alkyl);

each R 34 is independently selected from the group consisting of -0(G 5 alkyl) and a heteroaryl optionally substituted with 1-6 R 35 ;

each R 35 is a -heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(G-5 alkyl);

each X is selected from the group consisting of 0 and S;

each p is independently 0 or 1.

[018] Another embodiment disclosed herein includes a compound having the structure of Formula Id:

as well as prodmgs and pharmaceutically acceptable salts thereof.

[019] In another embodiment of Formula (Id): R 2 , R 4 , and R 5 are independently absent or selected from the group consisting of H, halide, unsubstituted -(C1-3 haloalkyl), and unsubstituted -(C1-3 alkyl);

R 3 is selected from the group consisting of -aryl optionally substituted with 1-5 R 7 and - heteroaryl optionally substituted with 1-4 R 8 ;

R 6 is selected from the group consisting of -(C1-4 alkylene) p aryl substituted with 1-5 R 9 , - (C2-4 alkenylene)paryl substituted with 1-5 R 9 , -(C1-4 alkylene)pheteroaryl optionally substituted with 1-6 R 10 ; -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 11 , -(C1-4 alkylene)pCarbocyclyl optionally substituted with 1-12 R 12 , -(C1-4 alkylene)N(R 13 )(R 14 ), - N(R 15 )(R 16 ), -CF(C, -9 alkyl) 2 , -(CM alkylene) P 0(C3-9 alkyl), and -(C2-9 alkynyl) optionally substituted with one or more halides; wherein each alkyl of -CF(Ci-9 alkyl) 2 is, independently, optionally substituted with one or more halides; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents; wherein -(C1-4 alkenylene) is, optionally substituted with one or more substituents;

R 7 is selected from the group consisting of halide and -N(R 17 )2;

each R 8 is independently selected from the group consisting of H, halide, unsubstituted - (Ci-9 alkyl). unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(C1-4 alkylene) p XR 19 , -C(=0)N(R' 5 ) 2 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyi optionally substituted with 1-12 R 21 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents;

alternatively, two adjacent R 8 are taken together to form a ring which is selected from the group consisting of-heterocyclyl optionally substituted with 1-10 R 22 and -carbocyclyi optionally substituted with 1-12 R 21 ;

each R 9 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -XR 23 ,-C(=0)N(R 15 ) 2 , -(CM alkylene) p N(R 24 ) 2 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(CM alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(CM alkylene) is, independently, optionally substituted with one or more substituents;

each R 10 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -XR 23 , -C(=0)N(R 15 ) 2 , -(CM alkylene) p N(R 24 ) 2 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 11 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(G-9 alkynyl), unsubstituted -(G-9 haloalkyl), -(G-4 alkylene)pOR 19 , -(G-4 alkylene ) p heterocyclyl optionally substituted with 1 -10 R 22 , -(G-4 alkylene)pcarbocyclyl optionally substituted with 1-12 R 21 , -N(R 15 )(R 25 ), -C(=0)(R 26 ), -(G -4 alkylene)C(=0)OR 27 , -(G-4 alkylene)aryl optionally substituted with one or more halides, -(G-4 alkylene)pheteroaryl optionally substituted with one or more halides, and -S02(R 28 ); wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents;

alternatively, two R 11 attached to the same carbon atom can together represent =0 to form a carbonyl group;

each R 12 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(G-9 alkenyl), unsubstituted -(G-9 alkynyl), unsubstituted -(G-9 haloalkyl), -(G-4 alkylene) P OR 19 , -N(R 15 )(R 29 ), -C(=0)(R 26 ), -C(=0)OR 27 , -(CM alkylene)pheterocyclyl optionally substituted with 1 -10 R 22 , and -(G-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(G-4 alkylene) is, independently , optionally substituted with one or more substituents;

R 13 is selected from the group consisting of H, unsubstituted -(G-9 alkyl), unsubstituted - (G-9 alkenyl), unsubstituted -(G-9 alkynyl), unsubstituted -(G-9 haloalkyl), -(G-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein -(G-4 alkylene) is, optionally substituted with one or more substituents;

R 14 is selected from the group consisting of unsubstituted -(G-9 alkyl), unsubstituted -(G- 9 alkenyl), unsubstituted -(G-9 alkynyl), unsubstituted -(G-9 haloalkyl), -(G-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein -(G-4 alkylene) is, optionally substituted with one or more substituents; each R 15 is selected from the group consisting of H, unsubstituted -(G-5 alkyl), unsubstituted -(G-5 alkenyl), unsubstituted -(G-5 alkynyl), and unsubstituted -(G-5 haloalkyl);

R 16 is selected from the group consisting of -(G-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 20 , and— (G-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 17 is independently selected from the group consisting of H, unsubstituted -(G-5 alkyl), unsubstituted -(G-5 alkenyl), unsubstituted -(G-5 alkynyl), and unsubstituted -(G-5 haloalkyl); alternatively, two adjacent R 17 are taken together to form a -heterocyclyl ring optionally substituted with 1-10 R 22 ;

R 18 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), - (C=0)R 15 , and -(C1-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents,

each R 19 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted— (C1-5 haloalkyl), -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 20 independently is selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -N(R 15 ) 2 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 21 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN;

each R 22 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -N(R 15 ) 2 , -C(=0)R 34 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1- 12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 23 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)N(R 15 ) 2 , -(Ci- 4 alkylene) p aryl optionally substituted with 1-10 R 30 , -(Ci -4 alkylene)pheterocyclyl optionally substituted with 1 -12 R 31 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 24 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl). -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene)N(R 15 )2; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 25 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 32 , -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(C1-4 alkylene) OR 33 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 26 is selected from the group consisting of H, unsubstituted -(C3-5 alkyl), unsubstituted - (C2 5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted witli one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene ) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 27 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), and -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(Ci-s alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 28 is selected from the group consisting of unsubstituted -(C1-5 alkyl), unsubstituted -(C2- 5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene ) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents;

each R 29 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 32 , -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(C1-4 alkylene)OR 33 , and -C(=0)0(Ci-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents; each R 30 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN;

each R 31 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, C(=0)R 34 , -N(R 24 ) 2 , and -(C1- alkylene) p carbocyclyl optionally substituted with 1- 12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 32 is independently selected from the group consisting of halide and unsubstituted - (Ci-5 alkyl);

each R 33 is independently selected from the group consisting of H and unsubstituted -(G-

5 alkyl);

each R 34 is independently selected from the group consisting of -0(G-5 alkyl) and a heteroaryl optionally substituted with 1-6 R 35 ;

each R 35 is a -heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl);

each X is selected from the group consisting of 0 and S;

each p is independently 0 or 1.

[020] Another embodiment disclosed herein includes a compound having the structure of Formula le:

le

as well as prodrugs and pharmaceutically acceptable salts thereof.

[021] In another embodiment of Formula (le):

R 1 , R 4 , and R 5 are independently absent or selected from the group consisting of H, halide, unsubstituted -(C1-3 haloalkyl), and unsubstituted -(C1-3 alkyl);

R 3 is selected from the group consisting of -aryl optionally substituted with 1-5 R 7 and - heteroaryl optionally substituted with 1-4 R 8 ;

R 6 is selected from the group consisting of -(C1-4 alkylene) p aryl substituted with 1-5 R 9 , - (C2-4 alkenylene)paryl substituted with 1-5 R 9 , -(C1-4 alkylene)pheteroaryl optionally substituted with 1-6 R 10 ; -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 11 , -(C1-4 alkylene)pCarbocyclyl optionally substituted with 1-12 R 12 , -(C1-4 alkylene)N(R lj )(R 14 ), - N(R 15 )(R 16 ), -CF(Ci-9 alkyl) 2 , -(C1-4 alkylene) p O(C 3 - 9 alkyl), and -(C2-9 alkynyl) optionally substituted with one or more halides; wherein each alkyl of -CF(G-g alkyl)2 is, independently, optionally substituted with one or more halides; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents; wherein -(G-4 alkenylene) is, optionally substituted with one or more substituents,

R 7 is selected from the group consisting of halide and -N(R 17 )2;

each R 8 is independently selected from the group consisting of H, halide, unsubstituted - (Ci-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstiuited -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, N(R 15 )(R 18 ), -(C1- alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(C1- alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyi optionally substituted with 1-12 R 21 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents;

alternatively, two adjacent R 8 are taken together to form a ring which is selected from the group consisting of-heterocyclyl optionally substituted with 1-10 R 22 and -carbocyclyi optionally substituted with 1-12 R 21 ;

each R 9 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(G-9 haloalkyl), -XR 23 ,-C(=0)N(R 15 ) 2 , -(G-4 alkylene) p N(R 24 ) 2 , -(G-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(G-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 10 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(G-9 alkenyl), unsubstituted -( -9 alkynyl), unsubstituted -(G-9 haloalkyl), -CN, -XR 23 , -C(=0)N(R 15 ) 2 , -(G-4 alkylene) p N(R 24 ) 2 , -(G- 4 alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(G-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 11 is independently selected from the group consisting of halide, unsubstituted -(G- 9 alkyl), unsubstituted -(G-9 alkenyl), unsubstituted -(G-9 alkynyl), unsubstituted -(G-9 haloalkyl), -(G-4 alkylene) p OR 19 , -(G-4 alkylene ) p heterocyclyl optionally substituted with 1-10 R 22 , -(G-4 alkylene)pCarbocyclyl optionally substituted with 1-12 R 21 , -N(R 15 )(R 25 ), -C(=0)(R 26 ), -(G- 4 alkylene)C(=0)OR 27 , -(G-4 alkylene)aryl optionally substituted with one or more halides, -(G-4 alkylene)pheteroaryl optionally substituted with one or more halides, and -SC> 2 (R 28 ); wherein each -(Ci-4 alkylene) is, independently, optionally substituted with one or more substituents;

alternatively, two R 11 attached to the same carbon atom can together represent =0 to form a carbonyl group;

each R 12 is independently selected from the group consisting of halide, unsubstituted -(Ci- 9 alkyl), unsubstituted -(C 2 -9 alkenyl), unsubstituted -(C 2 -9 alkynyl), unsubstituted -(C 1 -9 haloalkyl), -(Ci-4 alkylene)pOR 19 , -N(R 15 )(R 29 ), -C(=0)(R 26 ), -C(=0)OR 27 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 R 22 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently , optionally substituted with one or more substituents;

R 13 is selected from the group consisting of H, unsubstituted -(C 1 -9 alkyl), unsubstituted - (C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 20 , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents;

R 14 is selected from the group consisting of unsubstituted -(C 1 -9 alkyl), unsubstituted -(C 2 9 alkenyl), unsubstituted -(C 2 -9 alkynyl), unsubstituted -(C 1 -9 haloalkyl), -(C 1 - 4 alkylene)pheterocyclyl optionally substituted with 1-10 R n , and -carbocyclyl optionally substituted with 1-12 R 21 ; wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents; each R 15 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C 2 -5 alkenyl), unsubstituted -(C 2 -5 alkynyl), and unsubstituted -(C 1 -5 haloalkyl);

R 16 is selected from the group consisting of -(C 1 - 4 alkylene) p heterocj'clyl optionally substituted witli 1-10 R 20 , and— (C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 17 is independently selected from the group consisting of H, unsubstituted -(C 1 -5 alkyl), unsubstituted -(C 2 -5 alkenyl), unsubstituted -(C 2 -5 alkynyl), and unsubstituted -(C 1 -5 haloalkyl); alternatively, two adjacent R 17 are taken together to form a -heterocyclyl ring optionally substituted with 1-10 R 22 ;

R 18 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C 2 -5 alkenyl), unsubstituted -(C 2 -5 alkynyl), unsubstituted -(C 1 -5 haloalkyl), - (C=0)R 15 , and -(C 1 - 4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C 1 -5 alkyl); wherein -(C 1 - 4 alkylene) is, independently, optionally substituted with one or more substituents; each R 19 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 20 independently is selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -N(R 15 ) 2 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 21 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN;

each R 22 is independently selected from the group consisting of halide, unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -N(R I5 ) 2 , -C(=0)R 34 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1- 12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 23 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)N(R 15 )2, -(C1-4 alkylene ) p aryl optionally substituted with 1-10 R 30 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-12 R 31 . and -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 24 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene)N(R 15 )2; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 25 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 32 , -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(C1-4 alkylene)OR 33 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 26 is selected from the group consisting of H, unsubstituted -(C3-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene ) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 27 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), and -(Ci-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

R 28 is selected from the group consisting of unsubstituted -(C1-5 alkyl), unsubstituted -(C2- 5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene)pheteroaryl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene ) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents;

each R 29 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 R 32 , -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 R 21 , -(C1-4 alkylene)OR 33 , and -C(=0)0(Ci-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 30 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN;

each R 31 is independently selected from the group consisting of halide, unsubstituted -(G- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(G-5 haloalkyl), -CN, -OH, -C(=0)R 34 , -N(R 24 ) 2 , and -(G- 4 alkylene) p carbocyclyl optionally substituted with 1- 12 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents;

each R 32 is independently selected from the group consisting of halide and unsubstituted - (Ci-s alkyl);

each R 33 is independently selected from the group consisting of H and unsubstituted -(Ci-

5 alkyl);

each R 34 is independently selected from the group consisting of -0(Ci-5 alkyl) and a heteroaryl optionally substituted with 1-6 R 35 ;

each R 35 is a -heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl);

each X is selected from the group consisting of 0 and S;

each p is independently 0 or 1.

[022] Some embodiments include stereoisomers and pharmaceutically acceptable salts of a compound of Formulas I, la, lb, Ic, Id, and Ie. Some embodiments include pharmaceutically acceptable salts of a compound of Formulas I, la, lb, Ic, Id, and Ie.

[023] Some embodiments include pro-drugs of a compound of Formulas I, la, lb, Ic, Id, and Ie.

[024] Some embodiments of the present disclosure include pharmaceutical compositions comprising a compound of Formulas I, la, lb, Ic, Id, and Ie and a pharmaceutically acceptable carrier, diluent, or excipient.

[025] Other embodiments disclosed herein include methods of inhibiting one or more members of the Wnt pathway, including one or more Wnt proteins by administering to a patient affected by a disorder or disease in which aberrant Wnt signaling is implicated, such as cancer and other diseases associated with abnormal angiogenesis, cellular proliferation, cell cycling and mutations in Wnt signaling components, a compound according to Formula (I). Accordingly, the compounds and compositions provided herein can be used to treat cancer, to reduce or inhibit angiogenesis, to reduce or inhibit cellular proliferation and correct a genetic disorder due to mutations in Wnt signaling components.

[026] Other embodiments disclosed herein include methods of inhibiting DYRK1A by administering to a patient affected by a disorder or disease in which DYRK1 A overexpression is implicated, such as Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Down Syndrome, Frontotemporal Dementia with Parkinsonism- 17 (FTDP-17), Lewy body dementia, Parkinson's Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy, Huntington's Disease, Multiple Sclerosis; diseases and disorders associated with acquired brain injury such as Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor and Stroke.

[027] Non-limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, osteochondrodysplasia, Alzheimer's disease, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Miillerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto- onycho-dennal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.

[028] Some embodiments of the present disclosure include methods to prepare compounds of Formulas I, la, lb, Ic, Id, and Ie.

[029] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the disclosure, as claimed.

DETAILED DESCRIPTION

[030] Provided herein are compositions and methods for inhibiting one or more members of the Wnt pathway, including one or more Wnt proteins. Other W r nt inhibitors and methods for using the same are disclosed in U.S. Application Ser. Nos. 13/614,296; 14/019,229; and 14/664,517, all of which are incorporated by reference in their entirety herein.

[031] Provided herein are compositions and methods for inhibiting DYRK1A. Other DYRK1A inhibitors and methods for using the same are disclosed in U.S. Application Ser. No. 14/664, 17, which is incorporated by reference in its entirety herein.

[032] Some embodiments provided herein relate to a method for treating a disease including, but not limited to, neurological diseases or disorders, cancers, chronic inflammation, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, bone and cartilage diseases, lung disease. osteoarthritis, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, bone density and vascular defects in the eye (Osteoporosis - pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Mullerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman's syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.

[033] In some embodiments, non-limiting examples of bone and cartilage diseases which can be treated with the compounds and compositions provided herein include bone spur (osteophytes), craniosynostosis, fibrodysplasia ossificans progressive, fibrous dysplasia, giant cell tumor of bone, hip labral tear, meniscal tears, osteoarthritis, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), osteochondritis dissecans, osteochondroma (bone tumor), osteopetrosis, relapsing polychondritis, and Salter-Harris fractures.

[034] In some embodiments, non-limiting examples of a neurological disease or disorder associated with tau protein, amyloid or alpha-synuclein pathology which can be treated with the compounds and compositions provided herein include, but are not limited to, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Down Syndrome, Frontotemporal Dementia with Parkinsonism- 17 (FTDP-17), Lewy body dementia, Parkinson's Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy, Huntington's Disease, Multiple Sclerosis; diseases and disorders associated with acquired brain injury such as Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor, and Stroke.

[035] In some embodiments, non-limiting examples of diseases in which chronic inflammation is involved which can be treated with the compounds and compositions provided herein include eye disorders, joint pain, arthritis (rheumatoid, osteo, psoriatic gout), cancers (colon, breast, lung, pancreas, and others), gastrointestinal disorders (ulcerative colitis and inflammatory bowel diseases), pulmonary disorders (chronic obstructive pulmonary disorder and asthma), allergies, skin disorders (atopic dermatitis and psoriasis), diabetes, pancreatitis, tendonitis, hepatitis, heart disease, myocarditis, stroke, lupus, and neurological disorders such as multiple sclerosis, Parkinson's and dementia including Alzheimer's disease. [036] In some embodiments, non-limiting examples of cancers which can be treated with the compounds and compositions provided herein include colon, ovarian, pancreatic, breast, liver, prostate, and hematologic cancers.

[037] In some embodiments, pharmaceutical compositions are provided that are effective for treatment of a disease of an animal, e.g., a mammal, caused by either the pathological activation or mutations of the Wnt pathway or DYRKIA overexpression. The composition includes a pharmaceutically acceptable carrier and a compound as described herein.

Definitions

[038] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents, applications, published applications, and other publications are incorporated by reference in their entirety. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

[039] As used herein, "alkyl" means a branched, or straight chain chemical group containing only carbon and hydrogen, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso- butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl and neo-pentyl. Alkyl groups can either be unsubstituted or substituted with one or more substituents. In some embodiments, alkyl groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).

[040] As used herein, "alkenyl" means a straight or branched chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond, such as ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2-butenyl, and the like. In various embodiments, alkenyl groups can either be unsubstituted or substituted with one or more substituents. Typically, alkenyl groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).

[041] As used herein, "alkynyl" means a straight or branched chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon triple bond, such as ethynyl, 1-propynyl, 1-butynyl, 2-butynyl, and the like. In various embodiments, alkynyl groups can either be unsubstituted or substituted with one or more substituents. Typically, alkynyl groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).

[042] As used herein, "alkylene" means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen, such as methylene, ethylene, n-propylene. iso-propylene, n-butylene, iso-butylene, sec-butylene, tert-butylene, n-pentylene, iso-pentylene, sec-pentylene and neo-pentylene. Alkylene groups can either be unsubstituted or substituted with one or more substituents. In some embodiments, alkylene groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).

[043] As used herein, "alkenylene" means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond, such as ethenylene, 1-propenylene, 2-propenylene, 2-methyl-l-propenylene, 1- butenylene, 2-butenylene, and the like. In various embodiments, alkenylene groups can either be unsubstituted or substituted with one or more substituents. Typically, alkenylene groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).

[044] As used herein, "alkynylene" means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon triple bond, such as ethynylene, 1 -propynylene, 1 -butynylene, 2-butynylene, and the like . In various embodiments, alkynylene groups can either be unsubstituted or substituted with one or more substituents. Typically, alkynylene groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).

[045] As used herein, "alkoxy" means an alkyl-0— group in which the alkyl group is as described herein. Exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, pentoxy, hexoxy and heptoxy, and also the linear or branched positional isomers thereof.

[046] As used herein, "haloalkoxy" means a haloalkyl-0— group in which the haloalkyl group is as described herein. Exemplary haloalkoxy groups include fluoromethoxy, dirluoromethoxy, trifluoromethoxy, and also the linear or branched positional isomers thereof.

[047] As used herein, "carbocyclyl" means a cyclic ring system containing only carbon atoms in the ring system backbone, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl. Carbocyclyls may include multiple fused rings. Carbocyclyls may have any degree of saturation provided that none of the rings in the ring system are aromatic. Carbocyclyl groups can either be unsubstituted or substituted with one or more substituents. In some embodiments, carbocyclyl groups include 3 to 10 carbon atoms, for example, 3 to 6 carbon atoms.

[048] As used herein, "aryl" means a mono-, bi-, tri- or polycyclic group with only carbon atoms present in the ring backbone having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic. Aryl groups can either be unsubstituted or substituted with one or more substituents. Examples of aryl include phenyl, naphthyl, tetrahydronaphthyl, 2,3-dihydro-lH- indenyl, and others. In some embodiments, the aryl is phenyl.

[049] As used herein, "arylalkylene" means an aryl-alkylene- group in which the aryl and alkylene moieties are as previously described. In some embodiments, arylalkylene groups contain a Ci-4alkylene moiety. Exemplary arylalkylene groups include benzyl and 2-phenethyl.

[050] As used herein, the term "heteroaryl" means a mono-, bi-, tri- or polycyclic group having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms independently selected from the group consisting of N, O, and S. Heteroaryl groups can either be unsubstituted or substituted with one or more substituents. Examples of heteroaryl include thienyl, pyridinyl, furyl, oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl, thiodiazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolyl benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnolinyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, purinyl, thienopyridinyl, pyrido[2,3-i/]pyrimidinyl, pyrrolo[2,3-&]pyridinyl, quinazolinyl, quinolinyl, thieno[2,3-c]pyridinyl, pyrazolo[3,4-6]pyridinyl, pyrazolo[3,4- c]pyridinyl, pyrazolo[4,3-c]pyridine, pyrazolo[4,3-&]pyridinyl, tetrazolyl. chromane, 2,3- dihydrobenzo[6][l,4]dioxine, benzo[ci][l,3]dioxole, 2,3-dihydrobenzofuran, tetrahydroquinoline, 2,3-dihydrobenzo[6][l,4]oxathiine, isoindoline, and others. In some embodiments, the heteroaryl is selected from thienyl, pyridinyl, furyl, pyrazolyl, imidazolyl, isoindolinyl, pyranyl, pyrazinyl, and pyrimidinyl.

[051] As used herein, "halo", "halide" or "halogen" is a chloro, bromo, fluoro, or iodo atom radical. In some embodiments, a halo is a chloro, bromo or fluoro. For example, a halide can be fluoro.

[052] As used herein, "haloalkyl" means a hydrocarbon substituent, which is a linear or branched, alkyl, alkenyl or alkynyl substituted with one or more chloro, bromo, fluoro, and/or iodo atom(s). In some embodiments, a haloalkyl is a fluoroalkyls, wherein one or more of the hydrogen atoms have been substituted by fluoro. In some embodiments, haloalkyls are of 1 to about 3 carbons in length (e.g., 1 to about 2 carbons in length or 1 carbon in length). The term "haloalkylene" means a diradical variant of haloalkyl, and such diradicals may act as spacers between radicals, other atoms, or between a ring and another functional group.

[053] As used herein, "heterocyclyl" means a nonaromatic cyclic ring system comprising at least one heteroatom in the ring system backbone. Heterocyclyls may include multiple fused rings. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 3-11 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from one to three of O, N or S, and wherein when the heterocvcle is five membered, it can have one or two heteroatoms selected from 0, N, or S. Examples of heterocyclyl include azirinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, 1,4,2- dithiazolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydroiuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, pyrazolidinyl imidazolidinyl, thiomorpholinyl, and others. In some embodiments, the heterocyclyl is selected from azetidinyl, morpholinyl, piperazinyl, pyrrolidinyl, and tetrahydropyridinyl.

[054] As used herein, "monocyclic heterocyclyl" means a single nonaromatic cyclic ring comprising at least one heteroatom in the ring system backbone. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 3-7 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from one to three of 0, N or S, and wherein when the heterocvcle is five membered, it can have one or two heteroatoms selected from O, N, or S. Examples of heterocyclyls include azirinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, 1,4,2-dithiazolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3- dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, pyrazolidinyl imidazolidinyl, thiomorpholinyl, and others.

[055] As used herein, "bicyclic heterocyclyl" means a nonaromatic bicyclic ring system comprising at least one heteroatom in the ring system backbone. Bicyclic heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, bicyclic heterocycles have 4-11 members with the heteroatom(s) being selected from one to five of O, N or S. Examples of bicyclic heterocyclyls include 2-azabicyclo[l. l OJbutane, 2- azabicyclo[2.1.0]pentane, 2-azabicyclo[l. l . l]pentane, 3-azabicyclo[3.1.0]hexane, 5- azabicyclo[2.1.1]hexane, 3-azabicyclo[3.2.0]heptane, octahydrocyclopenta[c] pyrrole, 3- azabicyclo[4.1.0]heptane, 7-azabicyclo[2.2.1]heptane, 6-azabicyclo[3.1.1]heptane, 7- azabicyclo[4.2.0]octane, 2-azabicyclo[2.2.2]octane, and the like.

[056] As used herein, "spirocyclic heterocyclyl" means a nonaromatic bicyclic ring system comprising at least one heteroatom in the ring system backbone and with the rings connected through just one atom. Spirocyclic heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, spirocyclic heterocycles have 5-11 members with the heteroatom(s) being selected from one to five of O, N or S. Examples of spirocyclic heterocyclyls include 2-azaspiro[2.2]pentane, 4-azaspiro[2.5]octane, l-azaspiro[3.5]nonane, 2- azaspiro[3.5]nonane, 7-azaspiro[3.5]nonane, 2-azaspiro[4.4]nonane, 6-azaspiro[2.6]nonane, 1,7- diazaspiro[4.5]decane, 2,5-diazaspiro[3.6]decane, and the like.

[057] The term "substituted" refers to moieties having substituents replacing a hydrogen on one or more non -hydrogen atoms of the molecule. It will be understood that "substitution" or "substituted with" includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. Substituents can include, for example, -(C1-9 alkyl) optionally substituted with one or more of hydroxyl, -NH 2 , -NH(Ci 3 alkyl), and -N(Ci-3 alkyl)2; -(C1-9 haloalkyl); a halide; a hydroxyl; a carbonyl [such as -C(0)OR, and -C(0)R]; a thiocarbonyl [such as -C(S)OR, -C(0)SR, and -C(S)R]; -(C1-9 alkoxy) optionally substituted with one or more of halide, hydroxyl, -NH2, -NH(Ci-3 alkyl), and -N(Ci-3 alkyl)2; - OPO(OH) 2 ; a phosphonate [such as -PO(OH) 2 and -PO(OR') 2 ]; -OPO(OR')R"; -NRR'; - C(0)NRR'; -C(NR)NR'R"; -C(NR')R"; a cyano; a nitro; an azido; -SH; -S-R; -OS0 2 (OR); a sulfonate [such as -S0 2 (OH) and -S0 2 (OR)]; -S0 2 NR'R"; and -S0 2 R; in which each occurrence of R. R' and R" are independently selected from H; -(C1-9 alkyl); Ce-io aryl optionally substituted with from 1-3R'"; 5-10 membered heteroaiyl having from 1-4 heteroatoms independently selected from N, 0, and S and optionally substituted with from 1-3 R" '; C3-7 carbocyclyl optionally substituted with from 1-3 R'"; and 3-8 membered heterocyclyl having from 1 -4 heteroatoms independently selected from N, O, and S and optionally substituted with from 1-3 R" '; wherein each R'" is independently selected from -(Ci-e alkyl), -(C1-5 haloalkyl), a halide (e.g., F), ahydroxyl, -C(0)OR, -C(0)R, -(Ci-6 alkoxyl), -NRR', -C(0)NRR', and a cyano, in which each occurrence of R and R' is independently selected from H and -(Ci-6 alkyl). In some embodiments, the substituent is selected from -(Ci-6 alkyl), -(Ci-β haloalkyl), a halide (e.g., F), a hydroxyl, -C(0)OR, -C(0)R, -(Ci-e alkoxyl), -NRR', -C(0)NRR', and a cyano, in which each occurrence of R and R' is independently selected from H and -(C1-5 alkyl).

[058] As used herein, when two groups are indicated to be "linked" or "bonded" to form a "ring", it is to be understood that a bond is formed between the two groups and may involve replacement of a hydrogen atom on one or both groups with the bond, thereby forming a carbocyclyl, heterocyclyl. aryl, or heteroaryl ring. The skilled artisan will recognize that such rings can and are readily formed by routine chemical reactions. In some embodiments, such rings have from 3-7 members, for example, 5 or 6 members. [059] The skilled artisan will recognize that some chemical structures described herein may be represented on paper by one or more other resonance forms; or may exist in one or more other tautomeric forms, even when kinetically, the artisan recognizes that such tautomeric forms represent only a very small portion of a sample of such compound(s). Such compounds are clearly contemplated within the scope of this disclosure, though such resonance forms or tautomers are not explicitly represented herein.

[060] The compounds provided herein may encompass various stereochemical forms. The compounds also encompass diastereomers as well as optical isomers, e.g., mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound.

[061] The present disclosure includes all pharmaceutically acceptable isotopically labeled compounds of Formulas I, la, lb, Ic, Id, and Ie, wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature. Examples of isotopes suitable for inclusion in the compounds of the disclosure include, but are not limited to, isotopes of hydrogen, such as 2 H (deuterium) and H (tritium), carbon, such as n C, 1 C and 14 C, chlorine, such as 6 C1, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 1 N and 15 N, oxygen, such as 15 0, 17 0 and 18 0, phosphorus, such as 2 P, and sulfur, such as 5 S.

[062] The term "administration" or "administering" refers to a method of providing a dosage of a compound or pharmaceutical composition to a vertebrate or invertebrate, including a mammal, a bird, a fish, or an amphibian, where the method is, e.g., orally, subcutaneously, intravenously, intralymphatic, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, ontologically, neuro-otologically, intraocularly, subconjuctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intracisternally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic device . The method of administration can vary depending on various factors, e.g., the components of the pharmaceutical composition, the site of the disease, the disease involved, and the severity of the disease.

[063] A "diagnostic" as used herein is a compound, method, system, or device that assists in the identification or characterization of a health or disease state. The diagnostic can be used in standard assays as is known in the art.

[064] The term "mammal" is used in its usual biological sense. Thus, it specifically includes humans, cattle, horses, monkeys, dogs, cats, mice, rats, cows, sheep, pigs, goats, and non- human primates, but also includes many other species.

[065] The term "pharmaceutically acceptable carrier", "pharmaceutically acceptable diluent" or "pharmaceutically acceptable excipient" includes any and all solvents, co-solvents, complexing agents, dispersion media, coatings, isotonic and absorption delaying agents and the like which are not biologically or othenvise undesirable. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. In addition, various adjuvants such as are commonly used in the art may be included. These and other such compounds are described in the literature, e.g., in the Merck Index, Merck & Company, Rahway, NJ. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Brunton et al. (Eds.) (2017); Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 13th Ed.. The McGraw-Hill Companies.

[066] The temi "pharmaceutically acceptable salt" refers to salts that retain the biological effectiveness and properties of the compounds provided herein and, which are not biologically or otherwise undesirable. In many cases, the compounds provided herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Many such salts are known in the art, for example, as described in WO 87/05297. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methane sulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

[067] "Patient" as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate, or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate. In some embodiments, the patient is a human.

[068] A "therapeutically effective amount" of a compound as provided herein is one which is sufficient to achieve the desired physiological effect and may vary according to the nature and severity of the disease condition, and the potency of the compound. "Therapeutically effective amount" is also intended to include one or more of the compounds of Formulas I, la, lb, Ic, Id, and Ie, in combination with one or more other agents that are effective to treat the diseases and/or conditions described herein. The combination of compounds can be a synergistic combination. Synergy, as described, for example, by Chou and Talalay, Advances in Enzyme Regulation (1984), 22, 27-55, occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease. This amount can further depend upon the patient's height, weight, sex, age and medical history.

[069] A therapeutic effect relieves, to some extent, one or more of the symptoms of the disease.

[070] "Treat," "treatment," or "treating," as used herein refers to administering a compound or pharmaceutical composition as provided herein for therapeutic purposes. The term "therapeutic treatment" refers to administering treatment to a patient already suffering from a disease thus causing a therapeutically beneficial effect, such as ameliorating existing symptoms, ameliorating the underlying metabolic causes of symptoms, postponing or preventing the further development of a disorder, and/or reducing the severity of symptoms that will or are expected to develop.

[071] "Drug-eluting" and/or controlled release as used herein refers to any and all mechanisms, e.g., diffusion, migration, permeation, and/or desorption by which the drug(s) incorporated in the drug-eluting material pass therefrom over time into the surrounding body tissue. [072] "Drug-eluting material" and/or controlled release material as used herein refers to any natural, synthetic or semi-synthetic material capable of acquiring and retaining a desired shape or configuration and into which one or more drugs can be incorporated and from which incorporated drug(s) are capable of eluting over time.

[073] "Elutable drug" as used herein refers to any drug or combination of drugs having the ability to pass over time from the drug-eluting material in which it is incorporated into the surrounding areas of the body.

Compounds

[074] The compounds and compositions described herein can be used as antiproliferative agents, e.g., anti-cancer and anti-angiogenesis agents, and/or as inhibitors of the Wnt signaling pathway, e.g., for treating diseases or disorders associated with aberrant Wnt signaling. In addition, the compounds can be used as inhibitors of one or more kinases, kinase receptors, or kinase complexes. Such compounds and compositions are also useful for controlling cellular proliferation, differentiation, and/or apoptosis.

[075] The compounds and compositions described herein can be used to inhibit DYRK1A for treating a disorder or disease in which DYRK1A overexpression is implicated, such as Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Down Syndrome, Frontotemporal Dementia with Parkinsonism- 17 (FTDP-17), Lewy body dementia, Parkinson's Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy, Huntington's Disease, Multiple Sclerosis; diseases and disorders associated with acquired brain injury such as Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor, and Stroke.

[076] Some embodiments of the present disclosure include compounds of Formula

I

I

salts, pharmaceutically acceptable salts, or prodrugs thereof.

[077] Some embodiments of the present disclosure include compounds of Formula

la

salts, pharmaceutically acceptable salts, or prodrugs thereof.

[078] Some embodiments of the present disclosure include compounds of Formula

salts, pharmaceutically acceptable salts, or prodrugs thereof.

[079] Some embodiments of the present disclosure include compounds of Formula

Ic

salts, pharmaceutically acceptable salts, or prodrugs thereof.

[080] Some embodiments of the present disclosure include compounds of Formula

salts, pharmaceutically acceptable salts, or prodrugs thereof.

[081] Some embodiments of the present disclosure include compounds of Formula

Ie

or salts, pharmaceutically acceptable salts, or prodmgs thereof.

[082] In some embodiments of Formula I, Y 3 is CH or nitrogen.

[083] In some embodiments of Formula I, Y 1 , Y 2 , Y 4 , and Y 5 are independently selected from the group consisting of carbon and nitrogen.

[084] In some embodiments of Formula I, Y 1 is nitrogen, Y 2 , Y 4 , and Y 5 are carbon, Y 3 is CH, and 4 is absent.

[085] In some embodiments of Formula I, Y 2 is nitrogen, Y 1 , Y 4 , and Y 5 are carbon,

Y 3 is CH, and R 5 is absent.

[086] In some embodiments of Formula I, Y 3 is nitrogen and Y 1 , Y 2 , Y 4 , and Y 5 are carbon;

[087] In some embodiments of Formula I, Y 4 is nitrogen, Y 1 , Y 2 , and Y 5 are carbon,

Y 3 is CH, and R 1 is absent.

[088] In some embodiments of Fonnula I, Y 5 is nitrogen, Y 1 , Y 2 , and Y 4 are carbon,

Y 3 is CH, and R 2 is absent.

[089] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 1 , R 2 , R 4 , and R 5 are independently absent or selected from the group consisting of H, halide (e.g., F, CI, Br, I), unsubstituted -(C1-3 haloalkyl), and unsubstituted -(C1-3 alkyl) (e.g., C1-3, C1-2, Ci),.

[090] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 1 , R 2 , R 4 , and R 5 are independently selected from the group consisting of H and halide (e.g., F, CI, Br, I).

[091] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 1 , R 2 , R 4 , and R 5 are independently selected from the group consisting of H and F.

[092] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 1 , R 2 , R 4 , and R 5 are all H.

[093] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 1 is F, and R 2 , R 4 , and R 5 are all H.

[094] In some embodiments of Formulas T, Ta, Tb, Tc, Td, and Te, R 2 is F, and R 1 , R 4 , and R 5 are all H.

[095] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 4 is F, and R 1 , R 2 , and R 5 are all H. [096] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 5 is F, and R 1 , R 2 , and R 4 are all H.

[097] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is selected from the group consisting of -aryl optionally substituted with 1-5 R 7 and -heteroaryl optionally substituted with 1-4 R 8 .

[098] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is phenyl ring optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R 7 .

[099] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 7 is selected from the group consisting of halide (e.g., F, CI, Br, I) and -N(R 17 )2.

[0100] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 7 is one halide (e.g., F, CI, Br, I) and one -N(R 17 ) 2 .

[0101] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 7 is one F and one

-NH 2

[0102] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 7 is one F and one -NH(Ci- 4 alkyl)( e.g., -NH(Ci 3 alkyl), -NH(Ci 2 alkyl), -NHMe).

[0103] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is a 5-membered heteroaryl ring optionally substituted as defined anywhere herein.

[0104] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is 5-membered heteroaryl ring optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R 8 .

[0105] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is selected from the group consisting of:

wherein each of R 6 -R 64 is, independently, a substituent as defined anywhere herein or a single bond connecting R 3 to the diazanaphthalene ring; wherein only one of R 6 -R 39 (when present) is a bond, only one of R 40 -R 43 (when present) is a bond, only one of R 44 -R 46 (when present) is a bond, only one of R 47 -R 49 (when present) is a bond, only one of R 50 -R 52 (when present) is a bond, only one of R 5 -R 55 (when present) is a bond, only one of R 56 -R 58 (when present) is a bond, only one of R 59 -R 60 (when present) is a bond, only one of R 61 -R 62 (when present) is a bond, and only one of R 6 -R 64 (when present) is a bond; for purposes of clarification, any one of the nitrogen atoms attached to R 36 , R 40 , R 44 , R 47 , or R 50 can serve as the point of attachment of R 3 to the diazanaphthalene ring; likewise, any one of the carbon atoms attached to R 37 , R 38 , R 39 , R 41 , R 42 , R 43 , R 45 , R 46 , R 48 , R 49 , R 51 , R 52 , R 53 , R M , R 55 , R 56 , R 57 , R 58 , R 59 , R 60 , R 61 , R 62 , R 63 , or R 64 can serve as the point of attachment of R 3 to the diazanaphthalene ring; so that:

when the nitrogen atom to which R 36 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 36 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 37 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 37 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 38 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 38 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 39 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 39 is a single bond connecting R 3 to the diazanaphthalene ring; when the nitrogen atom to which R 40 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 40 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 41 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 41 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 42 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 42 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 43 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 43 is a single bond connecting R 3 to the diazanaphthalene ring; when the nitrogen atom to which R 44 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 44 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 45 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 45 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 46 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 46 is a single bond connecting R 3 to the diazanaphthalene ring; when the nitrogen atom to which R 47 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 47 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 48 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 48 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 49 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 49 is a single bond connecting R 3 to the diazanaphthalene ring; when the nitrogen atom to which R 50 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 50 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 51 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 51 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 52 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 52 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 53 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 53 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 54 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 54 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 55 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 55 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 56 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 56 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 57 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 57 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 58 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 58 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 59 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 59 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 60 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 60 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 61 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 61 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 62 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 62 is a single bond connecting R 3 to the diazanaphthalene ring; when the carbon atom to which R 63 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 63 is a single bond connecting R 3 to the diazanaphthalene ring; and

when the carbon atom to which R 64 is attached serves as the point of attachment of R 3 to the diazanaphthalene ring, then R 64 is a single bond connecting R 3 to the diazanaphthalene ring.

[0106] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 36 is selected from the group consisting of a single bond, H, unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl),-(Ci-4 alkylene)XR 19 , -(Ci-4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1- 3, 1-2, 1) R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1- 6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(G- 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0107] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 37 , R 38 , and R 39 are independently selected from the group consisting of a single bond, H, halide (e.g., F, CI, Br, I), unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(G- 9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(G- 4 alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(G- 4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(C 1- 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0108] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, one of R 36 and R 37 , R 37 and R 38 , or R 38 and R 39 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 and -carbocyclyl optionally substituted with 1-12 (e.g., 1-1 1, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 .

[0109] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 40 is selected from the group consisting of a single bond, H, unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(G- 9 haloalkyl) ,-(G- 4 alkylene)XR 19 , -C(=0)N(R 15 ) 2 , -(G-4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1- 3, 1-2, 1) R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1- 6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(G- 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0110] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 41 , R 42 , and R 43 are independently selected from the group consisting of a single bond, H, halide (e .g., F, CI, Br, I), unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(G- 9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(G- 4 alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1 ) R 20 , and -carbocyclyl optionally substituted with 1 -12 (e.g., 1 -1 1 , 1 -10, 1 -9, 1 -8, 1 -7, 1 -6, 1 -5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(G-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0111] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, one of R 40 and R 41 , R 41 and R 42 , or R 43 and R 40 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1 -10 (e.g., 1 -9, 1 -8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 and -carbocyclyl optionally substituted with 1 -12 (e.g., 1 -1 1, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ;

[0112] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 44 is selected from the group consisting of a single bond, H, unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl),-(Ci-4 alkylene)XR 19 , C(=0)N(R 15 ) 2 , -(Ci-4 alkylene)pheterocyclyl optionally substituted with 1 -10 (e.g., 1 -9, 1 -8, 1-7, 1-6, 1-5, 1-4, 1- 3, 1-2, 1 R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-1 1 , 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1 -3, 1-2, 1) R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0113] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 45 and R 46 are independently selected from the group consisting of a single bond, H, halide (e.g., F, CI, Br, I), unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(Ci -9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(C1-4 alkylene) P XR 19 , -C(=0)N(R 15 ) 2 , -(CM alkylene) p heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1 -2, 1) R 20 , and -carbocyclyl optionally substituted with 1 -12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1 -5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0114] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, one of R 44 and R 45 or R 45 and R 45 are taken together to form a ring which is selected from the group consisting of - heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1 -4, 1 -3, 1-2, 1) R 22 and -carbocyclyl optionally substituted with 1-12 (e.g., 1-1 1, 1-10, 1-9, 1 -8, 1-7, 1-6, 1-5, 1 -4, 1 -3, 1-

2, 1) R 21 .

[0115] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 47 is selected from the group consisting of a single bond, H, unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl),-(Ci-4 alkylene)XR 19 , -C(=0)N(R 15 ) 2 , -(Ci-4 alkylene)pheterocyclyl optionally substituted with 1 -10 (e.g., 1 -9, 1 -8, 1-7, 1-6, 1-5, 1-4, 1-

3, 1-2, 1) R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-1 1, 1-10, 1-9, 1 -8, 1-7, 1 - 6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(C 1 -4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0116] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 48 and R 49 are independently selected from the group consisting of a single bond, H, halide (e.g., F, CI, Br, I), unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(Ci -9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(Ci- 4 alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(Ci-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0117] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, one of R 47 and R 48 or R 47 and R 49 are taken together to form a heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 .

[0118] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 50 is selected from the group consisting of a single bond, H, unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl),-(Ci- 4 alkylene)XR 19 , -C(=0)N(R 15 ) 2 , -(Ci-4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1- 3, 1-2, 1) R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1- 6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(C 1 - 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0119] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 51 and R 52 are independently selected from the group consisting of a single bond, H, halide (e.g., F, CI, Br, I), unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(Ci -9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(Ci- 4 alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0120] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 51 and R 52 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 .

[0121] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 53 , R 54 , and R 55 are independently selected from the group consisting of a single bond, H, halide (e.g., F, CI, Br, I), unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(G -9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(Ci- 4 alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein. [0122] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, there is the proviso that when R 54 is a single bond connecting R 3 to the diazanaphthalene ring, R 53 and R 55 are not methyls.

[0123] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, one of R 53 and R 54 or R 54 and R 55 are taken together to form a ring which is selected from the group consisting of - heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1- 2, 1) R 21 .

[0124] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 56 , R 57 , and R 58 are independently selected from the group consisting of a single bond, H, halide (e.g., F, CI, Br, I), unsubstituted -(Ci-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(Ci -9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(Ci- 4 alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0125] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R % and R 57 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 .

[0126] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 59 and R 60 are independently selected from the group consisting of a single bond, H, halide (e.g., F, CI, Br, I), unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C 1-9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(Ci- 4 alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(C 1- 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0127] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 59 and R 60 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 .

[0128] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 61 and R 62 are independently selected from the group consisting of a single bond, H, halide (e.g., F, CI, Br, I), unsubstituted -(C 1 -9 alkyl), unsubstituted -(C 2 -9 alkenyl), unsubstituted -(C 2 -9 alkynyl), unsubstituted -(Ci -9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(Ci- 4 alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(C 1 - 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0129] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 63 and R 64 are independently selected from the group consisting of a single bond, H, halide (e.g., F, CI, Br, I), unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C 1 -9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(Ci- 4 alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(C 1 - 4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0130] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 63 and R 64 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 .

[0131] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each X 1 is O or S.

[0132] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 3 is selected from the group consisting of: furanyl optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R 8 , thiophenyl optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R 8 , pyrrolyl optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R 8 ,

wherein each m is independently 1 to 4 (e.g., 1-3, 1-2, 1). [0133] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 3 is a 6-10- membered heteroaryl ring optionally substituted as defined anywhere herein.

[0134] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 3 is 6-10- membered heteroaryl ring optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R 8 .

[0135] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 6 is selected from the group consisting of -(C1-4 alkylene) p aryl substituted with 1-5 R 9 , -(C2-4 alkenylene) p aryl substituted with 1-5 R 9 , -(C1- alkylene)pheteroaryl optionally substituted with 1-6 R 10 ; -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 11 , -(Ci- 4 alkylene) p carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1- 7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 12 , -(Ci_ 4 alkylene)N(R 13 )(R 14 ), -N(R 15 )(R 16 ), -CF(Ci -9 alkyl) 2 , -(C1-4 alkylene)pO(C3-9 alkyl), and -(C2-9 alkynyl) optionally substituted with one or more halide (e.g., F, CI, Br, I)s; wherein each alkyl of-CF(Ci-9 alkyl)2 is, independently, optionally substituted with one or more halides; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein; wherein -(C1-4 alkenylene) is, optionally substituted with one or more substituents as defined anywhere herein.

[0136] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 6 is -heterocyclyl optionally substituted with 1 -2 R" .

[0137] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 6 is a - CFfcheterocyclyl optionally substituted with 1-2 R 11 .

[0138] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 6 is either a piperidinyl or a pyrrolidinyl both optionally substituted with 1-2 R 11 .

[0139] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 6 is a piperidinyl substituted with one -N(R 15 )(R 25 ).

[0140] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 15 and R 25 are independently selected from the group consisting of H, Me, and -Ci-4 haloalkyl.

[0141] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 8 is independently selected from the group consisting of H, halide (e.g., F, CI, Br, I), unsubstituted - (Ci-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -N(R 15 )(R 18 ), -(C1-4 alkylene) p XR 19 , -C(=0)N(R 15 ) 2 , -(CM alkylene)pheterocyclyl optionally substituted with 1 -10 (e.g., 1 -9, 1 -8, 1 -7, 1 -6, 1 -5, 1 -4, 1 -3, 1 -2, 1) R 20 , and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(C 1 - 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein. [0142] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, two adjacent R 8 are taken together to form a ring which is selected from the group consisting of -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 and -carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 .

[0143] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 9 is independently selected from the group consisting of halide (e.g., F, CI, Br, I), unsubstituted -(Ci-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -XR 23 ,-C(=0)N(R 15 ) 2 , -(Ci-4 alkylene)pN(R 24 ) 2 , -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 , and -(C 1 -4 alkylene)pCarbocyclyl optionally substituted with 1-12 (e.g., 1-1 1, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1- 4, 1-3, 1-2, 1) R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0144] In some embodiments of Formula I there is the roviso that when Y 2 is N then

R 9 is not -OMe or

[0145] In some embodiments of Formula lb, R 9 is not -OMe or .

[0146] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 10 is independently selected from the group consisting of halide (e.g., F, CI, Br, I), unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -CN, -XR 23 , -C(=0)N(R 15 ) 2 , -(Ci-4 alkylene) p N(R 24 ) 2 , -(G- 4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 , and -(C 1-4 alkylene)pCarbocyclyl optionally substituted with 1-12 (e.g., 1-1 1, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1- 4, 1-3, 1-2, 1) R 21 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0147] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 11 is independently selected from the group consisting of halide (e.g., F, CI, Br, I), unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(Ci-4 alkylene) p OR 19 , -(C1-4 alkylene ) p heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 , -(C1-4 alkylene ) p carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 , -N(R 15 )(R 25 ), -C(=0)(R 26 ), -(G- 4 alkylene)C(=0)OR 27 , -(C1-4 alkylene)aryl optionally substituted with one or more halides, -(G-4 alkylene)pheteroaryl optionally substituted with one or more halides, and -S02(R 28 ); wherein each -(Ci-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0148] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, two R 11 attached to the same carbon atom can together represent =0 to form a carbonyl group.

[0149] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 12 is independently selected from the group consisting of halide (e.g., F, CI, Br, I), unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(CM alkylene)pOR 19 , -N(R 15 )(R 29 ), -C(=0)(R 26 ), -C(=0)OR 27 , -(CM alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 , and -(CM alkylene)pCarbocyclyl optionally substituted with 1-12 (e.g., 1-1 1, 1-10, 1 -9, 1-8, 1-7, 1 -6, 1-5, 1 - 4, 1-3, 1-2, 1) R 21 ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0150] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 13 is selected from the group consisting of H, unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted -(C2 9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylene ) p heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20 , and -carbocyclvl optionally substituted with 1-12 (e.g., 1-1 1, 1-10, 1-9, 1-8, 1 -7, 1-6, 1 -5, 1-4, 1-3, 1-2, 1) R 21 ; wherein -(CM alkylene) is, optionally substituted with one or more substituents as defined anywhere herein.

[0151] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 14 is selected from the group consisting of unsubstituted -(C1-9 alkyl), unsubstituted -(C2-9 alkenyl), unsubstituted - (C2-9 alkynyl), unsubstituted -(C1-9 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20 , and -carbocyclvl optionally substituted with 1-12 (e.g., 1-1 1, 1-10, 1-9, 1-8, 1 -7, 1-6, 1 -5, 1-4, 1-3, 1-2, 1) R 21 ; wherein -(G- 4 alkylene) is, optionally substituted with one or more substituents as defined anywhere herein.

[0152] In some embodiments of Formulas I. Ia, lb, Ic, Id. and Ie, each R 15 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl).

[0153] In some embodiments of Formulas I, Ia, lb, Ic, Id, and Ie, R 16 is selected from the group consisting of-(Ci-4 alkylene)pheterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1 - 8, 1 -7, 1 -6, 1 -5, 1 -4, 1 -3, 1 -2, 1 ) R 20 , and— (C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 (e.g., 1-1 1, 1-10, 1-9, 1-8, 1-7, 1 -6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(G- 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein. [0154] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, 17 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), and unsubstituted -(C1-5 haloalkyl).

[0155] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, two adjacent R 17 are taken together to form a -heterocyclyl ring optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 22 .

[0156] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 18 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C=0)R 15 , and -(C1-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl); wherein -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0157] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 19 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted - (C2 5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(Ci-4 alkylene) p carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1- 9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0158] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 20 independently is selected from the group consisting of halide (e.g., F, CI, Br, I), unsubstituted -(Ci- 5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -N(R 15 )2, and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(Ci- 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0159] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 21 is independently selected from the group consisting of halide (e.g., F, CI, Br, I), unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN.

[0160] In some embodiments of Formulas T, Ta, Tb, Tc, Td, and Ie, each R 22 is independently selected from the group consisting of halide (e.g., F, CI, Br, I), unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -N(R 15 ) 2 , -C(=0)R 34 , and -(G- 4 alkylene) p carbocyclyl optionally substituted with 1- 12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(Ci- 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0161] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 23 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene )N(R 15 ) 2 , -(C 1-4 alkylene ) p aryl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1- 5, 1-4, 1-3, 1-2, 1) R 30 , -(Ci- 4 alkylene)pheterocyclyl optionally substituted with 1-12 (e.g., 1-11, 1- 10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 31 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each - (C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0162] In some embodiments of Fonnulas I, la, lb, Ic, Id, and Ie, each R 24 is independently selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted - (C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alky lene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl), and -(C1-4 alkylene)N(R 15 ) 2 ; wherein each alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0163] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 25 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 32 , -(C1-4 alkylene)pcarbocyclyl optionally substituted with 1-12 (e.g., 1-1 1, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1- 4, 1-3, 1-2, l) R 21 , -(Ci-4 alkylene)OR 33 ; wherein each -(Ci-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0164] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 26 is selected from the group consisting of H, unsubstituted -(C3-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), -(C1-4 alkylene ) p heteroaryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl); wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0165] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 27 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene) p heteroaryl optionally substituted with one or more halides or unsubstituted -(C1-5 alkyl), and -(C1-4 alkylene)pheterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl); wherein each -(Ci-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0166] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 28 is selected from the group consisting of unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted - (C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p aryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), -(C1-4 alkylene ) p heteroaryl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl), and -(Ci-4 alky lene) p heterocyclyl optionally substituted with one or more halides or one or more unsubstituted -(Ci-5 alkyl); wherein -(C1-4 alkylene) is, optionally substituted with one or more substituents as defined anywhere herein.

[0167] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 29 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 32 , -(CM alkylene) p carbocyclyl optionally substituted with 1-12 (e.g., 1-1 1, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1- 4, 1-3, 1-2, l) R 21 , -(Ci-4 alkylene)OR 33 ; wherein each -(Ci-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0168] In some embodiments of Fomiulas I, la, lb, Ic, Id, and Ie, each R 29 is selected from the group consisting of H, unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -(C1-4 alkylene) p heterocyclyl optionally substituted with 1-10 (e g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 32 , -(C1-4 alkylene)pCarbocyclyl optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1- 4, 1-3, 1-2, l) R 21 , -(Ci- 4 alkylene)OR 33 , and alkyl); wherein each -(G- 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0169] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 30 is independently selected from the group consisting of halide (e.g., F, CI, Br, I), unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), and -CN.

[0170] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 31 is independently selected from the group consisting of halide (e.g., F, CI, Br, I), unsubstituted -(C1-5 alkyl), unsubstituted -(C2-5 alkenyl), unsubstituted -(C2-5 alkynyl), unsubstituted -(C1-5 haloalkyl), -CN, -OH, -C(=0)R 34 , -N(R 24 ) 2 , and -(C1-4 alkylene) p carbocyclyl optionally substituted with 1- 12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 21 ; wherein each -(Ci- 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.

[0171] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 32 is independently selected from the group consisting of halide (e.g., F, CI, Br, I) and unsubstituted - (Ci-5 alkyl).

[0172] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 33 is independently selected from the group consisting of H and unsubstituted -(C1-5 alkyl).

[0173] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 34 is a heteroaryl optionally substituted with 1-6 (e.g., 1-5, 1-4, 1-3, 1-2, 1) R 35 .

[0174] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 34 is independently selected from the group consisting of -0(G-5 alkyl) and a heteroaryl optionally substituted with 1-6 (e.g., 1-5, 1-4, 1-3, 1-2, 1) R 35 .

[0175] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each R 5 is a - heterocvclyl optionally substituted with one or more halides or one or more unsubstituted -(C1-5 alkyl).

[0176] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each X is selected from the group consisting of O and S.

[0177] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each p is independently 0 or 1.

[0178] In some embodiments of Fomiulas I, la, lb, Ic, Id, and Ie, each -(C1-4 alkylene) is -(C1-3 alkylene).

[0179] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each -(C1-4 alkylene) is -(C1-2 alkylene).

[0180] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each -(C1-4 alkylene) is -(G alkylene).

[0181] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, each -(C1-4 alkylene) is -□¾-.

[0182] In some embodiments of Formulas T, Ta, Tb, Tc, Td, and Te, each -(C1-4 alkylene) is optionally substituted with halide (e.g., F, CI, Br, I).

[0183] In some embodiments of Formulas I, each -(C1-4 alkylene) is optionally substituted with F. [0184] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is selected from the group consisting of pyrazolyl, imidazolyl, triazolyl, thiadiazolyl, and oxazolyl, each optionally substituted with 1-4 R 8 .

[0185] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is selected from the group consisting of pyrazol-4-yl, imidazol-5-yl, l,2,3-triazol-4-yl, thiadiazol-2-yl, and oxazol- 5-yl, each optionally substituted with 1-4 R 8 .

[0186] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is an unsubstituted pyrazol-4-yl,.

[0187] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is a pyrazol-4- yl,substi ted with one -(C1-3 alkyl).

[0188] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is a imidazol-5- yl substituted with one -(C1-3 alkyl).

[0189] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is a imidazol-5- yl substituted with two -(C1-3 alkyl).

[0190] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is an unsubstituted l,2,3-triazol-4-yl.

[0191] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is a 1,2,3-triazol- 4-yl substituted with one -(C1-3 alkyl).

[0192] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is an unsubstituted thiadiazol-2-yl .

[0193] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is a thiadiazol- 2-yl substituted with one -(C1-3 alkyl).

[0194] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is an unsubstituted oxazol-5-yl.

[0195] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is a oxazol-5-yl substituted with one -(C1-3 alkyl).

[0196] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 i is

[0197] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 38 is a single bond connecting R 3 to the diazanaphthalene ring, i.e., R 3 has the following formula: [0198] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 3 is and n is 1 to 3.

[0199] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 36 is selected from the group consisting of H, unsubstituted -(Cu alkyl), unsubstituted -(C1-2 haloalkyl), and -(C3-4 carbocyclyl) optionally substituted with 1-2 R 21 .

[0200] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 36 is selected from the group consisting of H, methyl, -CF3, and cyclopropyl optionally substituted with 1-2 R 21 .

[0201] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 3e is selected from the group consisting of H and methyl.

[0202] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 36 is methyl.

[0203] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 36 is -CD 3 .

[0204] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 37 is selected from the group consisting of H, halide (e.g., F, CI, Br, I), unsubstituted -(C 1-2 alkyl), unsubstituted -(Ci- 2 haloalkyl), and -(Ci -2 alkylene)OR iy .

[0205] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 37 is selected from the group consisting of H, F, methyl, -CF 3 , -(CH 2 )OH, and -(CH 2 )OMe.

[0206] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 37 is selected from the group consisting of H, F, and methyl.

[0207] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 37 is H.

[0208] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 39 is selected from the group consisting of H and halide (e.g., F, CI, Br, I).

[0209] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 39 is selected from the group consisting of H and F.

[0210] In some embodiments of Formulas I, la, lb, Ic, Id, and Ie, R 39 is H. [0211] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is

[0212] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 12 is a single bond connecting R 3 to the diazanaphthalene ring, i.e., R 3 has the following formula:

[0213] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is and n is 1 to 3.

[0214] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 40 is selected from the group consisting of H, unsubstituted -(C1-3 alkyl), unsubstituted -(C1-2 haloalkyl), and -(C3-4 carbocyclyl) optionally substituted with 1 -2 R 21 .

[0215] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 40 is selected from the group consisting of H, methyl, -CF 3 , and cyclopropyl optionally substituted with 1-2 R 21 .

[0216] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 40 is selected from the group consisting of H and methyl.

[0217] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 40 is methyl.

[0218] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 40 is -CD3.

[0219] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 42 is selected from the group consisting of H and halide (e.g., F, CI, Br, I).

[0220] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 42 is selected from the group consisting of H and F.

[0221] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 43 is selected from the group consisting of H, halide (e.g., F, CI, Br, I), unsubstituted -(C1-2 alkyl), and unsubstituted - (Ci-2 haloalkyl).

[0222] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 43 is selected from the group consisting of H, F, methyl, and -CF3. [0223] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 43 is selected from the group consisting of H and methyl.

[0224] In some embodiments of Formulas I, la, lb, Ic. Id, and le, R 40 and R 43 are both methyl.

[0225] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is

[0226] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is J R 57 and X is S.

[0227] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is and X is O.

[0228] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 56 is a single bond connecting R 3 to the diazanaphthalene ring, i.e., R 3 has the following formula:

[0229] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is

[0230] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R > 3 3 iise

[0231] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 57 is selected from the group consisting of H and halide (e.g., F, CI, Br, I). [0232] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 57 is selected from the group consisting of H and F.

[0233] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 58 is selected from the group consisting of H, halide (e.g., F, CI, Br, I), unsubstituted -(Ci-2 alkyl), and unsubstituted - (Ci- 2 haloalkyl).

[0234] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 58 is selected from the group consisting of H, F, methyl, and -CF3.

In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is

e embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is

0237] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is

[0238] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 62 is a single bond connectin R 3 to the diazanaphthalene ring, i.e., R 3 has the following formula:

[0239] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is

[0240] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is [0241] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 51 is selected from the group consisting of H, halide (e.g., F, CI, Br, I), unsubstituted -(C1-2 alkyl), unsubstituted -(Ci- z haloalkyl), and -N(R 15 )(R 18 ).

[0242] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 61 is selected from the group consisting of H, F, methyl, -CF 3 , -NHMe, and -NMe2.

[0243] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 51 is selected from the group consisting of H and methyl.

[0244] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 61 is methyl.

[0245] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is

[0246] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 49 is a single bond connecting R 3 to the diazanaphthalene ring, i.e., R 3 has the following formula:

[0247] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is

[0248] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 45 is a single bond connecting R 3 to the diazanaphthalene ring, i.e., R 3 has the following formula:

[0249] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 46 is a single bond connecting R 3 to the diazanaphthalene ring, i.e., R 3 has the following formula: [0250] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 44 is selected from the group consisting of H and unsubstituted -(C1-2 alkyl).

[0251] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 44 is selected from the group consisting of H and methyl.

[0252] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 44 is methyl.

[0253] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 44 is -CD 3 .

[0254] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 3 is and n is 1 to 3.

[0255] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 47 is selected from the group consisting of H, unsubstituted -(C1-3 alkyl), unsubstituted -(C1-2 haloalkyl), and -(C3-4 carbocyclyl) optionally substituted with 1-2 R 21 .

[0256] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 47 is selected from the group consisting of H, methyl, -CF3, and cyclopropyl optionally substituted with 1-2 R 21 .

[0257] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 47 is selected from the group consisting of H and methyl.

[0258] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 48 is selected from the group consisting of H. halide (e.g., F, CI, Br, I), unsubstituted -(C1-2 alkyl), and unsubstituted - (Ci-2 haloalkyl).

[0259] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 48 is selected from the group consisting of H, F, methyl, and -CF 3 .

[0260] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 21 is selected from the group consisting of halide (e.g., F, CI, Br, I), unsubstituted -(C1-3 alkyl), and unsubstituted - (Ci-2 haloalkyl).

[0261] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 21 is selected from the group consisting of F, methyl, and -CF 3 .

[0262] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 22 is selected from the group consisting of H and unsubstituted -(C1-2 alkyl).

[0263] In some embodiments of Formulas I, la, lb, Ic, Id, and le, R 22 is selected from the group consisting of H and methyl. [0264] Illustrative compounds of Formulas I, la, lb, Ic, Id, and Ie are shown in Table (below).

[0265] Illustrative compounds of Formula (I) are shown in Table 1.

Table 1.

"¾or i e.

100

117



151

215 Administration and Pharmaceutical Compositions

[0266] Some embodiments include pharmaceutical compositions comprising: (a) a therapeutically effective amount of a compound provided herein, or its corresponding enantiomer, diastereoisomer or tautomer, or pharmaceutically acceptable salt; and (b) a pharmaceutically acceptable carrier.

[0267] The compounds provided herein may also be useful in combination (administered together or sequentially) with other known agents.

[0268] Non-limiting examples of diseases which can be treated with a combination of a compound of Formulas I, la, lb, Ic, Id, or Ie and other another active agent are colorectal cancer, ovarian cancer, chronic inflammation, diabetic retinopathy, pulmonary fibrosis, and osteoarthritis. For example, a compound of Formula (I) can be combined with one or more chemotherapeutic compounds.

[0269] In some embodiments, colorectal cancer can be treated with a combination of a compound of Formulas I, la, lb, Ic, Id, or Ie and one or more of the following drugs: 5- Fluorouracil (5-FU), which can be administered with the vitamin-like drug leucovorin (also called folinic acid); capecitabine (XELODA ® ), irinotecan (CAMPOSTAR ® ), oxaliplatin (ELOXATIN ® ). Examples of combinations of these drugs which could be further combined with a compound of Formulas I, la, lb, Ic. Id, or Ie are FOLFOX (5-FU, leucovorin, and oxaliplatin). FOLFIRI (5-FU, leucovorin, and irinotecan), FOLFOXIRI (leucovorin, 5-FU, oxaliplatin, and irinotecan) and Cape Ox (Capecitabine and oxaliplatin). For rectal cancer, chemo with 5-FU or capecitabine combined with radiation may be given before surgery (neoadjuvant treatment).

[0270] In some embodiments, ovarian cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: Topotecan, Liposomal doxorubicin (DOXIL ® ), Gemcitabine (GEMZAR ® ), Cyclophosphamide (CYTOXAN ® ), Vmorelbine (NAVELBINE ® ), Ifosfamide (IFEX ® ), Etoposide (VP- 16), Altretamine (HEXALEN ® ), Capecitabine (XELODA ® ), Irinotecan (CPT-11, CAMPTOSAR ® ), Melphalan, Pemetrexed (ALIMTA ® ) and Albumin bound paclitaxel (nab-paclitaxel, ABRAXANE ® ). Examples of combinations of these drugs which could be further combined with a compound of Formulas I, la, lb, Ic, Id, or Ie are TIP (paclitaxel [Taxol], ifosfamide, and cisplatin), VelP (vinblastine, ifosfamide, and cisplatin) and VIP (etoposide [VP-16], ifosfamide, and cisplatin)

[0271] In some embodiments, a compound of Formulas I, la, lb, Ic, Id, or Ie can be used to treat cancer in combination with any of the following methods: (a) Hormone therapy such as aromatase inhibitors, LHRH [luteinizing hormone-releasing hormone] analogs and inhibitors, and others; (b) Ablation or embolization procedures such as radiofrequency ablation (RFA), ethanol (alcohol) ablation, microwave thermotherapy and cryosurgery (cryotherapy); (c) Chemotherapy using alkylating agents such as cisplatin and carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil and ifosfamide; (d) Chemotherapy using antimetabolites such as azathioprine and mercaptopurine; (e) Chemotherapy using plant alkaloids and terpenoids such as vinca alkaloids (i.e. Vincristine, Vinblastine, Vinorelbine and Vindesine) and taxanes; (f) Chemotherapy using podophyllotoxin, etoposide, teniposide and docetaxel; (g) Chemotherapy using topoisomerase inhibitors such as irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, and teniposide; (h) Chemotherapy using cytotoxic antibiotics such as actinomycin, anthracyclines, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, plicamycin and mitomycin; (i) Chemotherapy using tyrosine-kinase inhibitors such as Imatinib mesylate (GLEEVEC ® , also known as STI-571), Gefitinib (Iressa, also known as ZD 1839), Erlotinib (marketed as TA CEVA ® ), Bortezomib (VELCADE ® ) , tamoxifen , tofacitinib, crizotinib, Bcl-2 inhibitors (e.g. obatoclax in clinical trials, ABT-263, and Gossypol), PARP inhibitors (e.g. Iniparib, Olaparib in clinical trials), PI3K inhibitors (e.g. perifosine in a phase III trial), VEGF Receptor 2 inhibitors (e.g. Apatinib), AN-152, (AEZS-108), Braf inhibitors (e.g. vemurafenib, dabrafenib and LGX818), MEK inhibitors (e.g. trametinib and MEK162), CDK inhibitors, (e.g. PD-0332991), salinomycin and Sorafenib; (j) Chemotherapy using monoclonal antibodies such as Rituximab (marketed as MABTHERA ® or RITUXAN ® ), Trastuzumab (Herceptin also known as ErbB2), Cetuximab (marketed as ERBITUX ® ), and Bevacizumab (marketed as AVASTIN ® ); and (k) radiation therapy.

[0272] In some embodiments, diabetic retinopathy can be treated with a combination of a compound of Fomiulas I, la, lb, Ic, Id, or Ie and one or more of the following natural supplements: Bilberry, Butcher's broom, Ginkgo, Grape seed extract, and Pycnogenol (Pine bark).

[0273] In some embodiments, idiopathic pulmonary fibrosis/pulmonary fibrosis can be treated with a combination of a compound of Formulas I, la, lb, Ic, Id, or Ie and one or more of the following drugs: pirfenidone (pirfenidone was approved for use in 2011 in Europe under the brand name Esbriet ® ), prednisone, azathioprine, N-acetylcysteine, interferon-γ lb, bosentan (bosentan is currently being studied in patients with IPF, [The American Journal of Respiratory and Critical Care Medicine (2011), 184(1), 92-9]), Nintedamb (BIBF 1120 and Vargatef), QAX576 [British Journal of Pharmacology (2011 ), 163(1), 141-172], and anti -inflammatory agents such as corticosteroids.

[0274] In some embodiments, a compound of Formulas I, la, lb, Ic, Id, or Ie can be used to treat idiopathic pulmonary fibrosis/pulmonary fibrosis in combination with any of the following methods: oxygen therapy, pulmonary rehabilitation and surgery. [0275] In some embodiments, a compound of Formulas I, la, lb, Ic, Id, or Ie can be used to treat osteoarthritis in combination with any of the following methods: (a) Nonsteroidal antiinflammatory drugs (NSAIDs) such as ibuprofen, naproxen, aspirin and acetaminophen; (b) physical therapy; (c) injections of corticosteroid medications; (d) injections of hyaluronic acid derivatives (e.g. Hyalgan, Synvisc); (e) narcotics, like codeine; (f) in combination with braces and/or shoe inserts or any device that can immobilize or supportyour jointto help you keep pressure off it (e.g., splints, braces, shoe inserts or other medical devices); (g) realigning bones (osteotomy); (h) joint replacement (arthroplasty); and (i) in combination with a chronic pain class.

[0276] In some embodiments, macular degeneration can be treated with a combination of a compound of Formulas I, la, lb, Ic, Id, or Ie and one or more of the following drugs: Bevacizumab (Avastin ® ), Ranibizumab (Lucentis ® ), Pegaptanib (Macugen), Aflibercept (Eylea ® ), verteporfin (Visudyne ® ) in combination with photodynamic therapy (PDT) or with any of the following methods: (a) in combination with laser to destroy abnormal blood vessels (photocoagulation); and (b) in combination with increased vitamin intake of antioxidant vitamins and zinc.

[0277] In some embodiments, retinitis pigmentosa can be treated with a combination of a compound of Formulas I, la, lb, Ic, Id, or Ie and one or more of the following drugs: UF-021 (Ocuseva™), vitamin A palmitate and pikachurin or with any of the following methods: (a) with the Argus ® II retinal implant; and (b) with stem cell and/or gene therapy.

[0278] Administration of the compounds disclosed herein or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration, including, but not limited to, orally, subcutaneously, intravenously, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, ontologically, neuro- otologically, intraocularly, subconjuctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, mtracisternally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic devices. In some embodiments, the administration method includes oral or parenteral administration.

[0279] Compounds provided herein intended for pharmaceutical use may be administered as crystalline or amorphous products. Pharmaceutically acceptable compositions may include solid, semi-solid, liquid, solutions, colloidal, liposomes, emulsions, suspensions, complexes, coacervates and aerosols. Dosage forms, such as, e.g., tablets, capsules, powders, liquids, suspensions, suppositories, aerosols, implants, controlled release or the like. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, milling, grinding, supercritical fluid processing, coacervation, complex coacervation, encapsulation, emulsification, complexation, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose. The compounds can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills (tablets and or capsules), transdermal (including electrotransport) patches, implants and the like, for prolonged and/or timed, pulsed administration at a predetermined rate.

[0280] The compounds can be administered either alone or in combination with a conventional pharmaceutical carrier, excipient or the like. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self- emulsifying drug delivery systems (SEDDS) such as d-a-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose -based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene - polyoxypropylene -block polymers, and wool fat. Cyclodextrins such as α-, β, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3- hydroxypropyl- -cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds described herein. Dosage forms or compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared. The contemplated compositions may contain 0.001%-100% of a compound provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, sec Remington: The Science and Practice of Pharmacy, 22 nd Edition (Pharmaceutical Press, London, UK. 2012).

[0281] In one embodiment, the compositions will take the form of a unit dosage form such as a pill or tablet and thus the composition may contain, along with a compound provided herein, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like. In another solid dosage form, a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils, PEG's, poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose base capsule). Unit dosage forms in which one or more compounds provided herein or additional active agents are physically separated are also contemplated; e.g., capsules with granules (or tablets in a capsule) of each drug; two-layer tablets; two-compartment gel caps, etc. Enteric coated or delayed release oral dosage forms are also contemplated.

[0282] Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. a compound provided herein and optional pharmaceutical adjuvants in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution, colloid, liposome, emulsion, complexes, coacervate or suspension. If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like).

[0283] In some embodiments, the unit dosage of compounds of Formulas I, la, lb, Ic, Id, and Ie is about 0.25 mg/Kg to about 50 mg/Kg in humans.

[0284] In some embodiments, the unit dosage of compounds of Formulas I, la, lb, Ic, Id, and Ie is about 0.25 mg/Kg to about 20 mg/Kg in humans.

[0285] In some embodiments, the unit dosage of compounds of Formulas I, la, lb, Ic, Id, and Ie is about 0.50 mg/Kg to about 19 mg/Kg in humans.

[0286] In some embodiments, the unit dosage of compounds of Formulas I, la, lb, Ic, Id, and Ie is about 0.75 mg/Kg to about 18 mg/Kg in humans.

[0287] In some embodiments, the unit dosage of compounds of Formulas I, la, lb, Ic, Id, and Ie is about 1.0 mg/Kg to about 17 mg/Kg in humans.

[0288] In some embodiments, the unit dosage of compounds of Formulas I, la, lb, Ic, Id, and Ie is about 1.25 mg/Kg to about 16 mg/Kg in humans.

[0289] In some embodiments, the unit dosage of compounds of Formulas I, Ta, Tb, Ic, Id, and Ie is about 1.50 mg/Kg to about 15 mg/Kg in humans.

[0290] In some embodiments, the unit dosage of compounds of Formulas I, la, lb, Ic, Id, and Ie is about 1.75 mg/Kg to about 14 mg/Kg in humans. [0291] In some embodiments, the unit dosage of compounds of Formulas I, la, lb, Ic, Id, and Ie is about 2.0 mg/Kg to about 13 mg/Kg in humans.

[0292] In some embodiments, the unit dosage of compounds of Formulas I, la, lb, Ic, Id, and Ie is about 3.0 mg/Kg to about 12 mg/Kg in humans.

[0293] In some embodiments, the unit dosage of compounds of Formulas I, la, lb, Ic, Id, and Ie is about 4.0 mg/Kg to about 11 mg/Kg in humans.

[0294] In some embodiments, the unit dosage of compounds of Formulas I, la, lb, Ic, Id, and Ie is about 5.0 mg/Kg to about 10 mg/Kg in humans.

[0295] In some embodiments, the compositions are provided in unit dosage forms suitable for single administration.

[0296] In some embodiments, the compositions are provided in unit dosage forms suitable for twice a day administration.

[0297] In some embodiments, the compositions are provided in unit dosage forms suitable for three times a day administration.

[0298] Injectables can be prepared in conventional forms, either as liquid solutions, colloid, liposomes, complexes, coacervate or suspensions, as emulsions, or in solid forms suitable for reconstitution in liquid prior to injection. The percentage of a compound provided herein contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the patient. However, percentages of active ingredient of 0.01% to 10% in solution are employable, and could be higher if the composition is a solid or suspension, which could be subsequently diluted to the above percentages.

[0299] In some embodiments, the composition will comprise about 0.1-10% of the active agent in solution.

[0300] In some embodiments, the composition will comprise about 0.1-5% of the active agent in solution.

[0301] In some embodiments, the composition will comprise about 0.1-4% of the active agent in solution.

[0302] In some embodiments, the composition will comprise about 0.15-3% of the active agent in solution.

[0303] In some embodiments, the composition will comprise about 0.2-2% of the active agent in solution.

[0304] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-96 hours. [0305] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-72 hours.

[0306] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-48 hours.

[0307] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-24 hours.

[0308] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-12 hours.

[0309] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-6 hours.

[0310] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m 2 to about 300 mg/m 2 .

[0311] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m 2 to about 200 mg/m 2 .

[0312] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m 2 to about 100 mg/m 2 .

[0313] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 10 mg/m 2 to about 50 mg/m 2 .

[0314] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 50 mg/m 2 to about 200 mg/m 2 .

[0315] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 75 mg/m 2 to about 175 mg/m 2 .

[0316] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of about 100 mg/m 2 to about 150 mg/m 2 .

[0317] It is to be noted that concentrations and dosage values may also vary depending on the specific compound and the severity of the condition to be alleviated. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

[0318] In one embodiment, the compositions can be administered to the respiratory tract (including nasal and pulmonary) e.g., through a nebulizer, metered-dose inhalers, atomizer, mister, aerosol, dry powder inhaler, insufflator, liquid instillation or other suitable device or technique.

[0319] In some embodiments, aerosols intended for delivery to the nasal mucosa are provided for inhalation through the nose. For optimal delivery to the nasal cavities, inhaled particle sizes of about 5 to about 100 microns are useful, with particle sizes of about 10 to about 60 microns being preferred. For nasal delivery, a larger inhaled particle size may be desired to maximize impaction on the nasal mucosa and to minimize or prevent pulmonary deposition of the administered formulation. In some embodiments, aerosols intended for delivery to the lung are provided for inhalation through the nose or the mouth. For delivery to the lung, inhaled aerodynamic particle sizes of about less than 10 μτα are useful (e.g., about 1 to about 10 microns). Inhaled particles may be defined as liquid droplets containing dissolved drug, liquid droplets containing suspended drug particles (in cases where the drug is insoluble in the suspending medium), dry particles of pure drug substance, drug substance incorporated with excipients, liposomes, emulsions, colloidal systems, coacervates, aggregates of drug nanoparticles, or dry particles of a diluent which contain embedded drug nanoparticles.

[0320] In some embodiments, compounds of Formulas I, la, lb, Ic, Id, and Ie disclosed herein intended for respiratory delivery (either sy stemic or local) can be administered as aqueous formulations, as non-aqueous solutions or suspensions, as suspensions or solutions in halogenated hydrocarbon propellants with or without alcohol, as a colloidal system, as emulsions, coacervates, or as dry powders. Aqueous formulations may be aerosolized by liquid nebulizers employing either trydraulic or ultrasonic atomization or by modified micropump systems (like the soft mist inhalers, the Aerodose ® or the AERx ® systems). Propellant-based systems may use suitable pressurized metered-dose inhalers (pMDIs). Dry powders may use dry powder inhaler devices (DPIs), which are capable of dispersing the drug substance effectively. A desired particle size and distribution may be obtained by choosing an appropriate device.

[0321] In some embodiments, the compositions of Formulas I, la, lb, Ic, Id, and Ie disclosed herein can be administered to the ear by various methods. For example, a round window catheter (e.g., U.S. Pat. Nos. 6,440, 102 and 6,648,873) can be used.

[0322] Alternatively, formulations can be incorporated into a wick for use between the outer and middle ear (e.g., U.S. Pat. No. 6, 120,484) or absorbed to collagen sponge or other solid support (e.g., U.S. Pat. No. 4, 164,559).

[0323] If desired, formulations of the disclosure can be incorporated into a gel formulation (e.g., U.S. Pat. Nos. 4,474,752 and 6,91 1,21 1). [0324] In some embodiments, compounds of Formulas I, la, lb, Ic, Id, and Ie disclosed herein intended for delivery to the ear can be administered via an implanted pump and deliver system through a needle directly into the middle or inner ear (cochlea) or through a cochlear implant stylet electrode channel or alternative prepared drug delivery channel such as but not limited to a needle through temporal bone into the cochlea.

[0325] Other options include delivery via a pump through a thin film coated onto a multichannel electrode or electrode with a specially imbedded drug delivery channel (pathways) carved into the thin film for this purpose. In other embodiments the acidic or basic solid compound of Formulas I, la, lb, Ic, Id, and Ie can be delivered from the reservoir of an external or internal implanted pumping system.

[0326] Formulations of the disclosure also can be administered to the ear by intratympanic injection into the middle ear, inner ear, or cochlea (e.g., U.S. Pat. No. 6,377,849 and Ser. No. 11/337,815).

[0327] Intratympanic injection of therapeutic agents is the technique of injecting a therapeutic agent behind the tympanic membrane into the middle and/or inner ear. In one embodiment, the formulations described herein are administered directly onto the round window membrane via transtympanic injection, h another embodiment, the ion channel modulating agent auris-acceptable formulations described herein are administered onto the round window membrane via a non-transtympanic approach to the inner ear. In additional embodiments, the formulation described herein is administered onto the round window membrane via a surgical approach to the round window membrane comprising modification of the crista fenestrae cochleae.

[0328] In some embodiments, the compounds of Formulas I, la, lb, Ic, Id, and Ie are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG (like PEG ointments), and the like.

[0329] Suppositories for rectal administration of the drug (either as a solution, colloid, suspension or a complex) can be prepared by mixing a compound provided herein with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt or erode/dissolve in the rectum and release the compound. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol. In suppository forms of the compositions, a low -melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter, is first melted. [0330] Solid compositions can be provided in various different types of dosage forms, depending on the physicochemical properties of the compound provided herein, the desired dissolution rate, cost considerations, and other criteria. In one of the embodiments, the solid composition is a single unit. This implies that one unit dose of the compound is comprised in a single, physically shaped solid form or article. In other words, the solid composition is coherent, which is in contrast to a multiple unit dosage form, in which the units are incoherent.

[0331] Examples of single units which may be used as dosage forms for the solid composition include tablets, such as compressed tablets, film-like units, foil-like units, wafers, lyophilized matrix units, and the like. In one embodiment, the solid composition is a highly porous lyophilized form. Such lyophilizates, sometimes also called wafers or lyophilized tablets, are particularly useful for their rapid disintegration, which also enables the rapid dissolution of the compound.

[0332] On the other hand, for some applications the solid composition may also be formed as a multiple unit dosage form as defined above. Examples of multiple units are powders, granules, microparticles, pellets, mini-tablets, beads, lyophilized powders, and the like. In one embodiment, the solid composition is a lyophilized powder. Such a dispersed lyophilized system comprises a multitude of powder particles, and due to the lyophilization process used in the formation of the powder, each particle has an irregular, porous microstructure through which the powder is capable of absorbing water very rapidly, resulting in quick dissolution. Effervescent compositions are also contemplated to aid the quick dispersion and absorption of the compound.

[0333] Another type of multiparticulate system which is also capable of achieving rapid drug dissolution is that of powders, granules, or pellets from water-soluble excipients which are coated with a compound provided herein so that the compound is located at the outer surface of the individual particles. In this type of system, the water-soluble low molecular weight excipient may be useful for preparing the cores of such coated particles, which can be subsequently coated with a coating composition comprising the compound and, for example, one or more additional excipients, such as a binder, a pore former, a saccharide, a sugar alcohol, a film -forming polymer, a plasticizer, or other excipients used in pharmaceutical coating compositions.

[0334] Also provided herein are kits . Typically, a kit includes one or more compounds or compositions as described herein. In certain embodiments, a kit can include one or more delivery systems, e.g., for delivering or administering a compound as provided herein, and directions for use of the kit (e.g., instructions for treating a patient). In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with cancer. In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with one or more of hepatocellular carcinoma, colon cancer, leukemia, lymphoma, sarcoma, ovarian cancer, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, bone and cartilage diseases, Alzheimer's disease, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, bone density and vascular defects in the eye (Osteoporosis - pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Mullerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease, and Rett syndrome.

Methods of Treatment

[0335] The compounds and compositions provided herein can be used as inhibitors and/or modulators of one or more components of the Wnt pathway, which may include one or more Wnt proteins, and thus can be used to treat a variety of disorders and diseases in which aberrant Wnt signaling is implicated, such as cancer and other diseases associated with abnormal angiogenesis, cellular proliferation, and cell cycling. Accordingly, the compounds and compositions provided herein can be used to treat cancer, to reduce or inhibit angiogenesis, to reduce or inhibit cellular proliferation, to correct a genetic disorder, and/or to treat a neurological condition/disorder/disease due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Non -limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, scleroderma, mycotic and viral infections, bone and cartilage diseases, neurological conditions/diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), motor neuron disease, multiple sclerosis or autism, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Mullerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al- Awadi/Raas- othschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha- thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader- Willi syndrome, Beckwith-Wiedemann Syndrome, Nome disease and Rett syndrome.

[0336] With respect to cancer, the Wnt pathway is known to be constitutively activated in a variety of cancers including, for example, colon cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, prostate cancer , pancreatic cancer and leukemias such as CML, CLL and T-ALL. Accordingly, the compounds and compositions described herein may be used to treat these cancers in which the Wnt pathway is constitutively activated. In certain embodiments, the cancer is chosen from hepatocellular carcinoma, colon cancer, leukemia, lymphoma, sarcoma and ovarian cancer.

[0337] Other cancers can also be treated with the compounds and compositions described herein.

[0338] More particularly, cancers that may be treated by the compounds, compositions and methods described herein include, but are not limited to, the following:

[0339] 1) Breast cancers, including, for example ER + breast cancer, ER " breast cancer, her2 breast cancer, her2 + breast cancer, stromal tumors such as fibroadenomas, phyllodes tumors, and sarcomas, and epithelial tumors such as large duct papillomas; carcinomas of the breast including in situ (noninvasive) carcinoma that includes ductal carcinoma in situ (including Paget's disease) and lobular carcinoma in situ, and invasive (infiltrating) carcinoma including, but not limited to, invasive ductal carcinoma, invasive lobular carcinoma, medullary carcinoma, colloid (mucinous) carcinoma, tubular carcinoma, and invasive papillary carcinoma; and miscellaneous malignant neoplasms. Further examples of breast cancers can include luminal A, luminal B, basal A, basal B, and triple negative breast cancer, which is estrogen receptor negative (ER ), progesterone receptor negative, and her2 negative (her2 ~ ). In some embodiments, the breast cancer may have a high risk Oncotype score.

[0340] 2) Cardiac cancers, including, for example sarcoma, e.g., angiosarcoma, fibrosarcoma, rhabdomyosarcoma, and liposarcoma; myxoma; rhabdomyoma; fibroma; lipoma and teratoma.

[0341] 3) Lung cancers, including, for example, bronchogenic carcinoma, e.g., squamous cell, undifferentiated small cell, undifferentiated large cell, and adenocarcinoma; alveolar and bronchiolar carcinoma; bronchial adenoma; sarcoma; lymphoma; chondromatous hamartoma; and mesothelioma. [0342] 4) Gastrointestinal cancer, including, for example, cancers of the esophagus, e.g., squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma; cancers of the stomach, e.g., carcinoma, lymphoma, and leiomyosarcoma; cancers of the pancreas, e.g., ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, and vipoma; cancers of the small bowel, e.g., adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma; cancers of the large bowel, e.g., adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, and leiomyoma.

[0343] 5) Genitourinary tract cancers, including, for example, cancers of the kidney, e.g., adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, and leukemia; cancers of the bladder and urethra, e.g., squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma; cancers of the prostate, e.g., adenocarcinoma, and sarcoma; cancer of the testis, e.g., seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, and lipoma.

[0344] 6) Liver cancers, including, for example, hepatoma, e.g., hepatocellular carcinoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma; hepatocellular adenoma; and hemangioma.

[0345] 7) Bone cancers, including, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochrondroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors.

[0346] 8) Nervous system cancers, including, for example, cancers of the skull, e.g., osteoma, hemangioma, granuloma, xanthoma, and osteitis deformans; cancers of the meninges, e.g., meningioma, meningiosarcoma, and gliomatosis; cancers of the brain, e.g., astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, oligodendrocytoma, schwannoma, retinoblastoma, and congenital tumors; and cancers of the spinal cord, e.g., neurofibroma, meningioma, glioma, and sarcoma.

[0347] 9) Gynecological cancers, including, for example, cancers of the uterus, e.g., endometrial carcinoma; cancers of the cervix, e.g., cervical carcinoma, and pre tumor cervical dysplasia; cancers of the ovaries, e.g., ovarian carcinoma, including serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma, granulosa theca cell tumors, Sertoli Leydig cell tumors, dysgerminoma, and malignant teratoma; cancers of the vulva, e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, and melanoma; cancers of the vagina, e.g., clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma, and embryonal rhabdomyosarcoma; and cancers of the fallopian tubes, e.g., carcinoma.

[0348] 10) Hematologic cancers, including, for example, cancers of the blood, e.g., acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, and myelodysplastic syndrome, Hodgkin's lymphoma, non-Hodgkin's lymphoma (malignant lymphoma) and Waldenstrom's macroglobulinemia.

[0349] 11) Skin cancers and skin disorders, including, for example, malignant melanoma and metastatic melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, and scleroderma.

[0350] 12) Adrenal gland cancers, including, for example, neuroblastoma.

[0351] More particularly, tumors of the central nervous system that may be treated by the compounds, compositions and methods described herein include:

[0352] 1) Astrocytic tumors, e.g., diffuse astrocytoma (fibrillary, protoplasmic, gemistocytic, mixed), anaplastic (malignant) astrocytoma, glioblastoma multiforme (giant cell glioblastoma and gliosarcoma), pilocytic astrocytoma (pilomyxoid astrocytoma), pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma, and gliomatosis cerebri.

[0353] 2) Oligodendroglial tumors, e.g., oligodendroglioma and anaplastic oligodendroglioma.

[0354] 3) Oligoastrocytic tumors, e.g., oligoastrocytoma and anaplastic oligoastrocj oma.

[0355] 4) Ependymal tumors, e.g., subependymoma, myxopapillary ependymoma, ependymoma, (cellular, papillary, clear cell, tanycytic), and anaplastic (malignant) ependymoma.

[0356] 5) Choroid plexus tumors, e.g., choroid plexus papilloma, atypical choroid plexus papilloma, and choroid plexus carcinoma.

[0357] 6) Neuronal and mixed neuronal-glial tumors, e.g., gangliocytoma, ganglioglioma, dysembryoplastic neuroepithelial tumor (DNET), dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos), desmoplastic infantile astrocytoma/ganglioglioma, central neurocytoma, anaplastic ganglioglioma, extraventricular neurocytoma, cerebellar liponeurocytoma, Papillary glioneuronal tumor, Rosette-forming glioneuronal tumor of the fourth ventricle, and paraganglioma of the filum terminale.

[0358] 7) Pineal tumors, e.g., pineocytoma, pineoblastoma, papillary tumors ofthe pineal region, and pineal parenchymal tumor of intermediate differentiation. [0359] 8) Embryonal tumors, e.g., medulloblastoma (medulloblastoma with extensive nodularity, anaplastic medulloblastoma, desmoplastic, large cell, melanotic, medullomyoblastoma), medulloepithelioma, supratentorial primitive neuroectodermal tumors, and primitive neuroectodermal tumors (PNETs) such as neuroblastoma, ganglioneuroblastoma, ependymoblastoma, and atypical teratoid/rhabdoid tumor.

[0360] 9) Neuroblastic tumors, e.g., olfactory (esthesioneuroblastoma), olfactory neuroepithelioma, and neuroblastomas of the adrenal gland and sympathetic nervous system.

[0361] 10) Glial tumors, e.g., astroblastoma, chordoid glioma of the third ventricle, and angiocentric glioma.

[0362] 11) Tumors of cranial and paraspinal nerves, e.g., schwannoma, neurofibroma Perineurioma, and malignant peripheral nerve sheath tumor.

[0363] 12) Tumors of the meninges such as tumors of meningothelial cells, e.g., meningioma (atypical meningioma and anaplastic meningioma); mesenchymal tumors, e.g., lipoma, angiolipoma, hibernoma, liposarcoma, solitary fibrous tumor, fibrosarcoma, malignant fibrous histiocytoma, leiomyoma, leiomyosarcoma, rhabdomyoma, rhabdomyosarcoma, chondroma, chondrosarcoma, osteoma, osteosarcoma, osteochondroma, haemangioma, epithelioid hemangioendothelioma, haemangiopericytoma, anaplastic haemangiopericytoma, angiosarcoma, Kaposi Sarcoma, and Ewing Sarcoma; primary melanocytic lesions, e.g., diffuse melanocytosis, melanocytoma, malignant melanoma, meningeal melanomatosis; and hemangioblastomas.

[0364] 13) Tumors of the hematopoietic system, e.g., malignant Lymphomas, plasmocytoma, and granulocj ic sarcoma.

[0365] 14) Germ cell tumors, e.g., germinoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, and mixed germ cell tumors.

[0366] 15) Tumors of the sellar region, e.g., craniopharyngioma, granular cell tumor, pituicytoma, and spindle cell oncocytoma of the adenohypophysis.

[0367] Cancers may be solid tumors that may or may not be metastatic. Cancers may also occur, as in leukemia, as a diffuse tissue. Thus, the term "tumor cell," as provided herein, includes a cell afflicted by any one of the above identified disorders.

[0368] A method of treating cancer using a compound or composition as described herein may be combined with existing methods of treating cancers, for example by chemotherapy, irradiation, or surgery (e.g., oophorectomy). In some embodiments, a compound or composition can be administered before, during, or after another anticancer agent or treatment.

[0369] The compounds and compositions described herein can be used as anti- angiogenesis agents and as agents for modulating and/or inhibiting the activity of protein kinases. thus providing treatments for cancer and other diseases associated with cellular proliferation mediated by protein kinases. For example, the compounds described herein can inhibit the activity of one or more kinases. Accordingly, provided herein is a method of treating cancer or preventing or reducing angiogenesis through kinase inhibition.

[0370] In addition, and including treatment of cancer, the compounds and compositions described herein can function as cell-cycle control agents for treating proliferative disorders in a patient. Disorders associated with excessive proliferation include, for example, cancers, scleroderma, immunological disorders involving undesired proliferation of leukocytes, and restenosis and other smooth muscle disorders. Furthermore, such compounds may be used to prevent de -differentiation of post-mitotic tissue and/or cells.

[0371] Diseases or disorders associated with uncontrolled or abnormal cellular proliferation include, but are not limited to, the following:

• a variety of cancers, including, but not limited to, carcinoma, hematopoietic tumors of lymphoid lineage, hematopoietic tumors of myeloid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system and other tumors including melanoma, seminoma and Kaposi's sarcoma.

• a disease process which features abnormal cellular proliferation, e.g., benign prostatic hyperplasia, familial adenomatosis polyposis, neurofibromatosis, atherosclerosis, arthritis, glomerulonephritis, restenosis following angioplasty or vascular surgery, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections. Fibrotic disorders such as skin fibrosis; scleroderma; progressive systemic fibrosis; lung fibrosis; muscle fibrosis; kidney fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic scar formation; uterine fibrosis; renal fibrosis; cirrhosis of the liver, liver fibrosis; fatty liver disease (FLD); adhesions, such as those occurring in the abdomen, pelvis, spine or tendons; chronic obstructive pulmonary disease; fibrosis following myocardial infarction; pulmonary fibrosis; fibrosis and scarring associated with diffuse/interstitial lung disease; central nervous system fibrosis, such as fibrosis following stroke; fibrosis associated with neuro-degenerative disorders such as Alzheimer's Disease or multiple sclerosis; fibrosis associated with proliferative vitreoretinopathy (PVR); restenosis; endometriosis; ischemic disease and radiation fibrosis.

• defective apoptosis-associated conditions, such as cancers (including but not limited to those types mentioned herein), viral infections (including but not limited to herpesvirus, poxvirus, Epstein-Barr vims, Sindbis vims and adenovirus), prevention of AIDS development in HIV-infected individuals, autoimmune diseases (including but not limited to systemic lupus erythematosus, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, autoimmune mediated glomerulonephritis, inflammatory bowel disease and autoimmune diabetes mellitus), neuro-degenerative disorders (including but not limited to Alzheimer's disease, lung disease, amyotrophic lateral sclerosis, retinitis pigmentosa, Parkinson's disease, AIDS-related dementia, spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial infarctions, stroke and reperfusion injury, arrhythmia, atherosclerosis, toxin-induced or alcohol related liver diseases, hematological diseases (including but not limited to chronic anemia and aplastic anemia), degenerative diseases of the musculoskeletal system (including but not limited to osteoporosis and arthritis), tendinopathies such as tendinitis and tendinosis, aspirin- sensitive rhinosinusitis, cystic fibrosis, multiple sclerosis, kidney diseases and cancer pain.

• genetic diseases due to mutations in Wnt signaling components, such as polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Mullerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas- Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome, Norrie disease and Rett syndrome.

[0372] The compounds and compositions provided herein have been found to possess immunomodulatory activities and are expected to control the innate and adaptive immune system (e.g. macrophages, microglia, dendritic cells, B and T cells) and suppress pro-inflammatory cytokine release (e.g. TNF, IL-6, IL-1, IFN ) which is well known to be involved in chronic inflammation in a wide variety of disease areas. Therefore compounds and compositions provided herein can used to treat chronic inflammation associated with disorders and diseases including but not limited to eye disorders, joint pain, arthritis (rheumatoid, osteo, psoriatic gout), cancers (colon, breast, lung, pancreas, and others), gastrointestinal disorders (ulcerative colitis and inflammatory bowel diseases), pulmonary disorders (chronic obstructive pulmonary disorder and asthma), allergies, skin disorders (atopic dermatitis and psoriasis), diabetes, pancreatitis, tendonitis, hepatitis, heart disease, myocarditis, stroke, lupus, and neurological disorders such as multiple sclerosis, Parkinson's and dementia including Alzheimer's disease.

[0373] The compounds and compositions provided herein can be used as inhibitors and/or modulators of the enzyme DYRK1A, and thus can be used to treat a variety of disorders and diseases associated with tau protein, amyloid, alpha-synuclein, TDP-43 or FUS pathology including, but not limited to, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), down syndrome, frontotemporal dementia (FTD) including FTD with Parkinsonism-17 (FTDP-17), behavioural variant frontotemporal dementia (bvFTD), FTD in patients with motor neuron disease (MND) (typically amyotrophic lateral sclerosis, also called FTD-ALS), corticobasal degeneration (CBD) (also called corticobasal ganglionic degeneration), progressive supranuclear palsy, primary progressive aphasia (PPA), globular glial tauopathy (GGT), myotonic dystrophy type 1 (DM1) (also called Steinert disease), myotonic dystrophy type 2 (DM2) (also called proximal myotonic myopathy), Guam complex, argyrophilic grain disease, dementia pugilistica, post-encephalitic parkinsonism, Lewy body dementia, Parkinson's disease, Pick's disease, and additional diseases with pronounced neurodegeneration such as autism, dementia, epilepsy, Huntington's disease, multiple sclerosis; diseases and disorders associated with acquired brain injury such as chronic traumatic encephalopathy, traumatic brain injury, tumor, and stroke.

[0374] Non-limiting examples of neurological disorders (e.g., neurological conditions and neurological diseases) which can be treated with the compounds and compositions provided herein include Alzheimer's disease, aphasia, apraxia, arachnoiditis, ataxia telangiectasia, attention deficit hyperactivity disorder, auditory processing disorder, autism, alcoholism, Bell's palsy, bipolar disorder, brachial plexus injury, Canavan disease, carpal tunnel syndrome, causalgia, central pain syndrome, central pontine myelinolysis, centronuclear myopathy, cephalic disorder, cerebral aneurysm, cerebral arteriosclerosis, cerebral atrophy, cerebral gigantism, cerebral palsy, cerebral vasculitis, cervical spinal stenosis, Charcot-Marie-Tooth disease, Chiari malformation, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic pain, Coffm-Lowry syndrome, complex regional pain syndrome, compression neuropathy, congenital facial diplegia, corticobasal degeneration, cranial arteritis, craniosynostosis, Creutzfeldt-Jakob disease, cumulative trauma disorder, Cushing's syndrome, cytomegalic inclusion body disease (CIBD), Dandy-Walker syndrome, Dawson disease, De Morsier's syndrome, Dejerine-Klumpke palsy, Dejerine-Sottas disease, delayed sleep phase syndrome, dementia, dermatomyositis, developmental dyspraxia, diabetic neuropathy, diffuse sclerosis, Dravet syndrome, dysautonomia, dyscalculia, dysgraphia, dyslexia, dystonia, empty sella syndrome, encephalitis, encephalocele, encephalotrigeminal angiomatosis, encopresis, epilepsy, Erb's palsy, erythromelalgia, essential tremor, Fabry's disease, Fahr's syndrome, familial spastic paralysis, febrile seizure, Fisher syndrome, Friedreich's ataxia, fibromyalgia, Foville's syndrome, Gaucher's disease, Gerstmann's syndrome, giant cell arteritis, giant cell inclusion disease, globoid cell leukodystrophy, gray matter heterotopia, Guillain-Barre syndrome, HTLV-1 associated myelopathy, Hallervorden-Spatz disease, hemifacial spasm, hereditary spastic paraplegia, heredopathia atactica polyneuritiformis, herpes zoster oticus, herpes zoster, Hirayama syndrome, holoprosencephaly, Huntington's disease, hydranencephaly, hydrocephalus, hypercortisolism, hypoxia, immune-mediated encephalomyelitis, inclusion body myositis, incontinentia pigmenti, infantile phytanic acid storage disease, infantile efsum disease, infantile spasms, inflammatory myopathy, intracranial cyst, intracranial hypertension, Joubert syndrome, Karak syndrome, Kearns- Sayre syndrome, Kennedy disease, Kinsbourne syndrome, Klippel Feil syndrome, Krabbe disease, Kugelberg-Welander disease, kuru, Lafora disease, Lambert-Eaton myasthenic syndrome, Landau- Kleffner syndrome, lateral medullary (Wallenberg) syndrome, Leigh's disease, Lennox-Gastaut syndrome, Lesch-Nyhan syndrome, leukodystrophy, Lewy body dementia, lissencephaly, locked- in syndrome, Lou Gehrig's disease, lumbar disc disease, lumbar spinal stenosis, Lyme disease, Machado-Joseph disease (Spinocerebellar ataxia type 3), macrencephaly, macropsia, megalencephaly, Melkersson-Rosenthal syndrome, Meniere's disease, meningitis, Menkes disease, metachromatic leukodystrophy, microcephaly, micropsia, Miller Fisher syndrome, misophonia, mitochondrial myopathy, Mobius syndrome, monomelic amyotrophy, motor neuron disease, motor skills disorder, Moyamoya disease, mucopolysaccharidoses, multi -infarct dementia, multifocal motor neuropathy, multiple sclerosis, multiple system atrophy, muscular dystrophy, myalgic encephalomyelitis, myasthenia gravis, myelinoclastic diffuse sclerosis, myoclonic Encephalopathy of infants, myoclonus, myopathy, myotubular myopathy, myotonia congenital, narcolepsy, neurofibromatosis, neuroleptic malignant syndrome, lupus erythematosus, neuromyotonia, neuronal ceroid lipofuscinosis, Niemann-Pick disease, O'Sullivan-McLeod syndrome, occipital Neuralgia, occult Spinal Dysraphism Sequence, Ohtahara syndrome, olivopontocerebellar atrophy, opsoclonus myoclonus syndrome, optic neuritis, orthostatic hypotension, palinopsia, paresthesia, Parkinson's disease, paramyotonia Congenita, paraneoplastic diseases, paroxysmal attacks, Parry- Romberg syndrome, Pelizaeus-Merzbacher disease, periodic paralyses, peripheral neuropathy, photic sneeze reflex, phytanic acid storage disease, Pick's disease, polymicrogyria (PMG), polymyositis, porencephaly, post-polio syndrome, postherpetic neuralgia (PHN), postural hypotension, Prader-Willi syndrome, primary lateral sclerosis, prion diseases, progressive hemifacial atrophy, progressive multifocal leukoencephalopathy, progressive supranuclear palsy, pseudotumor cerebri, Ramsay Hunt syndrome type I, Ramsay Hunt syndrome type II, Ramsay Hunt syndrome type III, Rasmussen's encephalitis, reflex neurovascular dystrophy, Refsum disease, restless legs syndrome, retrovirus-associated myelopathy, Rett syndrome, Reye's syndrome, rhythmic movement disorder, Romberg syndrome, Saint Vitus dance, Sandhoff disease, schizophrenia, Schilder's disease, schizencephaly, sensory integration dysfunction, septo-optic dysplasia, Shy-Drager syndrome, Sjogren's syndrome, snatiation, Sotos syndrome, spasticity, spina bifida, spinal cord tumors, spinal muscular atrophy, spinocerebellar ataxia, Steele -Richardson- Olszewski syndrome, Stiff-person syndrome, stroke, Sturge-Weber syndrome, subacute sclerosing panencephalitis, subcortical arteriosclerotic encephalopathy, superficial siderosis, Sydenham's chorea, syncope, synesthesia, syringomyelia, tarsal tunnel syndrome, tardive dyskinesia, tardive dysphrenia, Tarlov cyst, Tay-Sachs disease, temporal arteritis, tetanus, tethered spinal cord syndrome, Thomsen disease, thoracic outlet syndrome, tic douloureux, Todd's paralysis, Tourette syndrome, toxic encephalopathy, transient ischemic attack, transmissible spongiform encephalopathies, transverse myelitis, tremor, trigeminal neuralgia, tropical spastic paraparesis, trypanosomiasis, tuberous sclerosis, ubisiosis, Von Hippel-Lindau disease (VHL), Viliuisk Encephalomyelitis (VE), Wallenberg's syndrome, Werdnig, Hoffman disease, west syndrome, Williams syndrome, Wilson's disease, and Zellweger syndrome.

[0375] The compounds and compositions may also be useful in the inhibition of the development of invasive cancer, tumor angiogenesis and metastasis.

[0376] In some embodiments, the disclosure provides a method for treating a disease or disorder associated with aberrant cellular proliferation by administering to a patient in need of such treatment an effective amount of one or more of the compounds of Formulas I, la, lb, Ic, Id, and le, in combination (simultaneously or sequentially) with at least one other agent.

[0377] In some embodiments, the disclosure provides a method of treating or ameliorating in a patient a disorder or disease selected from the group consisting of: cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, bone or cartilage disease, and osteoarthritis, the method comprising administering to the patient a therapeutically effective amount of a compound according to Formulas T, Ta, Tb, Tc, Td, or Te, or a pharmaceutically acceptable salt thereof.

[0378] In some embodiments, the disclosure provides a method of treating or ameliorating in a patient a disorder or disease selected from the group consisting of: chronic inflammation, systemic inflammation, diabetes, cancer, pulmonar fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, a bone or cartilage disease, a neurological condition/disorder/disease, osteoarthritis, lung disease, a fibrotic disorder.

[0379] In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of Formulas I, la, lb, Ic, Id, or le, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0380] In some embodiments, the method of treats a disorder or disease in which aberrant Wnt signaling is implicated in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound of Formulas I, la, lb, Ic, Id, or le, or a pharmaceutically acceptable salt thereof.

[0381] In some embodiments, the disorder or disease is the pain and inflammation associated with cancer.

[0382] In some embodiments, the disorder or disease is the pain and inflammation associated with a joint.

[0383] In some embodiments, the disorder or disease is the pain and inflammation associated with the knee.

[0384] In some embodiments, the disorder or disease is the pain and inflammation associated with the hip.

[0385] In some embodiments, the disorder or disease is the pain and inflammation associated with the shoulder.

[0386] In some embodiments, the disorder or disease is the pain and inflammation associated with arthritis.

[0387] In some embodiments, the disorder or disease is the pain and inflammation associated with gastrointestinal disorders.

[0388] In some embodiments, the disorder or disease is the pain and inflammation associated with pulmonary disorders.

[0389] In some embodiments, the disorder or disease is the pain and inflammation associated with allergies.

[0390] In some embodiments, the disorder or disease is the pain and inflammation associated with skin disorders.

[0391] In some embodiments, the disorder or disease is the pain and inflammation associated with diabetes.

[0392] In some embodiments, the disorder or disease is the pain and inflammation associated with pancreatitis. [0393] In some embodiments, the disorder or disease is the pain and inflammation associated with tendonitis.

[0394] In some embodiments, the disorder or disease is the pain and inflammation associated with heart disease.

[0395] In some embodiments, the disorder or disease is the pain and inflammation associated with lupus.

[0396] In some embodiments, the disorder or disease is the pain and inflammation associated with a neurological disorder.

[0397] In some embodiments, the disorder or disease is the pain and inflammation associated with multiple sclerosis.

[0398] In some embodiments, the disorder or disease is the pain and inflammation associated with Parkinson's.

[0399] In some embodiments, the disorder or disease is cancer.

[0400] In some embodiments, the disorder or disease is systemic inflammation.

[0401] In some embodiments, the disorder or disease is metastatic melanoma.

[0402] In some embodiments, the disorder or disease is fatty liver disease.

[0403] In some embodiments, the disorder or disease is liver fibrosis.

[0404] In some embodiments, the disorder or disease is tendon regeneration.

[0405] In some embodiments, the disorder or disease is diabetes.

[0406] In some embodiments, the disorder or disease is degenerative disc disease.

[0407] In some embodiments, the disorder or disease is osteoarthritis.

[0408] In some embodiments, the disorder or disease is diabetic retinopathy.

[0409] In some embodiments, the disorder or disease is pulmonary fibrosis.

[0410] In some embodiments, the disorder or disease is idiopathic pulmonary fibrosis

(IPF).

[0411] In some embodiments, the disorder or disease is degenerative disc disease.

[0412] In some embodiments, the disorder or disease is rheumatoid arthritis.

[0413] In some embodiments, the disorder or disease is scleroderma.

[0414] In some embodiments, the disorder or disease is a mycotic or viral infection.

[0415] In some embodiments, the disorder or disease is a bone or cartilage disease.

[0416] In some embodiments, the disorder or disease is a neurological disorder.

[0417] In some embodiments, the disorder or disease is Alzheimer's disease.

[0418] In some embodiments, the disorder or disease is osteoarthritis.

[0419] In some embodiments, the disorder or disease is lung disease. [0420] In some embodiments, the disorder or disease is a genetic disease caused by mutations in Wnt signaling components, wherein the genetic disease is selected from: polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Miillerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas- Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split- hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha- thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader- Willi syndrome, Beckwith-Wiedemann Syndrome, Nome disease and Rett syndrome.

[0421] In some embodiments, the patient is a human.

[0422] In some embodiments, the cancer is chosen from: hepatocellular carcinoma, colon cancer, breast cancer, pancreatic cancer, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, chronic lymphocytic leukemia (CLL), acute myeloid leukemia, acute lymphocytic leukemia, Hodgkin lymphoma, lymphoma, sarcoma and ovarian cancer.

[0423] In some embodiments, the cancer is chosen from: lung cancer - non-small cell, lung cancer - small cell, multiple myeloma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer - basal and squamous cell, skin cancer - melanoma, small intestine cancer, stomach (gastric) cancers, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, laryngeal or hypopharyngeal cancer, kidney cancer, Kaposi sarcoma, gestational trophoblastic disease, gastrointestinal stromal tumor, gastrointestinal carcinoid tumor, gallbladder cancer, eye cancer (melanoma and lymphoma), Ewing tumor, esophagus cancer, endometrial cancer, colorectal cancer, cervical cancer, brain or spinal cord tumor, bone metastasis, bone cancer, bladder cancer, bile duct cancer, anal cancer and adrenal cortical cancer.

[0424] In some embodiments, the cancer is hepatocellular carcinoma.

[0425] In some embodiments, the cancer is colon cancer.

[0426] In some embodiments, the cancer is colorectal cancer.

[0427] In some embodiments, the cancer is breast cancer.

[0428] In some embodiments, the cancer is pancreatic cancer.

[0429] In some embodiments, the cancer is chronic myeloid leukemia (CML).

[0430] In some embodiments, the cancer is chronic myelomonocytic leukemia.

[0431] In some embodiments, the cancer is chronic lymphocytic leukemia (CLL).

[0432] In some embodiments, the cancer is acute myeloid leukemia. [0433] In some embodiments, the cancer is acute lymphocytic leukemia.

[0434] In some embodiments, the cancer is Hodgkin lymphoma.

[0435] In some embodiments, the cancer is lymphoma.

[0436] In some embodiments, the cancer is sarcoma.

[0437] In some embodiments, the cancer is ovarian cancer.

[0438] In some embodiments, the cancer is lung cancer - non-small cell.

[0439] In some embodiments, the cancer is lung cancer - small cell.

[0440] In some embodiments, the cancer is multiple myeloma.

[0441] In some embodiments, the cancer is nasopharyngeal cancer.

[0442] In some embodiments, the cancer is neuroblastoma.

[0443] In some embodiments, the cancer is osteosarcoma.

[0444] In some embodiments, the cancer is penile cancer.

[0445] In some embodiments, the cancer is pituitary tumors.

[0446] In some embodiments, the cancer is prostate cancer.

[0447] In some embodiments, the cancer is retinoblastoma.

[0448] In some embodiments, the cancer is rhabdomyosarcoma.

[0449] In some embodiments, the cancer is salivary gland cancer.

[0450] In some embodiments, the cancer is skin cancer - basal and squamous cell

[0451] In some embodiments, the cancer is skin cancer - melanoma.

[0452] In some embodiments, the cancer is small intestine cancer.

[0453] In some embodiments, the cancer is stomach (gastric) cancers.

[0454] In some embodiments, the cancer is testicular cancer.

[0455] In some embodiments, the cancer is thymus cancer.

[0456] In some embodiments, the cancer is thyroid cancer.

[0457] In some embodiments, the cancer is uterine sarcoma.

[0458] In some embodiments, the cancer is vaginal cancer.

[0459] In some embodiments, the cancer is vulvar cancer.

[0460] In some embodiments, the cancer is Wilms tumor.

[0461] In some embodiments, the cancer is laryngeal or hypopharyngeal cancer.

[0462] In some embodiments, the cancer is kidney cancer.

[0463] In some embodiments, the cancer is Kaposi sarcoma.

[0464] In some embodiments, the cancer is gestational trophoblastic disease.

[0465] In some embodiments, the cancer is gastrointestinal stromal tumor.

[0466] In some embodiments, the cancer is gastrointestinal carcinoid tumor. [0467] In some embodiments, the cancer is gallbladder cancer.

[0468] In some embodiments, the cancer is eye cancer (melanoma and lymph

[0469] In some embodiments, the cancer is Ewing tumor.

[0470] In some embodiments, the cancer is esophagus cancer.

[0471] In some embodiments, the cancer is endometrial cancer.

[0472] In some embodiments, the cancer is colorectal cancer.

[0473] [n some embodiments, the cancer is cervical cancer.

[0474] In some embodiments, the cancer is brain or spinal cord tumor.

[0475] In some embodiments, the cancer is bone metastasis.

[0476] In some embodiments, the cancer is bone cancer.

[0477] In some embodiments, the cancer is bladder cancer.

[0478] In some embodiments, the cancer is bile duct cancer.

[0479] In some embodiments, the cancer is anal cancer.

[0480] In some embodiments, the cancer is adrenal cortical cancer.

[0481] In some embodiments, the disorder or disease is a neurological condition/disorder/disease, wherein the neurological condition/disorder/disease is selected from: Alzheimer's disease, frontotemporal dementias, dementia with Lewy bodies, prion diseases, Parkinson's disease, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, amyotrophic lateral sclerosis (ALS), inclusion body myositis, autism, degenerative myopathies, diabetic neuropathy, other metabolic neuropathies, endocrine neuropathies, orthostatic hypotension, multiple sclerosis and Charcot-Marie-Tooth disease.

[0482] In some embodiments, the disorder or disease is a neurological condition/disorder/disease associated with tau protein, amyloid, alpha-synuclem pathology. Tar DNA-binding Protein of 43KDa (TDP-43), Prion protein PrP or fused in sarcoma (FUS).

[0483] In some embodiments, the disorder or disease is a neurological condition/disorder/disease, wherein the neurological condition/disorder/disease is selected from the group consisting of: Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Down Syndrome, Frontotemporal Dementia with Parkinsonism- 17 (FTDP-17), Lewy body dementia, Parkinson's Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy. Huntington's Disease, Multiple Sclerosis; diseases and disorders associated with acquired brain injury such as Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor, and Stroke. [0484] In some embodiments, the disorder or disease is a fibrotic disorder, wherein the fibrotic disorder is selected from the group consisting of: skin fibrosis; scleroderma; progressive systemic fibrosis; lung fibrosis; muscle fibrosis; kidney fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic scar formation; uterine fibrosis; renal fibrosis; cirrhosis of the liver, liver fibrosis; adhesions; chronic obstructive pulmonary disease; fibrosis following myocardial infarction; pulmonar fibrosis; fibrosis and scarring associated with diffuse/interstitial lung disease; central nervous system fibrosis; fibrosis associated with proliferative vitreoretinopathy (PVR); restenosis; endometriosis; ischemic disease, and radiation fibrosis.

[0485] In some embodiments, the disorder or disease is chronic inflammation associated with eye disorders, joint pain, arthritis (rheumatoid, osteo, psoriatic gout), cancers (colon, breast, lung, pancreas, and others), gastrointestinal disorders (ulcerative colitis and inflammatory bowel diseases), pulmonary disorders (chronic obstructive pulmonary disorder and asthma), allergies, skin disorders (atopic dermatitis and psoriasis), diabetes, pancreatitis, tendonitis, hepatitis, heart disease, myocarditis, stroke, lupus, and neurological disorders such as multiple sclerosis, Parkinson's and dementia including Alzheimer's disease.

[0486] In some embodiments, a compound of Formulas I, la, lb, Ic, Id. or Ie inhibits DYRK1A.

[0487] In some embodiments, a compound of Formulas I, la, lb, Ic, Id. or Ie inhibits

GSK3.

[0488] In some embodiments, a compound of Formulas I, la, lb, Ic, Id. or Ie inhibits

GSK3 .

[0489] In some embodiments, a compound of Fomiulas I, la, lb, Ic, Id. or Ie inhibits DYRK1A and GSK3 .

[0490] In some embodiments, the compound of Formulas I, la, lb, Ic, Id, or Ie inhibits one or more proteins in the Wnt pathway.

[0491] In some embodiments, the compound of Formulas I, la, lb, Ic, Id, or Ie inhibits signaling induced by one or more Wnt proteins.

[0492] In some embodiments, the Wnt proteins are chosen from: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, W T6, WNT7A, WNT7B, W T8A, WNT8B, WNT9A, WNT9B, WNT1 OA, WNT 10B, WNT1 1 , and WNT 16.

[0493] In some embodiments, the compound of Formulas I, la, lb, Ic, Id, or Ie inhibits a kinase activity.

[0494] In some embodiments, the method treats a disease or disorder mediated by the Wnt pathway in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formulas I, la, lb, Ic, Id, or Ie, or a pharmaceutically acceptable salt thereof.

[0495] In some embodiments, the compound of Formulas I, la, lb, Ic, Id, or Ie inhibits one or more Wnt proteins.

[0496] In some embodiments, the method treats a disease or disorder mediated by kinase activity in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formulas I, la, lb, Ic, Id, or Ie. or a pharmaceutically acceptable salt thereof.

[0497] In some embodiments, the disease or disorder comprises tumor growth, cell proliferation, or angiogenesis.

[0498] In some embodiments, the method inhibits the activity of a protein kinase receptor, the method comprises contacting the receptor with an effective amount of a compound (or compounds) of Formulas I, la, lb, Ic, Id, or Ie, or a pharmaceutically acceptable salt thereof.

[0499] In some embodiments, the method treats a disease or disorder associated with aberrant cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formulas I. Ia, lb, Ic, Id, or Ie, or a pharmaceutically acceptable salt thereof.

[0500] In some embodiments, the method prevents or reduces angiogenesis in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formulas I, Ia, lb, Ic, Id, or Ie, or a pharmaceutically acceptable salt thereof.

[0501] In some embodiments, the method prevents or reduces abnormal cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formulas I, la, lb, Ic, Id, or Ie, or a pharmaceutically acceptable salt thereof.

[0502] In some embodiments, the method treats a disease or disorder associated with aberrant cellular proliferation in a patient, the method comprises administering to the patient a pharmaceutical composition comprising one or more of the compounds of claim 1 in combination with a pharmaceutically acceptable carrier and one or more other agents.

[0503] Moreover, the compounds and compositions, for example, as inhibitors of the cyclin-dependent kinases (CDKs), can modulate the level of cellular RNA and DNA synthesis and therefore are expected to be useful in the treatment of viral infections such as HIV, human papilloma virus, herpes virus, Epstein -Barr virus, adenovirus, Sindbis virus, pox virus and the like. [0504] Compounds and compositions described herein can inhibit the kinase activity of, for example, CDK/cyclin complexes, such as those active in the Go or Gi stage of the cell cycle, e.g., CDK2, CDK4, and/or CDK6 complexes.

Evaluation of Biological Activity

[0505] The biological activity of the compounds described herein can be tested using any suitable assay known to those of skill in the art, see, e.g., WO 2001/053268 and WO 2005/009997. For example, the activity of a compound may be tested using one or more of the test methods outlined below.

[0506] In one example, tumor cells may be screened for Wnt independent growth. In such a method, tumor cells of interest are contacted with a compound (i.e. inhibitor) of interest, and the proliferation of the cells, e.g. by uptake of tritiated thymidine, is monitored. In some embodiments, tumor cells may be isolated from a candidate patient who has been screened for the presence of a cancer that is associated with a mutation in the W r nt signaling pathway. Candidate cancers include, without limitation, those listed above.

[0507] In another example, one may utilize in vitro assays for Wnt biological activity, e.g. stabilization of β-catenin and promoting growth of stem cells. Assays for biological activity of Wnt include stabilization of β-catenin, which can be measured, for example, by serial dilutions of a candidate inhibitor composition. An exemplary assay for Wnt biological activity contacts a candidate inhibitor with cells containing constitiitively active Wnt/ -catenin signaling. The cells are cultured for a period of time sufficient to stabilize β-catenin, usually at least about 1 hour, and lysed. The cell lysate is resolved by SDS PAGE, then transferred to nitrocellulose and probed with antibodies specific for β-catenin.

[0508] In a further example, the activity of a candidate compound can be measured in a Xenopus secondary axis bioassay (Leyns, L. et al. Cell (1997), 88(6), 747-756).

[0509] In another example, in vitro assays for DYRK1A biological activity may be used, e.g. regulation of microtubule-associated protein tau (MAPT/Tau) phosphorylation in neuronal cell line such as the human SH-SY5Y neuroblastoma cell line. Assays for DYRK1A- regulated level of phosphorylation can include monitoring levels of basal pSer396 Tau, which can be measured, for example, by serial dilutions of a candidate inhibitor composition using a ten micromolar top concentration and detected by ELISA or Western Blotting. An exemplary assay for DYRK- 1 A-regulated phosphorylation uses the SH-SY5Y cells cultured in a 96 well plate format for a period of time sufficient to stabilize microtubules and Tau phosphorylation, usually at least 2 days, then treated with a 1/3 serial dilution of compounds overnight and lysed. The cell lysate is resolved by SDS PAGE, then transferred to nitrocellulose and probed with an antibody specific for pSer396 Tau. The chemiluminescence signal for HRP -linked antibodies used in western blotting is detected using a Carestream Image Station and blot densitometry for pSer396 and beta-actin are analyzed using ImageJ (NIH).

[0510] In a further example, the activity of a candidate compound can be measured by ELISA by adding the lysate mentioned above onto total Tau-coated plates and detected with a specific pSer396 antibody. Colorimetric detection of ELISA signal is performed by Cytation3 plate reader (Biotek).

[0511] To further illustrate this disclosure, the following examples are included. The examples should not, of course, be constnied as specifically limiting the disclosure. Variations of these examples within the scope of the claims are within the purview of one skilled in the art and are considered to fall within the scope of the disclosure as described, and claimed herein. The reader will recognize that the skilled artisan, armed with the present disclosure, and skill in the art is able to prepare and use the disclosure without exhaustive examples.

EXAMPLES

Compound preparation

[0512] The starting materials used in preparing the compounds of the disclosure are known, made by known methods, or are commercially available. It will be apparent to the skilled artisan that methods for preparing precursors and functionality related to the compounds claimed herein are generally described in the literature. The skilled artisan given the literature and this disclosure is well equipped to prepare any of the compounds.

[0513] It is recognized that the skilled artisan in the art of organic chemistry can readily carry out manipulations without further direction, that is, it is well within the scope and practice of the skilled artisan to carry out these manipulations. These include reduction of carbonyl compounds to their corresponding alcohols, oxidations, acylations, aromatic substitutions, both electrophilic and nucleophilic, etherifications, esterification and saponification and the like. These manipulations are discussed in standard texts such as March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure 7 th Ed., John Wiley & Sons (2013), Carey and Sundberg, Advanced Organic Chemistry 5 th Ed.. Springer (2007), Comprehensive Organic Transformations: A Guide to Functional Group Transformations, 2 nd Ed., John Wiley & Sons (1999) (incorporated herein by reference in its entirety) and the like.

[0514] The skilled artisan will readily appreciate that certain reactions are best carried out when other functionality is masked or protected in the molecule, thus avoiding any undesirable side reactions and/or increasing the yield of the reaction. Often the skilled artisan utilizes protecting groups to accomplish such increased yields or to avoid the undesired reactions. These reactions are found in the literature and are also well within the scope of the skilled artisan. Examples of many of these manipulations can be found for example in P. Wuts Greene 's Protective Groups in Organic Synthesis, 5th Ed., John Wiley & Sons (2014), incorporated herein by reference in its entirety.

[0515] Trademarks used herein are examples only and reflect illustrative materials used at the time of the disclosure. The skilled artisan will recognize that variations in lot, manufacturing processes, and the like, are expected. Hence the examples, and the trademarks used in them are non-limiting, and they are not intended to be limiting, but are merely an illustration of how a skilled artisan may choose to perform one or more of the embodiments of the disclosure.

[0516] (¾) nuclear magnetic resonance spectra (NMR) were measured in the indicated solvents on a Bruker NMR spectrometer (Avance TM DRX300, 300 MHz for ¾ or Avance TM DRX500, 500 MHz for ¾) or Vanan NMR spectrometer (Mercury 400BB, 400 MHz for Ή). Peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane. The peak multiplicities are denoted as follows, s, singlet; d, doublet; t, triplet; q, quartet; ABq, AB quartet; quin, quintet; sex, sextet; sep, septet; non, nonet; dd, doublet of doublets; ddd, doublet of doublets of doublets; d/ABq, doublet of AB quartet; dt, doublet of triplets; td, triplet of doublets; dq, doublet of quartets; m, multiplet.

[0517] The following abbreviations have the indicated meanings:

AIBN = azobisisobutyronitrile

B0C2O = di-fert-butyl dicarbonate

BrettPhos = 2-(dicyclohexylphosphino)3,6-dimethoxy-2',4',6'-triisopropyl -l, l'-biphenyl

BrettPhos Pd G3 = [(2-Di-cyclohexylphosphino-3,6-dimethoxy-2',4',6'- triisopropyl-Ι,Γ- biphenyl)-2-(2 ' -amino -1, 1' -biphenyl)Jpalladium(ll) methanesulfonate

brine = saturated aqueous sodium chloride

CDCI3 = deuterated chloroform

DABCO = l,4-diazabicyclo[2.2.2]octane

DBU = 1.8-diazabicyclo[5.4.0]undec-7-ene

DCE = dichloroethane

DCM = dichloromethane

DEAD = diisopropyl azodicarboxylate

Dess-Martin periodinane = l, l,l-triacetoxy-l, l-dihydro-l,2-benziodoxol-3(lH)-one DIPEA = N,N-diisopropylethylamine

DMA = dimethylacetamide DMAP = 4-dimethylaminopyridine

DME = dimethoxyethane

DMF = N,N-dimethylformamide

DMSO- e = deuterated dimethylsulfoxide

ESIMS = electron spray mass spectrometry

EtOAc = ethyl acetate

HATU = l-[Bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4.5-b]pyri dinium hexafluorophosphate

HC1 = hydrochloric acid

HOAc = acetic acid

ISCO = Teledyne ISCO, Inc brand Comb-Flash ® Rf 200

KOAc = potassium acetate

LAH = lithium aluminum hydride

LC/MS = Liquid chromatography-mass spectrometry

LiHMDS = lithium bis(trimethylsilyl)amide

MCPBA = meta-chloroperoxybenzoic acid

MeCN = acetonitrile

MeOH = methanol

MPLC :::: medium-pressure liquid chromatography

MsCl = methane sulfonyl chloride (mesyl chloride)

MTBE = methyl tert-butyl ether

MW = microwave irradiation

NaBFFsCN = sodium cyanoborohydride

NBS = N-bromosuccmimide

NaHC03 = sodium bicarbonate

Na(OAc) 3 BH = sodium triacetoxyborohydride

NMR = nuclear magnetic resonance

ON = overnight

Pd/C = palladium on carbon

Pdi(dba)3 = tris(dibenzylideneacetone)dipalladium(0)

Pd(dppf)Cl2 = 1, 1 '-bis(diphenylphosphino)ferrocene-palladium(ZT)dichloride

Pd(PPh 3 ) 4 = tetrakis(triphenylphosphine)palladium(0)

Pd(OAc)2 = palladium(II) acetate

P(o-tolyl)3 = tns(o-tolyl)phosphine r.t. = room temperature

TBDMSC1 = fcrt-butyldimethylsilyl chloride

TEA = triethylamine

THF = tetrahydrofuran

TLC = thin layer chromatography

TMEDA = tetramethylethylenediamine

XantPhos = 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

[0518] The following example schemes are provided for the guidance of the reader, and collectively represent an example method for making the compounds provided herein. Furthermore, other methods for preparing compounds of the disclosure will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. The skilled artisan is thoroughly equipped to prepare these compounds by those methods given the literature and this disclosure. The compound numberings used in the synthetic schemes depicted below are meant for those specific schemes only and should not be constmed as or confused with same numberings in other sections of the application. Unless otherwise indicated, all variables are as defined above.

General procedures

[0519] Compounds of Formulas I and la of the present disclosure can be prepared as depicted in Scheme 1.

Scheme 1

[0520] Scheme 1 describes a method for preparation of l,6-naphthyridin-7-yl- carboxamide derivatives (XVI) by first coupling 2-bromo-5-iodopyridin-4-amine (II) with ethyl acrylate (III) to produce ethyl (E)-3-(4-amino-6-bromopyridin-3-yl)acrylate (IV). The acrylate IV is then cyclized with MeSNa to give 7-bromo-l,6-naphthyridin-2(lH)-one (V). Aromatization with POCI3 gave 7-bromo-2-chloro-l,6-naphthyridine (VI). Compound VI can either be reacted with (4-methoxyphenyl)methanamine (VII) followed by acid cleavage to give the amine (IX). Amine IX can be couple with a variety of acids followed by coupling to a variety of aromatic rings by any of three different routes to yield the desired l,6-naphthyridin-7-yl -carboxamide derivatives (XVI). Compound VI can also be couple with by either of two Suzuki Coupling routes (Routes 1 or 2) or by a Stille reaction route (Route 3) to produce bromide (XIV) which can then be reacted with a variety of carboxamide (XV) to yield the desired l,6-naphthyridin-7-yl -carboxamide derivatives (XVI).

[0521] In other embodiments, compounds of Formulas I and Ic of the present disclosure can be prepared as depicted in Scheme 2.

XVll

Scheme 2

[0522] Scheme 2 describes a method for preparation of cinnolin-3-yl-carboxamide derivatives (XVI) by first nitrating 6-bromocinnolin-4-ol (XVII) to form 6-bromo-3-nitrocinnolin- 4-ol (XVIII). Compound XVIII can be couple with by either of two Suzuki Coupling routes or by a Stille reaction route to produce various 3-nitrocinnolin-4-ol (XXIII) derivatives. Reduction of the hydroxy to chloride followed by reduction of the nitro to amine gives the 6-substituted cinnolin- 3 -amine (XXV). Amine XXV can be couple with a variety of acids (XXVI) to yield the desired cinnolin-3-yl-carboxamide derivatives (XVI).

[0523] In another embodiment, compounds of Formulas I and Ic of the present disclosure can be prepared as depicted in Scheme 3. XXX

Scheme 3

[0524] Scheme 3 describes an alternative method for preparation of cinnolin-3 -yl- carboxamide derivatives (XXVII) starting with 2,2-diethoxyacetonitrile (XXVIII). The alkoxide- catalyzed formation of the imidate (XXIX). Reaction with (4-bromophenyl)hydrazine (XXX) forms the acetimidohydrazide (XXXI) which then cyclized by acid-catalyzation to the 6- bromocinnolin-3 -amine (XXXII). Compound XXXII can be couple with by either of two Suzuki Coupling routes or by a Stille reaction route to produce various 6-substituted cinnolin-3 -amine (XXV) derivatives. Amine XXV can be couple with a variety of acids (XXVI) to yield the desired cinnolin-3 -yl-carboxamide derivatives (XVI).

[0525] In other embodiments, compounds of Formulas I and Id of the present disclosure can be prepared as depicted in Scheme 4.

XLI

Scheme 4

[0526] Scheme 4 describes a method for preparation of l,7-naphthyridin-6-yl- carboxamide derivatives (XLI) by first coupling 2-(5-bromopyridin-3-yl)acetonitrile (XXXV) with a variety of 3 -groups by either of two Suzuki Coupling routes (Routes 1 or 2) or by a Stille reaction route (Route 3) to produce various 2-(5-substitutedpyridin-3-yl)acetonitrile (XXXVI) derivatives. Formation of the N-oxide (XXXVII) followed by the regioselective cyanation of the pyridine ring with trimethylsilanecarbonitrile leads after cyclization with HBr in HOAc to the 3-substituted-8- bromo-l,7-naphthyridin-6-amine (XXXIX). Palladium catalyzed reduction of the bromine with ammonium formate yields the 3-substituted-l,7-naphthyridin-6-amine (XL) which can be couple with a variety of acids (XXVI) to yield the desired l,7-naphthyridin-6-yl-carboxamide derivatives (XLI).

[0527] In another embodiment, compounds of Formulas I and Id of the present disclosure can be prepared as depicted in Scheme 5. Br Br Br.

NBS, DCE, AIBN "Br MeCN/H 2 0 -^V "CN 70°C, 24 h H 2 SO„, 60°C, 3 h

N N N" ^CN

XLI

Scheme 5

[0528] Scheme 5 describes an alternative method for preparation of 1 ,7-naphthyridin- 6-yl-carboxamide derivatives (XLT) by bromination of 5-bromo-3-methylpicoliiionitrile (XLTT) with NBS followed by SN2 displacement of the bromine by cyanide to form compound XLIV. Cyclization of dicyano compound XLIV with HBr in HOAc provides 3,8-dibromo-l,7- naphthyridin-6 -amine (XLV). Palladium catalyzed reduction of the bromine with ammonium formate yields the 3-bromo-L7-naphthyridin-6-amine (XLVI) which can be coupled with a variety of R -groups by either of two Suzuki Coupling routes or by a Stille reaction route to produce various 3-substituted-l,7-naphthyridin-6-amine derivatives (XL) which can be couple with a variety of acids (XXVI) to yield the desired l,7-naphthyridin-6-yl-carboxamidc derivatives (XLI).

[0529] In other embodiments, compounds of Formulas I and Ie of the present disclosure can be prepared as depicted in Scheme 6.

Scheme 6

[0530] Scheme 6 describes a method for preparation of 2,7-naphthyridin-3-yl- carboxamide derivatives (LVI) by first reacting diethyl 3-oxopentanedioate (XLVIII) with malonitrile (XLTX) followed by acid cyclization to the 2,7-naphthyridinetetraone (L). Chlorodehydroxylation of compound L produces the 3,6~dichloro~2,7~naphthyridine (LII). Compound LII can either be reacted with (4-methoxyphenyl)methanamine (VII) followed by acid cleavage to give the amine (LIV). Amine LIV can be couple with a variety of acids followed by coupling to a variety of aromatic rings by any of three different routes to yield the desired 2,7- naphthyridin-3-yl -carboxamide derivatives (LVT). Compound LTI can also be couple with by either of two Suzuki Coupling routes (Routes 1 or 2) or by a Stille reaction route (Route 3) to produce chloride (LVII) which can then be reacted with a variety of carboxamide (XV) to yield the desired 2,7-naphthyridin-3-yl-carboxamide derivatives (LVI).

Illustrative Compound Examples

[0531] Preparation of intermediate 7-bromo-2-chloro-l,6-naphthyridine (IX) is depicted below in Scheme 7.

Step 1

[0532] To a solution of 2-bromopyridin-4-amine (LVIII) (584 g, 3.38 mol, 1 eq) and sodium acetate (554 g, 6.75 mol, 2 eq) in HOAc (2000 mL) was added a solution of iodine monochlonde (559 g, 3.44 mol, 176 mL, 1.02 eq) in HOAc (1000 mL) drop-wise at 70°C, the resulting mixture was stirred at 70°C for 3 h. The mixture was concentrated to remove HOAc and poured into water (20 L) . The aqueous solution was extracted with EtOAc ( 10 L x 3) . The combined organic layers were washed with saturated aq. Na2C03 (20 L), saturated aq. Na2S20s (10 L), brine (10 L), dried over Na2S04, filtered and concentrated to give a yellow residue, which was purified by column chromatography (1 : 1→1 :0 petroleum ether:DCM) to obtain 2-bromo-5-iodopyridin-4- amine (TT) as a yellow solid (340 g, 1 .14 mol, 33.7% yield). Ή NMR (400 MHz, DMSO- 6 ) δ ppm 6.56 - 6.53 (3H, m), 7.73 - 7.72 (1H, d, J= 5.2 Hz); ESIMS found for C 5 H 4 BrIN 2 mlz 299.9 (M+l).

Step 2

[0533] 2-Bromo-5-iodopyridin-4-amine (II) (340 g, 1.14 mol, 1 eq) was dissolved in DMF ( 1500 mL) and ethyl acrylate (III) (228 g, 2.27 mol, 247 mL, 2 eq), TEA (173 g, 1.71 mol, 237 mL, 1.5 eq), tris(o-tolyl)phosphme (34.6 g, 114 mmol, 0.1 eq) and Pd(OAc) 2 (12.8 g, 56.9 mmol, 0.05 eq) were added. The reaction was placed under nitrogen and heated at 100°C for 3 h. The reaction mixture was concentrated and EtOAc (7 L) was added, filtered. The filtrate was washed with brine ( 15 L), dried over Na2S04, filtered and concentrated to give ethyl (E)-3-(4- amino-6-bromopyridin-3-yl)acrylate (IV) (320 g, crude) as a yellow solid. It was used directly in next step without further purification. ¾ NMR (400 MHz, DMSO-J 6 ) δ ppm 1.25 (3H, t, J = 7.2 Hz), 4.20-4.15 (2H, m), 6.51 ( 1H, d, J = 15.6 Hz), 6.76 (1H, s), 6.78 (2H, s), 7.73 (1H, d, J = 16.0 Hz), 8.22 (1H, s); ESIMS found for CioHiiBrN 2 0 2 m/z 272.0 (M+l). Step 3

[0534] To a solution of ethyl (E)-3-(4-amino-6-bromopyridin-3-yl)acrylate (IV) (300 g, 1.11 mol, 1 eq) in EtOH (1.5 L) was added NaSMe (85.3 g, 1.22 mol, 77.6 mL, 1.1 eq), the resulting mixture was stirred at 50°C for 1 hour. The reaction mixture was poured into water (3.0 L) and acidified to pH~5 with 1.0 N aq. HC1 and filtered. The collected solid was suspended in tert-butyl methyl ether (2.0 L), filtered and the collected solid was concentrated to give 7-bromo- l,6-naphthyridin-2(lH)-one (V) as a yellow solid (207 g, 920 mmol, 83.1% yield). It was used directly in next step. 'HNMR (400 MHz, DMSO-<¾) δ ppm 6.62 - 6.60 (1H, m), 7.36 (1H, s), 7.98 (1H, d, J = 9.6 Hz), 8.87 - 8.55 (1H, m), 12.09 (1H, s); ESIMS found for CsftBrNzO m/z 226.0 (M+l).

Step 4

[0535] To a solution of 7-bromo-l ,6-naphthyridin-2(lH)-one (V) (140 g, 622 mmol, 1 eq) in MeCN (950 mL) was added POCh (238 g, 1.56 mol, 145 mL, 2.5 eq) and DMF (19.0 g, 260 mmol, 20 mL, 0.42 eq), the resulting mixture was stirred at 80°C for 2 h. After cooling to room temperature, the mixture was poured into water (2000 mL) and neutralized to pH~7 with 1.0 N aq. NaOH, it was extracted with EtOAc ( 1.0 L x 3). The combined organic layers were washed with brine (2.0 L), dried over Na2S04, filtered and concentrated to give a yellow residue, which was purified by column chromatography (10: 1→5: 1, petroleum ether: EtOAc) to give 7-bromo-2- chloro-l,6-naphthyridine (VI) (102 g, 400 mmol, 64.2% yield, 95.1% purity) as a light-yellow solid. ¾ NMR (400 MHz, DMSO-ds) δ ppm 7.54 (1H, d, J=8.8 Hz), 8.10 ( 1H, s), 8.24 (1H, m), 9.06 (1H, s); ESIMS found for C 8 H 4 BrClN 2 m/z 244.95 (M+l).

Step 5

[0536] A heavy walled resealable tube was loaded, under an argon atmosphere, with copper (I) oxide (3.0 g, 20.97 mmol), 7-bromo-2-chloro-l,6-naphthyridine (VI) (10.2 g, 41.89 mmol) and ammonia hydrate (60 mL, 431.38 mmol). The sealed flask was heated at 80°C for 4 h. The reaction was cooled to room temperature and poured into water (500 mL). The solid was collected by filtration and dried under vacuum to give 2-chloro-l,6-naphthyridin-7-amine (IX) as yellow solid (5.68 g, 31 .6 mmol, 75.5% yield). 'H NMR (499 MHz, DMSO-4,) δ ρρηι 6.55 (2 H, s), 6.58 ( 1 H, s), 7.13 ( 1 H, d, J=8.51 Hz), 8.23 (1 H, d, J=8.51 Hz), 8.88 (1 H, s); ESIMS found for GJLClNa ra/z 180.0 (M+l). [0537] Preparation of intermediate 6-bromocinnolin-3 -amine (XXXII) is depicted below in Scheme 8.

XXX

XXVIII XXIX

H 2 S0 4 40°C, 72 h

Scheme 8

Step 1

[0538] To a stirred solution of 2,2-diethoxyacetonitrile (XXVIII) (5.0 g, 38.71 mmol) in dry MeOH (80 mL) was added a 25% solution of sodium methoxide (1 mL). After the addition, the reaction mixture was stirred at room temperature for 24 h, quenched with dry ice, and then concentrated under vacuum. The resulting residue was diluted with water and EtOAc. The organic layer was separated and aqueous was extracted with EtOAc (3 x 100 mL). The combined organic layers were dried (Na2S04) and the solvent was removed in vacuo to produce the product methyl 2,2-diethoxyacetimidate as colorless oil (XXIX) (4.7 g, 29.2 mmol, 75.3% yield). 'H NMR (499 MHz, DMSO- ,) δ ppm 1.14 (6 H, t, J=7.14 Hz), 3.51 (4 H, qd, J=7.04, 1.10 Hz), 3.65 (3 H, s), 4.81 (1 H, s), 7.94 (1 H, s); ESIMS found for C7H15NO3 m/z 163.1 (M+2).

Step 2

[0539] To a solution of methyl 2,2-diethoxyacetimidate (XXIX) (4.7 g, 29.2 mmol) in anhydrous MeOH (20 mL) was added (4-bromophenyl)hydrazine hydrochloride (XXX) (supplier, CombiBlocks) (3.26 g, 14.6 mmol) and sodium methoxide (0.79 g, 14.58 mmol). the mixture was heated to 70°C for 1 h. After completion, the MeOH was removed by vacuum and the residue was dissolve in EtOAc (100 mL), washed with brine (3x50 mL), dried, and evaporated to dryness. The crude product was purified by silica column (0→100% EtOAc/Hexanes) to yield '- (4-bromophenyl)-2,2-diethoxyacetimidohydrazide (XXXI) as brown oil (2.09 g, 6.61 mmol, 22.7% yield). ESIMS found for Ci 2 Hi S BrN 3 0 2 m/z 316.1 ( 79 BrM+l). Step 3

[0540] The N'-(4-bromophenyl)-2,2-diethoxyacetimidohydrazide (XXXI) (2.09 g, 6.61 mmol) was mixed with sulfuric acid (4.0 mL, 75.1 mmol) and the reaction was stirred at 40°C for 72 h. The solution was poured into ice and neutralized with 2 M NaOH to pH=7.0. The product was purified by silica column (0→20% 7N ML-MeOH/CHCh) to produce 6-bromocinnolin-3- amine (XXXII) as a red solid (177 mg, 0.79 mmol, 12.0 % yield). ESIMS found for C 8 H 6 BrN 3 »¾/z 225.0 ( 79 BrM+l).

[0541] Preparation of intermediate 3-bromo-l,7-naphthyridin-6-amine (XLVI) depicted below in Scheme 9.

XLII XLIII XLIV

HBr/HOAc r. , 30 min

Scheme 9

Step 1

[0542] A heterogenous solution of 5 3romo-3-methylpicolinonitrile (XLII) (500 g, 2.54 mol), N-bromosuccinimide (452 g, 2.54 mol) in DCE (2.0 L) was added AIBN (416. g, 2.54 mol), and the resulted solution was stirred at 70°C for 24 h. The mixture was diluted with water (1.0 L) and extracted with EtOAc (2.0 L). The organic layer was washed with brine (1.0 L) and concentrated to dryness. The residue was purified by chromatography on silica gel (100: 1→20: 1 petroleum ether/EtOAc) to obtain 5-bromo-3-(bromomethyl)picolinonitrile (XLIII) as a white solid (140 g, 507 mmol, 20.0% yield). ¾ NMR (499 MHz, DMSO- 6 ) δ ppm 4.78 (2 H, s), 8.57 (1 H, d, J=2.20 Hz), 8.88 (1 H, d, J=2.20 Hz); ESIMS found for C ftBrzNz mlz 274.9 (M+l).

Step 2

[0543] To a mixture of 5-bromo-3-(bromomethyl)picolinonitrile (XLIII) (30.0 g, 108 mmol) in CH 3 CN (30.0 mL), H 2 0 (30.0 mL) and EtOAc (30.0 mL) was added TMSCN (272 mL, 2.17 mol), then TBAF (1 M, 152 mL) was added. The resulted solution was stirred at 20°C for 10 min. The mixture was diluted with water (300 mL) and extracted with EtOAc (300 mL χ 2). The organic layer was washed with brine (300 mL χ 2), dried over Na2SC>4 and concentrated to dryness. The residue was purified by chromatography on silica gel (50: 1→20: 1 petroleum ether/EtOAc) to give 5-bromo-3-(cyar!omethyl)pico1inomtnle (XLIV) as a light-yellow solid (9.20 g, 41.4 mmol, 38.1% yield). ¾ NMR (499 MHz, DMSO-J 6 ) δ ppm 4.33 (2 H, s), 8.40 (1 H, d, J=2.20 Hz), 8.92 (1 H, d, J=2.20 Hz); ESIMS found for C 8 H 4 BrN 3 mlz 221.95 (M+l).

Step 3

[0544] 5-Bromo-3-(cyatiornethyl)picoIinonitrile (XLIV) (9.00 g, 40.5 mmol) was added slowly to a 40% solution of HBr in HOAc (5.5 mL, 40.5 mmol) and stirred at 20°C for 1 h. The mixture was poured into water (150 mL) and filtered. The residue was dissolved in EtOAc (1.50 L) and washed with sat. NaHCC (300 mL), then brine (500 mL χ 2). The organic layer was dried over a2S04 and concentrated to obtain 3.8-dibromo-1.7-naphthyridin-6-amine (XLV) as a yellow solid (11.5 g, 37.9 mmol, 93.6% yieldl Ή NMR (499 MHz, DMSO-d 6 ) δ ppm 6.54 (1 H, s), 6.69 (2 H, br s), 8.42 (1 H, d, J=2.20 Hz), 8.58 (1 H, d, J=2.20 Hz); ESIMS found for C 8 H 5 Br2N 3 mlz 301.9 (M+l).

Step 4

[0545] A mixture of 3,8-dibromo-l,7-naphthyridm-6~amme (XLV) (11.0 g. 36.3 mmol), ammonium formate (4.88 g, 77.3 mmol) in DMF (50.0 mL) was added Pd(PPh;;).i (3.36 g, 2,90 mmol) under N 2 , the resulted solution was stirred at 50°C for 16 h. The mixture was poured into water (150 mL) and extracted with EtOAc ( 150 mL χ 3). The organic layer was washed with brine (100 mL χ 2), dried overNaaSO* and concentrated to gi ve a residue. The residue was purified by Prep-HPLC (column: Phenoraenex Syncrgi Max-RP 250* 80mm* ΙΟμιη; mobile phase: [water(0. l%TFA)-MeCN];B%: 5%-35%,35MIN,60%min) to obtain 3-bromo-l ,7- naphthyridm-6-amme (XL VI) as a green solid (5.37 g, 24.0 mmol, yield: 66.1%). ¾ NMR (400 MHz, DMSO-c/δ) δ ppm 8.87 (1H, s), 6.37 (2H, s), 6.56 (1H, s), 8.35 (1H, d, J= 2.4Hz), 8.52 (1H, d, J= 2.4Hz); ESIMS found for C 8 ¾BrN 3 mlz 224.0 (M+l).

[0546] Preparation of intermediate 6-chloro-2,7-naphthyridin-3-amine (LTV) is depicted below in Scheme 10.

LIV LIU

Scheme 10

Step 1

[0547] Malonitrile (XLIX) (155 roL, 2.47 mol) and diethylamine (50.1 mL, 486 mmol) were added to EtOH (2.5 L) at room temperature. To the stirred solution was added diethyl 3-oxopentanedioate (XL VIII) (450 mL, 2.47 mol) in portions and the resulting dark yellow/orange solution was stirred at room temperature overnight. The mixture was cooled to 0°C, H2SO4 (1.2 L, 22.5 mol) and H2O (528 mL, 29.3 mol) was added slowly to the mixture. The resultant solution was stirred at 100°C for 30 min. The mixture was cooled to 20°C and slowly poured into water (800 mL). generating a yellow solid. The mixture solution was filtered and dried under vacuum at 60°C to produce 2,7-naphthyridine-l,3,6,8(2H,4H,5H,7H)-tetraone (L) as a white solid (340 g, 1.75 mol, 70.8% yield). ESIMS found for CsHeNzCWz 195.05 (M+l).

Step 2

[0548] 2,7-Naphthyridine-l,3,6,8(2H,4H,5H,7H)-tetraone (L) (100 g, 515 mmol) was added to POC1? (500 mL, 5.38 mol). The mixture was heated to 160°C in an autoclave for 24 hrs. The reaction mixture was quenched by addition to water ( 1.0 L) at 0°C and a 2 C(¼ (500 g), the mixture was diluted with additional water (500 mL) and extracted with EtOAc (200 mL x 3). The combined organic layers were washed with saturated salt solution (200 roL χ 3), dried over Na?S0 , filtered and concentrated under reduced pressure to give the erode product. The crude product was purified by silica gel column chromatography (50/1 -→20/l petroleum ether/EtOAc) to produce l,3,6,8-tetrachioro-2,7~naphthyridine (LI) as a white solid (25.7 g, 96.3 mmol, 18.7% yield). ). ¾ NMR (400 MHz, CDCI3) 5 ppm 7.58 (2H, s); ESIMS found for CeKjCUJsb IM/Z 268.9 (M+l). Step 3

[0549] A mixture of l,3,6,8-tetrac oro-2,7-naphmyridine (LI) (90.0 g, 336 mmol) in THF (900 mL) was degassed by bubbling Ή 2 or 2 min. Pd(dppf)Cl2 (24.6 g, 33.6 mmol). TMEDA (127 mL, 839 rrsmol) and NaBl¾CN (105 g, 1.68 mmol) were added in sequence. The mixture was stirred at room temperature under argon for 3 h. The reaction was quenched by adding water (1.00 L) at 25°C and extracted with EtOAc (500 mL χ 3). The combined organic layers were washed with brine (500 mL x 3), dried over NajSO.;, filtered and concentrated under reduced pressure to give a residue. The residue was purified by MPLC (20: 1 petroleum ether/EtOAc, Rr = 0.6) to produce 3,6-dichloro-2,7-naphthyridine (LII) (100 g. 449 mmol, 66.8% yield) as yellow solid. Ή NMR (400 MHz, CDC1 3 ) δ ppm 7.67 (2H, s), 9.25 (2H, s); ESIMS found for mlz 199.0 (M+1).

Step 4

[0550] 4-Methoxybenzylamme (VII) (104 mL, 803 mmol) was added to 3,6-dichloro- 2,7-naphthyridine (LII) (50 g, 251 mmol), and heated at 100°C for 16 h. The reaction was purified without further work -up. The crude product was triturated with MTBE (300 mL) at 25°C for 20 min and then filtrated to give 6-chk>ro-N-(4~medioxybenzyl)-2,7-iiaphthyridin-3-aniine (LIII) as an off-white solid (180 g, crude). ¾ NMR (400 MHz, DMSO-£¾) δ ppm 3.92 (3H, s), 4.44-4.45 (2H, d, J=4.0 Hz), 6.44 (IH, s), 6.86-6.88 (2H, d, J = 8.0 Hz), 7.27-7.29 (2H, d, J= 8.0 Hz), 7.50 (IH, s), 7.81-7.84 (IH, t, J = 6.2 Hz), 8.90 (IH, s), 9.07 (IH, s); ESIMS found for Ci 6 Hi 4 ClN 3 0 mlz 301.1 (M+1).

Step 5

[0551] 6-Chioro- -(4-methoxybenzyl)-2,7-naphthyrKlui-3-aimne (LIII) (90.0 g. 300 mmol) was added to TFA (790 mL, 10.7 mol) and heated at 75°C for 2.5 h under N 2 . Tire reaction mixture was concentrated tinder reduced pressure to remove TFA. The residue was triturated with EtOH (400 mL) at 25°C for 20 min and filtrated to produce 6-chloro-2,7-naphthyridin-3-amine (LIV) as a white solid (63.0 g, 328 mmol, 54.6% yield). ¾ NMR (499 MHz, DMSO-i¾) δ ppm 6.48 (IH, s), 7.46 (IH, s), 8.87 (IH, s), 8.99 (IH, s); ESIMS found for CsHeClNs iw/z 180.0 (M+1).

[0552] Preparation of intermediate l-(bromomethyl)-l-(trifluoromethyl) cyclopropane (LX) is depicted below in Scheme 11.

LVIII LIX LX

Scheme 11

Step 1

[0553] l-(Trifluoromethyl)cyclopropane-l-carboxylic acid (LVIII) (3.7334 g, 24.23 mmol) was dissolved in THF (162 mL) and cooled to 0°C. LAH (1.1614 g, 29.07 mmol) was then added and the reaction heated to 40°C overnight. The reaction was cooled to 0°C. Water (2 mL) was added to quench the reaction followed by 2 N NaOH (0.3 mL). The reaction was stirred forming a precipitate which was filtered off and washed with ether. The aqueous phase was removed, and the organic phase was washed with brine, dried, and carefully concentrated to give (l-(trifluoromethyl)cyclopropyl)methanol (LIX) (1.5376 g, 10.98 mmol, 45.3% yield) as a clear, volatile liquid.

Step 2

[0554] To a solution of (l-(trifluoromethyl)cyclopropyl)methanol (LIX) (1.6 g, 11.42 mmol) in DCM (23 mL) was added L¾N (1.9 mL, 13.7 mmol). The reaction was cooled to 0°C and MsCl was added dropwise. The reaction was stirred at 0°C for 1 h. The reaction was poured into water and extracted with DCM. The organic phase was separated, washed with brine, dried, and concentrated. The crude mesylate was then dissolved in acetone (22 mL). LiBr (4.96 g, 57.1 mmol) was added, and the reaction stirred at room temperature overnight. The acetone was carefully removed, and the residue was partitioned between water and ether. The aqueous phase was separated and reextracted with ether. The organic phases were combined, washed with brine, dried, and carefully concentrated to give 1 -(bromomethyl)- l-(trifluoromethyl)cyclopropane (LX) ( 1.2867 g, 6.34 mmol, 55.5% yield) as a gold liquid with residual amounts of acetone. ¾ NMR (499 MHz, DMSO-£¾) δ ppm 1.04 (2 H, tquin, J=5.17, 5.17, 1.74, 1.74, 1.74, 1.74 Hz), 1.23 - 1.27 (2 H, m), 3.77 (2 H, s).

[0555] Preparation of intermediate tert-butyl (5-bromothiazol-2-yl)(4- mcthoxybcnzyl)carbamatc (LXIV) is depicted below in Scheme 12. Lxra

Scheme 12

Step 1

[0556] A mixture of 5-bromothiazol-2 -amine hydrobromide (LXI) (1.99 g. 7.66 mmol) and B0C2O (2.21 g, 10.1 mmol) in pyridine (6 mL) was stirred at room temperature for 2 h. The solvent was removed, and the residue was purified by silica gel column chromatography (40g) (0→50% EtOAc/hexanes) to produce fert-butyl (5-bromothiazol-2-yl)carbamate (LXII) as a white solid (1.6 g, 5.73 mmol, 74.9% yield). ESIMS found for CsHnBrNzC S mlz 222.9 ( 81 BrM+H - ¾u).

Step 2

[0557] To a solution of tert-butyl (5-bromothiazol-2-yl)carbamate (LXII) (1.3 g, 4.66 mmol) in DCM (23 mL) was added DBU (2.1 mL, 14.04 mmol) was followed by l-(chloromethyl)- 4-methoxybenzene (LXIII) (0.95 mL, 7.01 mmol). The reaction mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (24g) (0→10% EtOAc/hexanes) to produce tert- butyl (5-bromothiazol-2-yl)(4-methoxybenzyl)carbamate (LXIV) as an off-white solid (974 mg, 2.44 mmol, 52.4% yield). ESIMS found for mlz 399.1 (M+H).

[0558] Preparation of intermediate fert-butyl 4-((5-bromopyridin-3- yl)oxy)piperidine- -carboxylate (XL VII) is depicted below in Scheme 13.

LXV LXVII

Scheme 13

Step 1 [0559] A mixture of 5-bromopyridin-3-ol (LXV) (2 g, 11.49 mmol), fert-butyl 4- ((methylsulfonyl)oxy)piperidine-l-carboxylate (LXVI) (3.53 g, 12.64 mmol) and CS2CO3 (4.87 g, 14.94 mmol) in DMF (20 mL) was stirred at 80°C for 16 h. The mixture was diluted with water and then extracted with EtOAc. The organic layer was washed with water, brine, and dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified on a silica gel column (0→35% EtOAc/hexane) to give fert-butyl 4-((5-bromopyridin-3-yl)oxy)piperidine-l- carboxylate (LXVII) as a white solid (2.88 g, 8.06 mmol, 70.1% yield). ESIMS found for Ci5H 2 iBrN 2 03 mlz 357.05 (M+H).

[0560] Preparation of intermediate ferZ-butyl 3-(((6-bromopyrazin-2-yl)oxy)methyl) azetidine-l-carboxylate (LXX) is depicted below in Scheme 14.

LXVIII LXX

Scheme 14

Step 1

[0561] A mixture of 2,6-dibromopyrazine (LXVIII) (1.1 g, 4.62 mmol), fert-butyl 3- (hydroxymethyl)azetidine-l-carboxylate (LXIX) (0.95g, 5.09 mmol) and Cs 2 C0 3 (3.01 g, 9.25 mmol) in DMF (6 mL) was stirred at 80°C for 4 h. The mixture was diluted with water and then extracted with EtO Ac/brine. The organic layer was washed with water, brine, and dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified on a silica gel column (0→100% EtOAc/hexane) to give fert-butyl 4-((5-bromopyridin-3-yl)oxy)piperidine-l- carboxylate (LXX) as a yellow oil (1.52 g,4.416 mmol, 95.5% yield). ESIMS found for Ci 3 Hi 8 BrN 3 0 3 mlz 344.05 (M+H).

[0562] Preparation of intermediate 2-( 1 -(ferf-butoxycarbonyl)piperidin-4-yl)oxazole- 4-carboxylic acid (LXXIII) is depicted below in Scheme 15.

LXXI LXXIII

Scheme 15

Step 1

[0563] To a solution of tert-butyl 4-aminopiperidine-l-carboxylate (LXXII) (2 g, 9.99 mmol) in dry DMF (9.99 ml) was added 2,6-dichloropyrazine (LXXI) (1.488 g, 9.99 mmol). To the mixture was added DIPEA (5.22 mL, 30.0 mmol) and the reaction was stirred at 95°C or 20 h. The solution was poured into water (200 mL). The solution was allowed to stand for 16 h. The solid was filtered and dried under vacuum, to produce fert-butyl 4-((6-chloropyrazin-2- yl)amino)piperidine-l-carboxylate) (LXXIII) as an off-white solid (1.0172 g, 3.25 mmol, 32.6% yield. ESIMS found for C14H21CIN4O2 mlz 335.1 (M+Na).

[0564] The following intermediates were prepared in accordance with the procedure described in the above Scheme 15.

LXXIV

[0565] ferf-Butyl 3-[[(6-chloropyrazin-2-yl)amino]methyl]-3-fluoro-azetidine-l - carboxylate (LXXIV): Off-white solid, (56.4% yield). ESIMS found Ci 3 Hi 8 ClFN 4 02 mlz 338.95 (M+Na).

[0566] fert-Butyl (3S,4S)-4-((6-chloropyrazin-2-yl)amino)-3-fluoropiperidine-l - carboxylate (LXXV): Off white solid (54.0% yield). ESIMS found C14H20CIFN4O2 mlz 352.90 (M+H).

[0567] Preparation of intermediate 6-bromo-N-(ferf-butyl)pyrazin-2 -amine (LXXVII) is depicted below in Scheme 16.

LXVIII LXXVII

Scheme 16

Step 1

[0568] 2,6-Dibromopyrazine (LXVIII) (2 g, 8.41 mmol) was added to tert- butylamine (LXXVI) (4.4 mL, 41.87 mmol) and stirred at 100°C for 6 h. Excess amine was removed under vacuum and the residue was purified by silica gel column chromatography (0→20% EtOAc/hexanes) to produce 6-bromo-N-(fert-butyl)pyrazin-2-amine (LXXVII) as an off-white solid (1.82 g, 7.91 mmol, 94.1% yield). ESIMS found for C 8 Hi 2 BrN 3 mlz 230. (M+H).

[0569] The following intermediate was prepared in accordance with the procedure described in the above Scheme 16.

LXXVIII

[0570] 6-Bromo-N-isopropylpyrazin-2 -amine (LXXVIII): Yellow wax, (1.08 g, 5.00 mmol, 93.0% yield). ESIMS found C 7 Hi 0 BrN 3 mlz 218.0 ( 81 BrM+H).

[0571] Preparation of intermediate fra«s-4-((ferf-butoxycarbonyl)(methyl)amino) cyclohexane-l-carboxylic acid (LXXXI) is depicted below in Scheme 17. Scheme 17

Step 1

[0572] To a solution of methyl fr «5-4-((teri-butoxycarbonyl)amino)cyclohexane-l- carboxylate (LXXIX) (1.3 g, 5 mmol) in DMF (15 mL) and cooled to 0°C was added sodium hydride (60% in oil, 240 mg, 6 mmol) over 30 minutes. The mixture is stirred at room temperature for 1 h. then cooled to 0°C and treated with iodomethane (0.38 mL, 6 mmol). After stirring overnight at room temperature, the mixture is poured into a saturated aqueous NH4CI and extracted with EtOAc. The combined organic phase is washed with water and brine, dried over anhydrous Na2S04 and concentrated under reduced pressure. The obtained residue is purified by column chromatography on silica gel (10: 1 n-hexane-EtOAc) to obtain methyl ira«s-4-((teri- butoxycarbonyl)(methyl)amino)cyclohexane-l-carboxylate (LXXX) (1.3 g, 4.79 mmol, 94.8% yield).

Step 2

[0573] To a stirred solution of methyl fraws-4-((fer^butoxycarbonyl)(methyl)amino) cyclohexane-l -carboxylate (LXXX) (130 mg, 4.79 mmol) in a mixture of MeOH ( 10 mL) and THF (10 mL) was added 2 N aqueous NaOH (4.79 mL, 9.58 mmol) and the mixture was stirred for 4 h. The solvent was concentrated, the residue taken in water and acidified with IN HC1 and extracted with EtOAc. The organics were washed with 2 x water then 1 x brine. The organics were then separated and dried (MgSCK) before concentration to dryness to obtain frara-4-((fert- butoxycarbonyl)(methyl)amino)cyclohexane-l-carboxylic acid (LXXXI) as a thick gum (1.198 g, 4.65 mmol, 97.2% yield) which was used for next step without purification.

[0574] Preparation of intermediate l-((3-methyloxetan-3-yl)methyl)piperidine-4- carboxylic acid (LXXXV) is depicted below in Scheme 18.

Lxxxm

LXXXI I LXXXIV LXXXV

Scheme 18

Step 1

[0575] A solution of methyl piperidine-4-carboxylate (LXXXII) (254 mg, 1.77 mmol), 3-(bromomethyl)-3-methyloxetane (LXXXIII) (439 mg, 2.66 mmol), and potassium carbonate (736 mg, 5.32 mmol) in MeOH (5 mL) was heated by microwave irradiation at 90°C overnight. The solvent was removed under vacuum and the residue taken up in DCM and filtered. The organic layer was evaporated to give methyl l-((3-methyloxetan-3-yl)methyl)piperidine-4- carboxylate (LXXXIV) as a brown oil (490 mg) which was used without further purification. ESIMS found for Ci 2 H 2 iN0 3 m!z 228.2 (M+H).

Step 2

[0576] To a stirred solution of methyl l-((3-methyloxetan-3-yl)methyl)piperidine-4- carboxylate (LXXXIV) (403 mg, 1.77 mmol) in THF (3 mL) and water (3 mL) was added lithium hydroxide (46.7 mg, 1.95 mmol). The reaction was stirred at room temperature for overnight. The reaction was evaporated and then treated twice with toluene to remove residue water. The crude product was mixed with DCM/hexane, filtered and dried to produce l-((3-methyloxetan-3- yl)methyl)piperidine-4-carboxylic acid (LXXXV) as a light brown solid (405 mg) which was used without further purification. ESIMS found for C11H19NO3 mlz 214.1 (M+H).

[0577] Preparation of intermediate 4-((dimethylamino)methyl)b

(LXXXIX) is depicted below in Scheme 19.

LXXXVI LXXXVII

Me 2 N

NaBH 3 CN

MeOH, HOAc

60°C, 18h

LXXXIX LXXXVIII

Scheme 19

Step 1

[0578] To a solution of 4-formylbenzoic acid (LXXXVI) (2.12 g, 14.1 mmol) in THF (7.2 mL) was added Boc 2 0 (4.92 g, 28.2 mmol) and DMAP (0.35 g, 2.82 mmol). The reaction was stirred at 80°C for 2 h. The reaction was extracted with EtO Ac -saturated NaHCC and the organic layer was separated, dried over Na2S04 and evaporated to dryness under vacuum. The residue was purified by silica column (0→100% EtOAc-Hexanes) to give ferf-butyl 4-formylbenzoate (LXXXVII) as off white solid (2.23 g, 10.8 mmol, 76.6% yield). ESIMS found for G 2 Hi 4 0 3 mlz 207.1 (M+H).

Step 2

[0579] A solution of tert-butyl 4-formylbenzoate (LXXXVII) (2.23 g, 10.8 mmol), 2.0 M solution of dimethylamine in MeOH (7 mL, 14.06 mmol) and HO Ac (310 μΐ,, 5.41 mmol) in MeOH (125.7 mL) was stirred at room temperature for 10 min. To the mixture was added with NaB¾CN (883 mg, 14.06 mmol) and the mixture stirred at 60°C for 18 h. The mixture was concentrated, and the residue was purified by column chromatography (0→100% EtOAc- Hexanes). The fractions containing the product were concentrated to yield iert-butyl 4- ((dimethylammo)methyl)benzoate (LXXXVIII) as a yellow oil (920 mg, 3.71 mmol, 34.4% yield). ESIMS found for Ci 4 H 2 iN0 2 mlz 236.2 (M+H).

Step 3

[0580] To a suspension of HQ (7.23 mL, 14.5 mmol) in 1,4-dioxane (5 mL) was added tert-butyl 4-((dimethylamino)methyl)benzoate (LXXXVIII) (0.92 g, 3.91 mmol). The reaction was heated under reflux for 16 h. The reaction was then cooled and the solid was collected by filtration, washed with dioxane and dried under vacuum to produce 4- ((dimethylamino)methyl)benzoic acid (LXXXIX) as a white solid (427 mg, 1.98 mmol, 50.6% yield). ESIMS found for Ci 0 Hi 3 NO 2 m/z 180. (M+H).

[0581] Preparation of intermediate r-methyl-l',2',3',6'-tetrahydro-[2,4'-bipyridine]-4- carboxylic acid (XCIII) is depicted below in Scheme 20.

XCII XCIII

Scheme 20

Step 1 [0582] A solution of terf-butyl 2-chloroisonicotinate (XC) (supplier: Synthonix) (2.0 g, 9.36 mmol), l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,2 ,3,6- tetrahydropyridine (XCI) (supplier: Ark Pharm) (2.55 g, 1 1.4 mmol), K 3 P0 4 (5.96 g, 28.1 mmol), Pd(dppf)Cl2 (870 mg, 1.07 mmol) in dioxane (85 mL). The solution was purged with Argon and heated by microwave irradiation at 120 C C . The solvent was removed under vacuum and the residue was purified by silica gel column chromatography (24g) (0→10% MeOH/CHC ) to produce tert- butyl r-methyl-r,2',3',6'-tetrahydro-[2,4'-bipyridine]-4-carboxyla te (XCII) as a tan solid (2.5 g, 9.1 mmol, 97.3% yield). ESIMS found for C16H22N2O2 mlz 275.15 (M+H).

Step 2

[0583] To a suspension of HC1 (23 mL, 91.9 mmol) in 1,4-dioxane (30 mL) was added fert-butyl l '-methyl-r,2',3',6'-tetraliydro-[2,4'-bipyndme]-4-carboxylat e (XCII) (2.5 g, 9.1 1 mmol). The reaction was heated under reflux for 16 h. The reaction was then cooled and the solid was collected by filtration, washed with MTBE and dried under vacuum to produce Γ -methyl - r,2',3',6'-tetrahydro-[2,4'-bipyridine]-4-carboxylic acid (XCIII) as a white solid ( 1.88 g, 7.38 mmol, 81.0% yield). ESIMS found for Ci 2 Hi 4 N 2 (Wz 219.1 (M+H).

[0584] Preparation of intermediate 2-((l-methylpiperidin-4-yl)thio)isonicotinic acid (XCVI) is depicted below in Scheme 21.

xc xcv XCVI

Scheme 21

Step 1

[0585] To a solution of l-methylpiperidine-4-thiol (XCIV) (200 mg, 1.52 mmol) in DMF (2 mL) was added NaH (61 mg, 1.53 mmol) at 0°C stirred for 30 min. ferf-Butyl-2- chloroisonicotinate (XC) (supplier: Synthonix) (400 mg, 1.87 mmol) was then added and the reaction mixture was stirred at room temperature overnight. The solvent was removed under vacuum and the residue was purified by silica gel column chromatography (24g) (0→10% 1.7N NH 3 in MeOH/CHCl 3 ) to produce tert-butyl 2-((l-methylpiperidin-4-yl)thio)isonicotinate (XCV) as an off-white solid (271 mg, 0.88 mmol, 57.7% yield). ESIMS found for C16H24N2O2S mlz 309.2 (M+H). Step 2

[0586] To a suspension of HC1 (0.88 mL, 3.52 mmol) in 1,4-dioxane (0.88 mL) was added fert-butyl 2-((l-methylpiperidin-4-yl)thio)isonicotinate (XCV) (271 mg, 0.88 mmol). The reaction was heated at reflux overnight. The reaction was then cooled and the solid was collected by filtration, washed with diethyl ether and dried under vacuum to produce 2-((l-methylpiperidin- 4-yl)thio)isonicotimc acid (XCVI) as a white solid (136 mg, 0.418 mmol, 47.8% yield). ESIMS found for C12H16 2O2S mlz 253.1 (M+H).

[0587] Preparation of intermediate 2-(4-(tert-butoxycarbonyl)piperazin-l-yl) isonicotinic acid (C) is depicted below in Scheme 22.

xcvni

Scheme 22

Step 1

[0588] To a solution of ethyl 2-chloroisonicotinatc (XCVII) (10 g, 53.88 mmol) in DMA (108 mL) was added ferf-butyl piperazine-l-carboxylate (XCVIII) (0.32 mL, 2.89 mmol) and DIPEA (18.8 mL, 107.75 mmol). The reaction was stirred at 110°C for 16 h. The mixture was poured into water, extracted with EtOAc, and dried over Na2S04. The solvent was removed under high vacuum and the residue was purified on a silica gel column (120g) (0→100% hexane/EtOAc) to give fert-butyl 4-(4-(cthoxycarbonyl)pyridin-2-yl)pipcrazinc-l-carboxylatc (XCIX) as a brown oil (10.84 g, 32.32 mmol, 60.0% yield). ESIMS found for C17H25N3O4 mlz 336.15 (M+H).

Step 2

[0589] To a solution of ferf-butyl 4-(4-(ethoxycarbonyl)pyridin-2-yl)piperazine-l- carboxylate (XCIX) (10.7 g, 31.9 mmol) in Me OH (130 mL) and water (26 mL) was added 4 M aqueous lithium hydroxide (7.98 mL, 31.9 mmol). The reaction was stirred at room temperature for 16 h. The reaction was poured into water and neutralized with concentrated HC1 (31.9 mL, 31.9 mmol) and extracted with EtOAc. The organic layer was dried over Na2S04 and evaporated under high vacuum to produce 2-(4-(fer^butoxycarbonyl)piperazin-l-yl)isonicotinic acid (C) as a white solid (8.79 g, 28.6 mmol, 89.7% yield) which was used without further purification. ESIMS found for Ci 5 H 2 iN 3 (Wz 308.15 (M+H).

[0590] The following intermediates were prepared in accordance with the procedure described in the above Scheme 22.

CI

[0591] 2-Morpholinoisonicotinic acid (CI): Off-white solid, (631 mg, 3.03 mmol, 38.7% yield). ESIMS found C10H (M+H).

CII

[0592] 2-(7-(feri-Butoxycarbonyl)-2,7-diazaspiro[3.5]nonan-2-yl)iso nicotinic acid (CII): White solid, (360 mg, 1.04 mmol, 84.9% yield). ESIMS found C18H25N3O4 mlz 348. (M+H).

cm

[0593] 2-((2-(Dimethylamino)ethyl)amino)isonicotinic acid (CHI): Wliite solid, (357 mg, 1.45 mmol, 93.6% yield). ESIMS found Ο 0 Ηι 5 Ν 3 θ2 IM/Z 210.1 (M+H).

CIV

[0594] 2-(4-(Dimethylamino)piperidin-l-yl)isonicotinic acid (CIV): Off-white solid, (1.2 g, 4.20 mmol, 98.7% yield). ESIMS found G3H19N3O2 mlz 250.1 (M+H).

CV [0595] 2-(4-Methyl-l,4-diazepan-l-yl)isonicotinic acid (CV): Light brown solid, (1.0 g, 3.68 mmol, 97.5% yield). ESIMS found (M+H).

CVI

[0596] 2-(Methyl(l-methylpiperidin-4-yl)amino)isonicotinic acid (CVI): Brown solid, (230 mg, 0.80 mmol, 91.0% yield). ESIM mlz 250. (M+H).

CVII

[0597] 6-(4-Methylpiperazin-l-yl)nicotinic acid (CVII): White solid, (5.5 g, 21.3 mmol, 98.7% yield). ESIMS found G1H15N3O2 mlz 222.1 (M+H).

[0598] Preparation of intermediate 2-((l-(fer?-butoxycarbonyl)piperidin-4-yl)oxy) isonicotinic acid (CX) is depicted below in Scheme 23.

Scheme 23

Step 1

[0599] To a solution of 2-fluoropyridinc-4-carboxylic acid (CVIII) (6.65 g, 47.13 mmol) in DMSO (180 mL) was added ferf-butyl 4-hydroxypiperidine-l-carboxylate (CIX) (14.23 g, 70.69 mmol) and 2-fluoropyridine-4-carboxylic acid (6.65 g, 47.13 mmol). To this mixture was added NaH (8.48 g, 212.08 mmol) in 3 portions, this mixture was stirred at room temperature for 48 h. The reaction was poured into 1 N NaOH, the water layer was washed with EtOAc, the water layer was then acidified with concentrated HC1 (20 mL), extracted with EtOAc and dried over Na 2 S04. The solvent was removed, and the residue was purified by C18 Silica Gel column chromatography (0-40% MeCN/0.1% formic acid in water) to produce 2-((l-(fert- butoxycarbonyl)piperidin-4-yl)oxy)isonicotinic acid (CX) (12.85 g, 39.9 mmol, 84.6% yield) as a white solid. ¾ NMR (499 MHz, DMSO-J 6 ) δ ppm 1.41 (s, 9 H), 1.52 - 1.62 (m, 2 H), 1.90 - 1.98 (m, 2 H), 3.12 - 3.23 (m, 2 H), 3.64 - 3.72 (m, 2 H), 5.21 (tt, .7=8.13, 3.95 Hz, 1 H), 7.15 (s, 1 H), 7.36 (dd, .7=5.21, 1.37 Hz, 1 H), 8.31 (d, .7=5.21 Hz, 1 H), 13.62 (br s, 1 H); ESIMS found for Ci6H 2 2N 2 0 5 mlz 323.1 (M+H).

[0600] Preparation of intermediate 4-((l-(ferf-butoxycarbonyl)piperidin-4-yl)oxy) benzoic acid (CXIII) is depicted below in Scheme 24.

CXI CXII CXIII

Scheme 24

Step 1

[0601] To a solution of DEAD (12.3 mL, 27.08 mmol) (40% in toluene) was added to a mixture of ethyl 4-hydroxybenzoate (CXI) (3.0 g, 18.05 mmol), tert-hutyl 4- hydroxypiperidine-l-carboxylate (CIX) (4.72 g, 23.47 mmol) and triphenylphosphane (6.16 g, 23.47 mmol) in THF (40 mL) at 0°C. The mixture was stirred from 0°C to room temperature over 1 day before concentrating in vacuo. The residue was diluted with EtO Ac, washed with 1 N NaOH and brine, and then evaporated under vacuum. The crude product was purified by chromatography (0→30% EtOAc/hexanes) to give fert-butyl 4-(4-ethoxycarbonylphenoxy)piperidine-l- carboxylate (CXII) (5.4 g, 15.45 mmol, 85.6% yield) as a colorless oil. ESIMS found for Ci 9 H 2 7N0 5 mlz 372 A (M+Na).

Step 2

[0602] To a solution of fert-butyl 4-(4-ethoxycarbonylphenoxy)piperidine-l- carboxylate (CXII) (5.4 g, 15.45 mmol) in MeOH (10 mL) and THF (10 mL) was added LiOH (15.5 mL, 61.82 mmol) and the mixture stirred at 60°C for 2h. The mixture was concentrated, and the residue triturated with water. The resulting solution was acidified with 2 N HCl until a solid precipitated. The solid was filtered and washed with water to afford 4-[(l-/¾rt-butoxycarbonyl-4- pipendyl)oxyJbenzoic acid (CXIII) (4.7 g, 14.63 mmol, 94.6% yield) as a white solid. Ή NM (499 MHz, DMSO-c ) δ ppm 1.40 (9 H, s), 1.47 - 1.57 (2 H, m), 1.89 - 1.97 (2 H, m), 3.12 - 3.23 (2 H, m), 3.63 - 3.70 (2 H, m), 4.63 - 4.71 (1 H, m), 7.04 (2 H, d, J=9.06 Hz), 7.87 (2 H, d, J=9.06 Hz); ESIMS found for C17H23NO5 mlz 344.1 (M+Na). [0603] Preparation of intermediate l-(l-(terf-butoxycarbonyl)piperidin-4-yl)-lH- pyrazole-4-carboxylic acid (CXVII) is depicted below in Scheme 25.

cxrv CXVI CXVII

Scheme 25

Step 1

[0604] To a suspension of NaH (0.24 g, 5.99 mmol) in DMF (15 mL) at 0°C under argon was added ethyl lH-pyrazole-4-carboxylate (CXIV) (0.7 g, 5 mmol). After stirring for 30 min, ferf-butyl 4-(p-tolylsulfonyloxy)piperidine-l-carboxylate (CXV) (2.13 g, 5.99 mmol) was added and the mixture heated at 80°C for 1 h. The reaction was poured into water and extracted with EtOAc. The organic layer was washed with brine, dried, filtered and concentrated under vacuum. The crude product was purified by silica gel chromatography (0→40% EtOAc/Hexanes) to afford tert-butyl 4-(4-(ethoxycarbonyl)-lH-pyrazol-l -yl)piperidine-l -carboxylate (CXVT) as a white solid (1.25 g, 3.87 mmol, 77.4% yield). ESIMS found for C16H25N3O4 m/z 346.2 (M+Na).

Step 2

[0605] To a solution of fert-butyl 4-(4-(ethoxycarbonyl)-lH-pyrazol-l-yl)piperidine- 1-carboxylate (CXVI) (1.25 g, 3.87 mmol) in MeOH (4 mL) and THF (4 mL) was added LiOH (3.87 mL, 15.46 mmol). The reaction stirred at 60°C for 2 h. The mixture was concentrated, and the residue triturated in water. The solution was acidified with 2 N HCl and the resulting solid was filtered to afford l-(l-(rer^butoxycarbonyl)piperidin-4-yl)-lH-pyrazole-4-carbo xylic acid (CXVII) as a white solid ( 1.04 g, 3.52 mmol, 91.1% yield). ESIMS found for Ci4H 2 iN 3 0 4 m/z 318.1 (M+Na).

[0606] Preparation of intermediate 2-( 1 -(fert4jutoxycarbonyl)pipcridin-4-yl)oxazolc- 4-carboxylic acid (CXXII) is depicted below in Scheme 26.

Scheme 26

Step 1

[0607] To a suspension of methyl (2S)-2-amino-3 -hydroxy-propanoate hydrochloride (CXIX) (3.21 g, 20.63 mmol) (1.1 eq) in DCM (40 mL) was added DABCO (6.31 g, 56.27 mmol) (3.0 eq). The reaction mixture was stirred at room temperature for 20 min before adding tert-butyl 4-formylpiperidine-l-carboxylate (CXVIII) (4.0 g, 18.76 mmol) (1.0 eq). The reaction mixture was stirred at room temperature for 30 min. The reaction mixture was cooled to 0°C, and 1- chloropyrrolidine-2,5-dione (2.75 g, 20.63 mmol) (1.1 eq) was added and stirred at the room temperature for 16 h. Saturated aqueous Na2S2C>3 was added to the reaction mixture and extracted with DCM. The organic layer was washed with saturated aqueous NaHCC and brine, dried over Na2S04, and evaporated in vacuo. The crude product was purified by silica gel chromatography (0→50% EtOAc/Hexanes) to afford methyl 2-(l-(fert-butoxycarbonyl)piperidin-4-yl)-2,5- dihydrooxazole-4-carboxylate (CXX) as a light brown oil (4.9 g, 15.7 mmol, 83.6% yield). ESIMS found for Ci 5 H 2 4N 2 0 5 m/z 213.1 (M+H-Boc).

Step 2

[0608] To a suspension of methyl 2-(l-(fert-butoxycarbon}'l)piperidin-4-yl)-2,5- dihydrooxazole-4-carboxylate (CXX) (3.63 g, 20.39 mmol) (4.9 g, 15.69 mmol) and K 2 C0 3 (2.82 g, 20.39 mmol) in DCM (50 mL) was added l-bromopyrrolidine-2,5-dione (3.63 g, 20.39 mmol). The reaction mixture heated at reflux for 16 h. Water (100 mL) was then added and the mixture extracted with DCM. The organic layer was separated, washed with brine, dried over Na2S04, and evaporated in vacuo. The crude product was purified by silica gel chromatography (0→50% EtOAc/hexanes) to give methyl 2-(l-(fer/-butoxycarbonyl)piperidin-4-yl)oxazole-4-carboxyla te (CXXI) as a light brown oil (3.7 g, 11.92 mmol, 76.0% yield). ESIMS found for C15H22N2O5 mlz 333.10 (M+Na).

Step 3

[0609] To a solution of methyl 2-(l-(ferf-butoxycarbonyl)piperidin-4-yl)-2,5- dihydrooxazole-4-carboxylate (CXXI) in MeOH (20 mL) and THF (20 mL) was added 3 M aqueous LiOH (11.54 mL, 34.61 mmol). The mixture stirred at 60°C for 1 h. The mixture was then concentrated to remove the organic solvents. The residual water was acidified with 2 N HCl and the mixture extracted with EtOAc. The organic layer was washed with brine, dried, filtered and concentrated to afford 2-(l-(feri-butoxycarbonyl)piperidin-4-yl)oxazole-4-carboxyli c acid (CXXII) as a brown foam (4.6 g, 15.52 mmol, 89.7% yield). ESIMS found for C14H20N2O5 mlz 319.10 (M+Na).

[0610] Preparation of intermediate 2-(3-(dimethylamino)azetidin-l-yl)thiazole-4- carboxylic acid (CXXVII) is depicted below in Scheme 27.

CXXVII

Scheme 27

Step 1

[0611] To a solution of 2-chlorothiazolc-5-carboxylic acid (CXXIII) (1.0 g, 6.11 mmol), di-ferf-butyl dicarbonate (3.07 g, 14.06 mmol) in THF (19.8 mL) was added DMAP (0.15 g, 1.22 mmol). The reaction was heated at 60°C for 1 h. The solvent was removed under vacuum and the residue was purified by silica gel (40g) (0→50% EtOAc/hexanes) to produce /ert-butyl 2- chlorothiazole-4-carboxylate (CXXIV) as a clear liquid (1.05 g, 4.79 mmol, 78.4% yield). ESIMS found for C 8 Hi 0 ClNO 2 S mlz 220.0 (M+H).

Step 2

[0612] To a suspension of ferf-butyl 2-chlorothiazole-4-carboxylate (CXXIV) (265 mg, 1.21 mmol) in DMSO (10 mL) was added N,N-dimethylazetidin-3 -amine (CXXV) (313.2 mg, 1.81 mmol) and DIPEA (1.05 mL, 6.03 mmol). The mixture was heated at reflux for 1 day and the mixture was cooled to room temperature . The reaction was poured into water and the aqueous layer was extracted with EtOAc. The organic layer was dried and evaporated under vacuum. The residue was purified by column chromatography (0-40% 20% Me OH (7 N NH 3 )-CHC1 3 /CHC1 3 ) to afford fert-butyl 2-(3-(dimethylamino)azetidin-l-yl)thiazole-4-carboxylate (CXXVI) as a brown oil (67 mg, 0.24 mmol, 19.6% yield). ESIMS found for Ci 3 H 2 iN 3 0 2 S mlz 284.1 (M+H).

Step 3

[0613] To a stirred solution of ferf-butyl 2-(3-(dimethylamino)azetidin-l-yl)thiazole- 4-carboxylate (CXXVI) (200 mg. 0.71 mmol) in dioxane (15 mL) was added HC1 (4 N in dioxane) (1.76 mL, 7.06 mmol). The reaction was heated at 100°C for 16 h. The white solid was filtered and washed with MTBE, brine and dried to produce 2-(3-(dimethylamino)azetidin-l-yl)thiazole-4- carboxylic acid (CXXVII) as a white solid (450 mg, 1.50 mmol, 212% yield). ESIMS found for C 9 Hi 3 N 3 0 2 S m/z 228.1 (M+H).

[0614] The following intermediate was prepared in accordance with the procedure described in the above Scheme 27.

CXXVIII

[0615] 2-(3-(Dimethylamino)azetidin-l-yl)oxazole-4-carboxylic acid (CXXVIII): White solid, (543.9 mg, 1.91 mmol, 90.1% yield). ESIMS found C 9 Hi 3 N 3 0 3 mlz 212.0 (M+H). [0616] Preparation of intermediate l-(methyl-d3)-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-pyrazole (CXXX) is depicted below in Scheme 28.

CXXIX CXXX

Scheme 28

Step 1

[0617] To a stirred suspension of 4-(4,4,5,5-tctramcthyl-l,3,2-dioxaborolan-2-yl)- lH-pyrazole (CXXIX) (1.435 g, 7.4 mmol) and Cs 2 C0 3 (2.89 g, 8.87 mmol) in DMF (15 mL) was added trideuterio(iodo)methane (0.51 mL, 8.13 mmol) and the mixture was stirred at room temperature overnight. The reaction mixture was filtered, and the filtrates were concentrated and dried under high vacuo to obtain 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l- (trideuteriomethyl)pyrazole (CXXX) (3.9 g, 18.48 mmol, 249.8% yield) as a white solid which was used for next step without purification. ESIMS found for CioHu FLJBNzCh mlz 212. (M+l).

[0618] Preparation of intermediate fr «5-4-[[fert-butyl(dimethyl)silyl]oxymethyl] cyclohexanecarboxylic acid (CXXXIII) is depicted below in Scheme 29.

Scheme 29

Step 1

[0619] To a mixture of methyl fr «s-4-(hydroxymethyl)cyclohexanecarboxylate (CXXXI) (5.0 g, 29.03 mmol), imidazole (3.95 g, 58.07 mmol), and feri-butyl-chloro-dimethyl- silane (4.81 g, 31.94 mmol) in DMF (50 mL) was stirred at room temperature for 48 h. The solvents were concentrated to 1/2 volume, water (200 mL) was added and extracted with MTBE. The organic layer was separated and washed with 1 N HC1, H 2 0 and brine. The organics were dried over anhydrous Na2SC>4 and the solvent was concentrated to dryness to obtain methyl trans-4-[[tert- butyl(dimethyl)silyl]oxymethyl]cyclohexanecarboxylate (CXXXII) (8.09 g,28.24 mmol, 97.3% yield) as a colorless oil. ESIMS found for Ci 5 H 30 O 3 Si mlz 287.1 (M+l). Step 2

[0620] To a stirred solution of methyl fr «5-4-[[fert-butyl(dimethyl)silyl]oxymethyl] cyclohexanecarboxylate (CXXXII) (8.05 g, 28.1 mmol) in a mixture of THF (20mL) and MeOH (20mL) was added 2 M solution of NaOH (28.1 mL, 56.2 mmol). The mixture was stirred at room temperature for 5 h. The solvent was reduced to 1/3 volume, acidified with 1 N HC1 and the resulting solid was filtered, washed with water and dried under high vacuo to obtain 5 grams of the desired product. The filtrates were extracted with EtOAc (2x), washed with water, brine, dried over anhydrous Na2SOt, concentrated, and dried in vacuo to obtain another 1.1 g of trans-4-[[tert- butyl(dimethyl)silyl]oxymethyl]cyclohexanecarboxylic acid (CXXXIII) (Total 6.1 g, 22.39 mmol, 79.7% yield) as a white solid. ¾ NMR (499 MHz, DMSO-i 6 ) δ ppm 0.01 (6 H, s), 0.83 - 0.87 (8 H, m), 0.88 - 0.96 (2 H, m), 1.19 - 1.32 (2 H, m), 1.32 - 1.43 (1 H, m), 1.74 (2 H, br dd, .7=13.31, 3.16 Hz), 1.84 - 1.94 (2 H, m), 2.09 (1 H, tt, J=12.18, 3.46 Hz), 3.38 (2 H, d, .7=6.31 Hz), 11.98 (1 H, br s); ESIMS found for Ci4¾ 8 0 3 Si mlz 273.1 (M+l).

Example 1.

[0621] Preparation of N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-4- ((l-methylpiperidin-4-yl)oxy)benzamide (145), is depicted below in Scheme 30.

145

Scheme 30

Step 1 [0622] To a solution of 7-bromo-2-chloro-l,6-naphthyridine (VI) (240 mg, 0.99 mmol) in DME (3 mL) and EtOH (4 niL) was added l-methyl-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-pyrazole (CXXXIV) (246 mg, 1.18 mmol), Na 2 C0 3 (313 mg, 2.96 mmol) in water (2 mL). The mixture was purged with argon for 1 min before adding Pd(PPh:,)4 (114 mg, 0.10 mmol). The reaction was heated at 90°C for 16 h. The reaction was washed with EtO Ac -brine and purified by silica column chromatography (0→100% EtOAc-hexanes) to give 7-bromo-2-(l- methyl-lH-pyrazol-4-yl)-l,6-naphthyridine (CXXXV) as a yellow solid (85 mg, 0.29 mmol, 29.8% yield). MS: 290.0 (M+l). Ή NMR (499 MHz, DMSO-d 6 ) δ ppm 3.94 (3H, s), 8.00 - 8.06 (2 H, m), 8.24 (1 H, s), 8.53 (1 H, dd, J=8.78, 0.82 Hz), 8.57 (1 H, s), 9.11 (1 H, s); ESIMS found for Ci 2 H 9 BrN 4 mlz 289.0 (M+l).

Step 2

[0623] To a microwave tube was added 7-bromo-2-(l -methyl- lH-pyrazol-4-yl)-l, 6- naphthyridine (CXXXV) (84 mg, 0.29 mmol), 4-((l-methylpiperidin-4-yl)oxy)benzamide (CXXXVI) (81.7 mg, 0.35 mmol), cesium carbonate (189 mg, 0.58 mmol), XantPhos (33.6 mg, 0.06 mmol), and Pd 2 (dba) 3 (26.6 mg, 0.03 mmol) and 1,4-dioxane (2 mL). Argon gas was bubbled into the mixture for 1 min and then the mixture was heated under microwave irradiation at 1 10°C for 40 min. The reaction mixture was washed with EtO Ac-brine. The organics were combined and dried over Na 2 S04, concentrated in vacuo and the crude was purified by prep TLC (10% NH 3 /MeOH in CHC1 3 ). The pure fraction band were cut and washed with 10% NH 3 /MeOH in CHCL and filtered. The solvent was concentrated and dried under high vacuo to obtain 4-[(l- methyl-4-piperidyl)oxy] -N-[2-(l -methylpyrazol-4-yl)- 1 ,6-naphthyridin-7-yl]benzamide 145 (12.8 mg, 0.03 mmol, 10.0% yield) as a yellow solid. ¾ NMR (499 MHz, DMSO-t4) δ ppm 1.62 - 1.72 (2 H, m), 1.91 - 2.01 (2 H, m), 2.14 - 2.25 (2 H, m), 2.18 (3 H, s), 2.57 - 2.66 (2 H, m), 3.94 (3 H, s), 4.51 (1 H, tt, J=8.20, 4.01 Hz), 7.03 - 7.09 (2 H, m), 7.84 (1 H, d, J=8.78 Hz), 8.07 (2 H, d, J=8.78 Hz), 8.24 (1 H, d, J=0.82 Hz), 8.43 (1 H, dd, J=8.51, 0.82 Hz), 8.58 (1 H, s), 8.62 (1 H, s), 9.13 (1 H, d, J=0.82 Hz), 10.78 (1 H, s); ESIMS found for C 25 H 26 N 6 0 2 mlz 443.2 (M+l).

Example 2.

[0624] Preparation of (S)-N-(2-(l -methyl-lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)- 2-(2-methylpyrrolidin-l-yl)acetamide (47), is depicted below in Scheme 31.

Scheme 31

Step 1

[0625] To a stirred solution of 2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7- amine (CXXXVII) (50 mg, 0.22 mmol) and TEA (80 μί, 0.55 mmol) in dry THF (5 n L) was chloroacetic anhydride (45.5 mg, 0.27 mmol) and the mixture was heated with microwave irradiation at 70°C for 1 h. (2S)-2-Methylpyrrolidine (CXXXVIII) (38 mg, 0.44 mmol) was then added and the mixture was stirred at 70°C for 12 h. Reaction mixture was concentrated and the resulting crude was purified by column chromatography (0→10% 7N N¾ in MeOH/CHC ). The pure fractions were collected and concentrated the resulting solid was triturated with EtOAc to obtain (S)-N-(2-(l -methyl- lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(2-methylpyrrolidi n-l - yl)acetamide 47 as a beige solid (30 mg, 0.09 mmol, 38.6% yield). 'H NMR (499 MHz, DMSO- c¾) 6 ppm 1.09 (3 H, d, J=6.04 Hz), 1.41 (1 H, dddd, J=12.25, 10.33, 8.44, 6.31 Hz), 1.68 - 1.84 (2

H, m), 1.91 - 2.01 (1 H, m), 2.40 (1 H, q, J=8.69 Hz), 2.56 - 2.66 (1 H, m), 3.14 (1 H, d, J=16.19 Hz), 3.13 - 3.20 (1 H, m), 3.56 (1 H, d, J=16.19 Hz), 3.93 (3 H, s), 7.84 (1 H, d, .7=8.51 Hz), 8.23 (1 H, s), 8.41 (1 H, d, J=8.78 Hz), 8.48 (1 H, s), 8.58 (1 H, s), 9.07 (1 H, s), 10.02 (1 H, s); ESIMS found for C mlz 351.2 (M+l).

Example 3.

[0626] Preparation of frara-4-amino-N-(2-(l -methyl- lH-pyrazol-4-yl)-l, 6- naphthyridin-7-yl)cyclohexane-l-carboxamide (41) and fraras-N-(2-(l-methyl-lH-pyrazol-4-yl)-

I, 6-naphthyridin-7-yl)-4-mo holinocyclohexane-l-carboxamide (5) are depicted below in Scheme 32.

Scheme 32

Step 1

[0627] A mixture of irara-4-((fer^butox}'carbonyl)amino)cyclohexane-l-carboxylic acid (CXXXIX) (supplier: CombiBlocks) (324 mg, 1.33 mmol), DIEA (0.58 mL, 3.33 mmol) and HATU (506 mg, 1.33 mmol) in DMF (4 mL) was stirred for 5 min before adding 2-(l-methyl-lH- pyrazol-4-yl)-l,6-naphthyridin-7-amine (CXXXVII) (250 mg, 1.11 mmol) and the mixture was heated to 80°C overnight. The reaction mixture was diluted with water, extracted with EtOAc, washed with saturated aqueous NaHC03, and brine. The organics were separated and concentrated in vacuo. The residue was suspended in EtOAc, sonicated and the solids were collected by filtration and dried under high vacuo to obtain terf-butyl (fra?2s-4-((2-(l-methyl-lH-pyrazol-4-yl)-l,6- naphthyridin-7-yl)carbamoyl)cyclohexyl) carbamate (CXL) as an off-white solid (304 mg, 0.67 mmol, 60.8% yield). ¾ NMR (499 MHz, DMSO-£¾) δ ppm 1.15 - 1.26 (2 H, m), 1.39 (9 H, s), 1 .43 - 1 .54 (2 H, m), 1 .86 (4 H, br t, .7=13.17 Hz), 2.44 - 2 49 (1 H, m), 3.17 - 3.26 (1 H, m), 3.93 (3 H, s), 6.75 (1 H, br d, J=7.68 Hz), 7.81 (1 H, d, J=8.51 Hz), 8.21 (1 H, s), 8.36 - 8.41 (1 H, m), 8.46 (1 H, s), 8.55 (1 H, s), 9.05 (1 H, s), 10.57 (1 H, s); ESIMS found for C 2 4H 30 N 6 O 3 mlz 451.3 (M+l).

Step 2

[0628] To a stirred solution of tert-butyl (fr « , -4-((2-(l-methyl-lH-pyrazol-4-yl)- l,6-naphthyridin-7-yl)carbamoyl)cyclohexyl) carbamate (CXL) (300 mg, 0.67 mmol) in DCM (3 mL) was added TFA (1.0 mL, 12.98 mmol) and the mixture was stirred for 1 h. The solvent was concentrated, treated with 7N NH3/MeOH, absorbed on silica gel and was purified by ISCO (10→100% CHC1 3 /10% 7 N NH 3 Me OH in CHC1 3 ) to obtain fra«s-4-amino-N-(2-(l-methyl-lH- pyrazol-4-yl)-l,6-naphthyridin-7-yl)cyclohexane-l-carboxamid e 41 as a white solid (233 mg, 0.66 mmol, 99.9% yield). ¾ NMR (499 MHz, DMSO-c¾) δ ppm 1.00 - 1.10 (2 H, m), 1.48 (2 H, qd, J=12.85, 3.16 Hz), 1.79 - 1.87 (4 H, m), 2.44 - 2.55 (2 H, m), 3.93 (3 H, s), 7.80 (1 H, d, J=8.51 Hz), 8.21 (1 H, s), 8.38 (1 H, dd, J=8.60, 0.50 Hz), 8.47 (1 H, s), 8.55 (1 H, s), 9.05 (1 H, s), 10.57 (1 H, s); ESIMS found for C mlz 351.2 (M+l).

Step 3

[0629] A mixture of irara -4-amino-N-(2-(l -methyl- lH-pyrazol-4-yl)-l, 6- naphthyridin-7-yl)cyclohexane-l-carboxamide 41 (110 mg, 0.31 mmol), l-bromo-2-(2- bromoethoxy)ethane (CXLI) (80.1 mg, 0.35 mmol), and DIPEA (137 μ]_, 0.79 mmol) in MeCN (2 mL) was stirred at 90°C for 24 h. The solvents were concentrated, and the residue taken in CHCI3, washed with water and brine. The organic layer was dried over anhydrous Na2SC>4 and evaporated to dryness under vacuum. The crude product was purified by preparative TLC (60% CHC¾/10% 7 N NH 3 Me OH in CHCI3) to obtain ?ra«i-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl )- 4-moφholinocyclohexane-l-carboxamide 5 as an off -white solid (89 mg, 0.21 mmol, 67.4% yield). ¾ NMR (499 MHz, DMSO-d 6 ) δ ppm 1.16 - 1.29 (2 H, m), 1.43 - 1.56 (2 H, m), 1.87 - 1.97 (4 H, m), 2.18 - 2.26 (1 H, m), 2.45 - 2.49 (4 H, m), 2.51 - 2.54 (1 H, m), 3.53 - 3.59 (4 H, m), 3.93 (3 H, s), 7.80 (1 H, d, J=8.51 Hz), 8.21 (1 H, s), 8.38 (1 H, d, J=8.78 Hz), 8.47 (1 H, s), 8.55 (1 H, s), 9.05 (1 H, s), 10.58 (1 H, s); ESIMS found for C mlz 421.3 (M+l).

Example 4.

[0630] Preparation of N-(2-(6-(isopropylamino)pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl)- l-(piperidin-4-yl)-lH-l,2,3-triazole-4-carboxamide (862) and l-(l-(2-fluoroethyl)piperidin-4-yl)- N -(2-(6-(isopropylamino)pyrazin-2-yl)- 1 ,6-naphthyridin-7-yl)- lH-1 ,2,3 -triazole-4-carboxamide (863) are depicted below in Scheme 33.

862 863

Scheme 33

Step 1

[0631] To a microwave tube was added bis(tributyltin) (0.76 mL, 1.5 mmol), Pd(PPh3)4 (26 mg, 0.02 mmol), and 1,4-dioxane (10 mL). The mixture was purged with argon for 1 min before adding 6-bromo-N-isopropylpyrazin-2 -amine (LXXVIII) (221 mg, 1.02 mmol) and LiCl (130 mg, 3.07 mmol). The reaction was heated microwave irradiation at 120°C for 1 h. The reaction was washed with saturated NaHCC -EtOAc. The organic layers were dried the product was purified by silica column (0→70% [20% 7N NH 3 -MeOH/EtOAc]/hexanes) to produce N- isopropyl-6-(tributylstannyl)pyrazin-2 -amine (CXLII) as a white solid (302 mg, 0.71 mmol, 69.3% yield). ESIMS found for Ci 9 H 3 -N 3 Sn mlz 428.1 (M+l).

Step 2

[0632] To a sealed tube was added N-isopropyl-6-(tributylstannyl)pyrazin-2 -amine (CXLII) (285 mg, 0.67 mmol), 2-chloro-l,6-naphthyridin-7-amine (IX) (120 mg, 0.67 mmol), and DMF (2 mL). The mixture was purged with argon for 1 min before adding Cul (25.4 mg, 0.13 mmol) and Pd(PPh 3 )4 (77.5 mg, 0.07 mmol). The reaction was heated using microwave irradiation at 125°C for 1 h. The reaction was worked-up with saturated NaHC03-EtOAc extraction. The organic layers were separated, dried over NaSCH and evaporated to dryness. The residue was purified by silica column (0→70% [20% 7N NH 3 -MeOH/EtOAc]/hexanes) to produce 2-(6- (isopropylamino) pyrazin-2-yl)-l,6-naphthyndm-7-amme (CXLIII) as a black wax (70 mg, 0.25 mmol, 37.4% yield). ESIMS found for Ci 5 Hi 6 N 6 mlz 281.2 (M+l).

Step 3

[0633] To a solution of 2-(6-(isopropylamino)pyrazin-2-yl)-l,6-naphthyridin-7- amine (CXLIII) (70 mg, 0.25 mmol) in pyridine (3 mL) was added lH-l,2,3-triazole-4-carbonyl chloride (CXLIV) (59 mg, 0.45 mmol). The reaction was stirred at room temperature for 4 h. The reaction was worked-up with saturated NaHCC -EtOAc extraction. The organic layers were separated, dried over NaSC>4 and evaporated to dryness. The residue was purified by silica column (0→20% 7 N NH 3 in MeOH-CHCl 3 ) to give N-(2-(6-(isopropylamino)pyrazin-2-yl)-l,6- naphthyridin-7-yl)-lH-l,2,3-triazole-4-carboxamide (CXLV) as a white solid (9 mg, 0.02 mmol, 9.6% yield). ESIMS found for Ci 8 Hi 7 N 9 0 mlz 376.2 (M+l).

Step 4

[0634] To a suspension of N-(2-(6-(isopropylamino)pyrazin-2-yl)-l,6-naphthyridin- 7-yl)-lH-l,2,3-triazole-4-carboxamide (CXLV) (22 mg, 0.06 mmol) in DMF (1 mL) at 0°C under argon was added NaH (8.4 mg, 0.21 mmol). After stirring for 15 min, tert-butyl 4- ((methylsulfonyl)oxy)piperidine-l-carboxylate (CXL I) (20 mg, 0.07 mmol) was added and the mixture stirred at 80°C for 4 h. The reaction was poured into water and extracted with EtOAc. The organic layer was washed with brine; dried over Na2S04, filtered and concentrated. The crude product was purified by silica gel chromatography (0→70% EtOAc/hexanes) to afford fert-butyl 4-(4-((2-(6-(isopropylamino)pyrazin-2-yl)-l,6-naphthyridin-7 -yl)carbamoyl)-lH-l,2,3 riazo yl) piperidine-l-carboxylate (CXLVII) as a white solid (9 mg, 0.02 mmol, 27.5% yield). ESIMS found for C 2 8H 34 io0 3 mlz 559.3 (M+l).

Step 5

[0635] To a solution of tert-butyl 4-(4-((2-(6-(isopropylamino)pyrazin-2-yl)-l,6- naphthyridin-7-yl)carbamoyl)-lH-l,2,3-triazol-l-yl) piperidine-l-carboxylate (CXLVII) (9 mg, 0.02 mmol) in DCM (2 mL) was added TFA (6.3 μί, 0.08 mmol). The solution was stirred at room temperature for 2 h. The reaction was worked-up with 2 N aqueous NaOH/EtOAc extraction. The organic layers were separated, dried over NaSC and evaporated to dryness. The residue was purified by column chromatography (0→20% 7N NH 3 -MeOH/CHCl 3 ) to yield N-(2-(6- (isopropylamino)pyrazin-2-yl)-l ,6-naphthyridin-7-yl)- 1 -(piperidin-4-yl)-lH- 1 ,2,3-triazole-4- carboxamide 862 as a yellow solid (2.2 mg, 0.005 mmol, 28.3% yield). Ή NMR (499 MHz, METHANOLS) δ ppm 1.33 (6 H, d, J=6.59 Hz), 2.16 - 2.25 (2 H, m), 2.27 - 2.35 (2 H, m), 2.85 - 2.93 (2 H, m), 3.26 (2 H, dt, J=13.04, 3.50 Hz), 4.31 (1 H, spt, J=6.40 Hz), 4.78 - 4.83 (1 H, m), 7.94 (1 H, s), 8.28 (1 H, s), 8.49 - 8.54 (1 H, m), 8.54 - 8.59 (1 H, m), 8.83 (1 H, s), 8.85 (1 H, s), 9.19 (1 H, s); ESIMS found for C 23 H 2 6NioO mlz 459.3 (M+l).

Step 6

[0636] A suspension of N-(2-(6-(isopropylamino)pyrazin-2-yl)-l,6-naphthyridin-7- yl)-l-(piperidm-4-yl)-lH-l,2,3-triazole-4-carboxamide 862 (9 mg, 0.02 mmol), DIPEA (10.3 μΕ, 0.06 mmol) and l-fluoro-2-iodo-ethane (CXLVIII) (3.2 μΐ, 0.04 mmol) in MeCN (2 mL) was heated with microwave irradiation in a sealed tube at 110°C for 30 min. The mixture was concentrated, and the crude product purified by column chromatography (0→5% 7 N NH 3 - MeOH/CHCh). The fractions containing the product were concentrated and the residue triturated in ether and the resulting solid was filtered and dried to afford l-(l-(2-fluoroethyl)piperidin-4-yl)- N-(2-(6-(isopropylamino) pyrazin-2-yl)-l ,6-naphthyridin-7-yl)- 1H- 1 ,2,3 -triazole-4-carboxamide 863 as a yellow solid (1.1 mg, 0.002 mmol, 11.1% yield). Ή NMR (499 MHz, METHANOL-^) δ ppm 1.33 (6 H, d, J=6.59 Hz), 2.25 - 2.38 (4 H, m), 2.40 - 2.49 (2 H, m), 2.80 (2 H, dt, J=28.40, 4.70 Hz), 3.10 - 3.15 (2 H, m), 4.30 (1 H, dt, .7=13.00, 6.60 Hz), 4.62 (2 H, dt, .7=47.90, 4.70 Hz), 7.94 (1 H, s), 8.27 (1 H, s), 8.51 - 8.54 (1 H, m), 8.55 (1 H, s), 8.83 (1 H, s), 8.84 (1 H, s), 9.19 (1 H, s); ESEVIS found for C 25 H 2y FNi 0 O mlz 505.3 (M+l).

Example 5 [0637] Preparation of N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4- carboxamide (918) and l-isobutyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)pi peridine-4- carboxamide (923) are depicted below in Scheme 34.

CLI

Scheme 34

Step 1

[0638] A mixture of 7-bromoquinazolin-2 -amine (CXLIX) (Supplier: CombiBlocks) (2.01 g, 8.97 mmol), l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazole (XCXXXIV) (2.33 g, 11.21 mmol), Pd(dppf)Cl 2 (1.32 g, 1.61 mmol), and K 3 P0 4 (11.21 mL, 22.41 mmol) in 1,4-dioxane (35 mL) was purged with 2 gas for 15 min and then was heated to 90°C for 16 h. The reaction mixture was added to water (300 mL), stirred for 1 h. The precipitate was collected by filtration and purified by ISCO (25→ 100% CHC1 3 /10% 7N NH 3 MeOH in CHCL) to obtain 7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2 -amine (CL) as a grey solid (1.4 g, 6.22 mmol, 69.3% yield). ESIMS found for Ci 2 HnN 5 mlz 226 A (M+l).

Step 2

[0639] To a stirred solution of l-(rerf-butoxycarbonyl)piperidine-4-carboxylic acid (CLI) (309.5 mg, 1.35 mmol) in DCM (5 mL) was added TEA (0.38 mL, 2.7 mmol) and few drops of DMF followed by the addition of oxalvl chloride (0.23 mL, 2.7 mmol) at 0°C. The reaction mixture was stirred for 2 h allowing the temperature to warm from 0 °C to room temperature. The solvent was concentrated and dried under high vacuo to obtain the acid chloride (CLII). [0640] The acid chloride obtained above in DCE was added to a stirring mixture of 7- (1 -methyl- lH-pyrazol-4-yl)quinazolin-2 -amine (CL) (150 mg, 0.67 mmol), TEA (0.38 mL, 2.7 mmol) and DMAP (33 mg, 0.27 mmol) in THF (5 mL). The mixture was heated to 50°C overnight. The reaction mixture was absorbed on silica gel and purified by ISCO (10→50% CHCL/10% 7N NH 3 Me OH in CHC1 3 ) to obtain fert-butyl 4-((7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2- yl)carbamoyl)piperidine-l-carboxylate (CLIII) as a light brown solid (109 mg, 0.25 mmol, 18.5% yield). ESIMS found for C 23 H28N 6 0 3 mlz 437.2 (M+l).

Step 3

[0641] To a stirred solution of fert-butyl 4-((7-( l-methyl-lH-pyrazol-4-yl)quinazolin- 2-yl)carbamoyl)piperidine-l-carboxylate (CLIII) (100 mg, 0.23 mmol) in DCM (1 mL) was added TFA (0.5 mL, 6.49 mmol) and the mixture was stirred for 1 h. The solvent was concentrated, treated with 7N NLL/MeOH, absorbed on silica gel and was purified by column chromatography (10→100% CHC1 3 /10% 7N NH 3 Me OH in CHC1 3 ). The pure fractions were combined, concentrated, and dried under high vacuo to obtain N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2- yl)piperidine-4-carboxamide 918 as a beige solid (57 mg, 0.17 mmol, 74.0% yield). ¾ NMR (499 MHz, DMSO-c/fi) δ ppm 1.50 (2 H, qd, J=12.17, 3.84 Hz), 1.72 (2 H, br d, J=l 1.53 Hz), 2.45 - 2.53 (2 H, m), 2.74 - 2.83 (1 H, m), 2.97 (2 H, br d, J=12.08 Hz), 3.91 (3 H, s), 7.82 (1 H, dd, J=8.23, 1.65 Hz), 7.91 (1 H, s), 8.01 (1 H, d, J=8.23 Hz), 8.14 (1 H, s), 8.45 (1 H, s), 9.34 (1 H, s), 10.53 (1 H, s); ESIMS found for Ci 8 H 2 oN 6 0 mlz 337.2 (M+l).

Step 4

[0642] To a stirred solution of N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl) piperidine-4-carboxamide 918 (50 mg, 0.15 mmol) and isobutyraldehyde (CLIV) (0.02 mL, 0.22 mmol) in a mixture of MeOH (0.75 mL) and DCE (0.75 mL) was added Na(OAc) 3 BH (63 mg, 0.30 mmol). The mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with DCM, washed with saturated NaHC0 3 and brine solution. The organics were dried over anhydrous Na2S04, solvents concentrated, and the residue was purified by preparative TLC (50% CHC1 3 /10% 7N NH 3 MeOH in CHC1 3 ) to obtain l-isobutyl-N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolm-2- yl)piperidine-4-carboxamide 923 as a white solid (18.0 mg, 0.046 mmol, 30.9% yield). *H NMR (499 MHz, DMSO-ifc) δ ppm 0.86 (6 H, d, J=6.59 Hz), 1.59 - 1.70 (2 H, m), 1.72 - 1.83 (3 H, m), 1.85 - 1.93 (2 H, m), 2.02 (2 H, d, J=7.41 Hz), 2.62 - 2.72 (1 H, m), 2.86 (2 H, br d, J=l 1.53 Hz), 3.91 (3 H, s), 7.83 (1 H, dd, J=8.51, 1.65 Hz), 7.91 (1 H, s), 8.01 (1 H, d, J=8.23 Hz), 8.14 (1 H, s), 8.45 (1 H, s), 9.35 (1 H, s), 10.58 (1 H, s); ESIMS found for C 2 2H 2 8N 6 0 mlz 393.2 (M+l). Example 6.

[0643] Preparation of N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1- (methylsulfonyl)piperidine-4-carboxamide (979) and N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin- 2-yl)- -(pyrimidin-2-ylmethyl)piperidine-4-carboxamide (1007) are depicted below in Scheme 35.

1007

Scheme 35

Step 1

[0644] A mixture of N-(7-(l -methyl-lH-pyrazol-4-}'l)quinazolin-2-yl)piperidine-4- carboxamide 918 (60 mg, 0.18 mmol), methanesulfonyl chloride (20 μί, 0.19 mmol) and DIPEA (80 μί, 0.45 mmol) in DCM (1 mL) was stirred at room temperature for 24 h. The reaction mixture was diluted with EtOAc, washed with water, brine, dried over anhydrous Na2S04, and concentrated. The crude product was purified by preparative TLC (60% 10% 7 N NH 3 MeOH in CHC1 3 /CHC1 3 ) to obtain N-(7 -( 1 -methyl- 1 H-pyrazol -4 -yl)quinazolin-2-yl) - 1 -(methylsulfonyl)piperidine -4 - carboxamide 979 as a beige solid (2 mg, 0.005 mmol, 2.6% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.62 - 1.72 (2 H, m), 1.97 (2 H, br dd, J=13.17, 2.74 Hz), 2.78 (2 H, td, .7=11.94, 2.47 Hz), 2.82 - 2.88 (1 H, m), 2.90 (3 H, s), 3.59 - 3.66 (2 H, m), 3.91 (3 H, s), 7.84 (1 H, dd, J=8.51, 1.65 Hz), 7.92 (1 H, d, .7=0.82 Hz), 8.02 (1 H, d, .7=8.51 Hz), 8.15 (1 H, d, J=0.82 Hz), 8.45 (1 H, s), 9.36 (1 H, s), 10.72 (1 H, s); ESIMS found for Ci 9 H 2 2N 6 0 3 S m/z 415.1 (M+l).

Step 2 [0645] A mixture of N-(7-(l -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)piperidine-4- carboxamide 918 (60 mg, 0.18 mmol), 2-(chloromethyl)pyrimidine (CLV) (34.4 mg, 0.27 mmol) and DIPEA (90 μί, 0.53 mmol) in DMF (0.75 mL) was stirred at 75°C for 24 h. The reaction mixture was diluted with EtOAc, washed with water, brine, dried over anhydrous Na2SC>4, and concentrated. The crude product was purified by preparative TLC (60% 10% 7 N NH 3 MeOH in CHCI3/CHCI3) to give N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-l-(pyrimidin -2- ylmethyl)piperidine-4-carboxamide 1007 as a beige solid (23 mg, 0.05 mmol, 28.6% yield). ¾ NMR (499 MHz, DMSO-d 6 ) δ ppm 1.65 (2 H, qd, J= 12.21, 3.70 Hz), 1.79 (2 H, br d, J=10.70 Hz), 2.12 - 2.22 (2 H, m), 2.61 - 2.69 (1 H, m), 2.95 (2 H, br d, J=l 1.53 Hz), 3.72 (2 H, s), 3.91 (3 H, s), 7.40 (1 H, t, J=4.94 Hz), 7.82 (1 H, dd, J=8.51, 1.65 Hz), 7.91 (1 H, s), 8.01 (1 H, d, J=8.23 Hz), 8.14 (1 H, s), 8.44 (1 H, s), 8.79 (2 H, d, J=4.94 Hz), 9.34 (1 H, s); ESIMS found for C 23 H 24 N 8 0 m!z 429.2 (M+l).

Example 7.

[0646] Preparation of fro« , -4-(hydroxymethyl)-N-(7-(thiazol-5-yl)quinazolin-2- yl)cyclohexane-l-carboxamide (4586) and fr «5 , -4-((3-fluoroazetidin-l-yl)methyl)-N-(7-(thiazol- 5-yl)quinazolin-2-yl)cyclohexane-l-carboxamide (1519) are depicted below in Scheme 36.

CLVI

CLIX 1519

Scheme 36

Step 1

[0647] To a sealed tube was added 5-(tributylstannyl)thiazole (CLVI) (supplier: CombiBlocks) (1.32 g, 3.51 mmol), copper(I)iodide (60 mg, 0.33 mmol), 2-amino-7- bromoquinazoline (CXLIX) (750 mg, 3.35 mmol) and PPh 3 (390 mg, 0.33 mmol) in DMF (12 mL). The mixture was purged with nitrogen for 1 min and then stirred at 110°C for 16h. The reaction was cooled to room temperature and filtered through Celite ® . The filtrate was concentrated, and the residue purified by chromatography (0→15% 7 N NFfe-MeOH/CHCh). The fractions containing the product were concentrated, suspended in CHCI3, the solid was collected by filtration and dried under high vacuo to afford 7-(thiazol-5-yl)quinazolin-2 -amine (CLVII) as a brown solid (410 mg, 1.80 mmol, 53.7% yield). ESIMS found for CnH 8 N 4 S mlz 229.0 (M+l).

Step 2

[0648] A mixture of DIPEA (0.94 mL, 5.39 mmol), DMAP (0.04 g, 0.36 mmol), HATU (0.85 g, 2.25 mmol), frara-4-(((tert-butyldimethylsilyl)oxy)methyl)cyclohexane-l- carboxylic acid (CXXXIII) (0.61 g, 2.25 mmol) and 7-(thiazol-5-yl)quinazolin-2 -amine (CLVII) (0.41 g, 1.8 mmol) in DMF (10 mL) was stirred at 70°C for 2 h. Then another equivalent of HATU was added and the mixture was stirred for another 2 h at the same temperature . The reaction mixture was then concentrated and the residue absorbed on silica and purified by ISCO (10→100% EtOAc/hexanes) to obtain ir «i-4-(((teri-butyldimethylsilyl)oxy)methyl)-N-(7-(thiazol-5 - yl)quinazolin-2-yl) cyclohexane-l-carboxamide (CLVIII) as an off-white solid (425 mg, 0.88 mmol, 49.0% yield) which was used without further purification for the next step. ESIMS found for C 25 H34N 4 02SSi mlz 483.2 (M+l).

Step 3

[0649] To a solution of fr ra-4-(((teri-butyldimethylsilyl)oxy)methyl)-N-(7-(thiazol- 5-yl)quinazolin-2-yl)cyclohexane-l-carboxamide (CLVIII) (0.43 g, 0.88 mmol) in THF (5 mL) was added 1 M solution of TBAF (1.32 mL, 1.32 mmol). The mixture was stirred at room temperature for 16 h. The reaction mixture was absorbed on silica gel and was purified by chromatography (10→100% CHC1 3 /10% 7 N NH 3 MeOH in CHC1 3 ) to obtain transA- (hydroxymethyl)-N-(7-(thiazol-5-yl)quinazolin-2-yl)cyclohexa ne-l-carboxamide 4586 as an off- white solid (125 mg, 0.34 mmol, 38.5% yield). ¾ NMR (499 MHz, DMSO- 6 ) δ ppm 0.92 - 1.01 (2 H, m), 1.26 - 1.36 (1 H, m), 1.37 - 1.48 (2 H, m), 1.80 (2 H, br dd, .7=12.90, 2.47 Hz), 1.87 - 1.93 (2 H, m), 2.58 - 2.67 (1 H, m), 3.24 (2 H, t, J=5.76 Hz), 4.39 (1 H, t, .7=5.21 Hz), 7.95 (1 H, dd, J=8.51, 1.65 Hz), 7.99 - 8.03 (1 H, m), 8.12 (1 H, d, .7=8.51 Hz), 8.65 (1 H, s), 9.24 (1 H, s), 9.47 (1 H, d, J=0.82 Hz), 10.67 (1 H, s); ESIMS found for C19H20N4O2S mlz 369.1 (M+l).

Step 4

[0650] A suspension of Dess-Martin periodinane (120 mg, 0.29 mmol) and trans-4- (hydroxymethyl)-N-(7-(thiazol-5-yl)quinazolin-2-yl)cyclohexa ne-l-carboxamide 4586 (70 mg, 0.19 mmol) in a mixture of DCM (6 mL) and DMF (0.50 mL) was stirred at room temperature over the weekend. The reaction mixture was filtered, the solid was washed with DCM, and dried under high vacuo to obtain crude fr « , -4-formyl-N-(7-(thiazol-5-yl)quinazolin-2-yl)cyclohexa ne-l- carboxamide (CLIX) as an off-white color solid (62.6 mg, 0.17 mmol, 89.9% yield) which was used for next step without further purification. ESIMS found for C19H18N4O2S mlz 367.1 (M+l).

Step 5

[0651] A mixture of 3-fluoroazetidine hydrochloride (CLX) (30 mg, 0.28 mmol), fr «5-4-formyl-N-(7-(thiazol-5-yl)quinazolin-2-yl)cyclohexane- l-carboxamide (CLIX) (70 mg, 0.19 mmol) and TEA (0.04 mL, 0.29 mmol) in DCE (1.5 mL) was stirred for 20 min. Na(OAc) 3 BH (60 mg, 0.28 mmol) was then added and the mixture was stirred at room temperature overnight. The reaction mixture was absorbed on silica gel and was purified by ISCO (10→80% CHC /10% 7 N NH3 MeOH in CHCI3). The pure fraction was concentrated, the residue suspended in CHCI3, the solid was collected by filtration, and dried under high vacuo to obtain trans A-{( - fluoroazetidin-1 -yl)methyl)-N-(7-(thiazol-5 -yl)quinazolin-2-yl)cyclohexane- 1 -carboxamide 1519 as an off-white solid (30 mg, 0.07 mmol, 37.4% yield). ¾ NMR (499 MHz, DMSO-J 6 ) δ ppm 0.92 (2 H, qd, J=12.72, 3.29 Hz), 1.22 - 1.32 (1 H, m), 1.40 (2 H, qd, .7=12.76, 3.16 Hz), 1.80 (2 H, br dd, .7=13.04, 2.88 Hz), 1.88 (2 H, br d, J=10.70 Hz), 2.29 (2 H, d, J=6.86 Hz), 2.58 - 2.66 (1 H, m), 2.97 - 3.08 (2 H, m), 3.49 - 3.59 (2 H, m), 5.12 (1 H, dqum, J=58.00, 5.00, 5.00, 5.00, 5.00 Hz), 7.95 (1 H, dd, J=8.37, 1.78 Hz), 8.00 (1 H, d, .7=1.65 Hz), 8.12 (1 H, d, .7=8.23 Hz), 8.65 (1 H, s), 9.24 (1 H, s), 9.46 (1 H, s), 10.66 (1 H, s); ESIMS found for C22H24FN5OS mlz 426.2 (M+l).

Example 8.

[0652] Preparation of N-(7-(2-aminothiazol-5-yl)quinazolin-2-yl)-2-(4- methylpiperazin-l-yl)isonicotinamide (1589) is depicted below in Scheme 37.

1589

Scheme 37

Steps 1-2

[0653] A mixture of KOAc (130 mg, 1.32 mmol), Pd(dppf)Cl 2 (36.5 mg, 0.04 mmol), 2-amino-7-bromoquinazoline (CXLIX) (supplier: CombiBlocks) (100 mg, 0.45 mmol), and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (170 mg, 0.67 mmol) in 1,4-dioxane (4 mL) was added to a microwave vial purged with Argon for 1 min. The reaction was heated with microwave irradiation at 90°C for 2 h. tert-Butyl (5-bromothiazol-2-yl)(4-methoxybenzyl) carbamate (LXIV) (178 mg, 0.45 mmol), Pd(dppf)Cl 2 (36.5 mg, 0.04 mmol), and K 3 P0 4 (2 M in water) (0.68 mL, 1.36 mmol) were added and the mixture was purged with Argon for 1 min. The vial was resealed, and the mixture was heated with microwave irradiation at 120°C for 30 min. The solvent was removed under vacuum and the residue was purified by silica gel column chromatography (12g) (0→10% 1.7 n H 3 in MeOH/CHCfe) to produce tert-butyl (5-(2- aminoquinazolin-7-yl)thiazol-2-yl)(4-methoxybenzyl) carbamate (CLXI) as a tan solid ( 100 mg, 0.22 mmol, 48.3% yield). ESIMS found for C 2 4H25N 5 0 3 S mlz 464.2 (M+l).

Step 3-4

[0654] To a suspension of 2-(4-methylpiperazin-l -yl)isonicotinic acid (CLXIII) (supplier: Enamine) (127 mg, 0.43 mmol) in DCM (3 mL) was added oxalyl chloride (60 μΕ, 0.69 mmol) followed by 2 drops of DMF. The mixture was stirred at room temperature for 3 h and concentrated. The crude acid chloride (CLXIV) was used in the next step without purification. To the residue was added pyridine (3 mL) followed by ferf-butyl (5-(2-aminoquinazolin-7-yl)thiazol- 2-yl)(4-methoxybenzyl) carbamate (CLXII) (100 mg, 0.22 mmol) and the reaction was stirred at 60°C for 16 h. The solvent was stripped, and the residue was purified by silica gel column chromatography (12g) (0→10% 1.7N NH 3 in MeOH/CHCl 3 ) to produce ferf-butyl (4- methoxybenzyl)(5-(2-(2-(4-methylpiperazin-l-yl)isonicotinami do)quinazolin-7-yl)thiazol-2- yl)carbamate (CLXV) as a tan solid (62 mg, 0.09 mmol, 43.1% yield). ESIMS found for C 35 H 3 gN 8 0 4 S mlz 667.3 (M+l).

Step 5

[0655] A solution of ferf-butyl (4-methoxybenzyl)(5-(2-(2-(4-methylpiperazin-l- yl)isonicotinamido)quinazolin-7-yl)thiazol-2-yl)carbamate (CLXV) (62 mg, 0.09 mmol) in TFA (1 mL) was stirred at 65°C for 16 h. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (12g) (0→15% 1.7N NH 3 in MeOFI/CHCl 3 ) to produce N-(7-(2-Aminothiazol-5-yl)quinazolin-2-yl)-2-(4-methylpipera zin-l - yl)isonicotinamide 1589 as a yellow solid (62.mg, 0.09 mmol, 26.5% yield). 'H NMR (499 MHz, DMSO-t e) δ ppm 2.23 (3 H, s), 2.42 (4 H, t, J=4.94 Hz), 3.55 - 3.63 (4 H, m), 7.09 (1 H, dd, =5.08, 1.23 Hz), 7.38 (1 H, s), 7.55 (3 H, d, J=3.57 Hz), 7.83 (1 H, s), 7.86 (1 H, dd, J=8 64, 1.78 Hz), 8.02 (1 H, d, J=8.51 Hz), 8.25 ( 1 H, d, J=5.21 Hz), 9.41 (1 H, s), 1 1.24 (1 H, br s); ESIMS found for C 22 H 22 N 8 OS mlz 447.2 (M+l).

Example 9.

[0656] Preparation of N-(3-(l -methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2-(4- methylpiperazin-l-yl)isonicotinamide (2867) is depicted below in Scheme 38.

2867

Scheme 38

Step 1

[0657] A mixture of l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazole (CXXXIV) (4.51 g, 21.7 mmol), Pd(dppf)Cl 2 ( 1.18 g, 1.45 mmol), K 3 P0 4 (6.14 g, 28.93 mmol) and 2-(5-bromopyridin-3-yl)acetonitrile (XXXV) (2.85 g, 14.46 mmol) was suspended in a mixture of 1,4-dioxane (60 mL) and water (1 mL). The reaction was purged with Argon for 1 min and then heated to 90°C for 16 h. The organic layer was separated, dried over Na2S04 and evaporated under reduced vacuum. The residue was purified by silica gel column chromatography (12g) (0→8% 1.7 N NH 3 in MeOH/DCM) to produce 2-(5-( l-methyl-lH-pyrazol-4-yl)pyridin-3- yl)acetonitnle (CLXVI) as a brown solid (2.29 g, 1 1.6 mmol, 79.9% yield). ESIMS found for C11H10N4 mlz 199.1 (M+l).

Step 2

[0658] To a round bottom flask was added 2-(5-(l -methyl-lH-pyrazol-4-yl)pyridin- 3-yl)acetonitnle (CLXVI) (2.29 g, 1 1.55 mmol) CHC1 3 (58 mL), followed by the addition of MCPBA (2.79 g, 16.17 mmol). The reaction mixture is stirred at room temperature for 16 h. The LCMS showed incomplete reaction so another 2-[5-(l-methylpyrazol-4-yl)-3-pyndylJacetonitrile (2.29 g, 11.55 mmol) was added and stirred at room temperature for 6 h. The reaction mixture was concentrated under vacuum and the residue was purified by silica gel column chromatography (24g) (0→5% MeOH/CHCl 3 ) to produce 3-(cyanomethyl)-5-(l-methyl-lH-pyrazol-4-yl)pyridine 1-oxide (CLXVII) (1.53 g, 7.14 mmol, 61.8% yield). ESIMS found for CnHi 0 N 4 O mlz 215.1 (M+l).

Step 3

[0659] To a solution of 3-(cyanomethyl)-5-(l-methyl-lH-pyrazol-4-yl)pyridine 1- oxide (CLXVII) (1.54 g, 7.19 mmol) in DCE (14.4 mL) was added TMSCN (0.04 mL, 0.31 mmol), This solution was stirred at room temperature for 5 min before adding dimethylcarbamyl chloride (0.66 mL. 7.19 mmol). The reaction was then heated at 60°C for 1 h. The solvent was removed under vacuum and the product was purified by silica gel (40g) (0→5% MeOH/CHC13) to produce 3-(cyanomethyl)-5-(l-methyl-lH-pyrazol-4-yl)picolinonitrile (CLXVIII) as an off white solid (1.07 g, 4.79 mmol, 66.7% yield). ESIMS found for Ci 2 H 9 N 5 mlz 224.1 (M+l).

Step 4

[0660] A solution of 3-(cyanomethyl)-5-(l-methyl-lH-pyrazol-4-yl)picolinonitrile (CLXVIII) (1.07 g, 4.79 mmol) in HBr (33% in acetic Acid) (4.97 mL, 28.76 mmol) was stirred at 0°C for 1 h. EtOAc was added, the precipitate was filtered, and the organic layer was neutralized with aqueous saturated NaHCC , extracted with EtOAc which was dried overNa2S04. The organic layers were evaporated to dryness under vacuum and the residue purified by silica gel column Chromatography (40g) (0→10% MeOH/CHCl 3 ) to produce 8-bromo-3-(l -methyl- lH-pyrazol-4- yl)-l,7-naphthyridin-6-amine (CLXIX) as a light-yellow solid (180 mg, 1.09 mmol, 12.3% yield). ESIMS found for Ci 2 Hi 0 BrN 5 mlz 304.0 (M+l).

Step 5

[0661] A mixture of 8-bromo-3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6- amine (CLXIX) (181.3 mg, 0.60 mmol), ammonium formate (188 mg. 2.98 mmol) and Pd(PPli3)4 (69 mg, 0.06 mmol) in DMF (3.0 mL) was heated to 50°C for 20 h. The reaction mixture was cooled, and the solvent removed. The crude product was adsorbed onto Celite and purified by silica gel (solid load) column chromatography (40g) (0→10% MeOH CHCb) to produce 3-(l-methyl- lH-pyrazol-4-yl)-l,7-naphthyridin-6-amine (CLXX) as an off-white solid (62 mg, 0.28 mmol, 46.2% yield). ¾ NMR (499 MHz, DMSO-i¾) δ ppm 3.90 (3 H, s), 6.11 (2 H, s), 6.55 (1 H, s), 8.07 (1 H, d, .7=1.92 Hz), 8.09 (1 H, s), 8.40 (1 H, s), 8.80 (1 H, s), 8.82 (1 H, d, J=2.20 Hz); ESIMS found for Ci 2 HnN 5 mlz 226 A (M+l).

Step 6

[0662] To a suspension of 3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphtliyridin-6-amine (CLXX) (61 mg, 0.27 mmol), 2-(4-methylpiperazin-l-yl)isonicotinic acid dihydrochloride (CLXIII) (120 mg, 0.41 mmol), DMAP (33 mg, 0.27 mmol) and HATU (155 mg, 0.41 mmol) in DMF (2.7 mL) was added DIPEA (0.28 mL, 1.62 mmol). The resulting mixture was stirred at 80°C for 16 h. The reaction mixture was cooled to room temperature and poured into water. The resulting solid was filtered and purified by silica gel chromatography (0→10% 1.7 N NH 3 in MeOH/CHCh) to produce N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4- methylpiperazin-l-yl) isonicotinamide 2867 as a tan solid (50.0 mg, 0.117 mmol, 43.1% yield). Ή NMR (499 MHz, DMSO-£¾) δ ppm 2.23 (3 H, s), 2.40 - 2.46 (4 H, m), 3.56 - 3.65 (4 H, m), 3.93 (3 H, s), 7.15 (1 H, dd, .7=5.08, 1.23 Hz), 7.46 (1 H, s), 8.21 (1 H, s), 8.26 (1 H, d, J=4.94 Hz), 8.51 (1 H, s), 8.56 (1 H, d, J=2.20 Hz), 8.65 (1 H, s), 9.21 (1 H, t, .7=0.82 Hz), 9.24 (1 H, d, J=2.20 Hz), 11.20 (1 H, s); ESIMS found for C23H24N8O mlz 429.2 (M+l).

Example 10.

[0663] Preparation of N-(3-(2-methylthiazol-5-yl)-l,7-naphthyridin-6-yl)-l-(oxetan - 3-y

4622

Scheme 39

Step 1 [0664] A mixture of N-(3-bromo-l,7-naphthyridin-6-yl)piperidine-4-carboxamide (CLXXI) (50 mg, 0.15 mmol), oxetan-3-one (CLXXII) (20 μί, 0.59 mmol) and TEA (70 μΐ, 0.50 mmol) in DCE (2 mL) was stirred for 30 min at room temperature, then NaB¾CN (160 mg, 0.75 mmol) was added and the mixture was stirred at 37°C for 5 h. The reaction mixture was concentrated, and the resulting residue was adsorbed on silica gel and then purified by column chromatography (0→10% MeOH/CHCh). Pure fractions were collected and concentrated, and the resulting solid was triturated with DCM/hexane, filtered and dried under high vacuum to obtain N- (3-bromo-1.7-naphthyridin-6-yl)-l-(oxetan-3-yl)piperidine-4- carboxamide (CLXXIII) as a beige solid (52 mg, 0.13 mmol, 89.1% yield). ESIMS found for CnH^BrN^ mlz 391.1 (M+l).

Step 2

[0665] A mixture of N-(3 -bromo- 1 ,7-naphthyridin-6-yl)- 1 -(oxetan-3 -yl)piperidine-4- carboxamide (CLXXIII) (52 mg, 0.13 mmol), 2-methyl-5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)thiazole (CLXXIV) (45 mg, 0.20 mmol), Pd(dppf)Cl 2 (10 mg, 0.01 mmol), and K3PO4 (0.2 mL, 0.40 mmol) in 1,4-dioxane (3 mL) was purged with N 2 gas for 5 min. The reaction mixture was heated with microwave irradiation at 110°C for 30 min. Reaction mixture cooled down to room temperature, the organic layer was separated and concentrated, and the resulting residue was purified by column chromatography (0→10% MeOH/CHC ). The pure fractions were collected and concentrated, and the resulting solid was triturated with DCM, filtered and dried to obtain N-(6-(2-methylthiazol-5-yl)-2,7-naphthyridin-3-yl)-l-(oxetan -3-yl) piperidine-4- carboxamide 4622 as an off-white solid (35 mg, 0.09 mmol, 64.3% yield). ¾ NMR (499 MHz, DMSO ) δ ppm 1.64 - 1.74 (2 H, m), 1.75 - 1.86 (4 H, m), 2.54 - 2.63 (1 H, 111), 2.72 - 2.78 (5 H, m), 3.35 - 3.42 (1 H, m), 4.43 (2 H, t, J=6.17 Hz), 4.53 (2 H, t, J=6.45 Hz), 8.41 (1 H, s), 8.53 (1 H, d, J=1.92 Hz), 8.58 (1 H, s), 9.17 (1 H, s), 9.22 (1 H, d, J=2.20 Hz), 10.72 (1 H, s); ESIMS found for C 21 H 23 N 5 O 2 S mlz 410.15 (M+l).

Example 11.

[0666] Preparation of N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4- methylpiperazin-l-yl)thiazole-5-carboxamide (4632) is depicted below in Scheme 40.

Scheme 40

Step 1

[0667] To a solution of 6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-amine (CLXXV) (100 mg, 0.44 mmol) in pjTidine (4 mL) was added 2-bromothiazole-5-carbonyl chloride (CLXXVI) (120.7 mg, 0.53 mmol). The reaction was stirred at room temperature for 18 h and worked-up with saturated NaHCC -EtOAc extraction. The organic layers were combined, dried over azSCH, and evaporated to dryness. The residue was purified by silica column (0→10% 7 N NH 3 MeOH/CHCls) to produce 2-bromo-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin- 3-yl)thiazole-5-carboxamide (CLXXII) as a white solid (107 mg, 0.26 mmol, 58.0% yield). ESIMS found for Ci 6 HnBrN 6 OS m/z 415.1 (M+l).

Step 2

[0668] A mixture of BrettPhos Pd G3 (1 1.7 mg, 0.01 mmol), BrettPhos (7 mg, 0.01 mmol), 2-bromo-N-(6-(l -methyl- lH-pyrazol-4-}'l)-2,7-naphthyridin-3-yl)thiazole-5-carboxami de (CLXXII) (107 mg, 0.26 mmol) and 1-methylpiperazine (CLXXVIII) (40 μί, 0.36 mmol) in THF (8 mL) was purged with argon. LiHMDS (1.0 M solution in THF) (0.65 mL, 0.65 mmol) was added and the resulting mixture stirred in a sealed tube at room temperature under the argon atm for 18 h. The reaction was washed saturated NaHCC -EtOAc extraction. The organic layers were combined, dried over Na2SC>4, and evaporated to dryness. The residue was purified by silica gel chromatography (0→10% 7 N NH 3 -MeOH/CHCl3). The fractions containing the product were concentrated and the resulting solid was filtered and dried under vacuo to afford N-(3 -(1 -methyl - lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)-2-(4-methylpiperazin -l-yl)thiazole-5-carboxamide 4632 as an orange solid (20.3 mg, 0.05 mmol, 18.1% yield). ¾ NMR (499 MHz, DMSO-d 6 ) δ ppm 2.23 (3 H, s), 2.40 - 2.46 (4 H, m), 3.50 - 3.57 (4 H, m), 3.92 (3 H, s), 8.01 (1 H, s), 8.14 (1 H, s), 8.38 (2 H, s), 8.42 (1 H, s), 9.28 (1 H, s), 9.34 (1 H, s), 10.98 (1 H, s); ESIMS found for C 2 iH 2 2N 8 OS mlz 435.2 (M+l).

Example 12.

[0669] Preparation of fr «5-4-(dimethylamino)-N-(6-(thiazol-5-yl)-2,7-naphthyridin- 3

4239

Scheme 41

Step 1

[0670] To a stirred solution of fraws-4-amino-N-(6-chloro-2,7-naphthyridin-3-yl) cyclohexane-l-carboxamide (CLXXIX) (80 mg, 0.25 mmol) in MeOH (1.5 mL) was added formaldehyde (0.05 mL, 0.74 mmol). After stirring 15 min, Na(OAc) 3 BH (160 mg, 0.74 mmol) was added and the mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated, and the resulting residue partitioned between EtOAc and 1 N NaOH. The organic layer was separated, washed with water, brine, and dried over anhydrous Na2S04, and concentrated to dryness under vacuum obtain fr «5-N-(6-chloro-2,7-naphthyridin-3-yl)-4-(dimethylamino) cyclohexane-l-carboxamide (CLXXX) as an off-white solid (76 mg, 0.22 mmol, 88.2% yield) which was used for next step without purification. ESIMS found for C17H21CIN4O mlz 333.1 (M+l).

Step 2 [0671] A mixture of fr «5-N-(6-chloro-2,7-naphthyridin-3-yl)-4-(dimetliylamino) cyclohexane-l-carboxamide (CLXXX) (40 mg, 0.12 mmol), 5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)thiazole (CLXXXI) (30 mg, 0.15 mmol) and SPhos-Pd G4 (10 mg, 0.010 mmol) was taken in 1,4-dioxane (0.50 mL) and was added 2 M solution of K3PO4 (150 pL, 0.30 mmol). The mixture was purged with N 2 gas for 10 min and then stirred at 70°C for 16 h. The organic layer was carefully separated, absorbed on silica gel and purified by ISCO followed by prep TLC using (60% CHC1 3 /10% 7 N NH 3 Me OH in CHC1 3 ) to obtain fra«i-4-(dimethylamino)-N-(6-(thiazol-5- yl)-2,7-naphthyridin-3-yl) cyclohexane-l-carboxamide 4239 as a white solid (12 mg, 0.03 mmol, 26.2% yield). Ή NMR (499 MHz, DMSO ) δ ppm 1.14 - 1.22 (2 H, m), 1.42 - 1.53 (2 H, m), 1.87 (2 H, br d, J=10.98 Hz), 1.93 (2 H, br d, J=11.53 Hz), 2.13 - 2.17 (1 H, m), 2.18 (6 H, s), 2.52 - 2.56 (1 H, m), 8.43 (1 H, s), 8.50 (1 H, s), 8.73 (1 H, s), 9.20 (1 H, s), 9.32 (1 H, s), 9.37 (1 H, s), 10.78 (1 H, s); ESIMS found for C 2 oH 2 3N 5 OS mlz 382.2 (M+l).

Example 13.

[0672] Preparation of N-(6-(l-methyl-5-(mo holinomethyl)-lH-pyrazol-4-yl)-2,7- naphthyridin-3-yl)- -mo holinoisonicotinamide (3941) is depicted below in Scheme 42.

CLXXXII

CLXXXV CLXXXIV

3941

Scheme 42

Steps 1-2

[0673] 4-Bromo-l -methyl- lH-pyrazole-5 -carbaldehyde (CLXXXII) (supplier: CombiBlocks) (2.18 g, 11.55 mmol), Pd(dppf)Cl2 (0.54 g, 0.66 mmol), Bis(pinacolato)diboron (4.44 g, 17.49 mmol), and KOAc (2.2 g, 22.37 mmol) in 1,4-dioxane (35 niL) were added to a sealed tube, purged with Argon for 1 min, and then heated to 100°C for 6 h. 6-Chloro-2,7- naphthyndm-3 -amine (L1V) (1.0 g, 5.57 mmol), K 3 P0 4 (13.9 mL, 27.84 mmol), and Pd(dppf)Cl 2 (0.54 g, 0.66 mmol) were added and the mixture purged with Argon for 1 min. The tube was resealed and heated to 100°C for 16 h. The solvent was evaporated under high vacuum and the residue purified by silica gel column chromatography (0→10% MeOH CHCh) to produce 4-(6- amino-2,7-naphthyridin-3-yl)-l-methyl-lH-pyrazole-5-carbalde hyde (CLXXXIV) as an off-white solid (390 mg, 1.54 mmol, 27.7% yield). ESIMS found for Ci 3 HnN 5 0 mlz 254.1 (M+l).

Step 3

[0674] To a solution of 4-(6-amino-2,7-naphthyridin-3-yl)-2-methylpyrazole-3- carbaldehyde (CLXXXIV) (133 mg, 0.53 mmol), TEA (150 1.08 mmol), morpholine (100 μί, 1.16 mmol) in DCE (5 mL) was added Na(OAc)3BH (342 mg, 1.61 mmol). The reaction was stirred at room temperature for 16 h. The solvent was evaporated under high vacuum and the residue purified by silica gel column chromatography (12g) (0→10% 1.7 N NH 3 in MeOH/CHCl 3 ) to produce 6-( 1 -methyl-5 -(morpholinomethyl)- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -amine

(CLXXXV) as an off-white solid (69 mg, 0.21 mmol, 40.5% yield). ESEVIS found for Ci 7 H 2 oN 6 0 m/z 325.2 (M+l). Step 4-5

[0675] To a suspension of 2-ηιοφ1ιο1ίηοί8οηίοούηίο acid (CI) (30 mg, 0.16 mmol) in DCM (1 mL) was added oxalyl chloride (28 ί, 0.32 mmol) followed by 2 drops of DMF. The mixture was stirred at room temperature for 1 h and concentrated under vacuum. The crude acid chloride (CLXXXVI) was used in the next step without purification. To this solid was added pyridine (1 mL) and 6-(l-methyl-5-(moφholinomethyl)-lH-pyrazol-4-yl)-2,7-naphth yridin-3- amine (CLXXXV) (30 mg, 0.08 mmol). This mixture was heated to 40°C for 16 h. To this mixture was added H2O (20 mL) and brine (10 mL). The aqueous layer was extracted with DCM and the DCM was dried over Na2S04, filtered and the solvent was removed under vacuum. The residue was purified by silica gel (12g) (0→10% 1.7 N NH 3 in MeOH/CHC ) to produce N-(6-(l-Methyl- 5-(morpholinomethyl)-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) -2-moφholinoisonicotinamide 3941 as an off-white solid (10 mg, 0.02 mmol, 24.2% yield). ¾ NMR (499 MHz, DMSO-c 6 ) δ ppm 2.44 (4 H, br s), 3.50 - 3.56 (4 H, m), 3.56 - 3.61 (4 H, m), 3.72 - 3.77 (4 H, m), 3.93 (3 H, s), 4.12 (2 H, s), 7.20 (1 H, dd, J=5.08, 1.23 Hz), 7.47 (1 H, s), 8.08 (1 H, s), 8.16 (1 H, s), 8.29 (1 H, d, J=5.21 Hz), 8.60 (1 H, s), 9.35 (1 H, s), 9.43 (1 H, s), 11.28 (1 H, s); ESIMS found for C27H30N8O3 m/z 515.3 (M+l).

[0676] The following compounds were prepared in accordance with the procedures described in the above Examples 1-13.

[0677] N-(2-( 1 -Methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)

cyclopropanecarboxamide 2.

[0678] White solid (8.7 mg, 0.030 mmol, 10.3% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 0.81 - 0.86 (2 H, m), 0.86 - 0.91 (2 H, m), 2.05 - 2.13 (1 H, m), 3.93 (3 H, s), 7.80 (1 H, d, J=8.78 Hz), 8.21 (1 H, d, J=0.82 Hz), 8.38 (1 H, d, J=8.51 Hz), 8.45 (1 H, s), 8.54 (1 H, s), 9.06 (1 H, s), 10.98 (1 H, s); ESIMS found for Ci 6 Hi 5 N 5 0 mlz 294.1 (M+l).

[0679] N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)piperi dine-4- carboxamide 11.

[0680] White solid (120 mg,0.36 mmol, 53.7% yield). ¾ NMR (499 MHz, DMSO- d ) δ ppm 1.53 (2 H, qd, J=12.17, 4.12 Hz), 1.71 (2 H, br d, J=10.43 Hz), 2.43 - 2.49 (2 H, m), 2.65 (1 H, tt, J=11.53, 3.70 Hz), 2.94 - 3.02 (2 H, m), 3.93 (3 H, s), 7.80 (1 H, d, J=8.51 Hz), 8.21 (1 H, s), 8.38 (1 H, d, J=8.51 Hz), 8.48 (1 H, s), 8.55 (1 H, s), 9.05 (1 H, s), 10.56 (1 H, s); ESIMS found for C mlz 337.2 (M+l).

16

[0681] l-Isobutyl-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin- 7-yl) piperidine-4-carboxamide 16.

[0682] White solid (8.0 mg, 0.020 mmol, 9.8% yield). ¾ NMR (500 MHz, DMSO- c/„) 5 ppm 0.86 (6 H, d, J=6.59 Hz), 1.62 - 1.72 (2 H, m), 1.74 - 1.81 (3 H, m), 1.86 (2 H, td, J=l 1.53, 1.65 Hz), 2.02 (2 H, d, J=7.41 Hz), 2.52 - 2.59 (1 H, m), 2.84 - 2.90 (2 H, m), 3.93 (3 H, s), 7.81 (1 H, d, J=8.78 Hz), 8.21 (1 H, s), 8.39 (1 H, d, J=0.82 Hz), 8.48 (1 H, s), 8.55 (1 H, s), 9.05 (1 H, s), 10.61 (1 H, s); ESIMS found for CziHisNsO mlz 393.2 (M+l).

56

[0683] 2-(Cyclobutyl(methyl)amino)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6- naphthyridin-7-yl)acetamide 56.

[0684] Off-white solid (30 mg, 0.09 mmol, 50.7% yield). ¾ NMR (499 MHz, DMSO- e) 5 ppm 1.53 - 1.70 (2 H, m), 1.80 - 1.93 (2 H, m), 1.97 - 2.06 (2 H, m), 2.22 (3 H, s), 3.08 (1 H, qum, J=7.75 Hz), 3.13 (2 H, s), 3.93 (3 H, s), 7.84 (1 H, d, J=8.51 Hz), 8.23 (1 H, s), 8.39 - 8.44 (1 H, m), 8.47 (1 H, s), 8.58 (1 H, s), 9.07 (1 H, s), 10.05 (1 H, s); ESIMS found for C mlz 351.2 (M+l).

62 [0685] ( )-N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)pyrr olidine-2- carboxamide 62.

[0686] Yellow solid (20 mg, 0.06 mmol, 56.6% yield). ¾ NMR (499 MHz, DMSO- d ) δ ppm 1.68 (2 H, quin, J=6.86 Hz), 1.80 - 1.90 (1 H, m), 2.06 - 2.17 (1 H, m), 2.87 (1 H, dt, J=10.22, 6.42 Hz), 2.97 (1 H, dt, .7=10.09, 6.62 Hz), 3.82 (1 H, dd, .7=9.06, 5.49 Hz), 3.93 (3 H, s), 7.83 (1 H, d, .7=8.51 Hz), 8.22 (1 H, s), 8.41 (1 H, d, .7=8.51 Hz), 8.48 (1 H, s), 8.57 (1 H, s), 9.06 (1 H, s), 10.46 (1 H, s); ESIMS (M+l).

71

[0687] N-(2-( 1 -Methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)- 1 - (methylsulfonyl)piperidine-4-carboxamide 71.

[0688] White solid (26 mg,0. 06 mmol, 33.4% yield). ¾ NMR (499 MHz, DMSO- d 6 ) 5 ppm 1.64 - 1.77 (2 H, m), 1.96 (2 H, br dd, .7=13.31, 2.61 Hz), 2.66 - 2.72 (1 H, m), 2.76 (2 H, td, .7=11.94, 2.20 Hz), 2.90 (3 H, s), 3.60 - 3.67 (2 H, m), 3.93 (3 H, s), 7.82 (1 H, d, .7=8.51 Hz), 8.22 (1 H, s), 8.39 (1 H, d, .7=8.51 Hz), 8.48 (1 H, s), 8.56 (1 H, s), 9.07 (1 H, s), 10.76 (1 H, s); ESIMS found for C mlz 415.15 (M+l).

[0689] Ν^-ίΙ-Με^Ι-ΙΗ-ρίΤΕΐζο ^ -Ι,ό-η ρΙιΙΙι^άίη-Τ^ ^-ίΓηοφ^Ιίη^- yl)acetamide 86.

[0690] Off-white solid (18 mg, 0.05 mmol, 35.6% yield). ¾ NMR (499 MHz, DMSO-c e) δ ppm 2.41 (1 H, dd, .7=12.08, 10.15 Hz), 2.45 - 2.49 (1 H, m), 2.57 - 2.68 (3 H, m), 2.82 (1 H, dd, J=12.08, 1.92 Hz), 3.43 (1 H, td, .7=10.84, 3.29 Hz), 3.67 - 3.73 (1 H, m), 3.79 - 3.86 (1 H, m), 3.93 (3 H, s), 7.82 (1 H, d, .7=8.51 Hz), 8.22 (1 H, s), 8.39 (1 H, d, J=8.78 Hz), 8.48 (1 H, s), 8.56 (1 H, s), 9.05 (1 H, s), 10.63 (1 H, s); ESIMS found for C mlz 353.2 (M+l).

95 [0691] N-(2-( 1 -Methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)- 1 -(oxazol-2- ylmethyl)piperidine-4-carboxamide 95.

[0692] White solid (26 mg, 0.06 mmol, 47.4% yield). ¾ NMR (499 MHz, DMSO- d ) δ ppm 1.62 - 1.73 (2 H, m), 1.80 (2 H, br d, J=10.70 Hz), 2.10 (2 H, td, J=l 1.60, 2.06 Hz), 2.52 - 2.58 (1 H, m), 2.89 (2 H, br d, J=l 1.25 Hz), 3.67 (2 H, s), 3.93 (3 H, s), 7.18 (1 H, d, J=0.82 Hz), 7.81 (1 H, d, J=8.51 Hz), 8.08 (1 H, d, J=0.82 Hz), 8.21 (1 H, s), 8.38 (1 H, d, J=7.96 Hz), 8.47 (1 H, s), 8.55 (1 H, s), 9.05 (1 H, s), 10.60 (1 H, s); ESIMS found for C mlz 418.2 (M+l).

99

[0693] N-(2-(l -Methyl-lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)-l -(pyrimidin-2- ylmethyl)piperidine-4-carboxamide 99.

[0694] Beige solid (15 mg, 0.04 mmol, 39.3% yield). ¾ NMR (499 MHz, DMSO-i 6 ) 5 ppm 1.68 (2 H, qd, J=12.12, 3.70 Hz), 1.76 - 1.82 (2 H, m), 2.12 - 2.20 (2 H, m), 2.51 - 2.59 (1 H, m), 2.96 (2 H, br d, J=11.25 Hz), 3.72 (2 H, s), 3.93 (3 H, s), 7.40 (1 H, t, J=4.94 Hz), 7.80 (1 H, d, J=8.51 Hz), 8.21 (1 H, s), 8.38 (1 H, d, J=8.51 Hz), 8.47 (1 H, s), 8.54 (1 H, s), 8.79 (2 H, d, J=4.94 Hz), 9.04 (1 H, s), 10.60 (1 H, s); ESIMS found for C mlz 429.2 (M+l).

105

[0695] 2-(4-Methyl-l,4-diazepan-l-yl)-N-(2-(l-methyl-lH-pyrazol-4-y l)-l,6- naphthyridin-7-yl)acetamide 105.

[0696] Yellow gum (5 mg, 0.01 mmol, 5.9% yield). Ή NMR (499 MHz, DMSO ) δ ppm 1.78 (2 H, br s), 2.29 (3 H, s), 2.59 (4 H, br s), 2.83 (4 H, br s), 3.38 (2 H, s), 3.93 (3 H, s), 7.83 (1 H, br d, J=8.23 Hz), 8.23 (1 H, s), 8.41 (1 H, br d, J=8.51 Hz), 8.48 (1 H, s), 8.58 (1 H, s), 9.08 (1 H, s), 10.09 (1 H, br s); ESIMS found for C mlz 380.2 (M+l).

112 [0697] N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(pi pendm-l- yl)propanamide 112.

[0698] Brown solid (49 mg, 0.13 mmol, 40.4% yield). ¾ NMR (499 MHz, DMSO- d ) δ ppm 1.20 (3 H, d, J=6.86 Hz), 1.41 - 1.47 (2 H, m), 1.58 (4 H, dq, J=11.49, 5.87 Hz), 2.51 - 2.58 (4 H, m), 3.47 (1 H, q, J=6.86 Hz), 3.93 (3 H, s), 7.83 (1 H, d, J=8.51 Hz), 8.22 (1 H, s), 8.38 - 8.43 (1 H, m), 8.47 (1 H, s), 8.57 (1 H, s), 9.07 (1 H, s), 10.23 (1 H, s); ESIMS found for C mlz 365.2 (M+1).

122

[0699] 2-( 1 -Isobutylpyrrolidin-3 -yl)-N-(2-( 1 -methyl- lH-pyrazol-4-yl)-l ,6- naphthyridin-7-yl)acetamide 122.

[0700] White solid (4 mg, 0.01 mmol, 13.7% yield). ¾ NMR (499 MHz, DMSO- 6 ) δ ppm 0.85 (6 H, dd, J=6.59, 1.65 Hz), 1.37 - 1.46 (1 H, m), 1.65 (1 H, dquin, J=13.55, 6.84, 6.84, 6.84, 6.84 Hz), 1.89 - 1.99 (1 H, m), 2.08 - 2.19 (3 H, m), 2.38 - 2.49 (2 H, m), 2.51 - 2.58 (3 H, m), 2.63 - 2.69 (1 H, m), 3.93 (3 H, s), 7.80 (1 H, d, J=8.78 Hz), 8.21 (1 H, s), 8.38 (1 H, d, J=8. 1 Hz), 8.48 (1 H, s), 8.55 (1 H, s), 9.04 (1 H, s), 10.65 (1 H, s); ESIMS found for C mlz 393.3 (M+1).

147

[0701] N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4- methylpiperazin-1 -yl)isonicotinamide 147.

[0702] Yellow solid (21.3 mg, 0.050 mmol, 14.4% yield). ¾ NMR (499 MHz, DMSO- 6 ) δ ppm 2.23 (3 H, s), 2.43 (4 H, t, J=4.94 Hz), 3.57 - 3.64 (4 H, m), 3.94 (3 H, s), 7.13 - 7.20 (1 H, m), 7.46 (1 H, s), 7.87 (1 H, d, .7=8.51 Hz), 8.25 (1 H, s), 8.26 (1 H, d, J=4.94 Hz), 8.45 (1 H, d, .7=8.51 Hz), 8.59 (1 H, s), 8.63 (1 H, s), 9.15 (1 H, s), 11.18 (1 H, s); ESIMS found for C2 3 H 2 4N 8 0 mlz 429.2 (M+1).

151

[0703] N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyndin-7-yl)-6-(4- methylpiperazin- 1 -yl)nicotinamide 151.

[0704] White solid (29.3 mg, 0.07 mmol, 24.8% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 2.22 (3 H, s), 2.37 - 2.43 (4 H, m), 3.61 - 3.68 (4 H, m), 3.94 (3 H, s), 6.90 (1 H, d, J=9.33 Hz), 7.84 (1 H, d, J=8.78 Hz), 8.20 (1 H, dd, J=9.06, 2.47 Hz), 8.24 (1 H, s), 8.42 (1 H, d, J=8.78 Hz), 8.58 (1 H, s), 8.61 (1 H, s), 8.85 (1 H, d, J=2.47 Hz), 9.12 (1 H, s), 10.78 (1 H, s); ESIMS found for C mlz 429.2 (M+l)

153

[0705] N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(pi pendm-4- yloxy)isonicotinamide 153.

[0706] Yellow solid (5.3 mg, 0.01 mmol, 13.8% yield). ¾ NMR (499 MHz, DMSO- d ) δ ppm 1.47 - 1.58 (2 H, m), 1.93 - 2.01 (2 H, m), 2.56 - 2.63 (2 H, m), 2.93 - 3.02 (2 H, m), 3.94 (3 H, s), 5.05 - 5.14 (1 H, m), 7.34 (1 H, s), 7.50 (1 H, dd, J=5.35, 1.51 Hz), 7.88 (1 H, d, J=8.51 Hz), 8.25 (1 H, s), 8.31 (1 H, d, .7=5.21 Hz), 8.45 (1 H, d, .7=8.51 Hz), 8.60 (2 H, d, .7=8.51 Hz), 9.15 (1 H, s), 11.20 (1 H, br s); ESIMS found for C mlz 430.2 (M+l).

164

[0707] 2-((2-(Dimethylamino)ethyl)amino)-N-(2-(l-methyl-lH-pyrazol- 4-yl)-l,6- naphthyridin-7-yl)isonicotinamide 164.

[0708] Light yellow wax (16 6 mg, 0.04 mmol, 7.0% yield). ¾ NMR (499 MHz, DMSO-J 6 ) δ ppm 2.19 (6 H, s), 2.43 (2 H, t, J=6.72 Hz), 3.36 - 3.43 (2 H, m), 3.94 (3 H, s), 6.63 (1 H, brt, J=5.35 Hz), 7.03 (1 H, dd, J=5.21, 1.37 Hz), 7.05 (1 H, s), 7.87 (1 H, d, .7=8.51 Hz), 8.11 (1 H, d, J=5.49 Hz), 8.24 (1 H, s), 8.45 (1 H, d, .7=8.23 Hz), 8.60 (2 H, d, J=6.04 Hz), 9.14 (1 H, s), 10.97 (1 H, s); ESIMS found for C mlz 417.2 (M+l).

170

[0709] 4-((Dimethylamino)methyl)-N-(2-(l-methyl-lH-pyrazol-4-yl)-l, 6- naphthyridin-7-yl)benzamide 170.

[0710] Yellow solid (20.5 mg, 0.05 mmol, 14.9% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 2.18 (6 H, s), 3.47 (2 H, s), 3.94 (3 H, s), 7.44 (2 H, d, J=8.23 Hz), 7.86 (1 H, d, J=8.51 Hz), 8.05 (2 H, d, J=8.23 Hz), 8.24 (1 H, s), 8.42 - 8.46 (1 H, m), 8.59 (1 H, s), 8.64 (1 H, s), 9.14 (1 H, s), 10.93 (1 H, s); ESIMS found for C mlz 387.2 (M+1).

172

[0711] N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-3-((4 - methylpiperazin- 1 -yl)methyl)benzamide 172.

[0712] Yellow solid (12.4 mg, 0.03 mmol, 6.5% yield). ¾ NMR (500 MHz, DMSO- d 6 ) δ ppm 2.15 (3 H, s), 2.24 - 2.37 (4 H, m), 2.37 - 2.47 (4 H, m), 3.54 (2 H, s), 3.94 (3 H, s), 7.45 - 7.50 (1 H, m), 7.51 - 7.57 (1 H, m), 7.86 (1 H, d, J=8.78 Hz), 7.97 (1 H, d, J=7.68 Hz), 7.98 (1 H, s), 8.25 (1 H, s), 8.44 (1 H, d, J=8.51 Hz), 8.59 (1 H, s), 8.64 (1 H, s), 9.14 (1 H, s), 10.97 (1 H, s); ESIMS found for C mlz 442.2

194

[0713] N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-3- phenylpropanamide 194.

[0714] Yellow wax (31.4 mg, 0.09 mmol, 38.3% yield) . ¾ NMR (500 MHz, DMSO- £¼) δ ppm 2.74 - 2.81 (2 H, m), 2.92 - 2.98 (2 H, m), 3.93 (3 H, s), 7.16 - 7.20 (1 H, m), 7.28 (2 H, s), 7.29 (1 H, d, J=2.20 Hz), 7.81 (1 H, d, J=8.51 Hz), 8.22 (1 H, s), 8.38 (1 H, d, J=8. 1 Hz), 8.49 (1 H, s), 8.57 (1 H, s), 9.05 (1 H, s), 10.70 (1 H, s); ESIMS found for C mlz 358.2 (M+1).

202

[0715] 2-Methyl-N-(2-(l-methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7- yl)-l,2,3,4- tetrahydroisoquinoline-7-carboxamide 202.

[0716] Yellow solid (30.4 mg, 0.07 mmol, 21.1% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 2.37 (3 H, s), 2.63 (2 H, t, J=5.90 Hz), 2.89 (2 H, t, J=5.76 Hz), 3.56 (2 H, s), 3.94 (3 H, s), 7.25 (1 H, d, J=7.96 Hz), 7.81 (1 H, s), 7.84 (1 H, dd, J=7.96, 1.92 Hz), 7.85 (1 H, d, J=8.78 Hz), 8.24 (1 H, s), 8.41 - 8.47 (1 H, m), 8.59 (1 H, s), 8.63 (1 H, s), 9.13 (1 H, s), 10.84 (1 H, s); ESIMS found for C23H22 6O mlz 399.2 (M+l).

209

[0717] N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)benzof uran-6- carboxamide 209.

[0718] Yellow solid (18.6 mg, 0.05 mmol, 22.7% yield). ¾NMR (499 MHz, DMSO- d 6 ) δ ppm 3.95 (3 H, s), 7.09 (1 H, dd, J=2.20, 0.82 Hz), 7.80 (1 H, d, J=8.23 Hz), 7.87 (1 H, d, J=8.51 Hz), 8.02 (1 H, dd, J=8.23, 1.37 Hz), 8.20 (1 H, d, J=2.20 Hz), 8.25 (1 H, s), 8.40 (1 H, s), 8.45 (1 H, d, J=8.51 Hz), 8.60 (1 H, s), 8.67 (1 H, s), 9.16 (1 H, s), 11.03 (1 H, s); ESIMS found for C m/z 370.1 (M+l).

216

[0719] N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)quinox aline-6- carboxamide 216.

[0720] Yellow solid (7.1 mg, 0.02 mmol, 4.2% yield). Ή NMR (499 MHz, DMSO- da) δ ppm 3.95 (3 H, s), 7.89 (1 H, d, J=8.78 Hz), 8.24 (1 H, d, J=8.78 Hz), 8.26 (1 H, s), 8.45 (1 H, dd, J=8.78, 1.92 Hz), 8.47 (1 H, d, J=8.51 Hz), 8.61 (1 H, s), 8.70 (1 H, s), 8.86 (1 H, d, J=1.92 Hz), 9.08 (2 H, dd, J=8.10, 1.78 Hz), 9.19 (1 H, s), 11.46 (1 H, s); ESIMS found for C mlz 382.1 (M+l).

[0721] N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-l-(pi pendm-4-yl)- lH-pyrazole-4-carboxamide 228.

[0722] White solid (7.0 mg, 0.017 mmol, 29.1% yield). ¾ NMR (500 MHz, DMSO- d 6 ) 5 ppm 1.77 (2 H, qd, J=11.94, 3.98 Hz), 2.00 (2 H, br dd, J=11.80, 1.92 Hz), 2.56 - 2.63 (2 H, m), 3.01 - 3.07 (2 H, m), 3.94 (3 H, s), 4.20 - 4.29 (1 H, m), 7.83 (1 H, d, J=8.78 Hz), 8.19 (1 H, s), 8.23 (1 H, s), 8.41 (1 H, d, J=8.23 Hz), 8.58 (1 H, s), 8.59 (1 H, s), 8.62 (1 H, s), 9.11 (1 H, s), 10.65 (1 H, s); ESIMS found for C 2 iH 2 2N 8 0 mlz 403.2 (M+l).

229

[0723] N-(2-( 1 -Methyl- lH-pyrazol-4-yl)-l ,6-naphthyridin-7-yl)- 1 -( 1 - methylpiperidin-4-yl)-lH-pyrazole-4-carboxamide 229.

[0724] Yellow solid (8 mg, 0.02 mmol, 22.3% yield). ¾ NMR (499 MHz, DMSO- d 6 ) 5 ppm 1.88 - 2.00 (2 H, m), 2.01 - 2.10 (4 H, m), 2.21 (3 H, s), 2.86 (2 H, br d, J=11.80 Hz), 3.94 (3 H, s), 4.17 (1 H, tt, J=l l .l l, 4.12 Hz), 7.83 (1 H, d, J=8.51 Hz), 8.20 (1 H, s), 8.23 (1 H, s), 8.41 (1 H, d, J=7.96 Hz), 8.58 (2 H, d, J=6.59 Hz), 8.63 (1 H, s), 9.11 (1 H, s), 10.65 (1 H, s); ESIMS found for C mlz Ml .2 (M+l).

234

[0725] Isopropyl 4-(4-((2-( 1 -methyl-lH-pyrazol-4-yl)-l ,6-naphthyridin-7- yl)carbamoyl) - 1 H-pyrazol - 1 -yl)piperidine - 1 -carboxylate 234.

[0726] White solid (9.6 mg, 0.02 mmol, 24.0% yield). Ή NM (499 MHz, DMSO- d 6 ) δ ppm 1.21 (6 H, d, J=6.04 Hz), 1.80 (2 H, qd, J=12.08, 4.39 Hz), 2.08 (2 H, br dd, J=12.35, 2.20 Hz), 2.98 (2 H, br s), 3.94 (3 H, s), 4.04 - 4.12 (2 H, m), 4.45 (1 H, tt, J=\ 1.32, 3.91 Hz), 4.80 (1 H, spt, J=6.22 Hz), 7.83 (1 H, d, J=8.78 Hz), 8.21 (1 H, s), 8.23 (1 H, s), 8.41 (1 H, d, J=7.96 Hz), 8.58 (1 H, s), 8.59 (1 H, s), 8.65 (1 H, s), 9.11 (1 H, s), 10.65 (1 H, s)ESIMS found for C mlz 489.3 (M+l).

[0727] N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(pi peridin-4-yl) oxazole-4-carboxamide 241.

[0728] Off-white solid (64.0 mg, 0.159 mmol, 61.4% yield). ¾ NMR (499 MHz, DMSO ) δ ppm 1.63 (2 H, qd, J=l 1.85, 3.70 Hz), 1.95 (2 H, br dd, J=12.49, 2.61 Hz), 2.59 (2 H, td, J=11.80, 2.47 Hz), 2.96 - 3.05 (3 H, m), 3.94 (3 H, s), 7.87 (1 H, d, J=8.51 Hz), 8.24 (1 H, s), 8.45 (1 H, d, J=8.51 Hz), 8.54 (1 H, s), 8.60 (1 H, s), 8.88 (1 H, s), 9.12 (1 H, d, J=0.82 Hz), 9.85 (1 H, br s); ESIMS found for C21H21N7O2 mlz 404.2 (M+l).

242

[0729] N-(2-( 1 -Methyl- 1 H-pyrazol -4 -yl)-l ,6-naphthyridin-7-yl)-2-( 1 - methylpiperidin-4-yl)oxazole-4-carboxamide 242.

[0730] White solid (31.0 mg, 0.074 mmol, 59.9% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.73 - 1.85 (2 H, m), 1.99 - 2.08 (4 H, m), 2.19 (3 H, s), 2.79 (2 H, br d, J=11.25 Hz), 2.88 (1 H, tt, J=11.25, 3.70 Hz), 3.94 (3 H, s), 7.87 (1 H, d, J=8.78 Hz), 8.24 (1 H, s), 8.45 (1 H, d, J=8.51 Hz), 8.54 (1 H, s), 8.60 (1 H, s), 8.88 (1 H, s), 9.12 (1 H, s), 9.86 (1 H, s); ESIMS found for C22H23N7O2 mlz 418.2 (M+l).

280

[0731] 2-(2-Fluoroethyl)-N-(2-(l-methyl-5-(piperidin-l-ylmethyl)-lH -pyrazol-4- yl)-l,6-naphthyridin-7-yl)-2-azaspiro[3.3]heptane-6-carboxam ide 280.

[0732] Beige solid (5 mg, 0.01 mmol, 20.6% yield). ¾ NM (499 MHz, METHANOLS) δ ρρηι 1.41 - 1.47 (2 H, m), 1.51 - 1.58 (4 H, m), 2.41 - 2.48 (2 H, m), 2.49 - 2.57 (5 H, m), 2.76 (2 H, dt, .7=28.10, 5.00 Hz), 3.23 - 3.30 (2 H, m), 3.35 (2 H, s), 3.43 (2 H, s), 4.01 (3 H, s), 4.22 (2 H, s), 4.44 (2 H, dt, J=47.90, 5.00 Hz), 7.83 (1 H, d, J=8.51 Hz), 8.07 (1 H, s), 8.33 (1 H, dd, J=8.51, 0.82 Hz), 8.59 (1 H, s), 8.99 (1 H, d, J=0.82 Hz); ESIMS found for C27H34FN7O mlz 492.3 (M+l).

283

[0733] 2-(Diethylamino)-N-(2-(l-methyl-5-(piperidin-l-ylmethyl)-lH- pyrazol-4- yl)-l ,6-naphthyridin-7-yl)acetamide 283.

[0734] Beige solid (3 mg, 0.007 mmol, 4.4% yield). ¾ NMR (499 MHz, METHANOLS) δ ppm 1.16 (6 H, t, J=7.14 Hz), 1.40 - 1.48 (2 H, m), 1.53 (4 H, quin, J=5.56 Hz), 2.51 (4 H, br s), 2.74 (4 H, q, J=7.14 Hz), 3.30 (2 H, br s), 4.01 (3 H, s), 4.22 (2 H, s), 7.86 (1 H, d, J=8.51 Hz), 8.09 (1 H, s), 8.36 (1 H, d, .7=8.51 Hz), 8.64 (1 H, s), 9.02 (1 H, s); ESIMS found for C 2 4H 3 3N 7 0 mlz 436.3 (M+l).

314

[0735] N-(2-(l -Methyl -5 -^οφΗο1ίηοΓηε11ιν1)-1Η-ργΓαζο1-4-γ1)-1,6 -ηαρ1ι11ιγή(1ίη-7- yl)-2 -morpholinoisonicotinamide 314.

[0736] Off-white solid (10.1 mg, 0.02 mmol, 14.5% yield). Ή NMR (499 MHz, DMSO-J 6 ) δ ppm 2.51 - 2.54 (4 H, m), 3.50 - 3.56 (4 H, m), 3.56 - 3.61 (4 H, m), 3.70 - 3.77 (4 H, m), 3.95 (3 H, s), 4.30 (2 H, s), 7.24 (1 H, dd, J=5.08, 1.23 Hz), 7.49 (1 H, s), 7.94 (1 H, d, J=8.51 Hz), 8.21 (1 H, s), 8.30 (1 H, d, J=5.21 Hz), 8.43 - 8.48 (1 H, m), 8.67 (1 H, s), 9.17 (1 H, s), 11.21 (1 H, s); ESIMS found for C 2 7H 3 +l).

317

[0737] N-((4,4-Difluorocyclohexyl)methyl)-2-(5-(2-fluoroethyl)-4,5, 6,7- tetrahy dropy razolo [ 1 ,5 -a] py razin -3 -yl) - 1 , 6 -naphthyridin -7 -amine 317.

[0738] Beige solid (8 mg, 0.02 mmol, 5.7% yield). ¾ NMR (500 MHz, DMSO-c¾) δ ppm 1.66 - 1.76 (2 H, m), 1.77 - 1.91 (2 H, m), 1.93 - 1.99 (2 H, m), 2.08 - 2.17 (2 H, m), 2.68 - 2.77 (1 H, m), 3.01 (3 H, dt, J=29.10, 5.00 Hz), 3.08 (2 H, br t, J=5.35 Hz), 4.20 (2 H, br t, J=5.35 Hz), 4.29 (2 H, s), 4.68 (3 H, dt, J=47.80, 5.00 Hz), 7.85 (1 H, d, J=8.78 Hz), 8.29 (1 H, s), 8.37 (1 H, d, J=8.78 Hz), 8.43 (1 H, s), 9.05 (1 H, s), 10.71 (1 H, s); ESIMS found for C 23 H 25 F 3 N 6 0 mlz 459.2 (M+l).

333

[0739] N-(2-( 1 -Methyl- lH-pyrazol-3 -yl)-l ,6-naphthyridin-7-yl)-2-(4- methylpiperazin-1 -yl)isonicotinamide 333.

[0740] White solid (6 mg, 0.02 mmol, 8.6% yield). ¾ NMR (499 MHz, DMSO-de) δ ppm 1.65 (6 H, d, J=22.00 Hz), 4.52 (3 H, s), 8.09 (1 H, d, J=8.51 Hz), 8.58 (1 H, s), 8.61 (1 H, s), 8.66 (1 H, d, J=8.78 Hz), 9.29 (1 H, s), 10.23 (1 H, br s); ESIMS found for Ci 5 Hi 5 FN 6 0 mlz 315.1 (M+l).

347

[0741] N-(2-(l-Methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyndm-7-yl)-l -((l- (trifluoromethyl)cyclopropyl)meth}'l)piperidine-4-carboxamid e 347.

[0742] White solid (35 mg, 0.08 mmol, 62.9% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 0.73 (2 H, s), 0.91 - 1.00 (2 H, m), 1.59 - 1.71 (2 H, m), 1.81 (2 H, br d, J=10.98 Hz),

1.89 - 2.00 (2 H, m), 2.55 - 2.66 (1 H, m), 2.96 (2 H, br d, J=l 1.25 Hz), 4.37 (3 H, s), 8.06 (1 H, s), 8.38 (1 H, s), 8.48 (1 H, d, J=9.06 Hz), 8.58 (1 H, d, J=9.06 Hz), 9.38 (1 H, s), 11.10 (1 H, s);

ESIMS found for C22H 2 4F 3 7 0 mlz 460.2 (M+l).

358

[0743] 2-(4-Methoxypiperidin-l-yl)-N-(2-(l-methyl-lH-l,2,3-triazol- 4-yl)-l,6- naphthyridin-7-yl)acetamide 358.

[0744] Off-white solid (12 mg, 0.03 mmol, 19.8% yield). ¾ NMR (499 MHz, DMSO-c e) δ ppm 1.47 - 1.57 (2 H, m), 1.84 - 1.94 (2 H, m), 2.34 - 2.42 (2 H, m), 2.76 - 2.83 (2 H, m), 3.20 - 3.24 (1 H, m), 3.24 (3 H, s), 3.25 (2 H, s), 4.52 (3 H, s), 8.06 (1 H, d, J=8.78 Hz), 8.60 (2 H, s), 8.64 (1 H, d, J=8.51 Hz), 9.25 (1 H, s), 10.25 (1 H, s); ESIMS found for C19H23N7O2 mlz 382.2 (M+l).

372

[0745] N 2 -Methyl-N 5 -(2-(l-methyl-lH-l,2,3-triazol-4-yl)-l,6-naphthyridin- 7-yl) pyridine-2,5-dicarboxamide 372.

[0746] White solid (4 mg, 0.009 mmol, 7.0% yield). ¾ NMR (499 MHz, DMSO-i/ 6 ) δ ppm 2.86 (3 H, d, J=4.94 Hz), 4.55 (3 H, s), 8.12 (1 H, d, J=8.51 Hz), 8.15 - 8.19 (1 H, m), 8.58 (1 H, dd, J=8.10, 2.33 Hz), 8.62 (1 H, s), 8.67 - 8.72 (1 H, m), 8.81 (1 H, s), 8.95 (1 H, q, J=4.85 Hz), 9.23 (1 H, dd, J=2.20, 0.82 Hz), 9.35 (1 H, s), 11.60 (1 H, br s); ESIMS found for Ci9Hi 6 N 8 0 2 m/z 389.15 (M+l).

[0747] 2-(4-(Dimethylamino)piperidin-l-yl)-N-(2-(l-methyl-lH-l,2,3- triazol-4-yl)- l,6-naphthyridin-7-yl)isonicotinamide 376.

[0748] Off-white solid (15 mg, 0.03 mmol, 33.4% yield). ¾ NMR (499 MHz, DMSO ) δ ppm 1.31 - 1.44 (2 H, m), 1.84 (2 H, br d, J=10.98 Hz), 2.19 (6 H, s), 2.32 - 2.39 (1 H, m), 2.84 - 2.95 (2 H, m), 4.44 (2 H, br d, J=12.90 Hz), 4.54 (3 H, s), 7.12 (1 H, dd, J=5.21, 1.10 Hz), 7.47 (1 H, s), 8.10 (1 H, d, J=8.51 Hz), 8.25 (1 H, d, J=4.94 Hz), 8.62 (1 H, s), 8.68 (1 H, d, J=8.51 Hz), 8.79 (1 H, s), 9.33 (1 H, s), 11.34 (1 H, s); ESIMS found for C24H27 9O mlz 458.25 (M+l).

379

[0749] 2-(4-Methyl-l,4-diazepan-l-yl)-N-(2-(l-methyl-lH-l,2,3-tnazo l-4-yl)-l,6- naphthyridin-7-yl)isonicotinamide 379.

[0750] Beige solid (9.5 mg, 0.02 mmol, 25.7% yield). Ή NMR (499 MHz, DMSO- ck) δ ppm 1.89 - 1.98 (2 H, m), 2.27 (3 H, s), 2.49 (2 H, br s), 2.59 - 2.67 (2 H, m), 3.69 (2 H, t, J=6.17 Hz), 3.79 - 3.85 (2 H, m), 4.54 (3 H, s), 7.07 (1 H, dd, J=5.08, 1.24 Hz), 7.23 (1 H, s), 8.10 (1 H, d, J=8.51 Hz), 8.22 (1 H, d, J=4.94 Hz), 8.62 (1 H, s), 8.66 - 8.73 (1 H, m), 8.79 (1 H, s), 9.33 (1 H, s), 11.33 (1 H, s); ESIMS found for C23H25N9O mlz 444.2 (M+l).

400

[0751] 4,4-Difluoro-N-(2-( 1 -methyl- lH-imidazol-5 -yl)- 1 ,6-naphthyridin-7-yl) cyclohexane-l-carboxamide 400.

[0752] Off-white solid (5 mg, 0.01 mmol, 5.6% yield). ¾ NMR (499 MHz, DMSO- £¼) δ ppm 1.63 - 1.76 (2 H, m), 1.76 - 1.92 (2 H, m), 1.96 (2 H, br d, J=13.17 Hz), 2.07 - 2.19 (2 H, m), 2.68 - 2.78 (1 H, m), 4.15 (3 H, s), 7.90 - 7.97 (3 H, m), 8.41 (1 H, d, J=8.51 Hz), 8.51 (1 H, s), 9.10 (1 H, s), 10.78 (1 H, s); ESIMS found for C19H19F2N5O mlz 312.2 (M+l).

416

[0753] 3-Isopropoxy-N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyrid in-7-yl) propanamide 416.

[0754] White solid (3 mg, 0.009 mmol, 28.4% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 1.08 (6 H, d, J=6.04 Hz), 2.67 (2 H, t, J=6.17 Hz), 3.58 (1 H, dt, J=12.28, 6.07 Hz), 3.69 (2 H, t, J=6.17 Hz), 4.15 (3 H, s), 7.91 (1 H, br s), 7.91 (1 H, s), 7.93 (1 H, d, J=8.78 Hz), 8.41 (1 H, d, J=8.78 Hz), 8.52 (1 H, s), 9.09 (1 H, s), 10.69 (1 H, s); ESIMS found for C18H21N5O2 mlz 340.2 (M+l).

447

[0755] N-(2-(l,2-Dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)- 2- methylthiazole-5-carboxamide 447.

[0756] Reddish brown solid (10 mg, 0.02 mmol, 16.9% yield). Ή NMR (499 MHz, DMSO- ,) δ ppm 2.42 (3 H, s), 2.72 (3 H, s), 4.12 (3 H, s), 7.81 (1 H, s), 7.92 (1 H, d, J=8.78 Hz), 8.41 (1 H, d, J=8.78 Hz), 8.54 (1 H, s), 8.71 (1 H, s), 9.15 (1 H, s), 11.32 (1 H, s); ESIMS found for CisHisNeOS mlz 365.1 (M+l).

448

[0757] 4-Fluoro-N-(2-(l-methyl-lH-imidazol-5-yl)-l,6-naphthyndm-7- yl)bcnzamidc 448.

[0758] Off-white solid (5 mg, 0.01 mmol, 5.9% yield). ¾ NMR (499 MHz, DMSO- ck) δ ppm 3.99 (3 H, s), 7.34 - 7.42 (3 H, m), 7.60 (1 H, s), 7.81 (1 H, s), 7.92 (1 H, s), 8.14 - 8.21 (2 H, m), 8.43 (1 H, d, J=8.78 Hz), 8.57 (1 H, d, J=9.06 Hz), 9.33 (1 H, s), 11.46 (1 H, br s); ESIMS found for G 9 H 14 FN 5 O mlz 348.15 (M+l).

450

[0759] N-(2-(l-Methyl H-imidazol-5-yl)-l,6-naphthyridin-7-yl)-3-(pyrrolidm^ ylmethyl)benzamide 450.

[0760] Beige solid (5 mg, 0.01 mmol, 5.5% yield). Ή NMR (499 MHz, DMSO-de) δ ppm 1.72 (4 H, br s), 2.48 (4 H, br s), 3.67 (2 H, s), 4.18 (3 H, s), 7.45 - 7.50 (1 H, m), 7.55 (1 H, br d, J=7.68 Hz), 7.91 - 7.99 (4 H, m), 8.02 (1 H, s), 8.46 (1 H, d, J=8.78 Hz), 8.67 (1 H, s), 9.18 (1 H, s), 11.02 (1 H, s); ESIMS 413.2 (M+l).

477

[0761] N-(2-(l-Methyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)isoin doline-5- carboxamide 477.

[0762] Beige solid (23 mg, 0.06 mmol, 32.5% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ppm 4.14 (4 H, s), 4.18 (3 H, s), 7.40 (1 H, d, J=7.68 Hz), 7.91 - 7.94 (3 H, m), 7.96 - 7.99 (2 H, m), 8.45 (1 H, d, J=8.78 Hz), 8.67 (1 H, s), 9.17 (1 H, s), 10.93 (1 H, s); ESIMS found for C 2 iHi 8 N 6 0 mlz 371.1 (M+l).

523

[0763] 4-Isopropoxy-N-(2-(5 ,6,7, 8-tetrahydroimidazo [ 1 ,2-a]pyrazin-3 -yl)- 1,6- naphthyridin-7-yl)benzamide 523.

[0764] Yellow solid (2.9 mg, 0.006 mmol, 34.0% yield). 'HNMR (499 MHz, DMSO- d 6 ) δ ppm 1.31 (6 H, d, J=6.04 Hz), 3.16 (2 H, br t, J=5.35 Hz), 3.97 (2 H, s), 4.57 (2 H, t, J=5.49 Hz), 4.70 - 4.82 (1 H, m), 7.03 (2 H, d, J=9.06 Hz), 7.90 - 7.94 (2 H, m), 8.07 (2 H, d, J=8.78 Hz), 8.40 (1 H, dd, J=8.78, 0.82 Hz), 8.62 (1 H, s), 9.12 (1 H, s), 10.81 (1 H, s); ESIMS found for C24H24N6O2 mlz 429.2 (M+l). 540

[0765] l-(2,2-Difluoropropyl)-N-(2-(oxazol-5-yl)-l,6-naphthyridin-7 -yl)piperidine- 4-carboxamide 540.

[0766] White solid (6.7 mg, 0.02 mmol, 18.3% yield). Ή NM (499 MHz, DMSO- d 6 ) δ ppm 1.63 (3 H, t, J=19.21 Hz), 1.66 - 1.75 (2 H, m), 1.75 - 1.83 (2 H, m), 2.22 (2 H, td, J=11.80, 2.20 Hz), 2.56 (1 H, tt, .7=11.66, 4.12 Hz), 2.71 (2 H, t, .7=14.13 Hz), 2.95 (2 H, br d, J=11.53 Hz), 7.94 (1 H, d, J=8.51 Hz), 8.17 (1 H, s), 8.55 - 8.60 (2 H, m), 8.69 (1 H, s), 9.20 (1 H, s), 10.76 (1 H, s); ESIMS found 402.2 (M+1).

556

[0767] fr<ms-N-(2-(2-Methyloxazol-5 -yl)-l ,6-naphthyridin-7-yl)-3- morpholinocyclobutane- 1 -carboxamide 556.

[0768] Beige solid (14 mg, 0.04 mmol, 29.5% yield). ¾ NMR (499 MHz, DMSO-t e) δ ppm 2.08 - 2.17 (2 H, m), 2.24 - 2.32 (6 H, m), 2.58 (3 H, s), 2.89 (1 H, quin, J=7.07 Hz), 3.26 - 3.31 (1 H, m), 3.59 (4 H, t, J=4.39 Hz), 7.87 (1 H, d, J=8.51 Hz), 8.03 (1 H, s), 8.52 (1 H, d, J=8. 1 Hz), 8.57 (1 H, s), 9.15 (1 H, s), 10.67 (1 H, s); ESIMS found for C 2 i¾N 5 <¾ mlz 394.2 (M+1).

566

[0769] N-(2-(2-Metllyloxazol-5-yl)-l,6-naphthyridin-7-yl)-4-moφllo linopiperidine- 1 -carboxamide 566.

[0770] Beige solid (70 mg, 0.17 mmol, 37.5% yield). Ή NMR (499 MHz, DMSO-c 6 ) δ ppm 1.28 - 1.42 (2 H, m), 1.80 (2 H, br d, .7=10.70 Hz), 2.36 (1 H, tt, .7=10.94, 3.60 Hz), 2.43 - 2.49 (4 H, m), 2.57 (3 H, s), 2.84 (2 H, br t, .7=11.80 Hz), 3.52 - 3.60 (4 H, m), 4.23 (2 H, br d, J=13.45 Hz), 7.80 (1 H, d, J=8.78 Hz), 8.00 (1 H, s), 8.25 (1 H, s), 8.48 (1 H, d, .7=8.51 Hz), 9.10 (1 H, s), 9.41 (1 H, s); ESIMS found for C 22 H 2( ,N 6 0 3 mlz 423.2 (M+1).

585 [0771] 2-Methyl-N-(2-(2-methyloxazol-5 -yl)-l ,6-naphthyridin-7-yl)-5,6- dihydroimidazo[ l,2-a]pyrazine-7(8H)-carboxamide 585.

[0772] Beige solid (25 mg, 0.06 mmol, 14.5% yield). ¾ NMR (499 MHz, DMSO-t/e) δ ppm 2.07 (3 H, d, J=0.82 Hz), 2.58 (3 H, s), 3.90 - 3.97 (2 H, m), 3.97 - 4.02 (2 H, m), 4.69 (2 H, s), 6.79 (1 H, d, J=0.82 Hz), 7.83 (1 H, d, J=8.78 Hz), 8.01 (1 H, s), 8.28 (1 H, s), 8.50 (1 H, d, J=7.96 Hz), 9.14 (1 H, s), 9.80 (1 H, s); ESIMS found for C20H19N7O2 mlz 390.2 (M+1).

589

[0773] 2-( lH-Imidazol- 1 -yl)-N-(2-(2-methyloxazol-5-yl)- 1 ,6-naphthyridin-7-yl) acetamide 589.

[0774] Beige solid (15 mg, 0.04 mmol, 18.3% yield). : H NMR (499 MHz, DMSO-t/e) δ ppm 2.57 (3 H, s), 5.07 (2 H, s), 6.99 (1 H, s), 7.26 (1 H, s), 7.80 (1 H, s), 7.91 (1 H, d, J=8.78 Hz), 8.03 (1 H, s), 8.46 (1 H, s), 8.55 (1 H, d, J=8.51 Hz), 9.21 (1 H, s), 11.17 (1 H, s); ESIMS found for CnHuNeCh mlz 335.1 (M+1).

591

[0775] 3-((l-Methylpiperidin-4-yl)oxy)-N-(2-(oxazol-5-yl)-l,6-napht hyridin-7- yl)benzamide 591.

[0776] Yellow solid (5 mg, 0.01 mmol, 6.8% yield). ¾ NMR (499 MHz, DMSO-£/ 6 ) δ ppm 1.64 - 1.73 (2 H, m), 1.94 - 2.01 (2 H, m), 2.15 - 2.25 (2 H, m), 2.19 (3 H, s), 2.60 - 2.66 (2 H, m), 4.49 - 4.56 (1 H, m), 7.14 - 7.23 (1 H, m), 7.43 (1 H, t, J=8.10 Hz), 7.63 - 7.66 (2 H, m), 8.00 (1 R d, J=8.51 Hz), 8.21 (1 H, s), 8.60 - 8.66 (1 H, m), 8.71 (1 H, s), 8.72 (1 H, s), 9.29 (1 H, s), 11.10 (1 H, s); ESIMS found for mlz 430.2 (M+1).

592

[0777] N-(2-(Oxazol- -yl)-l ,6-naphthyridin-7-yl)isonicotinamide 592.

[0778] Beige solid (39.0 mg, 0.123 mmol, 33.9% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 7.96 - 7.99 (2 H, m), 8.01 (1 H, d, J=8.51 Hz), 8.21 (1 H, s), 8.64 (1 H, dd, J=8.51, 0.82 Hz), 8.71 (1 H, s), 8.73 (1 H, s), 8.79 - 8.81 (2 H, m), 9.30 (1 H, s), 11.44 (1 H, s); ESIMS found for Ci 7 HiiN 5 0 2 mlz 318.1 (M+1).

613

[0779] fr i75-4-((3-Fluoroazetidm-l-yl)methyl)-N-(2-(thiazol-5-yl)-l,6 - naphthyridin-7 -yl)cyclohexane - 1 -carboxamide 613.

[0780] Pale yellow solid (10.5 mg, 0.02 mmol, 15.1% yield). ¾ NMR (499 MHz, DMSO- e) δ ppm 0.86 - 0.98 (2 H, m), 1.25 - 1.34 (1 H, m), 1.44 (2 H, qd, J=12.76, 3.16 Hz), 1.77 - 1.83 (2 H, m), 1.84 - 1.90 (2 H, m), 2.29 (2 H, d, .7=6.59 Hz), 2.52 - 2.56 (1 H, m), 2.97 - 3.08 (2 H, m), 3.50 - 3.59 (2 H, m), 5.12 (1 H, dquin, J=58.00, 5.00, 5.00, 5.00, 5.00 Hz), 8.17 (1 H, d, 7=8.51 Hz), 8.50 (1 H, s), 8.54 (1 H, d, J=8.78 Hz), 8.87 (1 H, s), 9.16 (1 H, s), 9.29 (1 H, s), 10.67 (1 H, s); ESIMS found for C22H 24 FN 5 OS mlz 426.15 (M+1).

624

[0781] 4-(Piperidin-4-yloxy)-N-(2-(thiazol-5-yl)-l ,6-naphthyridin-7-yl)benzamide

624

[0782] Beige solid (13.0 mg, 0.030 mmol, 35.6% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.41 - 1.54 (2 H, m), 1.90 - 1.99 (2 H, m), 2.56 - 2.63 (2 H, m), 2.95 (2 H, dt, J=12.62, 3.84 Hz), 3.17 (1 H, d, 7=4.39 Hz), 4.55 (1 H, tt, J=8.88, 4.15 Hz), 7.06 (2 H, d, J=9.06 Hz), 8.07 (2 H, d, .7=8.78 Hz), 8.21 (1 H, d, .7=8.51 Hz), 8.58 (1 H, d, .7=8.51 Hz), 8.66 (1 H, s), 8.89 (1 H, s), 9.24 (1 H, s), 9.31 (1 H, s), 10.89 (1 H, s); ESIMS found for C 23 H 21 N 5 O 2 S mlz 432.1 (M+1).

625

[0783] N-(2-(Thiazol-5-yl)-l,6-naphthyridin-7-yl)isonicotinamide 625.

[0784] Beige solid (12.0 mg, 0.036 mmol, 7.0% yield). ¾ NMR (500 MHz, DMSO- d 6 ) δ ppm 7.95 - 8.00 (2 H, m), 8.26 (1 H, d, J=8.51 Hz), 8.59 - 8.64 (1 H, m), 8.67 - 8.68 (1 H, m), 8.78 - 8.83 (2 H, m), 8.91 (1 H, s), 9.28 (1 H, d, J=0.82 Hz), 9.32 (1 H, s), 11.44 (1 H, br s); ESIMS found for Ci 7 HnN 5 OS mlz 334.1 (M+1).

634

[0785] Ν-(2-(2-Μ6 1ΐ1ιίαζο1-5^1)-1,6-ηαρ1ιΐ1ιγή(1ίη-7^1)ηιο 1ιο1ίη6-4- carboxamide 634.

[0786] Beige solid (27.0 mg, 0.076 mmol, 18.4% yield). ¾ NMR (500 MHz, DMSO- d 6 ) δ ppm 2.73 (3 H, s), 3.48 - 3.54 (4 H, m), 3.59 - 3.65 (4 H, m), 8.05 (1 H, d, J=8.51 Hz), 8.19 - 8.23 (1 H, m), 8.46 (1 H, dd, J=8.78, 0.82 Hz), 8.59 (1 H, s), 9.09 (1 H, d, J=0.82 Hz), 9.48 (1 H, s); ESIMS found for Ci 7 Hi 7 N 5 0 2

640

[0787] l-Methyl-N-(2-(2-methylthiazol-5-yl)-l,6-naphthyridii -7-yl)piperidine-4- carboxamide 640.

[0788] Beige solid (9.0 mg, 0.025 mmol, 7.5% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 1.63 - 1.74 (2 H, m), 1.76 - 1.81 (2 H, m), 1.84 - 1.91 (2 H, m), 2.16 (3 H, s), 2.52 - 2.56 (1 H, m), 2.74 (3 H, s), 2.82 (2 H, br d, J=11.53 Hz), 8.11 (1 H, d, J=8.51 Hz), 8.47 (1 H, s), 8.49 (1 H, d, J=8.51 Hz), 8.60 (1 H, s), 9.13 (1 H, s), 10.71 (1 H, s); ESIMS found for G 9 H 21 N 5 OS mlz 368.2 (M+l).

641

[0789] -(2-(2-Methylthiazol-5 -yl)-l ,6-naphthyridm-7-yl)isonicotinamide 641.

[0790] White solid (6.0 mg, 0.017 mmol, 4.6% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 2.75 (3 H, s), 7.94 - 8.00 (2 H, m), 8.18 (1 H, d, J=8.78 Hz), 8.57 (1 H, d, J=8.78 Hz), 8.63 (2 H, s), 8.77 - 8.82 (2 H, m), 9.25 (1 H, s), 11.41 (1 H, br s); ESIMS found for Ci 8 Hi 3 N 5 OS mlz 348.1 (M+l).

642 [0791] N-(2-(2-Methylthiazol-5-yl)-l,6-naphthyridin-7-yl)nicotinami de 642.

[0792] White solid (9.0 mg, 0.026 mmol, 7.9% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 2.75 (3 H, s), 7.54 - 7.60 ( 1 H, m), 8.17 (1 H, d, J=8.78 Hz), 8.41 ( 1 H, dt, J=7.96, 1.92 Hz), 8.56 ( 1 H, d, J=8.51 Hz), 8.63 (1 H, s), 8.64 (1 H, s), 8.78 (1 H, dd, J=4.80, 1.51 Hz), 9.19 (1 H, d, J=1.65 Hz), 9.24 (1 H, s), 1 1.37 (1 H, s); ESIMS found for Ci 8 Hi 3 N 5 OS mlz 348.1 (M+l).

643

[0793] 2-(4-Methylpiperazin-l-yl)-N-(2-(2-methylthiazol-5-yl)-l,6-n aphthyridm-7- yl)isonicotinamide 643.

[0794] Brown solid (6.0 mg, 0.014 mmol, 7.4% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 2.24 (3 H, s), 2.40 - 2.46 (4 H, m), 2.74 (3 H, s), 3.58 - 3.64 (4 R m), 7.16 ( 1 H, dd, J=5.08, 1.23 Hz), 7.47 (1 H, s), 8.17 (1 H, d, J=8.51 Hz), 8.27 (1 H, d, J=5.21 Hz), 8.56 (1 H, dd, J=8.78, 0.82 Hz), 8.63 (2 H, s), 9.24 (1 H, d, J=0.82 Hz), 1 1.27 (1 H, s); ESIMS found for C23H23N7OS mlz 446.2 (M+l).

662

[0795] 4-(Dimetliylamino)-N-(2-(2-methylthiazol-5-yl)- 1 ,6-naplitliyndin-7-yl) piperidine-l-carboxamide 662.

[0796] Beige solid (10.0 mg, 0.025 mmol, 12.2% yield). ¾ NMR (500 MHz, DMSO- d 6 ) δ ppm 1 28 - 1.38 (2 H, m), 1.74 - 1.80 (2 H, m), 2.18 (6 H, s), 2.27 - 2.34 (1 H, m), 2.73 (3 H, s), 2.80 - 2.89 (2 H, m), 4.21 (2 H, br d, J=13.45 Hz), 8.03 (1 H, d, J=8.78 Hz), 8.18 (1 H, s), 8.45 (1 H, dd, J=8.78, 0.82 Hz), 8.58 (1 H, s), 9.08 (1 H, s), 9.41 ( 1 H, s); ESIMS found for C 2 oH 2 4N 6 OS mlz 397.2 (M+l).

692

[0797] N-(2 -(Isothiazol -4 -yl) - 1 ,6 -naphthyridin-7 -yl) - 1 -methylpiperidine -4- carboxamide 692. [0798] Beige solid (50 mg, 0.14 mmol, 32.3% yield). ¾ NMR (499 MHz, DMSO-t e) δ ppm 1.80 - 1.94 (2 H, m), 2.03 - 2.14 (2 H, m), 2.51 - 2.53 (1 H, m), 2.81 (3 H, s), 2.98 (2 H, br s), 3.49 (2 H, br s), 8.14 (1 H, d, J=8.78 Hz), 8.53 - 8.62 (2 H, m), 9.21 (1 H, s), 9.38 (1 H, s), 9.90 (1 H, s), 10.96 (1 H, s); ESIMS found for Ci 8 Hi 9 N 5 OS mlz 354.1 (M+l).

764

[0799] N-(2-(Pyridin-3-yl)-l,6-naphthyridin-7-yl)cyclopropanecarbox amide 764.

[0800] White solid (30 mg, 0.10 mmol, 51.2% yield). ¾ NMR (499 MHz, DMSO- ck) δ ppm 0.82 - 0.91 (4 H, m), 2.22 - 2.33 (1 H, m), 7.57 (1 H, dd, .7=7.82, 4.80 Hz), 7.98 (1 H, dd, J=8.23, 1.65 Hz), 8.08 (1 H, s), 8.19 (1 H, d, J=8.23 Hz), 8.30 (1 H, dt, .7=8.23, 1.78 Hz), 8.68 (1 H, dd, J=4.67, 1.37 Hz), 9.08 (1 H, d, J=1.92 Hz), 9.54 (1 H, s), 11.04 (1 H, s); ESIMS found for C17H14N4O mlz 291.1 (M+l).

804

[0801] N-(2-(5-Aminopyridin-3-yl)-l,6-naphtliyridin-7-yl)-4-(piperi din-4- yloxy)benzamide 804.

[0802] Beige solid (1.3 mg, 0.003 mmol, 37.8% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 1.47 - 1.59 (2 H, m), 1.93 - 2.02 (2 H, m), 2.62 - 2.72 (2 H, m), 3.00 (2 H, dt, J=12.76, 4.19 Hz), 4.53 - 4.65 (1 H, m), 5.59 (2 H, s), 7.07 (2 H, d, J=8.78 Hz), 7.88 (1 H, t, J=2.20 Hz), 8.05 - 8.10 (3 H, m), 8.12 (1 H, d, .7=8.51 Hz), 8.54 - 8.60 (1 H, m), 8.61 (1 H, d, .7=1.92 Hz), 8.76 (1 H, s), 9.28 (1 H, s), 10.90 mlz 441.2 (M+l).

807

[0803] N-(2-(6-Aminopyridin-3-yl)- 1 ,6-naphthyridin-7-yl)-2-(4-methylpiperazin- 1 - yl)isonicotinamide 807.

[0804] Beige solid (25 mg, 0.06 mmol, 29.0% yield). ¾ NMR (499 MHz, DMSO-t/e) δ ppm 2.23 (3 H, s), 2.43 (4 H, t, .7=4.94 Hz), 3.56 - 3.66 (4 H, m), 6.56 - 6.65 (3 H, m), 7.16 (1 H, dd, .7=4.94, 1.10 Hz), 7.47 (1 H, s), 8.08 (1 H, d, J=8.78 Hz), 8.26 (1 H, d, J=4.94 Hz), 8.35 (1 H, dd, J=8.78, 2.20 Hz), 8.46 (1 H, d, J=8.78 Hz), 8.66 (1 H, s), 8.92 (1 H, d, J=2.47 Hz), 9.18 (1 H, s), 11.19 (1 H, s); ESIMS found for C 2 4H 2 4N 8 0 mlz 441.2 (M+1).

[0805] N-(2-(6-(((3-Fluoroazetidin-3-yl)methyl)amino)pyrazin-2-yl)- l,6- naphthyridin-7-yl)cyclopropanecarboxamide 871.

[0806] Yellow solid (1 mg, 0.003 mmol, 24.1% yield). ¾ NMR (499 MHz, METHANOLS) δ ρρηι 0.91 - 0.98 (2 H, m), 1.02 - 1.09 (2 H, m), 1.94 - 2.01 (1 H, m), 3.33 - 3.39 (2 H, m), 3.64 - 3.69 (2 H, m), 4.04 (2 H, d, J=22.50 Hz), 8.06 (1 H, s), 8.49 - 8.53 (1 H, m), 8.55 - 8.58 (1 H, m), 8.66 (1 H, s), 8.89 (1 H, s), 9.13 (1 H, d, J=0.82 Hz); ESIMS found for C 21 H 22 FN 7 O mlz 408.2 (M+1).

877

[0807] N-(2-(6-(Piperidin-4-ylamino)pyrazin-2-yl)-l,6-naphthyridin- 7- yl)tetrahydro-2H-pyran-4-carboxamide 877.

[0808] Beige solid (40 mg, 0.09 mmol, 70.3% yield). ¾ NMR (500 MHz, DMSO-ifc) δ ppm 1.32 - 1.44 (2 H, m), 1.64 - 1.81 (4 H, m), 1.91 - 2.00 (2 H, m), 2.57 - 2.67 (2 H, m), 2.81 - 2.91 (1 H, m), 2.96 - 3.04 (2 H, m), 3.35 - 3.40 (2 H, m), 3.93 (3 H, dt, J=9.26, 1.96 Hz), 7.28 (1 H, d, J=7.14 Hz), 8.05 (1 H, s), 8.36 (1 H, d, J=8.51 Hz), 8.60 (1 H, d, .7=8.51 Hz), 8.62 (1 H, s), 8.78 (1 H, s), 9.23 (1 H, s), 10.78 (1 H, s); ESIMS found for C23H27N7O2 mlz 434.2 (M+1).

892

[0809] N-(2 -(6 -(Azetidin-3 -ylmethoxy)pyrazin-2 -yl) - 1 ,6 -naphthyridin-7 -yl) -4- fluorobenzamide 892.

[0810] Yellow solid (12 mg, 0.03 mmol, 58.5% yield). ¾ NMR (499 MHz, DMSO- ck) δ ppm 3.11 (1 H, br d, J=4.12 Hz), 3.39 - 3.47 (2 H, m), 3.62 (2 H, br s), 4.65 (2 H, br d, J=6.86 Hz), 7.38 (2 H, t, J=8.78 Hz), 8.19 (2 H, dd, J=8.78, 5.49 Hz), 8.47 (1 H, s), 8.49 (1 H, d, J=8.51 Hz), 8.70 (1 H, d, .7=8.51 Hz), 8.79 (1 H, s), 9.33 (1 H, s), 9.35 (1 H, s), 1 1.14 (1 H, br s); ESIMS found for C23H19FN6O2 m/z 431.2 (M+l).

[0811] N-(2-(lH-Pyrrolo[2,3-c]pyridin-4-yl)-l,6-naphtliyridin-7-yl) -l-(l- methylpiperidin-4-yl)-lH-pyrazole-4-carboxamide 896.

[0812] Yellow solid (2 mg, 0.004 mmol, 21.5% yield). ¾ NMR (499 MHz, METHANOLS) δ ppm 2.12 - 2.23 (4 H, m), 2.26 - 2.34 (2 H, m), 2.36 (3 H, s), 3.04 (2 H, br d, J=12.08 Hz), 4.25 - 4.35 (1 H, m), 7.27 (1 H, d, J=2.74 Hz), 7.76 (1 H, d, J=3.02 Hz), 8.11 - 8.19 (2 H, m), 8.47 (1 H, s), 8.56 (1 H, d, J=8.78 Hz), 8.74 (1 H, br s), 8.84 (1 H, br s), 8.85 (1 H, s), 9.20 (1 H, s); ESIMS found for C 2 5H 2 4N 8 0 m/z 453.2 (M+l).

909

[0813] N-(7 -( 1 -Methyl- 1 H-pyrazol -4 -yl)quinazolin-2-yl)cyclopropanecarboxamide

909

[0814] White solid (12 mg, 0.04 mmol, 23.0% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 0.81 - 0.90 (4 H, m), 2.22 - 2.31 (1 H, m), 3.91 (3 H, s), 7.83 (1 H, dd, J=8.51, 1.65 Hz), 7.89 - 7.92 (1 H, m), 8.01 (1 H, d, J=8.23 Hz), 8.14 (1 H, d, J=0.82 Hz), 8.45 (1 H, s), 9.36 (1 H, s), 10.91 (1 H, s); ESIMS found for Ci 6 Hi 5 N 5 0 mlz 294 A (M+l).

954

[0815] (S)-N-(7-(l -Methyl- lH-pyrazol-4-yl)quinazolm-2-yl)-2-(2-methylpyrrolidin- l-yl)acetamide 954.

[0816] White solid (30 mg, 0.09 mmol, 64.6% yield). ¾ NMR (499 MHz, DMSO- c¾) 6 ppm 1.09 (3 H, d, J=6.04 Hz), 1.39 (1 H, dddd, J=12.28, 10.29, 8.30, 6.45 Hz), 1.66 - 1.82 (2 H, m), 1.90 - 1.98 (1 H, m), 2.39 (1 H, q, J=8.51 Hz), 2.56 - 2.66 (1 H, m), 3.14 (1 H, d, .7=16.19 Hz), 3.14 - 3.21 (1 H, m), 3.60 (1 H, d, .7=16.47 Hz), 3.91 (3 H, s), 7.85 (1 H, dd, J=8.37, 1.51 Hz), 7.98 (1 H, d, J=0.82 Hz), 8.03 (1 H, d, .7=8.51 Hz), 8.16 (1 H, s), 8.47 (1 H, s), 9.37 (1 H, s), 10.16 (1 H, s); ESIMS found for Ci9H 2

963

[0817] 2-(Cyclobutyl(methyl)amino)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2- yl)acetamide 963.

[0818] White solid (25 mg, 0.07 mmol, 43.1% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.53 - 1.68 (2 H, m), 1.78 - 1.91 (2 H, m), 1.97 - 2.06 (2 H, m), 2.22 (3 H, s), 3.09 (1 H, quin, .7=7.82 Hz), 3.17 (2 H, s), 3.91 (3 H, s), 7.85 (1 H, dd, J=8.51, 1.65 Hz), 7.98 (1 H, d, .7=1.37 Hz), 8.03 (1 H, d, -7=8.51 Hz), 8.16 (1 H, s), 8.47 (1 H, s), 9.37 (1 H, s), 10.18 (1 H, s); ESIMS found for Ci 9 H 2 2N 6 0 mlz 351.2 (M+l).

969

[0819] (R)-N-(7-( 1 -Methyl-lH-pyrazol-4-yl)qumazolin-2-yl)pyrrolidine-2- carboxamide 969.

[0820] Off-white solid (5 mg, 0.02 mmol, 14.1% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.90 - 2.04 (3 H, m), 2.17 - 2.29 (1 H, m), 3.58 - 3.70 (1 H, m), 3.73 - 3.83 (1 H, m), 3.87 - 3.90 (3 H, m), 4.47 - 4.54 (1 H, m), 6.88 (1 H, br s), 7.35 (1 H, br s), 7.50 (1 H, dd, J=8.23, 1.65 Hz), 7.79 (1 H, d, J=8.23 Hz), 8.07 (1 H, br s), 8.38 (1 H, s), 9.05 (1 H, br s); ESIMS found for CivHisNeO m!z 323.2 (M+l).

978

[0821] N-(7-(l-Methyl-lH-pyrazol-4-yl)quinazolm-2-yl)-2-(piperidin- l- yl)propanamide 978.

[0822] Beige solid (26 mg, 0.07 mmol, 21.4% yield). Ή NMR (499 MHz, DMSO-t/e) 5 pm 1.18 (3 H, d, J=6.86 Hz), 1.37 - 1.44 (2 H, m), 1.55 (4 H, br d, J=3.84 Hz), 2.51 - 2.57 (4 H, m), 3.44 - 3.51 (1 H, m), 3.91 (3 H, s), 7.84 (1 H, dd, J=8.37, 1.51 Hz), 7.97 (1 H, s), 8.03 (1 H, d, J=8.51 Hz), 8.16 (1 H, s), 8.47 (1 H, s), 9.37 (1 H, s), 10.32 (1 H, s); ESIMS found for C2oH 2 4N 6 0 m!z 365.2 (M+l).

985

[0823] N-(7-(l -Methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-moφholinoacetamide

985

[0824] Beige solid (14.0 mg, 0.040 mmol, 4.5% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 2.54 - 2.61 (4 H, m), 3.32 (2 H, s), 3.60 - 3.66 (4 H, m), 3.91 (3 H, s), 7.85 (1 H, dd, J=8.37, 1.51 Hz), 7.97 (1 H, s), 8.03 (1 H, d, J=8.51 Hz), 8.16 (1 H, s), 8.47 (1 H, s), 9.37 (1 H, s), 10.28 (1 H, s); ESIMS found for Ci8H 2 oN 6 02 mlz 353.15 (M+l).

994

[0825] N-(7-( 1 -Methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(morpholin-2- yl)acetamide 994.

[0826] Beige solid (35 mg, 0.10 mmol, 33.0% yield). "H NMR (499 MHz, DMSO- ck) δ ppm 2.40 (1 H, dd, J=11.94, 10.29 Hz), 2.53 - 2.62 (2 H, m), 2.64 (1 H, br s), 2.70 (1 H, br dd, J=14.82, 7.68 Hz), 2.81 - 2.88 (1 H, m), 3.42 (1 H, td, J=10.77, 3.43 Hz), 3.69 (1 H, br d, J=10.70 Hz), 3.78 - 3.86 (1 H, m), 3.91 (3 H, s), 7.83 (1 H, dd, J=8.37, 1.51 Hz), 7.92 (1 H, d, J=1.37 Hz), 8.02 (1 H, d, J=8.23 Hz), 8.15 (1 H, s), 8.46 (1 H, s), 9.35 (1 H, s), 10.60 (1 H, s); ESIMS found for CisftoNeCh

1003

[0827] N-(7-( 1 -Methyl- lH-pyrazol-4-yl)quinazolm-2-yl)- 1 -(oxazol-2-ylmethyl) piperidine-4-carboxamide 1003.

[0828] Off-white solid (22 mg, 0.05 mmol, 28.1% yield). ¾ NMR (499 MHz, DMSO- e) δ ppm 1.64 (2 H, qd, J=12.21, 3.70 Hz), 1.81 (2 H, br d, J=11.25 Hz), 2.11 (2 H, td, J=11.60, 2.06 Hz), 2.59 - 2.70 (1 H, m), 2.88 (2 H, br d, J=11.53 Hz), 3.67 (2 H, s), 3.91 (3 H, s), 7.17 (1 H, d, J=0.82 Hz), 7.83 (1 H, dd, J=8.37, 1.51 Hz), 7.91 (1 H, d, J=0.82 Hz), 8.01 (1 H, d, J=8.51 Hz), 8.08 (1 H, s), 8.14 (1 H, d, J=0.82 Hz), 8.44 (1 H, s), 9.34 (1 H, s), 10.59 (1 H, s); ESIMS found for C22H23N7O2 mlz 418.2 (M+l).

1013

[0829] 2-(4-Methyl-l ,4-diazepan-l -yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin- 2-yl)acetamide 1013.

[0830] Beige solid (35 mg, 0.09 mmol, 61.8% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ppm 1.71 - 1.80 (2 H, m), 2.26 (3 H, s), 2.53 - 2.59 (4 H, m), 2.79 - 2.85 (4 H, m), 3.43 (2 H, s), 3.91 (3 H, s), 7.84 (1 H, dd, J=8.37, 1.51 Hz), 7.97 (1 H, s), 8.03 (1 H, d, J=8.51 Hz), 8.16 (1 H, s), 8.47 (1 H, s), 9.37 (1 H, s), 10.24 (1 H, s); ESIMS found for C20H25N7O mlz 380.2 (M+l).

1029

[0831] 2-( 1 -Isobutylpyrrolidin-3 -yl)-N-(7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2- yl)acetamide 1029. [0832] Beige solid (4 mg, 0.01 mmol, 17.1% yield). 'H NMR (499 MHz, DMSO-i 6 ) δ ppm 0.86 (6 H, d, J=6.59 Hz), 1.38 - 1.46 (1 H, m), 1.66 (1 H, dt, .7=13.65, 6.76 Hz), 1.91 - 2.02 (1 H, m), 2.09 - 2.21 (3 H, m), 2.40 - 2.49 (2 H, m), 2.52 - 2.58 (1 H, m), 2.62 - 2.70 (3 H, m), 3.91 (3 H, s), 7.83 (1 H, dd, J=8.23, 1.65 Hz), 7.91 (1 H, d, J=0.82 Hz), 8.01 (1 H, d, J=8.51 Hz), 8.14 (1 H, s), 8.45 (1 H, s), 9.34 (1 H, s), 10.60 (1 H, s); ESIMS found for C 2 2H 2 8N 6 0 mlz 393.25 (M+l).

1047

[0833] N-(7-(l-Methyl-lH-pyrazol-4-yl)quinazolm-2-yl)-3-(4-methylpi perazin-l-yl) benzamide 1047.

[0834] Yellow solid (5.8 mg, 0.014 mmol, 8.7% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 2.24 (3 H, s), 2.45 - 2.49 (4 H, m), 3.21 - 3.27 (4 H, m), 3.92 (3 H, s), 7.17 (1 H, dd, J=8.23, 1.92 Hz), 7.34 (1 H, t, J=7.82 Hz), 7.40 - 7.46 (1 H, m), 7.55 - 7.60 (1 H, m), 7.88 (1 H, dd, J=8.51, 1.65 Hz), 7.99 (1 H, d, .7=1.37 Hz), 8.07 (1 H, d, .7=8.51 Hz), 8.16 (1 H, s), 8.47 (1 H, s), 9.44 (1 H, s), 11.03 (1 H, s); ESIMS found for C24H25N7O mlz 428.2 (M+l).

1052

[0835] N-(7-( 1 -Methyl- lH-pyrazol-4-yl)quinazolm-2-yl)-4-(( 1 -methylpiperidin-4- yl)oxy)benzamide 1052.

[0836] Yellow solid (6.7 mg, 0.01 mmol, 30.8% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 1.61 - 1.72 (2 H, m), 1.93 - 2.01 (2 H, m), 2.15 - 2.24 (2 H, m), 2.19 (3 H, s), 2.59 - 2.64 (2 H, m), 3.91 (3 H, s), 4.50 - 4.54 (1 H, m), 7.03 - 7.09 (2 H, m), 7.86 - 7.89 (1 H, m), 7.97 (1 H, d, J=0.82 Hz), 7.99 (2 H, d, J=8.78 Hz), 8.06 (1 H, d, J=8.51 Hz), 8.16 (1 H, s), 8.47 (1 H, s), 9.42 (1 H, s), 10.91 (1 H, br s); ESIMS found for CzsHzeNeOz mlz 443.2 (M+l).

1054

[0837] N-(7-(l-Methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4-methylp iperazin-l-yl) isonicotinamide 1054. [0838] Yellow solid (3.0 mg, 0.07 mmol, 6.4% yield). ¾ NM (499 MHz, DMSO- £¼) δ ppm 2.23 (3 H, s), 2.40 - 2.45 (4 H, m), 3.55 - 3.63 (4 H, m), 3.92 (3 H, s), 7.10 (1 H, dd, .7=4.94, 1.10 Hz), 7.39 (1 H, s), 7.90 (1 H, dd, J=8.37, 1.51 Hz), 7.99 (1 H, s), 8.08 (1 H, d, .7=8.51 Hz), 8.16 (1 H, s), 8.25 (1 H, d, J=5.21 Hz), 8.47 (1 H, s), 9.45 (1 H, s), 11.23 (1 H, br s); ESIMS found for C23H24N8O mlz A29.2 (M+l).

1058

[0839] N-(7-(l-Methyl-lH-pyrazol-4-yl)quinazolm-2-yl)-6-(4-methylpi perazin-l- yl)nicotinamide 1058.

[0840] Yellow solid (11 mg, 0.03 mmol, 2.3% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 2.23 (3 H, s), 2.40 (4 H, t, .7=4.94 Hz), 3.63 - 3.67 (4 H, m), 3.91 (3 H, s), 6.90 (1 H, d, J=9.06 Hz), 7.86 (1 H, dd, J=8.37, 1.51 Hz), 7.96 - 7.99 (1 H, m), 8.06 (1 H, d, J=8.51 Hz), 8.10 (1 H, dd, J=9.06, 2.47 Hz), 8.16 (1 H, s), 8.46 (1 H, s), 8.77 (1 H, d, J=2.47 Hz), 9.41 (1 H, s), 10.90 (1 H, s) ESIMS found for C 2 3H 2 4N 8 0 mlz 429.2 (M+l).

1060

[0841] N-(7-(l -Methyl- lH-pyrazol-4-yl)quinazolm-2-yl)-2-(piperidin-4- yloxy)isonicotinamide 1060.

[0842] Yellow solid (3.5 mg, 0.008 mmol, 5.6% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.47 - 1.58 (2 H, m), 1.92 - 1.99 (2 H, m), 2.55 - 2.62 (2 H, m), 2.92 - 3.01 (2 H, m), 3.91 (3 H, s), 5.05 - 5.13 (1 H, m), 7.25 - 7.29 (2 H, m), 7.42 (1 H, dd, J=5.21, 1.37 Hz), 7.89 (1 H, br d, J=9.33 Hz), 7.99 (1 H, s), 8.07 (1 H, d, J=8.51 Hz), 8.16 (1 H, s), 8.29 (1 H, d, J=5.21 Hz), 8.47 (1 H, s), 9.43 (1 H, s); ESIMS 430.2 (M+l).

1071

[0843] 2-((2-(Dimethylamino)ethyl)amino)-N-(7-(l-methyl-lH-pyrazol- 4- yl)quinazolin-2-yl)isonicotinamide 1071. [0844] Light yellow wax (5.5 mg, 0.01 mmol, 2.7% yield). ¾ NMR (499 MHz, DMSO- e) δ ppm 2.18 (6 H, s), 2.42 (2 H, t, J=6.72 Hz), 3.34 - 3.42 (2 H, m), 3.91 (3 H, s), 6.63 (1 H, br t, J=5.49 Hz), 6.94 (1 H, dd, J=5.21, 1.37 Hz), 6.98 (1 H, s), 7.90 (1 H, dd, J=8.51, 1.65 Hz), 7.99 (1 H, s), 8.08 (1 H, d, J=8.51 Hz), 8.10 (1 H, d, J=5.21 Hz), 8.17 (1 H, s), 8.48 (1 H, s), 9.43 (1 H, s), 11.08 (1 H, br s); ESIMS found for C22H24 8O mlz 417.2 (M+l).

1077

[0845] 4-((Dimethylamino)methyl)-N-(7-(l-methyl-lH-pyrazol-4-yl)qui nazolin-2- yl)benzamide 1077.

[0846] Yellow solid (4.1 mg, 0.01 mmol, 3.0% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 2.17 (6 H, s), 3.47 (2 H, s), 3.91 (3 H, s), 7.43 (2 H, d, J=8.23 Hz), 7.88 (1 H, dd, J=8.51,

I .65 Hz), 7.96 - 8.00 (3 H, m), 8.07 (1 H, d, J=8.51 Hz), 8.16 (1 H, s), 8.47 (1 H, s), 9.43 (1 H, s),

I I .04 (1 H, s); ESIMS found (M+l).

1079

[0847] N-(7-( 1 -Methyl- lH-pyrazol-4-yl)quinazolm-2-yl)-3-((4-methylpiperazin- 1 - yl)methyl)benzamide 1079.

[0848] Yellow solid (28 mg, 0.06 mmol, 14.3% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 2.13 (3 H, s), 2.22 - 2.35 (4 H, m), 2.35 - 2.47 (3 H, m), 3.52 (2 H, s), 3.91 (3 H, s), 7.43 - 7.49 (1 H, m), 7.50 - 7.56 (1 H, m), 7.88 (1 H, br d, J=1.65 Hz), 7.89 - 7.91 (2 H, m), 7.96 - 7.99 (1 H, m), 8.07 (1 H, d, J=8.23 Hz), 8.16 (1 H, s), 8.47 (1 H, s), 9.43 (1 H, s), 11.08 (1 H, br s); ESIMS found for C25H27N7O mlz 442.2 (M+l).

1101

[0849] N-(7-(l -Methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-3-phenylpropanamide

1101.

[0850] Yello solid (9.7 mg, 0.03 mmol, 11.8% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 2.85 - 2.91 (2 H, m), 2.91 - 2.98 (2 H, m), 3.91 (3 H, s), 7.17 - 7.22 (1 H, m), 7.28 (2 H, s), 7.29 (2 H, d, J=1.37 Hz), 7.83 (1 H, dd, J=8.23, 1.65 Hz), 7.91 (1 H, d, .7=1.37 Hz), 8.01 (1 H, d, .7=8.51 Hz), 8.14 (1 H, s), 8.45 (1 H, s), 9.35 (1 H, s), 10.65 (1 H, s); ESIMS found for C 2 iHi 9 N 5 0 m/z 358.2 (M+l).

1109

[0851] 2-Methyl-N-(7-(l-methyl-lH-pyrazol-4-yl)quinazolm-2-yl)-l,2, 3,4- tetrahydroisoquinoline-7-carboxamide 1109.

[0852] Yellow solid (2.6 mg, 0.006 mmol, 1.9% yield). 'H NMR (499 MHz, DMSO- d 6 ) δ ppm 2.37 (3 H, s), 2.63 (2 H, t, J=5.90 Hz), 2.89 (2 H, t, J=5.76 Hz), 3.55 (2 H, s), 3.91 (3 H, s), 7.24 (1 H, d, J=7.96 Hz), 7.74 (1 H, s), 7.77 (1 H, dd, J=7.96, 1.37 Hz), 7.88 (1 H, dd, J=8.51, 1.65 Hz), 7.98 (1 H, s), 8.07 (1 H, d, J=8.51 Hz), 8.16 (1 H, s), 8.47 (1 H, s), 9.43 (1 H, s), 10.98 (1 H, br s); ESIMS found for C 23 H22N 6 0 mlz 399.2 (M+l).

1116

[0853] N-(7-( 1 -Methyl- lH-pyrazol-4-yl)quinazolin-2-yl)benzofuran-6-carboxamide

1116.

[0854] Brown solid (10.2 mg, 0.03 mmol, 12.4% yield). ¾ NMR (500 MHz, DMSO- d 6 ) δ ppm 3.92 (3 H, s), 7.09 (1 H, dd, J=2.20, 0.82 Hz), 7.79 (1 H, d, J=7.68 Hz), 7.89 (1 H, dd, J=8.51, 1.65 Hz), 7.95 (1 H, dd, J=8.10, 1.51 Hz), 8.00 - 8.03 (1 H, m), 8.08 (1 H, d, J=8.23 Hz), 8.17 (1 H, d, J=0.82 Hz), 8.20 (1 H, d, J=2.20 Hz), 8.31 (1 H, d, J=0.82 Hz), 8.48 (1 H, s), 9.45 (1 H, d, J=0.82 Hz), 11.15 (1 H, s); ESIMS found for C 2 iHi 5 N 5 0 2 mlz 370.1 (M+l).

1123

[0855] N-(7-(l-Methyl-lH-pyrazol-4-yl)quinazolin-2-yl)quinoxaline-6 -carboxamide

1123.

[0856] Brown solid (15.8 mg, 0.04 mmol, 9.8% yield). ¾ NMR (500 MHz, DMSO- d 6 ) δ ppm 3.92 (3 H, s), 7.91 (1 H, dd, J=8.51, 1.65 Hz), 8.01 - 8.04 (1 H, m), 8.10 (1 H, d, J=8.51 Hz), 8.18 (1 H, s), 8.23 (1 H, d, J=8.51 Hz), 8.38 (1 H, dd, J=8.64, 2.06 Hz), 8.49 (1 H, s), 8.78 (1 H, d, .7=1.92 Hz), 9.06 - 9.10 (2 H, m), 9.48 (1 H, s), 11.54 (1 H, s); ESIMS found for C 2 iHi 5 N 7 0 m/z 382.1 (M+l).

1136

[0857] N-(7-( 1 -Methyl- lH-pyrazol-4-yl)quinazolin-2-yl)- 1 -( 1 -methylpiperidin-4- yl)- 1 H-pyrazole-4-carboxamide 1136.

[0858] Yellow solid (1 1 mg, 0.003 mmol, 10.01% yield). ¾ NMR (499 MHz, METHANOL-^) 5 ppm 2.11 - 2.23 (4 H, m), 2.24 - 2.31 (2 H, m), 2.35 (3 H, s), 3.03 (2 H, br d, J=11.80 Hz), 3.99 (3 H, s), 4.25 - 4.33 (1 H, m), 7.85 (1 H, dd, J=8.37, 1.51 Hz), 8.00 (1 H, d, J=8.51 Hz), 8.06 (1 H, s), 8.08 (1 H, s), 8.14 (1 H, s), 8.25 (1 H, s), 8.46 (1 H, s), 9.31 (1 H, s); ESIMS found for C22H24 8O

[0859] Isopropyl 4-(4-((7-( 1 -methyl- lH-pyrazol-4-yl)quinazolin-2-yl)carbamoyl)- lH-pyrazol- 1 -yl)pipcridinc- 1 -carboxylatc 1141.

[0860] White solid (2 mg, 0.004 mmol, 16.5% yield). ¾ NMR (499 MHz, METHANOLS) δ ppm 1.28 (6 H, d, .7=6.31 Hz), 1.95 - 2.03 (2 H, m), 2.16 (2 H, br d, .7=10.70 Hz), 3.04 (2 H, br s), 3.98 (3 H, s), 4.28 (2 H, br d, J=13.17 Hz), 4.49 (1 H, tt, J=11.53, 3.98 Hz), 4.90 (1 H, dt, J=12.62, 6.31 Hz), 7.85 (1 H, dd, J=8.51, 1.37 Hz), 8.00 (1 H, d, J=8.51 Hz), 8.06 (1 H, s), 8.08 (1 H, s), 8.15 (1 H, s), 8.25 (1 H, s), 8.45 (1 H, s), 9.31 (1 H, s); ESIMS found for C25H 2 8N 8 0 3 mlz 489.3 (M+l).

1186

[0861] 2-(2-Fluoroethyl)-N-(7-(l-methyl-5-(piperidin-l-ylmethyl)-lH -pyrazol-4-yl) quinazolin-2-yl)-2-azaspiro[3.3]heptane-6-carboxamide 1186.

[0862] Beige solid (15 mg, 0.03 mmol, 27.2% yield). Ή NMR (499 MHz, DMSO-t/e) δ ppm 1.34 - 1.42 (2 H, m), 1.45 - 1.53 (4 H, m), 2.33 (4 H, d, J=8.23 Hz), 2.35 - 2.44 (4 H, m), 2.60 - 2.74 (2 H, m), 3.19 (2 H, br s), 3.57 (1 H, quin, J=7.96 Hz), 3.67 (2 H, s), 3.92 (3 H, s), 4.37 (2 H, dt, J=47.60, 5.00 Hz), 7.78 (1 H, dd, J=8.51, 1.65 Hz), 7.86 (1 H, s), 7.92 (1 H, s), 8.04 (1 H, d, J=8.23 Hz), 9.39 (1 H, s), 10.50 (1 H, s); ESIMS found for C 2 7H 34 FN 7 0 mlz 492.3 (M+1).

1189

[0863] 2^Die†Jiylamino)-N-(7^1-methyl-5-(piperidin-l-ylmethyl)-lH -pyrazol-4- yl)quinazolin-2-yl)acetamide 1189.

[0864] Beige gum (10 mg, 0.02 mmol, 14.8% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ρρι 1.04 (6 H, t, J=7.14 Hz), 1.37 (2 H, br d, J=3.84 Hz), 1.43 - 1.51 (4 H, m), 2.31 - 2.39 (4 H, m), 2.65 (4 H, q, J=7.14 Hz), 3.29 (2 H, s), 3.67 (2 H, s), 3.92 (3 H, s), 7.81 (1 H, dd, J=8.51, 1.65 Hz), 7.86 (1 H, s), 7.94 - 7.98 (1 H, m), 8.06 (1 H, d, J=8.51 Hz), 9.43 (1 H, s), 10.22 (1 H, s); ESIMS found for C24H33N7O

1210

[0865] N-(7-(5-Amino-l-methyl-lH-pyrazol-4-yl)quinazolin-2-yl)-2-(4 - methylpiperazin-1 -yl)isonicotinamide 1210.

[0866] Light yellow solid (14 mg, 0.03 mmol, 53.7% yield). l W NMR (499 MHz, DMSO-i 6 ) δ ppm 2.23 (3 H, s), 2.42 (4 H, t, J=4.94 Hz), 3.56 - 3.61 (4 H, m), 3.63 (3 H, s), 5.82 (2 H, s), 7.10 (1 H, dd, J=5.21, 1.10 Hz), 7.39 (1 H, s), 7.71 (1 H, s), 7.78 - 7.83 (1 H, m), 7.83 (1 H, s), 8.01 (1 H, d, J=8.51 Hz), 8.25 (1 H, d, J=4.94 Hz), 9.39 (1 H, s), 11.18 (1 H, s); ESIMS found for C 23 H 25 N 9 O mlz 444.2 (M+l).

1220

[0867] N-(7-( 1 -Methyl -5 -(morpholinomethyl)- lH-pyrazol-4-yl)quinazolin-2-yl)-2- morpholinoisonicotinamide 1220.

[0868] Off-white solid (55.1 mg, 0.1 1 mmol, 44.6% yield). Ή NMR (499 MHz, DMSO- 6 ) δ ppm 2.39 (4 H, br s), 3.51 - 3.59 (8 H, m), 3.71 - 3.74 (4 H, m), 3.75 (2 H, s), 3.95 (3 H, s), 7.14 (1 H, dd, J=5.08, 0.96 Hz), 7.40 (1 H, s), 7.86 (1 H, dd, J=8.37, 1.51 Hz), 7.88 (1 H, s), 7.95 (1 H, s), 8.13 (1 H, d, J=8.51 Hz), 8.28 (1 H, d, J=5.21 Hz), 9.53 (1 H, s), 11.28 (1 H, s); ESIMS found for CzvftoNgCb mlz 51 .3 (M+l).

1223

[0869] N-((4,4-Difluorocyclohexyl)methyl)-7-(5-(2-fluoroethyl)-4,5, 6,7- tetrahydropyrazolo [ 1 ,5 -a]pyrazin-3 -yl)quinazolin-2 -amine 1223.

[0870] Beige solid (3 mg, 0.007 mmol, 4.1% yield). ¾ NMR (499 MHz, METHANOLS) δ ppm 1.85 - 1.97 (4 H, m), 2.03 - 2.10 (2 H, m), 2.14 - 2.23 (2 H, m), 2.76 (1 H, br s), 3.06 (2 H, dt, J=28.30, 4.70 Hz), 3.17 - 3.23 (2 H, m), 4.16 (2 H, s), 4.28 (2 H, t, J=5.49 Hz), 4.69 (2 H, dt, J=47.90, 5.00 Hz), 7.75 (1 H, dd, J=8.51, 1.65 Hz), 7.88 (1 H, s), 7.98 - 8.03 (2 H, m), 8.52 (1 H, br s), 9.29 (1 H, s); ESIMS found for C 2 3H2 5 F3N 6 0 mlz 459.2 (M+l).

1239 [0871] 2-Fluoro-2 -methyl -N-(7-( 1 -methyl- 1H- l,2,3-triazol-4-yl)quinazolin-2-yl) propanamide 1239.

[0872] Beige solid (8 mg, 0.03 mmol, 9.6% yield). ¾ NMR (499 MHz, DMSO-de) δ ppm 1.63 (6 H, d, J=22.00 Hz), 4.15 (3 H, s), 8.13 - 8.22 (2 H, m), 8.28 (1 H, d, J=1.37 Hz), 8.87 (1 H, s), 9.53 (1 H, s), 10.36 (1 H, d, J=3.02 Hz); ESIMS found for Ci 5 Hi 5 FN 6 0 mlz 315.1 (M+1).

1253

[0873] N-(7-( 1 -Methyl- 1H- 1 ,2,3-triazol-4-yl)quinazolin-2-yl)- 1 -(( 1 - (trifluoromcthyl)cyclopropyl)mcthyl)pipcridinc -4 -carboxamidc 1253.

[0874] Off-white solid (30 mg, 0.07 mmol, 35.0% yield). ¾ NMR (499 MHz, DMSO-t/e) δ ppm 0.73 (2 H, s), 0.93 - 0.99 (2 H, m), 1.64 (2 H, qd, J=12.12, 3.70 Hz), 1.80 (2 H, br d, J=10.43 Hz), 1.93 - 2.01 (2 H, m), 2.67 - 2.77 (1 H, m), 2.97 (2 H, br d, J=11.53 Hz), 4.15 (3 H, s), 8.07 - 8.11 (1 H, m), 8.11 - 8.14 (1 H, m), 8.19 - 8.22 (1 H, m), 8.85 (1 H, s), 9.45 (1 H, s), 10.68 (1 H, s); ESIMS found (M+1).

1254

[0875] N-(7-( 1 -Methyl- 1H- 1 ,2,3-triazol-4-yl)quinazolin-2-yl)- 1 -((3-methyloxetan- 3 -yl)methyl)piperidine -4 -carboxamide 1254.

[0876] Tan solid (3 mg, 0.007 mmol, 4.0% yield). ¾ NMR (499 MHz, DMSO-ds) δ ppm 1.31 (3 H, s), 1.60 - 1.69 (2 H, m), 1.78 (2 H, br dd, J= 11.66, 1.23 Hz), 1.95 - 2.03 (2 H, m), 2.59 - 2.64 (2 H, m), 3.04 - 3.13 (2 H, m), 3.35 - 3.39 (1 H, m), 4.15 (3 H, s), 4.19 (2 H, d, J=5.49 Hz), 4.36 (2 H, d, J=5.76 Hz), 8.06 - 8.11 (1 H, m), 8.11 - 8.16 (1 H, m), 8.19 (1 H, s), 8.85 (1 H, s), 9.44 (1 H, s), 10.68 (1 H, s); ESIMS found for C22H27N7O2 mlz 422.2 (M+1).

1264

[0877] 2-(4-Methoxypipendin-l-yl)-N-(7-(l-methyl-lH-l,2,3-tnazol-4- yl) quinazolin-2-yl)acetamide 1264. [0878] Beige solid (20 mg, 0.05 mmol, 23.7% yield). ¾ NMR (499 MHz, DMSO-t e) δ ppm 1.43 - 1.52 (2 H, m), 1.86 (2 H, br dd, 7=9.47, 3.98 Hz), 2.31 - 2.40 (2 H, m), 2.74 - 2.82 (2 H, m), 3.16 - 3.22 (1 H, m), 3.23 (3 H, s), 3.28 (2 H, s), 4.14 (3 H, s), 8.09 - 8.13 (1 H, m), 8.13 - 8.18 (1 H, m), 8.24 (1 H, s), 8.87 (1 H, s), 9.47 (1 H, s), 10.31 (1 H, s); ESIMS found for C19H23N7O2 miz 382.2 (M+1).

1278

[0879] N 2 -Methyl-N 5 -(7-(l-methyl-lH-l,2,3 riazol-4-yl)quinazolin-2-yl)pyridine- 2,5-dicarboxamide 1278.

[0880] Beige solid (87 mg, 0.20 mmol, 45.6% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ppm 2.85 (3 H, d, J=4.94 Hz), 4.15 (3 H, s), 8.14 - 8.22 (3 H, m), 8.26 (1 H, s), 8.50 (1 H, dd, J=8.23, 2.20 Hz), 8.88 (1 H, s), 8.92 - 8.97 (1 H, m), 9.15 (1 H, d, J=2.20 Hz), 9.56 (1 H, s), 11.58 (1 H, s); ESIMS found for

1282

[0881] 2-(4-(Dimethylainmo)piperidin-l-yl)-N-(7-(l-methyl-lH-l,2,3- triazol-4-yl) quinazolin-2-yl)isonicotinamide 1282.

[0882] Beige solid (11 mg, 0.02 mmol, 17.6% yield). Ή NMR (499 MHz, DMSO-de) δ ppm 1.30 - 1.44 (2 H, m), 1.83 (2 H, br d, .7=12.35 Hz), 2.19 (6 H, s), 2.28 - 2.36 (1 H, m), 2.84 - 2.95 (2 H, m), 4.15 (3 H, s), 4.41 (2 H, br d, .7=13.17 Hz), 7.06 (1 H, dd, J=4.94, 1.10 Hz), 7.39 (1 H, s), 8.15 - 8.18 (1 H, m), 8.18 - 8.22 (1 H, m), 8.24 (1 H, d, .7=5.21 Hz), 8.28 (1 H, s), 8.88 (1 H, s), 9.55 (1 H, s), 11.32 (1 H, br s); ESIMS found for C24H27N9O miz 458.2 (M+1).

1285

[0883] 2-(4-Methyl-l,4-diazepan-l-yl)-N-(7-(l-methyl-lH-l,2,3-triaz ol-4-yl) quinazolin-2-yl)isonicotinamidc 1285. [0884] Beige solid (10 mg, 0.02 mmol, 16.5% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ppm 1.87 - 1.97 (2 H, m), 2.26 (3 H, s), 2.47 (2 H, br d, J=5.76 Hz), 2.59 - 2.66 (2 H, m), 3.67 (2 H, t, J=6.04 Hz), 3.77 - 3.83 (2 H, m), 4.15 (3 H, s), 7.00 (1 H, dd, J=5.08, 0.96 Hz), 7.14 (1 H, s), 8.13 - 8.18 (1 H, m), 8.18 - 8.23 (2 H, m), 8.27 (1 H, s), 8.87 (1 H, s), 9.55 (1 H, s), 11.31 (1 H, br s); ESIMS found for C 2 3H 2

1288

[0885] 2-(Methyl(l -methylpiperidin-4-yl)amino)-N-(7-( 1 -methyl- 1H- 1 ,2,3 -triazol- 4-yl)quinazolin-2-yl)isonicotinamide 1288.

[0886] Off-white solid (4 mg, 0.008 mmol, 4.5% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 1.51 - 1.62 (2 H, m), 1.74 - 1.85 (2 H, m), 2.02 (2 H, br t, .7=10.84 Hz), 2.19 (3 H, s), 2.85 (2 H, br d, J=\ 1.25 Hz), 2.92 (3 H, s), 4.15 (3 H, s), 4.43 - 4.55 (1 H, m), 7.02 (1 H, dd, J=5.08, 1.23 Hz), 7.13 (1 H, s), 8.15 - 8.18 (1 H, m), 8.19 - 8.21 (1 H, m), 8.22 (1 H, d, J=4.94 Hz), 8.28 (1 H, s), 8.88 (1 H, s), 9.55 (1 H, s), 11.30 (1 H, br s); ESIMS found for C24H27N9O mlz 458.2 (M+l).

1297

[0887] N-(7-(4-Methyl-4H-l,2,4-triazol-3-yl)quinazolin-2-yl)-l-(3,3 ,3- trifluoropropyl)piperidine-4-carboxamide 1297.

[0888] Off-white solid (10 mg, 0.02 mmol, 14.8% yield). ¾ NMR (499 MHz, DMSO-c e) δ ppm 1.63 (2 H, qd, J=12.21, 3.43 Hz), 1.83 (2 H, br d, J=10.98 Hz), 1.94 - 2.03 (2 H, m), 2.40 - 2.55 (4 H, m), 2.70 (1 H, br t, J=l 1.53 Hz), 2.93 (2 H, br d, J=\ 1.25 Hz), 3.88 (3 H, s), 7.99 (1 H, dd, J=8.37, 1.51 Hz), 8.10 (1 H, s), 8.22 (1 H, d, J=8.51 Hz), 8.69 (1 H, s), 9.57 (1 H, s), 10.80 (1 H, s); ESIMS found for mlz 434.2 (M+l).

1306 [0889] 4,4-Difluoro-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2-yl )cj'clohexane- 1 -carboxamide 1306.

[0890] Dark pink solid (45 mg, 0.12 mmol, 27.3% yield). ¾ NMR (499 MHz, DMSO-A) δ ppm 1.63 - 1.75 (2 H, m), 1.76 - 1.94 (2 H, m), 1.95 - 2.02 (2 H, m), 2.07 - 2.18 (2 H, m), 2.85 - 2.96 (1 H, m), 3.84 (3 H, s), 7.39 (1 H, d, J=1.10 Hz), 7.77 (1 H, dd, J=8.23, 1.65 Hz), 7.84 (1 H, s), 7.85 - 7.87 (1 H, m), 8.11 (1 H, d, J=8.23 Hz), 9.47 (1 H, s), 10.79 (1 H, br s); ESIMS found for Ci 9 Hi 9 F 2 N 5 0 mlz 372.2 (M+l).

1322

[0891] 3-Isopropoxj'-N-(7-(l-methyl-lH-imidazol-5-yl)quinazolin-2- yl)propanamide 1322.

[0892] Beige solid (3 mg, 0.009 mmol, 4.3% yield). ¾ NMR (500 MHz, DMSO-t e) δ ppm 1.08 (6 H, d, J=6.04 Hz), 2.76 (2 H, t, J=6.17 Hz), 3.57 (1 H, dquin, J=\2. \6, 6.08, 6.08, 6.08, 6.08 Hz), 3.68 (2 H, t, J=6.31 Hz), 3.84 (3 H, s), 7.39 (1 H, s), 7.77 (1 H, dd, J=8.51, 1.37 Hz), 7.84 (2 H, s), 8.11 (1 H, d, J=8.51 Hz), 9.47 (1 H, s), 10.71 (1 H, s); ESIMS found for C18H21N5O2 mlz 340.15 (M+l).

1353

[0893] N-(7-( 1 ,2-Dimethyl-lH-imidazol-5 -yl)quinazolin-2-yl)-2-methylthiazole-5 - carboxamide 1353.

[0894] Beige solid (3 mg, 0.008 mmol, 4.9% yield). ¾ NMR (500 MHz, DMSO-£ 6 ) δ ppm 2.41 (3 H, s), 2.72 (3 H, s), 3.70 (3 H, s), 7.25 (1 H, s), 7.76 (1 H, dd, J=8. 1, 1.65 Hz), 7.81 (1 H, s), 8.16 (1 H, d, J=8.23 Hz), 8.60 (1 H, s), 9.55 (1 H, s), 11.43 (1 H, s); ESIMS found for Ci 8 Hi 6 N 6 OS mlz 365.1 (M+l).

1354

[0895] 4-Fluoro-N-(7-( l-methyl-lH-imidazol-5-yl)quinazolin-2-yl)benzamide 1354. [0896] White solid (130 mg, 0.09 mmol, 19.5% yield). ¾ NMR (499 MHz, DMSO- £¼) δ ppm 3.86 (3 H, s), 7.36 (2 H, t, 7=8.92 Hz), 7.42 (1 H, d, .7=1.10 Hz), 7.83 (1 H, dd, J=8.23,

I .65 Hz), 7.85 (1 H, s), 7.91 (1 H, s), 8.07 - 8.13 (2 H, m), 8.17 (1 H, d, .7=8.51 Hz), 9.55 (1 H, s),

I I .25 (1 H, s); ESIMS found (M+1).

1356

[0897] N-(7-(l-Methyl-lH-imidazol-5-yl)quinazolin-2-yl)-3-(pyrrolid in-l- ylmethyl)benzamide 1356.

[0898] Pink solid (55 mg, 0.13 mmol, 30.0% yield). ¾ NMR (499 MHz, DMSO ) δ ppm 1.66 - 1.75 (4 H, m), 2.45 (4 H, br s), 3.65 (2 H, s), 3.86 (3 H, s), 7.42 (1 H, s), 7.47 (1 H, d, 7=7.96 Hz), 7.54 (1 H, d, 7=7.68 Hz), 7.82 - 7.86 (2 H, m), 7.87 - 7.91 (2 H, m), 7.94 (1 H, s), 8.17 (1 H, d, J=8.51 Hz), 9.55 (1 H, s), 11.18 (1 H, s); ESIMS found for C 24 H 24 N 6 0 m/z 413.1 (M+1).

1383

[0899] N-(7-(l-Methyl-lH-imidazol-5-yl)quinazolin-2-yl)isoindoline- 5- carboxamide 1383.

[0900] Brick red solid (15 mg, 0.04 mmol, 54.4% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 3.86 (4 H, s), 4.13 (3 H, s), 7.39 (1 H, d, 7=7.68 Hz), 7.42 (1 H, s), 7.83 - 7.86 (3 H, m), 7.86 - 7.89 (1 H, m), 7.91 (2 H, s), 8 16 (1 H, d, .7=8.23 Hz), 9 55 (1 H, s); ESIMS found for C 2 iHi 8 N 6 0 m/z 371.15 (M+1)

1438

[0901] N-(7-(Oxazol-5-yl)quinazolin-2-yl)-l-(2-(pyrrolidin-l-yl)ace tyl)piperidine- 4-carboxamide 1438.

[0902] White solid (5.0 mg, 0.01 mmol, 4.7% yield). 'H NMR (499 MHz, DMSO-c 6 ) δ ppm 1.44 - 1.54 (1 H, m), 1.62 - 1.73 (1 H, m), 1.77 - 1.83 (2 H, m), 1.86 - 1.90 (4 H, m), 2.70 - 2.79 (1 H, m), 2.86 (1 H, br s), 3.07 (4 H, br s), 3.08 - 3.13 (1 H, m), 3.81 (1 H, br d, J=13.17 Hz), 3.93 - 4.02 (1 H, m), 4.08 - 4.17 (1 H, m), 4.40 (1 H, br d, J=12.90 Hz), 7.97 (1 H, dd, 7=8.51, 1.65 Hz), 8.04 (1 H, s), 8.08 (1 H, s), 8.16 (1 H, d, J=8.51 Hz), 8.62 (1 H, s), 9.48 (1 H, s), 10.83 (1 H, s), ESIMS found for C 2 3H2 6 N 6

1447

[0903] fr i75-4-(Hydroxymethyl)-N-(7-(2-methyloxazol-5-yl)quinazolin-2 - yl)cyclohexane-l -carboxamide 1447.

[0904] Off-white solid (7.5 mg, 0.02 mmol, 8.2% yield). ¾NMR (499 MHz, DMSO- dt) δ ppm 0.90 - 1.01 (2 H, m), 1.35 (1 H, td, J=5.83, 3.43 Hz), 1.37 - 1.47 (2 H, m), 1.80 (2 H, br dd, .7=13.17, 3.02 Hz), 1.90 (2 H, br dd, J=12.90, 2.20 Hz), 2.55 (3 H, s), 2.59 - 2.69 (1 H, m), 3.24 (2 H, t, J=5.76 Hz), 4.39 (1 H, t, J=5.35 Hz), 7.89 (1 H, dd, J=8.51, 1.65 Hz), 7.91 (1 H, s), 7.95 (1 H, s), 8.11 (1 H, d, J=8.51 Hz), 9.43 (1 H, s), 10.64 (1 H, s); ESIMS found for C 2 oH22N 4 0 3 mlz 367.2 (M+1).

1462

[0905] fr «5-N-(7-(2-Metliyloxazol-5-yl)quinazolin-2-yl)-3- morpholinocyclobutane-1 -carboxamide 1462.

[0906] Off-white solid (2 mg, 0.005 mmol, 23.5% yield). Ή NMR (499 MHz, DMSO- 6 ) δ ppm 2.11 - 2.18 (2 H, m), 2.23 - 2.30 (6 H, m), 2.55 (3 H, s), 2.78 - 2.87 (1 H, m), 3.55 - 3.62 (5 H, m), 7.88 (1 H, dd, J=8.51, 1.65 Hz), 7.92 (1 H, s), 7.96 (1 H, s), 8.08 - 8.14 (1 H, m), 9.42 (1 H, d, J=0.82 Hz), 10.63 (1 H, br s); ESIMS found for C 2 iH 2 3N 5 0 3 mlz 394.15 (M+1).

1471

[0907] l-(2,2-Difluoropropyl)-N-(7-(2-methyloxazol-5-yl)qumazolin-2 - yl)piperidine -4 -carboxamide 1471.

[0908] Brown solid (3.4 mg, 0.008 mmol, 9.0% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.63 (3 H, br t, J=19.21 Hz), 1.63 - 1.71 (2 H, m), 1.79 (2 H, br d, J=10.70 Hz), 2.24 (2 H, td, J=l 1.66, 2.20 Hz), 2.55 (3 H, s), 2.67 - 2.76 (3 H, m), 2.95 (2 H, br d, J=l 1.53 Hz), 7.89 (1 H, dd, J=8.51, 1.65 Hz), 7.92 (1 H, s), 7.96 (1 H, s), 8.12 (1 H, d, J=8.23 Hz), 9.44 (1 H, s), 10.70 (1 H, s); ESIMS found for C 2 iH

1472

[0909] N-(7-(2-Methyloxazol-5-yl)quinazolin-2-yl)-4-morpholinopiper idine-l- carboxamide 1472.

[0910] Yellow solid (25 mg, 0.06 mmol, 12.8% yield). 'H NMR (499 MHz, DMSO- d 6 ) δ ppm 1.33 - 1.46 (2 H, m), 1.79 (2 H, br d, J=l 1.25 Hz), 2.33 - 2.43 (1 H, m), 2.45 - 2.49 (4 H, m), 2.54 (3 H, s), 2.87 (2 H, br t, J=11.94 Hz), 3.51 - 3.61 (5 H, m), 4.10 (2 H, br d, J=12.90 Hz), 7.79 (1 H, dd, J=8.51, 1.65 Hz), 7.85 (1 H, s), 7.87 (1 H, s), 8.05 (1 H, d, J=8.23 Hz), 9.33 (1 H, s), 9.66 (1 H, br s); ESIMS found for C22H26N6O3 mlz 423.2 (M+l).

1491

[0911] 2-Methyl-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)-5,6-dihy droimidazo [l,2-a]pyrazine-7(8H)-carboxamide 1491.

[0912] Beige solid (15 mg, 0.04 mmol, 8.6% yield). ¾ NMR (499 MHz, DMSO-t e) δ ppm 2.05 (3 H, s), 2.54 (3 H, s), 3.87 - 3.93 (3 H, m), 3.97 - 4.03 (2 H, m), 4.62 (2 H, s), 6.81 (1 H, d, J=0.82 Hz), 7.80 - 7.83 (1 H, m), 7.84 (1 H, s), 7.87 (1 H, s), 8.07 (1 H, d, J=8.51 Hz), 9.37 (1 H, s); ESIMS found for ΟζοΗ,

1495

[0913] 2-( IH-lmidazol- 1 -yl)-N-(7-(2-methyloxazol-5-yl)quinazolin-2-yl)acetamide

1495.

[0914] Beige solid (6 mg, 0.02 mmol, 27.2% yield). Ή NMR (499 MHz, DMSO-de) δ ppm 2.54 (3 H, s), 5.36 (2 H, s), 6.90 (1 H, s), 7.18 (1 H, s), 7.65 (1 H, s), 7.92 (1 H, br dd, J=8.51, 1.65 Hz), 7.92 (1 H, s), 8.03 - 8.06 (1 H, m), 8.15 (1 H, d, J=8.51 Hz), 9.48 (1 H, s), 11.11 (1 H, s); ESIMS found for CivHuNeCh mlz 335.1 (M+l).

1497

[0915] 3-((l-Methylpiperidm-4-yl)oxy)-N-(7-(oxazol-5-yl)quinazolin- 2- yl)benzamide 1497.

[0916] Yellow solid (3 mg, 0.007 mmol, 3.2% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 1.62 - 1.71 (2 H, m), 1.92 - 2.00 (2 H, m), 2.15 - 2.24 (2 H, m), 2.18 (3 H, s), 2.58 - 2.65 (2 H, m), 4.46 - 4.53 (1 H, m), 7.18 (1 H, dt, J=8.23, 1.23 Hz), 7.42 (1 H, t, J=7.96 Hz), 7.54 - 7.61 (2 H, m), 8.01 (1 H, dd, J=8.37, 1.51 Hz), 8.08 - 8.13 (2 H, m), 8.22 (1 H, d, J=8.23 Hz), 8.63 (1 H, s), 9.56 (1 H, s), 11.20 (1 H, br s); ESIMS found for C24H 23 N 5 03 mlz 430.2 (M+1).

1518

[0917] fr «5-4-(Dimethylamino)-N-(7-(thiazol-5-yl)quinazolin-2-yl)cyc lohexane-l- carboxamide 1518.

[0918] Off-white solid (5 mg, 0.01 mmol, 14.7% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.14 - 1.22 (2 H, m), 1.44 (2 H, qd, J=12.72, 2.74 Hz), 1.82 - 1.90 (2 H, m), 1.90 - 1.98 (2 H, m), 2.13 - 2.17 (1 H, m), 2.18 (6 H, s), 2.59 - 2.66 (1 H, m), 7.95 (1 H, dd, J=8.51, 1.65 Hz), 8.00 (1 H, d, J=1.37 Hz), 8.13 (1 H, d, J=8.51 Hz), 8.65 (1 H, s), 9.24 (1 H, s), 9.47 (1 H, s), 10.69 (1 H, s); ESIMS found for C2o

1523

[0919] l-(Oxetan-3-yl)-N-(7-(thiazol-5-yl)quinazolm-2-yl)piperidine -4- carboxamide 1523.

[0920] Off-white solid (25 mg, 0.06 mmol 28.6% yield). ¾ NMR (499 MHz, DMSO-c/e) δ ppm 1.61 - 1.71 (2 H, m), 1.76 - 1.88 (4 H, m), 2.64 - 2.72 (1 H, m), 2.72 - 2.78 (2 H, m), 3.39 (1 H, quin, J=6.38 Hz), 4.43 (2 H, t, J=6.17 Hz), 4.53 (2 H, t, J=6.59 Hz), 7.95 (1 H, dd, J=8.37, 1.78 Hz), 7.99 - 8.03 (1 H, m), 8.13 (1 H, d, J=8.51 Hz), 8.66 (1 H, s), 9.25 (1 H, s), 9.47 (1 H, s), 10.73 (1 H, s); ESIMS fovmd for C20H21N5O2S mlz 396.15 (M+1).

1524

[0921] 1 -(2-(Pyrrolidin-l -yl)acetyl)-N-(7-(thiazol-5-yl)quinazolin-2-yl)piperidine-4- carboxamide 1524.

[0922] Beige solid (15 mg, 0.03 mmol, 28.2% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ρρηι 1.37 - 1.51 (1 H, m), 1.54 - 1.64 (1 H, m), 1.69 (4 H, br s), 1.79 - 1.91 (2 H, m), 2.49 (4 H, br s), 2.60 - 2.70 (1 H, m), 2.95 - 3.11 (2 H, m), 3.19 (1 H, br d, J=13.45 Hz), 3.33 - 3.38 (1 H, m), 4.10 (1 H, br d, J=13.72 Hz), 4.39 (1 H, br d, J=12.62 Hz), 7.96 (1 H, dd, J=8.37, 1.78 Hz), 8.02 (1 H, d, J=1.65 Hz), 8.13 (1 H, d, J=8.23 Hz), 8.66 (1 H, s), 9.25 (1 H, s), 9.48 (1 H, s), 10.79 (1 H, s); ESIMS found for C 2 3H2

1536

[0923] 2-(4-Methylpiperazin-l-yl)-N-(7-(thiazol-5-yl)quinazolin-2- yl)isonicotinamide 1536.

[0924] Brown solid (6.4 mg, 0.01 mmol, 4.8% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 2.23 (3 H, s), 2.39 - 2.45 (4 H, m), 3.56 - 3.62 (4 H, m), 7.10 (1 H, dd, J=5.08, 1.24 Hz), 7.39 (1 H, s), 8.02 (1 H, dd, J=8.37, 1.78 Hz), 8.07 - 8.12 (1 H, m), 8.20 (1 H, d, J=8.23 Hz), 8.26 (1 H, d, J=5.76 Hz), 8.68 (1 H, s), 9.26 (1 H, s), 9.57 (1 H, d, J=0.82 Hz), 11.35 (1 H, br s); ESIMS found for C22H21N7OS mlz 432.2 (M+l).

1598

[0925] N-(7-(Isothiazol-4-yl)quinazolin-2-yl)- 1 -methylpiperidine-4-carboxamide

1598.

[0926] Beige solid (80 mg, 0.23 mmol, 1.7% yield). ¾ NMR (499 MHz, DMSO-i 6 ) 5 ppm 1.77 - 1.90 (2 H, m), 2.05 - 2.16 (2 H, m), 2.50 - 2.53 (1 H, m), 2.81 (3 H, s), 2.95 - 3.07 (2 H, m), 3.50 (2 H, br d, J=9.06 Hz), 8.07 (1 H, dd, J=8.37, 1.78 Hz), 8.16 (1 H, d, J=8.23 Hz), 8.20 - 8.23 (1 H, m), 9.31 (1 H, s), 9.49 (1 H, d, J=0.82 Hz), 9.72 (1 H, s), 10.91 (1 H, s); ESIMS found for CisHieNsOS mlz 354.1 (M+l).

1612

[0927] cw-4-Methoxy-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin -2- yl)cyclohexane-l -carboxamide 1612.

[0928] Brown solid (6 mg, 0.02 mmol, 5.1% yield). ¾ NMR (499 MHz, DMSO-t/e) δ ppm 1.09 - 1.19 (2 H, m), 1.41 - 1.52 (2 H, m), 1.67 - 1.77 (1 H, m), 1.86 - 1.97 (2 H, m), 2.05 -

2.11 (1 H, m), 2.66 - 2.74 (1 H, m), 2.84 (3 H, s), 3.13 (1 H, tt, J=10.63, 4.19 Hz), 3.25 (3 H, s),

8.12 - 8.17 (1 H, m), 8.19 - 8.24 (2 H, m), 9.56 (1 H, s), 10.78 (1 H, s); ESIMS found for Ci 9 H 2 iN 5 0 2 S mlz 384.15 (M+l).

1625

[0929] l-Benzoyl-N-(7-(5-methyl-l,3,4-thiadiazol-2-yl)quinazolin-2- yl)piperidine- 4-carboxamide 1625.

[0930] Beige solid (21 mg, 0.05 mmol, 32.5% yield). Ή NMR (499 MHz, DMSO-c 6 ) δ ppm 1.54 - 1.67 (2 H, m), 1.76 - 1.91 (1 H, m), 1.91 - 2.05 (1 H, m), 2.84 (3 H, s), 2.88 - 2.99 (1 H, m), 3.01 - 3.19 (2 H, m), 3.61 - 3.76 (1 H, m), 4.43 - 4.62 (1 H, m), 7.39 - 7.42 (2 H, m), 7.44 - 7.48 (3 H, m), 8.15 - 8.18 (1 H, m), 8.21 - 8.24 (2 H, m), 9.58 (1 H, s), 10.90 (1 H, s); ESIMS found for C 2 4H 2 2N 6 0 2 S mlz 459.2 (M+l).

1632

[0931] 2-(7-Azabicyclo[2.2.1]heptan-7-yl)-N-(7-(5-methyl-l,3,4-thia diazol-2- yl)quinazolin-2-yl)acetamide 1632.

[0932] Off-white solid (30 mg, 0.08 mmol, 38.4% yield). Ή NMR (499 MHz, DMSO- 6 ) δ ppm 1.33 (4 H, d, J=7.14 Hz), 1.70 - 1.76 (4 H, m), 2.84 (3 H, s), 3.36 - 3.40 (2 H, m), 8.18 - 8.21 (1 H, m), 8.23 - 8.25 (1 H, m), 8.26 (1 H, d, J=0.82 Hz), 9.59 (1 H, s), 10.51 (1 H, s); ESIMS found for Ci 9 H 2 oN 6 OS mlz 381.2 (M+l).

1634

[0933] 2-(3-Oxa-8-azabicycloL3.2.1Joctan-8-yl)-N-(7-(5-methyl-l,3,4 -thiadiazol-2- yl)quinazolin-2-yl)acetamide 1634.

[0934] Beige solid (4 mg, 0.01 mmol, 7.5% yield). ¾ NMR (499 MHz, DMSO-i/ 6 ) δ ppm 1.76 - 1.82 (2 H, m), 1.87 - 1.92 (2 H, m), 2.84 (3 H, s), 3.17 (2 H, br s), 3.50 (2 H, dd, J=10.43, 1.65 Hz), 3.64 (2 H, d, J=10.15 Hz), 8.18 - 8.22 (1 H, m), 8.23 - 8.26 (1 H, m), 8.26 - 8.28 (1 H, m), 9.61 (1 H, s), 10.57 (1 H, s); ESIMS found for C19H20 6O2S mlz 397.2 (M+1).

[0935] N-(7-(5-Me l-l,3,4-thiadiazol-2-yl)quinazolin-2-yl)-2-(4-methylpiperazi n- l-yl)isonicotinamide 1656.

[0936] Yellow solid (13.8 mg, 0.03 mmol, 3.8% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 2.23 (3 H, s), 2.42 (4 H, t, J=4.94 Hz), 2.85 (3 H, s), 3.55 - 3.63 (4 H, m), 7.10 (1 H, dd, J=5.21, 1.37 Hz), 7.40 (1 H, s), 8.21 - 8.24 (1 H, m), 8.26 (1 H, d, J=5.21 Hz), 8.28 - 8.31 (2 H, m), 9.67 (1 H, s), 11.43 (1 H, s); ESIMS found for C 22 H 22 N 8 OS mlz 447.2 (M+1).

[0937] N-(7-(Pyridin-3-yl)quinazolin-2-yl)cyclopropanecarboxamide 1670.

[0938] Beige solid (20 mg, 0.07 mmol, 31.1% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ppm 0.81 - 0.95 (4 H, m), 2.07 - 2.16 (1 H, m), 7.61 (1 H, dd, J=7.82, 4.80 Hz), 8.22 (1 H, d, J=8.78 Hz), 8.61 (2 H, t, J=3.98 Hz), 8.64 (1 H, dt, J=7.96, 1.92 Hz), 8.74 (1 H, dd, J=4.67, 1.65 Hz), 9.25 (1 H, s), 9.45 (1 H, d, J=1.65 Hz), 11.10 (1 H, s); ESIMS found for G 7 H 14 N 4 O mlz 291.15 (M+1). 1710

[0939] N-(7-(5-Aminopyridin-3-yl)quinazolin-2-yl)-4-(piperidin-4-yl oxy)benzamide

1710.

[0940] White solid (5.4 mg, 0.01 mmol, 78.5% yield). Ή NM (499 MHz, DMSO- d 6 ) δ ppm 1.46 - 1.58 (2 H, m), 1.91 - 2.01 (2 H, m), 2.59 - 2.68 (2 H, m), 2.98 (2 H, dt, J=12.69, 4.08 Hz), 4.57 (1 H, dt, .7=8.85, 4.49 Hz), 5.53 (2 H, s), 7.06 (2 H, d, J=8.78 Hz), 7.34 ( 1 H, t, J=2.33 Hz), 7.89 ( 1 H, dd, .7=8.51, 1.65 Hz), 7.98 ( 1 H, s), 8.00 (2 H, d, J=8.78 Hz), 8.03 (1 H, d, .7=2.74 Hz), 8.20 (1 H, d, .7=8.51 Hz), 8.22 (1 H, d, .7=1.92 Hz), 9.58 (1 H, s), 11.04 (1 H, br s); ESIMS found for C 25 H 24 N fi

[0941] N-(7-(6-Aminopyridin-3-yl)quinazolin-2-yl)-2-(4-methylpipera zin-l- yl)isonicotinamide 1713.

[0942] Beige solid (14 mg, 0.03 mmol, 19.4% yield). : H NMR (500 MHz, DMSO-t/e) δ ppm 2.23 (3 H, s), 2.42 (4 H, br t, J=4.94 Hz), 3 54 - 3.63 (4 H, m), 6 35 (2 H, s), 6.59 (1 H, d, J=8.51 Hz), 7.10 (1 H, dd, J=5.08, 1.23 Hz), 7.40 (1 H, s), 7.91 - 7.99 (3 H, m), 8.13 ( 1 H, d, J=8.23 Hz), 8.26 ( 1 H, d, .7=5.21 Hz), 8.50 (1 H, d, J=1.92 Hz), 9.51 ( 1 H, s), 1 1.28 (1 H, br s); ESIMS found for C 2 4H 2 4 8 0 mlz 441.2 (M+l).

1773

[0943] N-(7-(6-(ter^Butylamino)pyrazin-2-yl)quinazolm-2-yl)-r-methy l-r,2',3',6'- tctrahydro-[2,4'-bipyridinc] -4-carboxamidc 1773.

[0944] Tan solid (47.7 mg, 0.10 mmol, 26.3% yield). ¾ NMR (499 MHz, DMSO-c 6 ) δ ppm 1.51 (9 H, s), 2.31 (3 H, s), 2.58 - 2.62 (2 H, m), 2.63 - 2.67 (2 H, m), 3.11 (2 H, br d, J=3.02 Hz), 6.87 ( 1 H, t, J=3.43 Hz), 7.07 (1 H, s), 7.73 ( 1 H, dd, J=4.94, 1.37 Hz), 8.00 (1 H, s), 8.10 (1 H, s), 8.19 - 8.25 (1 H, m), 8.31 (1 H, dd, J=8.64, 1.51 Hz), 8.48 (2 H, s), 8.71 (1 H, d, J=4.94 Hz), 9.62 (1 H, s), 11.55 (1 H, s); ESIMS found for C 28 H 3 oN 8 0 mlz 495.25 (M+l).

[0945] N-(7-(6-(((3-Fluoroazetidin-3-yl)methyl)ammo)pyrazin-2-yl)qu inazolin-2- yl)cyclopropanecarboxamide 1777.

[0946] Yellow solid (25.1 mg, 0.06 mmol, 80.8% yield). ¾NMR (499 MHz, DMSO- d 6 ) δ ppm 0.83 - 0.89 (4 H, m), 2.17 - 2.27 (1 H, m), 4.00 (2 H, dd, J=21.20, 6.10 Hz), 4.03 - 4.17 (4 H, m), 7.64 (1 H, t, J=6.04 Hz), 8.11 (1 H, s), 8.16 (1 H, d, J=8.51 Hz), 8.28 (1 H, dd, J=8.37, 1.51 Hz), 8.43 (1 H, s), 8.58 (1 H, s), 9.53 (1 H, s), 11.07 (1 H, s); ESIMS found for C 20 H 20 FN 7 O m/z 394.2 (M+l).

1783

[0947] N-(7-(6-(Piperidin-4-ylamino)pyrazin-2-yl)quinazolin-2-yl)te trahydro-2H- pyran-4-carboxamidc 1783.

[0948] Beige solid (10 mg, 0.02 mmol, 72.4% yield). Ή NMR (500 MHz, DMSO-c 6 ) 5 ppm 1.31 - 1.44 (2 H, m), 1.61 - 1.72 (2 H, m), 1.74 - 1.81 (2 H, m), 1.95 (2 H, br dd, J= 11.53, 2.74 Hz), 2.57 - 2.66 (2 H, m), 2.94 - 3.08 (3 H, m), 3.36 - 3.43 (2 H, m), 3.89 - 3.97 (3 H, m), 7.25 (1 H, br d, J=7.41 Hz), 7.98 (1 H, s), 8.14 (1 H, d, J=8.51 Hz), 8.22 (1 H, dd, J=8.37, 1.51 Hz), 8.39 (1 H, s), 8.46 (1 H, s), 9.50 (1 H, s), 10.74 (1 H, s); ESIMS found for C23H27N7O2 mlz 434.2 (M+l).

[0949] N-(7-(6-(((3S,4S)-3-Fluoropiperidin-4-yl)amino)pyrazin-2-yl) quinazolin-2- yl)cyclopropanecarboxamide 1785.

[0950] Orange solid (1.8 mg, 0.004 mmol, 15.2% yield). ¾ NMR (500 MHz, METHANOLS) δ ppm 0.92 - 1.00 (2 H, m), 1.07 - 1.12 (2 H, m), 1.54 - 1.64 (1 H, m), 2.05 - 2.11 (1 H, m), 2.22 - 2.31 (1 H, m), 2.74 - 2.87 (3 H, m), 2.99 - 3.06 (1 H, m), 4.32 - 4.43 (1 H, m), 4.46 - 4.63 (1 H, m), 7.95 (1 H, s), 8.09 (1 H, d, J=8.23 Hz), 8.24 (1 H, dd, J=8.51, 1.65 Hz), 8.39 (1 H, s), 8.58 - 8.62 (1 H, m), 9.40 (1 H, s); ESIMS found for C 21 H 22 FN 7 O mlz 407.2 (M+1).

1802

[0951] N-(7-(lH-Pyrrolo[2,3-c]pyridin-4-yl)quinazolin-2-yl)-l-(l-me thylpiperidin- 4-yl)-lH-pyrazole-4-carboxamide 1802.

[0952] Yellow solid (3 mg, 0.007 mmol, 12.6% yield). ¾ NMR (499 MHz, METHANOLS) δ ppm 1.94 (6 H, s), 2.11 - 2.23 (4 H, m), 2.24 - 2.32 (2 H, m), 3.03 (2 H, br d, J=12.35 Hz), 4.24 - 4.35 (1 H, m), 6.90 (1 H, d, J=3.02 Hz), 7.72 (1 H, d, J=3.02 Hz), 8.01 (1 H, dd, J=8.23, 1.65 Hz), 8.16 (1 H, s), 8.19 (1 H, d, J=8.23 Hz), 8.33 - 8.40 (2 H, m), 8.48 (1 H, s), 8.78 (1 H, s), 9.47 (1 H, s); ESIMS found for C25H24N8O mlz 453.2 (M+1).

1813

[0953] l-Isopropyl-N-(7-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2 - yl)quinazolin-2-yl) - 1 H-pyrazole -4 -carboxamide 1813.

[0954] Brown wax (4.6 mg, 0.01 mmol, 5.0% yield). ¾ NMR (499 MHz, DMSO-d 6 ) δ ppm 1.46 (6 H, d, J=6.86 Hz), 1.49 - 1.60 (2 H, m), 1.95 - 2.02 (2 H, m), 2.06 - 2.15 (2 H, m), 2.20 (3 H, s), 2.76 (2 H, br d, J=l 1.25 Hz), 3.80 - 3.91 (1 H, m), 4.55 (1 H, spt, J=6.63 Hz), 7.25 (1 H, d, J=7.14 Hz), 7.99 (1 H, s), 8.12 (1 H, s), 8.16 - 8.21 (1 H, m), 8.25 (1 H, dd, J=8.51, 1.65 Hz), 8.42 (1 H, d, J=1.37 Hz), 8.48 (1 H, s), 8.56 (1 H, s), 9.56 (1 H, s), 10.82 (1 H, s); ESIMS found for C25H29N9O mlz 472.3 (M+1).

[0955] N-(6-(l-Mcthyl-lH-pyrazol-4-yl)cinnolin-3-yl)cyclopropanccar boxamidc

1815.

[0956] Yellow solid (1.4 mg, 0.005 mmol, 4.0% yield). ¾ NMR (499 MHz, METHANOLS) δ ppm 0.84 - 0.94 (4 H, m), 2.01 - 2.08 (1 H, m), 4.00 (3 H, s), 7.99 (1 H, s), 8.06 (1 H, dd, J=6.17, 0.96 Hz), 8.14 (1 H, s), 8.21 (1 H, d, J=9.06 Hz), 8.42 (1 H, dd, J=9.06, 0.82 Hz), 9.29 (1 H, d, J=6.04 Hz); ESIMS found for Ci 6 Hi 5 N 5 0 mlz 294.1 (M+l).

1953

[0957] N-(6-(l-Methyl-lH-pyrazol-4-yl)cinnolin-3-yl)-3-(4-methylpip erazm-l-yl) benzamide 1953.

[0958] Yellow solid (8.7 mg, 0.02 mmol, 21.7% yield). ¾ NMR (500 MHz, DMSO- d 6 ) δ ppm 2.24 (3 H, s), 2.48 (4 H, br s), 3.24 - 3.29 (4 H, m), 3.93 (3 H, s), 7.19 (1 H, dd, J=8.23, 1.92 Hz), 7.38 (2 H, t J=7.96 Hz), 7.52 (2 H, br d, J=8.23 Hz), 7.70 - 7.74 (1 H, m), 8.07 (1 H, dd, J=9.06, 1.92 Hz), 8.16 (1 H, d, J=0.82 Hz), 8.23 (1 H, d, J=1.92 Hz), 8.37 (1 H, d, J=9.06 Hz), 8.45 (1 H, s), 8.81 (1 H, d, .7=0.82 Hz), 11 64 (1 H, s); ESIMS found for C24H25N7O mlz 428.2 (M+l).

2722

[0959] N-(3 -( 1 -Methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)

cyclopropanecarboxamide 2722.

[0960] White solid (9 mg, 0.03 mmol, 34.6% yield). ¾ NMR (499 MHz, DMSO-t/e) δ ppm 0.80 - 0.90 (4 H, m), 2.04 - 2.12 (1 H, m), 3.92 (3 H, s), 8.18 (1 H, d, J=0.82 Hz), 8.44 (1 H, d, .7=1.92 Hz), 8.45 (1 H, s), 8.48 (1 H, s), 9.12 (1 H, s), 9.17 (1 H, d, J=2.20 Hz), 10.99 (1 H, s); ESIMS found for Ci 6 Hi 5 N 5 0 mlz 294 A (M+l).

2731

[0961] N-(3-(l -Methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)piperidine-4- carboxamide 2731.

[0962] Beige solid (30 mg, 0.09 mmol, 43.3% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ppm 1.53 (2 H, qd, .7=12.17, 3.57 Hz), 1.70 (2 H, br d, .7=10.15 Hz), 2.44 - 2.49 (2 H, m), 2.63 - 2.71 (1 H, m), 2.97 (2 H, br d, J=13.45 Hz), 3.92 (3 H, s), 8.18 (1 H, s), 8.46 (1 H, d, J=2.20 Hz), 8.48 (1 H, s), 8.49 (1 H, s), 9.11 (1 H, s), 9.17 (1 H, d, J=2.20 Hz), 10.58 (1 H, s); ESIMS found for CisHzoNsO mlz 337.2 (M+l).

2736

[0963] l-Isobutyl-N-(3 -( 1 -methyl- lH-pyrazol-4-yl)- l,7-naphthyridin-6-yl) piperidine-4-carboxamide 2736.

[0964] Off-white solid (24 mg, 0.06 mmol, 73.5% yield). ¾ NMR (499 MHz, DMSO-c e) δ ppm 0.86 (6 H, d, J=6.31 Hz), 1.62 - 1.72 (2 H, m), 1.73 - 1.82 (3 H, m), 1.87 (2 H, td, J=l 1.66, 1.92 Hz), 2.02 (2 H, d, .7=7.41 Hz), 2.52 - 2.60 (1 H, m), 2.86 (2 H, br d, J=l 1.53 Hz), 3.92 (3 H, s), 8.18 (1 H, s), 8.46 (1 H, d, .7=1.65 Hz), 8.48 (1 H, s), 8.49 (1 H, s), 9.11 (1 H, s), 9.17 (1 H, d, J=2.20 Hz), 10.62 (1 H, s); ESIMS found for C 22 H 2 8 6 0 mlz 393.2 (M+l).

2767

[0965] (S)-N-(3-(l -Methyl-lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2-(2- methylpyrrolidin-1 -yl)acetamide 2767.

[0966] Beige solid (60 mg, 0.17 mmol, 77.1% yield). ¾ NMR (499 MHz, DMSO-i 6 ) 5 ppm 1.09 (3 H, d, J=6.04 Hz), 1.41 (1 H, dddd, J=12.32, 10.33, 8.37, 6.31 Hz), 1.67 - 1.84 (2 H, m), 1.92 - 2.01 (1 H, m), 2.40 (1 H, q, J=8.69 Hz), 2.57 - 2.65 (1 H, m), 3.14 (1 H, d, J=16.47 Hz), 3.13 - 3 20 (1 H, m), 3.56 (1 H, d, .7=16.19 Hz), 3.92 (3 H, s), 8.20 (1 H, d, .7=0.82 Hz), 8.48 (1 H, s), 8.49 (1 H, s), 8.54 (1 H, d, J=1.65 Hz), 9.12 (1 H, s), 9.20 (1 H, d, J=1.92 Hz), 10.05 (1 H, s); ESIMS found for C19H22N6O mlz 351.2 (M+l).

2776

[0967] 2-(Cyclobutyl(methyl)amino)-N-(3 -( 1 -methyl- lH-pyrazol-4-yl)- 1 ,7- naphthyridin-6-yl)acetamide 2776.

[0968] Beige solid (60 mg, 0.17 mmol, 77.1% yield). ¾ NMR (499 MHz, DMSO-t/e) δ ppm 1.81 - 1.96 (2 H, m), 2.09 - 2.20 (2 H, m), 2.25 - 2.34 (2 H, m), 2.50 (3 H, s), 3.35 (1 H, quin, J=7.82 Hz), 3.41 (2 H, s), 4.20 (3 H, s), 8.47 (1 H, s), 8.75 (1 H, s), 8.76 (1 H, s), 8.81 (1 H, d, J=1.65 Hz), 9.40 (1 H, s), 9.47 (1 H, d, J=2.20 Hz), 10.35 (1 H, s); ESIMS found for Ci 9 H 22 N 6 0 mlz 351.2 (M+l).

2782

[0969] (R)-N-(3-(l-Methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)py rrolidine-2- carboxamide 2782.

[0970] Beige solid (25 mg, 0.08 mmol, 35.4% yield). Ή MR (499 MHz, DMSO-t/e) 5 ppm 1.67 (2 H, quin, J=6.86 Hz), 1.81 - 1.90 (1 H, m), 2.06 - 2.16 (1 H, m), 2.88 (1 H, dt, J=10.15, 6.31 Hz), 2.97 (1 H, dt, J=10.15, 6.72 Hz), 3.82 (1 H, dd, J=9.06, 5.49 Hz), 3.92 (3 H, s), 8.19 (1 H, s), 8.49 (2 H, s), 8.52 (1 H, d, J=1.65 Hz), 9.11 (1 H, s), 9.19 (1 H, d, J=2.20 Hz), 10.47 (1 H, s); ESIMS found for Ci 7 Hi 8 N 6 0 mlz 323.2 (M+l).

2791

[0971] N-(3 -( 1 -Methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2-(piperidin- 1 -yl) propanamide 2791.

[0972] Off-white solid (34 mg, 0.09 mmol, 70.0% yield). Ή NMR (499 MHz, DMSO-i¾,) δ ppm 1.20 (3 H, d, J=6.86 Hz), 1.40 - 1.46 (2 H, m), 1.53 - 1.63 (4 H, m), 2.51 - 2.59 (4 H, m), 3.46 (1 H, q, J=6.86 Hz), 3.93 (3 H, s), 8.19 (1 H, s), 8.48 (1 H, s), 8.49 (1 H, s), 8.50 (1 H, d, J=1.92 Hz), 9.13 (1 H, s), 9.19 (1 H, d, J=2.20 Hz), 10.25 (1 H, s); ESIMS found for C20H24N6O mlz 365.2 (M+l).

2792

[0973] N-(3-(l-Methyl-lH-pyrazol-4-yl)-lJ-naphthyridin-6-yl)-l-(met hylsulfonyl) piperidine-4-carboxamide 2792.

[0974] White solid (11.3 mg, 0.03 mmol, 29.0% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 1.70 (2 H, qd, J=12.21, 3.98 Hz), 1.96 (2 H, br dd, J=13.45, 2.74 Hz), 2.66 - 2.72 (1 H, m), 2.76 (2 H, td, J=11.94, 2.47 Hz), 2.90 (3 H, s), 3.60 - 3.66 (2 H, m), 3.93 (3 H, s), 8.18 (1 H, d, J=0.82 Hz), 8.45 - 8.53 (3 H, m), 9.13 (1 H, s), 9.18 (1 H, d, J=2.20 Hz), 10.78 (1 H, s); ESIMS found for Ci 9 H 2 2 6 0 3 S mlz 415.2 (M+l).

2807

[0975] N-(3 -( 1 -Methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2-(morpholin-2-yl) acetamide 2807.

[0976] Brown solid (20 mg, 0.06 mmol, 52.4% yield). ¾ NMR (499 MHz, DMSO- dt) δ ppm 2.42 (1 H, dd, J=12.08, 10.15 Hz), 2.45 - 2.49 (1 H, m), 2.58 - 2.70 (3 H, m), 2.81 - 2.87 (1 H, m), 3.43 (1 H, td, J=10.91, 3.16 Hz), 3.70 (1 H, br d, J=10.70 Hz), 3.80 - 3.88 (1 H, m), 3.92 (3 H, s), 8.19 (1 H, s), 8.46 - 8.52 (3 H, m), 9.11 (1 H, s), 9.18 (1 H, d, J=2.20 Hz), 10.65 (1 H, s); ESIMS found for CwHaoNeCfc

2816

[0977] N-(3 -( 1 -Methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)- 1 -(oxazol-2- ylmethyl)piperidine-4 -carboxamide 2816.

[0978] Brown solid (22 mg, 0.05 mmol, 56.1 % yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 1.67 (2 H, qd, J=12.21, 3.70 Hz), 1.80 (2 H, br d, J=10.70 Hz), 2.10 (2 H, td, J=l 1.53, 1.92 Hz), 2.52 - 2.58 (1 H, m), 2.89 (1 H, br d, J=3.02 Hz), 3.67 (2 H, s), 3.92 (3 H, s), 7.18 (1 H, s), 8.08 (1 H, s), 8.18 (1 H, s), 8.46 (1 H, d, .7=1.92 Hz), 8.47 (1 H, s), 8.49 (1 H, s), 9.11 (1 H, s), 9.17 (1 H, d, .7=1.92 Hz), 10.63 (1 H, s); ESIMS found for C22H23N7O2 mlz 418.2 (M+l).

2820

[0979] N-(3 -( 1 -Methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)- 1 -(pyrimidin-2- ylmethyl)piperidine-4-carboxamide 2820.

[0980] Biege solid (17 mg, 0.04 mmol, 42.3% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ppm 1.68 (2 H, qd, .7=12.21, 3.70 Hz), 1.76 - 1.82 (2 H, m), 2.11 - 2.21 (2 H, m), 2.52 - 2.59 (1 H, m), 2.96 (2 H, br d, .7=11.53 Hz), 3.71 (2 H, s), 3.92 (3 H, s), 7.41 (1 H, t, .7=4.80 Hz), 8.17 (1 H, s), 8.46 (1 H, d, .7=2.20 Hz), 8.47 (1 H, s), 8.49 (1 H, s), 8.79 (2 H, d, .7=4.94 Hz), 9.11 (1 H, s), 9.17 (1 H, d, J=2.20 Hz), 10.62 (1 H, s); ESIMS found for C 23 H 24 N 8 0 mlz 429.2 (M+l).

2826

[0981] 2-(4-Methyl-l,4-diazepan-l-yl)-N-(3-(l-methyl-lH-pyrazol-4-y l)-l,7- naphthyridin-6-yl)acetamide 2826.

[0982] Beige solid (45 mg, 0.12 mmol, 53.4% yield). ¾ NMR (499 MHz, DMSO-d 6 ) δ ppm 1.78 (2 H, quin, .7=5.97 Hz), 2.28 (3 H, s), 2.57 - 2.63 (4 H, m), 2.80 - 2.87 (4 H, m), 3.38 (2 H, s), 3.92 (3 H, s), 8.19 (1 H, s), 8.49 (2 H, s), 8.54 (1 H, d, .7=1.92 Hz), 9.14 (1 H, s), 9.20 (1 H, d, .7=2.20 Hz), 10.11 (1 H, s); ESIMS found for C20H25N7O mlz 380.2 (M+l).

2864

[0983] N -(3 -( 1 -Methyl- lH-pyrazol-4-yl)-l ,7-naphthyndin-6-yl)-4-(piperidin-4- yloxy)benzamide 2864.

[0984] Off-white solid (20 mg, 0.05 mmol, 89.8% yield). ¾ NMR (499 MHz, DMSO ) δ ppm 1.41 - 1.52 (2 H, m), 1.94 (2 H, br dd, J=l 1.94, 2.33 Hz), 2.60 (2 H, brt, .7=10.29 Hz), 2.91 - 3.00 (2 H, m), 3.93 (3 H, s), 4.51 - 4.60 (1 H, m), 7.06 (2 H, d, J=8.78 Hz), 8.06 (2 H, d, J=8.78 Hz), 8.21 (1 H, s), 8.50 (1 H, s), 8.54 (1 H, d, J=1.65 Hz), 8.64 (1 H, s), 9.18 (1 H, s), 9.21 (1 H, d, J=2.20 Hz), 10.80 (1 H, s); ESIMS found for C24H24N6O2 mlz 429.2 (M+l).

2865

[0985] N-(3 -( 1 -Methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-4-(( 1 - methylpiperidin-4-yl)oxy)benzamide 2865.

[0986] Off-white solid (18 mg, 0.04 mmol 67.0% yield). ¾ NM (499 MHz, DMSO-i/ 6 ) δ ppm 1.61 - 1.72 (2 H, m), 1.97 (2 H, br dd, J=9.74, 3.70 Hz), 2.15 - 2.25 (2 H, m), 2.19 (3 H, s), 2.57 - 2.66 (2 H, m), 3.93 (3 H, s), 4.46 - 4.54 (1 H, m), 7.07 (2 H, d, J=9.06 Hz), 8.07 (2 H, d, .7=8.78 Hz), 8.21 (1 H, s), 8.50 (1 H, s), 8.54 (1 H, d, J=1.92 Hz), 8.63 (1 H, s), 9.18 (1 H, s), 9.21 (1 H, d, J=2.20 Hz), 10.82 (1 H, s); ESIMS found for C 25 H26N 6 02 mlz 443.2 (M+l).

2866

[0987] N-(3 -( 1 -Methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-2-(piperazin- 1-yl) isonicotinamide 2866.

[0988] Off-white solid (1 1 .1 mg, 0.03 mmol, 35.3% yield). Ή NMR (499 MHz, DMSO- 6 ) δ ppm 2.79 - 2.86 (4 H, m), 3.50 - 3.58 (4 H, m), 3.93 (3 H, s), 7.14 (1 H, dd, J=5.08, 1.24 Hz), 7.43 (1 H, s), 8.21 (1 H, s), 8.26 (1 H, d, J=4.94 Hz), 8.51 (1 H, s), 8.56 (1 H, d, .7=1.65 Hz), 8.65 (1 H, s), 9.21 (1 H, s), 9.24 (1 H, d, J=2.20 Hz), 11.20 (1 H, s); ESIMS found for C22H22N8O mlz 415.2 (M+l).

2871

[0989] N-(3 -( 1 -Methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-6-(4- methylpiperazin- 1 -yl)nicotinamide 2871.

[0990] Off-white solid (16 mg, 0.04 mmol, 64.5% yield). ¾ NMR (499 MHz, DMSO- 6 ) δ ppm 2.22 (3 H, s), 2.38 - 2.43 (4 H, m), 3.62 - 3.67 (4 H, m), 3.93 (3 H, s), 6.91 (1 H, d, J=9.06 Hz), 8.17 - 8.23 (2 H, m), 8.50 (1 H, s), 8.52 (1 H, d, J=1.92 Hz), 8.62 (1 H, s), 8.85 (1 H, d, J=2.47 Hz), 9.18 (1 H, s), 9.21 (1 H, d, J=2.20 Hz), 10.80 (1 H, s); ESIMS found for C23H24N8O mlz 429.2 (M+l).

2884

[0991] 2 (2-(Dimethylamino)ethyl)amino)-N-(3-(l-methyl-lH-pyrazol-4-y l)-l,7- naphthyridin-6-yl)isonicotinamide 2884.

[0992] Off-white solid (15.1 mg, 0.04 mmol, 40.8% yield). ¾ NMR (499 MHz, DMSO- e) δ ppm 2.21 (6 H, s), 2.46 (2 H, br t, .7=6.59 Hz), 3.37 - 3.44 (2 H, m), 3.93 (3 H, s), 6.65 (1 H, brt, J=5.35 Hz), 7.03 (1 H, dd, J=5.35, 1.51 Hz), 7.04 (1 H, s), 8.12 (1 H, d, J=5.21 Hz), 8.21 (1 H, s), 8.51 (1 H, s), 8.57 (1 H, d, J=2.20 Hz), 8.62 (1 H, s), 9.19 (1 H, s), 9.24 (1 H, d, .7=1.92 Hz), 11.00 (1 H, s); ESIMS found for mlz Ml 2 (M+l).

2890

[0993] 4-((Dimethylamino)methyl)-N-(3-(l-methyl-lH-pyrazol-4-yl)-l, 7- naphthyridin-6-yl)benzamide 2890.

[0994] Off-white solid (22.9 mg, 0.06 mmol, 66.7% yield). ¾ NMR (499 MHz, DMSO- 6 ) δ ppm 2.17 (6 H, s), 3.47 (2 H, s), 3.93 (3 H, s), 7.44 (2 H, d, .7=8.23 Hz), 8.05 (2 H, d, J=7.96 Hz), 8.21 (1 H, s), 8.50 (1 H, s), 8.56 (1 H, d, J=1.65 Hz), 8.65 (1 H, s), 9.19 (1 H, s), 9.22 (1 H, d, J=2.20 Hz), 10.95 (1 H, s); ESIMS found for C 2 2H 22 N 6 0 mlz 387.2 (M+l).

2892

[0995] N-(3 -( 1 -Methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-3-((4- methylpiperazin- 1 -yl)methyl)benzamide 2892.

[0996] Off-white solid (16.5 mg, 0.04 mmol, 31.1% yield). ¾ NMR (499 MHz, DMSO-t e) δ ppm 2.15 (3 H, s), 2.23 - 2.37 (4 H, m), 2.37 - 2.48 (4 H, m), 3.54 (2 H, s), 3.93 (3 H, s), 7.45 - 7.51 (1 H, m), 7.51 - 7.57 (1 H, m), 7.96 (1 H, d, J=7.68 Hz), 7 98 (1 H, s), 8.22 (1 H, s), 8.51 (1 H : s), 8.56 (1 H, d, J=1.65 Hz), 8.65 (1 H, s), 9.20 (1 H, s), 9.23 (1 H, d, J=1.92 Hz), 10.99 (1 H, s); ESIMS found for C25H

2914

[0997] N-(3 -( 1 -Methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)-3- phenylpropanamide 2914.

[0998] Off-white solid (22 mg, 0.06 mmol, 1.4% yield). ¾ NMR (499 MHz, DMSO-t e) 5 ppm 2.74 - 2.82 (2 H, m), 2.92 - 2.99 (2 H, m), 3.92 (3 H, s), 7.14 - 7.22 (1 H, m), 7.25 - 7.33 (4 H, m), 8.19 (1 H, s), 8.45 - 8.52 (3 H, m), 9.11 (1 H, s), 9.17 (1 H, d, J=2.20 Hz), 10.71 (1 H, s); ESIMS found for C 2 iHi 9 N 5 0 mlz 358.2 (M+l).

2922

[0999] 2-Methyl-N-(3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6- yl)-l,2,3,4- tetrahydroisoquinoline-7-carboxamide 2922.

[01000] Off-white solid (27 mg, 0.07 mmol, 59.2% yield). ¾ NMR (499 MHz, DMSO-i/ 6 ) δ ppm 2.37 (3 H, s), 2.59 - 2.66 (2 H, m), 2.89 (2 H, t, J=5.76 Hz), 3.56 (2 H, s), 3.93 (3 H, s), 7.26 (1 H, d, J=7.96 Hz), 7.81 (1 H, s), 7.84 (1 H, dd, J=7.82, 1.51 Hz), 8.21 (1 H, s), 8.51 (1 H, s), 8.55 (1 H, d, J=2.20 Hz), 8.64 (1 H, s), 9.19 (1 H, s), 9.22 (1 H, d, J=2.20 Hz), 10.86 (1 H, s); ESIMS found for C23H22N6

2929

[01001] N-(3-(l-Methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl)benzof uran-6- carboxamide 2929.

[01002] Off-white solid (18 mg, 0.05 mmol, 40.7% yield). ¾ NMR (499 MHz, DMSO- e) δ ppm 3.94 (3 H, s), 7.09 (1 H, dd, J=1.92, 0.82 Hz), 7.80 (1 H, d, J=8.23 Hz), 8.01 (1 H, dd, J=8.10, 1.51 Hz), 8.20 (1 H, d, J=2.20 Hz), 8.22 (1 H, s), 8.40 (1 H, s), 8.51 (1 H, s), 8.57 (1 H, d, .7=1.92 Hz), 8.68 (1 H, s), 9.21 (1 H, s), 9.23 (1 H, d, J=2.20 Hz), 11.05 (1 H, s); ESIMS found for C 2 iHi 5 N 5 0 2 mlz 370.1

2936

[01003] N-(3-(l-Methyl-lH-pyrazol-4-yl)-lJ-naphthyridin-6-yl)quinoxa line-6- carboxamide 2936.

[01004] Off-white solid (26.8 mg, 0.07 mmol, 58.6% yield). Ή NMR (499 MHz, DMSO-i¾,) δ ppm 3.94 (3 H, s), 8.23 (1 H, s), 8.24 (1 H, d, J=8.78 Hz), 8.44 (1 H, dd, J=8.64, 2.06 Hz), 8.52 (1 H, s), 8.60 (1 H, d, J=1.92 Hz), 8.72 (1 H, s), 8.85 (1 H, d, .7=1.92 Hz), 9.05 - 9.08 (1 H, m), 9.09 (1 H, d, .7=1.92 Hz), 9.24 (1 H, s), 9.25 (1 H, d, J=2.20 Hz), 11.48 (1 H, s); ESIMS found for C 2 iHi 5 N 7 0 mlz 382.1 (M+l).

2949

[01005] N-(3 -( 1 -Methyl- lH-pyrazol-4-yl)-l ,7-naphthyridin-6-yl)- 1 -( 1 - methylpiperidin-4-yl)-lH-pyrazole-4-carboxamide 2949.

[01006] White solid (23 mg, 0.06 mmol, 71.7% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.89 - 2.00 (2 H, m), 2.01 - 2.10 (4 H, m), 2.21 (3 H, s), 2.86 (2 H, br d, .7=11.53 Hz), 3.93 (3 H, s), 4.17 (1 H, tt, J= 11.22, 4.15 Hz), 8.19 (1 H, s), 8.21 (1 H, d, J=0.82 Hz), 8.50 (1 H, s), 8.51 (1 H, d, .7=1.92 Hz), 8.59 (1 H, s), 8.63 (1 H, s), 9.17 (1 H, s), 9.20 (1 H, d, .7=2.20 Hz), 10.67 (1 H, s); ESIMS found for C22H24N8O mlz Ml 2 (M+l).

2954 [01007] Isopropyl 4-(4-((3-(l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-yl) carbamoyl) - 1 H-py razol- 1 -y l)piperidine- 1 -carboxylate 2954.

[01008] White solid (9.5 mg, 0.02 mmol, 31.3% yield). ¾ NMR (499 MHz, DMSO- d ) δ ppm 1.21 (6 H, d, J=6.04 Hz), 1.80 (2 H, qd, J=12.03, 4.25 Hz), 2.08 (2 H, br dd, J=12.35, 2.20 Hz), 2.99 (2 H, br s), 3.93 (3 H, s), 4.07 (2 H, br d, J=9.06 Hz), 4.45 (1 H, tt, .7=11.29, 3.95 Hz), 4.80 (1 H, spt, J=6.22 Hz), 8.20 (1 H, s), 8.21 (1 H, d, J=0.55 Hz), 8.50 (1 H, s), 8.51 (1 H, d, 7=1.92 Hz), 8.59 (1 H, s), 8.64 (1 H, s), 9.17 (1 H, s), 9.20 (1 H, d, 7=2.20 Hz), 10.67 (1 H, s); ESIMS found for CzsftsNgO:,

3000

[01009] 2-(2-Fluoroethyl)-N-(3-(l-methyl-5-(piperidin-l-ylmethyl)-lH -pyrazol-4- yl)-l,7-naphthyridin-6-yl)-2-azaspiro[3.3]lieptane-6-carboxa mide 3000.

[01010] Off-white solid (30 mg, 0.06 mmol, 54.4% yield). ¾ NMR (499 MHz, DMSO-t e) 5 ppm 1.37 (2 H, br d, 7=3.84 Hz), 1.43 - 1.50 (4 H, m), 2.25 - 2.33 (4 H, m), 2.37 (4 H, br s), 2.60 (2 H, dt, J=28.90, 5.00 Hz), 3.12 (2 H, s), 3.22 (2 H, s), 3.24 - 3.31 (1 H, m), 3.67 (2 H, s), 3.92 (3 H, s), 4.36 (2 H, dt, J=47.90, 5.00 Hz), 7.94 (1 H, s), 8.49 (1 H, d, .7=1.65 Hz), 8.52 (1 H, s), 9.10 (1 H, d, .7=1.92 Hz), 9.14 (1 H, s), 10.56 (1 H, s); ESIMS found for C 2 7H 3 4FN 7 0 mlz 492.3 (M+l).

3003

[01011] 2-(Diethylamino)-N-(3-(l-methyl-5-(piperidin-l-ylmethyl)-lH- pyrazol-4- yl)-l ,7-naphthyridin-6-yl)acetamide 3003.

[01012] Beige solid (10 mg, 0.02 mmol, 12.3% yield). ¾ NMR (499 MHz, METHANOLS) δ ppm 1.15 (6 H, t, .7=7.14 Hz), 1.41 - 1.49 (2 H, m), 1.55 (4 H, quin, J=5.49 Hz), 2.43 (4 H, br s), 2.73 (4 H, q, 7=7.23 Hz), 3.30 (2 H, s), 3.70 (2 H, s), 3.99 (3 H, s), 7.89 (1 H, s), 8.55 (1 H, d, J=1.65 Hz), 8.57 (1 H, s), 9.12 (1 H, d, J=2.20 Hz), 9.15 (1 H, s); ESIMS found for C 2 4H 3 3N 7 0 mlz 436.3 (M+l).

3024

[01013] N-(3-(5-Amino-l-methyl-lH-pyrazol-4-yl)-l,7-naphthyridin-6-y l)-2-(4- methylpiperazin-1 -yl)isonicotinamide 3024.

[01014] Light yellow solid (5.4 mg, 0.01 mmol, 8.7% yield). ¾ NMR (499 MHz, DMSO ) δ ppm 2.28 (3 H, br s), 2.51 - 2.54 (4 H, m), 3.57 - 3.68 (2 H, m), 3.64 (4 H, s), 5.96 (2 H, s), 7.16 (1 H, d, J=4.94 Hz), 7.48 (1 H, s), 7.83 (1 H, s), 8.27 (1 H, d, J=4.94 Hz), 8.31 (1 H, d, J=2.20 Hz), 8.64 (1 H, s), 9.14 (2 H, dd, J=2.47, 1.65 Hz), 11.15 (1 H, s); ESIMS found for C 23 H 25 N 9 O mlz 444.2 (M+l).

3032

[01015] N-(3 -( 1 -Methyl-5 -(piperidm-1 -ylmethyl)-lH-pyrazol-4-yl)- 1 J-naphthyridin- 6-yl)-2-(7-methyl-2,7-diazaspiro[3.5]nonan-2-yl)isonicotinam ide 3032.

[01016] Off-white solid (16 mg, 0.03 mmol, 50.3% yield). ¾ NMR (499 MHz, DMSO- 6 ) δ ppm 1.34 - 1.41 (2 H, m), 1.43 - 1.52 (4 H, m), 1.76 (4 H, br t, J=5.08 Hz), 2.15 (3 H, s), 2.27 (4 H, br s), 2.39 (4 H, br s), 3.69 (2 H, s), 3.74 (4 H, s), 3.93 (3 H, s), 7.03 ( 1 H, s), 7.13 (1 H, dd, J=5.21, 1.37 Hz), 7.98 (1 H, s), 8.20 (1 H, d, J=5.49 Hz), 8.60 (1 H, d, J=1.92 Hz), 8.66 (1 H, s), 9.18 (1 H, d, J=1.92 Hz), 9.24 (1 H, s), 11.15 (1 H, s); ESIMS found for C 3 2¾9N 9 0 mlz 566.35 (M+l).

3034

[01017] N-(3 -( 1 -Methyl-5 -(morpholinomethyl)- lH-pyrazol-4-yl)- 1 ,7-naphthyridin-6- yl)-2-morpholinoisonicotinamide 3034. [01018] Off-white solid (39 mg, 0.08 mmol, 46.4% yield). ¾ NMR (499 MHz, DMSO- e) δ ppm 2.41 (4 H, br s), 3.51 - 3.55 (4 H, m), 3.55 - 3.59 (4 H, m), 3.71 - 3.76 (4 H, m), 3.78 (2 H, s), 3.95 (3 H, s), 7.21 (1 H, dd, J=5.08, 1.23 Hz), 7.47 (1 H, s), 7.98 (1 H, s), 8.29 (1 H, d, J=5.21 Hz), 8.57 (1 H, d, J=1.92 Hz), 8.69 (1 H, s), 9.17 (1 H, d, J=2.20 Hz), 9.25 (1 H, s), 11.24 (1 H, s); ESIMS found for C 2 7H 3 o +l).

[01019] N-((4,4-Difluorocyclohexyl)methyl)-3-(5-(2-fluoroethyl)-4,5, 6J- tetrahydropyrazolo[l ,5-a] pyrazin-3-yl)-l ,7-naphthyridin-6-amine 3037.

[01020] Off-white solid (10 mg, 0.02 mmol, 9.3% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.66 - 1.76 (2 H, m), 1.77 - 1.92 (2 H, m), 1.96 (2 H, br d, J=12.62 Hz), 2.08 - 2.19 (2 H, m), 2.68 - 2.77 (1 H, m), 2.98 (2 H, dt, J=28.60, 5.00 Hz), 3.08 (2 H, t, J=5.49 Hz), 4.11 (2 H, s), 4.20 (2 H, t, J=5.63 Hz), 4.67 (2 H, dt, J=47.90, 5.00 Hz), 8.14 (1 H, s), 8.20 (1 H, d, J=1.92 Hz), 8.55 (1 H, s), 9.07 (1 H, d, .7=2.20 Hz), 9.14 (1 H, s), 10.75 (1 H, s); ESIMS found for C 2 3H25F 3 N 6 0 mlz 459.2 (M+l).

3067

[01021] N-(3-(l-Methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyndm-6-yl)-l -((l- (trifluoromethyl)cyclopropyl) methyl)piperidine-4-carboxamide 3067.

[01022] Off-white solid (20 mg, 0.04 mmol, 39.8% yield). ¾ NMR (499 MHz, DMSO-£¾) δ ppm 0.73 (2 H, s), 0.93 - 0.99 (2 H, m), 1.61 - 1.73 (2 H, m), 1.79 (2 H, br d, J=9.88 Hz), 1.91 - 2.00 (2 H, m), 2.56 (1 H, tt, J=\ 1.63, 3.88 Hz), 2.97 (2 H, br d, J=l 1.25 Hz), 4.17 (3 H, s), 8.57 (1 H, s), 8.70 (1 H, d, J=1.65 Hz), 8.83 (1 H, s), 9.19 (1 H, s), 9.38 (1 H, d, J=2.20 Hz), 10.71 (1 H, s); ESIMS found for C22H24F3N7O mlz 460.2 (M+l).

3078 [01023] 2-(4-Methoxypiperidin-l-yl)-N-(3-(l-methyl-lH-l,2,3-triazol- 4-yl)-l,7- naphthyridin-6-yl)acetamide 3078.

[01024] Beige solid (40 mg, 0.10 mmol, 44.2% yield). ¾ NMR (499 MHz, DMSO-t/e) δ ppm 1.47 - 1.58 (2 H, m), 1.84 - 1.94 (2 H, m), 2.33 - 2.42 (2 H, m), 2.75 - 2.83 (2 H, m), 3.20 - 3.23 (1 H, m), 3.24 (2 H, s), 3.24 (3 H, s), 4.17 (3 H, s), 8.56 (1 H, s), 8.75 (1 H, d, J=1.65 Hz), 8.83 (1 H, s), 9.21 (1 H, s), 9.40 (1 H, d, J=1.92 Hz), 10.17 (1 H, s); ESIMS found for C19H23N7O2 mlz 382.2 (M+l).

3092

[01025] N 2 -Methyl-N 5 -(3^1-methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6 -yl) pyridine-2,5-dicarboxamide 3092.

[01026] Off-white solid (0.40 mg, 0.001 mmol, 0.78% yield). ESIMS found for

Ci 9 Hi 6 N 8 02 mlz 389.15 (M+l).

3096

[01027] 2-(4-(Dimethylammo)piperidin-l-yl)-N-(3-(l-methyl-lH-l,2,3-t riazol-4-yl)- l,7-naphthyridin-6-yl)isonicotinamide 3096.

[01028] Off-white solid (2.6 mg, 0.006 mmol, 4.3% yield). ¾ NMR (499 MHz, DMSO-£¾) δ ppm 1.23 (6 H, s), 1.37 - 1.48 (2 H, m), 2.27 - 2.36 (3 H, m), 2.83 - 2.94 (2 H, m), 4.18 (3 H, s), 4.45 - 4.54 (2 H, m), 7.14 (1 H, d, J=5.21 Hz), 7.49 (1 H, s), 8.26 (1 H, d, J=5.21 Hz), 8.74 (1 H, s), 8.81 (1 H, d, J=2.20 Hz), 8.87 (1 H, s), 9.30 (1 H, s), 9.45 (1 H, d, J=1.92 Hz), 11.28 (1 H, s); ESIMS found for C24H

3098

[01029] N-(3-(l-Methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyridin-6-yl) -2-(4- methylpiperazin-1 -yl)isonicotinamide 3098. [01030] Off-white solid (30 mg, 0.07 mmol, 96.7% yield). ¾ NMR (499 MHz, DMSO- e) δ ppm 2.24 (3 H, s), 2.43 (4 H, t, J=4.94 Hz), 3.58 - 3.65 (4 H, m), 4.18 (3 H, s), 7.17 (1 H, dd, J=5.08, 1.24 Hz), 7.47 (1 H, s), 8.27 (1 H, d, J=4.94 Hz), 8.73 (1 H, s), 8.80 (1 H, d, J=1.92 Hz), 8.86 (1 H, s), 9.29 (1 H, s), 9.44 (1 H, d, J=2.20 Hz), 11.27 (1 H, s); ESIMS found for C22H23N9O mlz 430.2 (M+l).

3099

[01031] 2-(4-Methyl-l,4-diazepan-l-yl)-N-(3-(l-methyl-lH-l,2,3-tnazo l-4-yl)-l,7- naphthyridin-6-yl)isonicotinamide 3099.

[01032] Off-white solid (10.1 mg, 0.02 mmol, 17.2% yield). ¾ NMR (499 MHz, DMSO ) δ ppm 1.92 - 1.99 (2 H, m), 2.30 (3 H, s), 2.52 - 2.59 (2 H, m), 2.68 (2 H, br s), 3.69 (2 H, t, J=6.17 Hz), 3.79 - 3.87 (2 H, m), 4.18 (3 H, s), 7.07 (1 H, dd, J=4.94, 1.10 Hz), 7.23 (1 H, s), 8.22 (1 H, d, J=5.21 Hz), 8.73 (1 H, s), 8.80 (1 H, d, J=1.92 Hz), 8.86 (1 H, s), 9.29 (1 H, s), 9.44 (1 H, d, J=2.20 Hz), 11.26 (1 H, s); ESIMS found for C23H25N9O mlz 444.2 (M+l).

3102

[01033] 2-(Methyl(l -methylpiperidin-4-yl)amino)-N-(3 -( 1 -methyl- 1H- 1 ,2,3 -triazol- 4-yl)-l,7-naphthyridin-6-yl)isonicotinamide 3102.

[01034] Off-white solid (10 mg, 0.02 mmol, 11.2% yield). ¾ NMR (499 MHz, DMSO-t/e) δ ppm 1.51 - 1.60 (2 H, m), 1.81 (2 H, qd, J=12.08, 3.57 Hz), 2.05 (2 H, br t, J=10.98 Hz), 2.21 (3 H, s), 2.87 (2 H, br d, J=13.45 Hz), 2.93 (3 H, s), 4.18 (3 H, s), 4.48 - 4.57 (1 H, m), 7.08 (1 H, dd, J=5.08, 1.24 Hz), 7.19 (1 H, s), 8.24 (1 H, d, J=5.21 Hz), 8.73 (1 H, s), 8.80 (1 H, d, J=1.92 Hz), 8.86 (1 H, s), 9.29 (1 H, s), 9.44 (1 H, d, J=1.92 Hz), 11.24 (1 H, s); ESIMS found for C24H27N9O mlz 458.2 (M+l).

3105

[01035] N-(3-(l-Methyl-lH-l,2,3-triazol-4-yl)-l,7-naphthyndm-6-yl)-2 -(piperazin-l- yl)isonicotinamide 3105. [01036] Off-white solid (40 mg, 0.10 mmol, 46.4% yield). ¾ NMR (500 MHz, DMSO- e) δ ppm 2.76 - 2.85 (4 H, m), 3.50 - 3.56 (4 H, m), 4.18 (3 H, s), 7.14 (1 H, dd, J=5.08, 1.23 Hz), 7.43 (1 H, s), 8.26 (1 H, d, J=4.67 Hz), 8.73 (1 H, d, J=0.82 Hz), 8.80 (1 H, d, J=1.92 Hz), 8.86 (1 H, s), 9.29 (1 H, s), 9.44 (1 H, d, J=2.20 Hz), 11.27 (1 H, br s); ESIMS found for C 21 H 21 N 9 O m/z 416.2 (M+l).

3111

[01037] N-(3-(4-Methyl-4H-l,2,4-tnazol-3-yl)-l,7-naphthyndm-6-yl)-l- (3,3,3- trifluoropropyl)piperidine-4-carboxamide 3 1

[01038] Dark brown solid (1.6 mg, 0.004 mmol, 4.8% yield). ¾ NMR (499 MHz, DMSO-£4) δ ppm 1.62 - 1.74 (2 H, m), 1.81 (2 H, br d, J=11.25 Hz), 1.95 - 2.01 (2 H, m), 2.40 - 2.54 (4 H, m), 2.59 (1 H, tt, J=l 1.70, 3.95 Hz), 2.94 (2 H, br d, J=l 1.25 Hz), 3.91 (2 H, s), 8.70 (1 H, s), 8.72 (1 H, s), 8.79 (1 H, d, J=2.20 Hz), 9.26 (1 H, d, J=2.20 Hz), 9.28 (1 H, s), 10.80 (1 H, s); ESIMS found for C20H22F3N

3118

[01039] l-Isobutyl-N-(3 -( 1 -methyl- lH-tetrazol-5 -yl)- l,7-naphthyridin-6-yl) piperidine-4-carboxamide 3118.

[01040] Brown solid (2.5 mg, 0.006 mmol, 2.9% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 0.86 (6 H, d, J=6.59 Hz), 1.63 - 1.73 (2 H, m), 1.74 - 1.83 (3 H, m), 1.88 (2 H, td, J=l 1.60, 2.06 Hz), 2.03 (2 H, d, J=7.41 Hz), 2.58 (1 H, tt, J=11.49, 3.88 Hz), 2.87 (2 H, br d, J=11.53 Hz), 4.32 (3 H, s), 8.74 (1 H, s), 8.97 (1 H, d, J=2.20 Hz), 9.26 (1 H, d, J=2.20 Hz), 9.32 - 9.35 (1 H, m), 10.84 (1 H, s); ESIMS found for CzoHzsNgO mlz 395.2 (M+l).

3120

[01041] 4,4-Difluoro-N-(3-( 1 -methyl- lH-imidazol-5-yl)- 1 ,7-naphthyridin-6-yl) cycloliexane-l-carboxamide 3120. [01042] Off-white solid (15 mg, 0.04 mmol, 26.7% yield). ¾ NMR (499 MHz, DMSO- e) δ ppm 1.66 - 1.77 (2 H, m), 1.77 - 1.93 (2 H, m), 1.97 (2 H, br d, J=12.62 Hz), 2.08 - 2.19 (2 H, m), 2.73 (1 H, br t, J=10.98 Hz), 3.87 (3 H, s), 7.48 (1 H, d, J=0.82 Hz), 7.87 (1 H, s), 8.50 (1 H, d, J=1.92 Hz), 8.60 (1 H, s), 9.08 (1 H, d, J=2.20 Hz), 9.19 (1 H, s), 10.80 (1 H, s); ESIMS found for C19H19F2 5O

3134

[01043] N-(3-(l-Metliyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)-2-( pyrrolidin-l-yl) propanamide 3134.

[01044] White solid (13.2 mg, 0.04 mmol, 20.9% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 1.31 (3 H, d, J=6.86 Hz), 1.74 (4 H, br s), 2.59 - 2.70 (4 H, m), 3.28 - 3.37 (1 H, m), 3.87 (3 H, s), 7.49 (1 H, d, J=0.82 Hz), 7.87 (1 H, s), 8.54 (1 H, d, J=1.92 Hz), 8.60 (1 H, s), 9.09 (1 H, d, J=2.20 Hz), 9.19 (1 H, s), 10.20 (1 H, s); ESIMS found for G 9 H 22 N 6 O mlz 351.2 (M+l).

3136

[01045] 3-Isopropoxj r -N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-y l) propanamide 3136.

[01046] Grey solid (5 mg, 0.01 mmol, 6.6% yield). Ή NMR (500 MHz, DMSO-t s) δ ppm 1.08 (6 H, d, J=6.31 Hz), 2.68 (2 H, br t, J=6.17 Hz), 3.58 (1 H, dt, J=12.08, 6.04 Hz), 3.70 (2 H, brt, J=6.04 Hz), 3.87 (3 H, s), 7.48 (1 H, s), 7.86 (1 H, s), 8.51 (1 H, s), 8.61 (1 H, s), 9.07 (1 H, d, J=1.37 Hz), 9.19 (1 H, s), 10.71 (1 H, s); ESIMS found for Ci8H 2 iN 5 0 2 mlz 340.2 (M+l).

3167

[01047] N-(3-(l,2-Dimethyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)- 2- methylthiazole-5 -carboxamide 3167.

[01048] Tan solid (12 mg, 0.03 mmol, 33.8% yield). ¾ NMR (499 MHz, DMSO-d 6 ) δ ppm 2.42 (3 H, s), 2.72 (3 H, s), 3.72 (3 H, s), 7.32 (1 H, s), 8.46 (1 H, d, J=1.92 Hz), 8.65 (1 H, s), 8.70 (1 H, s), 9.06 (1 H, d, J=2.20 Hz), 9.26 (1 H, s), 11.36 (1 H, br s); ESIMS found for CisHifiNeOS mlz 365.1 (M+l).

3168

[01049] 4-Fluoro-N-(3-(l-methyl-lH-imidazol-5-yl)-l,7-naphthyndm-6-y l) benzamide 3168.

[01050] Brown solid (18 mg, 0.05 mmol, 50.8% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 3.89 (3 H, s), 7.37 (2 H, t, J=8.78 Hz), 7.51 (1 H, d, J=0.82 Hz), 7.88 (1 H, s), 8.13 - 8.22 (2 H, m), 8.59 (1 H, d, .7=1.92 Hz), 8.76 (1 H, s), 9.13 (1 H, d, J=2.47 Hz), 9.27 (1 H, s), 11.13 (1 H, s); ESIMS found for Ci 9 Hi 4

3194

[01051] N-(3-(l-Methyl-lH-imidazol-5-yl)-l,7-naphthyridin-6-yl)isoin doline-5- carboxamide 3194.

[01052] Off-white solid (10 mg, 0.03 mmol 52.9% yield). ¾ NMR (499 MHz, DMSO- 6 ) 5 ppm 3.89 (3 H, s), 4.14 (4 H, br s), 7.40 (1 H, d, .7=7.96 Hz), 7.51 (1 H, s), 7.88 (1 H, s), 7.93 (1 H, dd, J=7.96, 1.37 Hz), 7.98 (1 H, s), 8.58 (1 H, d, J=1.92 Hz), 8.77 (1 H, s), 9.12 (1 H, d, mlz 371.15 (M+l).

3240

[01053] 4-Isopropoxy-N-(3-(5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-3 -yl)-l,7- naphthyridin-6-yl)benzamide 3240.

[01054] Yellow solid (24.2 mg, 0.05 mmol, 37.3% yield). 'HNMR (499 MHz, DMSO- d 6 ) δ ppm 1.31 (6 H, d, J=6.04 Hz), 3.10 (2 H, t, J=5.35 Hz), 3.97 (2 H, s), 4.18 (2 H, t, .7=5.35 Hz), 4.76 (1 H, spt, J=5.99 Hz), 7.03 (2 H, d, J=9.06 Hz), 7.50 (1 H, s), 8.08 (2 H, d, J=9.06 Hz), 8.48 (1 H, d, J=1.92 Hz), 8.74 (1 H, s), 9.10 (1 H, d, J=2.20 Hz), 9.23 (1 H, s), 10.83 (1 H, s); ESIMS found for C24H24 6O2 mlz 429.2 (M+l).

3249

[01055] N-(3 -(Oxazol-5 -yl)-l ,7-naphthyridin-6-yl)-l -(2-(pyrrolidin-l -yl) acetyl)piperidine-4-carboxamide 3249.

[01056] White solid (11.0 mg, 0.03 mmol, 34.1% yield). Ή NMR (499 MHz, DMSO- c¾) 5 ppm 1.42 - 1.53 (1 H, m), 1.55 - 1.67 (1 H, m), 1.69 (4 H, br s), 1.85 (2 H, br d, J=10.70 Hz), 2.47 (4 H, br s), 2.58 - 2.66 (1 H, m), 2.84 (1 H, tt, J=11.32, 3.77 Hz), 2.98 - 3.08 (1 H, m), 3.15 - 3.21 (1 H, m), 3.32 - 3.37 (1 H, m), 4.11 (1 H, br d, J=12.90 Hz), 4.40 (1 H, br d, J=12.90 Hz), 8.10 (1 H, s), 8.60 (1 H, s), 8.62 (1 H, d, .7=1.92 Hz), 8.66 (1 H, s), 9.19 - 9.23 (1 H, m), 9.29 (1 H, d, J=2.20 Hz), 10.80 (1 H, s); ESIMS found for C23H26N6O3 mlz 435.2 (M+1).

3257

[01057] l-(2,2-Difluoropropyl)-N-(3 -(oxazol-5 -yl)-l, 7-naplithyridin-6-yl)piperidine- 4-carboxamide 3257.

[01058] White solid (15 mg, 0.04 mmol, 38.3% yield). : H NMR (499 MHz, DMSO- d 6 ) δ ppm 1.63 (3 H, t, J=19.07 Hz), 1.65 - 1.74 (2 H, m), 1.76 - 1.82 (2 H, m), 2.22 (2 H, td, J=11.80, 2.20 Hz), 2.52 - 2.61 (1 H, m), 2.71 (2 H, t, J=14.00 Hz), 2.95 (2 H, br d, .7=11.53 Hz), 8.10 (1 H, s), 8.60 (1 H, s), 8.63 (1 H, d, .7=1.92 Hz), 8.66 (1 H, s), 9.21 (1 H, s), 9.28 (1 H, d, J=2.20 Hz), 10.74 (1 H, s); ESIMS found for C 2 oH2iF 2 N 5 02 mlz 402.2 (M+1).

3259

[01059] N-(3 -( 1 -Methyl-lH-imidazol-5-yl)- 1 ,7-naphthyridin-6-yl)-3-(pyrrolidin- 1- ylmethyl)benzamide 3259.

[01060] Off-white solid (6.5 mg, 0.02 mmol, 16.1% yield). ¾ NMR (499 MHz, DMSO-£¾) δ ppm 1.72 (4 H, dt, J=6.66, 3.12 Hz), 2.44 - 2.49 (4 H, m), 3.67 (2 H, s), 3.89 (3 H, s), 7.46 - 7.50 (1 H, m), 7.51 (1 H, s), 7.53 - 7.59 (1 H, m), 7.88 (1 H, s), 7.96 (1 H, d, J=7.68 Hz), 8.01 (1 H, s), 8.59 (1 H, d, .7=1.92 Hz), 8.76 (1 H, s), 9.12 (1 H, d, J=2.20 Hz), 9.27 (1 H, s), 11.06 (1 H, s); ESIMS found for Cz^NeO mlz 413.2 (M+1).

3311

[01061 ] 3 -(( 1 -Methylpiperidin-4-yl)oxy) -N-(3 -(oxazol -5 -yl) - 1 , 7-naphthyridin-6 -yl) benzamide 3311.

[01062] White solid (25 mg, 0.06 mmol, 86.4% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.62 - 1 .74 (2 H, m), 1.97 (2 H, br d, .7=10.15 Hz), 2.14 - 2.26 (2 H, m), 2.19 (3 H, s), 2.58 - 2.67 (2 H, m), 4.49 - 4.57 (1 H, m), 7.18 (1 H, dd, J=8.23, 1.65 Hz), 7.43 (1 H, t, J=8.10 Hz), 7.62 - 7.67 (2 H, m), 8.12 (1 H, s), 8.68 (1 H, s), 8.71 (1 H, d, J=1.65 Hz), 8.75 (1 H, s), 9.29 (1 H, s), 9.34 (1 H, d, J=1.92 Hz), 11.08 (1 H, s); ESIMS found for C 2 4H23N 5 0 3 mlz 430.2 (M+l).

3363

[01063] 2-(4-Mcthylpipcrazin-l-yl)-N-(3-(2-mcthylthiazol-5-yl)-l,7-n aphthyndm-6- yl)isonicotinamide 3363.

[01064] Off-white solid (30 mg, 0.07 mmol, 74.2% yield). ¾ NMR (499 MHz, DMSO- e) δ ppm 2.23 (3 H, s), 2.42 (4 H, t, J=4.94 Hz), 2.75 (3 H, s), 3.57 - 3.64 (4 H, m), 7.15 (1 H, dd, J=5.08, 0.96 Hz), 7.46 (1 H, s), 8.26 (1 H, d, J=4.94 Hz), 8.45 (1 H, s), 8.63 (1 H, d, J=2.20 Hz), 8.72 (1 H, s), 9.27 (1 H, s), 9.28 (1 H, d, J=2.20 Hz), 11.26 (1 H, s); ESIMS found for C 23 H 23 N 7 OS mlz 446.2 (M+l).

3403

[01065] N-(3-(2-Aminothiazol-5-yl)-l,7-naphthyridin-6-yl)-2-(4-methy lpiperazin-l- yl)isonicotinamide 3403.

[01066] Light yellow solid (25 mg, 0.06 mmol, 40.1% yield). ¾ NMR (500 MHz, DMSO- e) δ ppm 2.23 (3 H, s), 2.41 - 2.45 (3 H, m), 3.57 - 3.62 (3 H, m), 7.15 (1 H, dd, J=5.08, 1.23 Hz), 7.46 (1 H, s), 7.58 (2 H, s), 7.90 (1 H, s), 8.17 (1 H, d, J=2.20 Hz), 8.26 (1 H, d, J=5.49 Hz), 8.63 (1 H, d, J=0.82 Hz), 9.16 (1 H, t, J=0.82 Hz), 9.21 (1 H, d, J=2.47 Hz), 11.18 (1 H, br s); ESIMS found for C22H22N8OS mlz 447.15 (M+l).

3412

[01067] N -(3 -(Isothiazol-4-yl)-l J-naphthyndm-6-yl)- 1 -methylpiperidine-4- carboxamide 3412.

[01068] Off-white solid (25 mg, 0.07 mmoL 50.4% yield). ¾ NMR (499 MHz, DMSO ) δ ppm 1.62 - 1.74 (2 H, m), 1.76 - 1.82 (2 H, m), 1.87 (2 H, td, J=\ 1.66, 2.20 Hz), 2.16 (3 H, s), 2.51 - 2.58 (1 H, m), 2.81 (2 H, br d, J=11.25 Hz), 8.59 (1 H, s), 8.81 (1 H, d, J=1.92 Hz), 9.21 (1 H, s), 9.32 (1 H, s), 9.37 (1 H, d, J=2.20 Hz), 9.76 (1 H, s), 10.72 (1 H, s); ESIMS found for Ci 8 Hi 9 N 5 OS mlz 354.15 (M+l ).

3425

[01069] fr « --4-Methoxy-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphth yridin-6- yl)cyclohexane-l -carboxamide 3425.

[01070] Off-white solid (16 mg, 0.04 mmoL 50.8% yield). ¾ NMR (499 MHz, DMSO-t/e) δ ppm 1.09 - 1.19 (2 H, m), 1.46 - 1.56 (2 H, m), 1.88 - 1.97 (2 H, m), 2.05 - 2.12 (2 H, m), 2.52 - 2.60 (1 H, m), 2.85 (3 H, s), 3.09 - 3.16 (1 H, m), 3.25 (3 H, s), 8.67 (1 H, s), 8.92 (1 H, d, J=2.20 Hz), 9.27 (1 H, s), 9.43 (1 H, d, J=2.20 Hz), 10.76 (1 H, s); ESIMS found for G 9 H 21 N 5 O 2 S mlz 384.2 (M+l).

3439

[01071] l-Benzoyl-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)-l,7-naphthyr idin-6-yl) piperidine-4-carboxamide 3439.

[01072] Beige solid (4 mg, 0.009 mmol, 10.6% yield). Ή NMR (499 MHz, DMSO-t/e) 5 pm 1.64 (2 H, ddd, =7.55, 3.02, 1.23 Hz), 1.77 - 1.90 (1 H, m), 1.90 - 2.03 (1 H, m), 2.86 (3 H, s), 2.87 - 2.93 (2 H, m), 3.04 - 3.17 (1 H, m), 3.62 - 3.73 (1 H, m), 4.47 - 4.61 (1 H, m), 7.39 - 7.42 (2 H, m), 7.44 - 7.47 (3 H, m), 8.69 (1 H, s), 8.95 (1 H, d, J=1.65 Hz), 9.29 (1 H, s), 9.44 (1 H, d, J=2.20 Hz), 10.89 (1 H, s); ESIMS found for C24H22N6O2S mlz 459.2 (M+l).

3446

[01073] 2-(7-Azabicyclo[2 .1]heptan-7-yl)-N-(3-(5-methyl-l,3,4-thiadiazol-2-yl)- l,7-naphthyridin-6-yl)acetamide 3446.

[01074] Beige solid (10 mg, 0.03 mmol, 21.6% yield). ¾ NMR (499 MHz, DMSO-t/e) δ ppm 1.35 (4 H, br d, J=6.86 Hz), 1.72 - 1.78 (4 H, m), 2.86 (3 H, s), 3.24 (2 H, s), 3.36 - 3.41 (2 H, m), 8.70 (1 H, d, J=0.82 Hz), 9.02 ( 1 H, d, J=2.20 Hz), 9.30 (1 H, s), 9.47 (1 H, d, J=2.20 Hz), 10.35 (1 H, s); ESIMS found for Ci 9 H2oN 6 OS mlz 381.2 (M+l).

3470

[01075] N-(3 -(5 -Methyl- 1 ,3, 4-thiadiazol-2-yl)- 1 ,7-naphthyridin-6-yl)-2-(4- methylpiperazin-1 -yl)isonicotinamide 3470.

[01076] Brown solid (7 mg, 0.02 mmol, 21.2% yield). ¾ NMR (499 MHz, DMSO ) δ ppm 2.24 (3 H, s), 2.43 (4 H, t, J=5.08 Hz), 2.87 (3 H, s), 3.58 - 3.66 (4 H, m), 7.16 (1 H, dd, J=5.21, 1.10 Hz), 7.48 ( 1 H, s), 8.27 (1 H, d, J=5.21 Hz), 8.85 (1 H, s), 9.04 (1 H, d, J=2.20 Hz), 9.37 (1 H, s), 9.50 (1 H, d, J=2.20 Hz), 1 1.35 ( 1 H, s); ESIMS found for C 22 H 22 N 8 OS mlz 447.2 (M+l).

3474

[01077] N-(3 -(5 -Methyl- 1 ,3, 4-thiadiazol-2-yl)- 1 ,7-naphthyndin-6-yl)-2-(( 1 - methylpiperidin-4-yl)thio)isonicotinamide 3474.

[01078] Off-white solid (22 mg, 0.05 mmol, 36.2% yield). ¾ NMR (499 MHz, DMSO ) δ ppm 1.61 - 1.74 (2 H, m), 1.99 - 2.07 (2 H, m), 2.12 (2 H, br t, J=10.29 Hz), 2.17 (3 H, s), 2.65 - 2.74 (2 H, m), 2.86 (3 H, s), 3.80 - 3.89 (1 H, m), 7.64 (1 H, dd, J=5.08, 1.51 Hz), 7.82 (1 H, s), 8.60 - 8.66 (1 H, m), 8.83 (1 H, s), 9.04 (1 H, d, J=2.20 Hz), 9.37 (1 H, s), 9.50 (1 H, d, J=2.20 Hz), 11.45 (1 H, s); ESIMS found for C23H23N7OS2 mlz 478.2 (M+l).

3524

[01079] N-(3 -(5 -Aminopyridin-3-yl)- 1 ,7-naphthyridin-6-yl)-4-(piperidin-4-yloxy) benzamide 3524.

[01080] Beige solid (1.3 mg, 0.003 mmol, 7.6% yield). Ή NMR (499 MHz, DMSO- c¾) 5 pm 1.70 - 1.79 (2 H, m), 2.04 - 2.13 (2 H, m), 2.92 - 3.01 (2 H, m), 3.15 - 3.21 (2 H, m), 4.73 (1 H, dt, J=7.89, 4.15 Hz), 5.55 (2 H, s), 7.12 (2 H, d, J=8.78 Hz), 7.38 (1 H, t, J=2.33 Hz), 8.06 (1 H, d, J=2.47 Hz), 8.11 (2 H, d, J=8.78 Hz), 8.27 (1 H, d, J=1.65 Hz), 8.66 (1 H, d, J=1.65 Hz), 8.75 (1 H, s), 9.18 (1 H, d, J=2.20 Hz), 9.30 (1 H, s), 10.92 (1 H, s); ESIMS found for C25H 2 4N 6 0 2 mlz 441.2 (M+l).

3527

[01081] N-(3-(6-Aminopyridin-3-yl)-l,7-naphthyridin-6-yl)-2-(4-methy lpiperazin-l- yl)isonicotinamide 3527.

[01082] Beige solid (31.5 mg, 0.07 mmol, 50.9% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 2.23 (3 H, s), 2.43 (4 H, t, J=4.94 Hz), 3.56 - 3.64 (4 H, m), 6.37 (2 H, s), 6.61 (1 H, d, J=8.78 Hz), 7.16 (1 H, dd, J=5.08, 0.96 Hz), 7.47 (1 H, s), 8.01 (1 H, dd, J=8.78, 2.47 Hz), 8.26 (1 H, d, .7=5.21 Hz), 8.58 (2 H, dd, .7=6.59, 2.20 Hz), 8.69 (1 H, s), 9.24 (1 H, s), 9.26 (1 H, d, .7=2.20 Hz), 11.21 (1 H, s); ESIMS found for Cz^NsO mlz 441.2 (M+l).

3587

[01083] N-(3-(6-(teri-Butylamino)pyrazin-2-yl)-l,7-naplitliyridin-6- yl)-l'-methyl- r,2',3',6'-tetrahydro-[2,4'-bipyridine]-4-carboxamide 3587.

[01084] Tan solid (5.9 mg, 0.01 mmol, 6.8% yield). ¾ NMR (499 MHz, DMSO-de) δ ppm 1.52 (9 H, s), 2.31 (3 H, s), 2.57 - 2.63 (2 H, m), 2.63 - 2.69 (2 H, m), 3.11 (2 H, br d, J=3.02 Hz), 6.89 (1 H, t, J=3.57 Hz), 7.12 (1 H, s), 7.79 (1 H, dd, J=4.94, 1.37 Hz), 8.02 (1 H, s), 8.18 (1 H, s), 8.53 (1 H, s), 8.72 (1 H, d, J=4.94 Hz), 8.80 (1 H, s), 8.98 (1 H, d, J=1.65 Hz), 9.33 (1 H, s), 9.58 (1 H, d, J=2.20 Hz), 11.50 (1 H, s); ESIMS found for C 28 H 30 N 8 O mlz 495.3 (M+l).

3591

[01085] N-(3-(6-(((3-Fluoroazetidin-3-yl)methyl)amino)pyrazin-2-yl)- l,7- naphthyridin-6-yl)cyclopropanecarboxamide 3591.

[01086] Orange solid (57.2 mg, 0.14 mmol, 87.4% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 0.84 - 0.89 (4 H, m), 2.07 - 2.15 (1 H, m), 4.04 (2 H, dd, J=20.60, 6.10 Hz), 4.17 - 4.38 (4 H, m), 7.76 (1 H, t, J=6.17 Hz), 8.11 (1 H, s), 8.63 (1 H, s), 8.64 (1 H, s), 8.97 (1 H, d, J=1.65 Hz), 9.25 (1 H, s), 9.59 (1 H, d, J=2.20 Hz), 11.11 (1 H, s); ESIMS found for C 20 H 20 FN 7 O mlz 394.2 (M+l).

3597

[01087] N-(3-(6-(Piperidin-4-ylamino)pyrazin-2-yl)-l,7-naphthyridin- 6-yl) tetrahydro-2H-pyran-4-carboxamide 3597.

[01088] Yellow solid (68 mg, 0.16 mmol, 79.7% yield). ¾ NMR (499 MHz, DMSO- c ) 6 pm 1.32 - 1.44 (2 H, m), 1.65 - 1.80 (4 H, m), 1.92 - 1.99 (2 H, m), 2.58 - 2.70 (2 H, m), 2.81 - 2.91 (1 H, m), 2.96 - 3 04 (2 H, m), 3.34 - 3.41 (2 H, m), 3 88 - 4.01 (3 H, m), 7.29 (1 H, d, .7=7.14 Hz), 8.00 (1 H, s), 8.50 (1 H, s), 8.63 (1 H, s), 8.90 (1 H, d, J=1.92 Hz), 9.23 (1 H, s), 9.50 (1 H, d, J=2.20 Hz), 10.77 (1 H, s); ESIM mlz 434.2 (M+l).

3599 [01089] N-(3-(6-(((3S,4S)-3-Fluoropipendm-4-yl)amino)pyrazin-2-yl)-l ,7- naphthyridin-6-yl)cyclopropanecarboxamide 3599.

[01090] Yellow solid (12 mg, 0.03 mmol, 49.0% yield). ¾ NMR (499 MHz, DMSO- d ) δ ppm 0.82 - 0.92 (4 H, m), 1.33 - 1.48 (1 H, m), 2.02 - 2.15 (2 H, m), 2.56 - 2.66 (2 H, m), 2.84 - 2.94 (1 H, m), 3.22 (1 H, ddd, J=12.21, 7.55, 4.94 Hz), 4.18 - 4.28 (1 H, m), 4.35 - 4.54 (1 H, m), 7.52 (1 H, d, .7=7.68 Hz), 8.04 (1 H, s), 8.54 (1 H, s), 8.60 (1 H, s), 8.90 (1 H, d, .7=1.65 Hz), 9.24 (1 H, s), 9.51 (1 H, d, .7=1.92 Hz), 11.09 (1 H, s); ESIMS found for C21H22FN7O mlz 408.2 (M+l).

3612

[01091] N-(3-(6-(Azetidin-3-ylmethoxy)pyrazin-2-yl)-l,7-naphthyridin -6-yl)-4- fluorobenzamide 3612.

[01092] Yellow solid (40.3 mg, 0.09 mmol, 70.4% yield). 'HNMR (500 MHz, DMSO- d 6 ) δ ppm 3.08 - 3.17 (1 H, m), 3.90 (2 H, dd, .7=10.57, 6.72 Hz), 4.03 - 4.12 (2 H, m), 4.71 (2 H, d, J=6.04 Hz), 7.34 - 7.42 (2 H, m), 8.15 - 8.23 (2 H, m), 8.45 (1 H, s), 8.83 (1 H, d, .7=0.82 Hz), 9.17 (1 H, s), 9.18 (1 H, d, .7=1.65 Hz), 9.36 (1 H, s), 9.67 (1 H, d, J=2.20 Hz), 11.20 (2 H, br s); ESIMS found for

3616

[01093] N-(3-(lH-Pyrrolo[2,3-c]pyridin-4-yl)-l,7-naphthyridin-6-yl)- l-(l- methylpiperidin-4-yl)-lH-pyrazole-4-carboxamide 3616.

[01094] Yellow solid (2 mg, 0.004 mmol, 38.8% yield). ¾ NMR (499 MHz, DMSO- c ) 5 ppm 1.89 - 1.99 (2 H, m), 2.02 - 2.11 (4 H, m), 2.21 (3 H, s), 2.86 (2 H, br d, .7=11.53 Hz), 4.18 (1 H, tt, .7=11.05, 4.19 Hz), 6.83 (1 H, d, J=2.74 Hz), 7.79 (1 H, d, .7=3.02 Hz), 8.20 (1 H, s), 8.46 (1 H, s), 8.64 (1 H, s), 8.70 (1 H, d, .7=1.92 Hz), 8.76 (1 H, s), 8.87 (1 H, s), 9.28 (1 H, d, .7=2.20 Hz), 9.31 (1 H, s), 10.75 (1 H, s); ESIMS found for C 2 5H 2 4 8 0 mlz 453.2 (M+l).

3627

[01095] l-Isopropyl-N-(3-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2 -yl)-l,7- naphthyridin-6-yl)- lH-pyrazole-4-carboxamide 3627.

[01096] Yellow solid (2.3 mg, 0.005 mmol, 3.0% yield). Ή NMR (500 MHz, DMSO- c/ fi ) 5 ppm 1.46 (6 H, d, .7=6.59 Hz), 1.49 - 1.58 (2 H, m), 1.96 - 2.04 (2 H, m), 2.07 - 2.16 (2 H, m), 2.21 (3 H, s), 2.73 - 2.81 (2 H, m), 3.82 - 3.94 (1 H, m), 4.56 (1 H, dt, J=13.38, 6.62 Hz), 7.29 (1 H, br d, J=7.14 Hz), 8.01 (1 H, s), 8.19 (1 H, d, J=0.82 Hz), 8.54 (1 H, s), 8.63 (1 H, s), 8.72 (1 H, d, J=0.82 Hz), 8.95 (1 H, d, J=1.37 Hz), 9.28 (1 H, t, J=0.82 Hz), 9.53 (1 H, d, J=2.20 Hz), 10.76 (1 H, s); ESIMS found for C25H29N9O mlz 472.3 (M+l).

3629

[01097] N-(6-(l -Methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)

cyclopropanecarboxamide 3629.

[01098] White solid (8 mg, 0.03 mmol, 18.6% yield). ¾ NMR (499 MHz, DMSO-c/ 6 ) δ ppm 0.81 - 0.92 (4 H, m), 2.06 - 2.14 (1 H, m), 3.91 (3 H, s), 7.96 (1 H, s), 8.12 (1 H, s), 8.37 ( 1 H, s), 8.37 (1 H, s), 9.24 (1 H, s), 9.31 (1 H, t, .7=0.82 Hz), 11.08 (1 H, s); ESIMS found for C16H15N5O mlz 294.1 (M+l).

3638

[01099] N-(6-(l -Methyl- lH-pyrazol-4-yl)-2J-naphthyridin-3-yl)piperidine-4- carboxamide 3638.

[01100] Beige solid (100 mg, 0.23 mmol, 56.7% yield). ¾ NMR (500 MHz, DMSO- d 6 ) δ ppm 1.52 (2 H, qd, .7=12.21, 3.98 Hz), 1.67 - 1.74 (2 H, m), 2.43 - 2.49 (2 H, m), 2.66 (1 H, tt, .7=11.66, 3.43 Hz), 2.94 - 3.00 (2 H, m), 3.91 (3 H, s), 4.09 (1 H, q, .7=5.21 Hz), 7.98 (1 H, s), 8.12 (1 H, d, J=0.82 Hz), 8.38 (1 H, s), 8.40 (1 H, s), 9.23 (1 H, s), 9.29 - 9.33 (1 H, m), 10.66 (1 H, s); ESIMS found for Ci 8 H 2

3643

[01101] l-Isobutyl-N-(6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin- 3-yl) piperidine-4-carboxamide 3643.

[01102] Off-white solid (123 mg, 0.06 mmol, 65.7% yield). ¾ NMR (499 MHz, DMSO ) δ ppm 0.84 (6 H, d, J=6.59 Hz), 1.60 - 1.71 (2 H, m), 1.72 - 1.80 (3 H, m), 1.82 - 1.90 (2 H, m), 2.00 (2 H, d, .7=7.41 Hz), 2.55 (1 H, tt, J=11.60, 3.91 Hz), 2.85 (2 H, br d, J=\ 1.25 Hz), 3.91 (3 H, s), 7.98 (1 H, s), 8.12 (1 H, s), 8.37 (1 H, s), 8.41 (1 H, s), 9.22 (1 H, s), 9.30 (1 H, s), 10.70 (1 H, s); ESIMS found for C 2 2H 2 8N 6 0 mlz 393.2 (M+l).

3646

[01103] N-(6-(l-Methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l-(3, 3,3- trifluoropropyl)piperidine-4-carboxamide 3646.

[01104] Off-white solid ((35 mg, 0.08 mmol, 45.4% yield). Ή NMR (499 MHz, DMSO-t/e) δ ppm 1.65 (2 H, qd, J=12.26, 3.57 Hz), 1.80 (2 H, br d, J=l 1.53 Hz), 1.93 - 2.01 (2 H, m), 2.41 - 2.55 (4 H, m), 2.55 - 2.61 (1 H, m), 2.93 (2 R br d, J=11.25 Hz), 3.91 (3 H, s), 7.99 (1 H, s), 8.12 (1 H, s), 8.37 (1 H, s), 8.41 (1 H, s), 9.23 (1 H, s), 9.31 (1 H, s), 10.73 (1 H, s); ESIMS found for C 2 iH 23 F 3 N 6 0 mlz 433.2 (M+l).

3674

[01105] (S)-N-(6-(l -Methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(2- methylpyrrolidin-1 -yl)acetamide 3674.

[01106] Off-white solid (20 mg, 0.06 mmol, 49.4% yield). ¾ NMR (499 MHz, DMSO-t/e) δ ppm 1.09 (3 H, d, J=6.04 Hz), 1.41 (1 H, dddd, .7=12.28, 10.29, 8.30, 6.45 Hz), 1.67 - 1.84 (2 H, m), 1.91 - 2.01 (1 H, m), 2.40 (1 H, q, J=8.51 Hz), 2.57 - 2.66 (1 H, m), 3.12 - 3.19 (1 H, m), 3.15 (1 H, d, J=16.47 Hz), 3.57 (1 H, d, .7=16.19 Hz), 3.91 (3 H, s), 8.06 (1 H, s), 8.14 (1 H, s), 8.38 (1 H, s), 8.40 (1 H, s), 9.24 (1 H, s), 9.34 (1 H, s), 10.10 (1 H, s); ESIMS found for C19H22N6O mlz 3 1.2 (M+l).

3683

[01107] 2-(Cyclobutyl(methyl)amino)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7- naphthyridin-3 -yl)acetamide 3683.

[01108] White solid (25 mg, 0.07 mmol, 61.8% yield). Ή NMR (499 MHz, DMSO- c/ fi ) 5 pm 1.54 - 1.70 (2 H, m), 1.81 - 1.92 (2 H, m), 1.97 - 2.05 (2 H, m), 2.22 (3 H, s), 3.08 (1 H, quin, .7=7.82 Hz), 3.14 (2 H, s), 3.91 (3 H, s), 8.06 (1 H, s), 8.14 (1 H, s), 8.38 (1 H, s), 8.39 (1 H, s), 9.25 (1 H, s), 9.34 (1 H, s), 10.13 (1 H, s); ESIMS found for CisHziNeO mlz 351.2 (M+l).

3689

[01109] (R)-N-(6-(l-Methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)py rrolidine-2- carboxamide 3689.

[OHIO] Off-white solid (4 mg, 0.01 mmol, 37.8% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.67 (2 H, quin, J=6.86 Hz), 1.78 - 1.89 (1 H, m), 2.05 - 2.17 (1 H, m), 2.87 (1 H, dt, .7=10.15, 6.31 Hz), 2.97 (1 H, dt, .7=10.22, 6.69 Hz), 3.83 (1 H, dd, J=9.06, 5.49 Hz), 3.91 (3 H, s), 8.05 (1 H, s), 8.13 (1 H, s), 8.39 (1 H, s), 8.40 (1 H, s), 9.24 (1 H, s), 9.34 (1 H, s), 10.52 (1 H, s); ESIMS found for Ci 7 Hi 8 N 6 0 mlz 323.2 (M+l).

[01111] N-(6-(l -Methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(pipendm-l-yl) propanamide 3698.

[01112] Off-white solid (21 mg, 0.06 mmol 26.0% yield). ¾ NMR (499 MHz, DMSO-i/ 6 ) δ ppm 1.20 (3 H, d, J=7.14 Hz), 1.39 - 1.47 (2 H, m), 1.53 - 1.62 (4 H, m), 2.51 - 2.57 (4 H, m), 3.48 (1 H : q, J=6.95 Hz), 3.92 (3 H, s), 8.03 (1 H, s), 8.13 (1 H, s), 8.39 (1 H, s), 8.40 (1 H, s), 9.25 (1 H, s), 9.33 (1 H, s), 10.30 (1 H, s); ESIMS found for C 2 oH 24 N 6 0 mlz 365.2 (M+l).

3699

[01113] N-(6-(l-Methyl-lH-pyrazol-4-yl)-2J-naphthyridin-3-yl)-l-(met hylsulfonyl) piperidine-4-carboxamide 3699.

[01114] Pale yellow solid (43 mg, 0.10 mmol, 66.3% yield). Ή NMR (499 MHz, DMSO-J 6 ) δ ρρηι 1.64 - 1.75 (2 H, m), 1.96 (2 H, br dd, J=13.17, 2.74 Hz), 2.67 - 2.72 (1 H, m), 2.72 - 2.80 (2 H, m), 2.90 (3 H, s), 3.63 (2 H, br d, J=12.08 Hz), 3.91 (3 H, s), 8.00 (1 H, s), 8.12 (1 H, s), 8.38 (1 H, s), 8.41 (1 H, s), 9.24 (1 H, s), 9.32 (1 H, s), 10.85 (1 H, s); ESIMS found for Ci 9 H 22 N 6 0 3 S mlz 415.1 (M+l).

3714

[01115] N-(6-(l -Methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(moφholin-2-yl) acetamide 3714.

[01116] Brown solid (30 mg, 0.09 mmol, 30.6% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 2.41 (1 H, dd, J=12.08, 10.15 Hz), 2.47 (1 H, br d, J=4.94 Hz), 2.57 - 2.68 (3 H, m), 2.82 (1 H, dd, J=12.08, 1.65 Hz), 3.42 (1 H, td, J=10.77, 3.16 Hz), 3.66 - 3.71 (1 H, m), 3.82 (1 H, dtd, J=9.95, 5.18, 5.18, 2.47 Hz), 3.91 (3 H, s), 8.01 (1 H, s), 8.13 (1 H, s), 8.38 (1 H, s), 8.40 (1 H, s), 9.23 (1 H, s), 9.32 (1 H, s), 10.72 (1 H, s); ESIMS found for Ci8H 2 oN 6 0 2 mlz 353.2 (M+l).

3723

[01117] N-(6-( 1 -Methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1 -(oxazol-2- ylmethyl)piperidine-4-carboxamide 3723.

[01118] Brown solid (28 mg, 0.06 mmol, 42.9% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.60 - 1.72 (2 H, m), 1.80 (2 H, br d, J=10.70 Hz), 2.10 (2 H, td, J=l 1.80, 2.47 Hz), 2.52 - 2.58 (1 H, m), 2.85 - 2.92 (2 H, m), 3.67 (2 H, s), 3.91 (3 H, s), 7.17 (1 H, s), 7.98 (1 H, s), 8.08 (1 H, d, J=0.82 Hz), 8.12 (1 H, s), 8.37 (1 H, s), 8.40 (1 H, s), 9.22 (1 H, s), 9.31 (1 H, s), 10.70 (1 H, s); ESIMS found for C22H2

3727

[01119] N-(6-( 1 -Methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)- 1 -(pyrimidin-2- ylmethyl)piperidine-4-carboxamide 3727.

[01120] Brown solid (24 mg, 0.05 mmol, 36.0% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.61 - 1.73 (2 H, m), 1.78 (2 H, br d, .7=10.70 Hz), 2.10 - 2.19 (2 H, m), 2.52 - 2.61 (1 H, m), 2.95 (2 H, br d, J=l 1.53 Hz), 3.71 (2 H, s), 3.91 (3 H, s), 7.40 (1 H, t, J=4.94 Hz), 7.98 (1 H, s), 8.11 (1 H, s), 8.37 (1 H, s), 8.41 (1 H, s), 8.78 (2 H, d, J=4.67 Hz), 9.22 (1 H, s), 9.31 (1 H, s), 10.70 (1 H, s); ESIMS found for C 23 H24N 8 0 mlz 429.2 (M+l).

3733

[01121] 2-(4-Methyl-l,4-diazepan-l-yl)-N-(6-(l-methyl-lH-pyrazol-4-y l)-2,7- naphthyridin-3 -yl)acetamide 3733.

[01122] White solid (10 mg, 0.03 mmol, 22.8% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.77 (2 H, quin, J=5.90 Hz), 2.28 (3 H, s), 2.55 - 2.63 (4 H, m), 2.80 - 2.86 (4 H, m), 3.39 (2 H, s), 3.91 (3 H, s), 8.06 (1 H, s), 8.13 (1 H, s), 8.38 (1 H, s), 8.40 (1 H, s), 9.25 (1 H, s), 9.33 (1 H, s), 10.17 (1 H, s); ESIMS found for C20H25N7O mlz 380.2 (M+l).

[01123] 2-( 1 -Isobutylpyrrolidin-3 -yl)-N-(6-( 1 -methyl- lH-pyrazol-4-yl)-2,7- naphthyridin-3-yl)acetamide 3749.

[01124] White solid (4 mg, 0.01 mmol, 12.2% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ppm 0.85 (6 H, dd, J=6.59, 1.92 Hz), 1.41 (1 H, ddt, .7=12.28, 7.89, 6.11, 6.11 Hz), 1.65 (1 H, dquin, J=13.70, 6.80, 6.80, 6.80, 6.80 Hz), 1.89 - 2.00 (1 H, m), 2.07 - 2.19 (3 H, m), 2.38 - 2.48 (2 H, m), 2.51 - 2.57 (3 H, m), 2.62 - 2.68 (1 H, m), 3.91 (3 H, s), 7.99 (1 H, s), 8.12 (l H, s), 8.37 (1 H, s), 8.40 (1 H, s), 9.22 (1 H, s) : 9.31 (1 H, s) : 10.74 (1 H, s); ESIMS found for C 22 H 2 8N 6 0 mlz 393.2 (M+l).

3772

[01125] N-(6-(l -Methyl- lH-pyrazol-4-yl)-2J-naphthyndin-3-yl)-4-((l- methylpiperidin-4-yl)oxy)benzamide 3772.

[01126] Yellow solid (4.9 mg, 0.01 mmol, 27.9% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.61 - 1.72 (2 H, m), 1.92 - 2.01 (2 H, m), 2.15 - 2.26 (2 H, m), 2.18 (3 H, s), 2.58 - 2.67 (2 H, m), 3.92 (3 H, s), 4.47 - 4.55 (1 H, m), 7.07 (2 H, d, J=8.78 Hz), 8.04 - 8.09 (3 H, m), 8.15 (1 H, s), 8.40 (1 H, s), 8.56 (1 H, s), 9.31 (1 H, s), 9.36 (1 H, s), 10.88 (1 H, s); ESIMS found for C 25 H 26 N 6 0 2 mlz 443.2 (M+l).

3773

[01127] N-(6-(l-Methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(pi perazin-l-yl) isonicotinamide 3773.

[01128] Off-white solid (5.6 mg, 0.01 mmol, 29.3% yield). ¾ NMR (499 MHz, DMSO-t e) δ ppm 2.75 - 2.85 (4 H, m), 3.48 - 3.57 (4 H, m), 3.92 (3 H, s), 7.12 (1 H, dd, J=5.21, 1.10 Hz), 7.42 (1 H, s), 8.09 (1 H, s), 8.15 (1 H, s), 8.25 (1 H, d, J=5 21 Hz), 8.40 (1 H, s), 8.57 (1 H, s), 9.33 (1 H, s), 9.39 (1 H, s), 11.25 (1 H, br s); ESIMS found for C 22 H 22 N 8 0 mlz 415.2 (M+l).

3774

[01129] N-(6-( 1 -Methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4- methylpiperazin-1 -yl)isonicotinamide 3774.

[01130] Off-white solid (22 mg, 0.05 mmol, 23.1% yield). ¾ NMR (499 MHz, DMSO- e) δ ppm 2.24 (3 H, s), 2.43 (4 H, br t, J=4.94 Hz), 3.57 - 3.62 (4 H, m), 3.92 (3 H, s), 7.15 (1 H, dd, J=5.08, 0.96 Hz), 7.46 (1 H, s), 8.09 (1 H, s), 8.16 (1 H, s), 8.26 (1 H, d, J=4.94 Hz), 8.41 (1 H, s), 8.57 (1 H, s), 9.33 (1 H, s) : 9.39 (1 H, s) : 11.27 (1 H, s); ESIMS found for C 2 3H 2 4N 8 0 mlz 429.2 (M+l).

3778

[01131] N-(6-(l -Methyl- lH-pyrazol-4-yl)-2J-naphthyridin-3-yl)-6-(4- methylpiperazin- 1 -yl)nicotinamide 3778.

[01132] Yellow solid (62.2 mg, 0.15 mmol, 35.3% yield). ¾NMR (499 MHz, DMSO- d 6 ) δ ppm 2.22 (3 H, s), 2.39 (4 H, t, 7=5.08 Hz), 3.62 - 3.67 (4 H, m), 3.92 (3 H, s), 6.91 (1 H, d, 7=9.33 Hz), 8.04 (1 H, s), 8.15 (1 H, s), 8.19 (1 H, dd, .7=9.19, 2.61 Hz), 8.39 (1 H, s), 8.55 (1 H, s), 8.84 (1 H, d, 7=2.47 Hz), 9.30 (1 H, s), 9.35 (1 H, s), 10.86 (1 H, s); ESIMS found for C 23 H 24 N 8 O mlz 429.2 (M+l).

3780

[01133] N-(6-(l -Methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(pipendm-4- yloxy)isonicotinamide 3780.

[01134] Yellow solid (3.4 mg, 0.008 mmol, 9.5% yield). ¾ NMR (500 MHz, METHANOLS) δ ppm 1.72 - 1.85 (2 H, m), 2.07 - 2.14 (2 H, m), 2.82 - 2.89 (2 H, m), 3.12 - 3.16 (2 H, m), 3.99 (3 H, s), 5.22 - 5.29 (1 H, m), 7.30 - 7.34 (1 H, m), 7.45 (1 H, dd, .7=5.21, 1.37 Hz), 8.01 (1 H, s), 8.16 (1 H, d, J=0.82 Hz), 8.29 (1 H, s), 8.32 (1 H, dd, .7=5.21, 0.82 Hz), 8.64 (1 H, s), 9.22 - 9.28 (1 H, m), 9.29 - 9.35 (1 H, m); ESIMS found for C23H23N7O2 mlz 430.2 (M+l).

3783

[01135] N-(6-(l-Mcthyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-5-((l - methylpiperidin-4-yl)amino)nicotinamide 3783.

[01136] Yellow solid (51.8 mg, 0.12 mmol, 36.2% yield). ¾ NMR (499 MHz, DMSO- d ) δ ppm 1.39 - 1.52 (2 H, m), 1.84 - 1.92 (2 H, m), 1.99 (2 H, br t, .7=10.70 Hz), 2.17 (3 H, s), 2.73 (2 H, br d, J=11.53 Hz), 3.63 - 3.77 (1 H, m), 3.92 (3 H, s), 6.72 (1 H, d, 7=7.68 Hz), 6.98 (1 H, s), 6.99 (1 H, dd, J=5.21, 1.37 Hz), 8.09 (1 H, s), 8.10 (1 H, d, J=5.49 Hz), 8.15 (1 H, s), 8.40 (1 H, s), 8.54 (1 H, s), 9.31 (1 H, s), 9.37 (1 H, s); ESIMS found for C 2 4H 26 N80 mlz 443.2 (M+l).

3791

[01137] 2-((2-(Dimethylamino)ethyl)aiiiino)-N-(6-(l-metliyl-lH-pyraz ol-4 naphthyridin-3 -yl)isonicotinamide 3791.

[01138] Yellow solid (70.6 mg, 0.17 mmol, 49.9% yield). : H NMR (499 MHz, DMSO- d 6 ) δ ppm 2.19 (6 H, s), 2.43 (2 H, t, J=6.72 Hz), 3.36 - 3.42 (2 H, m), 3.92 (3 H, s), 6.64 (1 H, t, J=5.35 Hz), 7.01 (1 H, dd, J=5.21, 1.65 Hz), 7.04 (1 H, s), 8.09 (1 H, s), 8.11 (1 H, d, J=5.21 Hz), 8.15 (1 H, s), 8.40 (1 H, s), 8.54 (1 H, s), 9.31 (1 H, s), 9.38 (1 H, s), 11.05 (1 H, s); ESIMS found for C22H24N8O mlz Ml 2 (M+l)

3797

[01139] 4-((Dimethylamino)methyl)-N-(6-(l-methyl-lH-pyrazol-4-yl)-2, 7- naphthyridin-3-yl)benzamide 3797.

[01140] White solid (4.2 mg, 0.01 mmol, 3.1 % yield). 'HNMR (499 MHz, DMSO-i 6 ) δ ppm 2.17 (6 H, s), 3.47 (2 H, s), 3.92 (3 H, s), 7.45 (2 H, d, J=8.23 Hz), 8.05 (2 H, d, J=8.23 Hz), 8.08 (1 H, s), 8.15 (1 H, s), 8.40 (1 H, s), 8.58 (1 H, s), 9.32 (1 H, s), 9.37 (1 H, s), 11.01 (1 H, s); ESIMS found for C22H22N6O

3799

[01141] N-(6-(l-Methyl-lH-pyrazol-4-yl)-2J-naphthyridin-3-yl)-3-((4- methylpiperazin- 1 -yl)methyl)benzamide 3799.

[01142] White solid (8.1 mg, 0.02 mmol, 5.6% yield). 'H NMR (499 MHz, DMSO ) δ ppm 2.15 (3 H, s), 2.22 - 2.36 (4 H, m), 2.37 - 2.47 (4 H, m), 3.54 (2 H, s), 3.93 (3 H, s), 7.45 - 7.51 (1 H, m), 7.53 - 7.57 (1 H, m), 7.96 (1 H, d, J=7.68 Hz), 7.98 (1 H, s), 8.08 (1 H, s), 8.16 (1 H, s), 8.41 (1 H, s), 8.57 (1 H, s), 9.32 (1 H, s), 9.38 (1 H, s), 11.05 (1 H, s); ESIMS found for C25H27N7O mlz 442.2 (M+l).

3821

[01143] N-(6-(l -Methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-3- phenylpropanamide 3821.

[01144] White solid (15.1 mg, 0.04 mmol, 18.3% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 2.73 - 2.83 (2 H, m), 2.90 - 2.99 (2 H, m), 3.91 (3 H, s), 7.15 - 7.22 (1 H, m), 7.26 - 7.33 (4 H, m), 8.01 (1 R s), 8.13 (1 H, s), 8.38 (1 H, s), 8.41 (1 H, s), 9.22 (1 H, s), 9.31 (1 H, s), 10.79 (1 H, s); ESIMS found for C21H1

3829

[01145] 2-Methyl-N-(6-( l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-l,2,3,4- tetrahydroisoquinoline-7-carboxamide 3829.

[01146] Yellow solid (4.2 mg, 0.01 mmol, 12.7% yield). ¾ NMR (500 MHz, METHANOLS) δ ppm 2.50 (3 H, s), 2.80 (2 H, t, =6.17 Hz), 3.04 (2 H, t, J=6.04 Hz), 3.72 (2 H, s), 3.98 (3 H, s), 7.32 (1 H, d, J=7.96 Hz), 7.76 (1 H, d, J=0.82 Hz), 7.81 (1 H, dd, J=7.96, 1.92 Hz), 7.97 ( 1 H, s), 8.15 (1 H, s), 8.27 ( 1 H, s), 8.60 (1 H, s), 9.20 - 9.24 (1 H, m), 9.28 ( 1 H, t, J=0.82 Hz); ESIMS found for CzsHziNsO mlz 399.2 (M+l).

3836

[01147] N-(6-( 1 -Methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3 -yl)benzofuran-6- carboxamide 3836.

[01148] White solid (1 1.8 mg, 0.03 mmol, 9.0% yield). Ή NMR (500 MHz, DMSO- d 6 ) δ ppm 3.93 (3 H, s), 7.09 ( 1 H, dd, J=2.20, 0.82 Hz), 7.80 (1 H, d, J=8.23 Hz), 8.01 (1 H, dd, J=8.10, 1.51 Hz), 8.09 (1 H, s), 8.16 (1 H, d, J=0.82 Hz), 8.20 (1 H, d, J=2.20 Hz), 8.40 (1 H, d, J=0.82 Hz), 8.41 ( 1 H, s), 8.61 ( 1 H, s), 9.33 ( 1 H, t, J=0.82 Hz), 9.38 (1 H, t, J=0.82 Hz), 1 1.12 (1 H, s); ESIMS found for C 2 iHi 5 N 5 0 2 mlz 370.1 (M+l).

3843

[01149] N-(6-(l-Methyl H-pyrazol-4-yl)-2J-naphthyridin-3-yl)quinoxaline-6- carboxamide 3843.

[01150] White solid (4.6 mg, 0.01 mmol, 4.0% yield). Ή NMR (499 MHz, DMSO-t fi ) δ ppm 3.93 (3 H, s), 8.13 (1 H, s), 8.17 (1 H, s), 8.24 (1 H, d, J=8.78 Hz), 8.41 (1 H, s), 8.42 - 8.44 (1 H, m), 8.64 (1 H, s), 8.85 (1 H, d, J=l .92 Hz), 9.06 - 9.11 (2 H, m), 9.36 (1 H, s), 9.40 (1 H, s), 11.54 (1 H, s); ESIMS found for C21H15N7O mlz 382.1 (M+l).

3856

[01151] N-(6-(l -Methyl- lH-pyrazol-4-yl)-2J-naphthyridin-3-yl)-l-(l- methylpiperidin-4-yl)-lH-pyrazole-4-carboxamide 3856.

[01152] Yellow solid (21.5 mg, 0.05 mmol, 65.8% yield). ¾NMR (499 MHz, DMSO- d 6 ) 5 ppm 1.90 - 1.99 (2 H, m), 2.01 - 2.10 (4 H, m), 2.21 (3 H, s), 2.85 (2 H, br d, J=11.80 Hz), 3.92 (3 H, s), 4.17 (1 H, tt, .7=11.11, 4.25 Hz), 8.03 (1 H, s), 8.15 (1 H, s), 8.20 (1 H, s), 8.39 (1 H, s), 8.51 (1 H, s), 8.64 (1 H, s), 9.29 (1 H, s), 9.34 (1 H, s), 10.73 (1 H, s); ESIMS found for C22H24N8O mlz 417.2 (M+l).

3861

[01153] Isopropyl 4-(4-((6-(l-methyl-lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl) carbamoyl)-lH-pyrazol-l-yl)piperidine-l-carboxylate 3861.

[01154] White solid (11 mg, 0.02 mmol, 27.5% yield). Ή NMR (499 MHz, DMSO- c/ 6 ) ppm 1.21 (6 H, d, J=6.04 Hz), 1.76 - 1.85 (2 H, m), 2.08 (2 H, br dd, J=12.35, 1.92 Hz), 2.99 (2 H, br s), 3.92 (3 H, s), 4.07 (2 H, br d, J=12.90 Hz), 4.45 (1 H, tt, J=\ 1.29, 3.95 Hz), 4.80 (1 H, spt, J=6.27 Hz), 8.03 (1 H, s), 8.15 (1 H, s), 8.21 (1 H, s), 8.39 (1 H, s), 8.51 (1 H, s), 8.66 (1 H, s), 9.29 (1 H, s), 9.34 (1 H, s), 10.73 (1 H, s); ESIMS found for C25H 2 8N 8 0 3 mlz 489.3 (M+l).

3907

[01155] 2-(2-Fluoroethyl)-N-(6-(l-methyl-5-(piperidin-l-ylmethyl)-lH -pyrazol-4- yl)-2,7-naphthyridin-3-yl)-2-azaspiro[3.3]heptane-6-carboxam ide 3907.

[01156] Beige solid (10 mg, 0.02 mmol, 45.3% yield). ¾ NMR (499 MHz, METHANOLS) δ ppm 1 .45 (2 H, br d, .7=7.14 Hz), 1 .51 - 1.60 (4 H, m), 2.40 - 2.54 (8 H, m), 2.75 (2 H, dt, J=28.40, 5.00 Hz), 3.21 - 3.30 (1 H, m), 3.34 (2 H, s), 3.43 (2 H, s), 3.97 (2 H, br s), 3.99 (3 H, s), 4.44 (2 H, dt, J=47.90, 5.00 Hz), 7.98 (1 H, s), 8.06 (1 H, s), 8.47 (1 H, s), 9.19 (1 H, s), 9.29 (1 H, s); ESIMS found for C 2 7H 34 FN 7 0 mlz 492.3 (M+l).

3910

[01157] 2-(Diethylamino)-N-(6-(l-me l-5-(piperidin-l-ylmethyl)-lH-pyrazol-4- yl)-2,7-naphthyridin-3-yl)acetamide 3910.

[01158] Beige solid (4 mg, 0.009 mmol, 5.9% yield). ¾ NMR (499 MHz, METHANOLS) δ ppm 1.15 (7 H, t, J=7.14 Hz), 1.40 - 1.47 (2 H, m), 1.56 (5 H, dt, J=l l .l 1, 5.42 Hz), 2.47 (4 H, br s), 2.73 (4 H, q, J=6.86 Hz), 3.30 (2 H, br s), 3.99 (2 H, s), 3.99 (3 H, s), 8.00 (1 H, s), 8.10 (1 H, s), 8.51 (1 H, s), 9.22 (1 H, s), 9.34 (1 H, s); ESIMS found for C24H 33 7 0 mlz 436.3 (M+l).

3944

[01159] 4,4-Difluoro-N-(6-(5-(2-fluoroethyl)-4,5,6,7-tetrahydropyraz olo[l,5-a] pyrazin-3-yl)-2,7-naphthyridin-3-yl)cyclohexane-l-carboxamid e 3944.

[01160] Off-white solid (40 mg, 0.09 mmol, 17.3% yield). Ή NMR (499 MHz, DMSO-J 6 ) δ ppm 1.65 - 1.75 (2 H, m), 1.76 - 1.91 (2 H, m), 1.96 (2 H, br d, .7=13.17 Hz), 2.07 - 2.17 (2 H, m), 2.68 - 2.79 (1 H, m), 2.97 (2 H, dt, .7=29.10, 5.00 Hz), 3.05 (2 H, br t, J=5.35 Hz), 4.15 - 4.23 (4 H, m), 4.66 (2 H, dt, J=47.90, 5.00 Hz), 7.92 (1 H, s), 8.17 (1 H, s), 8.42 (1 H, s), 9.23 (1 H, s), 9.33 (1 H, s), 10.82 (1 H, s); ESIMS found for C2 3 H25F 3 N 6 0 miz 459.2 (M+1).

3960

[01161] 2-Fluoro-2 -methyl -N-(6-( 1 -methyl- 1H- l,2,3-triazol-4-yl)-2,7-naphthyridin- 3-yl)propanamide 3960.

[01162] White solid (3 mg, 0.01 mmol, 2.7% yield). ¾ NMR (499 MHz, DMSO-t/ 6 ) δ ppm 1.65 (6 H, d, J=22.00 Hz), 4.52 (3 H, s), 8.10 (1 H, d, .7=8.51 Hz), 8.59 (1 H, s), 8.61 (1 H, s), 8.67 (1 H, dd, .7=8.51, 0.82 Hz), 9.29 (1 H, s), 10.24 (1 H, br d, J=3.29 Hz); ESIMS found for CisHisFNeO miz 315.1 (M+1).

3974

[01163] N-(6-(l-Methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin-3-yl) -l-((l- (trifluoromcthyl)cyclopropyl)mcthj'l)pipcridinc-4-carboxamid c 3974.

[01164] Off-white solid (5 mg, 0.01 mmol, 9.0% yield). Ή NMR (499 MHz, DMSO- d 6 ) 6 ppm 1.61 - 1.73 (2 H, m), 1.76 - 1.84 (2 H, m), 1.91 - 1.99 (2 H, m), 2.58 (1 H, tt, J=l 1.53, 3.98 Hz), 2.97 (2 H, br d, .7=11.53 Hz), 4.39 (3 H, s), 8.35 (1 H, s), 8.36 (1 H, s), 8.56 (1 H, s), 9.41 (1 H, s), 9.50 (1 H, s), 10.89 (1 H, s); ESIMS found for C22H 2 4F 3 N 7 0 miz 460.2 (M+1).

3985

[01165] 2-(4-Methoxypiperidin-l-yl)-N-(6-(l-methyl-lH-l,2,3-triazol- 4-yl)-2,7- naphthyridin-3-yl)acetamide 3985. [01166] Off-white solid (20 mg, 0.05 mmol, 8.8% yield). ¾ NMR (499 MHz, DMSO- £¼) δ ppm 1.47 - 1.57 (2 H, m), 1.84 - 1.92 (2 H, m), 2.33 - 2.42 (2 H, m), 2.74 - 2.83 (2 H, m), 3.20 - 3.23 (1 H, m), 3.24 (3 H, s), 3.26 (2 H, s), 4.39 (3 H, s), 8.36 (1 H, s), 8.42 ( 1 H, s), 8.55 (1 H, s), 9.42 (1 H, s), 9.53 (1 H, s), 10.32 (1 H, s); ESIMS found for C19H23N7O2 mlz 382.2 (M+1).

3999

[01167] N 2 -Methyl-N 5 -(6-(l-methyl-lH-l,2,3-triazol-4-yl)-2,7-naphthyridin- 3-yl) pyridine-2,5-dicarboxamide 3999.

[01168] White solid (10 mg, 0.02 mmol, 10.5% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 2.86 (3 H, d, J=4.94 Hz), 4.41 (3 H, s), 8.15 - 8.20 (1 H, m), 8.39 (1 H, s), 8.48 (1 H, s), 8.56 (1 H, dd, J=8.10, 2.33 Hz), 8.75 (1 H, s), 8.92 - 8.98 (1 H, m), 9.22 (1 H, dd, J=2.20, 0.82 Hz), 9.52 (1 H, s), 9.58 (1 H, s), 11.67 (1 H, s); ESIMS found for mlz 389.2 (M+1).

[01169] 2-(4 Dimethylamino)piperidin-l-yl)-N-(6-(l-methyl-lH-l,2,3-triazo l-4-yl)- 2,7-naphthyridin-3-yl)isonicotinamide 4003.

[01170] Beige solid (10 mg, 0.02 mmol, 28.6% yield). Ή NMR (499 MHz, DMSO-c 6 ) δ ppm 1.37 (2 H, qd, J=11.94, 3.98 Hz), 1.80 - 1.88 (2 H, m), 2.20 (6 H, s), 2.32 - 2.42 (1 H, m), 2.83 - 2.95 (2 H, m), 4.38 - 4.41 (3 H, m), 4.44 (2 H, br d, J=13.45 Hz), 7.10 (1 H, dd, J=4.94, 1.10 Hz), 7.46 (1 H, s), 8.25 (1 H, d, J=5.21 Hz), 8.38 (1 H, s), 8.45 (1 H, s), 8.73 (1 H, s), 9.51 (1 H, s), 9.57 (1 H, s), 11.41 (1 H, br s); ESIMS found for C 24 H 27 N 9 O mlz 458.3 (M+1).

4006

[01171] 2-(4-Methyl-l,4-diazepan-l-yl)-N-(6-(l-methyl-lH-l,2,3-tnazo l-4-yl)-2,7- naphthyridin-3 -yl)isonicotinamidc 4006.

[01172] Beige solid (14 mg, 0.03 mmol, 38.5% yield). ¾ NMR (499 MHz, DMSO-c 6 ) δ ppm 1.88 - 1.98 (2 H, m), 2.27 (3 H, s), 2.48 (2 H, br s), 2.60 - 2.66 (2 H, m), 3.69 (2 H, t, J=6.17 Hz), 3.80 - 3.85 (2 H : m), 4.40 (3 H, s), 7.04 (1 H, dd, J=5.21, 1.37 Hz), 7.21 (1 H, s), 8.22 (1 H, d, J=5.49 Hz), 8.38 (1 H, s), 8.45 (1 H, s), 8.73 (1 H, s), 9.51 ( 1 H, s), 9.58 (1 H, s), 1 1.40 (1 H, s); ESIMS found for C23H25N9O mlz 444.3 (M+1).

4027

[01173] 4,4-Difluoro-N-(6-(l-methyl-lH-imidazol-5-yl)-2,7-naphthyrid in-3-yl) cyclohexane-1 -carboxamide 4027.

[01174] Off-white solid (20 mg, 0.05 mmol, 24.3% yield). ¾ NMR (499 MHz, DMSO-£¾) 5 ppm 1.64 - 1.76 (2 H, m), 1.77 - 1.92 (2 H, m), 1.96 (2 H, br d, J=12.62 Hz), 2.07 - 2.19 (2 H, m), 2.69 - 2.79 (1 H, m), 3.99 (3 H, s), 7.61 (1 H, s), 7.79 (1 H, s), 8.10 (1 H, s), 8.47 (1 H, s), 9.31 (1 H, s), 9.40 (1 H, s), 10.87 (1 H, s); ESIMS found for Ci 9 Hi 9 F 2 N 5 0 mlz 372.2 (M+1).

4041

[01175] N 6-(l -Me 1 H-imidazol-5-yl)-2,7-naphthyridin-3-yl)-2-(pyrrolidin-l-yl) propanamide 4041.

[01176] Brown solid (12 mg, 0.03 mmol, 10.4% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.30 (3 H, d, J=6.86 Hz), 1.74 (4 H, s), 2.55 - 2.71 (5 H, m), 3.34 - 3.40 (1 H, m), 4.00 (3 H, s), 7.62 (1 H, d, J=0.82 Hz), 7.80 (1 H, s), 8.14 (1 H, s), 8.47 (1 H, s), 9.31 (1 H, s), 9.42 (1 H, s), 10.26 (1 H, s); ESIMS found for C19H22N6O mlz 351.2 (M+1).

4074

[01177] N-(6-(l,2-Dimethyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)- 2- methylthiazole -5 -carboxamide 4074.

[01178] Light brown solid (0 mg, 0.05 mmol, 26.3% yield). Ή NMR (499 MHz, DMSO- fi ) δ ppm 2.40 (3 H, s), 2.72 (3 H, s), 3.90 (3 H, s), 7.46 (1 H, s), 8.08 (1 H, s), 8.52 (1 H, s), 8.71 (1 H, s), 9.38 (1 H, s), 9.45 (1 H, s), 1 1.40 (1 H, s) ; ESIMS found for Ci 8 Hi 6 N 6 OS mlz 365.1 (M+1).

4075

[01179] 4-Fluoro-N-(6 -( 1 -methyl - 1 H-imidazol-5 -yl) -2,7 -naphthyridin-3 -yl) benzamide 4075.

[01180] White solid (17 mg, 0.05 mmol, 15.7% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 4.01 (3 H, s), 7.37 (2 H, t, J=8.78 Hz), 7.64 (1 H, d, J=1.10 Hz), 7.81 (1 H, s), 8.17 (2 H, dd, J=8.92, 5.35 Hz), 8.19 (1 H, s), 8.31 (1 H, s), 8.64 (1 H, s), 9.39 (1 H, s), 9.46 (1 H, s), 11.18 (1 H, s); ESIMS found for C, 9H, 4 FN 5 0 mlz 348.1 (M+l).

4077

[01181] N-(6-(l-Meti yl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)-3-(pyrrolidin-l- ylmethyl)benzamide 4077.

[01182] White solid (67 mg, 0.15 mmol, 50.7% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 1.72 (4 H, br s), 2.47 (4 H, br s), 3.67 (2 H, s), 4.01 (3 H, s), 7.45 - 7.51 (1 H, m), 7.55 (1 H, d, J=7.68 Hz), 7.65 (1 H, s), 7.81 (1 H, s), 7.95 (1 H, d, J=7.96 Hz), 8.01 (1 H, s), 8.19 (1 H, s), 8.65 (1 H, s), 9.39 (1 H, s), 9.46 (1 H, s), 11.11 (1 H, s); ESIMS found for C24H 24 N 6 0 mlz 413. (M+l).

4104

[01183] N-(6-(l-Methyl-lH-imidazol-5-yl)-2,7-naphthyridin-3-yl)isoin doline-5- carboxamide 4104.

[01184] Off-white solid (0 mg, 0.03 mmol, 66.9% yield). ¾ NMR (499 MHz, DMSO- d ) δ ppm 4.01 (3 H, s), 4.15 (4 H, s), 7.41 (1 H, d, J=7.96 Hz), 7.64 (1 H, s), 7.81 (1 H, s), 7.93 (1 H, d, J=7.68 Hz), 7.98 (1 H, s), 8.18 (1 H, s), 8.65 (1 H, s), 9.39 (1 H, s), 9.45 (1 H, s), 11.02 (1 H, br s); ESIMS found for C 2 iHi 8 N 6 0 mlz 371.1 (M+l).

4150

[01185] 4-Isopropoxy-N-(6-(5,6J,8-tetrahydroimidazo[l,2-a]pyrazin-3- yl)-2,7- naphthyridin-3-yl)benzamide 4150.

[01186] White solid (5.6 mg, 0.01 mmol, 29.8% yield). Ή NM (499 MHz, DMSO- d 6 ) δ ppm 1.31 (6 H, d, J=6.04 Hz), 3.10 (2 H, br t, J=5.35 Hz), 3.95 (2 H, s), 4.35 (2 H, t, J=5.49 Hz), 4.72 - 4.82 (1 H, m), 7.03 (2 H, d, J=9.06 Hz), 7.61 (1 H, s), 8.04 - 8.09 (2 H, m), 8.10 (1 H, s), 8.61 (1 H, s), 9.35 (1 H, s), 9.40 (1 H, s), 10.89 ( 1 H, s); ESIMS found for C24H24N6O2 mlz 429.2 (M+l).

4159

[01187] N-(6-(Oxazol-5 -yl)-2,7-naphthyridin-3 -yl)-l -(2-(pyrrolidin-l -yl)acetyl) piperidine-4-carboxamide 4159.

[01188] Off-white solid (4 mg, 0.009 mmol, 43.0% yield). Ή NMR (499 MHz, DMSO- 6 ) δ ppm 1.43 - 1.53 (1 H, m), 1.56 - 1.66 (1 H, m), 1.69 (4 H, br s), 1.86 (2 H, br dd, J=13.04, 2.06 Hz), 2.48 (4 H, br s), 2.58 - 2.66 ( 1 H, m), 2.80 - 2.90 ( 1 H, m), 3.02 ( 1 H, br t, J=11.80 Hz), 3.16 - 3.22 (1 H, m), 3.35 (1 H, br s), 4.11 ( 1 H, br d, J=13.72 Hz), 4.37 - 4.43 (1 H, m), 8.44 (1 H, s), 8.5 1 (1 H, s), 8.72 (1 H, s), 9.20 (1 H, s), 9.33 ( 1 H, s), 9.38 (1 H, s), 10.91 (1 H, s); ESIMS found for CzsHzeNe +l).

4167

[01 189] 1 -(2,2-Difluoropropyl)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3- yl)piperidine- 4-carboxamide 4167.

[01190] White solid (17.6 mg, 0.04 mmol, 22.4% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.63 (3 H, t, J=19.21 Hz), 1.64 - 1.74 (2 H, m), 1.77 - 1.83 (2 H, m), 2.22 (2 H, td, J=11.66, 1.92 Hz), 2.53 - 2.62 (1 H, m), 2.71 (2 H, t, J=14.00 Hz), 2.95 (2 H, br d, J=11.53 Hz), 7.89 (1 H, s), 8.1 1 (1 H, s), 8.55 (1 H, s), 8.62 (1 H, s), 9.34 (1 H, s), 9.41 (1 H, s), 10.84 (1 H, s) ; ESIMS found for CzoftiFzNs 4218

[01191] 3-((l-Methylpiperidin-4-yl)oxy)-N-(6-(oxazol-5-yl)-2,7-napht hyridin-3-yl) benzamide 4218.

[01192] Yellow solid (2.4 mg, 0.005 mmol, 18.4% yield). 1 HNMR (499 MHz, DMSO- d 6 ) δ ρριη 1.62 - 1.74 (2 H, m), 1.93 - 2.02 (2 H, m), 2.15 - 2.27 (2 H, m), 2.19 (3 H, s), 2.59 - 2.68 (2 H, m), 4.50 - 4.59 (1 H, m), 7.17 - 7.25 (1 H, m), 7.43 (1 H, t, J=8.23 Hz), 7.61 - 7.67 (2 H, m), 7.92 (1 H, s), 8.20 (1 H, s), 8.64 (1 H, s), 8.71 (1 H, s), 9.44 (1 H, s), 9.48 (1 H, s), 11.17 (1 H, s); ESIMS found for C 2 3 N 5 03

4244

[01193] l-(Oxetan-3-yl)-N-(6-(thiazol-5-yl)-2,7-naphthyridin-3-yl)pi peridine-4- carboxamide 4244.

[01194] Off-white solid (55 mg, 0.14 mmol, 49.7% yield). Ή NMR (499 MHz, DMSO-i/ 6 ) δ ppm 1.64 - 1.74 (2 H, m), 1.75 - 1.87 (4 H, m), 2.59 (1 H, tt, J=11.29, 3.81 Hz), 2.70 - 2.79 (2 H, m), 3.38 (1 H, quin, J=6.38 Hz), 4.43 (2 H, t, J=6.17 Hz), 4.53 (2 H, t, J=6.59 Hz), 8.43 (1 H, s), 8.52 (1 H, s), 8.72 (1 H, s), 9.20 (1 H, s), 9.32 (1 H, s), 9.37 (1 H, s), 10.83 (1 H, s); ESIMS found for C2oH 2 i 5 0 2 S mlz 396.15 (M+l).

4257

[01195] 2-(4-Methylpiperazin-l-yl)-N-(6-(thiazol-5-yl)-2,7-naphthyri din-3-yl) isonicotinamide 4257.

[01196] Yellow solid (59.6 mg, 0.14 mmol, 38.4% yield). 'HNMR (499 MHz, DMSO- d 6 ) δ ppm 2.25 (3 H, s), 2.44 (4 H, br s), 3.61 (4 H, br s), 7.15 (1 H, dd, J=5.08, 1.23 Hz), 7.47 (1 H, s), 8.27 (1 H, d, J=5 21 Hz), 8.54 (1 H, s), 8.68 (1 H, s), 8.76 (1 H, s), 9.22 (1 H, s), 9.43 (1 H, s), 9.44 - 9.50 (1 H, m), 11.37 (1 H, s); ESIMS found for C 22 H 21 N 7 OS mlz 432.2 (M+l).

4319 [01197] N-(6-(Isothiazol-4-yl)-2,7-naphthyridin-3 -yl)-l -methylpiperidine-4- carboxamide 4319.

[01198] Off-white solid (70 mg, 0.20 mmol, 60.4% yield). ¾ NMR (499 MHz, DMSO-A) δ ppm 1.62 - 1.73 (2 H, m), 1.76 - 1.82 (2 H, m), 1.87 (2 H, td, J=l 1.66, 2.20 Hz), 2.16 (3 H, s), 2.52 - 2.58 (1 H, m), 2.78 - 2.85 (2 H, m), 8.39 (1 H, s), 8.52 (1 H, s), 9.32 (1 H, s), 9.33 (1 H, s), 9.43 (1 H, s), 9.69 (1 H, s), 10.81 (1 H, s); ESIMS found for Ci 8 Hi 9 N 5 OS mlz 354.1 (M+1).

4332

[01199] fr ra-4-Mcthoxy-N-(6-(5-mcthyl-l,3,4-thiadiazol-2-yl)-2,7-napht hyridin-3- yl)cyclohexane-l -carboxamide 4332.

[01200] Off-white solid (2 mg, 0.005 mmol, 6.3% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.08 - 1.17 (2 H, m), 1.45 - 1.54 (2 H, m), 1.92 (2 H, br d, J=12.08 Hz), 2.06 - 2.12 (2 H, m), 2.53 - 2.61 (1 H, m), 2.81 (3 H, s), 3.08 - 3.16 (1 H, m), 3.25 (3 H, s), 8.61 (2 H, d, J=0.82 Hz), 9.42 (1 H, s), 9.46 (1 H, s), 10.88 (1 H, s); ESIMS found for Ci 9 H 2 iN 5 0 2 S mlz 384.15 (M+1).

4346

[01201] l-Benzoyl-N-(6-(5-methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyr idin-3-yl) piperidine-4-carboxamide 4346.

[01202] Off-white solid (8 mg, 0.02 mmol, 21.2% yield). ¾ NMR (499 MHz, DMSO- c¾) 5 ppm 1.55 - 1.71 (2 H, m), 1.76 - 2.05 (2 H, m), 2.82 (3 H, s), 2.86 - 2.97 (2 H, m), 3.02 - 3.18 (1 H, m), 3.57 - 3.78 (1 H, m), 4.40 - 4.63 (1 H, m), 7.37 - 7.42 (2 H, m), 7.44 - 7.49 (3 H, m), 8.63 (1 H, s), 8.64 (1 H, s), 9.43 (1 H, s), 9.47 (1 H, s), 10.99 (1 H, s); ESIMS found for C24H22 6O2S mlz 459.2 (M+1).

4353

[01203] 2-(7-Azabicyclo[2.2.1]heptan-7-yl)-N-(6-(5-methyl-l,3,4-thia diazol-2-yl)- 2, 7-naphthyridin-3 -yl)acetamide 4353. [01204] Beige solid (7 mg, 0.02 mmol, 58.8% yield). ¾ NMR (499 MHz, DMSO-t e) δ ppm 1.34 (4 H, br d, J=7.14 Hz), 1.72 - 1.78 (4 H, m), 2.82 (3 H, s), 3.24 (2 H, s), 3.36 - 3.41 (2 H, m), 8.63 (1 H, s), 8.69 (1 H, s), 9.43 (1 H, s), 9.50 (1 H, s), 10.41 (1 H, s); ESIMS found for CioHzoNsOS mlz 381.1 (M+l).

4377

[01205] N-(6-(5-Methyl-l,3,4-thiadiazol-2-yl)-2,7-naphthyridin-3-yl) -2-(4- methylpiperazin-1 -yl)isonicotinamide 4377.

[01206] Yellow solid (13.9 mg, 0.03 mmol, 17.6% yield). 'HNMR (499 MHz, DMSO- d 6 ) δ ppm 2.23 (3 H, s), 2.43 (4 H, t, J=4.94 Hz), 2.82 (3 H, s), 3.57 - 3.65 (4 H, m), 7.16 (1 H, dd, .7=5.08, 0.96 Hz), 7.47 (1 H, s), 8.27 (1 H, d, .7=5.21 Hz), 8.71 (1 H, s), 8.79 (1 H, s), 9.51 (1 H, s), 9.53 (1 H, s), 11.42 (1 H, br s); ESIMS found for C22H22N8OS mlz 447.2 (M+l).

4431

[01207] N-(6-(5-Aminopyridin-3-yl)-2,7-naphthyridin-3-yl)-4-(piperid in-4-yloxy) benzamide 4431.

[01208] White solid (1 mg, 0.002 mmol, 29.1% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.79 - 1.89 (2 H, m), 2.09 - 2.15 (2 H, m), 3.03 - 3.15 (2 H, m), 3.21 - 3.28 (2 H, m), 4.76 - 4.84 (1 H, m), 5.50 (2 H, s), 7.14 (2 H, d, J=8.78 Hz), 7.79 (1 H, t, J=2.33 Hz), 8.02 (1 H, d, .7=2.47 Hz), 8.09 - 8.16 (2 H, m), 8.39 (1 H, s), 8.59 (1 H, d, .7=1.37 Hz), 8.70 (1 H, s), 9.42 (1 H, s), 9.50 (1 H, s), 10.99 (1 H, s); ESIMS found for mlz 441.2 (M+l).

4432

[01209] N-(6-(5-Aminopyndm-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methylp iperazm-l- yl)isoiiicotinamide 4432.

[01210] Brown solid (15 mg, 0.03 mmol, 18.6% yield). ¾ NMR (499 MHz, DMSO- dt) δ ppm 2.23 (3 H, s), 2.43 (4 H, t, J=4.94 Hz), 3.57 - 3.64 (4 H, m), 5.50 (2 H, s), 7.15 (1 H, dd, J=5.08, 1.23 Hz), 7.47 (1 H, s), 7.79 (1 H, t, J=2.20 Hz), 8.02 (1 H, d, J=2.47 Hz), 8.27 (1 H, d, J=4.94 Hz), 8.42 (1 H, s), 8.59 (1 H, d, .7=1.92 Hz), 8.71 (1 H, s), 9.44 (1 H, s), 9.52 (1 H, s), 11.34 (1 H, s); ESIMS found for C 2 4H 2 4N 8 0 mlz 441.2 (M+l).

4434

[01211] N-(6-(6-Aminopyridin-3-yl)-2,7-naphthyridin-3-yl)-2-(4-methy lpiperazin-l- yl)isonicotinamide 4434.

[01212] Beige solid (68 mg, 0.15 mmol, 84.4% yield). Ή NMR (499 MHz, DMSO-t/e) δ ppm 2.23 (3 H, s), 2.42 (4 H, t, J=5.08 Hz), 3.56 - 3.64 (4 H, m), 6.38 (2 H, s), 6.57 (1 H, d, J=8.78 Hz), 7.15 (1 H, dd, J=4.94, 1.10 Hz), 7.46 (1 H, s), 8.21 - 8.29 (3 H, m), 8.62 (1 H, s), 8.88 (1 H, d, J=2.47 Hz), 9.35 (1 H, s), 9.43 (1 H, s), 11.26 (1 H, s); ESIMS found for C 2 4H 2 4N 8 0 mlz 441.2 (M+l).

4498

[01213] N-(6-(6-(((3-Fluoroazetidin-3-yl)methyl)amino)pyrazin-2-yl)- 2,7- naphthyridin-3-yl)cyclopropanecarboxamide 4498.

[01214] Orange solid (14.7 mg, 0.04 mmol, 76.2% yield). ¾ NMR (499 MHz, DMSO- d ) δ ppm 0.85 - 0.91 (4 H, m), 2.07 - 2.15 (1 H, m), 3.50 - 3.67 (4 H, m), 4.01 (2 H, dd, J=24.50, 5.80 Hz), 7.53 (1 H, t, J=5.90 Hz), 8.11 (1 H, s), 8.54 (1 H, s), 8.63 (1 H, s), 8.77 (1 H, s), 9.38 (1 H, s), 9.44 (1 H, s), 11.20 (1 H, s); ESIMS found for C 20 H 20 FN 7 O mlz 394.2 (M+l).

4504

[01215] N-(6-(6-(Piperidin-4-ylamino)pyrazin-2-yl)-2,7-naphthyridin- 3-yl) tetrahydro-2H-pyran-4-carboxamide 4504. [01216] Beige solid (19 mg, 0.04 mmol, 46.8% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ppm 1.36 - 1.47 (2 H, m), 1.64 - 1.73 (2 H, m), 1.73 - 1.79 (2 H, m), 1.96 - 2.03 (2 H, m), 2.71 - 2.79 (2 H, m), 2.86 (1 H, tt, J=11.08, 4.29 Hz), 3.02 - 3.09 (2 H, m), 3.35 - 3.39 (2 H, m), 3.92 (2 H, dt, J=9.61, 2.06 Hz), 3.99 - 4.08 (1 H, m), 7.24 (1 H, d, J=7.14 Hz), 8.01 (1 H, s), 8.51 (1 H, s), 8.55 (1 H, s), 8.71 (1 H, s), 9.38 (1 H, s), 9.44 (1 H, s), 10.88 (1 H, s); ESIMS found for CzsHzvNvOz m/z 434.2 (M+l).

4523

[01217] N-(6-(lH-Pyrrolo[2,3-c]pyridin-4-yl)-2,7-naphthyridin-3-yl)- l-(l- methylpiperidin-4-yl)-lH-pyrazole-4-carboxamide 4523.

[01218] Yellow solid (1.2 mg, 0.003 mmol, 23.3% yield). ¾ NMR (499 MHz, METHANOLS) δ ppm 2.13 - 2.22 (4 H, m), 2.25 - 2.34 (2 H, m), 2.36 (3 H, s), 3.03 (2 H, br d, J=12.35 Hz), 4.23 - 4.35 (1 H, m), 7.08 (1 H, d, J=3.29 Hz), 7.73 (1 H, d, J=3.02 Hz), 8.15 (1 H, s), 8.30 (1 H, s), 8.48 (1 H, s), 8.69 (1 H, br s), 8.71 (1 H, s), 8.80 (1 H, br s), 9.37 (1 H, s), 9.50 (1 H, s); ESIMS found for C25H2

4535

[01219] fr «5-4-((2-Fluoroethyl)amino)-N-(2-(l-methyl-lH-pyrazol-4-yl) -l,6- naphthyridin-7-yl) cyclohexane-l-carboxamide 4535.

[01220] Off-white solid (25 mg, 0.06 mmol, 27.6% yield). ¾ NMR (499 MHz, DMSO-A) δ ppm 0.97 - 1.10 (2 H, m), 1.49 (2 H, qd, J=12.81, 2.47 Hz), 1.87 (2 H, br d, J=11.53 Hz), 1.92 - 2.01 (2 H, m), 2.35 - 2.44 (1 H, m), 2.52 - 2.57 (1 H, m), 2.83 (2 H, dt, J=26.90, 5.20 Hz), 3.93 (3 H, s), 4.44 (2 H, dt, J=47.90, 5.00 Hz), 7.80 (1 H, d, J=8.51 Hz), 8.21 (1 H, s), 8.38 (1 H, d, J=8.51 Hz), 8.47 (1 H, s), 8.55 (1 H, s), 9.05 (1 H, s), 10.57 (1 H, s); ESIMS found for C 21 H 25 FN 6 O mlz 397.2 (M+l).

4536 [01221] fr «5-4-((2-Methoxyethyl)amino)-N-(2-(l-methyl-lH-pyrazol-4-yl )-l,6- naphthyridin-7-yl) cyclohexane-l-carboxamide 4536.

[01222] Off-white solid (14 mg, 0.03 mmol, 15.0% yield). ¾ NMR (499 MHz, DMSO-A) δ ppm 0.96 - 1.08 (2 H, m), 1.49 (3 H, qd, J=12.85, 3.16 Hz), 1.86 (2 H, br d, .7=12.08 Hz), 1.94 (2 H, br dd, J=12.76, 2.61 Hz), 2.32 - 2.40 (1 H, m), 2.52 - 2.58 (1 H, m), 2.69 (2 H, t, J=5.76 Hz), 3.24 (3 H, s), 3.37 (2 H, t, J=5.76 Hz), 3.93 (3 H, s), 7.80 (1 H, d, J=8.51 Hz), 8.21 (1 H, s), 8.38 (1 H, d, J=8.78 Hz), 8.47 (1 H, s), 8.55 (1 H, s), 9.05 (1 H, s), 10.57 (1 H, s); ESIMS found for C22H28 6O2 mlz 409.2 (M+l).

4537

[01223] terf-Butyl (trans -4-((2-( 1 -methyl- lH-pyrazol-4-yl)- 1 ,6-naphthyridin-7-yl) carbamoyl)cyclohexyl)carbamate 4537.

[01224] Off-white solid (304 mg, 0.67 mmol, 60.8% yield) Ή NMR (499 MHz, DMSO-d 6 ) δ ppm 1.15 - 1.25 (2 H, m), 1.39 (9 H, s), 1.44 - 1.56 (2 H, m), 1.86 (4 H, br t, J=13.17 Hz), 2.43 - 2.48 (1 H, m), 3.15 - 3.26 (1 H, m), 3.93 (3 H, s), 6.75 (1 H, br d, J=7.68 Hz), 7.81 (1 H, d, J=8.51 Hz), 8.21 (1 H, s), 8.36 - 8.41 (1 H, m), 8.46 (1 H, s), 8.55 (1 H, s), 9.05 (1 H, s), 10.57 (1 H, s); ESIMS found for C 2 4H 30 N 6 O 3 mlz 451.3 (M+l).

4538

[01225] N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyndin-7-yl)-2-((l- methylpiperidin-4-yl)amino)isonicotinamide 4538.

[01226] Yellow wax (5.1 mg, 0.01 mmol, 3.7% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.40 - 1.53 (2 H, m), 1.89 (2 H, br d, .7=11.80 Hz), 2.00 (2 H, br t, J=10.70 Hz), 2.17 (3 H, s), 2.74 (2 H, br d, .7=11.80 Hz), 3.67 - 3.77 (1 H, m), 3.94 (3 H, s), 6.71 (1 H, d, .7=7.68 Hz), 6.99 (1 H, s), 7.01 (1 H, dd, J=5.35, 1.51 Hz), 7.87 (1 H, d, J=8.78 Hz), 8.10 (1 H, d, .7=5.21 Hz), 8.24 (1 H, s), 8.45 (1 H, d, J=7.96 Hz), 8.59 (2 H, d, J=3.57 Hz), 9.14 (1 H, s), 10.96 (1 H, s); ESIMS found for C 2 4H 26 N 8 0 mlz 443.2 (M+l).

4539

[01227] N-(2-(l-Methyl-lH-pyrazol-4-yl)-l,6-naphthyridin-7-yl)-2-(4- methylpiperazin- 1 -yl)thiazole -5 -carboxamide 4539.

[01228] Yellow solid (70 mg, 0.16 mmol, 45.5% yield). ¾ NMR (499 MHz, DMSO- ck) δ ppm 2.23 (3 H, s), 2.40 - 2.46 (4 H, m), 3.50 - 3.56 (4 H, m), 3.94 (3 H, s), 7.83 (1 H, d, .7=8.51 Hz), 8.22 (1 H, s), 8.37 (1 H, s), 8.41 (1 H, d, J=7.96 Hz), 8.49 (1 H, s), 8.57 (1 H, s), 9.11 (1 H, s), 10.91 (1 H, s); ESIMS found for C 2 iH 22 N s OS mlz 435.2 (M+l).

4544

[01229] N-(2-(l,2-Dimethyl-lH-imidazol-5-yl)-l,6-naphthyridin-7-yl)- 2-(pyrrolidin- l-yl)propanamide 4544.

[01230] Off-white solid (47 mg, 0.13 mmol, 41.1% yield). Ή NMR (499 MHz, DMSO-J 6 ) δ ppm 1.30 (3 H, d, J=6.86 Hz), 1.74 (4 H, br s), 2.42 (3 H, s), 2.57 - 2.69 (4 H, m), 3.33 - 3.37 (1 H, m), 4.10 (3 H, s), 7.79 (1 H, s), 7.88 (1 H, d, J=8.78 Hz), 8.38 (1 H, d, J=8.78 Hz), 8.49 (1 H, s), 9.07 (1 H, s), 10.16 (1 H, s); ESIMS found for C 2 oH 24 N 6 0 mlz 365.2 (M+l).

4548

[01231] trans -4-(Hydroxymethyl)-N-(2-(oxazol-5-yl)-l,6-naphthyridin-7-yl) cyclohexane-1 -carboxamide 4548.

[01232] Beige solid (5 mg, 0.04 mmol, 10.2% yield). ¾ NMR (499 MHz, DMSO ) δ ppm 0.95 (2 H, qd, J=12.81, 3.29 Hz), 1.37 (1 H, dtt, J=15.04, 5.93, 5.93, 3.02, 3.02 Hz), 1.46 (2 H, qd, J= 12.76, 3.16 Hz), 1.81 (2 H, br dd, J=13.31, 2.88 Hz), 1.86 - 1.93 (2 H, m), 2.52 - 2.58 (1 H, m), 3.24 (2 H, t, J=5.76 Hz), 4.39 (1 H, t, J=5.21 Hz), 7.94 (1 H, d, J=8.51 Hz), 8.17 (1 H, s), 8.55 - 8.59 (2 H, m), 8.69 (1 H, s), 9.19 (1 H, s), 10.69 (1 H, s); ESIMS found for Ci 9 H 2 oN 4 0 3 mlz 353.1 (M+l).

4551

[01233] N-(2-(Oxazol-5-yl)-l,6-naphthyridin-7-yl)-4-(piperidin-4-ylo xy)benzamide

4551

[01234] Beige solid (2 mg, 0.005 mmol, 16.5% yield). ¾ NMR (499 MHz, DMSO-i 6 ) 5 ppm 1.41 - 1.52 (2 H, m), 1.91 - 1.99 (2 H, m), 2.56 - 2.66 (2 H, m), 2.95 (2 H, dt, J= 12.49, 4.05 Hz), 4.51 - 4.59 (1 H, m), 7.06 (2 H, d, J=8.78 Hz), 7.98 (1 H, d, J=8.78 Hz), 8.07 (2 H, d, J=8.78 Hz), 8.20 (1 H, s), 8.62 (1 H, d, J=8.51 Hz), 8.71 (2 H, d, J=4.12 Hz), 9.27 (1 H, s), 10.91 (1 H, s); ESTMS found for C23H21N5O3∞

4558

[01235] fra¾v-4-(Hydroxymethyl)-N-(2-(2-methylthiazol-5-yl)-l ,6-naphthyridin-7-yl) cyclohexane - 1 -carboxamide 4558.

[01236] White solid (31 mg, 0.08 mmol, 45.8% yield). ¾ NMR (499 MHz, DMSO- d 6 ) 5 pm 0.95 (2 H, qd, J=12.76, 3.16 Hz), 1.36 (1 H, tdd, J= 11.94, 11.94, 6.17, 3.16 Hz), 1.45 (2 H, qd, J= 12.76, 3.16 Hz), 1.80 (2 H, br dd, J=13.17, 2.74 Hz), 1.86 - 1.93 (2 H, m), 2.51 - 2.56 (1 H, m), 2.73 (3 H, s), 3.24 (2 H, t, J=5.63 Hz), 4.40 (1 H, t, J=5.35 Hz), 8.10 (1 H, d, J=8.51 Hz), 8.46 - 8.51 (2 H, m), 8.60 (1 H, s), 9.13 (1 H, d, J=0.82 Hz), 10.66 (1 H, s); ESIMS found for C20H22N4O2S mlz 383.2 (M+l).

4559

[01237] fr ra-4-(Dimethylamino)-N-(2-(2-methylmiazol-5-yl)-l,6-naphthyr idin-7-y^ cyclohexane -1 -carboxamide 4559.

[01238] Beige solid (29 mg, 0.07 mmol, 53.3% yield). Ή MR (499 MHz, DMSO-t/e) 5 ppm 1.13 - 1.23 (2 H, m), 1 48 (2 H, qd, J=12.72, 3.02 Hz), 1.84 - 1.90 (2 H, m), 1.93 (2 H, br d, .7=11.80 Hz), 2.11 - 2.17 (1 H, m), 2.18 (6 H, s), 2.45 - 2.49 (1 H, m), 2.73 (3 H, s), 8.10 (1 H, d, J=8.78 Hz), 8.47 (1 H, s), 8.48 - 8.52 (1 H, m), 8.60 (1 H, s), 9.13 (1 H, s), 10.67 (1 H, s); ESIMS found for C2iH 25 N 5 OS mlz 396.2 (M+l).

4560

[01239] N-(2-(2-Methylthiazol-5-yl)-l,6-naphthyridin-7-yl)-l-(oxetan -3-yl) piperidine-4-carboxamide 4560.

[01240] Beige solid (5 mg, 0.01 mmol, 9.2% yield). ¾ NMR (499 MHz, METHANOLS) δ ppm 1.88 - 2.04 (6 H, m), 2.54 - 2.63 (1 H, m), 2.78 (3 H, s), 2.89 (2 H, br d, J=10.98 Hz), 3.53 (1 H, quin, J=6.45 Hz), 4.61 - 4.66 (2 H, m), 4.67 - 4.74 (2 H, m), 7.98 (1 H, d, J=8.51 Hz), 8.39 (1 H, d, J=8.51 Hz), 8.42 (1 H, s), 8.56 (1 H, s), 9.03 (1 H, s); ESIMS found for C 21 H 23 N 5 O 2 S mlz 410.1 (M+l).

4561

[01241] N 2-(2-Me1hylthiazol-5-yl) ,6-naphthyridin-7-yl) 2 pyrrolidin-l-yl) acetyl)piperidine-4-carboxamide 4561.

[01242] White solid (22 mg, 0.05 mmol, 33.5% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.41 - 1.54 (1 H, m), 1.54 - 1.66 (1 H, m), 1.67 - 1.72 (4 H, m), 1.85 (2 H, br d, J=10.43 Hz), 2.48 (4 H, br s), 2.55 - 2.64 (1 H, m), 2.73 (3 H, s), 2.79 - 2.88 (1 H, m), 2.98 - 3.06 (1 H, m), 3.15 - 3.22 (1 H, m), 3.34 - 3.40 (1 H, m), 4.11 (1 H, br d, J=13.72 Hz), 4.40 (1 H, br d, J=12.62 Hz), 8.11 (1 H, d, J=8.51 Hz), 8.47 (1 H, s), 8.50 (1 H, d, J=8.51 Hz), 8.60 (1 H, s), 9.14 (1 H, s), 10.79 (1 H, s); ESIMS found for C 2 4H 2 8N 6 0 2 S mlz 465.2 (M+l).

4564

[01243] 441uoro-N -(2-(6-(( 1 -methylazetidin-3 -yl)methoxy)pyrazin-2-yl)4 ,6- naphthyridin-7-yl)benzamide 4564.

[01244] Yellow solid (5 mg, 0.01 mmol, 40.4% yield). ¾ NMR (499 MHz, DMSO- < ) δ ppm 2.23 (3 H, s), 2.81 - 2.92 (1 H, m), 3.04 (2 H, t, J=6.31 Hz), 3.27 - 3.31 (2 H, m), 4.65 (2 H, d, .7=7.14 Hz), 7.38 (2 H, t, J=8.78 Hz), 8.19 (2 H, dd, J=8.78, 5.49 Hz), 8.49 (1 H, s), 8.51 (1 H, d, .7=8.51 Hz), 8.73 (1 H, d, -7=8.51 Hz), 8.82 (1 H, s), 9.35 (1 H, s), 9.38 (1 H, s), 11.21 (1 H, s); ESIMS found for C24H 2 iFN 6

4565

[01245] l-Isopropyl-N-(2-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2 -yl)-l,6- naphthyridin-7 -yl) - 1 H-pyrazole -4-carboxamide 4565.

[01246] Yellow solid (2.8 mg, 0.006 mmol, 3.1% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.47 (6 H, d, .7=6.86 Hz), 1.49 - 1.59 (2 H, m), 1.93 - 2.04 (2 H, m), 2.07 - 2.14 (2 H, m), 2.21 (3 H, s), 2.77 (2 H, br d, J=12.08 Hz), 3.81 - 3.92 (1 H, m), 4.56 (2 H, quin, J=6.66 Hz), 7.29 (1 H, d, -7=7.14 Hz), 8.07 (1 H, s), 8.21 (1 H, s), 8.38 (1 H, d, .7=8.51 Hz), 8.63 (1 H, d, .7=8.51 Hz), 8.65 (1 H, s), 8.73 (1 H, s), 8.81 (1 H, s), 9.29 (1 H, s), 10.77 (1 H, s); ESIMS found for C25H29N9O mlz 472.3 (M+l).

4569

[01247] N-(7-(l -Methyl- lH-pyrazol-4-yl)quinazolin-2-yl)-2-(( l-methylpiperidin-4- yl)ammo)isonicotinamide 4569.

[01248] Yellow solid (25.2 mg, 0 06 mmol, 34.6% yield). 'HNMR (499 MHz, DMSO- d 6 ) δ ppm 1.38 - 1.52 (2 H, m), 1.84 - 1.93 (2 H, m), 1.99 (2 H, br t, .7=10.70 Hz), 2.16 (3 H, s), 2.73 (2 H, br d, -7=11.53 Hz), 3.65 - 3.75 (1 H, m), 3.91 (3 H, s), 6.70 (1 H, d, J=7.68 Hz), 6.89 - 6.98 (2 H, m), 7.89 (1 H, dd, .7=8.51, 1.65 Hz), 7.99 (1 H, d, J=0.82 Hz), 8.06 - 8.10 (2 H, m), 8.17 (1 H, s), 8.47 (1 H, s), 9.43 (1 H, s), 11.06 (1 H, br s); ESIMS found for C 2 4H 2 6N 8 0 mlz 443.2 (M+l).

4570 [01249] N-(7-(l -Methyl-lH-pyrazol-4-yl)quinazolm-2-yl)-2-(4-methylpiperazin -l-yl) thiazole-5-carboxamide 4570.

[01250] Yellow solid (7.8 mg, 0.02 mmol, 1 1.7% yield). ¾ NMR (499 MHz, DMSO- d ) δ ppm 2.23 (3 H, s), 2.40 - 2.45 (4 H, m), 3.49 - 3.56 (4 H, m), 3.91 (3 H, s), 7.85 ( 1 H, dd, J=8.51, 1.65 Hz), 7.93 ( 1 H, d, J=0.82 Hz), 8.04 (1 H, d, J=8.51 Hz), 8.15 (1 H, s), 8.25 ( 1 H, s), 8.45 (1 H, s), 9.40 (1 H, s), 10.97 (1 H, s); ESIMS found for C 2 iH 2 2N 8 OS mlz 435.2 (M+l).

4573

[01251] N-(7-(l -Methyl-lH-l,2,3-tnazol-4-yl)qumazolin-2-yl)-4-(piperidin-4- yloxy) benzamide 4573.

[01252] Beige solid (5 mg, 0.01 mmol, 12.3% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ppm 1.45 - 1.54 (2 H, m), 1.93 - 2.00 (2 H, m), 2.63 (2 H, br t, J=9.88 Hz), 2.94 - 3.04 (2 H, m), 4.15 (3 H, s), 4. 1 - 4.62 ( 1 H, m), 7.06 (2 H, br d, J=8.23 Hz), 8.00 (2 H, br d, J=8. 1 Hz), 8.1 1 - 8.21 (2 H, m), 8.25 (1 H, s), 8.87 (1 H, s), 9.52 ( 1 H, s), 1 1.00 (1 H, br s); ESIMS found for C23H23N7O2 mlz 430.2 (M+l).

4574

[01253] N-(7-( 1 -Methyl- lH-tetrazol-5 -yl)quinazolm-2-yl)- 1 -(3,3,3-trifluoropropyl) piperidine-4-carboxamide 4574.

[01254] Off-white solid (5.5 mg, 0.01 mmol, 20.3% yield). ¾ NMR (499 MHz, DMSO- 6 ) δ ppm 1.63 (2 H, qd, J=12.21, 3.43 Hz), 1.83 (2 H, br d, J=l 1.80 Hz), 1.94 - 2.04 (2 H, m), 2.40 - 2.55 (4 H, m), 2.66 - 2.75 (1 H, m), 2.93 (2 H, br d, J=l 1.53 Hz), 4.27 (3 H, s), 7.99 (1 H, dd, J=8.23, 1.65 Hz), 8.22 - 8.26 (1 H, m), 8.29 (1 H, d, J=8.23 Hz), 9.64 (1 H, d, J=0.82 Hz), 10.87 (1 H, s); ESIMS found for C19H21F3N8O mlz 435.2 (M+l).

4576

[01255] N-(7-(l,2-Dimethyl-lH-imidazol-5-yl)quinazolin-2-yl)-2-(pipe ridin-l-yl) propanamide 4576. [01256] Beige gum (16 mg, 0.04 mmol, 10.1% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ppm 1.18 (3 H, d, J=6.86 Hz), 1.37 - 1.45 (2 H, m), 1.55 (4 H, br d, J=2.74 Hz), 2.40 (3 H, s), 2.51 - 2.57 (4 H, m), 3.49 (1 H, q, .7=6.68 Hz), 3.69 (3 H, s), 7.22 (1 H, s), 7.71 (1 H, dd, J=8.37, 1.51 Hz), 7.78 (1 H, s), 8.11 (1 H, d, J=8.51 Hz), 9.47 (1 H, s), 10.39 (1 H, s); ESIMS found for C 2 iH 2 6N 6 0 mlz 379.1 (M+l).

4577

[01257] 4-Isopropox)'-N-(7-(7-methyl-5,6,7,8-tetrahydroimidazo[l,2-a ]pyrazin-3-yl) quinazolin-2-yl)benzamide 4577.

[01258] Yellow solid (4.4 mg, 0.01 mmol, 47.3% yield). ¾ NMR (499 MHz, DMSO- ck) δ ppm 1.31 (6 H, d, .7=6.04 Hz), 2.42 (3 H, s), 2.82 (2 H, t, J=5.35 Hz), 3.65 (2 H, s), 4.24 (2 H, t, J=5.35 Hz), 4.75 (1 H, spt, .7=6.04 Hz), 6.99 - 7.05 (2 H, m), 7.43 (1 H, s), 7.82 (1 H, dd, J=8.51, 1.65 Hz), 7.86 (1 H, s), 7.98 - 8.04 (2 H, m), 8.12 (1 H, d, .7=8.51 Hz), 9.51 (1 H, s), 10.99 (1 H, br s); ESIMS found for C 2 5H2 6 N 6 02 mlz 443.2 (M+l).

4593

[01259] 2-((lS,4S)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(7-(5-met hyl-l,3,4- thiadiazol-2-yl)quinazolin-2-yl)acctamidc 4593.

[01260] Beige solid (3 mg, 0.008 mmol, 5.8% yield). ¾ NMR (499 MHz, DMSO-c 6 ) 5 ppm 1.65 (I H, br d, .7=9.61 Hz), 1.84 (1 H, dd, J=9.61, 1.65 Hz), 2.59 (1 H, d, .7=10.15 Hz), 2.84 (3 H, s), 2.95 (1 H, dd, .7=10.02, 1.51 Hz), 3.55 (2 H, d, J=6.04 Hz), 3.58 (1 H, dd, J=7.55, 1.51 Hz), 3.63 (1 H, s), 3.87 (1 H, d, J=7.68 Hz), 4.39 (1 H, s), 8.16 - 8.21 (1 H, m), 8.22 - 8.25 (1 H, m), 8.26 (1 H, d, J=0.82 Hz), 9.59 (1 H, s), 10.42 (1 H, s); ESIMS found for Ci 8 Hi 8 N 6 0 2 S mlz 383.1 (M+l).

4594

[01261] N-(7-(5-(Cyano(4-hydroxypiperidin-l-yl)methyl)pyridin-3-yl)q uinazolin-2- yl)cyclopropanecarboxamide 4594.

[01262] White solid (4 mg, 0.009 mmol, 5.2% yield). Ή NMR (499 MHz, DMSO ) δ ppm 0.83 - 0.92 (4 H, m), 1.35 - 1.43 (1 H, m), 1.48 - 1.58 (1 H, m), 1.73 - 1.80 (1 H, m), 2.07 - 2.16 (1 H, m), 2.25 - 2.33 (1 H, m), 2.33 - 2.40 (1 H, m), 2.55 - 2.62 (1 H, m), 2.87 - 2.95 (1 H, m), 3.51 - 3.59 (1 H, m), 4.64 (1 H, d, J=3.84 Hz), 5.63 (1 H, s), 8.27 (1 H, d, .7=8.51 Hz), 8.59 - 8.66 (2 H, m), 8.69 (1 H, t, .7=1.78 Hz), 8.77 (1 H, d, .7=1.92 Hz), 9.27 (1 H, s), 9.46 (1 H, d, .7=2.20 Hz), 11.13 (1 H, s); ESIMS found for CiMuNeOi m/z 429.2 (M+l).

4595

[01263] 4-Fluoro-N-(7-(6-((l-methylazetidin-3-yl)methoxy)pyrazin-2-y l)quinazolin- 2-yl)benzamide 4595.

[01264] White solid (5 mg, 0.01 mmol, 60.5% yield). Ή NMR (499 MHz, DMSO ) δ ppm 2.22 (3 H, s), 2.79 - 2.91 (1 H, m), 3.03 (2 H, brt, .7=6.17 Hz), 3.27 - 3.30 (2 H, m), 4.63 (2 H, d, .7=7.14 Hz), 7.37 (2 H, t, J=8.78 Hz), 8.11 (2 H, dd, .7=8.51, 5.49 Hz), 8.27 (1 H, d, J=8.78 Hz), 8.40 (1 H, br dd, J=8.51, 1.65 Hz), 8.39 (1 H, s), 8.58 (1 H, d, J=0.82 Hz), 9.09 (1 H, s), 9.64 (1 H, s), 11.30 (1 H, s); ESI m/z 445.2 (M+l).

4600

[01265] N-(6-(l -Methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-((l- mcthylpipcridin-4-yl)amino)isonicotinamidc 4600.

[01266] Off-white solid (18.5 mg, 0.04 mmol, 31.4% yield). ¾ NMR (499 MHz, DMSO-t/e) δ ppm 1.42 - 1.53 (2 H, m), 1.86 - 1.92 (2 H, m), 1.99 (2 H, br t, J=l 1.39 Hz), 2.17 (3 H, s), 2.73 (2 H, br d, .7=11.25 Hz), 3.67 - 3.76 (1 H, m), 3.93 (3 H, s), 6.71 (1 H, d, .7=7.68 Hz), 6.98 (1 H, s), 7.00 (1 H, dd, J=5.35, 1.51 Hz), 8.10 (1 H, d, J=5.21 Hz), 8.21 (1 H, s), 8.51 (1 H, s), 8.57 (1 H, d, J=1.92 Hz), 8.61 (1 H, d, J=0.82 Hz), 9.19 (1 H, s), 9.23 (1 H, d, J=2.20 Hz), 10.98 (1 H, s); ESIMS found for C24H 2 6N 8 0 mlz 443.2 (M+l).

4602

[01267] N-(6-(l -Methyl- lH-pyrazol-4-yl)-2,7-naphthyridin-3-yl)-2-(4- methylpiperazin- 1 -yl)thiazole-5 -carboxamide 4602.

[01268] Off-white solid (33 mg, 0.08 mmol, 34.9% yield). ¾ NMR (499 MHz, DMSO- e) δ ppm 2.23 (3 H, s), 2.43 (4 H, br t, J=4.94 Hz), 3.49 - 3.55 (4 H, m), 3.93 (3 H, s), 8.20 (1 H, s), 8.37 (1 H, s), 8.49 (3 H, s), 9.16 (1 H, s), 9.19 (1 H, d, J=1.92 Hz), 10.93 (1 H, s); ESIMS found for C 2 iH 2 2N 8 OS mlz 435.2 (M+l).

4609

[01269] fr «5-3-Morpholino-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)cy clobutanc- 1 -carboxamide 4609.

[01270] White solid (11 mg, 0.03 mmol, 13.3% yield). Ή NMR (500 MHz, DMSO- d 6 ) δ ppm 2.10 - 2.17 (2 H, m), 2.22 - 2.31 (6 H, m), 2.87 - 2.94 (1 H, m), 3.26 - 3.29 (1 H, m), 3.59 (4 H, br t, J=4.39 Hz), 8.10 (1 H, s), 8.62 (1 H, d, J=1.92 Hz), 8.63 (1 H, s), 8.67 (1 H, s), 9.18 - 9.22 (1 H, m), 9.29 (1 H, d, J=2.20 Hz), 10.69 (1 H, s); ESIMS found for C 2 oH2iN 5 0 3 mlz 380.2 (M+l).

4610

[01271] fr «5-4-(Hydroxymethyl)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3- yl) cyclohexane-1 -carboxamide 4610.

[01272] Pale yellow solid (7 mg, 0.02 mmol, 32.9% yield). ¾ NMR (500 MHz, DMSO-A) δ ppm 0.95 (2 H, qd, J=12.76, 2.88 Hz), 1.32 - 1.41 (1 H, m), 1.45 (2 H, qd, J=12.76, 3.43 Hz), 1.81 (2 H, br dd, J=13.17, 3.02 Hz), 1.89 (2 H, br dd, J=12.49, 2.33 Hz), 2.52 - 2.57 (1 H, m), 3.24 (2 H, t, J=5.76 Hz), 4.40 (1 H, t, J=5.35 Hz), 8.10 (1 H, s), 8.60 (1 H, s), 8.61 (1 H, d, J=1.92 Hz), 8.66 - 8.69 (1 H, m), 9.20 (1 H, t, J=0.82 Hz), 9.28 (1 H, d, .7=1.92 Hz), 10.67 (1 H, s), ESIMS found for Ci9H 2 oN 4 0 3

4611

[01273] N-(6-(Oxazol- -yl)-2,7-naphthyridin-3 -yl)piperidine-4-carboxamide 4611.

[01274] Beige solid (57.0 mg, 0.18 mmol, 68.3% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.54 (2 H, qd, J=12.21, 3.98 Hz), 1.68 - 1.76 (2 H, m), 2.44 - 2.49 (2 H, m), 2.63 - 2.71 (1 H, m), 2.95 - 3.02 (2 H, m), 8.10 (1 H, s), 8.60 (1 H, s), 8.62 (1 H, d, .7=1.92 Hz), 8.66 (1 H, s), 9.20 (1 H, s), 9.28 (1 H, d, J=2.20 Hz), 10.67 (1 H, s); ESIMS found for Ci 7 Hi 7 N 5 0 2 mlz 324.1 (M+l).

4612

[01275] 4-Mo holino-N-(6-(oxazol-5-yl)-2,7-naprlthyridin-3-yl)piperidine- l- carboxamide 4612.

[01276] Beige solid (20 mg, 0.05 mmol, 27.3% yield). Ή NMR (499 MHz, DMSO-t/e) δ ppm 1.34 (2 H, qd, .7=11.94, 3.70 Hz), 1.80 (2 H, br d, .7=10.70 Hz), 2.37 (1 H, tt, J=10.98, 3.57 Hz), 2.44 - 2.49 (4 H, m), 2.84 (2 H, brt, J=l 1.80 Hz), 3.53 - 3.61 (4 H, m), 4.23 (2 H, br d, J=13.17 Hz), 8.08 (1 H, s), 8.28 (1 H, s), 8.55 (1 H, d, .7=1.92 Hz), 8.65 (1 H, s), 9.15 (1 H, s), 9.22 (1 H, d, J=2.20 Hz), 9.43 (1 H, s); ESIMS found for C 2 iH 24 N 6 0 3 mlz 409.2 (M+l).

4614

[01277] N-(6-(Oxazol-5-yl)-2,7-naphthyridin-3-yl)-3-(piperidin-4-ylo xy)benzamide

4614.

[01278] White solid (30 mg, 0.07 mmol, 79.2% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 1.43 - 1.56 (2 H, m), 1.92 - 2.01 (2 H, m), 2.55 - 2.66 (2 H, m), 2.97 (2 H, dt, J=12.62, 4.12 Hz), 4.52 - 4.60 (1 H, m), 7.18 (1 H, dd, J=8.10, 1.78 Hz), 7.43 (1 H, t, J=8.10 Hz), 7.60 - 7.67 (2 H, m), 8.12 (1 H, s), 8.68 (1 H, s), 8.71 (1 H, d, J=2.20 Hz), 8.76 (1 H, s), 9.30 (1 H, s), 9.34 (1 H, d, J=2.20 Hz), 11.08 C2 3 H 2 iN 5 0 3 mlz 416.15 (M+1).

4615

[01279] 2-Mcthyl-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)-5,6-dihyd roimidazo[l,2- a]pyrazine-7(8H)-carboxamide 4615.

[01280] Beige solid (15 mg, 0.04 mmol, 22.3% yield). Ή NMR (499 MHz, DMSO-t e) δ ppm 2.06 (3 H, d, J=0.82 Hz), 3.92 - 3.97 (2 H, m), 3.97 - 4.03 (2 H, m), 4.68 (2 H, s), 6.79 (1 H, d, J=0.82 Hz), 8.09 (1 H, s), 8.31 (1 H, s), 8.57 (1 H, d, J=1.92 Hz), 8.66 (1 H, s), 9.19 (1 H, s), 9.25 (1 H, d, J=2.20 Hz), 9.82 (1 H, s); ESIMS found for G9H17N7O2 mlz 376.2 (M+1).

4616

[01281 ] 2-(lH-lrnidazol-l -yl)-N-(6-(oxazol-5-yl)-2,7-naphthyridin-3-yl)acetarnide

4616.

[01282] White solid (5.3 mg, 0.02 mmol, 8.8% yield). ¾ NMR (499 MHz, DMSO-i 6 ) δ ppm 5.05 (2 H, s), 6.91 (1 H, s), 7.16 - 7.24 (1 H, m), 7.67 (1 H, s), 8.10 (1 H, s), 8.54 (1 H, s), 8.63 (1 H, d, J=1.92 Hz), 8.66 (1 H, s), 9.25 (1 H, s), 9.31 (1 H, d, J=2.20 Hz), 11.15 (1 H, s); ESIMS found for Ci6Hi2N 6 0 2 m/z 321.1 (M+1).

4618

[01283] fro« --4-(Dimethylamino)-N-(6-(thiazol-5 -yl)-2,7-naphthyridin-3 -yl) cyclohexane-l-carboxamide 4618.

[01284] Beige solid (21.6 mg, 0.06 mmol, 41.1% yield). ¾ NMR (500 MHz, DMSO- d 6 ) δ ppm 1.14 - 1.25 (2 H, m), 1.48 (2 H, qd, .7=12.67, 2.61 Hz), 1.85 - 1.90 (2 H, m), 1.93 (2 H, br d, J=12.35 Hz), 2.13 - 2.17 (1 H, m), 2.18 (6 H, s), 2.46 - 2.54 (1 H, m), 8.58 (1 H, s), 8.66 (1 H, d, J=2.20 Hz), 8.69 (1 H, s), 9.19 - 9.22 (1 H, m), 9.27 (1 H, s), 9.27 (1 H, d, J=2.20 Hz), 10.67 (1 H, s); ESIMS found for C 2 oH 23 N 5 OS mlz 382.15 (M+1).

4623

[01285] N-(6-(2-Methylthiazol-5-yl)-2,7-naphthyridin-3-yl)-l-(2-(pyr rolidin-l-yl) acetyl)piperidine-4-carboxamide 4623.

[01286] Beige gum (15 mg, 0.03 mmol, 24.0% yield). ¾ NMR (499 MHz, DMSO-t/e) δ ρηι 1.47 (1 H, qd, J=12.21, 3.70 Hz), 1.57 - 1.67 (1 H, m), 1.69 (4 H, br s), 1.82 - 1.89 (2 H, m), 2.47 (4 R br s), 2.58 - 2.66 (1 H, m), 2.75 (3 H, s), 2.80 - 2.88 (1 H, m), 2.98 - 3 07 (1 H, m), 3.15 - 3.21 (1 H, m), 3.37 (1 H, d, J=14.27 Hz), 4.11 (1 H, br d, J=13.17 Hz), 4.40 (1 H, br d, J=13.45 Hz), 8.42 (1 H, s), 8.54 (1 H, d, J=2.20 Hz), 8.57 (1 H, s), 9.17 - 9.20 (1 H, m), 9.23 (1 H, d, J=2.20 Hz), 10.79 (1 H, s); ESIMS found for C24H28N 6 02S mlz 465.2 (M+l).

4634

[01287] N-(3 -( 1 -Methyl-5 -(piperidm-1 -ylmethyl)-lH-pyrazol-4-yl)- 1 ,7-naphthyridin- 6-yl)-2-(2,7-diazaspiro[3.5]nonan-2-yl)isonicotinamide 4634.

[01288] White solid (3.2 mg, 0.006 mmol, 4.0% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.33 - 1.41 (2 H, m), 1.43 - 1.51 (4 H, m), 1.68 - 1.75 (4 H, m), 2.41 (4 H, br s), 2.73 (4 H, br s), 3.75 (4 H, s), 3.92 (3 H, s), 4.02 (2 H, s), 7.02 (1 H, s), 7.12 (1 H, dd, J=5.21, 1.37 Hz), 8.05 (1 H, s), 8.17 (1 H, s), 8.20 (1 H, d, J=5.49 Hz), 8.58 (1 H, s), 9.34 (1 H, s), 9.42 (1 H, s), 11.20 (1 H, br s); ESIMS found (M+l).

4640

[01289] fr « , -3-Morpholino-N-(3-(oxazol-5-yl)-l,7-naphthyridin-6-yl )cyclobutane- 1-carboxamide 4640.

[01290] White solid (14 mg, 0.04 mmol, 36.6% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 2.09 - 2.17 (2 H, m), 2.22 - 2.31 (6 H, m), 2.90 (1 H, quin, J=7.07 Hz), 3.26 - 3.31 (1 H, m), 3.59 (4 H, t, J=4.39 Hz), 7.89 (1 H, s), 8.11 (1 H, s), 8.58 (1 H, s), 8.63 (1 H, s), 9.32 - 9.35 (1 H, m), 9.40 - 9.44 (1 H, m), 10.79 (1 H, s); ESIMS found for C2oH 2 iN 5 0 3 m/z 380.2 (M+l).

4641

[01291] fr i75-4-(Hydroxymethyl)-N-(3-(oxazol-5-yl)-l,7-naphthyridin-6- yl) cyclohexane-1 -carboxamide 4641 .

[01292] White solid (6.0 mg, 0.02 mmol, 6.7% yield). ¾ NMR (499 MHz, DMSO-ί/β) δ ppm 0.91 - 1.00 (2 H, m), 1.35 - 1.39 (1 H, m), 1.40 - 1.49 (2 H, m), 1.80 (2 H, br dd, J=13.45, 2.47 Hz), 1.89 (2 H, br d, J=10.43 Hz), 2.52 - 2.58 (1 H, m), 3.24 (2 H, t J=5.76 Hz), 4.40 (1 H, t, J=5.35 Hz), 7.89 (1 H, s), 8.10 (1 H, s), 8.54 (1 H, s), 8.62 (1 H, s), 9.34 (1 H, s), 9.41 (1 H, s), 10.78 (1 H, s); ESIMS found for Ci9H 2 oN 4 0 3 m/z 353.2 (M+l).

4643

[01293] 4-Mo holino-N-(3-(oxazol-5-yl)-l,7-naphthyridin-6-yl)piperidine-l - carboxamide 4643.

[01294] Off-white solid (35 mg, 0.09 mmol, 36.4% yield). Ή NMR (499 MHz, DMSO-i¾,) δ ppm 1.28 - 1.40 (2 H, m), 1.80 (2 H, br d, J=10.70 Hz), 2.37 (1 H, tt, J=10.91, 3.50 Hz), 2.43 - 2.49 (4 H, m), 2.85 (2 H, brt, J=l 1.80 Hz), 3.53 - 3.60 (4 H, m), 4.22 (2 H, br d, J=13.45 Hz), 7.86 (1 H, s), 8.02 (1 H, s), 8.20 (1 H, s), 8.60 (1 H, s), 9.28 (1 H, s), 9.36 (1 H, s), 9.58 (1 H, s); ESIMS found for C 2 iH24N 6

4646

[01295] 2-Methyl-N-(3 -(oxazol-5 -yl)- l,7-naphthyridin-6-yl)-5,6-dihydroimidazo[ 1 ,2- a]pyrazine-7(8H)-carboxamide 4646.

[01296] Beige solid (30 mg, 0.08 mmol, 33.9% yield). Ή NMR (499 MHz, DMSC ,) δ ppm 2.06 (3 H, s), 3.91 - 3.97 (2 H, m), 3.97 - 4.03 (1 H, m), 4.68 (2 H, s), 6.79 (1 H, s), 7.87 (1 H, s), 8.05 (1 H, s), 8.24 (1 H, s), 8.61 (1 H, s), 9.32 (1 H, s), 9.38 (1 H, s), 9.96 (1 H, s); ESIMS found for C19H17N7O2 m/z 376.2 (M+l).

4647

[01297] 2-( lH-Imidazol- 1 -yl)-N-(3-(oxazol-5-yl)- 1 ,7-naphthyridin-6-yl)acetamide

4647.

[01298] Beige solid (10 mg, 0.03 mmol, 34.9% yield). Ή NMR (499 MHz, DMSO-t/e) δ ppm 5.06 - 5.11 (2 H, m), 7.00 (1 H, s), 7.26 (1 H, s), 7.82 (1 H, s), 7.89 (1 H, s), 8.12 (1 H, s), 8.48 (1 H, s), 8.62 (1 H, s), 9.39 (1 H, s), 9.44 (1 H, s), 11.28 (1 H, s); ESIMS found for Ci6Hi 2 N 6 02

4650

[01299] N-(3 -(Thiazol-5 -yl)-l ,7-naphthyridin-6-yl)- 1 -(( 1 -(trifluoromethyl) cyclopropyl)methyl)piperidine-4-carboxamide 4650.

[01300] Off-white solid (15 mg, 0.03 mmol, 40.7% yield). ¾ NMR (499 MHz, DMSO-£¾) δ ppm 0.73 (2 H, s), 0.92 - 0.99 (2 H, m), 1.62 - 1.74 (2 H, m), 1.79 (2 H, br d, J=10.15 Hz), 1.90 - 1.99 (2 H, m), 2.57 (1 H, tt, J=11.60, 3.77 Hz), 2.97 (2 H, br d, J=l 1.53 Hz), 8.44 (1 H, s), 8.51 (1 H, s), 8.73 (1 H, s), 9.20 (1 H, s), 9.32 (1 H, s), 9.35 - 9.39 (1 H, m), 10.83 (1 H, s); ESIMS found for C 2 2H 2 2F 3 N 5 OS

4657

[01301] 4-Fluoro-N-(3-(6-((l-methylazetidin-3-yl)methoxy)pyrazin-2-y l)-lJ- naphthyridin-6-yl)benzamide 4657.

[01302] White solid (7.5 mg, 0.02 mmol, 40.4% yield). Ή NMR (499 MHz, DMSO- d 6 ) δ ppm 2.24 (3 H, s), 2.80 - 2.94 (1 H, m), 3.07 (2 H, t, J=6.45 Hz), 3.33 - 3.36 (3 H, m), 4.68 (2 H, d, J=7.14 Hz), 7.38 (2 H, t, J=8.92 Hz), 8.18 (2 H, dd, J=8.78, 5.49 Hz), 8.40 (1 H, s), 8.79 (2 H, d, J=5.76 Hz), 9.22 (1 H, s), 9.49 (1 H, s), 9.55 (1 H, s), 11.27 (1 H, br s); ESIMS found for C24H21FN6O2 mlz 445.2 (M+l).

4658

[01303] l-Isopropyl-N-(3-(6-((l-methylpiperidin-4-yl)amino)pyrazin-2 -yl)-l,7- naphthyridin-6 -yl) - 1 H-pyrazolc -4-carboxamidc 4658.

[01304] Yellow solid (2.2 mg, 0.005 mmol, 5.1% yield). ¾ NMR (499 MHz, DMSO- d 6 ) δ ppm 1.46 (6 H, d, J=6.59 Hz), 1.50 - 1.60 (2 H, m), 2.02 (2 H, br dd, J=8.92, 3.43 Hz), 2.12 - 2.19 (2 H, m), 2.23 (3 H, s), 2.78 (2 H, br d, J=10.98 Hz), 3.86 - 3.97 (1 H, m), 4.52 - 4.61 (1 H, m), 7.22 (1 H, d, J=7.41 Hz), 8.02 (1 H, s), 8.20 (1 H, s), 8.52 (1 H, s), 8.65 (1 H, s), 8.66 (1 H, s), 8.73 (1 H, s), 9.43 (1 H, s), 9.47 (1 H, s), 10.86 (1 H, s); ESIMS found for C 25 H29N 9 0 mlz 472.3 (M+l).

Example 14.

[01305] The screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cancer cell lines (e.g., colon cancer) or primary cells (e.g., IEC-6 intestinal cells) with a lentiviral construct that includes a Wnt-responsive promoter driving expression of the firefly luciferase gene.

[01306] SW480 colon carcinoma cells were transduced with a lentiviral vector expressing luciferase with a human Sp5 promoter consisting of a sequence of eight TCF/LEF binding sites. SW480 cells stably expressing the Sp5-Luc reporter gene and a hygromycin resistance gene were selected by treatment with 150 μg/mL of hygromycin for 7 days. These stably transduced SW480 cells were expanded in cell culture and used for all further screening activities. Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1 :3, 10-point dose-response curves starting from 10 μιΜ) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, CA) into 384-well white solid bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.1%. For Sp5-Luc reporter gene assays, the cells were plated at 4,000 cells/well in 384-well plates with a DMEM medium containing 1% fetal bovine serum, and 1% Penicillin- Streptomycin and incubated for 36 to 48 hours at 37°C and 5% CO2. Following incubation, 15 μ\ of BriteLite Plus luminescence reagent (Perkin Elmer) was added to each well of the 384-well assay plates. The plates were placed on an orbital shaker for 2 min and then luminescence was quantified using the Envision (Perkin Elmer) plate reader. Readings were normalized to DMSO only treated cells, and normalized activities were utilized for EC50 calculations using the dose- response log (inhibitor) vs. response -variable slope (four parameters) nonlinear regression feature available in GraphPad Prism 5.0 (or Dotmatics). For EC50 of >10 μΜ, the percent inhibition at 10 μΜ is provided.

[01307] Table 2 shows the measured activity for representative compounds of Formulas I, la, lb, Ic, Id, and Ie as described herein.

Table 2.

585 2.076 1536 0.663 3591 >10 (1 .3%) 4569 0.570

589 >10 (7.8%) 1589 0.184 3597 >10 (7.6%) 4570 3.264

591 6.058 1598 >10 (1 5.5%) 3599 >1 0 (41 .3%) 4573 3.228

592 >10 (5.0%) 1612 >10 (37.9%) 3612 3.922 4574 3.874

613 8.808 1625 >10 (37.3%) 3616 0.485 4576 >1 0 (35.3%)

624 0.750 1632 >10 (1 9.2%) 3627 1 .681 4577 >1 0 (28.9%)

625 0.964 1634 >10 (16.4%) 3629 0.396 4586 >1 0 (29.6%)

634 8.614 1656 1 .199 3638 0.593 4593 >1 0 (32.8%)

640 >10 (42.9%) 1670 3.712 3643 0.073 4594 >1 0 (35.6%)

641 0.977 1710 3.384 3646 0.219 4595 >1 0 (20.1 %)

642 0.869 1713 1 .144 3674 0.512 4600 8.043

643 0.688 1773 0.088 3683 0.603 4602 >1 0 (10.9%)

662 >10 (26.0%) 1777 >10 (35.4%) 3689 0.370 4609 >1 0 (0%)

692 >10 (38.6%) 1783 >10 (14.4%) 3698 0.288 46 0 >10 (9.1 %)

764 >10 (27.5%) 1785 4.268 3699 0.234 4611 >1 0 (35.7%)

804 0.289 1802 1 .402 3714 0.845 46 2 >1 0 (33.8%)

807 0.484 1813 0.396 3723 0.842 46 4 3.665

862 3.965 1815 >10 (12.9%) 3727 0.426 46 5 3.831

863 >10 (29.7%) 1953 >10 (9.7%) 3733 0.515 46 6 >1 0 (0%)

871 >10 (24.7%) 2722 >10 (1 3.7%) 3749 0.092 46 8 >1 0 (14.6%)

877 >10 (0%) 2731 >10 (30.9%) 3772 0.221 4622 >1 0 (50.0%)

892 4.277 2736 >10 (1 9.3%) 3773 2.825 4623 >1 0 (49.5%)

896 0.121 2767 >10 (20.7%) 3774 >1 0 (54.7%) 4632 0.922

909 >10 (56.1 %) 2776 0.836 3778 3.968 4634 >1 0 (51 .1 %)

918 >10 (5.0%) 2782 >10 (2.2%) 3780 1 .526 4640 0.163

923 >10 (34.8%) 2791 >10 (1 0.5%) 3783 1 .082 4641 3.717

954 >10 (29.6%) 2792 >10 (38.1 %) 3791 0.482 4643 3.020

963 >10 (1 1.8%) 2807 >1 0 (0%) 3797 0.427 4646 0.495

969 >10 (4.2%) 2816 >10 (1 5.4%) 3799 2.1 15 4647 >1 0 (34.5%)

978 >10 (37.2%) 2820 >10 (5.3%) 3821 0.1 76 4650 >1 0 (19.7%)

979 >10 (20.3%) 2826 >10 (1 1 .2%) 3829 0.994 4657 3.948

985 >10 (5.5%) 2864 >10 (47.3%) 3836 0.220 4658 0.164

Example 15.

[01308] Representative compounds were screened using the assay procedure for DYRK1A kinase activity as described below.

[01309] Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1 :3, 1 1 -point dose-response curves from 10 μΜ ΐο 0.00016 μΜ) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, CA) into 1536-well black-walled round bottom plates (Corning).

[01310] The DYRK1 A kinase assay was run using the Ser/Thr 18 peptide Z-lyte assay kit according to manufacturer's instmctions (Life Technologies- a Division of Thermo-Fisher). This is a non-radioactive assay using fluorescence resonance energy transfer (FRET) between coumarin and fluorescein to detect kinase activity which is represented as a ratio of coumarin emission/fluorescein emission.

[01311] Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in IX Kinase buffer to final concentrations of 0.19 30 μΜ, and 4 μΜ respectively. The mixture was allowed to incubate with the representative compounds for one hour at room temperature. All reactions were perfonned in duplicate. Unphosphorylated ("0% Control") and phosphorylated ("100% control") forms of Ser/Thr 18 served as control reactions. Additionally, an 11-point dose-response curve of Staurosporine (luM top) was run to serve as a positive compound control.

[01312] After incubation, Development Reagent A was diluted in Development Buffer then added to the reaction and allowed to further incubate for one hour at room temperature. The plate was read at Ex 400 Em 455 to detect the coumarin signal and Ex 400 Em 520 to measure the signal (EnVision Multilabel Plate Reader, PerkinElmer).

[01313] The Emission ratio (Em) was calculated as a ratio of the coumarin (C) emission signal (at 445 nm)/Fluorescein (F) emission signal (at 520 nm). The percent phosphorylation was then calculated using the following formula: [1 - ((Em ratio X F100%)-C100%)/ ((C0%-C100%) + (Em ratio X (F100% - F0%)))] . Dose-response curves were generated and inhibitory concentration (IC50) values were calculated using non-linear regression curve fit in the Dotmatics' Studies Software (Bishops Stortford, UK).

[01314] Table 3 shows the measured activity for representative compounds of Formulas I, la, lb, Ic, Id, and Ie as described herein.

Table 3.

347 9.990 1354 0.002 3249 0.026 4523 0.010

358 0.364 1356 0.005 3257 0.016 4535 0.009

372 0.067 1383 0.002 3259 0.024 4536 0.014

376 0.019 1438 0.100 3311 0.007 4537 0.035

379 0.011 1447 0.056 3363 0.1 19 4538 0.003

400 0.121 1462 0.370 3403 0.581 4539 0.002

416 0.031 1471 0.046 3412 0.040 4544 0.033

447 0.001 1472 0.246 3425 0.157 4548 0.019

448 >10 1491 0.039 3439 0.100 4551 0.005

450 0.001 1495 0.113 3446 2.092 4558 0.004

477 0.001 1497 0.030 3470 0.1 10 4559 0.014

523 0.004 1518 0.014 3474 0.071 4560 0.014

540 0.022 1519 0.01 1 3524 0.011 4561 0.007

556 0.054 1523 0.047 3527 0.294 4564 1 .027

566 0.077 1524 0.007 3587 0.001 4565 0.012

585 0.009 1536 0.004 3591 0.010 4569 0.008

589 0.050 1589 0.005 3597 0.006 4570 0.003

591 >10 1598 0.027 3599 0.008 4573 0.006

592 0.029 1612 0.021 3612 0.487 4574 1 .411

613 0.003 1625 0.025 3616 0.029 4576 0.675

624 0.003 1632 0.500 3627 0.007 4577 0.175

625 0.004 1634 0.342 3629 0.007 4586 0.002

634 0.029 1656 0.065 3638 0.006 4593 0.131

640 0.038 1670 0.006 3643 0.010 4594 0.035

641 0.008 1710 0.002 3646 0.002 4595 0.038

642 0.006 1713 0.027 3674 0.007 4600 0.030

643 0.010 1773 0.001 3683 0.008 4602 0.018

662 >10 1777 0.005 3689 0.071 4609 1 .983

692 1 .011 1783 0.007 3698 0.064 4610 0.029

764 0.008 1785 0.007 3699 0.002 4611 0.040

804 0.002 1802 0.007 3714 0.010 46 2 0.159

807 0.007 1813 0.002 3723 0.002 4614 0.010

862 0.203 1815 >10 3727 0.004 46 5 0.027

863 0.388 1953 0.317 3733 0.016 46 6 0.067

871 0.025 2722 0.023 3749 0.010 46 8 0.018

877 0.016 2731 0.021 3772 0.008 4622 0.040

892 0.142 2736 0.030 3773 0.016 4623 0.027

896 0.005 2767 0.034 3774 0.010 4632 0.005

909 0.013 2776 0.056 3778 0.004 4634 0.037

918 0.062 2782 0.867 3780 0.016 4640 0.019

923 0.044 2791 0.513 3783 0.004 4641 0.016

954 0.069 2792 0.012 3791 0.010 4643 0.064

963 0.045 2807 0.074 3797 0.008 4646 0.009

969 >10 2816 0.024 3799 0.012 4647 0.043

978 0.171 2820 0.037 3821 0.007 4650 0.003

979 >10 2826 0.082 3829 0.010 4657 0.024

985 0.126 2864 0.039 3836 0.005 4658 0.001

Example 16.

[01315] Representative compounds were screened using the assay procedure for GSK^ kinase activity as described below.

[01316] Each compound is dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1 :3, 11-point dose-response curves from 10 μΜ ΐο 0.0003 μΜ) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, CA) into 1 36-well black-walled round bottom plates (Corning).

[01317] The ϋ8Κ3β kinase assay is run using the Ser/Thr 09 peptide Z-lyte assay kit according to manufacturer's instructions (Life Technologies- a Division of Thermo-Fisher). This is a non-radioactive assay using fluorescence resonance energy transfer (FRET) between coumarin and fluorescein to detect kinase activity which is represented as ratio of coumarin emission/fluorescein emission.

[01318] Briefly, recombinant GSK3 kinase, ATP and Ser/Thr peptide 09 are prepared in IX Kinase buffer to final concentrations of 0.04 μg/mL, 46 μΜ, and 4 μΜ respectively. The mixture is allowed to incubate with the representative compounds for one hour at room temperature. All reactions were performed in duplicate. Unphosphorylated ("0% Control") and phosphorylated ("100% control") forms of Ser/Thr 18 serve as control reactions.

[01319] After incubation, diluted Development Buffer is added to the reaction and allowed to further incubate for one hour at room temperature. The plate is read at Ex 400 Em 455 to detect the coumarin signal and Ex 400 Em 520 to measure the signal (En Vision Multilabel Plate Reader, PerkinElmer).

[01320] The Emission ratio (Em) is calculated as a ratio of the coumarin (C) emission signal (at 445 nm)/Fluorescein (F) emission signal (at 520 nm). The percent phosphorylation is then calculated using the following formula: [1 - ((Em ratio X F 100%)-C 100%)/ ((C0%-C100%) + (Em ratio X (F 100% - F0%)))] .

[01321] Dose-response curves are generated and inhibitory concentration (IC50) values are calculated using non-linear regression curve fit in the Dotmatics' Studies Software (Bishops Stortford, UK).

[01322] Table 4 shows the activity of representative compounds of Formulas I, la, lb, Ic, Id, and Ie as provided herein.

Table 4.

194 0.017 1220 5.605 3096 >10 42 8 7.400

202 >10 1223 0.097 3098 >10 4239 0.187

209 >10 1239 0.112 3099 >10 4244 0.030

216 4.846 1253 0.015 3102 >10 4257 1 .622

228 0.753 1254 0.069 3105 >10 4319 0.199

229 2.896 1264 0.017 3111 2.137 4332 0.828

234 2.251 1278 0.134 3118 >10 4346 0.135

241 0.166 1282 0.453 3120 1.329 4353 2.450

242 6.854 1285 0.832 3134 2.593 4377 >10

280 0.335 1288 0.177 3136 0.982 4431 3.780

283 1 .183 1297 0.038 3167 >10 4432 >10

314 2.606 1306 0.377 3168 >10 4434 >10

317 0.007 1322 0.094 3194 >10 4498 0.001

333 2.772 1353 1.350 3240 >10 4504 0.077

347 >10 1354 1.169 3249 6.123 4523 >10

358 0.560 1356 2.781 3257 5.298 4535 0.188

372 0.255 1383 0.453 3259 >10 4536 0.319

376 0.665 1438 5.180 3311 >10 4537 0.543

379 0.359 1447 0.952 3363 9.990 4538 >10

400 0.036 1462 0.707 3403 >10 4539 2.227

416 0.049 1471 0.578 3412 >10 4544 0.018

447 0.048 1472 2.331 3425 2.292 4548 0.785

448 >10 1491 0.166 3439 0.463 4551 4.237

450 0.350 1495 0.254 3446 >10 4558 0.100

477 0.084 1497 >10 3470 >10 4559 0.1 10

523 0.362 1518 0.253 3474 >10 4560 0.127

540 0.644 1519 0.772 3524 >10 4561 0.182

556 0.086 1523 1.379 3527 >10 4564 >10

566 0.621 1524 0.407 3587 >10 4565 >10

585 0.109 1536 0.207 3591 2.273 4569 >10

589 0.156 1589 9.985 3597 >10 4570 2.185

591 >10 1598 4.185 3599 0.780 4573 0.161

592 >10 1612 0.049 3612 >10 4574 0.665

613 0.219 1625 0.008 3616 >10 4576 0.346

624 2.928 1632 0.943 3627 >10 4577 >10

625 8.265 1634 0.224 3629 0.002 4586 0.336

634 1 .147 1656 0.340 3638 0.027 4593 0.034

640 0.401 1670 0.120 3643 0.031 4594 0.528

641 2.564 1710 8.036 3646 0.004 4595 >10

642 3.063 1713 >10 3674 0.021 4600 >10

643 8.559 1773 0.995 3683 0.010 4602 >10

662 >10 1777 0.098 3689 0.008 4609 8.371

692 >10 1783 0.536 3698 0.009 46 0 >10

764 0.243 1785 0.135 3699 0.006 46 1 >10

804 4.683 1802 >10 3714 0.008 46 2 >10

807 >10 1813 >10 3723 0.010 4614 >10

862 >10 1815 >10 3727 0.018 4615 7.819

863 >10 1953 2.6237 3733 0.043 46 6 2.611

871 0.360 2722 0.326 3749 0.006 46 8 3.822

877 9.917 2731 5.506 3772 0.390 4622 4.628

892 >10 2736 3.732 3773 0.852 4623 1 .717

896 >10 2767 2.520 3774 0.397 4632 0.321

909 0.025 2776 >10 3778 0.187 4634 5.588

918 0.236 2782 2.454 3780 0.275 4640 0.012

923 0.204 2791 3.471 3783 2.339 4641 0.092

954 0.195 2792 1.152 3791 1.348 4643 0.165

963 0.045 2807 4.943 3797 0.409 4646 0.013

969 >10 2816 5.256 3799 0.243 4647 0.015

978 0.087 2820 7.061 3821 0.001 4650 0.036

979 >10 2826 5.373 3829 0.763 4657 >10

985 0.035 2864 >10 3836 1.471 4658 9.623 Example 17.

[01323] Representative compounds were screened using the assay procedure for tau phosphorylation activity described below.

[01324] SH-SY5Y cells (human neuroblastoma) were cultured in DMEM/F-12 medium supplemented with 15% FBS, Non-essential Amino Acid and Penicillin/Streptomycin. Two days before treatment, cells were seeded onto 96 well plates at 5 x 10 4 cells/well.

[01325] The above synthesized compounds were screened using the cell assay procedure to assess decrease Tau phosphorylation at Ser396 (pSer396) described below.

[01326] DMSO-resuspended compounds were dispensed to 8 wells as a serial titration from 10 μιΜ to 4.6 nM final in medium and cells were exposed overnight (16-18 h) in a humidified incubator at 36.6c before harvest. Wells were visually checked for cell death or change in morphology and supematants were tested for cytotoxicity by measurement of lactate dehydrogenase release (LDH, CytoToxOne kit, Promega) if necessary. As controls, commercially available DYRKIA inhibitors, Harmine and Indy which were shown to have good DYRK1A inhibition in the kinase assay with no CDK1 activity (EC50 18 and 53 nM respectively, 6 μιΜ for CDK1) but weak EC50 in the Tau assay >10 μΜ.

[01327] Cells were lysed with RIPA buffer complemented with phosphatase and protease inhibitors then lysates were spun down at 12,000g for 10 minto remove any cellular debris. Lysates are then either directly tested for pSer396 by ELISA (Life Technology, Kit KHB7031) or loaded on NuPage Bis-Tris gels for western blot analysis. Colorimetric detection of ELISA signal is performed by Cytation3 plate reader (Biotek) and the chemiluminescence signal for HRP -linked antibodies used in western blotting is detected using a Carestream Image Station. The same pSer396 antibody is used for detection of pTau in both assays.

[01328] Blot densitometry for pSer396 and β-actm were analyzed using ImageJ (NIH) and pSer396 Tau ELISA signal was used to plot, draw the curve fitting, and determine each compounds EC50 in Prism (GraphPad).

[01329] Table 5 shows the activity of representative compounds Formulas I, la, lb, Ic, Id, and Ie as provided herein.

Table 5.

41 >1 0 994 >10 3000 1 .831 4104 10.000

47 >1 0 1003 4.500 3098 >10 4159 0.989

56 1 .500 1007 >10 3105 >10 4239 0.491

62 0.699 1101 9.500 3120 2.429 4244 0.284

71 0.426 1186 5.400 3249 1 0.000 4319 0.553

86 1 .000 1223 1 .366 3629 0.021 4346 1 .545

95 1 .700 1253 0.188 3638 1 .500 4498 0.037

99 0.967 1264 0.902 3643 0.1 02 4504 10.000

112 1 .1 00 1278 5.053 3646 0.079 4535 0.925

122 0.481 1288 10.000 3674 0.1 92 4536 >1 0

194 3.000 1322 0.168 3683 0.1 79 4544 0.076

317 0.035 1491 3.700 3689 0.1 56 4558 7.000

358 1 .500 1518 5.400 3698 0.076 4559 2.400

447 0.562 1524 >10 3699 0.043 4560 0.992

450 3.755 1536 1 .178 3714 0.210 4561 2.1 00

477 10.000 1598 >10 3723 0.252 4573 10.000

523 3.937 1612 1 .100 3727 0.398 4586 8.800

556 0.487 1625 0.402 3733 0.227 46 0 >1 0

585 0.374 1670 0.604 3749 0.087 46 8 1 .054

589 10.000 1777 10.000 3772 7.283 4632 7.932

613 0.1 57 1785 5.655 3773 >10 4640 0.033

634 7.900 1815 >10 3780 >10 4641 0.826

640 0.877 1953 >10 3799 3.645 4643 0.1 95

764 0.807 2722 6.008 3821 0.029 4646 0.1 10

909 0.372 2731 >10 3907 0.367 4647 0.1 77

918 >1 0 2736 >10 3910 0.989 4650 0.1 92

Example 18.

[01330] Representative compounds were screened using the cell-based assay procedure for signal of Tau phosphorylation at Threonine 212 (pT212Tau) in a transiently double transfcctcd (Dyrkla- and MAPT-ovcrcxprcssing) cell type as described below.

[01331] HEK293T cells (transfectable human embryonic kidney cells) were cultured in DMEM medium supplemented with 10% FBS and 1% penicillin/streptomycin.

[01332] HEK293T cells were transiently transfected to overexpress Dyrkla and microtubule -associated protein Tau (MAPT) genes. Specifically, Dyrkla and MAPT expression vectors were obtained from OriGene (10 μg of each, catalog numbers SC314641 and RC216166, respectively). A MaxiPrep for each vector was ordered and received from GeneWiz, yielding 874.5 μg (resuspended at 1.749 μg μL) of the Dyrkla expression vector, and 898 μg (resuspended at 1.796 μg/μL) of MAPT.

[01333] HEK293T cells were seeded at l .OxlO 7 cells in 10 mL per T-75 flask. After overnight incubation, HEK293T cells in the T-75 flasks were transfected by creating a master mix of 10 μg of each expression vector per flask, with Lipofectamine™ 3000 Transfection Reagent (Invitrogen, L3000015) diluted in Opti-MEM medium according to the manufacturer's suggested protocol. One T-75 flask was designated as a no-vector negative control for pT212Tau signal.

[01334] After 4~6 hours of incubation in transfection reagents, transiently double transfected HEK293T cells were dissociated by treatment with trypsin EDTA and seeded at 1.0x10 5 cells in 100 μΐ ^ per well in 96-well plates. No-vector negative controls were seeded in separate 96- well plates to avoid the risk of the negative control cells picking up the overexpression during incubation. At the time of seeding, DMSO-resuspended Samumed compounds were dispensed to eight wells as a serial dilution from 10 μΜ to 4.6 nM final concentration in medium, or at 0.12 μΜ to 0.05 nM with particularly potent compounds. Cells were exposed to the representative compounds overnight (16-18 hours) in a 37°C incubator.

[01335] 96-Well flat-bottom plates were coated with 100 μΐ ^ per well anti-HT7 capture antibody (ThermoFisher, MN1000) diluted 1 :300 in IX PBS at 4°C overnight, with shaking at 500 rpm. After overnight capture antibody incubation, coated plates were washed four times with 200 μΐ. per well of IX PBS-0.05% Tween-20, and blocked for 1 hour with 200 μΐ. per well of IX PBS with 2% BSA. After 1 hour of blocking, plates were washed four times with 200 ^iL per well of IX PBS-0.05% Tween-20, prior to sample loading.

[01336] Wells of compound-treated cells were visually checked for cell death before being washed with 200 μΐ ^ per well of IX DPBS supplemented with phosphatase inhibitor diluted to IX. Cells were then lysed with 100 μί IX RIPA buffer supplemented with phosphatase and protease inhibitors (each diluted to a final IX). Cells were shaken at 500 rpm, 4°C for 20 minutes prior to further lysis (via manual scraping) and transfer to 96-well V-bottom collection plates (Coming, 3894). V-bottom plates were centrifuged at 4000 rpm, 4°C, for 15 minutes, and 100 μΐ ^ of lysate supernatant from each well was directly tested for pT212Tau signal by sandwich ELISA.

[01337] Specifically, lysates were directly transferred to the coated and blocked ELISA plates for 2 hours before plates were washed four times with 200 ^iL per well of IX PBS-0.05% Tween-20 and probed with 100 μΐ ^ per well of anti-pT212Tau antibody (ThermoFisher, 44-740G) diluted 1 :200 in IX PBS for 2 hours. Plates were washed four times with 200 μΐ ^ per well of IX PBS-0.05% Tween-20 and probed with 100 μί per well of anti-rabbit HRP conjugate (Cell Signaling Technology, 7074S) diluted 1 :600 in IX PBS for 1 hour. Plates were washed fourtimes with 200 μΐ, per well of IX PBS-0.05% Tween-20 before 100 μΐ, per well of TMB substrate solution (ThermoFisher, N301) was added. When colour development was observed, 100 μΐ ^ per well of stop solution (ThermoFisher, N600) was added, and colorimetric detection of pT212Tau signal was read at 450 nm with the Cytation 3 Cell Imaging Multi-Mode Reader (BioTek). The signal was used to plot, draw the curves fitting, and determine the EC50 values in GraphPad Prism for tested representative compounds.

[01338] Table 6 shows the activity of representative compounds Formulas I, la, lb, Ic, Id, and Ie as provided herein. Table 6.

Example 19.

[01339] Representative compounds were screened using the assay procedure to assess the effect on cell viability as described below.

[01340] SW480 colon carcinoma cells were transduced with a lentiviral vector expressing luciferase with a human Sp5 promoter consisting of a sequence of eight TCF/LEF binding sites. SW480 cells stably expressing the Sp5-Luc reporter gene and a hygromycin resistance gene were selected by treatment with 150 μg/mL of hygromycin for 7 days. These stably transduced SW480 cells were expanded in cell culture and used for all further screening activities. Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compound source plates. Serial dilution (1:3, 8-point dose-response curves from 10 μΜ ίο 0.0045 μΜ) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, CA) into 384-well white solid bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.1%.

[01341] For the Cell Viability Assays, the cells were plated at 2,000 cells/well in 384- well plates with a DMEM medium containing 1% fetal bovine serum, and 1% Penicillin- Streptomycin and incubated for four days hours at 37°C and 5% CO2. Eight replicates of DMSO- treated cells served as controls and cells treated with compound were performed in duplicate.

[01342] After incubation, 10 μΕ of CellTiter-Glo (Promega) was added to each well allowed to incubate for approximately 12 minutes. This reagent "results in cell lysis and generation of a luminescent signal proportional to the amount of ATP present. The amount of ATP is directly proportional to the number of cells present in culture, in agreement with previous reports. The CellTiter-Glo® Assay generates a "glow-type" luminescent signal, produced by the luciferase reaction (Promega.com)".

[01343] After incubation, the plates were read at Ex 560 nm Em 590 nm (Cytation 3, BioTek). Dose-response curves were generated and EC50 concentration values were calculated using non-linear regression curve fit in the GraphPad Prism (San Diego, CA) or Dotmatics' Studies Software (Bishops Stortford, UK). For EC50 of >10 μΜ, the percent inhibition at 10 μΜ is provided. [01344] Table 6 shows the activity of representative compounds of Formulas I, la, lb, Ic, Id, and Ie as provided herein.

Table 6.

640 >10 (40.4%) 1670 9.050 3643 6.989 4594 > 0 (15.0%)

641 1 .684 1710 >10 (39.6%) 3646 9.577 4595 4.568

642 1 .030 1713 1 .565 3674 6.899 4600 2.894

643 0.803 1773 0.095 3683 >1 0 (38.8%) 4602 >1 0 (26.1 %)

662 >10 (17.3%) 1777 >10 (27.6%) 3689 >1 0 (28.8%) 4609 >10 (6.1 %)

692 >10 (28.7%) 1783 >10 (38.8%) 3698 6.904 46 0 >1 0 (24.6%)

764 >10 (24.7%) 1785 >10 (34.3%) 3699 6.718 4611 >1 0 (33.7%)

804 0.272 1802 1 .366 3714 6.023 46 2 >1 0 (20.4%)

807 0.860 1813 1 .003 3723 >1 0 (43.7%) 46 4 3.341

862 4.384 1815 >10 (1 5.8%) 3727 6.660 46 5 2.672

863 >10 (27.5%) 1953 >10 (7.8%) 3733 >1 0 (37.3%) 46 6 >10 (2.6%)

871 >10 (33.5%) 2722 >10 (31 .0%) 3749 3.614 46 8 >1 0 (36.1 %)

877 >10 (1 1.7%) 2731 >10 (26.5%) 3772 8.162 4622 >1 0 (27.9%)

892 2.055 2736 >10 (1 0.7%) 3773 5.642 4623 >1 0 (14.1 %)

896 0.1 09 2767 >10 (37.0%) 3774 9.638 4632 >1 0 (40.9%)

909 >10 (45.6%) 2776 >10 (8.1 %) 3778 7.717 4634 >1 0 (50.0%)

918 >10 (10.2%) 2782 >10 (1 8.8%) 3780 2.260 4640 0.545

923 >10 (33.9%) 2791 >10 (24.8%) 3783 1 .969 4641 >1 0 (42.6%)

954 >10 (45.1 %) 2792 >10 (29.0%) 3791 3.419 4643 >1 0 (30.1 %)

963 >10 (27.9%) 2807 >10 (7.9%) 3797 7.024 4646 0.668

969 >10 (16.3%) 2816 >10 (23.2%) 3799 3.658 4647 >1 0 (41 .1 %)

978 >10 (50.0%) 2820 >10 (22.4%) 3821 0.231 4650 >1 0 (10.9%)

979 >10 (16.7%) 2826 >10 (20.4%) 3829 9.323 4657 1 .698

985 >10 (9.6%) 2864 4.060 3836 >1 0 (33.9%) 4658 0.245

Example 20.

[01345] Representative compounds were screened using primary human fibroblasts (derived from IPF patients) treated with TGF-βΙ to determine their ability to inhibit the fibrotic process.

[01346] Human Fibroblast Cell Culture: Primary human fibroblasts derived from IPF patients (LL29 cells) [ 1 Xiaoqiu Liu, et.al., "Fibrotic Lung Fibroblasts Show Blunted Inhibition by cAMP Due to Deficient cAMP Response Element-Binding Protein Phosphorylation", Journal of Pharmacology and Experimental Therapeutics (2005), 315(2), 678-687; ^atts, K. L., et.al., "RhoA signaling modulates cyclin Dl expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis", Respiratory Research (2006), 7(1), 88] were obtained from American Type Culture Collection (ATCC) and expanded in F12 medium supplemented with 15% Fetal Bovine Serum and 1% Penicillin/Streptomycin.

[01347] Compound Screening: Each compound was dissolved in DMSO as a 10 mM stock and used to prepare compovmd source plates. Serial dilution (1:2, 11-point dose-response curves from 10 μΜ to 0.94 nM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, CA) into 384-well clear bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.1%. LL29 cells were plated at 1,500 cells/well in 70 pL/well F12 medium supplemented with 1% Fetal Bovine Serum. TGF-βΙ (Peprotech; 20 ng/mL) was added to the plates to induce fibrosis (ref. 1 and 2 above). Wells treated with TGF-βΙ and containing DMSO were used as positive control, and cells with only DMSO were negative control. Cells were incubated at 37°C and 5% CO2 for 4 days. Following incubation for 4 days, SYTOX green nucleic acid stain (Life Technologies [Thermo Fisher Scientific]) was added to the wells at a final concentration of 1 μΜ and incubated at room temperature for 30 min. Cells were then fixed using 4% formaldehyde (Electron Microscopy Sciences), washed 3 times with PBS followed by blocking and permeabilization using 3% Bovine Serum Albumin (BSA; Sigma) and 0.3% Triton X-100 (Sigma) in PBS. Cells were then stained with antibody specific to a-smooth muscle actin (aSMA; Abeam) (ref. 1 and 2 above) in 3% Bovine Serum Albumin (BSA; Sigma) and 0.3% Triton X-100 (Sigma) in PBS, and incubated overnight at 4°C. Cells were then washed 3 times with PBS, followed by incubation with Alexa Flor-647 conjugated secondary antibody (Life Technologies [Thermo Fisher Scientific]) and DAPI in 3% Bovine Serum Albumin (BSA; Sigma) and 0.3% Triton X-100 (Sigma) in PBS at room temperature for 1 hour. Cells were then washed 3 times with PBS and plates were sealed for imaging. aSMA staining was imaged by excitation at 630 nm and emission at 665 nm and quantified using the Compartmental Analysis program on the Celllnsight CX5 (Thermo Scientific). Dead or apoptotic cells were excluded from analysis based on positive SYTOX green staining. % of total cells positive for aSMA were counted in each well and normalized to the average of 1 1 wells treated with TGF-βΙ on the same plate using Dotmatics' Studies Software. The normalized averages (fold change over untreated) of 3 replicate wells for each compound concentration were used to create dose-responses curves and EC50 values were calculated using non-linear regression curve fit in the Dotmatics' Studies Software. For EC50 of >10 μΜ, the percent inhibition at 10 μΜ is provided.

[01348] Table 7 shows the activity of representative compounds of Formulas I, la, lb, Ic, Id, and Ie as provided herein.

Table 7.

194 0.935 1220 >10 (5.5%) 3096 >10 (32.7%) 42 8 2.979

202 0.530 1223 1.821 3098 >10 (8.3%) 4239 >10 (50.0%)

209 0.436 1239 >10 (13.5%) 3099 >10 (44.4%) 4244 >10 (4.9%)

216 0.598 1253 >10 (47.2%) 3102 >10 (50.0%) 4257 2.516

228 0.376 1254 6.970 3105 >10 (21 .8%) 4319 1 .626

229 0.318 1264 >10 (5.7%) 3111 >10 (46.4%) 4332 >10 (23.6%)

234 0.329 1278 >10 (35.9%) 3118 4.905 4346 >10 (21.4%)

241 1 .577 1282 2.535 3120 >10 (27.0%) 4353 >10 (26.4%)

242 1 .416 1285 >10 (5.5%) 3134 >10 (19.7%) 4377 2.955

280 2.521 1288 8.01 1 3136 0.135 4431 2.489

283 3.912 1297 >10 (42.1 %) 3167 2.042 4432 1 .721

314 0.989 1306 1.804 3168 >10 (10.2%) 4434 1 .603

317 0.935 1322 1.997 3194 >10 (47.3%) 4498 0.436

333 >10 (25.2%) 1353 >10 (42.0%) 3240 >10 (15.9%) 4504 0.384

347 >10 (20.7%) 1354 5.092 3249 7.065 4523 2.383

358 >10 (9.8%) 1356 3.602 3257 >10 (36.0%) 4535 >10 (25.0%)

372 3.636 1383 3.290 3259 >10 (48.4%) 4536 1 .140

376 3.485 1438 >10 (29.6%) 3311 1.441 4537 5.274

379 2.145 1447 >10 (35.5%) 3363 >10 (34.7%) 4538 0.708

400 1 .475 1462 >10 (14.5%) 3403 2.429 4539 1 .098

416 0.355 1471 >10 (43.6%) 3412 >10 (46.2%) 4544 1 .092

447 0.517 1472 >10 (33.9%) 3425 >10 (19.3%) 4548 >10 (50.0%)

448 >10 (23.0%) 1491 >10 (6.1 %) 3439 >10 (14.3%) 4551 0.325

450 0.517 1495 >10 (48.5%) 3446 >10 (16.9%) 4558 0.277

477 0.632 1497 2.427 3470 3.229 4559 0.589

523 1 .634 1518 2.606 3474 >10 (37.0%) 4560 0.779

540 >10 (50.0%) 1519 2.399 3524 >10 (50.0%) 4561 0.664

556 >10 (27.6%) 1523 >10 (24.9%) 3527 3.496 4564 >10 (26.8%)

566 >10 (35.2%) 1524 4.775 3587 1.435 4565 >10 (31.0%)

585 2.513 1536 1.130 3591 4569 4.095

589 >10 (41.6%) 1589 0.91 1 3597 >10 (7.7%) 4570 >10 (5.5%)

591 >10 (13.3%) 1598 1.271 3599 3.008 4573 >10 (9.3%)

592 0.009 1612 >10 (42.0%) 3612 3.901 4574 >10 (32.8%)

613 0.650 1625 1.766 3616 3.164 4576 >10 (38.3%)

624 0.491 1632 >10 (28.8%) 3627 >10 (33.4%) 4577 >10 (42.7%)

625 3.009 1634 >10 (18.3%) 3629 0.097 4586 4.440

634 2.130 1656 1.756 3638 >10 (34.9%) 4593 >10 (41.4%)

640 0.671 1670 4.846 3643 2.503 4594 3.250

641 0.347 1710 >10 (10.4%) 3646 >10 (12.9%) 4595 >10 (2.8%)

642 0.988 1713 5.160 3674 0.604 4600 >10 (47.0%)

643 1 .433 1773 0.163 3683 0.597 4602 >10 (14.3%)

662 7.653 1777 >10 (41.1 %) 3689 0.893 4609 >10 (45.9%)

692 >10 (3.8%) 1783 >10 (53.7%) 3698 1.070 46 0 4.189

764 >10 (5.8%) 1785 4.004 3699 0.025 46 1 >10 (29.9%)

804 0.482 1802 >10 (47.6%) 3714 1.539 46 2 >10 (13.2%)

807 1 .408 1813 5.825 3723 >10 (9.1 %) 4614 2.256

862 5.032 1815 >10 (33.5%) 3727 0.149 4615 >10 (35.6%)

863 >10 (41.0%) 1953 >10 (55.5%) 3733 1.833 46 6 >10 (25.9%)

871 8.053 2722 1.01 1 3749 0.167 46 8 4.809

877 >10 (23.6%) 2731 5.319 3772 1.135 4622 >10 (29.4%)

892 3.978 2736 >10 (17.0%) 3773 3.318 4623 >10 (4.2%)

896 0.335 2767 >10 (13.8%) 3774 5.859 4632 >10 (35.5%)

909 1 .385 2776 >10 (39.0%) 3778 0.694 4634 >10 (39.9%)

918 >10 (31.2%) 2782 2.404 3780 4.759 4640 0.896

923 2.724 2791 6.131 3783 2.101 4641 2.422

954 2.135 2792 >10 (44.8%) 3791 4.946 4643 1 .512

963 1 .570 2807 >10 (35.2%) 3797 2.696 4646 0.665

969 >10 (40.2%) 2816 >10 (27.3%) 3799 2.578 4647 >10 (39.6%)

978 2.734 2820 8.909 3821 0.313 4650 >10 (23.0%)

979 >10 (23.2%) 2826 >10 (37.9%) 3829 0.759 4657 4.805

985 >10 (51.7%) 2864 >10 (7.3%) 3836 >10 (10.0%) 4658 1 .587 Example 21.

[01349] Representative compounds were screened using the cell-based assay procedure for secreted cytokines in a Lipopolvsaccharide-stimulated mouse glial cell line described below.

[01350] BV-2 cells (mouse microglial cells) were cultured in 1 : 1 DMEM medium supplemented with 10% FBS, and 1% penicillin/streptomycin.

[01351] BV-2 cells are plated at 35,000 cells/well in a volume of 100 μΐ for at least 4 hours before compounds are added. DMSO-resuspended compounds were first dispensed in a 96- well plate and serial diluted from 10 μΜ to 4.6 nM final concentration in medium. Compounds were added to cells overnight. 250 ng/mL of lipopolysaccharide (Escherichia coli 01 11 :B4, SIGMA) was added for 5 hours. Supernatant is removed and saved for further cytokine detection. The original plates with seeded cells were tested for cytotoxicity by measure of adenosine triphosphate (ATP) release by adding CellTiter-Glo ® diluted 1 :4 in distilled water (G7 73, Promega) and transferring lysed cells to a completely black 96-well plate to be read with the Cytation3. Supernatant was then diluted 1 : 2 with a diluent from V-PLEX cytokine Kit and directly tested for the secreted cytokines TNFa, IL-6 and KC-GRO using electrochemiluminescence (Meso Scale Discovery). The standard curve for each cytokine was used to convert the electrochemiluminescent signal into pg of protein per mL. The signal was used to plot, draw the curve fitting, and determine each compounds EC50 in Prism (GraphPad).

[01352] Table 9 shows the activity of representative compounds of Formulas I, la, lb, Ic, Id, and Ie as provided herein.

Table 9.

194 0.819 1210 1.100 3257 0.458 4523 1 .300

202 0.300 1220 0.877 3259 1.200 4535 0.162

209 0.864 1253 >10 3311 0.420 4536 0.089

216 0.378 1278 7.200 3412 1.500 4538 0.047

228 0.207 1282 1.000 3524 0.582 4539 0.080

229 0.062 1285 6.800 3587 0.011 4544 0.353

234 0.026 1288 6.100 3591 2.400 4548 0.400

314 0.138 1297 10.000 3597 10.000 4551 0.400

317 0.066 1353 0.812 3599 0.832 4558 0.165

376 1 .700 1356 1.100 3616 1.200 4559 0.411

379 0.734 1383 6.800 3627 0.708 4560 0.1 17

416 3.300 1447 0.605 3629 5.700 4561 0.129

447 0.083 1491 3.900 3638 1.400 4565 1 .000

450 3.000 1497 0.334 3643 3.900 4570 0.128

477 4.800 1518 1.080 3646 >10 4586 0.380

523 0.799 1519 0.069 3674 6.800 4593 2.500

540 10.000 1523 1.800 3683 >10 4600 6.400

556 2.200 1524 3.600 3689 >10 4602 2.900

585 0.257 1536 0.336 3698 4.800 46 0 0.261

592 0.449 1589 0.221 3699 >10 4614 0.718

613 0.106 1598 3.100 3714 1.620 4615 0.275

624 8.800 1612 2.200 3723 0.094 4618 0.108

625 0.130 1625 0.436 3727 >10 4622 1 .400

634 0.542 1670 2.900 3733 3.700 4623 1 .300

640 0.504 1710 5.500 3772 10.000 4632 0.700

641 0.433 1713 1.000 3773 0.305 4640 7.100

642 1 .300 1773 0.005 3774 0.972 4641 1 .700

643 10.000 1783 6.800 3778 0.720 4643 >10

764 5.100 1802 4.400 3783 5.300 4646 0.130

804 0.104 1813 0.952 3791 3.900 4650 >10

807 0.265 1953 2.900 3797 0.054 4657 0.928

871 0.306 2722 0.822 3799 0.079 4658 0.058

877 2.700 2731 1.200 3821 0.244

896 0.266 2736 0.109 3829 0.533

Example 22.

[01353] Representative compounds were screened using the following assay procedure to determine their ability to inhibit IL-6 and therefore demonstrate their anti -inflammatory properties.

[01354] Human Peripheral Blood Mononuclear Cells: Fresh Normal PB MNC (Catalog # PB001, All Cells, Alameda, CA) were shipped overnight at 4°C and resuspended in Roswell Park Memorial Institute (RPMI) 1640 Medium, with GlutaMAX Supplement (Catalog #61870127, ThermoFisher Scientific, Waltham, MA) supplemented with 1% Penicillin- Streptomycin (Catalog# 15140163, ThermoFisher Scientific, Waltham, MA) and 1% fetal bovine serum (FBS) ( Catalog # 16140089, ThermoFisher Scientific, Waltham, MA) assay media.

[01355] Compound Screening: Fresh normal human peripheral blood mononuclear cells (huPBMCs) were resuspended in 1% FBS-RPMI assay media with 1% Penicillin- Streptomycin 1% to a cell concentration of 1 x 10e6 cells/mL. Each compound was dissolved in DMSO (Catalog # D8418-100ml, Sigma-Aldrich, St. Louis, MO) as a 10 mM stock and used to prepare compound source plates. Serial dilution (1 :3, 10-point dose-response curves starting from 10 μΜ) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, CA) into 384-well white Proxiplate-Plus assay plates (Catalog #6008289, PerkinElmer, Shelton, CT) with appropriate DMSO backfill for a final DMSO concentration of 0.25%. huPBMCs were plated at 5000 cells/well in the 384-well Proxiplate-Plus assay plates and incubated at 37°C-5% CO2 for 2 hours. 50 ng/mL of Lipopolysacchandes from Escherichia coli 01 11 :B4 (Catalog #L5293-2ML, Sigma-Aldrich, St. Louis, MO) was added after 2 hours and cells were incubated for another 22 hours at 37°C-5% CO 2 . After 22 hour incubation, a mixture of anti-IL6 XL665 and anti-IL-6 Cryptate diluted in reconstitution buffer (Catalog #62IL6PEC, Cisbio Inc., Bedford, MA) was added to each well. Following incubation for 3 hours at room temperature, Homogeneous Time- Resolved Fluorescence (HTRF) was measured using the Envision (Perkin Elmer, Shelton, CT) at 665 nm and 620 nM. The ratio of fluorescence at 665 nm to 620 nm was used as a readout for IL- 6 quantification. All samples were processed in duplicate. Readings were normalized to DMSO treated cells and normalized activities were utilized for EC50 calculations. EC50 was determined using software generated by Dotmatics Limited (Windhill Bishops Stortford Herts, UK) using the Levenberg-Marquardt 4 parameter fitting procedure with finite different gradients. For EC50 of >10 μιΜ, the percent inhibition at 10 μΜ is provided.

[01356] Table 8 shows the activity of representative compounds of Formulas I, la, lb, Ic, Id, and Ie as provided herein.

Table 8.

242 3.615 1285 >10 (2.1 %) 3134 >10 (3.9%) 4377 >10 (5.7%)

280 5.707 1288 >10 (9.8%) 3136 >10 (9.8%) 4431 >10 (3.6%)

283 >10 (7.4%) 1297 >10 (4.3%) 3167 >10 (5.4%) 4432 >10 (1.4%)

314 >10 (47.6%) 1306 8.809 3168 >10 (0%) 4434 9.852

317 >10 (8.0%) 1322 >10 (5.9%) 3194 >10 (8.9%) 4498 3.087

333 >10 (5.4%) 1353 >10 (4.1 %) 3240 >10 (10.5%) 4504 >10 (7.3%)

347 >10 (4.0%) 1354 >10 (39.9%) 3249 8.319 4523 3.258

358 >10 (2.0%) 1356 8.065 3257 >10 (3.2%) 4535 2.855

372 >10 (0%) 1383 >10 (3.1 %) 3259 >10 (4.1 %) 4536 3.023

376 7.962 1438 >10 (9.6%) 3311 >10 (5.8%) 4537 >10 (3.0%)

379 2.075 1447 >10 (0%) 3363 >10 (5.6%) 4538 3.432

400 3.655 1462 >10 (0%) 3403 >10 (1.8%) 4539 >10 (37.4%)

416 5.757 1471 >10 (1.8%) 3412 >10 (2.7%) 4544 7.770

447 4.250 1472 >10 (7.6%) 3425 >10 (9.0%) 4548 >10 (3.2%)

448 5.128 1491 >10 (2.6%) 3439 >10 (12.7%) 4551 2.989

450 3.514 1495 >10 (3.2%) 3446 >10 (5.8%) 4558 9.226

477 9.828 1497 >10 (4.8%) 3470 >10 (9.4%) 4559 8.502

523 >10 (3.7%) 1518 >10 (30.1 %) 3474 >10 (3.9%) 4560 >10 (2.7%)

540 >10 (3.9%) 1519 >10 (2.9%) 3524 >10 (5.6%) 4561 4.563

556 >10 (4.9%) 1523 >10 (6.2%) 3527 >10 (0%) 4564 >10 (0%)

566 >10 (3.6%) 1524 >10 (50.0%) 3587 7.665 4565 >10 (10.2%)

585 >10 (9.4%) 1536 >10 (49.6%) 3591 >10 (4.4%) 4569 >10 (42.3%)

589 >10 (5.9%) 1589 2.876 3597 >10 (0%) 4570 >10 (18.4%)

591 >10 (0%) 1598 >10 (7.5%) 3599 >10 (40.1 %) 4573 >10 (9.6%)

592 >10 (25.3%) 1612 >10 (6.3%) 3612 5.051 4574 >10 (5.7%)

613 1 .099 1625 >10 (4.0%) 3616 2.368 4576 >10 (0%)

624 3.082 1632 >10 (4.2%) 3627 >10 (10.6%) 4577 >10 (2.6%)

625 >10 (6.5%) 1634 >10 (5.4%) 3629 2.765 4586 >10 (4.8%)

634 >10 (13.0%) 1656 >10 (6.0%) 3638 >10 (6.3%) 4593 >10 (4.8%)

640 7.340 1670 >10 (7.2%) 3643 >10 (9.8%) 4594 >10 (2.4%)

641 >10 (16.4%) 1710 >10 (7.2%) 3646 9.042 4595 >10 (5.3%)

642 >10 (22.4%) 1713 >10 (5.7%) 3674 >10 (1.7%) 4600 >10 (6.3%)

643 9.218 1773 >10 (40.7%) 3683 >10 (4.6%) 4609 >10 (9.1 %)

662 >10 (10.5%) 1777 >10 (2.4%) 3689 >10 (7.6%) 46 0 > 0 (10.3%)

692 6.732 1783 >10 (6.1 %) 3698 >10 (4.6%) 46 1 8.678

764 >10 (4.3%) 1785 >10 (8.9%) 3699 >10 (8.4%) 46 2 >10 (4.4%)

804 1 .594 1802 >10 (47.2%) 3714 5.704 4614 2.817

807 4.204 1813 >10 (42.0%) 3723 >10 (2.8%) 4615 >10 (5.8%)

862 >10 (5.6%) 1815 >10 (7.0%) 3727 >10 (6.2%) 46 6 >10(5.8%)

863 >10 (7.0%) 1953 >10 (12.8%) 3733 >10 (6.2%) 46 8 >10 (6.3%)

871 3.423 2722 8.903 3749 8.804 4622 >10 (2.3%)

877 >10 (6.8%) 2731 >10 (2.8%) 3772 >10 (10.6%) 4623 >10 (8.1 %)

892 >10 (2.5%) 2736 >10 (0%) 3773 >10 (1.1 %) 4632 >10 (6.8%)

896 1 .685 2767 >10 (0%) 3774 >10 (10.8%) 4634 >10 (1.9%)

909 4.861 2776 >10 (10.4%) 3778 >10 (4.2%) 4640 >10 (4.6%)

918 >10 (14.6%) 2782 >10(4.3%) 3780 >10 (6.7%) 4641 >10 (6.3%)

923 >10 (10.5%) 2791 >10 (5.3%) 3783 >10 (1.7%) 4643 >10 (5.7%)

954 >10 (5.7%) 2792 >10 (4.0%) 3791 >10 (0%) 4646 >10 (3.2%)

963 >10 (5.4%) 2807 7.313 3797 >10 (7.0%) 4647 >10 (6.5%)

969 >10 (4.1 %) 2816 >10 (2.2%) 3799 >10 (5.3%) 4650 >10 (7.1 %)

978 >10 (6.9%) 2820 >10 (3.3%) 3821 8.410 4657 >10 (9.2%)

979 >10 (6.4%) 2826 >10 (2.1 %) 3829 >10 (5.3%) 4658 6.532

985 >10 (3.2%) 2864 >10 (10.0%) 3836 >10 (1.4%)